id	label	sublabel	x	y	cluster	weight
1061523	akatinol memantine in patients with vascular cognitive disorders	2010	-0.2585	0.1787	11	0.6687
1165925	cytochrome p 450 immunolocalization in human liver	1986	-1.2428	-0.3453	83	1
3987637	potential long term effects of rivastigmine on disease progression may be linked to drug effects on vascular changes in alzheimer brains	2003	-0.2369	0.0399	72	18.475
4759358	donepezil in vascular dementia	2003	-0.3243	0.1121	33	0.9206
6243660	double blind trial of imipramine in alzheimer s disease patients with and without depression	1989	0.2917	0.0779	31	31.5753
10202780	cerebrolysin reduces microglial activation in vivo and in vitro a potential mechanism of neuroprotection	2000	-0.3335	0.005	70	0.75
10521629	haloperidol versus thioridazine in the treatment of behavioral symptoms in senile dementia of the alzheimer s type preliminary findings	1986	0.0849	0.1025	47	0.75
11918414	therapeutic activities among residents with dementia at a nursing home	2013	0.4399	-0.0044	104	0.8187
12808980	acetyl l carnitine in the treatment of mildly demented elderly patients	1990	-0.2856	0.0303	63	19.1867
13871583	l acetylcarnitine treatment of mental decline in the elderly	1994	-0.1379	0.0381	80	0.6881
15186240	a cross cultural study of alzheimer s disease caregivers	1998	-2.1412	2.1678	121	0.8768
15704505	depression and quality of life among family caregivers of patients with parkinson s disease in south korea	2007	0.6566	-0.1432	75	0.7724
18437227	safety tolerability and efficacy of rivastigmine in taiwanese patients with alzheimer s disease a prospective post marketing surveillance study	2009	-0.2432	0.0582	19	0.8256
19640728	improved global function and activities of daily living in patients with ad a placebo controlled clinical study with the neurotrophic agent cerebrolysin	2002	-0.3335	0.005	70	0.75
21063919	estrogen improves psychological function in asymptomatic postmenopausal women	1991	-0.7668	-0.7773	3	28.9792
22763952	reduction of plasma asymmetric dimethylarginine in obese patients with chronic kidney disease after three years of a low protein diet supplemented with keto amino acids a randomized controlled trial	2008	-1.2104	-0.3345	128	0.6714
23178188	the cognitive subjective and physical effects of a ginkgo biloba panax ginseng combination in healthy volunteers with neurasthenic complaints	1997	-0.4951	-0.0703	8	0.9713
23595113	cerebral and ocular toxicity induced by desferrioxamine	1985	-1.5747	-1.2603	101	0.8843
24004846	physostigmine responses as markers in affective disorder patients	1982	0.0571	0.5351	48	0.7271
24927722	some clinical studies with piracetam a nootropic substance	1978	-0.2585	0.1787	11	0.7146
25018822	circadian rhythm of salivary serotonin in patients with major depressive disorder	2007	0.3313	-0.0243	89	0.6868
25396414	wine consumption and dementia in the elderly a prospective community study in the bordeaux area	1997	-0.3446	0.2068	126	0.8268
27112123	a double blind study into the influence of estriol on a number of psychological tests in post menopausal women	1976	-0.7629	-0.7701	3	20.9694
27306700	optimal structural nested models for optimal sequential decisions	2004	0.246	0.0854	141	0.9973
27754594	the worldwide challenge of the dementias a role for b vitamins and homocysteine	2008	-0.8828	-0.0982	30	1.8247
28844373	double blind study of a multivitamin complex supplemented with ginseng extract	1996	-0.6492	-0.1181	65	0.9404
29749450	memantine for patients with alzheimer disease reply	2004	-0.3287	0.1829	22	20.1496
30614401	perceived helpfulness of telephone calls providing support for caregivers of family members with dementia	2004	0.705	-0.1571	76	15.8367
32991154	clinical trial of piracetam in disorders of consciousness due to head injury	1975	-0.3171	0.2625	15	0.75
35066726	a multinational randomised 12 week comparative study of donepezil and rivastigmine in patients with mild to moderate alzheimer s disease	2005	-0.2484	0.051	72	5.1114
35501073	neurotrophic effects of cerebrolysin in animal models of excitotoxicity	2000	-0.3335	0.005	70	0.75
36317822	research on senile dementia of the alzheimer s type	1985	-0.384	0.3371	59	0.8282
38098989	efficacy and safety of donepezil galantamine and rivastigmine for the treatment of alzheimer s disease a systematic review and meta analysis	2008	-0.229	0.0546	19	2.8121
38523360	prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels	1998	-0.7878	-0.1889	88	3
38748857	inflammatory mechanisms in alzheimer s disease implications for therapy	1994	-0.414	-0.0404	32	1
39182999	major and minor depression in alzheimer s disease prevalence and impact	1997	0.2181	0.0805	31	0.9999
39805860	a practical method for grading the cognitive state of patients for the clinician	1975	0.1921	-0.0384	60	1.595
41383725	efficacy of risperidone for prevention of postoperative delirium in cardiac surgery	2007	2.1939	-0.0434	2	14.1489
45660340	ginkgo biloba special extract in dementia with neuropsychiatric features a randomised placebo controlled double blind clinical trial	2011	-0.398	-0.0534	8	29.0396
48853759	valproate doesn t delay psychosis in alzheimer s	2009	0.3076	0.1434	81	0.7139
50830799	impact of psychoeducational interventions on distressed family caregivers	2000	0.5363	-0.1082	1	0.9939
51591921	using a therapy dog to alleviate the agitation and desocialization of people with alzheimer s disease	1999	0.486	-0.0409	21	0.9867
54082376	defining treatment response to donepezil in alzheimer s disease responder analysis of patient level data from randomized placebo controlled studies	2008	-0.2196	0.0521	6	0.8947
55287668	episodic memory impairment in preclinical alzheimer s disease	2006	-0.5503	0.3993	73	0.6545
56211140	improvement in quality of life in the elderly results of a placebo controlled study on the efficacy and tolerability of lecithin fluid in patients with impaired cognitive functions	2004	-0.289	0.2819	9	13.0131
56351667	randomized trials of estrogen for memory and dementia	2002	-0.4786	-0.0169	12	0.7446
57210477	the pharmacologic treatment of alzheimer s disease a guide for the general psychiatrist	1998	-0.3438	0.2071	126	0.8426
59918674	plasma clozapine levels and clinical response for treatment refractory schizophrenic patients	1995	-0.1161	0.1935	114	0.6873
60088640	the pharmacological effects of ginkgo biloba a plant extract on the brain of dementia patients in comparison with tacrine	1998	-0.4717	-0.0429	132	1.5015
60092708	nimodipine treatment improves cognitive functions in vascular dementia	1989	-0.8144	0.8208	102	13.8101
61152424	quetiapine in schizophrenic patients a high and low dose double blind comparison	2000	0.1304	0.1286	47	0.6846
61252280	the effect of ondansetron on postoperative delirium and cognitive function in aged orthopedic patients	2014	2.345	0.1894	103	0.7059
61992062	use of slow release melatonin in treatment resistant depression	2000	-0.3438	0.2071	126	0.8287
62411228	ginkgo biloba extract in peripheral arterial diseases meta analysis of controlled clinical studies	1992	-0.4758	-0.0347	132	0.6934
63013890	amantadine and memantine are nmda receptor antagonists with neuroprotective properties	1994	-0.2742	0.0723	23	0.9867
63062076	rivastigmine in dementia associated with parkinson s disease and alzheimer s disease similarities and differences	2007	-0.2153	0.1817	9	1.3268
63475786	non cognitive symptoms in alzheimer s disease	1997	-0.5194	0.3697	73	0.7496
64046613	efficacy and safety of antidepressants for treatment of depression in alzheimer s disease a metaanalysis	2007	0.1606	0.1034	31	5.5794
64096637	statistical package for the social sciences	2012	0.2261	-0.0085	17	0.75
65017333	a double blind randomized trial of sabeluzole a putative glutamate antagonist in obstructive sleep apnea	1996	0.2279	-0.0033	28	0.9404
68463649	plasma thiamine deficiency associated with alzheimer s disease but not parkinson s disease	1998	-0.7849	-0.099	86	2.7407
68515599	clinical disease evaluation	2014	-0.3925	0.3624	106	0.7422
68901995	the course of geriatric depression with reversible dementia a controlled study	1993	-0.0938	0.0049	84	0.7204
70070098	clinical efficacy and safety of akatinol memantine in treatment of mild to moderate alzheimer disease a donepezil controlled randomized trial	2006	-0.1959	0.118	92	1.4892
74059259	acetyl l carnitine a drug able to slow the progress of alzheimer s disease	1991	-0.3235	-0.0113	63	1.6343
74672813	ginkgo biloba for dementia	1999	-0.4817	-0.0755	68	1.7956
75245760	age specific relevance of usual blood pressure to vascular mortality a meta analysis of individual data for one million adults in 61 prospective studies	2002	-0.707	-0.1338	14	5.9991
76040391	vascular ischemic dementia an update	2002	-0.7263	0.0224	107	0.7015
77077316	effect of vitamins and aspirin on markers of platelet activation oxidative stress and homocysteine in people at high risk of dementia	2003	-0.8763	-0.1039	30	27.8792
77290285	evaluation of the implementation of a preferred music intervention for reducing agitation and anxiety in institutionalised elders with dementia	2006	0.5131	-0.1606	60	0.6696
78579298	a gero informatics tool to enhance the care of hospitalized older adults with cognitive impairment	2007	1.6418	-0.0325	24	0.8307
81334637	prevalence and risk factors for development of delirium in surgical and trauma intensive care unit patients	2008	2.2377	-0.0473	2	1
81474449	efficacy of donepezil in alzheimer s disease fact or artifarct letter	1999	-0.3242	0.1168	33	0.8096
86963519	fluphenazine plasma levels dosage efficacy and side effects	1995	-0.1168	0.194	114	0.7083
89206949	a double blind study of colchicine in behcet s disease	1980	-0.3327	0.0929	51	0.6177
91543343	management of behavioral symptoms in disturbed elderly patients comparison of trifluoperazine and haloperidol	1987	0.0852	0.1033	47	0.75
93533857	wechsler memory scale revised	1987	0.1984	-0.0052	17	1.5493
93550323	study of the efficacy and tolerability of l acetylcarnitine therapy in the senile brain	1986	-0.3156	0.0033	63	5.4476
94849137	valproic acid treatment of agitation in dementia	1998	0.1735	0.0799	16	2.954
95610901	alzheimer s disease and vascular dementia	2014	-0.4056	0.0825	85	0.7095
96024046	valproate in the treatment of behavioral agitation in elderly patients with dementia	1995	0.1732	0.0799	16	2.9118
96715011	effect of ginkgo biloba extract on mental performance double blind study using computerized measurement conditions in patients with cerebral insufficiency	1992	-0.4521	-0.0372	8	0.845
101525007	the use of life review activity with confused nursing home residents	1979	0.3441	-0.0892	10	0.9998
101766986	clinical effects of beni koji in mild essential hypertension a multi center double blind comparison with placebo	1996	-0.2977	0.0512	23	0.6425
102617557	six and 18 month changes in mild to moderate alzheimer s patients treated with acetylcholinesterase inhibitors what can we learn for clinical outcomes of therapeutic trials	2007	-0.0587	0.0835	58	0.7519
105107870	treatment of alzheimer s disease with short and long term oral tha and lecithin a double blind study	1990	-0.3327	0.0929	51	0.6906
105167849	effect of serotonin uptake inhibition on breathing during sleep and daytime symptoms in obstructive sleep apnea	1999	0.2279	-0.0033	28	0.9713
106460070	citicoline improves memory performance in elderly subjects	1997	-0.3985	-0.2565	62	2.6836
110692202	the california verbal learning test	1987	-0.3317	-0.0937	8	0.75
112071069	prophylactic consecutive administration of haloperidol can reduce the occurrence of postoperative delirium in gastrointestinal surgery	1999	2.201	-0.0446	2	1.5
112637169	cordial cognitive rehabilitation and cognitive behavioral treatment for early dementia in alzheimer disease a multicenter randomized controlled trial	2012	0.2683	-0.1156	10	2.7846
113269532	evidence based clinical update general anesthesia and the risk of delirium and postoperative cognitive dysfunction	2006	2.2253	-0.0295	36	0.9404
115216647	primary degenerative dementia without alzheimer pathology	1986	-0.2909	0.1288	53	0.7695
116688419	treatment of equilibrium disorders with ginkgo biloba extract a multicenter double blind drug vs placebo study	1986	-0.4814	-0.0649	68	0.9241
117366526	memantine for treatment of behavioural disturbances and psychotic symptoms in moderate to moderately severe alzheimer dementia a naturalistic study in outpatient services in austria	2010	0.3077	0.1439	81	0.7489
120863225	cognitive impairment in alzheimer disease	2004	-0.5186	0.3694	73	0.7737
122748151	interventions to improve quality of care the kaiser permanente alzheimer s association dementia care project	2004	0.5559	-0.1187	74	1.8841
123026139	vascular cognitive impairment evolution of the concept	2009	-0.8154	0.8222	102	0.6642
123099484	the impact of drugs against dementia on cognition in aging and mild cognitive impairment	2003	-0.2585	0.1787	11	0.6673
124205425	pharmacologic treatment of noncognitive behavioral disturbances in elderly demented patients	1990	0.1149	0.0721	58	1.7008
124896576	ginkgo for memory enhancement a randomized	2010	-0.4851	-0.0713	68	0.7091
125069525	apoe and memory in alzheimer s disease	1998	-0.5495	0.3992	73	0.6696
125227749	longitudinal assessment of symptoms of depression agitation and psychosis in 181 patients with alzheimer s disease	1996	0.1724	0.0879	16	0.9404
126408246	evidence for a therapeutic effect of ginkgo biloba special extract meta analysis of 11 clinical studies in patients with cerebrovascular insufficiency in old age	1994	-0.4587	-0.0435	8	1.761
126850418	efficacy and tolerability of memantine in patients with dementia syndrome a double blind placebo controlled trial	1991	-0.2473	0.0868	23	1.6827
127078018	web based interventions for family caregivers a scoping review	2014	0.5963	-0.1335	131	0.7294
127351797	neuroprotective effect of gacyclidine a multicenter double blind pilot trial in patients with acute traumatic brain injury	2004	-0.3446	0.2068	126	0.8245
129693246	the effectiveness of cbt in the treatment of depression and anxiety occurring both in isolation and in conjunction with other serious psychiatric conditions as seen within a community mental health service	2009	0.7627	-0.2018	77	0.7932
130525075	effects of 5023 se on pao2 at rest in elderly patients with cerebral impairment a double blind cross over trial versus placebo	1983	-0.2977	0.0512	23	0.6582
132455630	risperidone in the treatment of acute disruptive behavior in pediatrics patients with epilepsy	2005	0.5641	0.3999	40	0.7357
132928865	an open label clinical trial evaluating the safety and efficacy of donepezil in patients with mild to moderate alzheimer s disease	1997	-0.2408	0.0603	19	0.762
134419967	efficacy of rivastigmine in comparison to ginkgo for treating alzheimer s dementia	2012	-0.398	0.0312	53	0.6554
135972298	change in mental health status of young children participating in a respite service	2011	0.6854	-0.1437	97	0.8338
137950222	practice guidelines for the treatment of patients with delirium	2007	2.131	-0.0414	2	0.9804
138916937	efficacy of tablet huperzine a on memory cognition and behavior in alzheimer s disease	1995	-0.2514	0.1578	9	0.6499
141241920	treatment of alzheimer s disease with delta5 androstenes	2000	-0.3263	0.1826	22	2.3969
142128493	sleep disturbances in patients with alzheimer s disease	2001	0.2363	-0.007	28	1.8988
142342082	a comparison of pure alzheimer s disease and alzheimer s disease plus vascular lesions mixed dementia in the elderly	1990	-0.4056	0.0825	85	0.693
143513173	sustained use of cpap slows deterioration of cognition sleep and mood in patients with alzheimer s disease and obstructive sleep apnea a preliminary study	2009	0.2286	-0.0028	28	0.9959
144571446	clinical evaluation of some fnzymes in the serum in hepato biliary disease	1970	-0.393	0.3617	106	0.6669
144954506	once daily memantine	2013	-0.0768	0.0687	58	2.337
145477523	evaluation of prospective memory training for individuals with mild alzheimer s disease	2002	-0.3141	0.0962	50	0.6569
146766604	brain mapping activity and mental performance after chronic treatment with cdp choline in alzheimer s disease	1994	-0.3936	-0.2409	62	0.75
147976879	effects of the medicare alzheimer s disease demonstration on nursing home entry	1999	0.5621	-0.108	1	25.2235
148485189	the acute care ward experience for persons with dementia and their caregivers	2011	0.5569	-0.1195	74	0.848
149716167	neuropsychological changes in demented patients treated with acetyl l carnitine	1990	-0.2378	0.0628	78	1.4549
150206061	pooled analyses on cognitive effects of memantine in patients with moderate to severe alzheimer s disease	2008	-0.1811	0.1116	11	2.4596
153512915	optimal dosing of galantamine in patients with mild or moderate alzheimer s disease	2009	-0.311	0.0163	57	0.7061
153763870	poster 20 effects of a cognitive training program on outcomes in extended acute inpatient medical rehabilitation for patients with cardiac disease1	2003	2.1222	-0.0874	26	0.7425
162904136	eficacia diferencial de dos intervenciones psicoeducativas para cuidadores de familiares con demencia	2004	0.5311	-0.1116	1	0.9804
163344111	multicenter study comparing thioridazine with diazepam and placebo in elderly nonpsychotic patients with emotional and behavioral disorders	1984	0.0438	0.132	47	3.3908
163864813	long term effects of rivastigmine in moderately severe alzheimer s disease does early initiation of therapy offer sustained benefits	2002	-0.0691	0.0732	58	2.2235
164818971	nursing intervention to reduce anxiety and improve the adaptive capabilities among caregivers of terminal liver cancer patients	2011	0.6283	-0.1218	42	0.7243
164939493	occupational therapy and people with dementia in care homes	2010	0.5131	-0.1606	60	0.6695
165338889	the telephone interview for cognitive status	1988	-0.3317	-0.0945	8	0.7993
166336339	pilot study of haloperidol fluoxetine and placebo for agitation in alzheimer s disease	1997	0.1858	0.0879	16	21.7137
167981432	age influence on the immune system	1980	-0.2807	0.0621	44	0.75
168333064	a double blind placebo controlled study of clomipramine in depressed patients with alzheimer s disease	1996	0.2171	0.0793	31	30.7779
169789215	clinical efficacy of special extract egb 761 in dementia of the alzheimer type	1997	-0.41	0.0038	53	1.6148
169819460	anxiety symptoms as predictors of nursing home placement in patients with alzheimer s disease	2002	0.6749	-0.1727	77	0.7993
172609984	effects of intensive glucose lowering in type 2 diabetes	2008	-0.4346	1.495	56	1.9027
175903304	estrogen replacement therapy and postural stability in the elderly	1995	-0.7662	-0.7791	3	19.4782
176535219	short term effects of olanzapine in huntington disease	2001	-0.2283	-0.1467	112	0.9973
178114037	online video group counselling for family caregivers of persons with dementia an ongoing randomized controlled trial	2014	0.6861	-0.1443	97	0.6709
180469417	long term donepezil treatment in 565 patients with alzheimer s disease ad2000 randomised double blind trial	2004	-0.1824	0.0506	6	32.9235
180946569	effects of an angiotensin converting enzyme inhibitor ramipril on cardiovascular events in high risk patients the heart outcomes prevention evaluation study investigators	2000	-0.7455	-0.1539	14	5.9392
183504973	functional recovery after hip fracture	1987	1.9721	-0.0871	26	0.9994
184847544	alleviating agitation apprehension and related symptoms in geriatric patients a double blind comparison of a phenothiazine and a benzodiazepien	1975	0.0875	0.0984	47	0.9973
186479986	mental deterioration in old age results of two multicenter clinical trials with nimodipine the nimodipine study group	1993	-0.3443	0.1102	53	1.8003
186974930	feasibility efficacy and safety of antipsychotics for intensive care unit delirium the mind randomized placebo controlled trial	2010	2.1916	-0.0434	2	6.5938
188790921	ginkgo biloba extract egb 761 in dementia intent to treat analyses of a 24 week multi center double blind placebo controlled randomized trial	2003	-0.4213	-0.0711	8	27.6591
190545792	associated hormonal declines in aging dheas	2005	-1.3848	-1.7808	54	0.75
191966441	the dentate gyrus neurogenesis a therapeutic target for alzheimer s disease	2003	-0.3539	-0.0018	70	1.5987
192531880	therapeutic results with cerebrolysin in the treatment of dementia	1997	-0.3335	0.005	70	0.75
194106374	a comparative study of the driving effects of dextroamphetamine and yogic meditation on muscle control for the performance of balance on balance board	1991	-0.387	0.3785	98	0.6827
195566167	oxiracetam in the treatment of multi infarct dementia and primary degenerative dementia	1989	-0.2909	0.1288	53	0.8692
199043204	the use of selegiline in alzheimer s patients with behavior problems	1991	-0.1149	0.0932	37	7.0509
199914013	neuropsychological assessment of demented patients	1991	-0.2007	0.0876	78	0.6742
199968895	pilot study comparing in blind the therapeutic effect of two doses of agomelatine melatonin agonist and selective 5ht2c receptors antagonist in the treatment of major depressive disorders	2003	-0.3446	0.2068	126	0.8232
200435910	geriatric rehabilitation following fractures in older people a systematic review	2000	1.9721	-0.0871	26	0.9992
200962544	therapeutic results with nimodipine in primary degenerative dementia and multi infarct dementia	1989	-0.2902	0.1282	53	18.3983
201461438	prevalence and correlates of dysthymia and major depression among patients with alzheimer s disease	1995	0.2364	0.079	31	0.9404
202287788	the effect of family centered empowerment model on self efficacy of caregivers from stroke patients a clinical trial study	2013	0.6283	-0.1218	42	0.7269
203462134	comparison of therapeutic response to long term treatment with lecithin versus piracetam plus lecithin in patients with alzheimer s disease	1984	-0.2979	0.2123	15	17.8194
204317067	effects of the medicare alzheimer s disease demonstration on medicare expenditures	1998	0.467	-0.0961	1	20.9927
206615762	treatment of cognitive impairment secondary to degenerative dementia effectiveness of oxiracetam therapy	1993	-0.1943	0.0545	67	0.6706
207459867	nimodipine in the treatment of alzheimer s disease	1989	-0.3258	0.1681	22	15.1107
213500300	effects of cerebrolysin on amyloid beta deposition in a transgenic model of alzheimer s disease	2002	-0.3335	0.005	70	0.75
216420585	d cycloserine a putative cognitive enhancer facilitates activation of the n methyl d aspartate receptor ionophore complex in alzheimer brain	1991	-0.2955	0.1857	43	0.75
221256982	dementia alzheimer s disease	1994	-0.3328	0.2414	59	1.6111
231699564	sustained improvement of cognition and global function in patients with moderately severe alzheimer s disease a double blind placebo controlled study with the neurotrophic agent cerebrolysin	2002	-0.3335	0.005	70	0.75
236401370	neuropsychological testing profiles of patients with alzheimer s disease and mild cognitive impairment a case control study	2002	-0.2055	-0.1492	49	0.7206
246050520	glucose effects on complex memory and nonmemory tasks the influence of age sex and glucoregulatory response	1994	-0.4598	1.8033	96	0.7993
249642082	donepezil in patients with alzheimer s disease a critical appraisal of the ad2000 study die ad2000 studie	2005	-0.3242	0.1168	33	0.8024
250380657	novel neuritic clusters with accumulations of amyloid precursor protein and amyloid precursor like protein 2 immunoreactivity in brain regions damaged by thiamine deficiency	1996	-0.7867	-0.0986	86	0.845
250632415	treatment of dementia and behavioral disorders impact of medicare part d on the care of nursing home residents	2008	0.4399	-0.0044	104	0.7927
277000499	hydergin therapy of cerebrovascular insufficiency in patients requiring digitalis results of a double blind study author s transl	1979	-0.2966	0.1463	41	0.6237
279595965	ginkgo biloba extract in the treatment of cerebral disorders due to aging	1988	-0.4758	-0.0347	132	0.6774
289101649	treatment for hypertension interrupted by placebo the response of patients with high and low general health questionnaire scores	1986	-0.7628	-0.1427	135	0.735
310242731	the efficacy of cerebrolysin in patients with vascular dementia results of a chinese multicentre randomised double blind placebo controlled trial	1999	-0.727	0.0219	107	0.6942
316348488	double blind placebo controlled study with citicoline in apoe genotyped alzheimer s disease patients effects on cognitive performance brain bioelectrical activity and cerebral perfusion	1999	-0.3722	-0.2542	62	3.4295
325440780	naproxen and celecoxib do not prevent ad in early results from a randomized controlled trial	2007	-0.385	-0.0864	32	9.5705
343511078	clinical experience with donepezil aricept in the uk	1998	-0.0769	0.0702	58	1.5176
348364414	metal protein attenuation with iodochlorhydroxyquin clioquinol targeting a amyloid deposition and toxicity in alzheimer disease	2003	-1.0858	-0.5722	69	14.4097
362000470	treatment of old age disorders with ginkgo biloba extract	1988	-0.4764	-0.0354	132	0.6684
362823485	anti dementia agents research and prospects for therapy	1994	-0.2909	0.1288	53	0.7739
407946625	effects of oral premedication on cognitive status of elderly patients undergoing cardiac catheterization	2015	2.3431	0.1892	103	14.2204
417407611	therapy of alzheimer s dementia	1998	-0.3311	0.2607	59	0.7617
418428377	3dsrt evaluation of responses of alzheimer type dementia to donepezil hydrochloride therapy	2006	-0.2941	0.1105	50	0.7895
424992731	cognitive neuropsychology of alzheimer s disease	2004	-0.5335	0.384	73	1.4514
429500722	family caregivers of persons with dementia helping the caregivers make decisions	2000	0.6888	-0.1557	76	0.8471
569868034	alzheimer s disease senile dementia and related disorders	1978	-0.384	0.3371	59	0.8116
570103986	clinical evaluation of renoscintiphoto with 99mtc ca gluconate	1975	-0.393	0.3617	106	0.7583
578040726	effects of hormone therapy on cognition and mood in recently postmenopausal women findings from the randomized controlled keeps cognitive and affective study	2015	-0.7355	-0.7379	3	0.845
587138941	experience sampling based personalized feedback and positive affect a randomized controlled trial in depressed patients	2015	-0.3094	-0.1485	45	1.39
606983894	recently reduced hospital stay for elderly patients with colorectal cancer undergoing surgery by decreased frequency of surgical site infection and delirium	2008	2.7899	-0.0532	118	0.8252
609368839	a cognitive neuropsychological approach to alzheimer s disease	2003	-0.5186	0.3694	73	0.7656
639125329	diagnosis and treatment of senile dementia	1989	-0.3136	0.1226	53	1.7707
752895202	mrc bhf heart protection study of cholesterol lowering with simvastatin in 20536 high risk individuals a randomised placebo controlled trial commentary	2002	-0.7845	-0.1874	88	29.98
807064435	a study on gerontological nursing the effects of group reminiscence on depression of the elderly	1990	0.3574	-0.0939	39	0.8001
861539075	cognitive training in senile dementia	2005	-0.3847	0.3365	59	0.7999
958305217	deprenyl monotherapy improves visuo motor control in early parkinsonism	1998	-0.1918	0.1108	137	0.655
961590786	brain selective inhibition of acetylcholinesterase a novel approach to therapy for alzheimers disease	1993	-0.2806	0.1134	13	0.75
964391196	effects of the minnesota adaptation of the nyu caregiver intervention on depressive symptoms and quality of life for adult child caregivers of persons with dementia	2015	0.6566	-0.1432	75	0.7889
983575889	donepezil in vascular dementia profile report	2012	-0.3243	0.1121	33	0.9198
986586835	nicergoline a drug for dementia and vertigo	2004	-0.3852	0.1417	134	0.6586
1000383428	drug and exercise treatment of alzheimer disease and mild cognitive impairment a systematic review and meta analysis of effects on cognition in randomized controlled trials	2015	-0.2626	0.1647	9	0.6696
1015245030	a multicenter randomized double blind study of ginkgo biloba extract versus placebo in the treatment of tinnitus	1988	-0.4812	-0.0642	68	0.8486
1025968586	exogenous melatonin for delirium prevention a meta analysis of randomized controlled trials	2016	2.2034	-0.044	2	0.845
1032266713	treatment of mild and moderate alzheimer s disease	2013	-0.3118	0.0161	57	0.736
1114077364	ginkgo biloba extract egb 761 from an ancient asian plant to a modern european herbal medicinal product	2013	-0.3729	-0.0411	8	0.7993
1158443606	memantine and functional communication in alzheimer s disease results of a 12 week international randomized clinical trial	2012	-0.1848	0.1075	6	0.8113
1176695932	everyday cognition in adulthood and late life planning practical memory training for the aged	1989	0.5103	-0.2866	4	0.7993
1210611770	a randomized controlled trial to evaluate the efficacy of community based physical therapy in the treatment of people with rheumatoid arthritis	1998	-0.2945	-0.1543	45	0.6853
1212254261	comparison of motor performance of upper and lower extremities in dual task tests in patients with mild alzheimer s dementia	2016	-0.2939	0.1114	50	0.6801
1212742152	treatment options the latest evidence with galantamine reminyl	2002	-0.34	0.0345	12	0.8733
1215156841	cognitive enhancement effect of piracetam in patients with mild cognitive impairment and dementia	2000	-0.8148	0.8226	102	0.6837
1257711658	the effect of ginkgo biloba extract on neurophysiological and psychometric measurement results in patients with psychotic organic brain syndrome a double blind study against placebo	1989	-0.4651	-0.0509	8	23.2684
1275357281	omega 3 fatty acids and cardiovascular disease effects on risk factors molecular pathways and clinical events	2011	-1.2428	-0.3453	83	1
1275714076	iti 007 for the treatment of schizophrenia a 4 week randomized double blind controlled trial	2016	-0.1168	0.194	114	0.6897
1278992780	treatment of psychotic symptoms in alzheimer s patients	1990	0.3085	0.1434	81	0.846
1412043633	evaluation of visinin like protein 1 concentrations in the cerebrospinal fluid of patients with mild cognitive impairment as a dynamic biomarker of alzheimer s disease	2015	-0.2942	0.0285	57	0.6758
1414330075	ginkgo biloba for mild cognitive impairment and alzheimer s disease a systematic review and meta analysis of randomized controlled trials	2015	-0.375	-0.0366	70	0.7018
1469350553	an innovative intervention for the treatment of cognitive impairment emisymmetric bilateral stimulation improves cognitive functions in alzheimer s disease and mild cognitive impairment an open label study	2015	-0.1591	0.0558	67	0.6671
1472735294	a longitudinal study of alzheimer s disease measurement rate and predictors of cognitive deterioration	1994	-0.3304	-0.0056	63	0.9939
1478466572	physical restraint use a nursing perspective	2006	0.8093	-0.0994	42	0.916
1480998451	randomized controlled trial of a dementia care programme for families of home resided older people with dementia	2011	0.5526	-0.1252	77	23.0709
1481319827	a cluster randomized controlled trial of nonpharmacological interventions for old old subjects with a clinical dementia rating of 0 5 the kurihara project	2015	0.305	-0.0919	39	0.7272
1481722063	neuroleptic drug therapy in older adults newly admitted to nursing homes incidence dose and specialist contact	2004	0.2168	0.063	16	0.8843
1484005344	neonatal alcohol exposure induces long lasting impairment of visual cortical plasticity in ferrets	2003	-0.3068	0.1281	23	0.7993
1484410800	reality orientation psychological approaches to the confused elderly	1982	0.3227	-0.0922	10	0.9713
1484723468	cognitive features of vascular dementia	2012	-0.8148	0.8226	102	0.743
1485441779	increasing enjoyable activities to treat depression in nursing home residents with dementia a pilot study	2015	0.3956	-0.1048	39	0.7656
1487214404	pain status and sedation level in chinese children after cardiac surgery an observational study	2013	2.345	0.1894	103	0.6985
1487299295	cognitive motor intervention in alzheimer s disease long term results from the maria wolff trial	2015	-0.103	-0.096	8	0.6996
1488503034	acute nephritisa clinical study	1950	-0.393	0.3617	106	0.6822
1488741256	clioquinol review of its mechanisms of action and clinical uses in neurodegenerative disorders	2012	-1.0873	-0.5741	69	0.6864
1489084548	vinpocetine for cognitive impairment and dementia	2003	-0.3113	0.066	23	1.6904
1489480588	special care facility compared with traditional environments for dementia care a longitudinal study of quality of life	2004	0.6719	-0.0195	24	20.4496
1491098250	the relationship between a dementia diagnosis chronic illness medicare expenditures and hospital use	2004	0.5772	-0.1221	139	0.812
1491512019	cognitive impairment improves the predictive validity of the phenotype of frailty for adverse health outcomes the three city study	2009	0.5372	-0.2244	136	0.9939
1492022253	retrospective study on the benefits of combined memantine and cholinesterase inhibitor treatment in aged patients affected with alzheimer s disease the memage study	2014	-0.4204	-0.0632	82	0.7721
1492264953	effects of high frequency cranial electrostimulation on the rest activity rhythm and salivary cortisol in alzheimer s disease a pilot study	2006	0.3298	-0.0249	89	15.4143
1492360652	multi infarct dementia a cause of mental deterioration in the elderly	1974	-0.4582	-0.008	12	1.6836
1493773294	sf 36 health survey manual and interpretation guide	1993	-0.235	0.1992	9	0.7993
1493802553	interventions for preventing delirium in hospitalised patients	2007	2.2034	-0.044	2	0.845
1494057233	a randomized study of h3 antagonist abt 288 in mild to moderate alzheimer s dementia	2014	-0.3071	0.0257	23	1.3519
1494210462	dimebon and tacrine inhibit neurotoxic action of ?? amyloid in culture and block l type ca2 channels	2001	-0.5864	-0.1755	32	1
1494495319	cost effectiveness of memantine in alzheimer s disease an analysis based on a probabilistic markov model from a uk perspective	2004	-0.1709	0.0188	6	0.9997
1494673978	interventions for family caregivers of people with dementia	2008	0.6888	-0.1557	76	0.8478
1494951211	cost evaluation of a coordinated care management intervention for dementia	2009	0.5525	-0.1153	74	18.9675
1495177506	the effect of a disease management intervention on quality and outcomes of dementia care	2006	0.5734	-0.1262	74	1
1496380193	clinical aspects of alzheimer s disease and senile dementia	1981	-0.3847	0.3365	59	0.8267
1497087603	bipolar rapid cycling focus on depression as its hallmark	2001	0.1724	0.0879	16	0.9584
1497188297	unmet care needs and key outcomes in dementia	2005	0.5272	-0.0877	34	0.6786
1497461844	effects of different blood pressure lowering regimens on major cardiovascular events results of prospectively designed overviews of randomised trials	2003	-0.7617	-0.1539	14	0.9584
1497505709	atorvastatin for the treatment of mild to moderate alzheimer disease	2016	-0.3264	0.168	22	0.7319
1497950198	a retrospective study of cranial strain patterns in patients with idiopathic parkinson s disease	2002	0.2293	-0.2025	111	0.665
1498824860	continuous positive airway pressure reduces subjective daytime sleepiness in patients with mild to moderate alzheimer s disease with sleep disordered breathing	2006	0.2286	-0.0028	28	0.9973
1498917275	cognitive performance in alzheimer s disease patients receiving rivastigmine for up to 5 years	2005	-0.2245	0.0486	6	0.9988
1498935030	memantine improves goal attainment and reduces caregiver burden in parkinson s disease with dementia	2014	-0.1906	0.1279	11	14.7272
1499626471	why do we use physical restraints in the elderly	2005	0.8052	-0.0984	42	3.8448
1500332487	managing behavioral disturbances with psychoactive medications dos don ts and maybes	2013	0.3078	0.1426	81	0.6503
1500418897	the time course of alcohol impairment of general aviation pilot performance in a frasca 141 simulator	1993	-0.3865	0.3792	98	0.6722
1500434268	r e m psychotherapy a manualized approach for long term care residents with depression and dementia	2003	0.5971	-0.1331	131	0.7049
1500963439	major outcomes in moderately hypercholesterolemic hypertensive patients randomized to pravastatin vs usual care	2002	-0.7874	-0.189	88	3
1502336239	a systematic review of the use of aromatherapy in treatment of behavioral problems in dementia	2012	0.4044	-0.0336	34	2.7968
1502524639	mrc bhf heart protection study of cholesterol lowering with simvastatin in 5963 people with diabetes a randomised placebo controlled trial	2003	-0.7878	-0.1893	88	1.9999
1502593341	a prospective study of caregiver burden in an outpatient comprehensive geriatric assessment program	2006	0.6788	-0.15	75	0.7775
1503127833	effect of institutional respite care on the sleep of people with dementia and their primary caregivers	2007	0.559	-0.1168	142	0.8843
1503430420	donepezil in patients with severe alzheimer s disease double blind parallel group placebo controlled study	2006	-0.3718	0.0869	51	1.2854
1503668654	efficacy safety and tolerability of sertraline in patients with late life depression and comorbid medical illness	2004	0.103	0.1503	61	0.7342
1503881649	restoration of lipoxin a4 signaling reduces alzheimer s disease like pathology in the 3xtg ad mouse model	2015	-1.1027	-0.3021	5	0.75
1504599825	the effect of changing practice on fall prevention in a rehabilitative hospital the hospital injury prevention study	2004	2.2795	-0.0629	35	0.7993
1506516887	development and consequences of group living in sweden a new mode of care for the demented elderly	1993	0.6741	-0.0194	24	0.9584
1506742695	lithium red blood cell choline and clinical state a prospective study in manic depressive patients	1984	-0.4086	0.3103	120	0.6191
1507048682	outcomes of a randomized controlled trial of a clinical pharmacy intervention in 52 nursing homes	2008	0.624	-0.0219	52	3.907
1507257305	memantine and brain atrophy in alzheimer s disease a 1 year randomized controlled trial	2012	-0.2216	0.0118	46	15.5526
1507603519	piracetam induced improvement of mental performance a controlled study on normally aging individuals	1976	-0.3162	0.2611	15	18.0347
1508233557	the caregiver a life with alzheimer s	1999	-2.1425	2.1685	121	0.9324
1509364606	interventions for preventing and reducing the use of physical restraints in long term geriatric care	2011	0.8044	-0.0983	42	3.9521
1510386580	the savvy caregiver program the demonstrated effectiveness of a transportable dementia caregiver psychoeducation program	2007	0.5065	-0.1088	1	1.69
1511144845	can vitamin d supplementation prevent winter time blues a randomised trial among older women	2006	-0.9263	-0.257	79	0.7232
1511517753	association of missense and 5 splice site mutations in tau with the inherited dementia ftdp 17	1998	-0.2343	0.2592	66	0.9713
1511644762	family care as collaboration effectiveness of a multicomponent support program for elderly couples with dementia randomized controlled intervention study	2009	0.5448	-0.1162	74	7.3903
1511725268	a placebo controlled trial of atomoxetine in marijuana dependent individuals with attention deficit hyperactivity disorder	2010	-0.9922	1.2607	71	0.7948
1511946053	randomized clinical trial of daily aspirin therapy in multi infarct dementia a pilot study	1989	-0.4329	0.005	12	3.7211
1511972530	efficacy of rivastigmine on executive function in patients with parkinson s disease dementia	2010	-0.1859	0.0724	7	17.2527
1512073368	telephone based cognitive behavioral intervention for distressed rural dementia caregivers initial findings	2007	0.5947	-0.1331	131	15.9719
1512346046	multidisciplinary case conference reviews improving outcomes for nursing home residents carers and health professionals	2001	0.6316	-0.0227	52	0.9804
1512883130	efficacy and adverse effects of ginkgo biloba for cognitive impairment and dementia a systematic review and meta analysis	2015	-0.3761	0.0273	8	2.5438
1513458054	two randomized placebo controlled trials to evaluate the efficacy and tolerability of mirtazapine for the treatment of obstructive sleep apnea	2008	0.2286	-0.0028	28	0.9713
1513881453	age varying association between statin use and incident alzheimer s disease	2010	-0.7284	-0.1718	29	0.9973
1514186423	efficacy and safety of ginkgo biloba extract egb 761 in mild cognitive impairment with neuropsychiatric symptoms a randomized placebo controlled double blind multi center trial	2014	-0.4328	-0.0459	8	0.7993
1514206567	effects of ginkgo biloba extract egb 761 on neuropsychiatric symptoms of dementia findings from a randomised controlled trial	2007	-0.3657	-0.0493	8	19.1599
1515922783	hypertension and health related quality of life an epidemiological study in sweden	2001	-0.7617	-0.1539	14	0.916
1516041574	recovery from mild traumatic brain injury a focus on fatigue	2006	-1.1671	1.5699	64	0.7993
1516497081	a meta analysis of chinese herbal medicines for vascular dementia	2013	-0.375	-0.0366	70	0.6814
1516672349	effect of antipsychotic withdrawal on behavior and sleep wake activity in nursing home residents with dementia a randomized placebo controlled double blinded study the bergen district nursing home study	2004	0.209	0.0685	16	23.4824
1516724348	homocysteine a marker for cognitive performance a longitudinal follow up study	2003	-0.8796	-0.1043	30	0.9973
1520788160	the science of caregiver health	2015	0.5963	-0.1335	131	0.7427
1520905257	a group music intervention using percussion instruments with familiar music to reduce anxiety and agitation of institutionalized older adults with dementia	2012	0.4784	-0.0481	21	6.6396
1521192950	clinical and neuropsychological differences between mild parkinson s disease dementia and dementia with lewy bodies	2015	-0.1955	0.1283	7	0.8052
1521575886	high intensity environmental light in dementia effect on sleep and activity	2007	0.2903	-0.0163	17	5.7216
1522284801	a phase ii trial of tideglusib in alzheimer s disease	2015	-0.2556	0.0452	44	2.1939
1522413381	a multifactorial intervention program reduces the duration of delirium length of hospitalization and mortality in delirious patients	2005	2.1715	-0.045	2	3.9957
1522731215	longitudinal studies of cerebral glucose metabolism in late life depression and normal aging	2013	-0.4858	0.0852	117	0.7015
1522883215	targeted recruitment using cerebrospinal fluid biomarkers implications for alzheimer s disease therapeutic trials	2013	-0.295	0.0288	57	0.6769
1523783122	folic acid with or without vitamin b12 for cognition and dementia	2003	-0.8679	-0.1025	30	1.9543
1524130947	the effect of pharmacologic treatment of depression on glycated hemoglobin and quality of life in low income hispanics and african americans with diabetes a randomized double blind placebo controlled trial	2009	-0.7628	-0.1427	135	0.7437
1524488956	effects of moderate blood alcohol levels on automobile passing behavior	1969	-0.387	0.3785	98	0.68
1524687784	postoperative delirium in the elderly	2008	2.7899	-0.0532	118	0.8497
1524788255	the life review an interpretation of reminiscence in the aged	1963	0.3524	-0.0919	39	1.9404
1524848204	the effect of a high intensity functional exercise program on activities of daily living a randomized controlled trial in residential care facilities	2009	0.4421	-0.1145	60	18.1996
1524993883	stopp screening tool of older person s prescriptions and start screening tool to alert doctors to right treatment consensus validation	2008	0.7088	-0.0469	52	0.845
1525762719	effectiveness of collaborative care for older adults with alzheimer disease in primary care	2017	0.556	-0.1218	74	1
1526393440	placebo controlled cross over study of the monoaminergic stabiliser osu6162 in mental fatigue following stroke or traumatic brain injury	2012	-1.1658	1.568	64	16.8944
1526712561	can high risk older drivers be identified through performance based measures in a department of motor vehicles setting	2006	0.4853	-0.2604	4	1
1526927233	intensive blood glucose control and vascular outcomes in patients with type 2 diabetes	2008	-0.4341	1.494	56	1.9117
1527550792	extinction of fear potentiated startle blockade by infusion of an nmda antagonist into the amygdala	1992	-0.2951	0.1867	43	3.6351
1528771930	a randomized placebo controlled pilot trial of omega 3 fatty acids and alpha lipoic acid in alzheimer s disease	2014	-1.0536	-0.2883	5	1.5895
1529409337	cognitive stimulation to improve cognitive functioning in people with dementia	2012	0.2632	-0.0969	10	10.581
1530028553	brain plasticity and functional losses in the aged scientific bases for a novel intervention	2006	0.4694	-0.2466	4	1
1530651870	pharmacological management of huntington s disease an evidence based review	2006	-0.2288	-0.146	112	0.991
1530780272	statins for the prevention of dementia	2016	-0.7118	-0.1663	29	3.9401
1531404083	research criteria for subcortical vascular dementia in clinical trials	2000	-0.4521	-0.0063	12	3.5664
1532904557	d cycloserine a ligand for the n methyl d aspartate coupled glycine receptor has partial agonist characteristics	1989	-0.2884	0.1742	43	2.7552
1532918229	pharmacological treatment of alzheimer s disease molecular and neurobiological foundations	1997	-0.5495	0.3992	73	0.6699
1533053737	ginkgo biloba in alzheimer s disease a systematic review	2010	-0.4068	-0.051	8	0.9713
1534112212	treatment of bipolar mixed state with olanzapine	1999	-0.3438	0.2071	126	0.8302
1534458874	randomized controlled trial of a nonpharmacological intervention to improve abnormal sleep wake patterns in nursing home residents	2005	0.284	-0.017	17	4.992
1534541163	comparing treatment effects in a clinical sample of patients with probable alzheimer s disease treated with two different cholinesterase inhibitors	2007	-0.0587	0.0835	58	0.7312
1536395981	association between apolipoprotein e4 and cognitive decline in elderly adults	2007	-0.7693	-0.1855	29	19.5563
1537015532	ginkgo for elderly people with dementia and age associated memory impairment a randomized clinical trial	2003	-0.4201	-0.0689	8	6.8251
1537132448	pain in elderly people with severe dementia a systematic review of behavioural pain assessment tools	2006	0.8524	-0.0192	95	0.916
1538108915	ht1001 a proprietary north american ginseng extract improves working memory in schizophrenia a double blind placebo controlled study	2012	-0.2406	0.1647	9	14.3499
1538304336	memantine in behavioral variant frontotemporal dementia negative results	2011	-0.2335	0.2595	66	0.9939
1539182721	cognitive behavioral group intervention for spousal caregivers findings and clinical considerations	1996	0.5511	-0.1131	1	1.9777
1540086567	effect of a pharmacist led multicomponent intervention focusing on the medication monitoring phase to prevent potential adverse drug events in nursing homes	2011	0.7075	-0.0475	52	17.0867
1542518859	effects of piracetam on pediatric breath holding spells a randomized double blind controlled trial	2012	-0.3807	-0.2165	45	0.7368
1542573415	subtle cognitive impairment in elders with mini mental state examination scores within the normal range	2012	-0.0756	-0.1034	127	0.761
1542808053	effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults meta analysis of randomised trials	2008	-0.7617	-0.1539	14	0.916
1543174448	additional donepezil treatment for patients with geriatric depression who exhibit cognitive deficit during treatment for depression	2016	0.0094	0.1147	61	1.5052
1543276608	brief psychotherapy for caregivers of demented relatives	1988	0.5589	-0.1149	1	0.9713
1543424815	an evaluation of an adapted u s model of pharmaceutical care to improve psychoactive prescribing for nursing home residents in northern ireland fleetwood northern ireland study	2010	0.6504	-0.0293	52	2.7552
1543977399	rehabilitation of older adults with hip fracture cognitive function and walking abilities	2011	2.1047	-0.0879	26	0.7683
1544359545	geriatric depression scale gds recent evidence and development of a shorter version	1986	0.4834	-0.1436	60	0.916
1545435867	efficacy of memantine in delaying clinical worsening in alzheimer s disease ad responder analyses of nine clinical trials with patients with moderate to severe ad	2012	-0.0752	0.0673	58	1.4431
1546258268	high dose atorvastatin after stroke or transient ischemic attack	2006	-0.7268	-0.1692	29	0.9992
1546985873	catecholamine based treatment in ad patients expectations and delusions	2015	-0.3852	0.1417	134	0.6265
1547474569	effects on transthyretin in plasma and cerebrospinal fluid by dha rich n 3 fatty acid supplementation in patients with alzheimer s disease the omegad study	2013	-1.2086	-0.3339	128	14.2991
1548313603	the effect of therapeutic touch on behavioral symptoms of persons with dementia	2005	0.4489	-0.0393	21	0.9867
1548328331	progressive resistance strength training for improving physical function in older adults	2009	0.4434	-0.115	60	0.9404
1549000600	a higher dose of vitamin d reduces the risk of falls in nursing home residents a randomized multiple dose study	2007	-0.7348	-0.7384	3	0.7993
1551465153	a two part double blind placebo controlled trial of exogenous melatonin in rem sleep behaviour disorder	2010	-0.1493	0.1232	7	0.916
1551512084	dementia treatment let the evidence lead us	2007	-0.2909	0.1288	53	0.7611
1551592423	the effect of castration and peroral estrogen therapy on some psychological functions	1975	-0.7637	-0.7724	3	1
1551599804	donepezil for mild and moderate alzheimer s disease	2000	-0.311	0.0163	57	0.7322
1551823461	efficacy and safety of rivastigmine in patients with alzheimer s disease international randomised controlled trial	1999	-0.2269	0.0477	6	54.2015
1553319073	rivastigmine for vascular cognitive impairment	2013	-0.4516	-0.0103	12	0.8843
1554742340	medication review in hospitalised patients to reduce morbidity and mortality	2016	0.7094	-0.0475	52	0.7993
1554973131	a comparison of in home and telephone based skill training interventions with caregivers of persons with demetia	2004	0.552	-0.1209	1	0.9584
1555352193	new alzheimer disease target identified	2004	-0.4424	0.2875	105	0.851
1555463606	the effects of blood pressure lowering on development of cognitive impairment and dementia in patients without apparent prior cerebrovascular disease	2006	-0.6781	-0.1152	14	0.845
1555603004	a double blind trial of divalproex sodium for affective lability and alcohol use following traumatic brain injury	2009	-0.9922	1.2607	71	0.7065
1556459511	effects of a newly developed cognitive intervention in amnestic mild cognitive impairment and mild alzheimer s disease a pilot study	2011	0.1975	-0.1073	10	20.3056
1557656840	cognitive impairment in hip fracture patients timing of detection and longitudinal follow up	2003	1.9722	-0.088	26	0.9998
1558552946	microbiological assay for serum plasma and red cell folate using cryopreserved microtiter plate method	1997	-1.9284	0.3325	109	0.75
1558886884	rivastigmine monotherapy and combination therapy with memantine in patients with moderately severe alzheimer s disease who failed to benefit from previous cholinesterase inhibitor treatment	2005	-0.2121	0.053	72	1.7645
1559840592	a novel once daily fixed dose combination of memantine extended release and donepezil for the treatment of moderate to severe alzheimer s disease two phase i studies in healthy volunteers	2015	-0.2408	0.0602	19	0.7733
1559861699	dimebon latrepirdine enhances mitochondrial function and protects neuronal cells from death	2010	-0.586	-0.1761	32	1
1560062315	n 3 fatty acids and cardiovascular outcomes in patients with dysglycemia	2012	-1.2428	-0.3453	83	1
1560155389	functional outcomes for older adults with cognitive impairment in a comprehensive outpatient rehabilitation facility	2005	2.1229	-0.0869	26	0.7658
1561839887	effect of nursing implemented sedation and pain protocol on the level of sedation pain and amount of sedative and analgesic drugs use among opium addicted critically ill patients	2013	2.345	0.1894	103	0.7
1562784076	quantifying the performance impairment associated with fatigue	2002	-0.387	0.3785	98	0.6848
1564210886	respite services for caregivers research findings for service planning	1989	0.6846	-0.1439	97	14.1554
1564414202	respite care for people with dementia and their carers	2014	0.559	-0.1168	142	0.7993
1564566531	two year effects of interdisciplinary intervention for hip fracture in older taiwanese	2010	2.1135	-0.0877	26	1.5635
1564588342	the ginkgo biloba extract egb 761 protects and rescues hippocampal cells against nitric oxide induced toxicity involvement of its flavonoid constituents and protein kinase c	2002	-0.4161	-0.0871	8	0.9939
1565175854	therapeutic application of melatonin in mild cognitive impairment	2012	0.196	-0.0167	28	0.916
1565469103	huperzine a for alzheimer s disease	2008	-0.5779	-0.1503	32	0.9973
1565676850	a randomized comparison of transfusion triggers in elective orthopaedic surgery using leucocyte depleted red blood cells	2010	2.566	-0.0494	125	0.7993
1565992055	pharmacological basis for the use of nimodipine in central nervous system disorders	1989	-0.345	0.1098	53	1.8254
1566188171	the clinical effects of prolonged intravenous infusion of 5 fluoro 2 deoxyuridine	1965	-0.6082	0.5205	119	0.6148
1567727779	yoga enhanced cognitive behavioural therapy y cbt for anxiety management a pilot study	2015	0.7627	-0.2018	77	0.7965
1568292060	effects of buspirone and alprazolam on the cognitive performance of normal elderly subjects	1991	-0.4206	0.335	90	0.6343
1568866447	apolipoprotein e genotype specific short term cognitive benefits of treatment with the antihypertensive nilvadipine in alzheimer s patients an open label trial	2011	-0.2626	0.1647	9	0.6587
1569199809	alpha tocopherol and alzheimer s disease	1997	-0.4411	0.2863	105	17.4659
1569560629	cognitive rehabilitation group intervention for breast cancer survivors results of a randomized clinical trial	2015	-0.24	-0.2603	49	0.7356
1572889932	rivastigmine patch for treatment of alzheimer s disease in clinical practice in thailand	2013	-0.2355	0.0389	72	1.6902
1574002312	progressively lowered stress threshold a conceptual model for care of adults with alzheimer s disease	1987	0.5294	-0.0474	21	4.9074
1575078744	clinical efficacy and safety of donepezil on cognitive and global function in patients with alzheimer s disease a 24 week multicenter double blind placebo controlled study in japan e2020 study group	2000	-0.2361	0.0453	6	4.7627
1575781473	acute and hang over effects of alcohol on simulated driving performance	1991	-0.3865	0.3792	98	0.6607
1575834956	evidence of oxidative stress in alzheimer s disease brain and antioxidant therapy lights and shadows	2008	-0.4593	-0.0962	82	0.9713
1575864823	the function of cytidine coenzymes in the biosynthesis of phospholipides	1956	-0.3989	-0.2632	62	0.9959
1576728172	physical activity and public health in older adults recommendation from the american college of sports medicine and the american heart association	2007	0.4434	-0.115	60	0.845
1577745350	memantine for patients with alzheimer disease	2004	-0.3279	0.1756	22	1.743
1578026887	determining care management activities associated with mastery and relationship strain for dementia caregivers	2008	0.6771	-0.1495	75	16.0076
1579232294	effect of a high intensity functional exercise program on functional balance preplanned subgroup analyses of a randomized controlled trial in residential care facilities	2011	0.4629	-0.1292	60	1.6443
1579439412	the effects of nicotine on parkinson s disease	2000	0.0437	0.4832	48	1
1580015543	a cluster randomized trial of an educational intervention to reduce the use of physical restraints with psychogeriatric nursing home residents	2009	0.8117	-0.0988	42	4.9776
1580727571	the effect of ambient bright light therapy on depressive symptoms in persons with dementia	2007	0.3409	-0.0185	17	0.8843
1582434190	evaluating the effectiveness of the abilities focused approach to morning care of people with dementia	2012	0.395	-0.1042	39	0.7704
1582768841	can counseling and support reduce burden and depressive symptoms in caregivers of people with alzheimer s disease during the transition to institutionalization results from the new york university caregiver intervention study	2008	0.5311	-0.1116	1	0.9713
1583101023	withdrawal versus continuation of chronic antipsychotic drugs for behavioural and psychological symptoms in older people with dementia	2013	0.1693	0.056	80	1.8834
1583233660	effect of vitamins and aspirin on markers of platelet activation oxidative stress and homocysteine in people at high risk of dementia	2003	-0.8796	-0.1043	30	0.9999
1583506515	tying down the elderly a review of the literature on physical restraint	1989	0.8432	-0.1021	42	1
1583510262	one year follow up of the effectiveness of cognitive behavioral group therapy for patients depression a randomized single blinded controlled study	2015	-0.2945	-0.1543	45	0.7039
1584077124	nimodipine for primary degenerative mixed and vascular dementia	2002	-0.4075	0.0351	12	2.7399
1584685871	effects of a restraint minimization program on staff knowledge attitudes and practice a cluster randomized trial	2010	0.8067	-0.0991	42	22.235
1584716486	piracetam induced changes to membrane physical properties a combined approach by 31p nuclear magnetic resonance and conformational analysis	1995	-0.297	0.2265	15	1.7213
1586213696	effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease	2003	-0.5545	-0.0693	14	16.472
1586276655	abstract 16291 comparing predictors of heart failure and cancer caregiver satisfaction with hospice care	2014	0.6788	-0.1499	75	0.777
1586699954	effects of conjugated equine estrogen in postmenopausal women with hysterectomy the women s health initiative randomized controlled trial	2004	-0.7375	-0.7357	3	4.9584
1586998168	extended release daily memantine provides increasing cumulative benefits across clinical domains over 24 weeks in patients with moderate to severe alzheimer s disease an analysis of area under the curve p1 006	2014	-0.1971	0.1158	92	0.9217
1587061890	treatment persistency with rivastigmine and donepezil in a large state medicaid program	2005	-0.2388	0.0516	19	0.9867
1587341957	effects of cholinesterase inhibitors in parkinson s disease dementia a review of clinical data	2011	-0.2326	0.2003	55	0.7687
1587476559	significance of brain lesions in parkinson disease dementia and lewy body dementia	2009	-0.1371	0.2011	100	0.7851
1588003045	melatonin and bright light treatment for rest activity disruption in institutionalized patients with alzheimer s disease	2008	0.276	-0.0165	17	33.8805
1588342634	effect of a dementia care management intervention on primary care provider knowledge attitudes and perceptions of quality of care	2006	0.5734	-0.1262	74	0.9994
1589943662	the mediating effect of caregiver burden on the caregivers quality of life	2015	0.6791	-0.1508	75	0.7867
1589985034	treatment of dementia	2007	-0.2909	0.1288	53	0.7892
1590217935	effectiveness of a multifactorial intervention to reduce physical restraints in nursing home residents	2011	0.8	-0.098	42	2.9011
1590691689	targeting and managing behavioral symptoms in individuals with dementia a randomized trial of a nonpharmacological intervention	2010	0.3124	-0.071	1	22.6819
1590882028	music therapy for people with dementia	2003	0.4875	-0.0565	21	11.7516
1592910843	decreasing the burden in families caring for a relative with a dementing illness a controlled study	1985	0.558	-0.115	1	1.9802
1593442063	risks and benefits of estrogen plus progestin in healthy postmenopausal women principal results from the women s health initiative randomized controlled trial	2002	-0.734	-0.7329	3	10.956
1593761167	snoezelen benefits for nursing older clients	1997	0.4308	-0.0751	18	0.8843
1594055597	the identification and treatment of depression in patients maintained on dialysis	2005	0.4586	0.2348	116	0.7656
1594480253	dementia care mapping and patient centred care in australian residential homes an economic evaluation of the care study chere working paper 2008 4	2008	0.5272	-0.0877	34	0.7072
1594718675	enantioselective organocatalytic construction of pyrroloindolines by a cascade addition cyclization strategy synthesis of flustramine b	2004	-0.3032	0.1546	13	0.75
1595046345	methods for the economic evaluation of health care programmes	1997	0.4474	-0.1029	39	1.8444
1596063778	estrogen regulates metabolism of alzheimer amyloid beta precursor protein	1994	-0.7647	-0.7717	3	0.9999
1597581696	memantine for patients with alzheimer disease	2004	-0.285	0.1562	22	1.7268
1597817261	long term metformin usage and cognitive function among older adults with diabetes	2014	-0.3415	0.9111	113	0.845
1598602811	cochrane handbook for systematic reviews of interventions	2008	0.623	-0.1181	52	1.6836
1598623386	drug treatment treatment of behavioural and psychological symptoms of dementia with neuroleptics	2006	0.5483	0.3861	40	0.7029
1598801167	adenosine and brain ischemia	1995	-0.4137	0.0257	85	0.916
1599470299	short term effect of combined drug therapy and cognitive stimulation therapy on the cognitive function of alzheimer s disease	2010	-0.2975	-0.2456	49	0.695
1599632181	efficacy of musical interventions in dementia evidence from a randomized controlled trial	2014	0.5374	-0.0515	21	1.666
1600781210	pharmacological treatment of dementia a review	2002	-0.2902	0.1292	53	0.7704
1602275009	a double blind placebo controlled study of ginkgo biloba extract tanakan in elderly outpatient	1991	-0.4838	-0.0687	68	1.4759
1603277425	safety and tolerability of rivastigmine transdermal patch compared with rivastigmine capsules in patients switched from donepezil data from three clinical trials	2009	-0.251	0.0533	72	2.5536
1605020189	memantine is associated with longer survival than donepezil in a veterans affairs prescription database 1997 to 2008	2013	-0.0769	0.0701	58	1.5239
1605572142	risk factors associated with cognitive decline in the elderly with type 2 diabetes pooled logistic analysis of a 6 year observation in the japanese elderly diabetes intervention trial	2012	-0.4276	1.4428	56	0.7817
1605682576	risk factors for preoperative and postoperative delirium in elderly patients with hip fracture	2009	2.1944	-0.0495	2	0.7993
1606270551	physical frailty is associated with incident mild cognitive impairment in community based older persons	2010	0.538	-0.2242	136	0.9404
1607135210	cognitive function over time in the alzheimer s disease anti inflammatory prevention trial adapt results of a randomized controlled trial of naproxen and celecoxib	2008	-0.4359	-0.087	32	3.9977
1608072969	vascular care in patients with alzheimer s disease with cerebrovascular lesions a randomized clinical trial	2009	-0.0938	0.0049	84	0.7382
1608419697	effect of exogenous melatonin on sleep and motor dysfunction in parkinson s disease a randomized double blind placebo controlled study	2007	0.2052	-0.0173	28	1.8753
1608626424	music therapy in dementia a narrative synthesis systematic review	2013	0.5051	-0.0542	21	3.6695
1625449562	the use of melatonin in alzheimer s disease	2002	0.2505	-0.0163	28	2.9988
1630027882	depression and alzheimer s disease	1989	0.2932	0.0794	31	1
1632666839	postoperative blood transfusion strategy in frail anemic elderly patients with hip fracture the trife randomized controlled trial	2015	2.5659	-0.0494	125	0.845
1633272553	how does xenon produce anaesthesia	1998	3.1472	0.1092	110	0.75
1636066922	use of wrist activity for monitoring sleep wake in demented nursing home patients	1997	0.2992	-0.0174	17	1
1638784138	negative symptoms a path analytic approach to a double blind placebo and haloperidol controlled clinical trial with olanzapine	1997	0.6426	0.1008	91	0.75
1644143258	the global deterioration scale for assessment of primary degenerative dementia	1982	0.31	-0.0028	24	5.2129
1649820184	a multicenter placebo controlled trial of melatonin for sleep disturbance in alzheimer s disease	2003	0.2504	-0.015	28	32.8234
1654871652	neuropharmacologic investigation of the serotonin responsiveness in alcohol dependent patients and healthy probands	2008	-0.6362	0.0864	122	0.7317
1656430147	efficacy of risperidone treatment for psychoses associated with schizophrenia schizoaffective disorder bipolar disorder or senile dementia in 11 geriatric patients a case series	1995	0.617	0.4432	40	0.7578
1657459197	chronic behavioral disorders of human rem sleep a new category of parasomnia	1986	-0.1493	0.1232	7	0.8843
1661237936	cognitive changes associated with supplementation of testosterone or dihydrotestosterone in mildly hypogonadal men a preliminary report	2003	-0.9327	-1.0635	54	1
1661354326	cost effectiveness of memantine in moderately severe to severe alzheimer s disease a markov model in finland	2004	-0.1709	0.0188	6	0.9988
1662617756	effects of memantine on cerebrospinal fluid biomarkers of neurofibrillary pathology	2009	-0.2942	0.0285	57	0.7198
1663655962	a community based exercise programme to improve functional ability in people with alzheimer s disease a randomized controlled trial	2012	0.4895	-0.1929	25	22.8363
1665327661	effects of supplementation with omega 3 fatty acids on oxidative stress and inflammation in patients with alzheimer s disease the omegad study	2014	-1.1782	-0.3254	129	15.3596
1665868571	pragmatic cluster randomized trial of a policy to introduce low low beds to hospital wards for the prevention of falls and fall injuries	2010	2.2795	-0.0629	35	0.75
1672491049	effects of rivastigmine in alzheimer s disease patients with and without hallucinations	2010	-0.2332	0.0392	72	0.8054
1678920698	effects of long term vitamin e supplementation on cardiovascular events and cancer a randomized controlled trial	2005	-0.291	0.0713	37	0.7993
1687870758	hands touching hands affective and evaluative effects of an interpersonal touch	1976	0.5917	-0.0633	123	0.916
1688235741	psychiatric symptoms and nursing home placement of patients with alzheimer s disease	1990	0.2364	0.079	31	0.916
1693283493	immunization with amyloid ?? attenuates alzheimer disease like pathology in the pdapp mouse	1999	-0.4554	-0.0701	32	9.6018
1694591858	antipsychotics for delirium	2007	2.1517	-0.0415	2	1.9987
1704771326	behavioral symptoms in alzheimer s disease phenomenology and treatment	1987	0.0983	0.0934	16	8.3668
1707893729	sleep disorders in chronic traumatic brain injury	2007	-1.2578	1.7621	64	0.9988
1710061474	natural substances in psychiatry ginkgo biloba in dementia	1995	-0.4703	-0.0569	8	1.8317
1710857609	effects of low dose milnacipran on event related potentials and neuropsychological tests in persons with traumatic brain injury a preliminary study	2015	-0.9923	1.2607	71	0.6997
1714082650	the impact of cognitive skills remediation training on persons with alzheimer s disease or mixed dementia	1988	0.2852	-0.0909	10	18.2075
1718995988	effect of tetrahydroaminoacridine on cognition function and behaviour in alzheimer s disease	1991	-0.0746	0.063	58	0.6916
1719028472	why vitamin e therapy fails for treatment of alzheimer s disease	2010	-0.4593	-0.0954	82	0.9713
1725880273	category verbal fluency predicted changes in behavioral and psychological symptoms of dementia in patients with alzheimer s disease	2010	-0.3727	-0.0416	8	0.7626
1726357000	donepezil for vascular cognitive impairment	2004	-0.4366	-0.0049	12	1.7685
1731253253	in situ oxidative catalysis by neurofibrillary tangles and senile plaques in alzheimer s disease a central role for bound transition metals	2001	-1.0099	-0.5237	69	1
1736669609	massage and touch for dementia	2006	0.4135	-0.041	34	0.75
1741020416	efficacy of atypical antipsychotics in elderly patients with dementia	2004	0.2804	0.1617	16	17.7909
1746728193	nighttime insomnia treatment and education for alzheimer s disease a randomized controlled trial	2005	0.3476	-0.0473	28	15.9918
1748615737	5 ht6 receptors and alzheimer s disease	2013	-1.5583	0.2212	115	0.916
1751954123	dose effects associated with rivastigmine transdermal patch in patients with mild to moderate alzheimer s disease	2011	-0.2539	0.0531	72	19.208
1752793417	omega 3 fatty acids for the treatment of dementia	2016	-1.0944	-0.2999	5	0.75
1755663836	validation therapy for dementia	2003	0.4237	-0.0807	18	2.826
1755690969	cognitive and behavioural impairment among elderly people in institutions providing different levels of care	1991	0.9833	-0.0254	24	0.7072
1759290616	efficacy and safety of donepezil galantamine rivastigmine and memantine for the treatment of alzheimer s disease a systematic review and meta analysis	2014	-0.1971	0.1158	92	0.7139
1760829075	the human brain is intrinsically organized into dynamic anticorrelated functional networks	2005	-0.2499	0.1367	22	0.9404
1761725167	risperidone for the treatment of behavioral and psychological symptoms of dementia	2001	0.4684	0.3188	40	2.329
1762583610	homocysteine b vitamins and the incidence of dementia and cognitive impairment results from the sacramento area latino study on aging	2007	-0.8831	-0.0996	30	2.845
1763233189	neuraxial block and postoperative epidural analgesia effects on outcomes in the poise 2 trial	2016	2.2338	-0.0385	36	0.7113
1764838123	three year trajectory of individuals with anxiety and related disorders following cognitive behavioural therapy	2014	0.7627	-0.2018	77	0.7847
1766482021	persons with stroke and their nursing care in nursing homes	2005	0.4399	-0.0044	104	0.8116
1766928376	physical activity and risk of cognitive decline a meta analysis of prospective studies	2011	0.4164	-0.1968	25	1.9792
1768683478	a randomized clinical trial of theory based activities for the behavioral symptoms of dementia in nursing home residents	2011	0.3971	-0.0105	104	1.7292
1768941645	distributions of spinothalamic spinohypothalamic and spinotelencephalic fibers revealed by anterograde transport of pha l in rats	1991	0.2471	-0.0142	17	0.845
1777233453	dementia reconsidered the person comes first	1997	0.4138	-0.053	18	5.7402
1780318505	the main cost drivers in dementia a systematic review	2015	0.5543	-0.1157	74	0.8315
1790080432	systematic intervention for elderly inpatients with delirium a randomized trial	1994	2.1013	-0.0419	2	1
1792189485	beyond the prescription medication monitoring and adverse drug events in older adults	2011	0.7088	-0.0469	52	0.8843
1798472641	consequences of an intervention to reduce restrictive side rail use in nursing homes	2007	0.8172	-0.0991	42	1.958
1800325447	effects of social support and education on health care costs for patients with fibromyalgia	2001	0.5272	-0.0877	34	0.6759
1806989163	a retrospective classification of diagnoses in terms of dsm 5 for patients included in randomized controlled trials of ginkgo biloba extract egb 761	2016	-0.375	-0.0366	70	0.7599
1807608602	treating youth depression and anxiety a randomised controlled trial examining the efficacy of computerised versus face to face cognitive behaviour therapy	2013	0.7627	-0.2018	77	0.7743
1809817220	efficacy of acupuncture in combination with medicine for mild cognitive impairment after cerebral infarction a randomized controlled trial	2015	-0.3807	-0.2165	45	0.66
1821528411	caregivers for people with dementia what is the family physician s role	2000	0.7067	-0.1575	76	0.7799
1822032979	relation of the tocopherol forms to incident alzheimer disease and to cognitive change	2005	-0.451	-0.1026	82	1.9909
1824226498	what kind of anaesthetic to choose during cardiac surgery	2014	3.1484	0.109	110	0.7352
1826103850	melatonin treatment stabilizes chronobiologic and cognitive symptoms in alzheimer s disease	2000	0.2504	-0.0163	28	2.9972
1829544326	prospects for better perinatal health	1980	-0.318	0.202	13	0.75
1830428226	efficacy and safety of mmfs 01 a synapse density enhancer for treating cognitive impairment in older adults a randomized double blind placebo controlled trial	2015	-0.2892	0.2921	9	1.4173
1837131274	randomized controlled trial of homocysteine lowering vitamin treatment in elderly patients with vascular disease	2005	-0.8792	-0.1019	30	6.9698
1837213935	the cognitive effects of acute administration of herbal remedies to healthy volunteers	2002	-0.6634	-0.1226	65	1.5304
1839562273	brain aging and alzheimer s disease use it or lose it	2002	0.1961	-0.0058	17	2.4654
1839590036	cognitive functioning and cortisol profiles in first episode major depression	2015	0.3279	-0.0247	89	1.421
1840516745	the effects of dl 3 n butylphthalide in patients with vascular cognitive impairment without dementia caused by subcortical ischemic small vessel disease a multicentre randomized double blind placebo controlled trial	2016	-0.0942	0.0057	84	0.7504
1844380402	vitamin e paradox in alzheimer s disease it does not prevent loss of cognition and may even be detrimental	2009	-0.4578	-0.0946	82	20.774
1847168837	mini mental state a practical method for grading the cognitive state of patients for the clinician	1975	0.0702	-0.0152	6	333.3557
1847712199	ginkgo biloba for the improvement of cognitive performance in multiple sclerosis a randomized placebo controlled trial	2007	-0.2376	0.2065	55	1.7367
1848968105	memantine improves attention and episodic memory in parkinson s disease dementia and dementia with lewy bodies	2015	-0.1951	0.1286	7	17.9721
1849554245	selegiline in the treatment of alzheimer s disease a long term randomized placebo controlled trial czech and slovak senile dementia of alzheimer type study group	1999	-0.3427	0.2061	126	17.97
1851743247	d cycloserine a partial agonist at the glycine site coupled to n methyl d aspartate receptors improves visual recognition memory in rhesus monkeys	1996	-0.2979	0.1886	43	1.9734
1851821852	physical activity programs for persons with dementia	2008	0.4498	-0.185	25	3.9167
1852716069	the factors of ketamine that affect sedation in children with oncology procedures parent satisfaction perspective	2014	2.345	0.1894	103	0.7115
1855414630	hand motor activity cognition mood and the rest activity rhythm in dementia a clustered rct	2009	0.4813	-0.1832	25	16.1721
1856038917	olanzapine for primary negative symptoms	2015	0.104	0.1382	38	0.7694
1856465854	a systematic review and meta analysis of placebo controlled antidepressant studies in people with depression and dementia	2011	0.1876	0.085	31	3.7895
1858237712	long term effectiveness of rivastigmine patch or capsule for mild to severe alzheimer s disease a meta analysis	2015	-0.234	0.0387	72	0.8414
1859924179	haloperidol for agitation in dementia	2002	0.1663	0.081	16	3.7592
1860824088	snoezelen for dementia	2002	0.4261	-0.0756	18	2.9709
1861414381	cognitive performance is associated with glucose regulation in healthy elderly persons and can be enhanced with glucose and dietary carbohydrates	2000	-0.4598	1.8033	96	0.916
1864818198	galantamine for vascular cognitive impairment	2006	-0.4304	-0.0029	12	2.7357
1866017777	efficacy and tolerability of memantine extended release added to stable donepezil regimen in individuals with moderate to severe alzheimer s disease subset analysis of a randomized clinical trial p7 101	2015	-0.2397	0.0595	19	17.2688
1867505698	overview of depression and psychosis in alzheimer s disease	1989	0.2228	0.0843	16	1.9404
1867692464	olanzapine treatment of psychotic and behavioral symptoms in patients with alzheimer disease in nursing care facilities a double blind randomized placebo controlled trial	2000	0.1675	0.0842	16	47.5487
1869333042	pharmacological studies supporting the therapeutic use of ginkgo biloba extract for alzheimer s disease	2003	-0.424	-0.0718	8	0.9584
1870043354	pathological correlates of late onset dementia in a multicentre community based population in england and wales	2001	-0.4247	0.0027	12	1.832
1870573712	implantation of venous access devices under local anesthesia patients satisfaction with oral lorazepam	2015	2.345	0.1894	103	0.7083
1871317299	technology for improving medication monitoring in nursing homes	2005	0.7094	-0.0475	52	0.8758
1872529562	differential neuropsychiatric symptom responses to tacrine in alzheimer s disease relationship to dementia severity	1998	-0.1978	0.076	44	0.916
1873292146	changes in cognitive symptoms after a buspirone melatonin combination treatment for major depressive disorder	2015	-0.3415	0.9111	113	0.7467
1874212697	a 6 month open label study of the effectiveness and tolerability of galantamine in patients with alzheimer s disease	2004	-0.4204	-0.0632	82	0.7305
1876892944	nursing home placement in the donepezil and memantine in moderate to severe alzheimer s disease domino ad trial secondary and post hoc analyses	2015	-0.2667	0.0528	124	1.5818
1883210592	satisfaction with end of life care for nursing home residents with advanced dementia	2006	0.5963	-0.1335	131	0.7107
1883334148	is individual cognitive stimulation therapy beneficial for people with dementia	2014	0.2185	-0.072	10	0.8388
1885676552	rivastigmine for mild cognitive impairment in parkinson disease a placebo controlled study	2015	-0.1875	0.071	7	1.5383
1886943398	validation of the delirium rating scale revised 98 comparison with the delirium rating scale and the cognitive test for delirium	2001	2.1818	-0.0434	2	5.3647
1887800918	informal caregiver disability and access to preventive care in care recipients	2015	0.5971	-0.1331	131	0.7023
1890859916	the role of citicholine in neuropsychological training after traumatic brain injury	2000	-0.4003	-0.2667	62	0.8843
1891179592	efficacy of a comprehensive geriatric intervention in older patients hospitalized for hip fracture a randomized controlled trial	2005	2.1894	-0.0673	26	4.6036
1894609313	aromatherapy for dementia	2014	0.4011	-0.0342	34	1.6904
1894663696	a randomized clinical trial of alprazolam versus progressive muscle relaxation in cancer patients with anxiety and depressive symptoms	1991	0.0289	0.1124	38	0.7993
1894699684	effects of 5 ht6 receptor antagonism and cholinesterase inhibition in models of cognitive impairment in the rat	2009	-1.5582	0.2221	115	0.9713
1894821530	cholinesterase inhibitors for dementia with lewy bodies parkinson s disease dementia and cognitive impairment in parkinson s disease	2012	-0.178	0.1213	7	3.8234
1895024953	the efficacy and safety of lower doses of aripiprazole for the treatment of patients with acute exacerbation of schizophrenia	2006	-0.1168	0.194	114	0.692
1895538680	cholinesterase inhibitors for alzheimer s disease	2006	-0.2936	0.0398	6	28.2452
1897202984	prediction of treatment response to rivastigmine in alzheimer s dementia	2004	-0.1943	0.0545	67	0.6912
1898125120	dementia case management and risk of long term care placement a systematic review and meta analysis	2013	0.5569	-0.1195	74	0.8843
1901627834	endurance training in older men and women i cardiovascular responses to exercise	1984	0.5835	-0.2505	27	0.9999
1903404096	blood pressure and cognitive performance the framingham study	1987	-0.6771	-0.1149	14	1
1903506919	co ordinated multidisciplinary approaches for inpatient rehabilitation of older patients with proximal femoral fractures	2009	1.9722	-0.088	26	0.9999
1903618807	blood pressure lowering in patients without prior cerebrovascular disease for prevention of cognitive impairment and dementia	2009	-0.6414	-0.0982	14	1
1904131152	vitamin b12 deficiency in the elderly	1999	-0.9233	-0.1078	30	0.9959
1904458203	donepezil for dementia due to alzheimer s disease	2006	-0.2388	0.0573	6	4.8002
1909740577	psychiatric morbidity in dementia with lewy bodies a prospective clinical and neuropathological comparative study with alzheimer s disease	1999	-0.1926	0.1212	7	0.9994
1910469233	neurobiology and neuropathology of the human hypothalamus	1997	0.2069	-0.0065	17	0.75
1911640279	handbook of the psychology of aging	1985	0.5087	-0.2843	4	1.5987
1911808475	pioglitazone adjunctive therapy for depressive episode of bipolar disorder a randomized double blind placebo controlled trial	2015	-0.3416	0.9102	113	0.75
1913329037	effects of the medicare alzheimer s disease demonstration on caregiver burden and depression	1999	0.5622	-0.1065	1	25.2757
1913367972	human immunodeficiency virus associated neurocognitive disorders mind the gap	2010	-0.4008	0.502	87	0.916
1916537271	antipsychotic treatment of psychosis and agitation in the elderly	2000	0.5645	0.399	40	0.6942
1916550892	interdisciplinary intervention decreases cognitive impairment for older taiwanese with hip fracture 2 year follow up	2013	2.1208	-0.0867	26	16.1895
1916753622	effects of acetyl l carnitine in alzheimer s disease patients unresponsive to acetylcholinesterase inhibitors	2003	-0.3379	-0.0141	63	0.9404
1918769578	sb 742457 and donepezil in alzheimer disease a randomized placebo controlled study	2011	-1.5555	0.2217	115	19.4062
1919969592	brain perfusion follow up in alzheimer s patients during treatment with acetylcholinesterase inhibitors	2002	-0.1875	0.0661	67	3.0181
1920347567	the effects of combine treatment of memantine and donepezil on alzheimer s disease patients and its relationship with cerebral blood flow in the prefrontal area	2014	-0.2941	0.1105	50	0.6762
1922087192	meta analysis high dosage vitamin e supplementation may increase all cause mortality	2005	-0.3942	-0.0522	82	4.5493
1922088893	double blind treatment of major depression with dehydroepiandrosterone	1999	-1.4214	-1.842	20	3.9979
1923760566	antidepressants for agitation and psychosis in dementia	2011	0.1751	0.069	31	1.916
1923969306	hormone replacement therapy for cognitive function in postmenopausal women	2008	-0.7355	-0.7379	3	0.7993
1924478105	hypothalamic pituitary adrenal axis dysfunction in alzheimer s disease lack of association between longitudinal and cross sectional findings	1998	0.3313	-0.0243	89	0.7466
1924916469	vitamin e for alzheimer s dementia and mild cognitive impairment	2017	-0.4413	-0.0885	82	2.7497
1928257564	reducing delirium in elderly patients with hip fracture a multi factorial intervention study	2010	2.566	-0.0494	125	0.7867
1930587152	a disease management program for families of persons in hong kong with dementia	2008	0.5374	-0.1147	74	26.3852
1930672392	galantamine for alzheimer s disease and mild cognitive impairment	2006	-0.2571	-0.0149	46	2.657
1932814864	differential dose dependent changes in cognitive performance following acute administration of a ginkgo biloba panax ginseng combination to healthy young volunteers	2001	-0.6634	-0.1226	65	1.6184
1936589497	the use of a global statistical approach for the design and data analysis of clinical trials with multiple primary outcomes	2008	0.6423	0.1016	91	0.7284
1939289671	cognitive training and cognitive rehabilitation for mild to moderate alzheimer s disease and vascular dementia	2013	0.2878	-0.1106	10	0.9998
1941528024	ginkgo biloba for cognitive impairment and dementia	2009	-0.3904	-0.0748	8	18.2912
1943302189	service use in family caregivers of persons with dementia in belgium psychological and social factors	2007	0.7067	-0.1575	76	0.7839
1944050649	novel dehydroepiandrosterone troche supplementation improves the serum androgen profile of women undergoing in vitro fertilization	2015	-1.4116	-1.8491	20	0.8205
1944313983	a cognitive training program based on principles of brain plasticity results from the improvement in memory with plasticity based adaptive cognitive training impact study	2009	0.4695	-0.2281	4	6.6963
1945708268	low dose betaine supplementation leads to immediate and long term lowering of plasma homocysteine in healthy men and women	2003	-1.9284	0.3325	109	0.7752
1945836171	folic acid deficiency and homocysteine impair dna repair in hippocampal neurons and sensitize them to amyloid toxicity in experimental models of alzheimer s disease	2002	-0.8601	-0.1035	30	1.9523
1946000001	facilitation of conditioned fear extinction by systemic administration or intra amygdala infusions of d cycloserine as assessed with fear potentiated startle in rats	2002	-0.2958	0.1864	43	3.7961
1947395210	estrogen deficiency and risk of alzheimer s disease in women	1994	-0.7481	-0.7431	3	5
1947865549	effectiveness of fast track rehabilitation vs conventional care in laparoscopic colorectal resection for elderly patients a randomized trial	2012	2.7899	-0.0532	118	0.9713
1948364294	a comparison of the cognitive benefits of donepezil inpatients with cortical and subcortical vascular dementia abstract	2004	-0.1943	0.0545	67	0.6783
1948712038	atypical antipsychotics for aggression and psychosis in alzheimer s disease	2006	0.2064	0.0717	16	16.6532
1950830895	aroma therapy for dementia	2003	0.4009	-0.0307	34	1.9451
1951064739	postmenopausal estrogen replacement therapy and the risk of alzheimer s disease a population based case control study	1994	-0.7524	-0.751	3	3.9996
1952008960	effects of estrogen on brain development and neuroprotection implications for negative symptoms in schizophrenia	2003	-0.3852	0.1417	134	0.613
1953027527	a new rating scale for alzheimer s disease	1984	-0.2165	0.0523	6	83.7693
1953523985	prevalence of cobalamin deficiency in the framingham elderly population	1994	-0.9233	-0.1078	30	1
1954961492	vitamin b12 for cognition	2003	-0.8907	-0.1022	30	4.7972
1956388268	glycine and n methyl d aspartate receptors physiological significance and possible therapeutic applications	1998	-0.2975	0.1887	43	0.9404
1957558887	memantine er donepezil a review in alzheimer s disease	2015	-0.2089	0.1274	11	0.7878
1958133952	donepezil hydrochloride preserves regional cerebral blood flow in patients with alzheimer s disease	2001	-0.2186	0.0688	57	0.9999
1959246743	improved cognition in alzheimer s disease with short term d cycloserine treatment	1999	-0.2974	0.1876	43	22.4472
1959252561	dose dependent changes in cognitive performance and mood following acute administration of ginseng to healthy young volunteers	2001	-0.6583	-0.1215	65	3.8408
1959742141	b vitamins homocysteine and neurocognitive function in the elderly	2000	-0.8726	-0.1032	30	0.9999
1960152735	new approaches to health and well being for dementia day care clients family carers and day care staff	2008	0.3952	-0.0284	34	0.9804
1960339334	folate and vitamin b 12 status in relation to anemia macrocytosis and cognitive impairment in older americans in the age of folic acid fortification	2007	-0.8726	-0.1034	30	1
1962254068	memantine for dementia	2006	-0.1959	0.0604	6	25.7312
1962552915	cognitive and clinical outcomes of homocysteine lowering b vitamin treatment in mild cognitive impairment a randomized controlled trial	2012	-0.7712	-0.0963	30	3.9387
1962631311	prevalence and consequences of sleep disorders in traumatic brain injury	2007	-1.2594	1.7614	64	0.9992
1963489316	clinical and biochemical responses to therapy in alzheimer s disease and multi infarct dementia	1989	-0.4081	0.3096	120	0.6176
1963583371	donepezil preserves cognition and global function in patients with severe alzheimer disease	2007	-0.2072	0.0497	6	31.5029
1963638095	prevalence of alzheimer s disease in a community population of older persons higher than previously reported	1989	-0.2812	0.1118	13	0.845
1963667663	effects of transdermal nicotine on learning memory verbal fluency concentration and general health in a healthy sample at risk for dementia	2001	-0.2307	0.1568	9	0.6579
1963673786	a double blind placebo controlled evaluation of the safety and efficacy of vinpocetine in the treatment of patients with chronic vascular senile cerebral dysfunction	1987	-0.2713	0.0954	23	2.5295
1963706468	effects of differing intensities and formats of 12 months of exercise training on psychological outcomes in older adults	1993	0.5835	-0.2505	27	0.9998
1963714104	efficacy of fish oil on serum of tnf?? il 1?? and il 6 oxidative stress markers in multiple sclerosis treated with interferon beta 1b	2013	-1.1801	-0.326	129	0.7227
1963783263	estrogen therapy in postmenopausal women effects on cognitive function and dementia	1998	-0.75	-0.7507	3	17.9192
1963828576	meta analysis of psychosocial interventions for caregivers of people with dementia	2003	0.5197	-0.1086	1	35.0662
1963838674	efficacy and safety of topiramate in the treatment of obese subjects with essential hypertension	2005	-0.762	-0.1423	135	0.726
1963869616	clinical evaluation of acid related disease	1990	-0.3925	0.3624	106	0.6994
1963905681	the economic burden of alzheimer s disease care	1993	0.0635	-0.0295	93	0.9973
1964028976	unnecessary use of tranquillizers in elderly patients	1966	-0.0227	0.0713	47	1.4299
1964042388	the effects of melatonin versus placebo on delirium in hip fracture patients study protocol of a randomised placebo controlled double blind trial	2011	2.1076	-0.0399	2	18.3534
1964046945	donepezil in the treatment of alzheimer disease	2000	-0.328	0.1754	22	1.6218
1964072792	mild cognitive impairment a treatment at last	2004	-0.2325	0.1942	11	3.4682
1964163721	immediate and delayed effects of cognitive interventions in healthy elderly a review of current literature and future directions	2009	0.4302	-0.2139	4	1.9584
1964247625	piracetam and other structurally related nootropics	1994	-0.2843	0.2118	15	3.5268
1964280052	improving medication prescribing and utilization in the nursing home	1990	0.5411	0.0026	52	0.9999
1964287067	effects of osu6162 and acr16 on motor activity in rats indicating a unique mechanism of dopaminergic stabilization	2008	-1.1663	1.5705	64	0.845
1964351497	cognitive intervention in alzheimer disease a randomized placebo controlled study	2001	0.2572	-0.1073	10	36.684
1964380204	reliability and validity of the clinical dementia rating for community living elderly subjects without an informant	2013	-0.0747	-0.1034	127	0.8087
1964454256	caffeine protects alzheimer s mice against cognitive impairment and reduces brain ?? amyloid production	2006	-0.4858	0.0852	117	0.75
1964538442	beneficial effect of olanzapine in schizophrenic patients with obsessive compulsive symptoms	2000	0.104	0.1382	38	0.7092
1964593020	neuroleptic sensitivity in patients with senile dementia of lewy body type	1992	-0.1933	0.1214	7	2.9987
1964600081	specificity of symptoms of depression in alzheimer disease a longitudinal analysis	2005	0.2436	0.0888	31	0.7993
1964606698	estrogen and or androgen replacement therapy and cognitive functioning in surgically menopausal women	1988	-0.7553	-0.7635	3	25.9655
1964619726	effect of citicoline on ischemic lesions as measured by diffusion weighted magnetic resonance imaging	2000	-0.3997	-0.2645	62	1.8163
1964629948	rivastigmine in subcortical vascular dementia a randomized controlled open 12 month study in 208 patients	2003	-0.34	0.0345	12	0.916
1964722967	p 2 047 analysis of motor function in patients with alzheimer s dementia during double blind treatment of psychosis with olanzapine	2003	-0.2939	0.1114	50	0.7033
1964754986	the effects of oxiracetam isf 2522 in patients with organic brain syndrome a double blind controlled study with piracetam	1982	-0.3032	0.2858	15	1.6443
1964839585	a controlled naturalistic study on a weekly music therapy and activity program on disruptive and depressive behaviors in dementia	2010	0.4867	-0.0564	21	0.9404
1964855664	ii in vitro evidence that osu6162 and osu6162 produce their behavioral effects through 5 ht2a serotonin and d2 dopamine receptors	2011	-1.1671	1.5699	64	0.845
1964879289	fatigue in progressive multiple sclerosis results of a randomized double blind placebo controlled crossover trial of oral 4 aminopyridine	2001	-0.2419	0.2133	55	0.9713
1964882593	estrogen replacement therapy in older women comparisons between alzheimer s disease cases and nondemented control subjects	1994	-0.7491	-0.7462	3	7.9998
1964985003	multicomponent geriatric intervention for elderly inpatients with delirium a randomized controlled trial	2006	2.1013	-0.0419	2	1
1965041597	olanzapine does not enhance cognition in non agitated and non psychotic patients with mild to moderate alzheimer s dementia	2005	0.0289	0.1124	38	0.8329
1965050626	simvastatin strongly reduces levels of alzheimer s disease ?? amyloid peptides a??42 and a??40 in vitro and in vivo	2001	-0.7128	-0.1665	29	6.9775
1965120360	clinical application of operationalized criteria for depression of alzheimer s disease	2005	0.1846	0.0763	31	0.8843
1965139921	an economic evaluation of donepezil in mild to moderate alzheimer s disease results of a one year double blind randomized trial	2000	-0.5166	-0.0479	12	0.7157
1965201247	early treatment with risperidone for subsyndromal delirium after on pump cardiac surgery in the elderly a randomized trial	2012	2.214	-0.0434	2	2.657
1965370016	the effect of six months treatment with a 100 mg daily dose of dehydroepiandrosterone dhea on circulating sex steroids body composition and muscle strength in age advanced men and women	1998	-1.3867	-1.7919	20	4.7707
1965403335	a randomized controlled alzheimer s disease prevention trial s evolution into an exposure trial the preadvise trial	2012	-0.4634	-0.0729	8	0.991
1965405248	intensive geriatric rehabilitation of hip fracture patients a randomized controlled trial	2002	1.9721	-0.0871	26	0.9999
1965414691	chemical analysis and quality control of ginkgo biloba leaves extracts and phytopharmaceuticals	2009	-0.4856	-0.072	68	0.845
1965436107	caregiver time use an outcome measure in clinical trial research on alzheimer s disease	1995	0.0629	-0.0291	93	20.7377
1965446522	r3 donepezil use and impact on cost among patients with alzheimer s disease	2000	-0.3185	0.1176	33	1.6138
1965489088	neuroprotective activity of acetyl l carnitine studies in vitro	1994	-0.3129	0.0109	63	0.9959
1965521527	quetiapine treatment of psychotic symptoms and aggressive behavior in patients with dementia with lewy bodies a case series	2003	0.104	0.1382	38	0.6997
1965529356	efficacy of a medical food in mild alzheimer s disease a randomized controlled trial	2010	-0.4426	-0.1104	82	0.9867
1965532261	estrogen therapy for severe persistent depressions in women	1979	-0.769	-0.7802	3	1
1965537906	effect of light intensity on diurnal sleep wake distribution in young and old rats	1993	0.217	-0.0119	17	1.666
1965598001	chronic divalproex sodium use and brain atrophy in alzheimer disease	2011	-0.3852	0.1417	134	0.6197
1965607096	the specificity of depressive symptoms in patients with alzheimer s disease	2001	0.2442	0.0893	31	0.8332
1965629283	the effects on cognitive functions of a movement based intervention in patients with alzheimer s type dementia a pilot study	2011	0.4634	-0.1899	25	5.7346
1965641622	uv c irradiation induced peroxidative degradation of microsomal fatty acids and proteins protection by an extract of ginkgo biloba egn 761	1992	-0.4524	-0.038	8	0.7993
1965668843	pathologic evaluation of the human suprachiasmatic nucleus in severe dementia	1999	0.2446	-0.0154	28	4.9538
1965839734	fatigue and sleep disturbance following traumatic brain injury their nature causes and potential treatments	2012	-1.2594	1.7614	64	0.9988
1965888433	multifaceted therapeutic benefits of ginkgo biloba l chemistry efficacy safety and uses	2007	-0.5027	-0.0813	68	1.5493
1965898966	compression of risperidone and olanzapine in behavioral disturbances of alzheimer	2008	0.5483	0.3861	40	0.8095
1966016327	effect of long acting testosterone undecanoate treatment on quality of life in men with testosterone deficiency syndrome a double blind randomized controlled trial	2012	-0.9263	-0.257	79	0.7199
1966034582	program of all inclusive care for the elderly pace an innovative model of integrated geriatric care and financing	1997	0.4686	-0.0965	1	0.7993
1966048854	efficacy of rivastigmine on activities of daily living in sri lankan patients with alzheimer disease and on improving caregiver burden a prospective study	2009	0.1342	-0.0722	93	0.789
1966078222	lack of efficacy of hydergine in patients with alzheimer s disease	1990	-0.2805	0.1113	13	19.2467
1966083225	zuclopenthixol acetate 5 in viscoleo single dose treatment for acutely disturbed psychotic patients	1990	0.1301	0.1278	47	0.7637
1966103309	cholinesterase inhibition in parkinson s disease	1996	-0.1818	0.1096	7	2
1966106743	try try again improving older adults memory through practice	1993	0.5038	-0.2821	4	0.7064
1966151172	effects of a short term occupational therapy intervention in an acute geriatric unit a randomized clinical trial	2011	2.3671	-0.0642	35	14.4658
1966160222	systematic aerobic exercise and components of reaction time in older women	1988	0.5817	-0.2527	27	0.9939
1966401421	the physiology of willpower linking blood glucose to self control	2007	-0.4598	1.8033	96	0.7993
1966465767	the effects of multisensory environments on older people with dementia	1998	0.4261	-0.0757	18	2.9866
1966492595	lessons learned from a randomised controlled study of perioperative beta blockade in high risk patients undergoing emergency surgery	2006	2.5491	-0.0689	35	0.7657
1966496672	increased calcium current hypothesis of brain aging	1987	-0.3432	0.1147	53	0.7993
1966567426	rivastigmine transdermal patch skin tolerability results of a 1 year clinical trial in patients with mild to moderate alzheimer s disease	2010	-0.2433	0.0555	19	19.1188
1966607391	vitamin e and cognitive decline in older persons	2002	-0.4593	-0.0962	82	0.9804
1966618264	characterization of copper interactions with alzheimer amyloid ?? peptides identification of an attomolar affinity copper binding site on amyloid ??1 42	2008	-1.0099	-0.5237	69	1
1966645595	thiamine deficiency induces oxidative stress and exacerbates the plaque pathology in alzheimer s mouse model	2009	-0.7833	-0.0998	86	0.8843
1966657660	sleep disordered breathing hypoxia and risk of mild cognitive impairment and dementia in older women	2011	0.2362	-0.007	28	1.9518
1966897254	postoperative confusion after anesthesia in elderly patients with femoral neck fractures	1987	2.214	-0.0383	36	22.5503
1966901000	cardioprotective effect of sevoflurane and propofol during anaesthesia and the postoperative period in coronary bypass graft surgery a double blind randomised study	2012	3.1472	0.1092	110	0.7663
1966930988	effectiveness of music therapy 1 1 intervention with individuals having senile dementia of the alzheimer s type	1993	0.4613	-0.0566	21	4.7397
1967092492	piracetam as an aid to learning in dyslexia preliminary report	1979	-0.3171	0.2625	15	0.8843
1967096953	effects of supporting community living demented patients and their caregivers a randomized trial	2001	0.5338	-0.112	1	31.927
1967171541	imagery pretraining and memory training in the elderly	1983	0.5093	-0.2855	4	0.7773
1967172001	a controlled trial of fluoxetine in nondepressed patients with huntington s disease	1997	-0.2283	-0.1467	112	0.991
1967212159	postoperative delirium and melatonin levels in elderly patients	2001	2.204	-0.0446	2	0.916
1967265218	activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes	2006	-0.4434	1.5572	56	0.991
1967289410	the guidage study methodological issues a 5 year double blind randomized trial of the efficacy of egb 761 for prevention of alzheimer disease in patients over 70 with a memory complaint	2006	-0.3698	-0.1149	8	18.9047
1967365147	olanzapine reduces psychosis and behavioral symptoms associated with alzheimer s disease	1999	0.3077	0.1435	81	1.7776
1967426102	donepezil improved or stabilized cognition over one year in patients with mild and moderate alzheimer s disease	2000	-0.2172	0.1402	11	15.2109
1967483894	special care units for dementia in nursing homes a controlled study of effectiveness	1998	0.9824	-0.0257	24	14.4918
1967505365	the effects of acute doses of standardized ginkgo biloba extract on memory and psychomotor performance in volunteers	1999	-0.4789	-0.0612	8	2.8466
1967583546	a randomized controlled study on effects of ibuprofen on cognitive progression of alzheimer s disease	2009	-0.4317	-0.0821	32	21.9375
1967596143	analysis of case management programs for patients with dementia a systematic review	2012	0.5507	-0.1168	74	4.6332
1967598832	thiamine therapy in alzheimer s disease	1996	-0.7847	-0.0992	86	2.9908
1967605562	an ergot alkaloid preparation hydergine in geriatric therapy	1972	-0.2525	0.0856	41	3.4054
1967642097	11c pib in a nondemented population potential antecedent marker of alzheimer disease	2006	-0.052	-0.0404	46	1
1967645451	use of angiotensin receptor blockers and risk of dementia in a predominantly male population prospective cohort analysis	2010	-0.6414	-0.0982	14	1
1967667526	the health consequences of using physical restraints in nursing homes	2009	0.7924	-0.097	42	1.8003
1967674023	anti inflammatory drugs and alzheimer disease	1990	-0.414	-0.0404	32	1
1967692924	manic like symptoms in schizophrenic patients treated with olanzapine haloperidol and placebo	2001	0.104	0.1382	38	0.7098
1967757769	the use of trifluoperazine in geriatric patients with chronic brain syndrome	1962	0.166	0.093	47	0.9988
1967779348	an economic evaluation of donepezil in mild to moderate alzheimer s disease results of a 1 year double blind randomized trial	2003	-0.2103	0.0427	6	3.4521
1967784617	expression of monoamine oxidase b activity in astrocytes of senile plaques	1990	-0.1986	0.1207	37	0.9939
1967817378	treatment of postconcussional symptoms with cdp choline	1991	-0.3997	-0.2645	62	1.7707
1967830806	can cognitive exercise prevent the onset of dementia systematic review of randomized clinical trials with longitudinal follow up	2009	0.4694	-0.2466	4	1
1967922486	iron brain ageing and neurodegenerative disorders	2004	-1.0099	-0.5237	69	1
1967971307	modulation of mood and cognitive performance following acute administration of single doses of melissa officinalis lemon balm with human cns nicotinic and muscarinic receptor binding properties	2003	0.4009	-0.0293	34	1
1967974729	studies of illness in the aged the index of adl a standardized measure of biological and psychosocial function	1963	0.8409	-0.1059	1	4.8868
1968039775	deprenyl in the treatment of parkinson s disease	1982	-0.1918	0.1108	137	0.6985
1968043077	cognitive function in elderly non insulin dependent diabetic patients before and after inpatient treatment for metabolic control	1997	-0.4442	1.5721	56	1.9804
1968142720	drug levels on continuous intravenous infusion	1971	-0.6082	0.5205	119	0.6257
1968151016	treatment monitoring and response prediction with proton mr spectroscopy in ad	2006	-0.1615	0.0146	46	0.9999
1968163119	factors associated with family caregivers choice not to use services	1996	0.7067	-0.1575	76	0.7763
1968257988	some observations upon a new inhibitor of monoamine oxidase in brain tissue	1968	-0.1934	0.119	37	1.8431
1968277475	a randomized controlled trial exploring the effect of music on quality of life and depression in older people with dementia	2010	0.4846	-0.0563	21	25.0042
1968294120	effect of melatonin on incidence of delirium among patients with hip fracture a multicentre double blind randomized controlled trial	2014	2.2011	-0.0445	2	21.4308
1968294251	long term administration of oral physostigmine in alzheimer s disease	1988	-0.3084	0.1756	13	26.2721
1968329201	report on an open label prospective study of divalproex sodium for the behavioral and psychological symptoms of dementia as monotherapy and in combination with second generation antipsychotic medication	2007	0.1699	0.0798	16	0.9404
1968338902	use of rivastigmine transdermal patch in the treatment of alzheimer s disease	2008	-0.2382	0.0523	19	0.845
1968357864	regarding the fitness to ride a bicycle under the acute influence of alcohol	2015	-0.387	0.3785	98	0.6823
1968385408	frontotemporal dementia a randomised controlled trial with trazodone	2004	-0.2317	0.2546	66	23.7539
1968507488	a double blind placebo controlled multicentre study of tacrine for alzheimer s disease	1994	-0.2729	0.062	44	1.4329
1968541366	therapeutic efficacy of vincamine in dementia	1996	-0.3167	-0.002	23	0.75
1968546477	the effects of oral dehydroepiandrosterone on endocrine metabolic parameters in postmenopausal women	1990	-1.4151	-1.8401	20	3.7397
1968608234	new for old risperidone long acting injection in older patients	2007	0.617	0.4432	40	0.7792
1968665017	long term efficacy of cognitive training for age associated memory impairment a six month follow up study	1986	0.5094	-0.2855	4	2.613
1968671450	placebo controlled treatment trial of depression in elderly physically ill patients	1997	-0.1374	0.0374	80	0.6805
1968673381	quetiapine treatment for behavioral disturbances and psychotic symptoms in patients with vascular dementia a case series	2005	0.3085	0.1434	81	0.7872
1968679615	application of reminiscence treatment on older people with dementia a case study in pingtung taiwan	2009	0.3574	-0.0939	39	0.916
1968750846	patient and caregiver characteristics and nursing home placement in patients with dementia	2002	0.5676	-0.1086	1	0.8843
1968770674	a 6 month randomized double blind placebo controlled pilot discontinuation trial following response to haloperidol treatment of psychosis and agitation in alzheimer s disease	2011	0.1922	0.0601	80	19.5039
1968822057	a randomized controlled trial exploring the effect of music on agitated behaviours and anxiety in older people with dementia	2010	0.4853	-0.0506	21	25.5607
1968840823	memantine is a potent blocker of n methyl d aspartate nmda receptor channels	1989	-0.2735	0.0729	23	0.9992
1968899278	androgen therapy with dehydroepiandrosterone	2003	-1.384	-1.781	54	0.8179
1968938847	d penicillamine reduces serum oxidative stress in alzheimer s disease patients	2002	-1.1801	-0.326	129	0.6958
1969009328	circadian rhythm sleep disorders following mild traumatic brain injury	2007	-1.2577	1.7622	64	0.9994
1969009732	piracetam and dyslexia effects on reading tests	1987	-0.3176	0.263	15	0.7993
1969056024	vinpocetine enhances retrieval of a step through passive avoidance response in rats	1987	-0.3068	0.128	23	0.9994
1969071740	comparison of rapidly acting intramuscular olanzapine lorazepam and placebo a double blind randomized study in acutely agitated patients with dementia	2002	0.1761	0.098	16	6.3804
1969078168	effect of cortisol levels on working memory performance in elderly subjects with alzheimer s disease	2008	0.3248	-0.0245	89	0.7268
1969096958	clinical efficacy of ginkgo biloba special extract egb 761 in dementia of the alzheimer type	1997	-0.4278	-0.042	8	36.7098
1969114295	the effect of a personalized dementia care intervention for caregivers from australian minority groups	2016	0.5421	-0.1163	1	0.8098
1969259418	effects of donepezil on alzheimer s disease the relationship between cognitive function and rapid eye movement sleep	2004	-0.0655	0.0956	28	2.5077
1969311653	selegiline and oxidative stress in hiv associated cognitive impairment	2009	-0.4011	0.5019	87	1.9931
1969353858	tactile contact and evaluation of the toucher	2007	0.5917	-0.0633	123	0.845
1969436218	spect regional cerebral blood flow alterations in naltrexone precipitated withdrawal from buprenorphine	1994	-0.4206	0.335	90	0.6492
1969443674	valproic acid adjunctive therapy for hiv associated cognitive impairment a first report	2006	-0.4005	0.5012	87	0.9992
1969488846	mechanical restraint use among residents of skilled nursing facilities prevalence patterns and predictors	1991	0.8435	-0.1027	42	0.9999
1969515077	helping carers to care the 10 66 dementia research group s randomized control trial of a caregiver intervention in russia	2009	0.5141	-0.1118	1	5.5994
1969614954	imaging microvascular changes and cognitive function in dementia	2009	-0.8148	0.8226	102	0.7019
1969700412	spontaneous bilateral subdural hematomas associated with chronic ginkgo biloba ingestion	1996	-0.4649	-0.0599	8	1.991
1969738113	tocopherols and tocotrienols plasma levels are associated with cognitive impairment	2012	-0.4428	-0.1095	82	0.9867
1969884347	donepezil treatment of vascular dementia	2002	-0.4482	-0.0028	12	0.815
1969887156	monoamine oxidase b inhibitors in the treatment of alzheimers disease	2000	-0.3334	0.2021	22	1.761
1969895941	prevalence and characteristics of dementia in parkinson disease an 8 year prospective study	2003	-0.182	0.1125	7	8
1969969444	putting brain training to the test	2010	0.4654	-0.248	4	2.9939
1970013295	the common inhalation anesthetic isoflurane induces apoptosis and increases amyloid ?? protein levels	2006	2.2253	-0.0295	36	0.845
1970025509	effect of 12 month dehydroepiandrosterone replacement therapy on bone vagina and endometrium in postmenopausal women	1997	-1.418	-1.8391	20	2
1970045716	o2 04 07 treatment with donepezil in korean alzheimer patients with and without cerebrovascular factors one year follow up study	2008	-0.3141	0.0962	50	0.6813
1970105914	treatment of migraine with bms180048 response at 2 hours	1996	-0.2658	0.0614	44	0.6979
1970129710	the impact of perceived adequacy of social support on caregiving burden of family caregivers	2011	0.7067	-0.1575	76	0.7749
1970159591	comparing effects of methylphenidate sertraline and placebo on neuropsychiatric sequelae in patients with traumatic brain injury	2005	-0.9188	1.1391	71	1.6505
1970202213	a multidimensional approach in testing nootropic drug effects cerebrolysin	1990	-0.417	0.0419	41	0.6655
1970232374	validity of the ischemic score in degenerative and vascular dementia and depression in old age	1985	0.2301	-0.2027	111	0.6344
1970275767	acute cognitive effects of donepezil in young healthy volunteers	2009	-0.2008	0.1471	9	0.7798
1970347485	effects of piracetam on regional cerebral blood flow and mental functions in patients with organic dementia	1978	-0.42	0.3332	90	13.7608
1970434963	donepezil in a chronic drug user a potential treatment	2003	-0.2307	0.1568	9	0.6609
1970445748	synthesis and comparison of the meta analyses evaluating the efficacy of memantine in moderate to severe stages of alzheimer s disease	2013	-0.1687	0.0991	11	0.8266
1970449206	comparison of the efficacy of new and conventional antipsychotic drugs in the treatment of behavioral and psychological symptoms of dementia bpsd	2004	0.1304	0.1286	47	0.6842
1970463102	remembering mnemonics a three year follow up on the effects of mnemonics training in elderly adults	1987	0.5079	-0.2837	4	3.5806
1970493262	olanzapine therapy in elderly patients with schizophrenia	1999	0.617	0.4432	40	0.8173
1970515617	532 long term efficacy of olanzapine in the control of psychotic and behavioral symptoms in patients with alzheimer s dementia	2000	0.3085	0.1429	81	1.7301
1970538956	long term results of peripheral conditioning stimulation as an analgesic measure in chronic pain	1979	0.1927	-0.0097	17	0.75
1970613198	effects of relaxing music on agitation during meals among nursing home residents with severe cognitive impairment	1994	0.4713	-0.0479	21	2.9806
1970616575	efficacy of memantine an nmda receptor antagonist in the treatment of parkinson s disease	1992	-0.2735	0.0729	23	0.9804
1970686841	the effects of an enhanced environment on nursing home residents who pace	1998	0.6163	-0.0271	24	2.9118
1970695058	spontaneous fluctuations in brain activity observed with functional magnetic resonance imaging	2007	-0.1564	0.0882	22	1.7154
1970751113	physical fitness training and mental health	1981	0.5835	-0.2505	27	0.9994
1970767714	l deprenyl therapy improves verbal memory in amnesic alzheimer patients	1991	-0.1881	0.1169	37	23.0787
1970772051	oral physostigmine as treatment for dementia of the alzheimer type a long term outpatient trial	1990	-0.2976	0.1486	13	0.7993
1970814668	carbamazepine treatment of agitation in nursing home patients with dementia a preliminary study	1994	0.1281	0.0877	16	2.9163
1970818671	acetylcholinesterase inhibitors and sleep architecture in patients with alzheimer s disease	2006	0.1278	0.0269	28	0.8843
1970858190	cerebral metabolic changes accompanying conversion of mild cognitive impairment into alzheimer s disease a pet follow up study	2003	-0.052	-0.0404	46	1
1970863564	experience of antioxidant treatment in neuronal ceroid lipofuscinosis of spielmeyer sjogren type1	1977	-0.6362	0.0864	122	0.732
1970895138	o2 04 03 methylphenidate treatment for apathy in dementia of alzheimer type	2008	-0.3311	0.2607	59	0.7359
1970942266	the longitudinal basis of mild cognitive impairment mci	2000	-0.1892	0.0233	78	0.8258
1970946599	postoperative analgesia and recovery course after major colorectal surgery in elderly patients a randomized comparison between intrathecal morphine and intravenous pca morphine	2006	2.3839	-0.0463	130	17.5063
1970959510	systematic review of the effect of psychological interventions on family caregivers of people with dementia	2007	0.487	-0.1045	1	1.9523
1971028729	a double blind randomized fixed dose trial of fluoxetine vs amitriptyline in the treatment of major depression complicating alzheimer s disease	1997	0.1864	0.1033	31	7.7128
1971048984	a new and rapid colorimetric determination of acetylcholinesterase activity	1961	-0.2805	0.1142	13	0.8843
1971065011	end of life decision making for nursing home residents with dementia	2000	0.8524	-0.0193	95	0.8843
1971071080	spect identified neuroanatomical predictor of the cognitive effects of donepezil treatment in patients with alzheimer s disease	2008	-0.2817	0.1568	43	0.701
1971110371	a placebo controlled double blind randomized study of venlafaxine in the treatment of depression in dementia	2007	0.1953	0.0899	31	21.4331
1971116512	?? amyloid oligomers induce phosphorylation of tau and inactivation of insulin receptor substrate via c jun n terminal kinase signaling suppression by omega 3 fatty acids and curcumin	2009	-1.0105	-0.2751	5	0.845
1971129242	effects of a physical training programme on cognitive function and walking efficiency in elderly persons with dementia	2010	0.4708	-0.1902	25	32.6713
1971198407	pge1 bei seniler maculadegeneration pilot studie	1989	-0.6362	0.0864	122	0.739
1971257104	efficacy and tolerability of ginkgo biloba extract egb 761 in different types of dementia analyses of a randomized controlled trial	2009	-0.4856	-0.072	68	0.7682
1971281741	aerobic exercise and neurocognitive performance a meta analytic review of randomized controlled trials	2010	0.5108	-0.1983	25	4.9497
1971305021	myricetin and quercetin the flavonoid constituents ofginkgo biloba extract greatly reduce oxidative metabolism in both resting and ca2 loaded brain neurons	1994	-0.4639	-0.06	8	1.9994
1971308705	effects of piracetam on membrane fluidity in the aged mouse rat and human brain	1997	-0.3075	0.2489	15	0.9982
1971319948	enhanced long term potentiation during aging is masked by processes involving intracellular calcium stores	2004	-0.3426	0.1147	53	0.845
1971334793	physical activity including walking and cognitive function in older women	2004	0.5509	-0.2267	27	0.845
1971362786	impairment of vigilance and performance under lithium treatment studies in patients and normal volunteers	1977	-0.6362	0.0864	122	0.734
1971372603	a double blind comparison of trazodone and haloperidol for treatment of agitation in patients with dementia	1997	0.1307	0.0838	16	24.9159
1971401631	cholinesterase inhibitors in dementia	2002	-0.34	0.0345	12	0.845
1971565607	the prevalence of frontotemporal dementia	2002	-0.234	0.2589	66	2.9939
1971579987	cortical cholinergic function is more severely affected in parkinsonian dementia than in alzheimer disease an in vivo positron emission tomographic study	2003	-0.1853	0.0998	7	7.5493
1971649076	exposure to light in healthy elderly subjects and alzheimer s patients	1988	0.2809	-0.0167	17	2.8988
1971792062	safety and tolerability of rivastigmine capsule with memantine in patients with probable alzheimer s disease a 26 week open label prospective trial study ena713b us32	2010	-0.2401	0.0579	19	1.4528
1971797932	effects of rivastigmine treatment on the neuropsychiatric and behavioral disturbances of nursing home residents with moderate to severe probable alzheimer s disease a 26 week multicenter open label study	2005	-0.1877	0.0633	7	1.7436
1971806376	rivastigmine in wernicke korsakoff s syndrome five patients with rivastigmine showed no more improvement than five patients without rivastigmine	2007	-0.2545	0.053	72	0.8073
1971880978	olanzapine versus haloperidol treatment in first episode psychosis	1999	0.104	0.1382	38	0.6938
1971892868	effects of naltrexone on cognition in a treatment study of patients with schizophrenia and comorbid alcohol dependence	2006	-0.1544	0.2293	15	0.6328
1971894387	does a mirror deter wandering in demented older people	1991	0.6761	-0.022	24	0.7993
1971964419	d serine added to antipsychotics for the treatment of schizophrenia	1998	-0.2983	0.1888	43	0.9404
1972048937	frequency and characteristics of anxiety among patients with alzheimer s disease and related dementias	2003	0.6749	-0.1727	77	0.75
1972097338	psychosis in parkinsons disease	2004	0.3076	0.1434	81	0.6984
1972111813	physostigmine ameliorates the delusions of alzheimer s disease	1993	-0.3032	0.1546	13	0.7993
1972185744	action of acetyl l carnitine in neurodegeneration and alzheimer s disease	1992	-0.312	0.0182	63	0.8843
1972200288	extracts of ginkgo biloba and ginsenosides exert cerebral vasorelaxation via a nitric oxide pathway	1997	-0.3317	-0.0937	8	0.75
1972265703	a randomized controlled trial of the group reminiscence approach in patients with vascular dementia	2007	0.3037	-0.0923	39	15.5924
1972294144	validity and reliability of the alzheimer s disease cooperative study clinical global impression of change adcs cgic	1997	0.1846	0.0763	31	0.8843
1972300483	oral tetrahydroaminoacridine in long term treatment of senile dementia alzheimer type	1986	-0.2984	0.1611	13	17.0583
1972343913	the role of the cholinergic system in thiamin deficiency	1982	-0.7839	-0.0989	86	0.845
1972361200	cerebrospinal fluid acetylcholine and choline in vascular dementia of binswanger and multiple small infarct types as compared with alzheimer type dementia	1996	-0.4244	-0.0013	12	2.5944
1972370700	differential responsivity of mood behavior and cognition to cholinergic agents in elderly neuropsychiatric populations	1988	0.0571	0.5351	48	0.6504
1972384120	effect of antihypertensive agents on quality of life in the elderly	2004	-0.7616	-0.1531	14	0.9867
1972390556	controlled trial of dementia training with a peer support group for aged care staff	2007	0.6444	-0.08	18	1.871
1972416629	donepezil improves obstructive sleep apnea in alzheimer disease a double blind placebo controlled study	2008	0.2269	-0.0033	28	20.3959
1972516764	a pilot study evaluating the efficacy and safety of rivastigmine in patients with mixed dementia	2006	-0.3855	0.0603	50	0.6936
1972604261	rbc choline a biological marker of the outcome of lithium prophylaxis	1987	-0.4081	0.3096	120	0.6122
1972634662	rehabilitation outcomes in cognitively impaired patients admitted to skilled nursing facilities from the community	2004	2.1222	-0.0874	26	0.7685
1972721870	hospital and nursing home use from 2002 to 2008 among us older adults with cognitive impairment not dementia in 2002	2013	1.6418	-0.0325	24	0.7864
1972778639	intravenous patient controlled analgesia has a positive effect on the prognosis of delirium in patients undergoing orthopedic surgery	2014	2.345	0.1894	103	0.7188
1972788353	comparative study of action mechanisms of dimebon and memantine on ampa and nmda subtypes glutamate receptors in rat cerebral neurons	2003	-0.5864	-0.1755	32	1
1972796478	effects of galantamine on working memory and global functioning in patients with mild cognitive impairment a double blind placebo controlled study	2005	-0.1828	-0.0276	46	18.5032
1972809085	olanzapine zyprexa increased incidence of cerebrovascular events in dementia trials	2004	0.1847	0.0975	16	0.9999
1972857440	p 5 a 006 tolerability of rivastigmine transdermal patch in alzheimer dementia with psychotic features	2009	-0.2795	0.1044	133	0.6944
1972954420	a 1 year multicenter placebo controlled study of acetyl l carnitine in patients with alzheimer s disease	1996	-0.3281	-0.0053	63	27.6474
1972967105	interventions for caregivers of patients with alzheimer s disease a review and analysis of content process and outcomes	1996	0.5429	-0.1111	1	3.8508
1973101326	efficacy and tolerability of ginkgo biloba extract egb 761 in dementia a systematic review and meta analysis of randomized placebo controlled trials	2014	-0.3825	-0.0304	70	2.4796
1973116987	a preliminary study of d cycloserine treatment in alzheimer s disease	1998	-0.2952	0.1853	43	19.8428
1973159346	understanding the pathology of vascular cognitive impairment	2005	-0.7263	0.0224	107	0.746
1973206218	lecithin and memory training in suspected alzheimer s disease	1982	-0.3207	0.2317	59	2.529
1973219304	comparison of the efficacy of aroma acupressure and aromatherapy for the treatment of dementia associated agitation	2015	0.4144	-0.0409	34	0.75
1973231142	effects of reminiscence group in elderly people with alzheimer disease and vascular dementia in a community setting	2007	0.3285	-0.0927	39	1.69
1973246507	enhancing care for hospitalized older adults with cognitive impairment a randomized controlled trial	2012	1.6399	-0.0325	24	15.6831
1973263702	health care costs of people referred to an aged care assessment team the effect of cognitive impairment	1977	1.6418	-0.0325	24	0.7675
1973274681	open label study of donepezil in traumatic brain injury	2001	-0.8474	1.0199	71	0.991
1973403495	change in cognitive function by glucose tolerance status in older adults a 4 year prospective study of the rancho bernardo study cohort	2004	-0.4434	1.5572	56	0.9713
1973444891	donepezil in vascular dementia	2003	-0.2669	0.0508	124	0.8209
1973494395	long term donepezil treatment in patients with alzheimer s disease	2004	-0.3227	0.1342	33	2.3645
1973512378	effects of rivastigmine on behavioral and psychological symptoms of dementia in alzheimer s disease	2004	-0.1523	0.0601	44	0.9973
1973706152	unravelling the pathophysiology of delirium a focus on the role of aberrant stress responses	2008	2.1102	-0.0409	2	0.916
1973901886	post prandial hyperglycemia is an important predictor of the incidence of diabetic microangiopathy in japanese type 2 diabetic patients	2005	-0.4425	1.5571	56	0.9804
1973947161	effect of regular exercise on senile dementia patients	2008	0.4675	-0.1849	25	8.7217
1973959684	eeg patterns in various subgroups of endogenous depression	1991	-0.2894	0.1023	41	0.7017
1974018738	neuropsychological effects of tiagabine a potential new antiepileptic drug	1994	-0.4293	0.35	90	1.307
1974144862	bispectral index monitoring duration of bispectral index below 45 patient risk factors and intermediate term mortality after noncardiac surgery in the b unaware trial	2011	2.2338	-0.0385	36	0.75
1974225635	rivastigmine in subcortical vascular dementia a comparison trial on efficacy and tolerability for 12 months follow up	2001	-0.3493	0.0351	12	5.7141
1974242699	effect of anti inflammatory medications on neuropathological findings in alzheimer disease	2001	-0.3245	0.1979	22	0.7402
1974324306	analgesic effect of alprazolam in patients with chronic organic pain of malignant origin	1987	0.0289	0.1124	38	0.7993
1974395659	aging exercise and attention	1992	0.5809	-0.2507	27	4.9101
1974472707	nicergoline in senile dementia of alzheimer type and multi infarct dementia a double blind placebo controlled clinical and eeg erp mapping study	1995	-0.3167	-0.002	23	0.75
1974474435	memantine monotherapy for alzheimer s disease a systematic review and meta analysis	2015	-0.1947	0.1187	92	0.7663
1974505724	a comparison of cognitive behavioral therapy sertraline and their combination for adolescent depression	2006	0.0869	0.1467	61	1.4538
1974583546	frontotemporal lobar degeneration a consensus on clinical diagnostic criteria	1998	-0.233	0.2554	66	3.7497
1974590920	cholinergic dysfunction in diseases with lewy bodies	2000	-0.1889	0.1177	7	1.9992
1974591550	association between acute care and critical illness hospitalization and cognitive function in older adults	2010	1.6418	-0.0325	24	0.75
1974652155	the uniwellbeing course a randomised controlled trial of a transdiagnostic internet delivered cognitive behavioural therapy cbt programme for university students with symptoms of anxiety and depression	2015	0.7635	-0.2018	77	0.7694
1974704788	the timed up go a test of basic functional mobility for frail elderly persons	1991	0.4869	-0.1799	25	1.9686
1974716768	ampa potentiator treatment of cognitive deficits in alzheimer disease	2007	-0.3128	-0.1182	6	1.4636
1974867354	effects of dha rich n 3 fatty acid supplementation on gene expression in blood mononuclear leukocytes the omegad study	2012	-1.1003	-0.3008	5	19.3342
1974945853	a longitudinal study of cardiorespiratory fitness and cognitive function in healthy older adults	2003	0.5617	-0.2359	27	1.883
1974964904	a randomized dose response trial of citicoline in acute ischemic stroke patients	1997	-0.3997	-0.2647	62	1.9148
1975076148	cognitive interventions in healthy older adults and people with mild cognitive impairment a systematic review	2013	0.1991	-0.1084	10	0.9713
1975330078	examination of the cognitive effects of cimetidine in normal elderly volunteers	1999	-0.4206	0.335	90	0.6348
1975409580	effects of low blood pressure in cognitively impaired elderly patients treated with antihypertensive drugs	2015	-0.6916	-0.191	79	0.75
1975447710	neuroprotective and anti human immunodeficiency virus activity of minocycline	2005	-0.4005	0.5012	87	0.9994
1975465128	quetiapine treatment for behavioural and psychological symptoms of dementia in alzheimer s disease patients a 6 week double blind placebo controlled study	2008	0.0289	0.1124	38	0.7731
1975486662	d cycloserine a positive modulator of the n methyl d aspartate receptor enhances performance of learning tasks in rats	1989	-0.2966	0.1869	43	1.7367
1975492163	brain mitochondrial injury in human immunodeficiency virus seropositive hiv individuals taking nucleoside reverse transcriptase inhibitors	2005	-0.4008	0.502	87	0.9959
1975543185	ortho geriatric service a literature review comparing different models	2010	2.1944	-0.0495	2	0.9404
1975586101	baseline neurocognitive deficits in the catie schizophrenia trial	2006	0.6426	0.1008	91	0.75
1975599887	patterns of fatigue and its correlates over the first 2 years after traumatic brain injury	2008	-1.2594	1.7614	64	0.9959
1975640662	the effects of antihypertensive treatment on cognitive function results from the hope study	1996	-0.6775	-0.1157	14	1
1975642739	memory training in the community aged effects on depression memory complaint and memory performance	1981	0.5107	-0.2858	4	0.8843
1975663059	effects of ginkgo biloba special extract egb 761 in very mild cognitive impairment vmci	2011	-0.4106	-0.0534	8	0.9404
1975693728	multicenter clinical placebo controlled study with acetyl l carnitine lac in the treatment of mildly demented elderly patients	1988	-0.2261	0.0533	84	16.2342
1975736635	broad therapeutic benefits in patients with probable vascular dementia or alzheimer s disease with cerebrovascular disease treated with galantamine	2002	-0.3745	0.0862	94	1.7925
1975782323	prevalence of sleep disturbances disorders and problems following traumatic brain injury a meta analysis	2012	-1.2594	1.7614	64	0.991
1975806945	cholesterol depletion inhibits the generation of beta amyloid in hippocampal neurons	1998	-0.719	-0.1679	29	4.8805
1975829688	effects of estrogen on cognition mood and cerebral blood flow in ad a controlled study	2000	-0.7427	-0.7366	3	23
1975886348	oral physostigmine and lecithin improve memory in alzheimer disease	1983	-0.3237	0.2044	13	13.9409
1975897272	the monoamine stabilizer osu6162 attenuates voluntary ethanol intake and ethanol induced dopamine output in nucleus accumbens	2012	-1.1671	1.5699	64	0.845
1975945641	pharmacodynamics of citicoline relevant to the treatment of glaucoma	2002	-0.4003	-0.2667	62	0.845
1975975999	memantine in severe dementia results of the 9m best study benefit and efficacy in severly demented patients during treatment with memantine	1999	-0.2136	0.0615	6	19.3708
1976051007	gender differences in burden and depression among informal caregivers of demented elders in the community	2002	0.657	-0.144	75	0.7691
1976068659	cognitive performance of healthy young rats following chronic donepezil administration	2008	0.0183	0.3851	48	0.6426
1976082080	correlates of dropout efficacy and adverse events in treatment with acetylcholinesterase inhibitors in korean patients with alzheimer s disease	2002	-0.0587	0.0835	58	0.7998
1976116530	nimodipine facilitates associative learning in aging rabbits	1989	-0.3449	0.1101	53	1.9518
1976117775	management of neuropsychiatric symptoms of dementia in clinical settings recommendations from a multidisciplinary expert panel	2014	0.2222	0.0205	31	2.7933
1976245198	what we can learn from open label extensions of randomized clinical trials	2006	-0.5166	-0.0479	12	0.7346
1976250892	cognitive response to memantine in moderate to severe alzheimer disease patients already receiving donepezil an exploratory reanalysis	2006	-0.1816	0.0635	6	21.9258
1976313368	the effects of type 1 diabetes on cognitive performance a meta analysis	2005	-0.4453	1.5878	56	0.9998
1976358724	effectiveness of switching to the rivastigmine transdermal patch from oral cholinesterase inhibitors a naturalistic prospective study in alzheimer s disease	2015	-0.256	0.0511	72	0.7593
1976418050	the treatment of alzheimer s disease	1995	-0.3245	0.1979	22	0.8005
1976434061	hiv and antiretroviral therapy in the brain neuronal injury and repair	2007	-0.4005	0.5012	87	0.9959
1976447270	the impact of different doses of estrogen and progestin on mood and sexual behavior in postmenopausal women	1991	-0.7699	-0.7799	3	1
1976495166	additive effects of physical exercise and environmental enrichment on adult hippocampal neurogenesis in mice	2009	0.5368	-0.188	27	0.8843
1976527790	long term dhea replacement in primary adrenal insufficiency a randomized controlled trial	2008	-1.4117	-1.8491	20	0.807
1976565710	nonpharmacologic interventions for inappropriate behaviors in dementia a review summary and critique	2001	0.4421	-0.0386	21	6.4885
1976578549	treatment of age related memory complaints with ginkgo biloba extract a randomized double blind placebo controlled study	1998	-0.4328	0.0051	41	1.4619
1976580371	deprenyl selegiline combined with levodopa and a decarboxylase inhibitor in the treatment of parkinson s disease	1983	-0.1918	0.1108	137	0.6753
1976584935	vinpocetine blockade of sodium channels inhibits the rise in sodium and calcium induced by 4 aminopyridine in synaptosomes	2005	-0.3068	0.1281	23	0.845
1976597120	a stepped care intervention is effective for elderly people with subthreshold depression or anxiety	2009	0.6751	-0.1736	77	0.7558
1976646617	anesthetic management and one year mortality after noncardiac surgery	2005	2.2201	-0.038	36	1.8842
1976667708	analysis of rehabilitation activities within skilled nursing and inpatient rehabilitation facilities after hip replacement for acute hip fracture	2010	2.1885	-0.0861	26	0.8017
1976668870	unmet needs of caregivers of individuals referred to a dementia care program	2015	0.6788	-0.15	75	0.8305
1976737232	effect of central cholinergic stimulation on regional cerebral blood flow in alzheimer s disease	1991	-0.293	0.1677	13	0.916
1976809766	usefulness of the geriatric depression scale 15 item version among very old people with and without cognitive impairment	2013	0.4834	-0.1436	60	0.7993
1976929973	5 ht6 receptor and cognition	2011	-1.5582	0.2221	115	0.9404
1976968008	an individualized psychosocial approach for treatment resistant behavioral symptoms of dementia among aged care residents	2007	0.5272	-0.0878	34	0.7062
1977085392	serotonin signaling is associated with lower amyloid ?? levels and plaques in transgenic mice and humans	2011	0.0383	0.1961	61	0.9404
1977109968	health related quality of life of subjects with known and unknown hypertension results from the population based hortega study	2003	-0.7617	-0.1539	14	0.9404
1977230392	brain aging modulates the neuroprotective effects of estrogen on selective aspects of cognition in women a critical review	2008	-0.7569	-0.7669	3	2.9958
1977235517	effect of the application of low frequency rtms on cognitive function in chronic stroke patients	2014	-0.1943	0.0545	67	0.6693
1977257077	slowly progressive aphasia without generalized dementia	1982	-0.236	0.2606	66	0.9999
1977270916	reality orientation therapy in alzheimer disease useful or not a controlled study	1995	0.2843	-0.0885	10	3.8653
1977317670	randomized dim light controlled crossover test of morning bright light therapy for rest activity rhythm disorders in patients with vascular dementia and dementia of alzheimer s type	1998	0.3142	-0.0191	17	3.8253
1977374270	a prospective study of estrogen replacement therapy and the risk of developing alzheimer s disease the baltimore longitudinal study of aging	1997	-0.7413	-0.7393	3	13.9931
1977405703	clinical antipsychotic trials of intervention effectiveness catie alzheimer s disease trial	2003	0.4967	0.0613	91	17.7779
1977427195	tolerability and efficacy of memantine add on therapy to rivastigmine transdermal patches in mild to moderate alzheimer s disease a multicenter randomized open label parallel group study	2011	-0.222	0.0599	19	2.4198
1977463589	effects of folic acid supplementation on psychomotor performance and hemorheology in healthy elderly subjects	2006	-0.8989	-0.0918	30	19.3521
1977466344	improvement of cognitive function by mental and or individualized aerobic training in healthy elderly subjects	2002	0.5312	-0.2348	27	8.2618
1977498406	sustained cholinesterase inhibition in ad patients receiving rivastigmine for 12 months	2002	-0.2231	0.0415	72	1.6836
1977585036	extended results of the alzheimer s disease anti inflammatory prevention trial	2011	-0.4391	-0.0866	32	1.9899
1977598790	estradiol increases choline acetyltransferase activity in specific basal forebrain nuclei and projection areas of female rats	1985	-0.7647	-0.7717	3	1
1977604446	effect of blood pressure control and antihypertensive drug regimen on quality of life the african american study of kidney disease and hypertension aask pilot study	1996	-0.7628	-0.1427	135	0.7247
1977605314	social service interventions for caregivers of patients with dementia impact on health care utilization and expenditures	1993	0.5454	-0.1117	1	18.7303
1977638569	vitamin e and essential polyunsaturated fatty acids supplementation in schizophrenia patients treated with haloperidol	2016	-1.1801	-0.326	129	0.6941
1977644697	caregivers utilization of health services results from the medicare alzheimer s disease demonstration illinois site	2001	0.5756	-0.1217	139	16.2819
1977733636	efficacy of cognitive rehabilitation in patients with mild cognitive impairment treated with cholinesterase inhibitors	2007	0.1987	-0.1176	10	26.5045
1977749148	meta analysis of factors which influence delirium following cardiac surgery	2012	2.2276	-0.0441	2	0.75
1977755605	costs of care in a mild to moderate alzheimer clinical trial sample key resources and their determinants	2011	0.5272	-0.0877	34	0.7282
1977793582	evidence based interventions for nursing home residents with dementia related behavioral symptoms	2005	0.4399	-0.0044	104	0.7803
1977806295	psychological and electroencephalographic relationships in cryothalamectomy for parkinsonism	1970	-0.289	0.1016	41	0.7057
1977829177	higher dose 23 mg day donepezil formulation for the treatment of patients with moderate to severe alzheimer s disease	2012	-0.2662	0.0553	124	0.8774
1977842062	economic evaluation of donepezil for the treatment of alzheimer s disease in canada	1999	-0.1959	0.0351	6	0.9713
1977842209	an expedient route to the calabar bean alkaloids physovenine and physostigmine	2000	-0.3032	0.1546	13	0.7993
1977855994	ginseng abuse syndrome problems with the panacea	1979	-0.6515	-0.1195	65	1.9579
1977994579	chronic citicoline increases phosphodiesters in the brains of healthy older subjects an in vivo phosphorus magnetic resonance spectroscopy study	2002	-0.4003	-0.2667	62	0.845
1978031449	p 4 017 memantine donepezil dual therapy is superior to placebo donepezil therapy for treatment of moderate to severe alzheimer s disease	2003	-0.2408	0.0603	19	0.7822
1978061037	effects of combination estrogen plus progestin hormone treatment on cognition and affect	2006	-0.7429	-0.7473	3	30.8491
1978110057	therapeutic value of ginkgo biloba in reducing symptoms of decline in mental function	1998	-0.4164	-0.0864	8	0.9939
1978118094	effect of music therapy on anxiety and depression in patients with alzheimer s type dementia randomised controlled study	2009	0.4794	-0.0541	21	28.8079
1978146108	prospective randomised study of an orthopaedic geriatric inpatient service	1988	1.9721	-0.0871	26	0.9997
1978162301	the assessment of treatment integrity in a cognitive behavioral telephone intervention study with dementia caregivers	2014	0.5415	-0.1158	1	0.7993
1978211228	the efficacy and safety of risperidone in the treatment of psychosis of alzheimer s disease and mixed dementia a meta analysis of 4 placebo controlled clinical trials	2007	0.0503	0.1033	38	1.63
1978240156	effect of glucose and peripheral glucose regulation on memory in the elderly	1997	-0.4598	1.8033	96	0.7993
1978247162	the efficacy of cerebrolysin in vascular dementia	2009	-0.3243	0.1121	33	0.7984
1978325568	erythrocyte choline concentrations in psychiatric disorders	1991	-0.4086	0.3103	120	0.6296
1978342865	response of patients with alzheimer disease to rivastigmine treatment is predicted by the rate of disease progression	2001	-0.2339	0.047	6	21.659
1978372802	six month walking program changes cognitive and adl performance in patients with alzheimer	2011	0.4815	-0.1859	25	29.807
1978392406	effect of interferon beta 1b on cognitive functions in multiple sclerosis	2002	-0.2421	0.2104	55	1
1978420745	impact of early administration of sertraline on cognitive and behavioral recovery in the first year after moderate to severe traumatic brain injury	2010	-0.9922	1.2607	71	0.7223
1978425857	integrated dementia care in the netherlands a multiple case study of case management programmes	2009	0.5564	-0.1188	74	0.916
1978502700	delirium in older persons	2006	2.0894	-0.0443	2	16.4542
1978515333	p4 022 memantine monotherapy is effective andsafe for the treatment of mild to moderate alzheimer s disease a randomized controlled trial	2004	-0.2369	0.0577	19	1.4617
1978581043	pain treatment in post traumatic hip fracture in the elderly regional block vs systemic non steroidal analgesics	2010	2.2485	-0.0454	138	0.9982
1978708350	pharmacodynamic tolerability relationships of cholinesterase inhibitors for alzheimer s disease	2001	-0.2381	0.0525	19	1.8427
1978711369	the effectiveness of a mutual support group for family caregivers of a relative with dementia	2002	0.5408	-0.1158	74	0.9404
1978728630	longitudinal effects of estrogen replacement therapy on pet cerebral blood flow and cognition	2000	-0.7579	-0.7651	3	1.9999
1978741241	the use of cognitive behavioural therapy techniques for anxiety and depression in hospice patients a feasibility study	2008	0.7627	-0.2018	77	0.8259
1978768748	neuropsychological correlates of p300 in patients with alzheimer s disease	2012	-0.2809	0.1571	43	0.6351
1978772749	p 8 26 response to selegiline i deprenyl in senile dementia of alzheimer type relation to disease stage	1995	-0.5495	0.3992	73	0.7239
1978827622	safety of donepezil in extended treatment of alzheimer s disease	1999	-0.3185	0.1186	33	1.6515
1978887771	donepezil or memantine improved cognitive functioning in moderate to severe alzheimer disease	2012	-0.316	0.145	33	1.6083
1978903374	timed instrumental activities of daily living tasks relationship to cognitive function and everyday performance assessments in older adults	2002	0.4861	-0.2607	4	1
1978915018	an ergot preparation hydergine in the treatment of cerebrovascular disorders in the geriatric patient double blind study	1971	-0.2903	0.1011	41	1.8163
1978948228	factors influencing skin tolerability to the rivastigmine patch in patients with alzheimer s disease	2015	-0.244	0.0543	19	0.8854
1979030376	the study on cognition and prognosis in the elderly scope principal results of a randomized double blind intervention trial	2003	-0.7217	-0.1419	14	31.7829
1979032901	the effects of galantamine treatment on caregiver time in alzheimer s disease	2003	-0.2075	0.004	6	1.7273
1979038116	the use of aromatherapy to treat behavioural problems in dementia	2008	0.4064	-0.0321	34	0.9584
1979089280	alzheimer s disease treated patients showed different patterns for oxidative stress and inflammation markers	2013	-1.1801	-0.326	129	0.7019
1979100644	quantification of metformin by the hplc method in brain regions cerebrospinal fluid and plasma of rats treated with lipopolysaccharide	2010	-0.3415	0.9111	113	0.75
1979150324	increased serum il 1?? level in alzheimer s disease and mild cognitive impairment	2009	-0.3245	0.1979	22	0.7579
1979274603	efficient formal total synthesis of physostigmine and physovenine conformational analysis of key intermediates	2002	-0.3032	0.1546	13	0.75
1979325947	designing clinical trials for assessing the effects of cognitive training and physical activity interventions on cognitive outcomes the seniors health and activity research program pilot sharp p study a randomized controlled trial	2011	0.5343	-0.1871	27	18.6598
1979352946	the effect of a pre and postoperative orthogeriatric service on cognitive function in patients with hip fracture randomized controlled trial oslo orthogeriatric trial	2014	2.1926	-0.0489	2	18.1605
1979379797	melatonin secretion rhythm disorders in patients with senile dementia of alzheimer s type with disturbed sleep waking	1999	0.2449	-0.0173	28	6.9205
1979558709	multicenter double blind randomized placebo controlled trial of levetiracetam as add on therapy in patients with refractory partial seizures	2000	-0.2658	0.0614	44	0.6914
1979627666	cognitive profile of the chinese version of the dementia rating scale for chinese elderly with dementia	2003	-0.1886	0.0705	7	0.7596
1979633978	clinico genealogical study of alzheimer s disease	1991	-0.4416	0.2873	105	0.8601
1979675033	a 28 week double blind placebo controlled study with cerebrolysin in patients with mild to moderate alzheimer s disease	2001	-0.334	0.0043	70	0.845
1979684199	a randomized placebo controlled study of the efficacy and safety of sertraline in the treatment of the behavioral manifestations of alzheimer s disease in outpatients treated with donepezil	2004	0.1456	0.0864	16	31.0529
1979747563	aluminum iii facilitates the oxidation of nadh by the superoxide anion	1992	-1.5747	-1.2603	101	0.7993
1979774528	depression outcomes in psychiatric clinical practice using a self rated measure of depression severity	2011	0.4581	0.2355	116	0.7502
1979793891	investigating the enhancing effect of music on autobiographical memory in mild alzheimer s disease	2006	0.4716	-0.0703	21	4.9232
1979901474	electroencephalograph effects of single doses of ginkgo biloba and panax ginseng in healthy young volunteers	2003	-0.6633	-0.1226	65	1.5493
1979956862	five year outcomes for dementia defined solely by neuropsychological test performance	2003	-0.0747	-0.1034	127	0.8094
1980007375	?? ketoglutarate dehydrogenase in alzheimer brains bearing the app670 671 mutation	1998	-0.7874	-0.0992	86	0.845
1980026247	haloperidol prophylaxis decreases delirium incidence in elderly patients after noncardiac surgery a randomized controlled trial	2012	2.1951	-0.0437	2	12.4944
1980059384	ginkgo biloba extract egb 761 donepezil or both combined in the treatment of alzheimer s disease with neuropsychiatric features a randomised double blind exploratory trial	2009	-0.4	-0.0527	8	8.2274
1980060567	evaluation of the optimal preemptive dose of gabapentin for postoperative pain relief after lumbar diskectomy a randomized double blind placebo controlled study	2005	2.2251	-0.0433	2	0.9982
1980067391	an open trial of valproate for agitation in geriatric neuropsychiatric disorders	1997	0.174	0.0804	16	0.9804
1980085328	a randomized placebo controlled trial of paroxetine in nursing home residents with non major depression	2002	0.103	0.1503	61	0.7073
1980170637	efficacy and safety of idebenone in the long term treatment of alzheimer s disease a double blind placebo controlled multicentre study	1996	-0.2197	0.1016	23	0.6871
1980263164	cranial electrostimulation ces in patients with probable alzheimer s disease	2002	0.084	-0.0071	67	20.3858
1980394700	rey verbal learning test is a useful tool for differential diagnosis in the preclinical phase of alzheimer s disease comparison with mild cognitive impairment and normal aging	2003	-0.1816	0.0898	37	0.7756
1980452800	electroconvulsive therapy results in depressive illness from the leicestershire trial	1984	-0.3244	-0.142	45	0.6993
1980525435	effect of tacrine on behavioral symptoms in alzheimer s disease an open label study	1996	-0.1754	0.0958	44	1.7447
1980531733	the effect of person centred dementia care to prevent agitation and other neuropsychiatric symptoms and enhance quality of life in nursing home patients a 10 month randomized controlled trial	2013	0.365	-0.0062	18	0.9996
1980542913	effect of physical activity on cognitive function in older adults at risk for alzheimer disease a randomized trial	2008	0.4334	-0.174	25	13.8877
1980574540	nonsteroidal anti inflammatory drugs in alzheimer s disease	1995	-0.414	-0.0404	32	1
1980606866	citicoline improves verbal memory in aging	1996	-0.3977	-0.2616	62	22.4476
1980684846	citicoline treatment increases retinal dopamine content in rabbits	2002	-0.4003	-0.2667	62	0.7993
1980742278	a randomized double blind study comparing 25 and 50 mg tc 1734 azd3480 with placebo in older subjects with age associated memory impairment	2011	-0.2522	0.1582	9	0.6645
1980754242	practice constraints behavioral problems and dementia care primary care physicians perspectives	2007	0.5734	-0.1262	74	0.9994
1980806079	two year outcome of children treated for depression	1998	0.4581	0.2355	116	0.7534
1980871011	frailty syndrome and the risk of vascular dementia the italian longitudinal study on aging	2013	0.538	-0.2242	136	0.9867
1980872763	clinical safety tolerance and plasma levels of the oral anticholinesterase 1 2 3 4 tetrahydro 9 aminoacridin 1 ol maleate hp 029 in alzheimer s disease preliminary findings	1990	-0.2658	0.0614	44	0.7131
1980946667	underestimating the severity of bipolar depression a comparison of the hamilton depression rating scale items	2012	0.2621	0.0262	31	0.7639
1980955017	the prevalence of psychiatric symptoms and behavioural disturbances and the use of psychotropic drugs in norwegian nursing homes	2007	0.9841	-0.0257	24	0.7301
1980970063	patient predictors of response to treatment of depression in alzheimer s disease the diads study	2004	0.2426	0.0884	31	17.2872
1980970604	the cholinergic system in schizophrenia reconsidered anticholinergic modulation of sleep and symptom profiles	1999	0.0183	0.3851	48	0.643
1980983280	cognitive performances in newly referred patients with temporal lobe epilepsy comparison with normal subjects in basal condition and after treatment with controlled release carbamazepine	1996	0.2293	-0.2025	111	0.6251
1981016296	neuropsychological tests for monitoring delirium severity in elderly patients	1996	-0.2264	0.0532	84	0.7231
1981129287	sex hormones and cognitive function in older men	2002	-0.9327	-1.0635	54	1
1981199790	pre operative analgesia for patients with femoral neck fractures using a modified fascia iliaca block technique	2005	2.2485	-0.0454	138	0.9713
1981359936	melatonin increases survival and inhibits oxidative and amyloid pathology in a transgenic model of alzheimer s disease	2003	0.2294	-0.0176	28	1.9959
1981418853	caffeine withdrawal increases cerebral blood flow velocity and alters quantitative electroencephalography eeg activity	2000	-0.4209	0.3343	90	0.6398
1981473511	cognitive dysfunction in hiv patients despite long standing suppression of viremia	2009	-0.4004	0.502	87	1.9686
1981480895	altered circadian cortisol secretion in alzheimer s disease clinical and neuroradiological aspects	2001	0.3287	-0.0245	89	1.4857
1981541008	the apolipoprotein e ¤Á4 allele and decline in different cognitive systems during a 6 year period	2002	-0.7714	-0.1862	29	0.9804
1981578885	lethicin in the treatment of alzheimer s disease	1983	-0.2782	0.2187	9	1.4599
1981603125	behavioral and psychological symptoms in patients with dementia as a target for pharmacotherapy with risperidone	2004	0.1565	0.0927	16	16.6892
1981678595	pharmacological treatment of elderly patients randomised into a heart failure disease management program intervention trial hf geriatrics	2012	-0.5975	-0.0271	99	0.6818
1981722242	evaluation of a palliative care service problems and pitfalls	1994	0.8533	-0.0193	95	0.8843
1981723672	effect of multicomponent interventions on caregiver burden and depression the reach multisite initiative at 6 month follow up	2003	0.5234	-0.1084	1	1
1981922048	estrogen plus progestin and the risk of coronary heart disease	2003	-0.7376	-0.7326	3	2
1981961320	the effects of tacrine in patients with mild versus moderate stage alzheimer s disease	1994	-0.311	0.0163	57	0.7016
1981968341	effect of modafinil on subjective fatigue in multiple sclerosis and stroke patients	2009	-1.1671	1.5699	64	0.845
1981974367	effect of the acquisition enhancing drug piracetam on rat cerebral energy metabolism comparison with naftidrofuryl and methamphetamine	1976	-0.2983	0.2325	15	0.75
1982064952	alzheimer disease evidence for selective loss of cholinergic neurons in the nucleus basalis	1981	-0.3151	0.192	13	9.2196
1982128001	brief intervention for co occurring anxiety and depression in primary care a pilot study	2003	0.6749	-0.1727	77	0.7456
1982214580	vascular cognitive impairment	2003	-0.4178	0.0026	12	10.1359
1982257600	a 1 year controlled trial of acetyl l carnitine in early onset ad	2000	-0.3361	-0.0141	63	25.1682
1982278900	polyunsaturated fatty acids neuroinflammation and well being	2010	-1.1027	-0.3021	5	0.75
1982373748	vasodilators in senile dementias a review of the literature	1979	-0.293	0.0998	41	0.7993
1982388019	does serotonin augmentation have any effect on cognition and activities of daily living in alzheimer s dementia a double blind placebo controlled clinical trial	2007	0.0372	0.1959	61	19.6052
1982422562	old age and cognition enhancement of recent memory in aged rats by the calcium channel blocker nimodipine	1992	-0.3432	0.1147	53	0.845
1982447059	fish meat and risk of dementia cohort study	2002	-1.0652	-0.2911	5	3.9668
1982522566	cholinergic processes in blood samples from patients with major psychiatric disorders	1985	-0.4081	0.3096	120	0.6182
1982536057	subacute methylphenidate treatment for moderate to moderately severe traumatic brain injury a preliminary double blind placebo controlled study	1996	-0.8474	1.0199	71	0.9713
1982587661	fish consumption and cognitive function among older people in the uk baseline data from the opal study	2009	-1.0577	-0.2885	5	19.7779
1982617671	dementia and cognitive impairment in parkinson s disease	1988	-0.2007	0.0876	78	0.6734
1982697297	recruitment of the elderly into a pharmacologic prevention trial the ginkgo evaluation of memory study experience	2006	-0.331	-0.093	8	16.346
1982779257	docosahexaenoic acid and adult memory a systematic review and meta analysis	2015	-1.0951	-0.3005	5	0.75
1982815394	electrosleep therapy a controlled double blind study	1973	0.2261	-0.0085	17	0.75
1982816514	effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild alzheimer disease a randomized controlled trial	2009	-0.4918	-0.1064	32	5.839
1982816695	adding memantine to rivastigmine therapy in patients with mild to moderate alzheimer s disease results of a 12 week open label pilot study	2006	-0.2357	0.0395	72	1.6067
1982821943	the effect of staff training on agitation and use of restraint in nursing home residents with dementia a single blind randomized controlled trial	2010	0.7721	-0.0942	42	22.3291
1982874376	d cycloserine effects on long term retention of a conditioned response and on memory for contextual attributes	1999	-0.2975	0.1887	43	0.9804
1982876115	p1 071 alzheimer s disease	2004	-0.4416	0.2873	105	0.8732
1982921548	reliability and validity of the apathy evaluation scale	1991	-0.1977	0.0752	44	0.916
1982921708	a clinical trial to reduce restraints in nursing homes	1997	0.8403	-0.1017	42	23.9615
1982930764	clinical pharmacokinetics of arecoline in subjects with alzheimer s disease	1996	-0.2806	0.1134	13	0.78
1982992473	adverse outcomes after hospitalization and delirium in persons with alzheimer disease	2012	1.6418	-0.0325	24	0.75
1983021005	acetyl l carnitine 1 effects on mortality pathology and sensory motor performance in aging rats	1990	-0.3264	-0.0239	63	0.75
1983048388	impact of melatonin on driving performance	1998	-0.387	0.3785	98	0.6741
1983070519	thiamine dependent enzyme changes in temporal cortex of patients with alzheimer s disease	1990	-0.7851	-0.0993	86	2.9683
1983087888	postoperative admission to a dedicated geriatric unit decreases mortality in elderly patients with hip fracture	2014	2.1944	-0.0495	2	0.7993
1983145147	efficacy and safety of neuroleptics in behavioral disorders associated with dementia	1998	0.1606	0.0863	16	1.916
1983159577	the effects of a walking talking program on communication ambulation and functional status in residents with alzheimer disease	2002	0.4941	-0.17	25	8.4048
1983171150	efficacy of psychosocial intervention in patients with mild alzheimer s disease the multicentre rater blinded randomised danish alzheimer intervention study daisy	2012	0.6197	-0.1512	77	1.595
1983176411	memantine in alzheimer s disease	2013	-0.306	0.1659	22	3.4165
1983187546	single dose of methylphenidate improves cognitive performance in multiple sclerosis patients with impaired attention process	2009	-0.2413	0.2136	55	1.9557
1983209930	effects of methylphenidate on attention deficits after traumatic brain injury a multidimensional randomized controlled trial	2004	-0.8474	1.0199	71	0.9992
1983232916	time spent on informal and formal care giving for persons with dementia in sweden	2002	0.0626	-0.03	93	0.9959
1983258883	rs 86 in the treatment of alzheimer s disease cognitive and biological effects	1987	-0.2986	0.2134	15	0.75
1983390737	fatty acid analysis of blood plasma of patients with alzheimer s disease other types of dementia and cognitive impairment	2000	-1.0768	-0.2944	5	3.782
1983485985	preoperative risk factors for postoperative delirium	2001	2.2253	-0.0295	36	0.9404
1983493842	changes in hippocampal connectivity in the early stages of alzheimer s disease evidence from resting state fmri	2006	-0.2499	0.1367	22	0.9404
1983522355	sertraline for the treatment of depression in alzheimer disease	2010	0.1772	0.0811	31	28.5405
1983526026	a calcium antagonist vs a non calcium antagonist hypertension treatment strategy for patients with coronary artery disease the international verapamil trandolapril study invest a randomized controlled trial	2003	-0.7616	-0.1531	14	0.916
1983531379	effects of changes in fat fish and fibre intakes on death and myocardial reinfarction diet and reinfarction trial dart	1989	-1.2428	-0.3453	83	1
1983548345	cranial electrotherapy stimulation as a treatment for anxiety in chemically dependent persons	1986	0.2261	-0.0085	17	0.845
1983585951	the effect of age on the activity and molecular properties of human brain monoamine oxidase	1980	-0.188	0.1187	37	1.836
1983594459	perioperative methylprednisolone and outcome in neonates undergoing heart surgery	2012	2.5491	-0.0689	35	0.7765
1983640789	l deprenyl in the treatment of mild dementia of the alzheimer type results of a 15 month trial	1993	-0.1447	0.0997	37	26.7395
1983646709	central neurotoxicity of standard treatment in patients with newly diagnosed high grade glioma a prospective longitudinal study	2014	0.2301	-0.2027	111	0.6309
1983772248	group reminiscence therapy for cognitive and affective function of demented elderly in taiwan	2007	0.3391	-0.0929	39	2.927
1983913269	clinical pharmacokinetics of galantamine	2003	-0.3783	0.0982	94	0.8077
1984042519	dietary fat intake and the risk of incident dementia in the rotterdam study	1997	-1.0591	-0.2878	5	4.9535
1984098107	at the crossroads development and evaluation of a dementia caregiver group intervention to assist in driving cessation	2008	0.6283	-0.1218	42	0.7236
1984112731	a pha l analysis of ascending projections of the dorsal raphe nucleus in the rat	1991	0.2261	-0.0085	17	0.75
1984209021	impact of ?? blockade on complex cognitive functioning	1988	-0.3807	-0.2165	45	0.6592
1984261359	memantine in moderate to severe alzheimer s disease a meta analysis of randomised clinical trials	2007	-0.185	0.0625	6	11.6902
1984404080	a randomized double blind placebo controlled trial of two doses of ginkgo biloba extract in dementia of the alzheimers type	2005	-0.4183	-0.0705	8	35.7538
1984609418	neurophysiological evaluation of zidovudine in asymptomatic hiv 1 infection a longitudinal placebo controlled study	1995	-0.1943	0.0545	67	0.6984
1984627423	quiet music an intervention for mealtime agitation	1997	0.4845	-0.0519	21	1
1984682214	quetiapine versus olanzapine in the treatment of behavioral and psychological symptoms in patients with alzheimer s disease	2010	0.3082	0.1433	81	1.5848
1984696272	intrusions as a sign of alzheimer dementia chemical and pathological verification	1982	-0.3173	0.2025	13	0.7993
1984737558	effects of age sex and ethnicity on the association between apolipoprotein e genotype and alzheimer disease a meta analysis	1997	-0.7705	-0.1862	29	0.9999
1984744180	efficacy and safety of nimodipine in subcortical vascular dementia a subgroup analysis of the scandinavian multi infarct dementia trial	2000	-0.4402	-0.0007	12	22.1665
1984749403	discontinuation of antidepressants in people with dementia and neuropsychiatric symptoms desep study double blind randomised parallel group placebo controlled trial	2012	-0.0054	0.0447	80	1.6627
1984753653	peripheral neuropathy in behcet disease an electroneurophysiological study	2007	0.2293	-0.2025	111	0.6246
1984770039	memory and cognitive function in the elderly a preliminary trial of physostigmine	1980	0.0183	0.3851	48	0.6738
1984911824	ic 02 01 mri evidence for a disease modifying effect of ginkgo biloba extract in a dementia prevention trial	2008	-0.4758	-0.0347	132	0.7001
1984915014	comparison of thioridazine and diazepam in the control of nonpsychotic symptoms associated with senility double blind study	1973	0.0864	0.0987	47	20.8418
1984964878	hypercholesterolemia accelerates the alzheimer s amyloid pathology in a transgenic mouse model	2000	-0.7183	-0.1669	29	3.9712
1985048555	behavioral effects of memantine in alzheimer disease patients receiving donepezil treatment	2006	-0.1432	0.0822	6	25.6253
1985050648	a 12 week open trial of donepezil hydrochloride in patients with multiple sclerosis and associated cognitive impairments	2000	-0.2422	0.2113	55	1
1985068883	remcare reminiscence groups for people with dementia and their family caregivers effectiveness and cost effectiveness pragmatic multicentre randomised trial	2012	0.3584	-0.0934	39	19.021
1985086034	valproate therapy for agitation in dementia open label extension of a double blind trial	2003	0.1737	0.0797	16	2.9666
1985129563	risk factors for and management of cognitive dysfunction in multiple sclerosis	2011	-0.2417	0.2138	55	0.9959
1985148653	the combined effects of l theanine and caffeine on cognitive performance and mood	2008	-0.6623	-0.1216	65	0.7044
1985168335	dehydroepiandrosterone dhea a fountain of youth	1996	-1.4201	-1.8405	20	1
1985195352	gm 1 treatment of alzheimer s disease a pilot study of safety and efficacy	1990	-0.0746	0.063	58	0.6701
1985221779	changes in antipsychotic drug use in nursing homes during implementation of the obra 87 regulations	1994	0.5873	-0.0102	52	1.991
1985261900	a double blind comparison of alaproclate and placebo in the treatment of patients with senile dementia	1985	-0.1379	0.0381	80	0.6722
1985305469	serotonergic function and treatment of behavioral and psychological symptoms of frontotemporal dementia	2012	-0.2329	0.2522	66	1.6773
1985320432	a potential role for 5 androstene 3?? 7?? 17?? triol in obesity and metabolic syndrome	2011	-1.3848	-1.7808	54	0.7313
1985407530	senile dementia combined pharmacologic and psychologic treatment	1981	-0.3558	0.0699	41	1.4188
1985528178	efficacy and safety of rivastigmine in patients with alzheimer s disease international randomised controlled trialcommentary another piece of the alzheimer s jigsaw	1999	-0.2386	0.0468	6	17.5457
1985542781	3 322 toxicity of aluminum and alzheimer disease	2012	-1.0873	-0.5741	69	0.6812
1985555067	dopamine antagonistic anticholinergic and gabaergic effects on declarative and procedural memory functions	2000	0.0183	0.3851	48	0.6743
1985592735	testosterone replacement in older hypogonadal men a 12 month randomized controlled trial	1997	-1.1015	-1.3316	54	2
1985634563	effectiveness of cognitive behavioural therapy for anxiety and depression in primary care a meta analysis	2015	0.7627	-0.2018	77	0.8218
1985675058	a randomized placebo controlled trial of risperidone for the treatment of aggression agitation and psychosis of dementia	2003	0.1935	0.0906	16	43.4791
1985699034	belt restraint reduction in nursing homes design of a quasi experimental study	2010	0.8187	-0.1001	42	0.8843
1985759934	dehydroepiandrosterone sulfate levels are associated with more favorable cognitive function in women	2008	-1.4128	-1.8331	20	0.9804
1985766198	effects of panax ginseng consumed with and without glucose on blood glucose levels and cognitive performance during sustained mentally demanding tasks	2006	-0.6574	-0.1206	65	3.5889
1985868052	dissociating medication effects from learning and practice effects in a neurocognitive study of schizophrenia olanzapine versus haloperidol	2007	-0.2514	0.1578	9	0.6436
1985879372	factors affecting a?? plasma levels and their utility as biomarkers in adni	2011	-0.295	0.0288	57	0.6839
1985969204	l deprenyl in the treatment of mild dementia of the alzheimer type preliminary results	1993	-0.1807	0.0896	37	19.4839
1986040695	executive control function a rational basis for the diagnosis of vascular dementia	1999	-0.4456	-0.0019	12	1.8254
1986182018	the safety of a fast track program after laparoscopic colorectal surgery is comparable in older patients as in younger patients	2013	2.7899	-0.0532	118	0.7993
1986185846	lacunar lesions are independently associated with disability and cognitive impairment in cadasil	2007	-0.4493	-0.0027	12	0.9992
1986224014	effects of replacement dose of dehydroepiandrosterone in men and women of advancing age published erratum appears in j clin endocrinol metab 1995 sep 80 9 2799	1994	-1.4189	-1.839	20	2
1986258856	vascular dementia vd compared to alzheimer disease ad and semantic dementia sd	2009	-0.4055	0.0833	85	0.6794
1986259630	use of psychoactive medication and the quality of care in rest homes	1989	0.5411	0.0026	52	1
1986270429	better oral reading and short term memory in midlife postmenopausal women taking estrogen	2003	-0.7509	-0.7573	3	1.94
1986283880	cognitive correlates of cortical cholinergic denervation in parkinson s disease and parkinsonian dementia	2006	-0.1831	0.111	7	0.9988
1986313327	levodopa use and sleep in patients with dementia with lewy bodies	2009	-0.1493	0.1232	7	0.7998
1986318523	selective accumulation of aluminum and iron in the neurofibrillary tangles of alzheimer s disease a laser microprobe lamma study	1992	-1.0107	-0.5241	69	1
1986335688	the heterogeneity of anosognosia for memory impairment in alzheimer s disease a review of the literature and a proposed model	1998	0.2476	-0.1139	10	0.9804
1986349013	administration of olanzapine to prevent postoperative delirium in elderly joint replacement patients a randomized controlled trial	2010	2.1919	-0.0433	2	31.503
1986392550	a controlled trial of piracetam in intellectually impaired patients with parkinson s disease	1990	-0.2347	0.1981	9	18.8006
1986491645	problem solving counseling for caregivers of the cognitively impaired effective for whom	1999	0.5426	-0.1116	1	0.991
1986501759	neuroleptic and benzodiazepine use in long term care in urban and rural alberta characteristics and results of an education intervention to ensure appropriate use	2005	0.597	-0.0144	52	0.916
1986568015	having had a hip fracture association with dependency among the oldest old	2005	2.1039	-0.0876	26	0.7544
1986611496	effects of extended outpatient rehabilitation after hip fracture a randomized controlled trial	2004	1.9721	-0.0871	26	0.9988
1986621266	recruitment of volunteers to improve vitality in the elderly the revive study	2007	2.1988	-0.0457	2	0.9804
1986629932	cognitive response to pharmacological treatment for depression in alzheimer disease secondary outcomes from the depression in alzheimer s disease study diads	2004	0.1568	0.1144	31	20.5925
1986689424	prevention of potentially inappropriate prescribing for elderly patients a randomized controlled trial using stopp start criteria	2011	0.7094	-0.0475	52	0.845
1986696289	huperzine a as potential treatment of alzheimer s disease an assessment on chemistry pharmacology and clinical studies	2011	-0.5779	-0.1503	32	0.9959
1986761579	physical fitness aging and psychomotor speed a review	1980	0.5822	-0.2519	27	0.9404
1986812222	memantine in alzheimer s disease experience in an alzheimer s disease assessment unit	2012	-0.1959	0.1175	92	1.5111
1986819808	palliative care in advanced dementia a randomized controlled trial and descriptive analysis	2000	0.8502	-0.0193	95	18.6984
1986867488	an exploratory study of body accessibility	1966	0.5917	-0.0633	123	0.7993
1986892178	galantamine in the treatment of cognitive decline in patients with vascular dementia or alzheimer s disease with cerebrovascular disease	2003	-0.3656	0.0715	94	22.1739
1986930880	clinical evaluation of pain	2006	-0.3925	0.3624	106	0.7441
1986974900	randomized controlled trial of brief cognitive behaviour therapy versus treatment as usual in recurrent deliberate self harm the popmact study	2003	-0.2944	-0.1534	45	0.6841
1987000955	evaluation of cognitive technologies in geriatric rehabilitation a case study pilot project	2010	0.5131	-0.1606	60	0.6767
1987003014	the distinct cognitive syndromes of parkinson s disease 5 year follow up of the campaign cohort	2009	-0.1859	0.0725	7	0.75
1987054189	prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower than average cholesterol concentrations in the anglo scandinavian cardiac outcomes trial lipid lowering arm ascot lla a multicentre randomised controlled trial	2004	-0.5184	-0.0899	68	0.7073
1987226585	534 reduction of psychotic symptoms in patients with lewy body like symptoms treated with olanzapine	2000	0.104	0.1382	38	0.9763
1987264861	the effect of short term estrogen replacement therapy on cognition a randomized double blind cross over trial in postmenopausal women	1998	-0.7506	-0.7592	3	7.9279
1987307065	depression in patients with mild cognitive impairment increases the risk of developing dementia of alzheimer type a prospective cohort study	2004	-0.0942	0.0057	84	0.7398
1987310343	rivastigmine in frontotemporal dementia an open label study	2004	-0.234	0.2553	66	3.7798
1987355763	a double blind randomised comparison of risperidone and haloperidol in the treatment of behavioural and psychological symptoms in chinese dementia patients	2001	0.1422	0.1002	16	4.3586
1987358702	fluoxetine is not effective in the treatment of poststroke fatigue a double blind placebo controlled study	2007	-1.1671	1.5699	64	0.7993
1987360934	eeg mapping and psychopharmacological studies with denbufylline in sdat and mid	1992	-0.4164	0.0413	41	0.6572
1987379978	impact of antiretroviral therapy on quality of life in hiv infected southeast asian children in the predict study	2013	-0.9265	-0.2579	79	0.7252
1987431570	predictors of the decision to yield care of a person with dementia	2002	0.6791	-0.1508	75	0.8122
1987528060	zuclopenthixol and thioridazine in the treatment of aggressive elderly patients a double blind controlled multicentre study	1992	0.1297	0.1281	47	14.9628
1987621030	a controlled trial of tacrine in alzheimer s disease	1992	-0.2834	0.1266	13	22.1169
1987646963	effects of lovastatin on cognitive function and psychological well being	2000	-0.2977	-0.2464	49	0.7021
1987655773	the effect of deprenyl selegiline on the natural history of parkinson s disease	1989	-0.1908	0.1194	37	2.9158
1987695803	olanzapine in the treatment of elderly patients with schizophrenia and related psychotic disorders	1998	0.3085	0.1434	81	0.7948
1987699981	the clinical meaningfulness of adas cog changes in alzheimer s disease patients treated with donepezil in an open label trial	2007	-0.3146	0.0955	50	0.6462
1987733219	ad2000 donepezil in alzheimer s disease	2004	-0.2729	0.0857	33	22.7658
1987787559	effect of ultralow doses of antibodies to s 100 protein in animals with impaired cognitive function and disturbed emotional and neurological status under conditions of experimental alzheimer disease	2009	0.0571	0.5351	48	0.6199
1987802990	long term effects of rivastigmine capsules in patients with traumatic brain injury	2009	-0.8474	1.0199	71	0.9973
1987908556	long term nicergoline treatment of mild to moderate senile dementia results of a multicentre double blind placebo controlled study	1997	-0.1379	0.0381	80	0.6908
1987911931	cerebrospinal fluid levels of total tau phospho tau and a??42 predicts development of alzheimer s disease in patients with mild cognitive impairment	2003	-0.295	0.0288	57	0.683
1988022388	preoperative gabapentin decreases anxiety and improves early functional recovery from knee surgery	2005	2.2243	-0.0437	2	0.9988
1988102338	haloperidol in the acute treatment of migraine a randomized double blind placebo controlled study	2006	2.2267	-0.0443	2	0.7552
1988116266	memory plasticity across the life span uncovering children s latent potential	2007	0.5038	-0.2821	4	0.6939
1988173183	effectiveness of piracetam in cortical myoclonus	1993	-0.3068	0.2482	15	0.9404
1988209519	effect of folate supplementation on n terminal pro brain natriuretic peptide	2007	-1.2096	-0.3344	128	0.6882
1988281595	sex steroids and affect in the surgical menopause a double blind cross over study	1985	-0.769	-0.7802	3	1
1988291834	managing the anxious patient with advancing disease a flow diagram	1993	0.0289	0.1124	38	0.7993
1988315502	a double blind trial of risperidone and haloperidol for the treatment of delirium	2004	2.1622	-0.0421	2	3
1988316193	ginkgo biloba does not improve cognitive function in ms a randomized placebo controlled trial	2012	-0.2326	0.2003	55	0.7993
1988326578	treatment of alzheimer disease	1991	-0.3718	0.2336	105	2.5824
1988380717	restoration of neuronal plasticity by a phosphodiesterase type 1 inhibitor in a model of fetal alcohol exposure	2006	-0.3068	0.1281	23	0.8843
1988446339	efficacy of quetiapine in the treatment of behavioral symptoms in dementia	2002	0.5483	0.3861	40	0.7217
1988471351	a randomized controlled trial of a behavior advisory service for hospitalized older patients with confusion	2004	2.2773	-0.0628	35	15.9289
1988485844	tacrine in alzheimer s disease	1991	-0.3217	0.1392	13	12.1599
1988492690	safety and tolerability of once daily versus twice daily memantine a randomised double blind study in moderate to severe alzheimer s disease	2007	-0.1974	0.1165	92	0.7518
1988575213	affective changes with estrogen and androgen replacement theraphy in surgically menopausal women	1988	-0.7699	-0.7799	3	1
1988604027	investigation into the significance of task difficulty and divided allocation of resources on the glucose memory facilitation effect	2002	-0.4598	1.8033	96	0.9404
1988716175	reappraisal of european guidelines on hypertension management a european society of hypertension task force document	2009	-0.7322	-0.152	14	1
1988721068	double blind placebo controlled study of acetyl l carnitine in patients with alzheimer s dementia	1990	-0.3186	0.0036	63	26.5723
1988754227	neurometabolic correlations of donepezil and rivastigmine in dementia patients a different neuroprotective effect	2009	-0.2939	0.1114	50	0.6858
1988893294	neuropsychological test performance in healthy elderly volunteers before and after donepezil administration a randomized controlled study	2005	-0.3244	-0.142	45	0.696
1988904861	perceived helpfulness of telephone calls	2004	0.7066	-0.1584	76	0.845
1988940818	free testosterone and risk for alzheimer disease in older men	2004	-0.9327	-1.0635	54	1
1988959530	impact of maintenance therapy on hospitalization and expenditures for medicare beneficiaries with chronic obstructive pulmonary disease	2010	0.5772	-0.1221	139	0.7435
1988967696	the pharmacology of physostigmine	1998	-0.3032	0.1546	13	0.7993
1988970685	use of risperidone in psychosis associated with huntington s disease	1998	0.3076	0.1434	81	0.7077
1988984956	relationship between plasma concentration levels of risperidone and clinical effects in the treatment of delirium	2005	-0.1168	0.194	114	0.7009
1989070599	risk of dementia in parkinson s disease a community based prospective study	2001	-0.1841	0.1075	7	3
1989112928	physostigmine in alzheimer s disease	1979	-0.3173	0.2025	13	0.75
1989145937	usefulness of plasma haloperidol levels for monitoring clinical efficacy and side effects in alzheimer patients with psychosis and behavioral dyscontrol	2003	-0.117	0.1933	114	13.8488
1989157642	mastery over dementia an internet intervention for family caregivers of people with dementia	2010	0.7067	-0.1575	76	0.796
1989222460	depression in alzheimer s disease overview and treatment	2002	0.1663	0.1023	31	1.8254
1989238006	a preliminary study of the comparative effects of olanzapine and risperidone on cognition in schizophrenia	2004	-0.2419	0.165	9	0.7179
1989294823	criteria for the diagnosis of ischemic vascular dementia proposed by the state of california alzheimer s disease diagnostic and treatment centers	1992	-0.4242	0.0058	12	10.2063
1989350443	a memory assessment technique for use in geriatric psychopharmacology drug efficacy trial with naftidrofuryl	1977	-0.2519	0.1576	9	13.1142
1989350951	memory training for severe memory loss effects on senile dementia patients and their families	1982	0.2804	-0.0908	10	1.9402
1989366358	relationships of dehydroepiandrosterone sulfate in the elderly with functional psychological and mental status and short term mortality a french community based study	1996	-1.4208	-1.8426	20	3.9952
1989409193	the neuroprotective properties of the ginkgo biloba leaf a review of the possible relationship to platelet activating factor paf	1996	-0.45	-0.0581	8	0.9999
1989482792	nonverbal encouragement of participation in a course the effect of touching	2004	0.5917	-0.0633	123	0.845
1989486145	efficacy and tolerability of ginkgo biloba extract egb 761 by type of dementia analyses of a randomised controlled trial	2009	-0.4151	-0.0473	8	4.4377
1989649721	randomized placebo controlled trial of donepezil in patients with progressive supranuclear palsy	2001	-0.1598	0.0553	67	0.6579
1989721871	clonidine impairs sustained attention and memory in alzheimer s disease	1999	0.0571	0.5351	48	0.6283
1989727902	long term effects of antidepressants on cognition in patients with alzheimer s disease	2006	0.1577	0.115	31	0.7993
1989766588	acute but not chronic activation of the nmda coupled glycine receptor with d cycloserine facilitates learning and retention	1994	-0.2949	0.1865	43	3.8186
1989812931	p 2 064 a dose ranging study of aripiprazole treatment in patients with psychosis associated with alzheimer s dementia	2004	0.3077	0.143	81	1.4359
1989920002	intelligence and the frontal lobe the organization of goal directed behavior	1996	0.4805	-0.2649	4	0.9996
1989962022	estrogen replacement therapy may protect against intellectual decline in postmenopausal women	1995	-0.7665	-0.7755	3	1.9997
1990053502	neuropsychological test performance in healthy volunteers before and after donepezil administration	2004	-0.4377	0.3666	90	0.6681
1990057142	a double blind placebo controlled multicentre study of memantine in mild to moderate vascular dementia mmm500	2002	-0.3685	0.0168	12	38.5087
1990091159	effect of fish oil supplementation on fatty acid status coordination and fine motor skills in children with phenylketonuria	2007	-1.2096	-0.3344	128	0.678
1990118078	a multidisciplinary intervention program improved the outcome after hip fracture for people with dementia subgroup analyses of a randomized controlled trial	2012	2.0427	-0.088	26	1.8442
1990224774	risperidone in the treatment of psychosis of alzheimer disease results from a prospective clinical trial	2006	0.1464	0.0928	16	2.8567
1990238348	the comparative effectiveness of three versions of classroom reality orientation	1981	0.322	-0.0925	10	1.9912
1990247209	neurocognitive assessment in the clinical antipsychotic trials of intervention effectiveness catie project schizophrenia trial development methodology and rationale	2003	0.6426	0.1008	91	0.9404
1990361036	flexible dose clinical trials predictors and outcomes of antipsychotic dose adjustments	2005	-0.1168	0.194	114	0.6902
1990402866	thiothixene in the treatment of geriatric patients with chronic organic brain syndrome	1976	0.112	0.0982	47	2.6904
1990510530	a randomized placebo controlled dose comparison trial of haloperidol for psychosis and disruptive behaviors in alzheimer s disease	1998	0.1509	0.0845	16	30.4088
1990559218	fish consumption long chain omega 3 fatty acids and risk of cognitive decline or alzheimer disease a complex association	2009	-1.0201	-0.2753	5	1
1990559695	impact of rivastigmine patch and capsules on activities of daily living in alzheimer s disease	2011	-0.2408	0.0589	7	1.6877
1990614265	glucose enhancement of performance of memory tests in young and aged humans	1989	-0.4606	1.8032	96	0.845
1990653927	sleep apnea apoe4 and alzheimer s disease 20 years and counting	2002	0.2286	-0.0028	28	0.9867
1990683886	nimodipine increases csf somatostatin in affectively ill patients	1995	-0.3852	0.1417	134	0.652
1990805071	treatment of agitation in ad a randomized placebo controlled clinical trial	2000	0.1887	0.0687	16	38.6997
1990867542	does behavioral improvement with haloperidol or trazodone treatment depend on psychosis or mood symptoms in patients with dementia	2001	0.1499	0.0881	16	19.8026
1990915163	memantine for behavioral disturbances in frontotemporal dementia a case series	2007	-0.236	0.2606	66	1
1990994785	outcome criteria in clinical trials with elderly subjects	1990	-0.5976	-0.0271	99	0.728
1991084221	a diet enriched with the omega 3 fatty acid docosahexaenoic acid reduces amyloid burden in an aged alzheimer mouse model	2005	-1.0736	-0.2928	5	5.7537
1991087484	p01 288 efficacy of pharmacotherapy and cognitive therapy alone and in combination in major depressive disorder	2009	-0.3415	0.9111	113	0.7333
1991168471	memantine for agitation aggression and psychosis in moderately severe to severe alzheimer s disease a pooled analysis of 3 studies	2008	-0.1048	0.0688	6	6.8532
1991168967	ginkgo biloba specificity of neuropsychological improvement a selective review in search of differential effects	2009	-0.103	-0.0968	8	0.7993
1991176470	the spectrum of behavioral responses to cholinesterase inhibitor therapy in alzheimer disease	1999	-0.225	0.0623	44	1.7707
1991189029	exercise program for nursing home residents with alzheimer s disease a 1 year randomized controlled trial	2007	0.4736	-0.1725	25	40.1092
1991224431	a pilot study on a home based caregiver training program for improving caregiver self efficacy and decreasing the behavioral problems of elders with dementia in taiwan	2003	0.4983	-0.0895	1	21.1849
1991340779	physical and psychological effects of 6 week tactile massage on elderly patients with severe dementia	2010	0.4135	-0.041	34	0.75
1991390832	clinical efficacy of piracetam in cognitive impairment a meta analysis	2002	-0.2542	0.2398	15	3.7783
1991396032	vascular cognitive impairment	2006	-0.8148	0.8226	102	0.6924
1991396892	guidelines for the pharmacologic treatment of neurobehavioral sequelae of traumatic brain injury	2006	-0.8474	1.0199	71	0.9982
1991415921	effects of estrogen replacement therapy on dehydroepiandrosterone dehydroepiandrosterone sulfate and cortisol responses to exercise in postmenopausal women	1997	-1.4127	-1.8486	20	0.7994
1991447459	factor structure and scoring of the skt test battery	1993	-0.4005	-0.0536	8	0.9713
1991456204	sensitivity of the dementia rating scale in vascular dementia comparison between two sets of criteria to define cognitive impairment	2003	-0.0747	-0.1034	127	0.8095
1991470442	first clinical evaluation of ganstigmine in patients with probable alzheimer s disease	2003	-0.2658	0.0614	44	0.7365
1991517279	cornell scale for depression in dementia	1988	0.3102	0.0074	31	17.0811
1991561095	a trial of thiamine in alzheimer s disease	1991	-0.7852	-0.0989	86	20.1309
1991586267	clinical effectiveness of a manual based coping strategy programme start strategies for relatives in promoting the mental health of carers of family members with dementia pragmatic randomised controlled trial	2013	0.4699	-0.0976	1	0.8843
1991670228	omega 3 supplementation in mild to moderate alzheimer s disease effects on neuropsychiatric symptoms	2008	-1.0762	-0.2939	5	29.6451
1991676478	a design for testing clinical strategies biased adaptive within subject randomization	2000	0.246	0.0854	141	0.9939
1991689541	meta analysis the efficacy of nootropic agent cerebrolysin in the treatment of alzheimer s disease	2007	-0.3543	-0.0016	70	1.5776
1991690769	buspirone in treatment of agitated demented patient	1988	0.0875	0.0984	47	0.9404
1991696063	an ergot alkaloid preparation hydergine versus placebo for treatment of symptoms of cerebrovascular insufficiency double blind study	1972	-0.2895	0.1013	41	2.491
1991840287	nutritional status and dietary intake in institutionalized patients with alzheimer s disease and multiinfarct dementia	1987	0.5917	-0.0633	123	0.7993
1991903468	effects of rivastigmine transdermal patch and capsule on aspects of clinical global impression of change in alzheimer s disease a retrospective analysis	2010	-0.2789	0.1041	133	15.431
1991917075	effects of n 3 fa supplementation on the release of proresolving lipid mediators by blood mononuclear cells the omegad study	2015	-1.1001	-0.3007	5	17.2332
1991931917	pharmacologic treatment of agitation associated with dementia	1986	0.1253	0.0959	47	1.9799
1991952617	the clinical dementia rating cdr current version and scoring rules	1993	-0.0921	-0.0724	46	6.4968
1991993391	subacute meningoencephalitis in a subset of patients with ad after a??42 immunization	2003	-0.7069	-0.1638	29	0.9404
1992079870	a behavioral rehabilitation intervention for amnestic mild cognitive impairment	2008	0.4059	-0.192	4	0.8843
1992083624	effects of 8 weeks administration of korean panax ginseng extract on the mood and cognitive performance of healthy individuals	2007	-0.6628	-0.1226	65	16.553
1992109356	management of agitation and aggression associated with alzheimer disease	2009	0.2434	0.0307	80	2.971
1992112171	bright light therapy and melatonin in motor restless behaviour in dementia a placebo controlled study	2001	0.3433	-0.0225	17	1.9168
1992178834	managing persons with dementia in the nursing home	2008	0.4399	-0.0044	104	0.8071
1992212001	evaluation of dosage safety and effects of methylphenidate on post traumatic brain injury symptoms with a focus on mental fatigue and pain	2014	-1.0836	1.4226	64	1.5695
1992226115	the caregivers of stroke patients an investigation of factors associated with depression	1990	0.6566	-0.1432	75	0.785
1992228231	telephone delivered psychosocial intervention reduces burden in dementia caregivers	2008	0.5528	-0.1207	1	3.5612
1992305831	tetrabenazine as antichorea therapy in huntington disease a randomized controlled trial	2007	-0.2283	-0.1467	112	0.9999
1992587234	a randomized two year study of the efficacy of cognitive intervention on elderly people the donostia longitudinal study	2008	0.4039	-0.1909	4	18.396
1992634156	memantine in the treatment of executive function deficits in adults with adhd a pilot randomized double blind controlled clinical trial	2017	-0.1907	0.1284	11	0.7479
1992703315	randomised controlled trial to determine the clinical effectiveness and cost effectiveness of selective serotonin reuptake inhibitors plus supportive care versus supportive care alone for mild to moderate depression with somatic symptoms in primary care the thread threshold for antidepressant response study	2009	0.103	0.1503	61	0.7054
1992763827	brief tests such as the clock drawing test or cognistat can be useful predictors of conversion from mci to dementia in the clinical assessment of outpatients	2014	-0.0747	-0.1034	127	0.7996
1992811319	effect of testosterone supplementation on functional mobility cognition and other parameters in older men a randomized controlled trial	2008	-1.2687	-1.5977	54	1
1992836891	the use of music to aid memory of alzheimer s patients	1991	0.48	-0.0523	21	0.9959
1992884262	an exploration of perceptions of possible depression prevention services for caregivers of elderly or chronically ill adults in rural georgia	2012	0.5963	-0.1335	131	0.7325
1992891277	long term citicoline cytidine diphosphate choline use in patients with vascular dementia neuroimaging and neuropsychological outcomes	2003	-0.4001	-0.2649	62	17.417
1992916233	galantamine therapeutic effects beyond cognition	2000	0.0984	-0.0508	93	1.7367
1992960806	differences in psychological morbidity among australian and chinese caregivers of persons with dementia in residential care	2009	0.5465	-0.1166	74	0.8026
1992963388	risperidone for the treatment of neuropsychiatric features in dementia	2006	0.5483	0.3861	40	0.718
1992998861	prevention of dementia in randomised double blind placebo controlled systolic hypertension in europe syst eur trial	1998	-0.6305	-0.0942	14	43.5359
1992999217	sleep and alzheimer disease pathology a bidirectional relationship	2014	0.196	-0.0166	28	0.8843
1993102117	spatial distribution of white matter hyperintensities in alzheimer disease cerebral amyloid angiopathy and healthy aging	2008	-0.4516	-0.0103	12	0.7993
1993103089	inhibition of hippocampal function in mild cognitive impairment targeting the cholinergic hypothesis	2006	0.0183	0.3851	48	0.6815
1993212585	structural brain correlates of emotional disorder in multiple sclerosis	1986	0.2301	-0.2027	111	0.6326
1993240750	piracetam elevates muscarinic cholinergic receptor density in the frontal cortex of aged but not of young mice	1988	-0.2991	0.2328	15	0.7993
1993292496	dehydroepiandrosterone dhea hypes and hopes	2014	-1.3848	-1.7808	54	0.8166
1993358973	monoamines and related metabolite levels in the cerebrospinal fluid of patients with dementia of alzheimer type influence of treatment with l deprenyl	1991	-0.1876	0.1187	37	1.836
1993383247	plasma antioxidants are similarly depleted in mild cognitive impairment and in alzheimer s disease	2003	-0.4593	-0.0962	82	0.9713
1993394822	efficacy and safety of galantamine in long term treatment for mild cognitive impairment	2012	-0.289	0.2822	9	0.6365
1993435783	dexmedetomidine vs midazolam or propofol for sedation during prolonged mechanical ventilation two randomized controlled trials	2012	2.2375	-0.0482	2	1
1993446093	geriatric care management for low income seniors a randomized controlled trial	2007	0.556	-0.1218	74	1
1993455747	donepezil treatment improves cognitive performance in patients with very mild alzheimer s disease	2002	-0.246	0.0991	78	1.3779
1993525844	play it again sam there is no impact	1989	0.5758	-0.1188	1	0.9999
1993616406	agitated behaviors in the elderly i a conceptual review	1986	0.4622	-0.0172	21	5.8155
1993650173	a double blind randomized placebo controlled withdrawal trial comparing memantine and antipsychotics for the long term treatment of function and neuropsychiatric symptoms in people with alzheimer s disease main ad	2015	-0.0757	0.065	58	1.4434
1993662313	music enhances category fluency in healthy older adults and alzheimer s disease patients	2005	0.483	-0.0538	21	2.9361
1993668532	serum total cholesterol apolipoprotein e fc12 e4 allele and alzheimer s disease	1998	-0.7231	-0.168	29	2.916
1993772987	safety and tolerability of divalproex sodium in the treatment of signs and symptoms of mania in elderly patients with dementia results of a double blind placebo controlled trial	2001	0.1729	0.08	16	22.8026
1993788242	neuroprotective and symptomatological action of memantine relevant for alzheimer s disease a unified glutamatergic hypothesis on the mechanism of action	2000	-0.3858	0.0611	50	0.7993
1993818042	comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia a randomized double blind trial	1999	0.199	0.0844	16	30.6756
1993825148	rivastigmine transdermal patch in the treatment of dementia of the alzheimer s type	2007	-0.2564	0.0519	72	1.7514
1993876878	making hospitals safer for older adults updating quality metrics by understanding hospital acquired delirium and its link to falls	2013	1.6418	-0.0325	24	0.7398
1993918979	xenon anaesthesia may preserve cardiovascular function in patients with heart failure	2005	3.147	0.1092	110	0.75
1993935793	cognitive stimulation therapy for alzheimer s disease the effect of cognitive stimulation therapy on the progression of mild alzheimer s disease in patients treated with donepezil	2007	-0.1754	0.0554	67	1.3753
1993998677	safety and efficacy of oral physostigmine in the treatment of alzheimer disease	1993	-0.3015	0.1536	13	16.7728
1994048538	a regulatory perspective on psychiatric syndromes in alzheimer disease	2001	0.0731	0.0945	16	0.845
1994053112	efficacy and tolerability of quetiapine in the treatment of behavioral and psychological symptoms of dementia	2007	0.3077	0.1439	81	0.7737
1994061936	novel regimens and delivery systems in the pharmacological treatment of alzheimer s disease	2009	-0.2382	0.0523	19	0.845
1994067502	the cholinergic hypothesis of geriatric memory dysfunction	1982	-0.3058	0.1869	13	17.6215
1994127157	estrogen therapy selectively enhances prefrontal cognitive processes a randomized double blind placebo controlled study with functional magnetic resonance imaging in perimenopausal and recently postmenopausal women	2006	-0.7559	-0.7633	3	27.8121
1994131284	a new scale for clinical assessment in geriatric populations sandoz clinical assessment geriatric scag	1974	-0.29	0.1012	41	2.6157
1994197596	the efficacy and safety of donepezil in patients with alzheimer s disease results of a us multicentre randomized double blind placebo controlled trial	1996	-0.2513	0.0658	6	25.8288
1994240105	long term effects of music therapy on elderly with moderate severe dementia	2006	0.471	-0.0566	21	0.9994
1994264749	evaluation of memantine for neuroprotection in dementia	2000	-0.3061	0.0166	57	0.75
1994268409	sundowning and circadian rhythms in alzheimer s disease	2001	0.3098	-0.0185	17	0.9804
1994286762	memantine improves attention and verbal episodic memory in parkinson s disease dementia and dementia with lewy bodies a double blind placebo controlled multicentre trial	2013	-0.1377	0.1994	100	15.6574
1994320218	estrogen reduces neuronal generation of alzheimer beta amyloid peptides	1998	-0.7431	-0.7385	3	2
1994336029	eeg alpha photic driving abnormalities in chronic schizophrenia	1989	-0.289	0.1016	41	0.7018
1994408835	predictors of rehabilitation outcomes in frail patients treated in a geriatric hospital	2002	2.1222	-0.0874	26	0.7484
1994437479	effects of chronic nicotine and methylphenidate in adults with attention deficit hyperactivity disorder	2001	0.0437	0.4832	48	0.9997
1994459030	high impact running improves learning	2007	0.5509	-0.2267	27	0.8843
1994473527	cognitive impairment in huntington disease diagnosis and treatment	2011	-0.2288	-0.146	112	0.9804
1994506529	efficacy and safety of donepezil in patients with dementia with lewy bodies preliminary findings from an open label study	2006	-0.1886	0.0705	7	0.7403
1994751407	nimodipine in the treatment of old age dementias	1990	-0.3421	0.1142	53	19.3566
1994829604	benefits of early versus delayed memantine addition to donepezil monotherapy in patients with moderate to severe alzheimer s disease a pooled analysis of two randomized trials	2014	-0.2384	0.0587	19	2.3043
1994840681	comparing measures of decline to dementia in amnestic mci subjects in the national alzheimer s coordinating center nacc uniform data set	2012	-0.2007	0.0876	78	0.6785
1994886840	increase in the power of human memory in normal man through the use of drugs	1976	-0.3176	0.263	15	0.9973
1994892354	donepezil for severe alzheimer s disease	2006	-0.2743	0.0856	33	0.9669
1994901354	5 androgens and postmenopause effects of 6 months dhea supplementation in postmenopausal women	2002	-1.4116	-1.8491	20	0.8067
1994925004	nonsteroidal anti inflammatory drugs for the prevention of alzheimer s disease a systematic review	2004	-0.4181	-0.0725	32	2.9997
1994929688	light treatment for neuropsychiatric behaviors in alzheimer s disease	2007	0.3387	-0.0183	17	20.3864
1994934441	effect of yi gan san on psychiatric symptoms and sleep structure at patients with behavioral and psychological symptoms of dementia	2008	-0.3677	-0.05	8	0.75
1994942943	regional cerebral glucose metabolism in patients with parkinson s disease with or without dementia	1992	-0.4858	0.0852	117	0.7159
1995005968	does a functional activity programme improve function quality of life and falls for residents in long term care cluster randomised controlled trial	2008	0.4834	-0.1436	60	0.8843
1995043290	patient populations in clinical trials of the efficacy and tolerability of donepezil in patients with vascular dementia	2002	-0.4475	-0.0031	12	17.6122
1995045731	organisational determinants of the use of physical restraints a multilevel approach	2007	0.7933	-0.0977	42	1.8556
1995192490	the use of methylphenidate in paediatric traumatic brain injury	1997	-0.9922	1.2607	71	0.7082
1995202737	the antipsychotic discontinuation in alzheimer disease trial clinical rationale and study design	2012	0.1939	0.06	80	0.8084
1995302227	dementia the experience of family caregivers	1987	0.7067	-0.1575	76	0.81
1995412542	donepezil in parkinson s disease dementia a randomized double blind efficacy and safety study	2012	-0.1997	0.1287	11	4.0974
1995417164	alzheimer s patients	1994	-0.3298	0.1839	22	0.8752
1995516142	symptom response and side effects of olanzapine and risperidone in young adults with recent onset schizophrenia	2003	0.104	0.1382	38	0.7215
1995567305	delirium predicts 12 month mortality	2002	2.1014	-0.0419	2	1
1995568322	zuclopenthixol and haloperidol in patients with acute psychotic states a double blind multi centre study	1992	0.1304	0.1286	47	0.8044
1995568801	catalytic asymmetric synthesis of either enantiomer of the calabar alkaloids physostigmine and physovenine	1998	-0.3023	0.1543	13	0.7993
1995582902	six year outcome for cognitive behavioral treatment of residual symptoms in major depression	1998	0.0703	0.1434	61	0.7509
1995597901	treatment of the alcoholic organic brain syndrome double blind placebo controlled clinical psychometric and electroencephalographic mapping studies with modafinil	1993	-0.1547	0.2301	15	0.6352
1995652291	impact of ambient bright light on agitation in dementia	2010	0.3409	-0.0185	17	0.8843
1995668598	serotonin reuptake inhibition vs norepinephrine reuptake inhibition a double blind differential therapeutic study with fluvoxamine and oxaprotiline in endogenous and neurotic depressives	1987	-0.6362	0.0864	122	0.7428
1995679565	methylphenidate ritalin can ameliorate abnormal risk taking behavior in the frontal variant of frontotemporal dementia	2006	-0.2334	0.2578	66	1.9804
1995707007	platelet monoamine oxidase activity of psychiatric patients effect of treatment with monoamine oxidase inhibitors	2002	-0.1962	0.1508	37	0.8359
1995739462	efficacy and safety of eptastigmine for the treatment of patients with alzheimer s disease	1999	-0.259	0.0611	44	2.5004
1995781460	vitamin status and intake as primary determinants of homocysteinemia in an elderly population	1993	-0.8853	-0.1042	30	0.9982
1995785495	influence of leisure activity on the incidence of alzheimer s disease	2001	0.4602	-0.2374	4	0.845
1995804911	the effects of psychosocial methods on depressed aggressive and apathetic behaviors of people with dementia a systematic review	2005	0.424	-0.0773	18	1.9947
1995809230	no global neocortical nerve cell loss in brains from patients with senile dementia of alzheimer s type	1994	0.1967	-0.0068	17	2.3487
1995832143	rehabilitation of executive functioning with training in attention regulation applied to individually defined goals a pilot study bridging theory assessment and treatment	2011	0.4797	-0.2652	4	0.991
1995903801	cerebrolysin a review of its use in dementia	2009	-0.3709	-0.0074	70	0.75
1995993981	effect of a training programme to reduce stress in carers of patients with dementia	1989	0.5448	-0.1126	1	4.8788
1996016964	cluster randomized clinical trial isrctn23732000 to evaluate the effectiveness of a diagnosis recognition and treatment guide for depressive disorders in primary care	2009	-0.5976	-0.0271	99	0.6871
1996098822	effects of touch on self exploration and the therapeutic relationship	1973	0.5917	-0.0633	123	0.7993
1996181417	the screen for caregiver burden	1991	0.1351	-0.0723	93	0.7993
1996181878	educating nursing assistants to communicate more effectively with nursing home residents with dementia	1999	0.5831	-0.0653	18	2.8712
1996220933	betaine supplementation decreases plasma homocysteine in healthy adult participants a meta analysis	2013	-1.9287	0.3319	109	0.7971
1996269906	depression among caregivers of children with asthma and its impact on communication with health care providers	2012	0.6566	-0.1432	75	0.7781
1996288542	transgenic increase in n 3 n 6 fatty acid ratio protects against cognitive deficits induced by an immune challenge through decrease of neuroinflammation	2015	-1.1027	-0.3021	5	0.75
1996294388	cognitive therapy helpful in reducing pseudoseizures first randomized trial finds	2010	-0.2868	0.2068	15	0.6978
1996304263	implementing a screening and diagnosis program for dementia in primary care	2005	0.565	-0.1243	74	1.9997
1996316805	hospitalization rates in nursing home residents with dementia a pilot study of the impact of a special care unit	1990	0.9841	-0.0257	24	0.7137
1996444134	effect of exercise on depression	1990	0.5835	-0.2505	27	0.9999
1996507145	behavioural effects of etiracetam in rats	1981	-0.2983	0.2325	15	0.75
1996512945	memantine a review of its use in moderate to severe alzheimer s disease	2009	-0.1971	0.1158	92	0.7495
1996525898	double blind clinical and psychologic study of ergoloid mesylates hydergine in subjects with senile mental deterioration	1984	-0.1379	0.0381	80	0.848
1996579240	the a?? peptide of alzheimer s disease directly produces hydrogen peroxide through metal ion reduction	1999	-1.0107	-0.5241	69	1
1996598113	salivary cortisol in depressed patients versus control persons a systematic review and meta analysis	2010	0.3283	-0.0246	89	1.4177
1996742337	aromatherapy as a safe and effective treatment for the management of agitation in severe dementia the results of a double blind placebo controlled trial with melissa	2002	0.3983	-0.0296	34	31.7473
1996766499	alzheimer s disease and oxidative stress implications for novel therapeutic approaches	1999	-0.3374	-0.0148	63	0.9404
1996776294	length of clinical trials of dementia drugs position paper from the international working group on harmonization of dementia drug guidelines	1997	-0.2017	0.0492	6	4.6854
1996787470	efficacy and tolerability of rivastigmine in patients with dementia of the alzheimer type	1998	-0.229	0.0448	6	21.7737
1996830682	explicit criteria for determining inappropriate medication use in nursing home residents	1991	0.591	-0.0116	52	2.9142
1996886405	pilot clinical trial of gabapentin to decrease postoperative delirium in older patients	2006	2.2212	-0.0432	2	28.1992
1996916925	monoamine oxidase inhibitors and their pharmacological significance	1983	-0.1962	0.1508	37	0.8265
1996938899	the influence of environmental factors in incidents of disruptive behavior	1995	0.6759	-0.0228	24	0.845
1997016005	preventing delirium in older adults with recent hip fracture through multidisciplinary geriatric consultation	2012	2.1132	-0.0875	26	1.4784
1997025444	telephone based cognitive behavioral therapy for african american dementia caregivers with depression initial findings	2012	0.5971	-0.1331	131	0.75
1997093513	seeking to understand telephone support for dementia caregivers	2005	0.6868	-0.1552	76	17.913
1997116389	neuropsychological results of long term therapy with oxiracetam in patients with dementia of alzheimer type and multi infarct dementia in comparison with a control group	1989	-0.2007	0.0876	78	0.696
1997167741	the dose dependent cognitive effects of acute administration of ginkgo biloba to healthy young volunteers	2000	-0.5769	-0.0974	65	5.6826
1997190298	factors relating to the use of physical restraints in geriatric care settings	2001	0.8093	-0.0994	42	0.9713
1997249456	neuro radiological findings and the magnitude of cognitive benefit by memantine treatment a subgroup analysis of two placebo controlled clinical trials in vascular dementia	2000	-0.3858	0.0611	50	0.8112
1997312621	severe dementia in the elderly how to evaluate it	1998	-0.1886	0.0705	7	0.7382
1997328542	costs associated with delirium in mechanically ventilated patients	2004	2.1904	-0.0438	2	2.595
1997337458	a novel rat serotonin 5 ht6 receptor molecular cloning localization and stimulation of camp accumulation	1993	-1.5582	0.2221	115	0.9404
1997441104	comparing two programs of cognitive training in alzheimer s disease a pilot study	2002	0.2503	-0.1057	10	4.9093
1997496350	effect of light treatment on sleep and circadian rhythms in demented nursing home patients	2002	0.2847	-0.0166	17	7.9313
1997505208	hallucinations predict attentional improvements with rivastigmine in dementia with lewy bodies	2004	-0.1981	0.1237	7	0.9982
1997527830	memantine and prevention of worsening in functional communication post hoc analysis of a randomized placebo controlled trial in patients with moderate alzheimer s disease	2010	-0.5166	-0.0479	12	0.7542
1997548032	evaluation of sedation failure in the outpatient oral and maxillofacial surgery clinic	2007	2.3341	0.1905	103	0.7112
1997608603	p 8 18 akatinol memantine in alzheimer s disease	1995	-0.2994	0.1647	22	2.6668
1997759458	the effect of earplugs during the night on the onset of delirium and sleep perception a randomized controlled trial in intensive care patients	2012	2.2027	-0.0437	2	0.991
1997807118	dhea in elderly women and dhea or testosterone in elderly men	2006	-1.2677	-1.5951	54	22.7569
1997810478	rapid relief of anxiety in cancer patients with both alprazolam and placebo	1993	0.0289	0.1124	38	0.7993
1997813030	the effects of amantadine and pemoline on cognitive functioning in multiple sclerosis	1996	-0.242	0.2126	55	1.9959
1997837704	effect of exercise on mood in nursing home residents with alzheimer s disease	2007	0.4996	-0.1896	25	2
1997849248	memory enhancement in healthy older adults using a brain plasticity based training program a randomized controlled study	2006	0.4675	-0.2457	4	29.5222
1997873908	the treatment of fibromyalgia with cranial electrotherapy stimulation	2001	0.2267	-0.0086	17	0.845
1997886955	a 1 year randomized placebo controlled study of donepezil in patients with mild to moderate ad	2001	-0.2163	0.041	6	66.0295
1997922550	long term benefits of rivastigmine in dementia associated with parkinson s disease an active treatment extension study	2006	-0.1509	0.097	7	3.6652
1997969914	recovery of hippocampal network connectivity correlates with cognitive improvement in mild alzheimer s disease patients treated with donepezil assessed by resting state fmri	2011	-0.2889	0.132	50	1.3537
1997988834	intrathecal morphine for coronary artery bypass grafting and early extubation	1997	2.3864	-0.0463	130	0.8509
1998072549	falls among nursing home residents an examination of incident reports before and after restraint reduction programs	1994	0.8432	-0.1021	42	0.9999
1998076739	admission cognitive performance and functional gain following inpatient rehabilitation in geriatric patients with hip fractures	2003	2.1222	-0.0874	26	0.784
1998094853	application of choynowski s memory scale in assessment of patients with dementia	2012	-0.0747	-0.1034	127	0.7526
1998168137	does standardized rehabilitation and discharge planning improve functional recovery in elderly patients with hip fracture	2005	2.1885	-0.0861	26	0.7883
1998299683	5 ht6 receptors a novel target for cognitive enhancement	2005	-1.5582	0.2221	115	0.991
1998302888	significant entry of tubocurarine into the brain of rats by adsorption to polysorbate 80 coated polybutylcyanoacrylate nanoparticles an in situ brain perfusion study	1998	-1.5731	-1.2608	101	0.75
1998329763	effect of dietary fatty acids on inflammatory gene expression in healthy humans	2009	-1.1085	-0.3042	5	0.9804
1998369474	the neurochemistry of vascular dementia	1994	-0.4786	-0.0169	12	0.75
1998387149	current and remote blood pressure and cognitive decline	1999	-0.6718	-0.1131	14	2
1998430065	rbc and plasma choline in neuroleptic treated schizophrenic patients	1989	-0.4081	0.3096	120	0.6582
1998501993	protection against dsp 4 induced neurotoxicity by deprenyl is not related to its inhibition of mao b	1990	-0.1986	0.1207	37	0.9959
1998510250	cognitive psychiatric and motor response to galantamine in parkinson s disease with dementia	2003	-0.1831	0.0975	7	3.7679
1998571654	treatment outcomes in rem sleep behavior disorder	2013	-0.1493	0.1232	7	0.845
1998586446	neurochemical features of frontotemporal dementia	1999	-0.2317	0.2572	66	1
1998637501	rehabilitation of executive dysfunction following brain injury content free cueing improves everyday prospective memory performance	2007	0.4805	-0.2649	4	0.991
1998657319	effect of an interactive computerized psycho education system on patients suffering from depression	2008	0.5122	-0.1606	60	0.6678
1998662813	use of aromatherapy with hospice patients to decrease pain anxiety and depression and to promote an increased sense of well being	2002	0.4057	-0.0326	34	0.916
1998664054	do statins reduce risk of incident dementia and alzheimer disease the cache county study	2005	-0.7186	-0.1687	29	7.9891
1998699100	ace inhibitor lacks acute effect on cognition or brain blood flow in alzheimer s disease	1992	-0.4858	0.0852	117	0.6783
1998707756	multisensory stimulation for elderly with dementia a 24 week single blind randomized controlled pilot study	2008	0.4238	-0.0769	18	1.9918
1998896869	cognitive stimulation of patients with dementia preliminary results	1994	0.2663	-0.0877	10	41.2429
1998900947	mri surrogates for vascular dementia trials	2009	-0.3855	0.0603	50	0.7398
1998904890	troublesome and disruptive behaviors in dementia relationships to diagnosis and disease severity	1988	0.1665	0.0922	47	0.9994
1998907195	telerehabilitation a new model for community based stroke rehabilitation	2004	0.5122	-0.1606	60	0.6591
1998942724	sodium valproate in the treatment of behavioral disturbance in dementia	1993	0.0875	0.0984	47	0.9584
1998966700	a randomised double blind comparison of the efficacy and safety of citalopram compared to mianserin in elderly depressed patients with or without mild to moderate dementia	2000	0.196	0.0912	31	0.916
1999004633	cognitive training and cognitive rehabilitation for people with early stage alzheimer s disease a review	2004	0.2634	-0.1001	10	15.6352
1999006480	on the mechanisms of plasticity in young and older adults after instruction in the method of loci evidence for an amplification model	1996	0.5069	-0.284	4	1.9099
1999025071	hydergine revisited a statistical analysis of studies showing efficacy in the treatment of cognitively impaired elderly	1995	-0.289	0.2822	9	0.6405
1999162359	rating depression in normals and depressives observer versus self rating scales	1986	0.2621	0.0262	31	0.7986
1999183223	lithium versus placebo in acute depression a clinical trial	1987	-0.411	0.0798	51	0.6615
1999224495	piracetam in chronic brain failure	1979	-0.2436	0.2307	15	15.1629
1999233676	neuropsychiatric symptoms in alzheimer s disease past progress and anticipation of the future	2013	0.1484	0.0607	31	0.9999
1999285830	perioperative dexmedetomidine improves outcomes of cardiac surgery	2013	2.2331	-0.0379	36	0.7153
1999287932	excitotoxic neurodegeneration in alzheimer disease new hypothesis and new therapeutic strategies	1997	-0.2955	0.1857	43	0.75
1999304520	prolonged ca2 dependent afterhyperpolarizations in hippocampal neurons of aged rats	1984	-0.3426	0.1147	53	0.916
1999326187	the possible mechanisms of action of deprenyl in parkinson s disease	1978	-0.1873	0.1192	37	0.991
1999541840	a randomized double blind placebo controlled trial of memantine in a behaviorally enriched sample of patients with moderate to severe alzheimer s disease	2013	-0.1265	0.0942	11	16.397
1999568669	a randomized controlled trial of quetiapine versus placebo in the treatment of delirium	2010	2.1695	-0.0424	2	20.9835
1999576170	risperidone in the treatment of behavioural and psychological symptoms of dementia in patients diagnosed with vascular or mixed type dementia	2005	-0.0938	0.0049	84	0.7168
1999631936	association of apolipoprotein e allele 4 with late onset familial and sporadic alzheimer s disease	1993	-0.7705	-0.1862	29	0.9713
1999646454	the effect of reminiscence on the elderly population a systematic review	2003	0.3572	-0.0931	39	0.7993
1999664376	midlife cardiovascular risk factors and risk of dementia in late life	2005	-0.6414	-0.0982	14	1
1999683270	p 5 a 011 efficacy and safety of donepezil in vascular dementia results from the largest double blind trial in vascular dementia patients	2006	-0.3243	0.1121	33	0.8882
1999794510	what depressive symptoms are reported in alzheimer s patients	1997	0.4586	0.2348	116	0.7963
1999845644	reducing acute confusional states in elderly patients with hip fractures	1985	2.217	-0.0392	36	1
1999862868	differential change in specific depressive symptoms during antidepressant medication or cognitive therapy	2013	-0.3416	0.9102	113	0.756
1999870327	1689 ginkgo biloba extract egb 761 in mild cognitive impairment with neuropsychiatric symptoms a randomized placebo controlled trial	2013	-0.3677	-0.05	8	0.8943
1999900894	possible therapeutic value of melatonin in mild cognitive impairment a retrospective study	2007	0.0049	-0.0289	28	3.3424
2000069057	effects of three types of memory training in normal elderly	1999	0.4892	-0.268	4	3.5221
2000078561	prevention of age related spatial memory deficits in a transgenic mouse model of alzheimer s disease by chronic ginkgo biloba treatment	2003	-0.4383	-0.0869	8	0.9867
2000123680	atomoxetine for depression and other neuropsychiatric symptoms in parkinson disease	2010	-0.192	0.1235	7	1.7966
2000166791	does functionally based activity make a difference to health status and mobility a randomised controlled trial in residential care facilities the promoting independent living study pils	2007	0.4434	-0.115	60	0.8843
2000214620	establishment and impact of a dementia unit within the nursing home	1987	0.6761	-0.022	24	0.8843
2000265708	be smart exercise your heart exercise effects on brain and cognition	2008	0.5514	-0.226	27	0.845
2000330458	patient injury and physical restraint devices a systematic review	2003	0.8213	-0.1004	42	3.8674
2000348166	180 the caregiver s role in alzheimer s disease	1996	-2.1425	2.1685	121	0.9033
2000380420	galantamine treatment in alzheimer s disease with cerebrovascular disease responder analyses from a randomized controlled trial gal int 6	2008	-0.2417	-0.0107	6	14.9608
2000399989	paced auditory serial addition task a measure of recovery from concussion	1977	-0.2416	0.2146	55	0.9939
2000414376	interventions for preventing falls in acute and chronic care hospitals a systematic review and meta analysis	2008	2.2795	-0.0629	35	0.7993
2000433105	do interventions bringing current self care practices into greater correspondence with those performed premorbidly benefit the person with dementia a pilot study	2006	0.3956	-0.1048	39	0.7573
2000445173	a new method of classifying prognostic comorbidity in longitudinal studies development and validation	1987	2.148	-0.0459	2	1.916
2000499252	quetiapine for the treatment of drug induced psychosis in parkinson s disease	1999	0.3076	0.1434	81	0.6671
2000537420	marine omega 3 fatty acids and inflammatory processes effects mechanisms and clinical relevance	2015	-1.1027	-0.3021	5	0.8843
2000555003	validity of the trail making test as an indicator of organic brain damage	1958	-0.3317	-0.0937	8	0.75
2000620721	effects of cognitive communication stimulation for alzheimer s disease patients treated with donepezil	2004	0.2304	-0.082	10	34.3225
2000624544	fluoxetine treatment of children and adults with autistic disorder and mental retardation	1992	-0.1544	0.2293	15	0.6705
2000629464	fluctuations in attention pd dementia vs dlb with parkinsonism	2002	-0.1909	0.1176	7	1.9982
2000658130	mild cognitive impairment can fdg pet predict who is to rapidly convert to alzheimer s disease	2003	-0.0529	-0.0404	46	1
2000781871	midlife blood pressure and dementia the honolulu asia aging study	2000	-0.671	-0.1133	14	6.9987
2000804359	improving memory performance in the aged through mnemonic training a meta analytic study	1992	0.4663	-0.2547	4	12.5422
2000823766	testing the limits and the study of adult age differences in cognitive plasticity of a mnemonic skill	1989	0.5074	-0.2835	4	5.1895
2000837493	hepatotoxic effects of tacrine administration in patients with alzheimer s disease	1994	-0.2763	0.085	44	2.6904
2000849147	polyunsaturated fatty acids and their metabolites in brain function and disease	2014	-1.1027	-0.3021	5	0.7993
2000882567	improving medication use in newly admitted home healthcare patients a randomized controlled trial	2002	2.2795	-0.0629	35	0.7509
2000957650	the temporal limits of cognitive change from music therapy in elderly persons with dementia or dementia like cognitive nmpairment a randomized controlled trial	2007	0.4837	-0.055	21	2.9515
2000963920	deprenyl is metabolized to methamphetamine and amphetamine in man	1978	-0.1881	0.1176	37	0.7993
2001053592	randomised double blind placebo controlled trial of fish oil in the treatment of depression	2005	-1.0974	-0.3005	5	0.9988
2001061566	meta analysis of double blind randomized controlled clinical trials of acetyl l carnitine versus placebo in the treatment of mild cognitive impairment and mild alzheimer s disease	2003	-0.3145	0.0076	63	5.8672
2001092957	comparison of the diagnostic accuracy of neuropsychological tests in differentiating alzheimer s disease from mild cognitive impairment can the montreal cognitive assessment be better than the cambridge cognitive examination	2014	-0.2001	0.0881	78	0.6709
2001097837	effects of individualized music on confused and agitated elderly patients	1993	0.4816	-0.0518	21	1.9982
2001104060	eeg states of the brain information processing and schizophrenic primary symptoms	1982	-0.2894	0.1023	41	0.7031
2001183947	relationships among plasma dehydroepiandrosterone sulfate and cortisol levels symptoms of dissociation and objective performance in humans exposed to acute stress	2004	-1.4229	-1.8439	20	0.9973
2001206572	memantine for the treatment of alzheimer s disease tolerability and safety data from clinical trials	2008	-0.2792	0.0752	51	0.6573
2001301349	brain infarction and the clinical expression of alzheimer disease the nun study	1997	-0.4813	-0.0241	12	15.7015
2001310434	exercise treatment for depression efficacy and dose response	2005	0.512	-0.1989	25	0.9959
2001311361	vitamin b12 and folate in relation to the development of alzheimer s disease	2001	-0.8743	-0.1041	30	5.9841
2001428138	electrophysiological evidences of a bidirectional communication between the locus coeruleus and the suprachiasmatic nucleus	1989	0.2267	-0.0086	17	0.75
2001494202	the use of signposts and active training to modify ward disorientation in elderly patients	1981	0.3227	-0.0922	10	0.9959
2001517217	double blind randomized placebo controlled clinical trial on the efficacy and tolerability of a physostigmine patch in patients with senile dementia of the alzheimer type	1999	-0.2607	0.0548	44	1.5497
2001599368	peripheral insulin sensitizer drug metformin ameliorates neuronal insulin resistance and alzheimer s like changes	2011	-0.3416	0.9102	113	0.75
2001626980	relation of anosognosia to frontal lobe dysfunction in alzheimer s disease	1994	0.2476	-0.1139	10	0.9804
2001634619	memory scanning and structured learning in alzheimer s disease and parkinson s disease	1990	-0.5495	0.3992	73	0.668
2001646968	parameters affecting the course and results of delirium tremens treatment	1986	0.0849	0.1025	47	0.6483
2001661890	the incidence of adverse drug events in two large academic long term care facilities	2005	0.7094	-0.0475	52	0.7993
2001763887	lack of clinical efficacy of chronic oral physostigmine in alzheimer s disease	1983	-0.3141	0.2056	13	0.9804
2001771157	a randomised double blind placebo controlled trial of folic acid supplementation of cholinesterase inhibitors in alzheimer s disease	2008	-0.8615	-0.1054	30	21.4878
2001835393	postmortem serotoninergic correlates of cognitive decline in alzheimer s disease	2002	0.0383	0.1961	61	0.845
2001857101	education to assist spouses in coping with alzheimer s disease a controlled trial	1989	0.5554	-0.1148	1	19.6842
2001950185	a large naturalistic community based study of rivastigmine in mild to moderate ad the extend study	2006	-0.2326	0.2003	55	0.7689
2002153653	effect of bright light treatment on agitated behavior in institutionalized elderly subjects	1995	0.2982	-0.0181	17	0.9584
2002257186	effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes accord mind a randomised open label substudy	2011	-0.445	1.5721	56	1.991
2002297740	ovarian steroid deprivation results in a reversible learning impairment and compromised cholinergic function in female sprague dawley rats	1994	-0.7639	-0.7736	3	2.9863
2002309496	sustained cognitive improvement following treatment of alzheimer s disease with donepezil	2000	-0.0667	0.0787	58	1.5384
2002330450	design of depression in alzheimer s disease study 2	2006	0.1845	0.0761	31	18.4549
2002435920	5 12 21 donepezil provides long term clinical benefits for patients with alzheimer s disease ad	1997	-0.3184	0.1179	33	1.6631
2002444341	antioxidant vitamin intake and risk of alzheimer disease	2003	-0.2996	-0.0592	46	1
2002465934	ondansetron hydrochloride for the treatment of delirium after coronary artery surgery	2001	2.3341	0.1905	103	0.7154
2002495958	p1 306 safety and tolerability profile of aripiprazole in elderly patients with psychosis of alzheimer s disease a pooled analysis	2004	0.6164	0.4438	40	0.7883
2002524701	the psychosocial impact of interactive computer use within a vulnerable elderly population a report on a randomized prospective trial in a home health care setting	2001	0.5131	-0.1606	60	0.6562
2002570652	mental illness among new residents to residential care	1992	0.9833	-0.0254	24	0.7055
2002571399	frailty is associated with incident alzheimer s disease and cognitive decline in the elderly	2007	0.538	-0.2242	136	0.9584
2002580984	hormone therapy in menopausal women with cognitive complaints a randomized double blind trial	2007	-0.7448	-0.7519	3	27.6126
2002620284	risperidone in the treatment of behavioral disturbances in dementia	1998	0.5463	0.3853	40	14.9726
2002634186	pharmaco eeg test dose response predicts cholinesterase inhibitor treatment outcome in alzheimer s disease	2000	-0.1943	0.0545	67	0.691
2002645734	correlates of rapid neuroleptic response in male patients with schizophrenia	1990	-0.1168	0.194	114	0.6808
2002708656	safety and efficacy of a galantamine memantine combination in mild to moderate alzheimer s disease randomized controlled trial	2009	-0.2383	0.0587	19	2.3033
2002727667	effects of exercise programs to prevent decline in health related quality of life in highly deconditioned institutionalized elderly persons a randomized controlled trial	2010	0.4834	-0.1436	60	0.845
2002785656	p02 292 a randomized controlled trial on the efficacy of group psychoeducation family intervention for carers of persons with schizophrenia in shanghai	2010	0.5421	-0.1163	1	0.7727
2002915201	memantine forestalled driving impairment in early alzheimer s	2014	-0.3144	0.1739	22	0.8417
2002963113	the impact of speed of processing training on cognitive and everyday performance	2005	0.4845	-0.2594	4	21.9999
2002984627	effect of a structured course involving goal management training in older adults a randomised controlled trial	2007	0.4832	-0.2675	4	1.9584
2002993996	a pilot randomized trial of carbamazepine for behavioral symptoms in treatment resistant outpatients with alzheimer disease	2001	0.1743	0.0797	16	6.881
2002996527	longitudinal pet evaluation of cerebral glucose metabolism in rivastigmine treated patients with mild alzheimer s disease	2006	-0.2186	0.0688	57	0.9999
2003035963	a randomized double blind crossover comparison of risperidone and haloperidol in korean dementia patients with behavioral disturbances	2004	0.1573	0.0923	16	0.845
2003075709	the effectiveness of a home care program for supporting caregivers of persons with dementia in developing countries a randomised controlled trial from goa india	2008	0.5551	-0.1261	140	24.9239
2003188394	statin therapy and risk of dementia in the elderly a community based prospective cohort study	2004	-0.7232	-0.1682	29	2
2003260521	national estimates of the quantity and cost of informal caregiving for the elderly with dementia	2001	0.0635	-0.0295	93	0.991
2003273485	a randomized clinical trial of the effectiveness of a discharge planning intervention in hospitalized elders with hip fracture due to falling	2005	2.1885	-0.0861	26	0.8222
2003278257	quality of life and the effect of memantine in dementia with lewy bodies and parkinson s disease dementia	2011	-0.1426	0.1646	100	1.6826
2003296550	psychosis and behavioral disturbances in dementia effects of risperidone in 969 patients	1998	0.3076	0.1434	81	0.7384
2003305114	the effects of prolonged treatment with citicoline in temporary experimental focal ischemia	1996	-0.3997	-0.2646	62	1.8389
2003306914	update on the use of memantine in alzheimer s disease	2009	-0.1687	0.0991	11	0.8105
2003436042	a three year follow up of older adult participants in a memory skills training program	1988	0.5083	-0.284	4	4.3397
2003438690	evaluating the cognitive effects of donepezil 23 mg d in moderate and severe alzheimer s disease analysis of effects of baseline features on treatment response	2013	-0.215	0.1388	11	15.3996
2003441551	add on prolonged release melatonin for cognitive function and sleep in mild to moderate alzheimer s disease a 6 month randomized placebo controlled multicenter trial	2014	0.1952	-0.0165	28	18.3929
2003509055	effect of a comprehensive exercise program on function in nursing home residents with alzheimer s disease	2000	0.4398	-0.0044	104	0.8638
2003542463	a single home visit by an occupational therapist reduces the risk of falling after hip fracture in elderly women a quasi randomized controlled trial	2008	2.1885	-0.0861	26	0.7952
2003582932	an update on the role of the 5 hydroxytryptamine6 receptor in cognitive function	2008	-1.5582	0.2221	115	0.9584
2003625752	e care a telecommunications technology intervention for family caregivers of dementia patients	2007	0.5486	-0.1194	1	28.9271
2003642428	a mother as caregiver of a patient with alzheimer disease	2002	-2.1414	2.1679	121	0.9109
2003672912	cerebral blood flow and cognitive responses to rivastigmine treatment in alzheimer s disease	2002	-0.1759	0.0653	67	2.0462
2003753329	statin therapy is associated with reduced neuropathologic changes of alzheimer disease	2008	-0.7164	-0.1673	29	2.9387
2003838833	utility of ischemic scores in the differential diagnosis of alzheimer s disease and ischemic vascular dementia	1996	-0.4056	0.0825	85	0.6796
2003880934	calming music and hand massage with agitated elderly	2002	0.4463	-0.0387	21	25.6963
2003920589	association of negative life event stress with coagulation activity in elderly alzheimer caregivers	2003	0.559	-0.1168	142	0.7993
2003926727	effects of donepezil adjunctive treatment to ziprasidone on cognitive deficits in schizophrenia a double blind placebo controlled study	2007	-0.2008	0.1471	9	0.7912
2003937775	clinical evaluation of compounds for the treatment of memory dysfunction	1985	-0.3922	0.3605	106	14.0976
2003962855	total daily activity measured with actigraphy and motor function in community dwelling older persons with and without dementia	2012	0.4825	-0.1839	25	0.7542
2004022622	a randomized controlled trial comparing the memory effects of continuation electroconvulsive therapy versus continuation pharmacotherapy results from the consortium for research in ect core study	2010	-0.3244	-0.142	45	0.7268
2004031015	simulated presence therapy using selected memories to manage problem behaviors in alzheimer s disease patients	1995	0.4771	-0.0462	21	1.9909
2004053486	anti inflammatory agents as a therapeutic approach to alzheimer s disease	1992	-0.414	-0.0404	32	1
2004113511	donepezil makes difference in severe alzheimer s	2006	-0.3195	0.1177	33	0.8448
2004133257	the effects of respite on caregivers of alzheimer s patients one year evaluation of the michigan model respite programs	1993	0.559	-0.1168	142	0.7993
2004142478	glucose effects on memory and other neuropsychological tests in elderly humans	1990	-0.4606	1.8032	96	0.7993
2004158056	a randomized placebo controlled trial of the discontinuation of long term antipsychotics in dementia	2002	0.2163	0.064	16	26.3832
2004170303	behavioral treatment of deficit skills in dementia patients	1986	0.2861	-0.0914	10	0.845
2004257292	low serum cholesteryl ester docosahexaenoic acid levels in alzheimer s disease a case control study	2003	-1.0956	-0.3001	5	1.836
2004284087	evaluation of delirium in critically ill patients validation of the confusion assessment method for the intensive care unit cam icu	2001	2.2206	-0.0458	2	3
2004305668	pharmacokinetics and pharmacodynamics of the novel daily rivastigmine transdermal patch compared with twice daily capsules in alzheimer s disease patients	2008	-0.2383	0.051	19	5.7485
2004397727	a double blind study of adjunctive sertraline in haloperidol stabilized patients with chronic schizophrenia	1998	-0.1168	0.194	114	0.696
2004437758	management of aggression agitation and psychosis in dementia focus on atypical antipsychotics	2006	0.5641	0.3999	40	0.7465
2004438781	opposing effects of dhea replacement in elderly subjects on declarative memory and attention after exposure to a laboratory stressor	1998	-1.4225	-1.8434	20	21.9624
2004449178	symptoms of early dementia 11 questionnaire sed 11q a brief informant operated screening for dementia	2013	-0.0747	-0.1034	127	0.8078
2004458795	effects of physostigmine on stimulus encoding in a memory scanning task	1992	-0.3173	0.2025	13	0.7946
2004504487	p3 098 predictors of progression from mild cognitive impairment mci to dementia	2004	-0.1892	0.0233	78	0.8384
2004543627	non pharmacological treatment of sleep and wake disturbances in aging and alzheimer s disease chronobiological perspectives	1993	0.2273	-0.0111	17	3.4593
2004554863	progress in studies of huperzine a a natural cholinesterase inhibitor from chinese herbal medicine	2006	-0.5779	-0.1503	32	0.9939
2004581580	effect of buspirone a serotonin1a partial agonist on cognitive function in schizophrenia a randomized double blind placebo controlled study	2007	-0.2409	0.1654	9	0.7059
2004673095	the clinical efficacy of reflexology in nursing home residents with dementia	2008	0.4135	-0.041	34	0.75
2004713321	correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia	1978	-0.3153	0.201	13	11.9789
2004762037	antidepressant drug effects and depression severity a patient level meta analysis	2010	0.103	0.1503	61	0.7129
2004926275	e 6801 a 5 ht6 receptor agonist improves recognition memory by combined modulation of cholinergic and glutamatergic neurotransmission in the rat	2011	-1.5582	0.2221	115	0.916
2004974797	the health benefits of yoga and exercise a review of comparison studies	2010	1.6805	-0.9881	108	1
2005023775	effects of rivastigmine in patients with and without visual hallucinations in dementia associated with parkinson s disease	2006	-0.1732	0.1238	7	26.5484
2005055799	effects of memantine on behavioural symptoms in alzheimer s disease patients an analysis of the neuropsychiatric inventory npi data of two randomised controlled studies	2005	-0.1662	0.0848	6	2.9027
2005107024	estrogen replacement therapy and cognitive decline in older community women	1999	-0.7568	-0.7614	3	1
2005133023	comparison of different mri brain atrophy rate measures with clinical disease progression in ad	2004	-0.1606	0.0143	46	1
2005165494	striatal dopamine sexual activity and lifespan longevity of rats treated with deprenyl	1989	-0.1986	0.1207	37	0.9988
2005176250	5 12 22 a randomized double blind placebo controlled study of idebenone in alzheimer disease ad	1997	-0.3333	0.0923	51	0.6624
2005207559	folic acid supplementation in dementia a preliminary report	2003	-0.8521	-0.1011	30	25.6449
2005238814	pretraining enhances mnemonic training in elderly adults	1988	0.507	-0.2836	4	18.5141
2005250105	long term acetyl l carnitine treatment in alzheimer s disease	1991	-0.3115	0.0115	63	29.9768
2005259934	analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo 26 week alzheimer disease trial	2003	-0.2088	0.0429	72	19.7251
2005291945	a controlled trial of tacrine in alzheimer s disease the tacrine study group	1992	-0.2784	0.0771	37	1.7993
2005316985	iv p5 efficacy of a group physical therapy program in patients with parkinson s disease a randomized controlled trial	2006	-0.2945	-0.1543	45	0.7109
2005325014	clinical research in senile dementia of the alzheimer type	1985	-0.384	0.3371	59	0.8279
2005355670	effects of aerobic exercise on mild cognitive impairment a controlled trial	2010	0.481	-0.1971	25	7.9424
2005432482	postmenopausal dehydroepiandrosterone administration increases free insulin like growth factor i and decreases high density lipoprotein a six month trial	1998	-1.414	-1.8441	20	1.8128
2005529982	influence of the severity of cognitive impairment on the effect of the ginkgo biloba extract egb 761 in alzheimer s disease	2002	-0.4481	-0.0766	8	1.9932
2005598262	long term longitudinal measurements of plasma dehydroepiandrosterone sulfate in normal men	1992	-1.422	-1.8434	20	1.9959
2005609961	donepezil in alzheimer s disease what to expect after 3 years of treatment in a routine clinical setting	2007	-0.2255	0.0489	6	0.9998
2005656145	the effect of deydroepiandrosterone supplementation to symptomatic perimenopausal women on serum endocrine profiles lipid parameters and health related quality of life	1999	-1.4149	-1.8347	20	25.5555
2005656575	incidence and risk factors of postoperative delirium in patients with esophageal cancer	2012	2.7899	-0.0532	118	0.8148
2005713291	naftidrofuryl for ischaemic rest pain a controlled trial	1981	-0.3167	-0.002	23	0.7438
2005790571	caregivers of the frail elderly a national profile	1987	0.5752	-0.1194	1	0.9999
2005898434	an open study of adjunct oros methylphenidate in children and adolescents who are atomoxetine partial responders i effectiveness	2009	-0.9922	1.2607	71	0.6956
2005939543	anticoagulant therapy for senile dementia	1972	-0.3806	-0.2165	45	0.6681
2005988538	dhea replacement for postmenopausal women	2011	-1.4128	-1.8331	20	0.9404
2005994343	effects of estrogen replacement therapy on response to tacrine in patients with alzheimer s disease	1996	-0.7647	-0.7717	3	0.9997
2006001085	effects of cdp choline treatment on neurobehavioral deficits after tbi and on hippocampal and neocortical acetlycholine release	1997	-0.3989	-0.2632	62	0.9804
2006099430	increase in single l type calcium channels in hippocampal neurons during aging	1996	-0.3426	0.1147	53	0.9404
2006134369	antipsychotic therapy for dementia in elderly patients	2009	0.617	0.4432	40	0.8304
2006166262	statins incident alzheimer disease change in cognitive function and neuropathology	2008	-0.7113	-0.1664	29	4.9571
2006199770	update on alzheimer drugs donepezil	2003	-0.2122	0.1659	11	2.1668
2006269133	alzheimer disease protection	2008	-0.4416	0.2873	105	0.8583
2006301750	immunocytochemical study of the dorsal and median raphe nuclei in patients with alzheimer s disease prospectively assessed for behavioural changes	2000	0.0383	0.1961	61	0.845
2006421113	does active leisure protect cognition evidence from a national birth cohort	2003	0.5514	-0.226	27	0.845
2006442321	neurosteroids endogenous bimodal modulators of the gabaa receptor mechanism of action and physiological significance	1992	-1.422	-1.8434	20	1.9973
2006446384	supplemental group discussions in memory training for older adults	1990	0.5098	-0.2842	4	1.6443
2006520516	treatment of hyperactive children with monoamine oxidase inhibitors i clinical efficacy	1986	-0.1962	0.1508	37	0.8018
2006521806	differences between caregivers and noncaregivers in psychological health and physical health a meta analysis	2003	0.5362	-0.1124	1	5.5701
2006522230	environmental correlates of resident agitation in alzheimer s disease special care units	1998	0.6749	-0.0213	24	1.8802
2006570303	dimebon improves learning in animals with experimental alzheimer s disease	2000	-0.586	-0.1761	32	1
2006619327	day care for older dementia patients favorable effects on behavioral and psychological symptoms and caregiver stress	2008	0.4586	0.2348	116	0.7657
2006690432	gene expression of peripheral blood mononuclear cells as a tool in dietary intervention studies what do we know so far	2012	-1.1026	-0.3016	5	0.7993
2006734683	rivastigmine a review of its use in alzheimer s disease	1998	-0.2795	0.1044	133	0.7715
2007044705	the alzheimer s disease neuroimaging initiative a review of papers published since its inception	2012	-0.2218	0.0114	46	0.75
2007050333	a long term comparison of galantamine and donepezil in the treatment of alzheimer s disease	2003	-0.253	0.066	6	3.6479
2007151269	dynamic treatment regimes practical design considerations	2004	0.246	0.0854	141	0.9992
2007153152	a dyadic remediation program for care recipients with dementia	1995	0.256	-0.102	10	30.5954
2007157864	relevance of glutamate levels in the csf of patients with hiv 1 associated dementia complex	1999	-0.3852	0.1417	134	0.6138
2007266319	the nmda antagonist mk 801 blocks the extinction of pavlovian fear conditioning	1996	-0.2927	0.1846	43	1.595
2007378506	cns late effects after all therapy in childhood part i neuroradiological findings in long term survivors of childhood all an evaluation of the interferences between morphology and neuropsychological performance	1997	0.2301	-0.2027	111	0.6433
2007402149	errorless learning of face name associations in early alzheimer s disease	1999	0.2706	-0.0993	10	2.8781
2007408808	online support and education for dementia caregivers overview utilization and initial program evaluation	2004	0.5527	-0.1196	1	1.9869
2007430276	effects of reality orientation therapy on elderly patients in the community	1993	0.2903	-0.0882	10	26.2976
2007559562	donepezil benefits extend to advanced alzheimer s disease	2000	-0.3195	0.1168	33	0.8284
2007622468	a trial of buspirone for the control of disruptive behaviors in community dwelling patients with dementia	1994	-0.3936	-0.2409	62	0.6971
2007650891	alzheimer disease lack of effect of lecithin treatment for 3 months	1981	-0.3304	0.2191	13	21.8173
2007782200	occipital hypoperfusion on spect in dementia with lewy bodies but not ad	2001	-0.1926	0.1212	7	0.9939
2007828318	hydergine a review of 26 clinical studies	1979	-0.2903	0.1006	41	2.345
2007948644	cognitive dysfunction in multiple sclerosis ii impact on employment and social functioning	1991	-0.2419	0.2132	55	2.9899
2007958306	a randomized double blind trial of the effects of hormone therapy on delayed verbal recall in older women	2009	-0.7355	-0.7379	3	0.845
2008025002	cholinergic augmentation with donepezil enhances recovery in short term memory and sustained attention after traumatic brain injury	2004	-0.8474	1.0199	71	1
2008034393	fascia iliaca block prophylaxis for hip fracture patients at risk for delirium a randomized placebo controlled study	2009	2.246	-0.0445	138	19.5948
2008039770	rehabilitation of executive function facilitation of effective goal management on complex tasks using periodic auditory alerts	2002	0.4805	-0.2649	4	0.9997
2008071541	efficacy and safety of extract of ginkgo biloba as an adjunct therapy in chronic schizophrenia a systematic review of randomized double blind placebo controlled studies with meta analysis	2015	-0.375	-0.0366	70	0.7535
2008171469	short term effects of the calcium channel blocker nimodipine bay e 9736 in the management of primary degenerative dementia	1990	-0.3444	0.1038	53	21.8099
2008188719	single fascia iliaca compartment block for post hip fracture pain relief	2007	2.2485	-0.0454	138	0.9867
2008299305	p4 363 a randomized clinical trial of vitamin e and memantine in alzheimer s disease	2008	-0.5169	-0.0473	12	0.7712
2008457702	current practices in sedation and analgesia for mechanically ventilated critically ill patients a prospective multicenter patient based study	2007	2.345	0.1894	103	0.704
2008478418	dementia care consultation for family caregivers collaborative model linking an alzheimer s association chapter with primary care physicians	2009	0.5442	-0.1163	74	4.6516
2008490243	effect of quetiapine in psychotic parkinson s disease patients a double blind labeled study of 3 months duration	2007	-0.1733	0.1259	7	1
2008517013	does very low dose ibuprofen affect csf levels of a??1 42 or tau in human volunteers at risk for alzheimer s disease a randomized controlled trial	2010	-0.3232	0.2077	13	0.751
2008531997	treatment of the dying in the acute care hospital advanced dementia and metastatic cancer	1996	0.8524	-0.0193	95	0.8843
2008542656	effects of an exercise intervention for older heart failure patients on caregiver burden and emotional distress	2006	0.1342	-0.0722	93	0.7995
2008632198	reduced risk of alzheimer s disease with high folate intake the baltimore longitudinal study of aging	2005	-0.8848	-0.1035	30	0.9982
2008664666	effectiveness of an internet intervention for family caregivers of people with dementia results of a randomized controlled trial	2015	0.5535	-0.1205	1	0.991
2008752783	environmental interventions in assaultive behavior	1990	0.6761	-0.022	24	0.7993
2008829429	the impact of long term exercise training on psychological function in older adults	1993	0.5751	-0.2462	27	5.7972
2008879636	predictors of functional recovery one year following hospital discharge for hip fracture a prospective study	1990	1.9722	-0.088	26	0.9996
2008979655	huntington s disease a randomized controlled trial using the nmda antagonist amantadine	2002	-0.2288	-0.146	112	0.9997
2009023836	mitochondria as a target for neurotoxins and neuroprotective agents	2003	-0.586	-0.1761	32	1
2009043128	?? endorphin administration to acute schizophrenic patients a double blind study	1982	-0.3327	0.0929	51	0.6165
2009043856	testosterone and cognition in elderly men a single testosterone injection blocks the practice effect in verbal fluency but has no effect on spatial or verbal memory	2000	-0.9327	-1.0635	54	1
2009046537	olanzapine as a treatment of neuropsychiatric disorders of alzheimer s disease and other dementias a 24 month follow up of 68 patients	2003	-0.2363	0.2597	66	0.9999
2009077913	phototransduction by retinal ganglion cells that set the circadian clock	2002	0.2928	-0.0185	17	1
2009111659	low cholesterol stimulates the nonamyloidogenic pathway by its effect on the ?? secretase adam 10	2001	-0.7233	-0.1683	29	2
2009122652	dementia family caregiver training affecting beliefs about caregiving and caregiver outcomes	2001	0.5294	-0.1096	1	18.9211
2009141508	the safety tolerability and efficacy of once daily memantine 28 mg a multinational randomized double blind placebo controlled trial in patients with moderate to severe alzheimer s disease taking cholinesterase inhibitors	2013	-0.1825	0.0642	6	22.0887
2009318275	transdermal selegiline in hiv associated cognitive impairment pilot placebo controlled study	2000	-0.3632	0.428	87	2.6292
2009339691	the effects of apolipoprotein e on non impaired cognitive functioning a meta analysis	2011	-0.7714	-0.1862	29	0.9973
2009379995	alzheimer s disease pharmacological developments to the year 2000	1995	-0.3783	0.0982	94	0.8263
2009382793	prediction of drug responses in schizophrenia a method using a test dose of chlorpromazine	1997	-0.4384	0.3662	90	0.6473
2009494091	functional connectivity in the motor cortex of resting human brain using echo planar mri	1995	-0.2499	0.1367	22	0.9584
2009646399	cerebrolysin ameliorates performance deficits and neuronal damage in apolipoprotein e deficient mice	1999	-0.3335	0.005	70	0.8843
2009650738	accelerated rehabilitation after proximal femoral fracture a randomized controlled trial	1993	1.9722	-0.088	26	0.9994
2009693731	multisensory environments for leisure promoting well being in nursing home residents with dementia	2004	0.4237	-0.0765	18	1.9826
2009700819	effect of ethanol on psychomotor performance and on risk taking behaviour	2002	-0.387	0.3785	98	0.6896
2009865508	oral administration of chronic physostigmine does not improve cognitive or mnesic performances in alzheimer s presenile dementia	1982	-0.262	0.1903	11	1.7628
2009885559	an ergot alkaloid preparation hydergine in the treatment of dementia critical review of the clinical literature	1976	-0.2904	0.1004	41	1.5
2009894571	p1 354 long term treatment with galantamine in patients with alzheimer s disease and alzheimer s disease with cerebrovascular disease	2004	-0.3529	0.1335	94	1.5783
2010010729	piracetam facilitates retrieval but does not impair extinction of bar pressing in rats	1979	-0.2983	0.2325	15	0.7993
2010055842	steroid induced psychosis in a child treatment with risperidone	2012	0.5641	0.3999	40	0.7048
2010120109	neurotransmitter related enzymes and indices of hypoxia in senile dementia and other abiotrophies	1976	-0.3212	0.2278	13	2.5493
2010166974	a double blind comparison of citalopram and risperidone for the treatment of behavioral and psychotic symptoms associated with dementia	2007	0.1443	0.0726	16	32.7523
2010202486	apathy is not depression	1998	-0.1978	0.076	44	0.9584
2010225651	impaired driving performance associated with effect of time duration in patients with primary insomnia	2014	-0.3865	0.3792	98	0.6637
2010232680	efficacy of donepezil treatment in alzheimer patients with and without subcortical vascular lesions	2004	-0.3141	0.0962	50	0.7452
2010285979	a predictive model for delirium in hospitalized elderly medical patients based on admission characteristics	1993	2.208	-0.0422	2	3.9939
2010298801	is fatigue an independent factor associated with activities of daily living instrumental activities of daily living and health related quality of life in chronic stroke	2007	-1.1671	1.5699	64	0.7993
2010301693	lithium improves hiv associated neurocognitive impairment	2006	-0.4009	0.5012	87	1.9566
2010329001	differences in mood states health status and caregiver strain between family caregivers of oncology outpatients with and without cancer related pain	1997	0.657	-0.144	75	0.7861
2010343526	cognitive and biological correlates of response to donepezil in alzheimer s disease	2000	-0.5194	0.3697	73	0.7296
2010367297	systematic review of information and support interventions for caregivers of people with dementia	2007	0.552	-0.1209	1	0.9867
2010375213	transdermal nicotine effects on attention	1998	0.0437	0.4832	48	1
2010377590	a systematic review of the clinical effectiveness of donepezil rivastigmine and galantamine on cognition quality of life and adverse events in alzheimer s disease	2006	-0.285	0.0852	33	0.6561
2010387444	home based assessment for family carers a preventative strategy to identify and meet service needs	1997	0.6861	-0.1443	97	0.6693
2010441051	olanzapine versus amisulpride and placebo in the treatment of negative symptoms and deficit states of chronic schizophrenia	1999	0.104	0.1382	38	0.7154
2010482008	multicenter randomized comparison of the efficacy and safety of xenon and isoflurane in patients undergoing elective surgery	2003	3.1484	0.109	110	0.845
2010638175	dual task performance and cognition in community dwelling patients with alzheimer s disease	2014	-0.5194	0.3697	73	0.7304
2010640607	cognitive predictors of donepezil therapy response in alzheimer disease	2007	-0.206	-0.1485	49	0.7089
2010656891	which rivastigmine formula is better for heart in elderly patients with alzheimer s disease oral or patch	2014	-0.2647	0.0485	72	2.4584
2010682103	steroids for surgery during cardiopulmonary bypass in adults a meta analysis	2014	2.5489	-0.0698	35	0.7476
2010753973	effect of a perioperative cardiac output guided hemodynamic therapy algorithm on outcomes following major gastrointestinal surgery a randomized clinical trial and systematic review	2014	2.4565	-0.0674	35	1.4924
2010754109	the atorvastatin donepezil in alzheimer s disease study leade design and baseline characteristics	2008	-0.705	-0.1631	29	19.3741
2010811402	cholinergic dysfunction in vascular dementia	2005	-0.727	0.0219	107	0.7091
2010834661	depressed mood is not a risk factor for incident dementia in a community based cohort	2009	0.4823	-0.1846	25	0.7869
2010860427	treadmill training as an augmentation treatment for alzheimer s disease a pilot randomized controlled study	2014	0.4918	-0.1933	25	0.9804
2010910491	depressive symptoms and quality of life in home care assisted cancer patients	1996	0.4586	0.2348	116	0.7667
2011137689	donepezil plus vitamin e as a treatment in alzheimer disease	2003	-0.3264	0.168	22	0.7312
2011315628	cognitive test performance in detecting staging and tracking alzheimer s disease	1995	0.1907	-0.0032	17	0.7317
2011347889	phase 2 safety trial targeting amyloid ?? production with a ?? secretase inhibitor in alzheimer disease	2008	-0.2799	0.0625	44	0.7209
2011356501	long term efficacy of olanzapine in the control of psychotic and behavioral symptoms in nursing home patients with alzheimer s dementia	2001	0.0999	0.0927	16	21.6268
2011404623	a double blind investigation of piracetam nootropil vs placebo in geriatric memory	1977	-0.3084	0.2478	15	1.7854
2011528793	trazodone for behavioral disturbance in alzheimer s disease	1993	-0.5194	0.3697	73	0.865
2011669469	aniracetam ro 13 5057 for the treatment of senile dementia of alzheimer type results of a multicentre clinical study	1991	-0.3327	0.1757	13	0.7457
2011716448	cognitive function in nondemented older women who took estrogen after menopause	1998	-0.7589	-0.7646	3	4
2011772234	early results from double blind placebo controlled trial of high dose phosphatidylcholine in alzheimer s disease	1983	-0.3221	0.2076	13	16.2342
2011799623	development of a web based training program for dementia caregivers in hong kong	2015	0.7067	-0.1575	76	0.7791
2011812873	accelerated risk of hypertensive blood pressure recordings among alzheimer caregivers	1999	0.559	-0.1168	142	0.845
2011849432	anticholinergic therapy and dementia in patients with parkinson s disease	1996	-0.0942	0.0057	84	0.7271
2011883695	depression is associated with flatter cortisol rhythms in patients with coronary artery disease	2008	0.3277	-0.0245	89	1.4401
2011956235	pharmacokinetics and safety of a potential antidementia compound cl 275 838 after multiple oral doses in patients with dementia of alzheimer type or vascular dementia	1995	-0.4056	0.0825	85	0.6897
2011969090	clinical and neurochemical effects of acetyl l carnitine in alzheimer s disease	1995	-0.3035	0.0117	63	8.3063
2012042221	estrogen replacement therapy and cognitive function in older women	1993	-0.7625	-0.7702	3	8.9584
2012043101	the role of aromatization in testosterone supplementation effects on cognition in older men	2005	-0.9327	-1.0635	54	1
2012055846	compliance of patients with alzheimer s disease to treatment with transdermal rivastigmine and its effectiveness and tolerability in daily practice	2011	-0.244	0.0569	19	1.6125
2012179098	vitamins b12 b6 and folic acid for onset of depressive symptoms in older men results from a 2 year placebo controlled randomized trial	2008	-0.9263	-0.257	79	0.7238
2012234159	better cognitive and psychopathologic response to donepezil in patients prospectively diagnosed as dementia with lewy bodies a preliminary study	2000	-0.1938	0.1215	7	2.9987
2012235312	cognitive behavioral treatment for anxiety in patients with dementia two case studies	2008	0.6749	-0.1727	77	0.75
2012275070	estradiol but not raloxifene improves aspects of spatial working memory in aged ovariectomized rhesus monkeys	2002	-0.7648	-0.7776	3	0.991
2012330442	the influences of age and caffeine on psychomotor and cognitive function	1999	-0.387	0.3785	98	0.677
2012360522	a novel therapy for rem sleep behavior disorder rbd	2011	-0.1493	0.1232	7	0.845
2012393351	minimizing the use of restrictive devices in dementia patients at risk for falling	2004	0.805	-0.0984	42	3.712
2012444133	brief information on an early phase ii study with deprenyl in demented patients	1987	-0.1444	0.1011	37	0.8843
2012465538	p 392 delirium in surgery intensive unit	2012	2.566	-0.0485	125	0.7906
2012494420	effects of ethyl eicosapentaenoic acid omega 3 fatty acid supplementation on hot flashes and quality of life among middle aged women a double blind placebo controlled randomized clinical trial	2009	-0.9263	-0.257	79	0.7518
2012503029	nimodipine enhances spontaneous activity of hippocampal pyramidal neurons in aging rabbits at a dose that facilitates associative learning	1990	-0.3432	0.1147	53	0.845
2012522955	preexisting dementia in stroke patients baseline frequency associated factors and outcome	1997	-0.0938	0.0049	84	0.7414
2012547110	dementia in aids patients incidence and risk factors	1993	-0.401	0.5018	87	1.9763
2012554561	relationship between plasma risperidone and 9 hydroxyrisperidone concentrations and clinical response in patients with schizophrenia	2001	-0.1168	0.194	114	0.6925
2012585322	a randomized controlled trial of a community based dementia care coordination intervention effects of mind at home on caregiver outcomes	2015	0.5415	-0.1158	1	0.7778
2012601992	clinical study on treatment of vascular dementia with scalp acupuncture	2008	0.0843	-0.0067	67	0.6634
2012618926	the neurosteroid dehydroepiandrosterone sulfate is an allosteric antagonist of the gabaa receptor	1990	-1.4215	-1.8421	20	1.9973
2012621449	thiamine deficiency increases ?? secretase activity and accumulation of ?? amyloid peptides	2011	-0.7833	-0.0998	86	0.845
2012632767	ginkgo biloba extract induces gene expression changes in xenobiotics metabolism and the myc centered network	2010	-0.4856	-0.072	68	0.845
2012787451	clinical application of gentamicin pmma chains in chronic ostromyelitis	1990	-0.3925	0.3624	106	0.6847
2012806411	ageing cognitive change and the apoe ?ø4 allele	2002	-0.7705	-0.1862	29	0.9404
2012837809	cerebral perfusion correlates of conversion to alzheimer s disease in amnestic mild cognitive impairment	2007	-0.2817	0.1568	43	0.6805
2012871147	memantine a therapeutic approach in treating alzheimer s and vascular dementia	2005	-0.2909	0.1288	53	0.7616
2012965408	the pharmacological treatment of chronic headache with gingko biloba extract egb 781	1990	-0.4758	-0.0347	132	0.7356
2012966651	a model telephone information and support program for caregivers of alzheimer s patients	1990	0.6079	-0.1289	1	2.7457
2013108561	pharmacological protection against hypoxia induced amnesia in rats	1971	-0.3176	0.263	15	0.7993
2013109524	omega 3 fatty acids supplementation does not affect serum lipids in chronic hemodialysis patients	2011	-1.0853	-0.2965	5	0.7913
2013145243	evaluation of estrogen treatment in female patients with dementia of the alzheimer type	1994	-0.7647	-0.7717	3	0.9999
2013177991	efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in alzheimer disease a meta analysis	2003	0.0223	0.0581	16	11.284
2013204019	a trial of b vitamins and cognitive function among women at high risk of cardiovascular disease	2008	-0.8674	-0.1045	30	1.9713
2013207729	donepezil hcl e2020 maintains functional brain activity in patients with alzheimer disease results of a 24 week double blind placebo controlled study	2003	-0.2174	0.0689	57	20.9966
2013231002	extrapyramidal signs and psychiatric symptoms predict faster cognitive decline in alzheimer s disease	1994	0.0731	0.0945	16	0.845
2013333500	amyloid ?? dynamics are regulated by orexin and the sleep wake cycle	2009	0.1887	-0.0001	28	2.8114
2013435522	the actions of hydergine on the brain	1968	-0.2894	0.1023	41	0.75
2013444603	physical fitness and all cause mortality a prospective study of healthy men and women	1989	0.584	-0.2513	27	0.9999
2013553357	a randomized controlled trial of bright light therapy for agitated behaviors in dementia patients residing in long term care	1999	0.3063	-0.0182	17	9.8837
2013565978	predicting reduction of cerebrospinal fluid ?? amyloid 42 in cognitively healthy controls	2015	-0.2942	0.0285	57	0.7028
2013698499	combined treatment with cerebrolysin and donepezil in mild to moderate alzheimer s disease results of a double blind randomized clinical trial	2009	-0.2384	0.0587	19	2.1574
2013918772	red blood cell plasma choline ratio in elderly depressed and demented patients	1988	-0.4081	0.3096	120	0.6794
2013951467	mental decline in the elderly pharmacotherapy ergot alkaloids versus papaverine	1975	-0.2893	0.1007	41	2.6704
2013982841	dementia with lewy bodies findings from an international multicentre study	2000	-0.192	0.1214	7	19.9074
2014000620	vascular dementia may be the most common form of dementia in the elderly	2002	-0.4489	-0.0033	12	0.8843
2014022472	dementia friendly architecture environments that facilitate wayfinding in nursing homes	2009	0.6741	-0.0194	24	0.9713
2014025849	ovarian hormones and cognition in the aged female rat ii progesterone supplementation reverses the cognitive enhancing effects of ovariectomy	2004	-0.7504	-0.7583	3	0.7993
2014073184	effects of memantine on functional communication in patients with moderate ad results of a 12 week placebo controlled trial	2009	-0.2376	0.0591	19	15.2971
2014073649	double blind randomised placebo controlled trial of low dose melatonin for sleep disorders in dementia	2002	0.2568	-0.0166	28	28.7044
2014091144	3 year study of donepezil therapy in alzheimer s disease effects of early and continuous therapy	2006	-0.2241	0.0488	6	21.8731
2014194200	efficacy of aromatherapy lavandula angustifolia as an intervention for agitated behaviours in chinese older persons with dementia a cross over randomized trial	2007	0.4048	-0.032	34	23.2579
2014208353	dietary docosahexaenoic acid and docosapentaenoic acid ameliorate amyloid ?? and tau pathology via a mechanism involving presenilin 1 levels	2007	-1.0601	-0.2887	5	4.879
2014263073	statin associated memory loss analysis of 60 case reports and review of the literature	2003	-0.7279	-0.1709	29	1.9967
2014297568	dihydroergokryptine as long term treatment of alzheimer type dementia a multicenter two year follow up	1998	-0.417	0.0419	41	0.6613
2014333904	remembering numbers in old age mnemonic training versus self generated strategy training	2003	0.5062	-0.2833	4	0.9939
2014449752	the economic and social cost of dementia in ireland	2000	0.5543	-0.1157	74	0.814
2014489408	influence of aromatherapy on medication administration to residential care residents with dementia and behavioral challenges	2002	0.4008	-0.0306	34	1.9826
2014508408	olanzapine in the management of cancer pain	2002	0.0289	0.1124	38	0.845
2014659531	ziprasidone outcome and tolerability a practical clinical trial with plasma drug levels	2007	-0.1168	0.194	114	0.6956
2014699979	differential risk of death in older residents in nursing homes prescribed specific antipsychotic drugs population based cohort study	2012	0.1441	0.0526	80	0.9804
2014710717	piracetam in the treatment of cognitive impairment in the elderly	1982	-0.2876	0.3047	15	18.9211
2014792393	treatment effect size of memantine therapy in alzheimer disease and vascular dementia	2006	-0.3858	0.0611	50	0.7759
2014796351	response of elevated methylmalonic acid to three dose levels of oral cobalamin in older adults	2002	-0.9233	-0.1078	30	0.9867
2014808672	stopping antipsychotic drug therapy in demented nursing home patients a randomized placebo controlled study the bergen district nursing home study bednurs	2008	0.2161	0.062	16	23.9084
2014829325	training the elderly on the ability factors of spatial orientation and inductive reasoning	1986	0.4602	-0.2374	4	0.7993
2014841195	effect of a combined walking and conversation intervention on functional mobility of nursing home residents with alzheimer disease	2000	0.49	-0.1763	25	6.955
2014846870	monoamine oxidase and dementia treatment with an inhibitor of mao b activity	1990	-0.1954	0.1505	37	16.9117
2014886338	global prevalence of dementia a delphi consensus study	2005	0.5198	-0.1564	25	6.7717
2014946971	the dehydroepiandrosterone and wellness dawn study research design and methods	2007	-1.3836	-1.779	54	15.7277
2014988618	the peaceful mind program a pilot test of a cognitive behavioral therapy based intervention for anxious patients with dementia	2012	0.6731	-0.1721	77	17.3191
2015004507	inhibition of amyloid ?? aggregation and caspase 3 activation by the ginkgo biloba extract egb761	2002	-0.4038	-0.0808	8	6.8966
2015032641	general versus locoregional anesthesia in carotid surgery a prospective randomised trial	2006	2.2338	-0.0386	36	0.7051
2015115530	efficacy and tolerability of low dose donepezil in schizophrenia	2005	-0.2175	0.1416	11	0.7542
2015123130	multiple dose arecoline infusions in alzheimer s disease	1988	-0.2902	0.1316	13	1.832
2015187101	efficacy of memantine in patients with alzheimer s disease meta analyses of 9 clinical trials	2011	-0.2801	0.075	51	0.6567
2015225278	effect of interventions to reduce potentially inappropriate use of drugs in nursing homes a systematic review of randomised controlled trials	2011	0.597	-0.0144	52	0.8843
2015301420	qs257 a successful strategy for the recruitment of elderly patients to a randomized controlled trial	2008	-0.5975	-0.0271	99	0.7439
2015387434	caregivers and professionals partnership caregiver resource center assessing a hospital support program for family caregivers	2006	0.6888	-0.1557	76	0.8566
2015405906	p01 100 long term efficacy of olanzapine in the control of psychotic and behavioral symptoms in patients with alzheimer s dementia	2000	0.3082	0.1433	81	1.7027
2015414121	vascular determinants of cholinergic deficits in alzheimer disease and vascular dementia	2006	-0.4176	0.0026	12	0.8843
2015449679	cholinesterase inhibitor treatment alters the natural history of alzheimer s disease	2002	-0.2185	0.0507	6	1
2015467142	cognition based interventions for healthy older people and people with mild cognitive impairment	2011	0.4216	-0.1696	27	2.624
2015514721	a randomized trial of family caregiver support in the home management of dementia	1990	0.5528	-0.1143	1	4.9073
2015569360	aliskiren a novel orally effective renin inhibitor provides dose dependent antihypertensive efficacy and placebo like tolerability in hypertensive patients	2005	-0.7616	-0.1531	14	0.916
2015632929	chemistry and pharmacology of nootropics	1982	-0.2882	0.3063	15	0.75
2015651365	cardioprotective and anti oxidant effects of the terpenoid constituents ofginkgo bilobaextract egb 761	1997	-0.3317	-0.0937	8	0.75
2015670670	memantine treatment of cognitive symptoms in mild to moderate alzheimer disease secondary analyses from a placebo controlled randomized trial	2007	-0.1845	0.1062	6	19.1818
2015693764	donepezil in the prevention and treatment of post surgical delirium	2005	2.1879	-0.0435	2	28.7192
2015701223	memantine in vascular dementia	2003	-0.3848	0.061	50	15.3984
2015728861	efficacy and safety of clozapine and olanzapine an open label study comparing two groups of parkinson s disease patients with dopaminergic induced psychosis	2001	0.104	0.1382	38	0.7106
2015750656	alzheimer type dementia and verbal memory performances influence of selegiline therapy	1992	-0.2295	0.1562	9	16.1134
2015788572	economic evaluation of galantamine in the treatment of mild to moderate alzheimer s disease in the united states	2003	-0.1709	0.0188	6	0.9973
2015839697	the effects of piracetam in children with dyslexia	1985	-0.3176	0.263	15	0.7993
2015983043	extensive astrocyte infection is prominent in human immunodeficiency virus associated dementia	2009	-0.4008	0.502	87	0.9867
2016033324	rivastigmine transdermal patch 13 3 mg 24 h a review of its use in the management of mild to moderate alzheimer s dementia	2014	-0.256	0.0511	72	0.7647
2016109278	effects of rivastigmine on memory and cognition in multiple sclerosis	2008	-0.2414	0.2118	55	22.5835
2016109384	a randomized trial of a combined physical activity and environmental intervention in nursing home residents do sleep and agitation improve	1999	0.5026	-0.1757	25	0.845
2016109926	the sydney multicenter study of parkinson s disease the inevitability of dementia at 20 years	2008	-0.1905	0.1075	7	9.0097
2016129455	multiple dose kinetics and safety of a potential cognition enhancing compound cl 275 838 in patients with dementia of alzheimer type or vascular dementia	1995	-0.4056	0.0825	85	0.6743
2016136955	physostigmine effects in alzheimer s disease relationship to dementia severity	1986	-0.3654	0.2548	13	2.5149
2016149437	clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors	2002	-0.2386	0.0523	19	2.8743
2016153636	the effects of reminiscence on psychological well being in older adults a meta analysis	2007	0.3574	-0.0939	39	0.7993
2016322368	clinical results with nimodipine in alzheimer disease	1992	-0.3267	0.1688	22	0.9549
2016386797	a double blind comparative study of remoxipride and thioridazine in the acute phase of schizophrenia	1988	0.1009	0.117	38	1.3313
2016416821	studies of transketolase abnormality in alzheimer s disease	1988	-0.7847	-0.099	86	2.5742
2016473700	activation of identified septo hippocampal neurons by noxious peripheral stimulation	1985	0.2064	-0.0071	17	0.75
2016587303	placebo controlled trial of the xanthine derivative propentofylline in dementia	1994	-0.3265	0.1087	13	6.381
2016593100	critics on adjunctive memantine therapy for cognitive impairment in chronic schizophrenia a placebo controlled pilot study	2012	-0.2161	0.1463	11	1.4654
2016644726	effects of nursing interventions within an integrated care pathway for patients with hip fracture	2007	2.1885	-0.0861	26	0.7887
2016659621	metrifonate benefits cognitive behavioral and global function in patients with alzheimer s disease	1998	-0.2578	0.0732	44	6.6009
2016662621	mood physical working capacity and cognitive performance in the elderly as related to physical activity	1997	0.5818	-0.2511	27	1.7975
2016697624	donepezil improved memory in multiple sclerosis in a randomized clinical trial	2004	-0.2417	0.2096	55	25.7084
2016707441	long term effects of fluid ability training in old old age	1990	0.5062	-0.2833	4	0.9939
2016740748	the effects of coenzyme a on serum lipids in patients with hyperlipidemia results of a multicenter clinical trial	2013	-1.2096	-0.3344	128	0.6881
2016767193	modified hospital elder life program effects on abdominal surgery patients	2011	2.1979	-0.0458	2	0.9804
2016958718	long term efficacy and safety of donepezil in the treatment of alzheimer s disease an interim analysis of the results of a us multicentre open label extension study	1998	-0.2898	0.0863	44	2.511
2017074925	fast track surgery decreases the incidence of postoperative delirium and other complications in elderly patients with colorectal carcinoma	2014	2.7875	-0.0531	118	16.5548
2017121249	effects of essential oils and touch on resistance to nursing care procedures and other dementia related behaviours in a residential care facility	2002	0.3959	-0.0279	34	0.9867
2017126416	tolerability and efficacy of the monoaminergic stabilizer osu6162 pnu 96391a in huntington s disease a double blind cross over study	2014	-1.1663	1.5705	64	0.7993
2017215880	implementing innovative models of dementia care the healthy aging brain center	2011	0.556	-0.1218	74	1
2017221794	loxapine in psychogeriatrics a placebo and standard controlled clinical investigation	1982	0.1104	0.0982	47	2.7578
2017317827	cognitive effects of the acetylcholinesterase inhibitor donepezil in healthy non treatment seeking smokers a pilot feasibility study	2012	-0.2008	0.1471	9	0.7461
2017443170	the effect of aricept in persons with persistent memory disorder following traumatic brain injury a pilot study	2003	-0.8474	1.0199	71	0.9804
2017457116	h2 histamine receptor blockade in the treatment of alzheimer disease a randomized double blind placebo controlled trial of nizatidine	2002	-0.2633	0.1641	9	0.6606
2017550829	aqueous dissolution of alzheimer s disease abeta amyloid deposits by biometal depletion	1999	-1.0099	-0.5237	69	1
2017562658	pramipexole in comparison to l dopa a neuropsychological study	2003	-0.2307	0.1568	9	0.6504
2017587618	further evidence for the cholinergic hypothesis of aging and dementia from the canine model of aging	2005	0.0183	0.3851	48	0.6552
2017711500	effect of a clinical stroke on the risk of dementia in a prospective cohort	2006	-0.0938	0.0049	84	0.7145
2017748225	independent assessment of manic and depressive symptoms by self rating scale characteristics and implications for the study of mania	1991	0.2621	0.0262	31	0.7903
2017823945	choline status is not a reliable indicator of moderate changes in dietary choline consumption in premenopausal women	2009	-1.9284	0.3325	109	0.7125
2017872978	statins and cognitive function a systematic review	2013	-0.7266	-0.1701	29	0.9992
2017977370	biological and neuropsychological characterization of physostigmine responders and nonresponders in alzheimer s disease	1990	-0.4373	0.3649	90	15.6471
2018047970	deprenyl suppresses the oxidant stress associated with increased dopamine turnover	1989	-0.1966	0.1387	37	1.7975
2018112686	rivastigmine in parkinson s disease dementia	2006	-0.2335	0.1921	55	1.4427
2018118901	carnitine a nutritional biosynthetic and functional perspective	2004	-0.2861	0.0292	63	0.75
2018121350	apolipoprotein mediated transport of nanoparticle bound drugs across the blood brain barrier	2002	-1.5731	-1.2608	101	0.75
2018148977	the effect of reminiscence music therapy sessions on changes in depressive symptoms in elderly persons with dementia	2000	0.4794	-0.0565	21	1.9572
2018309238	efficacy and safety of donepezil over 3 years an open label multicentre study in patients with alzheimer s disease	2007	-0.2054	0.0474	6	18.954
2018333394	dramatic aggregation of alzheimer abeta by cu ii is induced by conditions representing physiological acidosis	1998	-1.0107	-0.5241	69	1
2018394636	effects of an abilities focused program of morning care on residents who have dementia and on caregivers	2000	0.6933	-0.1093	42	1.6259
2018417967	enhancing effect of ht008 1 on cognitive function and quality of life in cognitively declined healthy adults a randomized double blind placebo controlled trial	2008	-0.2406	-0.2586	49	14.5233
2018467160	imaging and neuropsychological correlates of cognitive and behavioral symptoms in alzheimer s disease	2014	-0.2809	0.1571	43	0.665
2018468596	iv glycine and oral d cycloserine effects on plasma and csf amino acids in healthy humans	2000	-0.2975	0.1887	43	0.9404
2018528537	a pilot placebo controlled study of trazodone and buspirone in alzheimer s disease	1994	-0.032	0.1089	44	1.7293
2018593447	maintenance on l deprenyl prolongs life in aged male rats	1990	-0.1924	0.1193	37	1.9969
2018650763	hydroxyl radicals iron oxidative stress and neurodegenerationa	2006	-1.5731	-1.2608	101	0.7993
2018751883	cognitive functions affected by scopolamine in alzheimer s disease and normal aging	1988	0.0183	0.3851	48	0.6855
2018780010	functional cognitive and behavioral effects of donepezil in patients with moderate alzheimer s disease	2002	-0.1841	0.0534	6	20.5522
2018840929	the cost of behavioral and psychological symptoms of dementia bpsd in community dwelling alzheimer s disease patients	2002	0.5272	-0.0877	34	0.7248
2018933197	vascular dementia italian sulodexide study va d i s s clinical and biological results	1997	-0.3167	-0.002	23	0.7993
2018974184	genetic or pharmacological iron chelation prevents mptp induced neurotoxicity in vivo a novel therapy for parkinson s disease	2003	-1.0107	-0.5241	69	1
2019088648	ginkgo biloba and risk of cancer secondary analysis of the ginkgo evaluation of memory gem study	2010	-0.4844	-0.0715	68	14.752
2019231747	reduction of psychotic symptoms in patients with lewy body like symptoms treated with olanzapine	2000	0.1034	0.1377	38	14.8545
2019244105	the raphe nuclei of the cat brain stem a topographical atlas of their efferent projections as revealed by autoradiography	1976	0.2267	-0.0086	17	0.75
2019249869	home health aide services barriers perceived by dementia family caregivers	1995	0.7067	-0.1575	76	0.8026
2019259852	zuclopenthixol melperone and haloperidol levomepromazine in the elderly meta analysis of two double blind trials at 15 nursing homes in norway	1992	0.1301	0.1278	47	0.856
2019305071	telephone delivered psychoeducational intervention for hong kong chinese dementia caregivers a single blinded randomized controlled trial	2013	0.6854	-0.1437	97	0.6922
2019364942	effects of candesartan in patients with chronic heart failure and reduced left ventricular systolic function intolerant to angiotensin converting enzyme inhibitors the charm alternative trial	2004	-0.7616	-0.1531	14	0.916
2019443766	effects of hormone replacement therapy on cognitive performance in elderly women	2001	-0.7517	-0.7603	3	28.7101
2019470268	effects of reminiscence and life review on late life depression a meta analysis	2003	0.3574	-0.0939	39	0.7993
2019519108	propentofylline in the treatment of alzheimer s disease and vascular dementia a review of phase iii trials	1998	-0.4188	0.0162	85	20.3793
2019570771	multicenter randomized clinical trial of donepezil for memory impairment in multiple sclerosis	2011	-0.2411	0.2132	55	22.8666
2019594371	changes in melatonin levels but not cortisol levels are associated with depression in patients with eating disorders	1989	0.3313	-0.0243	89	0.6976
2019613742	apomorphine and other dopaminomimetics basic pharmacology vol i	1982	-0.3252	0.2118	13	1
2019632502	a randomized trial of dementia care in nursing homes	1996	0.6112	-0.0247	52	5.6928
2019755331	prevalence and pharmacological management of behavioural and psychological symptoms amongst dementia sufferers living in care environments	2001	0.3613	0.0111	18	3.9424
2019839635	identification of drug related cognitive impairment in older individuals challenge studies with diphenhydramine	1997	-0.2626	0.1647	9	0.6644
2019895610	the effects of propranolol on cognitive function and quality of life a randomized trial among patients with diastolic hypertension	2000	-0.7628	-0.1427	135	0.7563
2019993459	30 problems in performing clinical trials in alzheimer s disease ad and vascular dementia vad	1996	-0.4056	0.0825	85	0.684
2020130665	evaluation of the ergogenic properties of ginseng	1994	-0.6512	-0.1191	65	1.9867
2020194098	treatment of dementia patients with psychotic and behavioural symptoms with quetiapine and donepezil	2000	0.3085	0.1434	81	0.7868
2020202552	the effects of light therapy on mini mental state examination scores in demented patients	2001	0.2965	-0.0173	17	21.0931
2020221148	treating learning impairments improves memory performance in multiple sclerosis a randomized clinical trial	2005	-0.2416	0.2147	55	0.9959
2020279836	randomized trial of behavioral activation cognitive therapy and antidepressant medication in the acute treatment of adults with major depression	2006	-0.3415	0.9111	113	0.7464
2020309999	reliable evidence of safety and efficacy of elderly patients in randomized clinical trials still needed	2007	-0.5975	-0.0271	99	0.7419
2020319328	a comparison of chlormethiazole and thioridazine in agitated confusional states of the elderly	1986	0.0843	0.1022	47	14.612
2020332226	modifying repetitive verbalizations of community dwelling patients with ad	1997	0.5001	-0.0899	1	0.9584
2020346027	is sertraline treatment or depression remission in depressed alzheimer patients associated with improved caregiver well being depression in alzheimer s disease study 2	2014	0.4568	0.2346	116	16.1941
2020362859	treatment of hypertension in patients 80 years and older the lower the better a meta analysis of randomized controlled trials	2010	-0.6916	-0.191	79	0.7993
2020370964	alteration in nicotine binding sites in parkinson s disease lewy body dementia and alzheimer s disease possible index of early neuropathology	1995	0.0437	0.4832	48	0.9997
2020389344	replacement therapy with piperazine oestrone sulphate harmogen and its effect on memory	1976	-0.759	-0.766	3	1.9981
2020476996	successful use of donepezil for the treatment of psychotic symptoms in patients with parkinson s disease	2002	-0.0959	0.0866	58	2.5057
2020498031	citicoline mechanisms and clinical efficacy in cerebral ischemia	2002	-0.4003	-0.2667	62	0.845
2020539828	risperidone versus zuclopenthixol in the treatment of schizophrenia with substance abuse comorbidity a long term randomized controlled crossover study	2006	0.1301	0.1278	47	0.7585
2020564763	general and specific cognitive dysfunctions in patients with alzheimer s disease	1992	0.1907	-0.0032	17	0.7271
2020635623	p1 026 consistent long term efficacy of rivastigmine in mild moderate and moderately severe alzheimer s disease	2004	-0.3118	0.0161	57	0.7192
2020667749	cost effectiveness cholinesterase inhibitors and memantine in vascular dementia	2009	-0.3446	0.2068	126	0.8272
2020696276	milacemide safety assessment in senile dementia of the alzheimer type	1992	-0.2439	0.2318	15	0.6505
2020705217	withdrawal of haloperidol thioridazine and lorazepam in the nursing home a controlled double blind study	1999	0.2492	0.0509	16	26.8445
2020769801	treatments for vascular dementia and alzheimer s disease	1999	-0.4056	0.0825	85	0.7147
2020789218	comparison of the potency kinetics and voltage dependency of a series of uncompetitive nmda receptor antagonists in vitro with anticonvulsive and motor impairment activity in vivo	1995	-0.2735	0.0729	23	0.9939
2020802678	propentofylline in the treatment of vascular dementia and alzheimer type dementia overview of phase i and phase ii clinical trials	1998	-0.4131	0.0429	85	2.6345
2020819361	attitudes of dutch german and swiss nursing staff towards physical restraint use in nursing home residents a cross sectional study	2009	0.8093	-0.0994	42	0.9584
2020844317	the brief psychiatric rating scale	1962	-0.1911	0.1104	137	0.75
2020942957	neuroleptic treatment of hiv associated psychosis	1994	0.1304	0.1286	47	0.7028
2020961258	tetrahydroaminoacridine lecithin combination treatment in patients with intermediate stage alzheimer s disease results of a canadian double blind crossover multicenter study	1990	-0.3061	0.1723	13	9.5821
2021011327	analysis of the effect of memantine in reducing the worsening of clinical symptoms in patients with moderate to severe alzheimer s disease	2007	-0.1809	0.0642	6	2.8474
2021024027	o043 effects of a dha rich n 3 fatty acid supplementation on gene expression changes in blood leukocytes the omegad study	2009	-1.1031	-0.3023	5	0.8823
2021028923	a multicenter open label 24 week follow up study for efficacy on cognitive function of donepezil in binswanger type subcortical vascular dementia	2010	-0.3502	0.0785	50	1.3651
2021046031	continuous intravenous morphine infusion for postoperative analgesia following posterior spinal fusion for idiopathic scoliosis	2010	2.3864	-0.0463	130	0.8591
2021159235	oxpentifylline in dementia a controlled study	1987	-0.3807	-0.2165	45	0.6739
2021166856	provisional diagnostic criteria for depression of alzheimer disease rationale and background	2002	0.2118	0.0764	31	4.4476
2021181758	apolipoprotein e high avidity binding to beta amyloid and increased frequency of type 4 allele in late onset familial alzheimer disease	1993	-0.7714	-0.1862	29	0.9713
2021206292	a conceptual framework for adaptive preventive interventions	2004	0.246	0.0854	141	0.9959
2021280501	alzheimer s disease a disorder of cortical cholinergic innervation	1983	-0.3193	0.2041	13	8.8772
2021296968	quetiapine may reduce hostility in patients with psychoses related to alzheimer s disease	1999	0.3078	0.1426	81	0.6762
2021323428	selegiline in the treatment of behavioural disturbance in alzheimer s disease	1997	-0.1503	0.1191	44	17.2042
2021348357	a predictor for side effects in patients with alzheimer s disease treated with deferoxamine mesylate	1993	-1.5731	-1.2588	101	15.7126
2021380055	detecting depression in alzheimer s disease evaluation of four different scales	2005	0.2621	0.0262	31	0.845
2021443412	long term effects of exercise on psychological functioning in older men and women	1991	0.5805	-0.2503	27	4.9451
2021446295	hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus	2009	-0.4394	1.5282	56	2.7993
2021556801	notch3 mutations in cadasil a hereditary adult onset condition causing stroke and dementia	1996	-0.45	-0.0021	12	1
2021573555	the efficacy of intrathecal morphine in post thoracotomy pain management	2007	2.3863	-0.0472	130	0.8942
2021576068	haloperidol concentrations in patients with alzheimer s dementia	1994	-0.4086	0.3103	120	0.6132
2021604439	cognitive effects after epidural vs general anesthesia in older adults a randomized trial	1995	2.2212	-0.0339	36	1.9404
2021611092	exacerbation of myoclonus by memantine in a patient with alzheimer disease	2007	-0.3144	0.1739	22	0.7968
2021621278	alcohol and the acceptance of social influence an experimental study	1974	-0.3865	0.3792	98	0.7069
2021634787	24 hour cortisol measures in adolescents with major depression a controlled study	1991	0.3313	-0.0243	89	0.6902
2021718502	association of incident alzheimer disease and blood pressure measured from 13 years before to 2 years after diagnosis in a large community study	2001	-0.7135	-0.1354	14	0.991
2021737078	stability of cognitive symptoms in dementia of the alzheimer type	1992	-0.3141	0.0962	50	0.6434
2021751687	p01 93 beneficial effects of memantine in every day medical practice results from a large greek observational study	2009	-0.4204	-0.0632	82	0.7608
2021818579	prefrontal cortex as the site of estrogen s effect on cognition	2001	-0.7624	-0.7727	3	1.9867
2021855470	a randomized placebo controlled trial of ginkgo biloba for the prevention of cognitive decline	2008	-0.4103	-0.0746	8	10.894
2021861716	effects of carbamazepine and valproate on haloperidol plasma levels and on psychopathologic outcome in schizophrenic patients	1999	-0.1168	0.194	114	0.698
2021978753	dietary supplementation with conjugated linoleic acid increased its concentration in human peripheral blood mononuclear cells but did not alter their function	2001	-1.1442	-0.3148	83	0.7532
2021978868	the cholinergic hypothesis of cognitive impairment caused by traumatic brain injury	2003	-0.8474	1.0199	71	0.9867
2022150546	idebenone in senile dementia of alzheimer type a multicentre study	1992	-0.2985	0.0512	23	0.6416
2022413616	correlates and consequences of eating dependency in institutionalized elderly	1986	0.5917	-0.0633	123	0.845
2022546930	enhanced recovery program following colorectal resection in the elderly patient	2012	2.7899	-0.0532	118	0.845
2022556603	does an exercise and incontinence intervention save healthcare costs in a nursing home population	2003	0.5272	-0.0878	34	0.68
2022608896	nootropic drugs animal models for studying effects on cognition	1984	-0.2882	0.3063	15	0.75
2022669291	psychosis of alzheimer disease validity of the construct and response to risperidone	2003	0.0728	0.0934	16	18.0297
2022673492	alzheimer s disease a metallic problem	2001	-1.0873	-0.5741	69	0.7595
2022722753	safety and efficacy of rivastigmine in patients with alzheimer s disease not responding adequately to donepezil an open label study	2008	-0.0752	0.0728	58	0.7298
2022737412	the effect of deprenyl and tocopherol on cognitive performance in early untreated parkinson s disease	1994	-0.2336	0.1906	9	1.4185
2022780938	do memory clinics improve the quality of life of carers a randomized pilot trial	1999	0.5357	-0.1118	1	0.845
2023021760	spinal blocks with and without morphine in women undergoing hysterectomies a randomized study	2010	2.3863	-0.0472	130	0.8535
2023049748	p4 381 comparison of amisulpride and risperidone in the treatment of psychosis in patients with dementia of the alzheimer s type	2008	0.6164	0.4438	40	0.7797
2023054003	metrifonate treatment of the cognitive deficits of alzheimer s disease	1998	-0.2741	0.0847	44	4.4206
2023091241	memory rehabilitation in alzheimer s disease a review of progress	2001	0.2584	-0.1097	10	4.983
2023121717	preclinical evidence of alzheimer s disease in persons homozygous for the e4 allele for apolipoprotein e	1996	-0.052	-0.0405	46	1
2023186645	impact of combined estradiol and norethindrone therapy on visuospatial working memory assessed by functional magnetic resonance imaging	2006	-0.758	-0.7661	3	1
2023205597	older adults strategic behavior effects of individual versus collaborative cognitive training	2004	0.4602	-0.2374	4	0.8554
2023235142	influence of the 5 ht6 receptor on acetylcholine release in the cortex pharmacological characterization of 4 2 bromo 6 pyrrolidin 1 ylpyridine 4 sulfonyl phenylamine a potent and selective 5 ht6 receptor antagonist	2003	-1.5582	0.2221	115	0.9867
2023243943	aminoadamantanes as nmda receptor antagonists and antiparkinsonian agents preclinical studies	1997	-0.2742	0.0723	23	0.9939
2023258470	the effect of escitalopram versus placebo on perceived stress and salivary cortisol in healthy first degree relatives of patients with depression a randomised trial	2012	0.3285	-0.025	89	1.4296
2023360831	impaired glucose metabolism slows executive function independent of cerebral ischemic lesions in japanese elderly the takahata study	2011	-0.4858	0.0852	117	0.673
2023429094	fc02 04 reduction of psychotic symptoms in patients with lewy body like symptoms treated with olanzapine	2000	0.104	0.1382	38	0.9719
2023487517	the effect of planned walking on communication in alzheimer s disease	1991	0.5026	-0.1757	25	0.916
2023634568	sequenced treatment alternatives to relieve depression star d rationale and design	2004	0.246	0.0854	141	0.9988
2023651401	estrogen replacement therapy and risk of alzheimer disease	1996	-0.743	-0.7364	3	5.9999
2023669307	alzheimer disease and rivastigmine treatment	2000	-0.328	0.1754	22	1.5891
2023692020	dementia of the alzheimer s type changes in hippocampal l 3h glutamate binding	1987	-0.2977	0.188	43	0.9867
2023713823	circulating cholesterol levels apolipoprotein e genotype and dementia severity influence the benefit of atorvastatin treatment in alzheimer s disease results of the alzheimer s disease cholesterol lowering treatment adclt trial	2006	-0.7198	-0.168	29	22.9758
2023718291	cognitive behaviour therapy for the chronic fatigue syndrome a randomized controlled trial	1996	-0.103	-0.0968	8	0.701
2023840993	piracetam therapy does not enhance cognitive functioning in children with down syndrome	2001	-0.2646	0.2432	15	3.15
2023848995	reality orientation and validation therapy dementia depression and functional status	1993	0.4389	-0.07	18	0.8843
2023850801	modafinil for fatigue in ms a randomized placebo controlled double blind study	2005	-0.2419	0.2123	55	0.9584
2023868026	efficacy and tolerability of donepezil 23 mg day versus donepezil 10 m day in indian patients with moderate to severe ad study 326 subanalysis	2014	-0.2662	0.0553	124	0.8398
2023876571	memantine and hiv associated cognitive impairment a neuropsychological and proton magnetic resonance spectroscopy study	2007	-0.3994	0.4991	87	20.9678
2023891836	group cognitive behavioral therapy for bipolar disorder a feasibility and effectiveness study	2001	0.415	-0.0781	18	0.706
2023897649	d cycloserine a novel cognitive enhancer improves spatial memory in aged rats	1994	-0.2928	0.1794	43	3.6146
2023899218	diabetes mellitus and risk of alzheimer disease and decline in cognitive function	2004	-0.4458	1.587	56	1
2023964473	cholinergic system and constructional praxis a further study of physostigmine in alzheimer s disease	1984	-0.3161	0.1995	13	3.8071
2023967416	a 24 week randomized trial of controlled release physostigmine in patients with alzheimer s disease	1999	-0.2532	0.0752	44	23.0397
2024081973	delirium is independently associated with poor functional recovery after hip fracture	2000	2.2027	-0.044	2	3.7499
2024097777	a randomized double blind placebo controlled study of aripiprazole for the treatment of psychosis in nursing home patients with alzheimer disease	2008	0.1863	0.093	16	0.9999
2024099471	memantine and prevention of worsening across multiple domains post hoc analysis of a randomized placebo controlled trial in patients with moderate alzheimer s disease	2010	-0.5166	-0.0479	12	0.7483
2024108378	efficacy of music therapy in the treatment of behavioral and psychiatric symptoms of dementia	2008	0.4695	-0.0564	21	14.5364
2024121824	developing an interactive physical activity group in a geriatric psychiatry facility	2001	0.511	-0.16	60	15.022
2024187599	use of physical restraints and antipsychotic medications in nursing homes a cross national study	2009	0.8149	-0.0996	42	2.8702
2024214628	cholinesterase inhibitors for patients with alzheimer s disease systematic review of randomised clinical trials	2005	-0.2815	0.0856	33	1.6535
2024245575	leisure or therapeutics snoezelen and the care of older persons with dementia	2000	0.4256	-0.076	18	0.991
2024276638	cholesterol lowering therapy in women and elderly patients with myocardial infarction or angina pectoris findings from the scandinavian simvastatin survival study 4s	1997	-0.788	-0.1891	88	1
2024283863	experiencing control in caregiving	1999	0.6888	-0.1557	76	0.8505
2024308799	efficacy of naftidrofuryl in patients with vascular or mixed dementia results of a multicenter double blind trial	2000	-0.0944	0.0059	84	15.3654
2024310593	favorable effect of transcranial electrostimulation on behavior disorders in elderly patients with dementia a double blind study	1996	0.2251	-0.0083	17	19.5058
2024311146	ginkgo biloba for cerebral insufficiency	1992	-0.4665	-0.0549	8	6.8002
2024346969	donepezil induced rem sleep augmentation enhances memory performance in elderly healthy persons	2001	0.1281	0.0261	28	0.9584
2024352468	collaborative meta analysis of randomised trials of antiplatelet therapy for prevention of death myocardial infarction and stroke in high risk patients	2002	-0.7877	-0.1885	88	1
2024430285	evaluation of dementia in the cardiovascular health cognition study	2003	-0.3317	-0.0945	8	0.75
2024498737	increased life expectancy resulting from addition of l deprenyl to madopar treatment in parkinson s disease a longterm study	1985	-0.1913	0.1192	37	2.8421
2024515452	persistence of the effects of cerebrolysin on cognition and qeeg slowing in vascular dementia patients results of a 3 month extension study	2010	-0.1942	0.0546	67	14.8691
2024637966	on the effect of a monoamine oxidase inhibitor on the behavior and tryptophan metabolism of schizophrenic patients	1957	-0.1962	0.1508	37	0.805
2024850658	d cycloserine reverses the working memory impairment of hippocampal lesioned rats in a spatial learning task	1992	-0.2952	0.1868	43	3.7852
2024906043	effects of the novel compound aniracetam ro 13 5057 upon impaired learning and memory in rodents	1982	-0.2938	0.2669	15	1.786
2025003635	diet and risk of dementia does fat matter the rotterdam study	2002	-1.0678	-0.2914	5	1.958
2025039880	aspirin for the primary prevention of cardiovascular events in women and men a sex specific meta analysis of randomized controlled trials	2006	-0.5188	-0.0906	68	0.7067
2025063317	epidemiology of adverse drug events in the nursing home setting	1995	0.7088	-0.0469	52	0.8057
2025080543	anger management for dementia caregivers a preliminary study using video and telephone interventions	2000	0.5346	-0.1078	1	19.7879
2025082419	spectral eeg changes after piracetam infusion in senile dementia of alzheimer type	1997	-0.2939	0.1114	50	0.6786
2025085189	preliminary findings of the effects of rivastigmine an acetylcholinesterase inhibitor on working memory in cocaine dependent volunteers	2014	-0.2415	0.1578	9	1.3114
2025115831	alzheimer s disease the unpaid burden of caring	1995	0.0635	-0.0295	93	0.9804
2025152196	effects of a?? immunization an1792 on mri measures of cerebral volume in alzheimer disease	2005	-0.1937	0.0128	46	1.7993
2025374158	the neuropsychological and mri findings in binswanger type vascular cognitive impairment no dementia vcind and vascular dementia vad	2012	-0.3858	0.0611	50	0.7147
2025386073	is age a risk factor of postoperative complications in colorectal cancer	2013	2.7899	-0.0532	118	0.8121
2025392695	reminiscence group therapy on depression and apathy in nursing home residents with mild to moderate dementia	2010	0.3574	-0.0939	39	0.845
2025438125	poststroke fatigue characteristics and related factors	2005	-1.1671	1.5699	64	0.7993
2025464345	treatment of alzheimer disease by continuous intravenous infusion of physostigmine	1995	-0.6072	0.5194	119	12.8374
2025537689	deprenyl selegiline in the treatment of parkinson s disease	1983	-0.1918	0.1108	137	0.6655
2025544470	study of alzheimer s disease	1983	-0.4424	0.2875	105	0.8601
2025626136	the relationship between physical restraint removal and falls and injuries among nursing home residents	1998	0.8311	-0.1014	42	1.916
2025735611	switching from oral cholinesterase inhibitors to the rivastigmine transdermal patch	2010	-0.2557	0.0526	72	1.6851
2025738603	treatment and prevention of mental disorders in low income and middle income countries	2007	0.5574	-0.1268	140	0.9804
2025739058	nicotine enhances sustained attention in the rat under specific task conditions	1998	0.0437	0.4832	48	0.9999
2025771431	the relationship between impaired glucose tolerance type 2 diabetes and cognitive function	2004	-0.4532	1.699	96	1.8842
2025776258	indication of an antipsychotic action of the opiate antagonist naloxone	1977	-0.6362	0.0864	122	0.7265
2025801062	selective impairment of learning and blockade of long term potentiation by an n methyl d aspartate receptor antagonist ap5	1986	-0.2977	0.188	43	0.9867
2025815749	a randomised controlled trial of cognitive behaviour therapy for clinical perfectionism a preliminary study	2007	-0.2945	-0.1543	45	0.6841
2025827588	goal oriented cognitive rehabilitation for people with early stage alzheimer disease a single blind randomized controlled trial of clinical efficacy	2010	0.2867	-0.1098	10	22.9385
2025916948	1166 development implementation and evaluation of a structured nursing intervention to prevent nausea nutrition deficit experienced by patients undergoing chemotherapy a randomized controlled clinical trial	2003	-0.5975	-0.0271	99	0.6908
2025942615	short term administration of selegiline for mild to moderate dementia of the alzheimer s type	1998	-0.1942	0.1785	11	16.4503
2025947444	milacemide a placebo controlled study in senile dementia of the alzheimer type	1992	-0.195	0.1795	11	0.6919
2025982460	plasma tricyclic drug levels in amitriptyline treated depressed patients	1979	-0.1168	0.194	114	0.7087
2026047746	rationale for transdermal drug administration in alzheimer disease	2007	-0.238	0.0499	19	3.8645
2026051875	memory training strategies and subjective complaints of memory in the aged	1981	0.5096	-0.2853	4	2.6314
2026112519	influence of transcutaneous electrical nerve stimulation on memory in patients with dementia of the alzheimer type	1992	0.2164	-0.0089	17	5.6114
2026126119	accumulation of amyloid precursor protein like immunoreactivity in rat brain in response to thiamine deficiency	1995	-0.7867	-0.0986	86	0.845
2026130669	effects of aerobic exercise training age and physical fitness on memory search performance	1988	0.5802	-0.2502	27	3.8697
2026220450	a randomized trial of cognitive rehabilitation in cancer survivors	2013	0.415	-0.0781	18	0.7083
2026236018	human red blood cell choline uptake with age and alzheimer s disease	1986	-0.4086	0.3103	120	0.6582
2026240880	modulation of cognition and mood following administration of single doses of ginkgo biloba ginseng and a ginkgo ginseng combination to healthy young adults	2002	-0.6576	-0.1207	65	3.7603
2026256071	a double blind placebo controlled study with oxiracetam in demented patients administered the luria nebraska neuropsychological battery	1988	-0.1379	0.0381	80	0.6877
2026310866	n 3 fatty acids and cardiovascular events after myocardial infarction	2010	-1.2407	-0.3452	83	20
2026326510	first head to head study comparing the efficacy of donepezil and galantamine in alzheimer s disease	2002	-0.2939	0.1114	50	0.6938
2026376363	rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment preliminary findings from an open trial	2001	-0.1808	0.1159	7	5
2026495098	vasopressin and beta endorphin responses to physostigmine are blunted in alzheimer s disease	1988	0.0571	0.5351	48	0.7656
2026505782	orthogeriatric care models and outcomes in hip fracture patients a systematic review and meta analysis	2014	2.1944	-0.0495	2	0.9584
2026553142	fdg pet improves accuracy in distinguishing frontotemporal dementia and alzheimer s disease	2007	-0.0645	0.0399	22	0.75
2026643203	does blood pressure lowering treatment prevents dementia or cognitive decline in patients with cardiovascular and cerebrovascular disease	2005	-0.6781	-0.1152	14	0.8843
2026692264	clonidine induced growth hormone secretion in elderly patients with senile dementia of the alzheimer type and major depressive disorder	1989	-0.3852	0.1417	134	0.6006
2026713237	sodium valproate in the treatment of aggressive behavior in patients with dementia a randomized placebo controlled clinical trial	2002	0.1657	0.0813	16	22.9819
2026717702	alterations of thiamine phosphorylation and of thiamine dependent enzymes in alzheimer s disease	1996	-0.7852	-0.0994	86	2.7438
2026765074	audio presence intervention for decreasing agitation in people with dementia	2001	0.486	-0.0409	21	0.9713
2026772921	diagnostic procedures for parkinson s disease dementia recommendations from the movement disorder society task force	2007	-0.1857	0.1112	7	1
2026856307	acute effects of exercise on neuropsychological function in elderly subjects	1988	0.5825	-0.2513	27	0.9988
2026888376	alzheimer s response	1993	-0.5503	0.3993	73	0.6703
2027025122	tues p63 somatic comorbidity in patients with dementia alzheimer disease versus mixed dementia and vascular dementia	1998	-0.4055	0.0833	85	0.6956
2027316175	is flunarizine a long acting oral atypical antipsychotic a randomized clinical trial versus haloperidol for the treatment of schizophrenia	2008	-0.1168	0.194	114	0.6907
2027318457	replacement of dehydroepiandrosterone in adrenal failure no benefit for subjective health status and sexuality in a 9 month randomized parallel group clinical trial	2003	-1.4161	-1.838	20	0.9999
2027345824	memory training and memory improvement in alzheimer s disease rules and exceptions	1992	0.2753	-0.0952	10	1.9148
2027351031	reducing antipsychotic drug use in nursing homes a controlled trial of provider education	1993	0.5903	-0.012	52	2.996
2027365236	caregiving as a risk factor for mortality the caregiver health effects study	1999	0.5401	-0.1131	1	7.869
2027366700	tacrine tetrahydroaminoacridine tha and lecithin in senile dementia of the alzheimer type a multicentre trial groupe francais d etude de la tetrahydroaminoacridine	1990	-0.2769	0.1367	13	7.552
2027406714	evaluating reminiscence for people with dementia a pilot study	2002	0.3299	-0.0925	39	1.6443
2027414336	a nordic multi center study on physical and daily activities for residents in nursing home settings design of a randomized controlled trial	2009	0.5131	-0.1606	60	0.6623
2027460468	mutations in progranulin cause tau negative frontotemporal dementia linked to chromosome 17	2006	-0.2332	0.2582	66	1.9804
2027520066	morning bright light therapy for sleep and behavior disorders in elderly patients with dementia	1994	0.3581	-0.0179	17	6.7587
2027524282	behavioral and cognitive outcomes of scu care	1991	0.6761	-0.022	24	0.9584
2027554217	methylphenidate combined with aripiprazole in children and adolescents with bipolar disorder and attention deficit hyperactivity disorder a randomized crossover trial	2009	-0.1547	0.2301	15	0.6247
2027595176	postoperative delirium a review of 80 primary data collection studies	1995	2.2004	-0.0423	2	0.9973
2027728315	olanzapine reduces psychotic symptoms and behavioral disturbances associated with alzheimer s disease	2000	0.3081	0.1433	81	1.7749
2027749018	quantitative eeg abnormalities and cognitive dysfunctions in frontotemporal dementia and alzheimer s disease	2003	-0.2809	0.1571	43	0.6779
2027795129	an experimental design for the development of adaptive treatment strategies	2005	0.246	0.0854	141	0.9997
2027805815	antihypertensive drugs in very old people a subgroup meta analysis of randomised controlled trials	1999	-0.7353	-0.1501	14	2
2027916004	preserving health of alzheimer caregivers impact of a spouse caregiver intervention	2007	0.5181	-0.1138	1	2.7021
2028007176	aggravated decrease in the activity of nucleus basalis neurons in alzheimer s disease is apolipoprotein e type dependent	1998	0.1927	-0.0097	17	0.75
2028020563	the consequences of non cognitive symptoms of dementia in medical hospital departments	2003	0.9833	-0.0254	24	0.704
2028053170	caregivers of people with alzheimer s disease a qualitative study from the indian 10 66 dementia research network	2003	0.5568	-0.1275	140	0.991
2028062432	identification of community residing individuals with dementia and their unmet needs for care	2011	0.5971	-0.1331	131	0.7089
2028140595	cognitive rehabilitation in the elderly a randomized trial to evaluate a new protocol	2007	0.4691	-0.2555	4	1.9993
2028154004	is memantine a breakthrough in the treatment of moderate to severe alzheimer s disease	2003	-0.1687	0.0991	11	0.8162
2028184358	the effects of group music with movement intervention on agitated behaviours of institutionalized elders with dementia in taiwan	2006	0.4629	-0.0626	21	8.7107
2028186493	adherence to continuous positive airway pressure treatment in patients with alzheimer disease and obstructive sleep apnea	2006	0.2286	-0.0028	28	0.9584
2028195866	nxx 066 in patients with alzhemer s disease a bridging study	1999	-0.2658	0.0614	44	0.7197
2028253896	hormonal changes in aging men a therapeutic indication	2001	-1.3848	-1.7808	54	0.7244
2028331472	lecithin and piracetam in alzheimer s disease	1987	-0.2986	0.2134	15	0.8843
2028415610	age and physical activity effects on reaction time and digit symbol substitution performance in cognitively active adults	1993	0.5808	-0.2505	27	0.7993
2028436804	mild cognitive impairment as a diagnostic entity	2004	-0.0184	-0.07	46	8.9712
2028459909	a randomised study to compare the efficacy tolerability and safety between memantine and donepezil in moderate to severe alzheimer s disease	2009	-0.2394	0.059	19	1.5545
2028491002	short dementia questionnaire for assessing the severity of cognitive impairment in patients with dementia	2001	-0.0747	-0.1034	127	0.7876
2028499883	alterations in circadian rhythmicity of the vasopressin producing neurons of the human suprachiasmatic nucleus scn with aging	1994	0.2493	-0.0148	17	2.6064
2028541643	the 5 ht6 receptor antagonist sb 271046 selectively enhances excitatory neurotransmission in the rat frontal cortex and hippocampus	2001	-1.5582	0.2221	115	0.9867
2028547764	hormone replacement therapy and cognition systematic review and meta analysis	2001	-0.74	-0.7413	3	17.964
2028720052	anxiety in dementia a critical review	2008	0.6751	-0.1736	77	0.916
2028763483	student led exercise sessions yield significant fitness gains for alzheimer s patients	2003	0.4866	-0.1791	25	2.982
2028843740	the effect of long term physostigmine administration in alzheimer s disease	1990	-0.2977	0.148	13	17.534
2028850322	the relations between observer rating and self report of depressive symptomatology	1993	0.2622	0.0272	31	0.7571
2028856417	vascular dementia clinical and neuroradiological correlation	2011	-0.0942	0.0057	84	0.7075
2028858660	choline in the treatment of rapid cycling bipolar disorder clinical and neurochemical findings in lithium treated patients	1996	-0.4086	0.3103	120	0.6111
2028868771	the plus intervention a pilot test with caregivers of depressed older adults	2002	0.5415	-0.1158	1	0.771
2028881255	rates of cognitive change in alzheimer disease observations across a decade of placebo controlled clinical trials with donepezil	2009	-0.0595	0.0836	58	0.8125
2028883654	effects of omega 3 fatty acids on inflammatory markers in cerebrospinal fluid and plasma in alzheimer s disease the omegad study	2009	-1.0737	-0.2926	5	23.9217
2028905629	estrogen exposures and memory at midlife a population based study of women	2003	-0.752	-0.7607	3	1.9991
2028935810	effects of nicotine on attention and inhibitory control in healthy nonsmokers	2011	-0.662	-0.1224	65	0.6939
2028998846	vascular dementia revisited diagnosis pathogenesis treatment and prevention	2002	-0.4482	-0.0028	12	0.916
2029183641	donepezil treatment of patients with severe alzheimer s disease in a japanese population results from a 24 week double blind placebo controlled randomized trial	2008	-0.2126	0.0422	6	23.165
2029191095	fish consumption and major depression	1998	-1.0972	-0.3014	5	0.9939
2029269825	exercise fails to improve neurocognition in depressed middle aged and older adults	2008	-0.2409	-0.2597	49	0.7376
2029287128	short term efficacy of donepezil in alzheimer s disease	1999	-0.3203	0.1165	33	2.4457
2029351122	an exercise program for women who are caring for relatives with dementia	2002	0.559	-0.1168	142	0.8843
2029421651	effectiveness of collaborative care for older adults with alzheimer disease in primary care a randomized controlled trial	2006	0.5524	-0.1208	74	38.197
2029436713	atenolol in hypertension is it a wise choice	2004	-0.7616	-0.1531	14	0.9404
2029450872	randomized clinical trial of the effectiveness of a home based intervention in patients with heart failure the ic dom study	2009	2.3692	-0.0634	35	0.7129
2029469073	ketamine attenuates delirium after cardiac surgery with cardiopulmonary bypass	2009	2.2276	-0.0441	2	0.7993
2029469913	effect of antibiotic treatment on outcome of fevers in institutionalized alzheimer patients	1990	0.8533	-0.0193	95	0.916
2029552699	vitamin e protects nerve cells from amyloid ??protein toxicity	1992	-0.291	0.0713	37	0.8843
2029597347	efficacy of a cognitive stimulation therapy programme for people with dementia	2011	0.2177	-0.0716	10	17.6415
2029630574	neuroleptics in the treatment of dementia	1988	0.0849	0.1025	47	0.7993
2029671311	p 5 a 006 long term safety and tolerability of memantine an open label extension study in patients with mild to moderate alzheimer s disease	2007	-0.2408	0.0603	19	0.7526
2029684564	risperidone in the treatment of psychosis and concomitant buccolinguomasticatory dyskinesia in the elderly	1997	0.617	0.4432	40	0.802
2029803811	a pilot randomised controlled trial of a brief cognitive behavioural group intervention to reduce recurrence rates in late life depression	2009	0.0708	0.1428	61	0.743
2029817026	long term treatment with estrogen and progesterone enhances acquisition of a spatial memory task by ovariectomized aged rats	2000	-0.7477	-0.752	3	4.8842
2029819764	melatonin treatment of day night rhythm disturbances and sundowning in alzheimer disease an open label pilot study using actigraphy	2004	0.2295	-0.0177	28	1.9973
2029835958	the effects of a dementia nurse care manager on improving caregiver outcomes outcomes	2009	0.5472	-0.1171	74	0.845
2029982441	therapeutic conversation to improve mood in nursing home residents with alzheimer s disease	2009	0.439	-0.0053	104	16.2359
2030016379	do neuroleptic drugs hasten cognitive decline in dementia prospective study with necropsy follow up	1997	0.3204	0.0399	16	0.9804
2030025114	randomized controlled trial of atorvastatin in mild to moderate alzheimer disease leade	2010	-0.6735	-0.1578	29	31.3981
2030079540	a 24 week randomized double blind study of donepezil in moderate to severe alzheimer s disease	2001	-0.1926	0.0464	6	64.3931
2030180616	the effect of a structured intervention on caregivers of patients with dementia and problem behaviors a randomized controlled pilot study	2004	0.6275	-0.1215	42	0.7291
2030324979	favorite music and hand massage two interventions to decrease agitation in residents with dementia	2008	0.4746	-0.0521	21	1.9653
2030329403	a 26 week analysis of a double blind placebo controlled trial of the ginkgo biloba extract egb 761 in dementia	2000	-0.4141	-0.0859	8	31.3289
2030368401	self efficacy and memory aging the impact of a memory intervention based on self efficacy	2008	0.4859	-0.2694	4	0.9804
2030422500	response to combination cholinergic noradrenergic treatments in a patient with alzheimer s disease	1993	-0.1911	0.1104	137	0.6564
2030447739	caregiving appraisal and interventions based on the progressively lowered stress threshold model	2002	0.5001	-0.0899	1	0.9404
2030455832	ginkgo biloba extract and long term cognitive decline a 20 year follow up population based study	2013	-0.4634	-0.0729	8	0.991
2030475446	the efficacy of intrathecal morphine with or without clonidine for postoperative analgesia after radical prostatectomy	2009	2.3863	-0.0472	130	0.8573
2030485621	i in vivo evidence for partial agonist effects of osu6162 and osu6162 on 5 ht2a serotonin receptors	2011	-1.1671	1.5699	64	0.8843
2030490613	p1 428 patterns of neuropsychiatric symptoms in alzheimer s dementia mixed dementia and vascular dementia	2004	-0.2909	0.1288	53	0.77
2030513035	clinical validity of the mattis dementia rating scale 2 in parkinson disease with mci and dementia	2012	-0.1886	0.0705	7	0.7832
2030580051	effects of donepezil on cognitive functioning in down syndrome	2003	-0.2008	0.1471	9	0.813
2030585730	group psychotherapy and people with dementia	2003	0.4471	-0.0927	18	0.9404
2030609731	relationship between baseline glycemic control and cognitive function in individuals with type 2 diabetes and other cardiovascular risk factors the action to control cardiovascular risk in diabetes memory in diabetes accord mind trial	2009	-0.4449	1.5721	56	1.9997
2030672678	antihistamine agent dimebon as a novel neuroprotector and a cognition enhancer	2006	-0.586	-0.1761	32	1
2030711203	cognitive findings of an exploratory trial of docosahexaenoic acid and lutein supplementation in older women	2008	-1.0091	-0.2729	5	1.9584
2030744221	snoezelen a multisensory environmental intervention	2002	0.4308	-0.0751	18	0.9584
2030817295	donepezil a review of its use in alzheimer s disease	2000	-0.2667	0.0527	124	1.6901
2030840973	explicit criteria for determining potentially inappropriate medication use by the elderly an update	1997	0.5418	0.0032	52	1
2030850051	glycine prodrug facilitates memory retrieval in humans	1991	-0.2977	0.188	43	0.991
2030939266	cognitive function physical activity and aging possible biological links and implications for multimodal interventions	2012	0.5368	-0.188	27	0.916
2030951185	fish docosahexaenoic acid and alzheimer s disease	2009	-1.0144	-0.2737	5	1.9999
2030972192	galantamine in vascular dementia and alzheimer s disease combined with cerebrovascular disease	2002	-0.3739	0.087	94	1.7568
2030976463	tube feeding in patients with advanced dementia a review of the evidence	1999	0.8533	-0.0193	95	0.8843
2030984630	first episode of major depressive disorder and vascular factors in coronary artery disease patients baseline characteristics and response to antidepressant treatment in the create trial	2010	0.2442	0.0893	31	0.7906
2031032188	transfusion requirements after cardiac surgery the tracs randomized controlled trial	2010	2.5491	-0.0689	35	0.7549
2031041233	effects of a central cholinesterase inhibitor on reducing falls in parkinson disease	2010	-0.186	0.0716	7	0.75
2031054440	thiamine dependent enzyme changes in the brains of alcoholics relationship to the wernicke korsakoff syndrome	1993	-0.7874	-0.0992	86	0.845
2031096222	predictors of continued physical restraint use in nursing home residents following restraint reduction efforts	1999	0.8432	-0.1021	42	0.9997
2031147951	p1 021 memantine treatment for mild to severe alzheimer s disease clinical trials summary	2004	-0.2801	0.075	51	0.6509
2031148569	an open labeled trial of adjunctive donepezil for cognitive impairments in patients with schizophrenia	2003	-0.2238	0.1562	9	2.139
2031149574	donepezil therapy in clinical practice a randomized crossover study	2000	-0.2392	0.0089	6	1.7388
2031164126	sb 399885 is a potent selective 5 ht6 receptor antagonist with cognitive enhancing properties in aged rat water maze and novel object recognition models	2006	-1.5582	0.2221	115	0.991
2031175219	basal circadian and pulsatile acth and cortisol secretion in patients with fibromyalgia and or chronic fatigue syndrome	2004	0.3313	-0.0243	89	0.6912
2031185570	prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower than average cholesterol concentrations in the anglo scandinavian cardiac outcomes trial lipid lowering arm ascot lla a multicentre randomised controlled trial	2003	-0.7878	-0.1882	88	3
2031231661	amyloid ?? induced pathological behaviors are suppressed by ginkgo biloba extract egb 761 and ginkgolides in transgenic caenorhabditis elegans	2006	-0.4302	-0.0801	8	1.9849
2031305166	mindfulness based stress reduction mbsr improves long term mental fatigue after stroke or traumatic brain injury	2012	-1.1671	1.5699	64	0.8843
2031367861	training related brain plasticity in subjects at risk of developing alzheimer s disease	2011	0.3164	-0.1289	10	0.7993
2031433969	redox active iron mediates amyloid ?? toxicity	2001	-1.0107	-0.5241	69	1
2031597989	docosahexaenoic acid prevents lipopolysaccharide induced cytokine production in microglial cells by inhibiting lipopolysaccharide receptor presentation but not its membrane subdomain localization	2008	-1.1027	-0.3021	5	0.75
2031645622	cognitive decline in individuals with high blood pressure a longitudinal study in the elderly	1999	-0.6736	-0.1138	14	2.7993
2031709382	donepezil is associated with delayed nursing home placement in patients with alzheimer s disease	2003	-0.2171	0.0496	6	7.8207
2031723430	the scandinavian multi infarct dementia trial a double blind placebo controlled trial on nimodipine in multi infarct dementia	2000	-0.4301	0.0035	12	22.0686
2031743984	alleviating neuropsychiatric symptoms in dementia the effects of ginkgo biloba extract egb 761 findings from a randomized controlled trial	2011	-0.374	-0.0361	70	18.0624
2031812635	effect of age on acute pain perception of a standardized stimulus in the emergency department	2001	2.345	0.1894	103	0.7041
2031831813	folate vitamin b12 homocysteine and the mthfr 677c t polymorphism in anxiety and depression the hordaland homocysteine study	2003	-0.8812	-0.1041	30	0.9867
2031853288	p079 implication of bcl 2 family proteins in the induction of jurkat t lymphocyte apoptosis by the main n 3 fatty acids present in fish oil docosahexaenoic and eicosapentaenoic acid	2007	-1.1031	-0.3023	5	0.8045
2031973474	use of environmental manipulation and classroom and modified informal reality orientation with institutionalized confused elderly patients	1985	0.3289	-0.0916	10	2.9843
2032012952	efficacy of memantine hydrochloride once daily in alzheimer s disease	2014	-0.1258	0.0955	11	0.7908
2032014173	beneficial effect of donepezil augmentation for the management of comorbid schizophrenia and dementia	2003	-0.2109	0.1792	11	1.3728
2032024946	redesigning acute care for cognitively impaired older adults optimizing health care services	2016	1.6418	-0.0325	24	0.7681
2032099695	dimethylglycine supplementation does not affect plasma homocysteine concentrations in pre dialysis chronic renal failure patients	2004	-1.9284	0.3325	109	0.7648
2032227661	group therapy in a home for the aged	1967	0.4381	-0.0696	18	0.7993
2032238660	an open trial of olanzapine for the treatment of delirium in hospitalized cancer patients	2002	2.1577	-0.0424	2	1.7367
2032262080	the role of postoperative analgesia in delirium and cognitive decline in elderly patients a systematic review	2006	2.2253	-0.0295	36	0.916
2032313326	precipitating factors for delirium in hospitalized elderly persons predictive model and interrelationship with baseline vulnerability	1996	2.203	-0.0416	2	14.7704
2032313795	clinical predictors of response to acetyl cholinesterase inhibitors experience from routine clinical use in newcastle	2003	-0.1886	0.0705	7	0.7412
2032314496	cerebral pharmacodynamics of physostigmine in alzheimer s disease investigated using single photon computerised tomography	1991	-0.293	0.1677	13	0.9867
2032360028	reducing physical restraints developing an educational program	1992	0.8432	-0.1021	42	0.9994
2032371154	pharmacologic strategies for augmenting cognitive performance in schizophrenia	1999	0.0183	0.3851	48	0.6506
2032413621	depressive symptom deterioration among predominantly hispanic diabetes patients in safety net care	2012	0.4581	0.2355	116	0.75
2032417055	long term treatment of elderly psychotic patients with risperidone	1997	0.5922	0.4225	40	1.5443
2032528029	efficacy and tolerability of iloperidone in elderly patients with psychotic and behavioural symptoms associated with dementia	2002	0.617	0.4432	40	0.7921
2032613394	neurotoxicity associated with dual actions of homocysteine at the n methyl d aspartate receptor	1997	-1.9284	0.3325	109	0.75
2032624001	carbamazepine treatment of agitation associated with dementia	1988	0.0875	0.0984	47	0.9404
2032628906	experimental evaluation of the effectiveness of group intervention for dementia caregivers	1987	0.5446	-0.1133	1	3.7614
2032684154	estrogen treatment in women with schizophrenia psychotic symptom and cognitive response	2003	0.3085	0.1434	81	0.7265
2032684859	effectiveness of geriatric rehabilitative care after fractures of the proximal femur in elderly women a randomised clinical trial	1988	1.9722	-0.088	26	1
2032734645	cerebrospinal fluid and serum concentrations of the n methyl d aspartate nmda receptor antagonist memantine in man	1995	-0.2735	0.0729	23	0.9982
2032833970	ondasetron versus haloperidol for the treatment of postcardiotomy delirium a prospective randomized double blinded study	2012	2.2276	-0.0441	2	0.7993
2033006731	an open label pilot study comparing rivastigmine and low dose aspirin for the treatment of symptoms specific to patients with subcortical vascular dementia	2002	-0.1873	0.0715	7	1.5522
2033089565	relationships between physical exercise and cognitive abilities in older adults	1989	0.579	-0.2502	27	2.9865
2033132507	dog assisted therapy for people with dementia a randomized controlled trial	2013	-0.5383	-0.0226	99	1.4476
2033163491	responders and non responders to ginkgo biloba a pilot study	2010	-0.4856	-0.072	68	0.7255
2033256757	differential cognitive outcomes in the hypertensive old people in edinburgh study	2005	-0.6916	-0.1919	79	0.7555
2033307745	efficacy and safety of a once daily formulation of ginkgo biloba extract egb 761 in dementia with neuropsychiatric features a randomized controlled trial	2010	-0.4083	-0.0532	8	26.0093
2033334997	amisulpride in the treatment of behavioural disturbances among patients with moderate to severe alzheimer s disease	2006	-0.1501	0.1196	44	0.7624
2033395259	effective behavioral interventions for decreasing dementia related challenging behavior in nursing homes	1999	0.4712	-0.039	18	0.9404
2033515263	double blind placebo controlled quantitative eeg and psychometric studies in elderlies on vigilance promoting effects of an almitrine raubasine combination duxil	1988	-0.4206	0.335	90	0.6274
2033569758	the effects of 3 week estrogen hormone replacement on cognition in elderly healthy females	2000	-0.7581	-0.7641	3	22.9713
2033597965	estimating the costs of informal care for people with alzheimer s disease methodological and practical challenges	2001	0.0635	-0.0295	93	0.9982
2033610699	a randomized trial of risperidone placebo and haloperidol for behavioral symptoms of dementia	1999	0.198	0.0855	16	27.6576
2033638298	differentiation of the dementias of alzheimer s and parkinson s disease with the dementia rating scale	1995	-0.1886	0.0705	7	0.8042
2033643297	subcutaneous olanzapine for hyperactive or mixed delirium in patients with advanced cancer a preliminary study	2010	2.2276	-0.0441	2	0.7546
2033667544	donepezil treatment of severe alzheimer s disease in nursing home settings a responder analysis	2008	-0.0665	0.0784	58	1.5687
2033667632	hippocampus dependent learning facilitated by a monoclonal antibody or d cycloserine	1992	-0.2875	0.1693	43	1.5
2033770569	use of galantamine to treat vascular dementia	2002	-0.3792	0.0982	94	0.8154
2033774309	safety and tolerability of donepezil 23 mg in moderate to severe alzheimer s disease	2011	-0.2247	0.0977	11	3.6056
2033800655	alzheimer disease depiction of increased cerebral myo inositol with proton mr spectroscopy	1993	-0.1606	0.0143	46	0.9999
2033870283	working memory training and transfer in older adults	2011	0.4334	-0.2153	4	1.5987
2033891953	cognitive intervention in amnestic mild cognitive impairment a systematic review	2012	0.1983	-0.1081	10	0.9584
2033947345	effects of omega 3 polyunsaturated fatty acid supplementation on redox status in chronic renal failure patients with dyslipidemia	2010	-1.0853	-0.2965	5	0.7681
2033989135	piracetam a review of pharmacological properties and clinical uses	2006	-0.3075	0.2489	15	0.916
2034029496	chronic transdermal nicotine patch treatment effects on cognitive performance in age associated memory impairment	2004	0.0437	0.4832	48	1
2034033400	a neuropsychological comparison of demented and nondemented patients with parkinson s disease	1999	-0.2007	0.0876	78	0.6833
2034135101	apolipoprotein e4 in patients with alzheimer s disease and vascular dementia	2002	-0.4056	0.0825	85	0.6814
2034212468	effects of age sex and ethnicity on the association between apolipoprotein e genotype and alzheimer disease a meta analysis apoe and alzheimer disease meta analysis consortium	1997	-0.7705	-0.1862	29	0.991
2034282610	activation pet as an instrument to determine therapeutic efficacy in alzheimer s diseasea	1993	-0.1598	0.0553	67	0.6669
2034370779	effects of ginkgo biloba in dementia systematic review and meta analysis	2010	-0.4128	-0.0532	8	13.1806
2034383806	patch clamp studies on the kinetics and selectivity of n methyl d aspartate receptor antagonism by memantine 1 amino 3 5 dimethyladamantan	1993	-0.2735	0.0729	23	1
2034475192	changes in cognitive domains during three years in patients with alzheimer s disease treated with donepezil	2009	-0.3141	0.0962	50	0.6565
2034533600	effect of a guideline based multicomponent intervention on use of physical restraints in nursing homes a randomized controlled trial	2012	0.8093	-0.0994	42	0.916
2034596923	pharmacokinetics of a novel transdermal rivastigmine patch for the treatment of alzheimer s disease a review	2009	-0.2377	0.0522	19	1.9804
2034604015	physical restraints in nursing homes a review of the literature since the nursing home reform act of 1987	1998	0.826	-0.1013	42	2.8744
2034639126	hormone therapy and risk of alzheimer disease a critical time	2002	-0.7419	-0.7419	3	3
2034648301	a multidisciplinary multifactorial intervention program reduces postoperative falls and injuries after femoral neck fracture	2007	2.2481	-0.0579	35	1.9158
2034649973	improving dementia care in assisted living residences addressing staff reactions to training	2009	0.5324	-0.0659	18	0.9404
2034709307	cognitive performance after small strokes correlates with ischemia not atrophy of the brain	1995	-0.4858	0.0852	117	0.6993
2034851450	erratum to ginkgo biloba in alzheimer s disease a systematic review	2011	-0.398	0.0312	53	0.7393
2034856442	effects of donepezil galantamine and rivastigmine in 938 italian patients with alzheimer s disease	2010	-0.2795	0.1044	133	0.7099
2034857263	the effects of memantine on a patient having preclinical dementia with lewy bodies	2013	-0.1952	0.1292	7	0.7913
2034897558	midlife vascular risk factors and alzheimer s disease in later life longitudinal population based study	2001	-0.6768	-0.1227	14	7.9998
2034924213	olanzapine treatment of the depressive symptoms in schizophrenia	2002	0.3077	0.1439	81	0.7531
2034942998	the prevention of progression of arterial disease and diabetes popadad trial factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease	2008	-0.5188	-0.0906	68	0.7305
2034963833	the cognitive benefits of galantamine are sustained for at least 36 months a long term extension trial	2004	-0.2055	0.0472	6	0.916
2034969383	reduced somatostatin like immunoreactivity in cerebral cortex from cases of alzheimer disease and alzheimer senile dementa	1980	-0.3232	0.2077	13	0.7993
2034977164	staff outcomes from the caring for aged dementia care resident study cadres a cluster randomised trial	2012	0.365	-0.0062	18	1
2035024556	proof of efficacy of the ginkgo biloba special extract egb 761 in outpatients suffering from mild to moderate primary degenerative dementia of the alzheimer type or multi infarct dementia	1996	-0.4469	-0.0569	8	41.8818
2035071552	redesigning care for patients at increased hospitalization risk the comprehensive care physician model	2014	0.5543	-0.1157	74	0.7992
2035144638	long term safety and efficacy of donepezil in patients with severe alzheimer s disease results from a 52 week open label multicenter extension study in japan	2009	-0.2667	0.0502	124	17.7718
2035154726	the impact of music therapy on language functioning in dementia	2000	0.481	-0.0614	21	8.81
2035248275	prevalence and types of sleep disturbances acutely after traumatic brain injury	2008	-1.2594	1.7614	64	0.9959
2035251339	cerebrospinal fluid tau levels in alzheimer s disease are elevated when compared with vascular dementia but do not correlate with measures of cerebral atrophy	2003	-0.2942	0.0285	57	0.677
2035262423	cognitive complaint and test performance in elderly patients suffering depression or dementia	1991	-0.2271	0.0538	84	0.7065
2035343397	clinical and cost effectiveness of donepezil rivastigmine and galantamine for alzheimer s disease a rapid and systematic review	2001	-0.2843	0.0857	33	0.6365
2035367367	adjunctive varenicline treatment with antipsychotic medications for cognitive impairments in people with schizophrenia a randomized double blind placebo controlled trial	2012	-0.2626	0.1647	9	0.6518
2035377197	use of physical restraints with cognitively impaired nursing home residents	2004	0.8265	-0.1001	42	2.9763
2035425623	an ergot preparation hydergine for relief of symptoms of cerebrovascular insufficiency	1972	-0.2902	0.1008	41	1.9027
2035563772	association between nutritional status and cognitive functioning in a healthy elderly population	1983	-0.8251	-0.101	86	1.8449
2035575526	neuropsychological evidence of conversion from mild cognitive impairment mci to dementia	2008	-0.1901	0.0234	78	0.8246
2035633963	an italian model of dementia special care unit results of a pilot study	1997	0.6741	-0.0194	24	0.9584
2035659819	multifactorial memory training with older adults how to foster maintenance of improved performance	1989	0.5067	-0.2829	4	22.6119
2035663078	nicotinic system involvement in alzheimer s and parkinson s diseases implications for therapeutics	1997	0.0437	0.4832	48	1
2035712787	problem solving training for family caregivers of women with disabilities a randomized clinical trial	2009	0.6854	-0.1437	97	0.6692
2035774055	no evidence that frailty modifies the positive impact of antihypertensive treatment in very elderly people an investigation of the impact of frailty upon treatment effect in the hypertension in the very elderly trial hyvet study a double blind placebo controlled study of antihypertensives in people with hypertension aged 80 and over	2015	-0.6916	-0.191	79	0.7993
2035784049	hypercaphia in clinical anasthesia	1966	-0.393	0.3617	106	0.7068
2035847425	therapeutic efficacy of pyritinol in patients with senile dementia of the alzheimer type sdat and multi infarct dementia mid	1992	-0.328	0.1269	13	1.5601
2035868540	interventions to reduce the burden of caregiving for an adult with dementia a meta analysis	2001	0.5244	-0.108	1	0.9988
2035910895	assessing therapeutic efficacy in a progressive disease a study of donepezil in alzheimer s disease	2006	-0.2194	0.0522	6	19.3349
2035970762	rituximab for the first line treatment of stage iii iv follicular lymphoma review of technology appraisal no 110 a systematic review and economic evaluation	2012	0.3589	-0.0934	39	0.9713
2035974802	multidimensional reaction to therapeutic touch in a hospital setting	1979	0.5917	-0.0633	123	0.9713
2035986126	a multicenter double blind study of controlled release physostigmine for the treatment of symptoms secondary to alzheimer s disease	1996	-0.2746	0.0945	44	4.6099
2036038081	modafinil ameliorates excessive daytime sleepiness after traumatic brain injury	2010	-1.2594	1.7614	64	1
2036070626	hiv dementia an evolving disease	2004	-0.4008	0.502	87	0.9973
2036142941	cognitive effects of adjunctive 24 weeks rivastigmine treatment to antipsychotics in schizophrenia a randomized placebo controlled double blind investigation	2006	-0.2387	0.1863	11	2.1726
2036180883	acetyl l carnitine alc treatment in elderly patients with fatigue	2008	-0.2861	0.0292	63	0.75
2036215613	daily rhythm of serum melatonin in patients with dementia of the degenerate type	1996	0.3256	-0.0242	89	0.7089
2036234078	voluntary exercise decreases amyloid load in a transgenic model of alzheimer s disease	2005	0.4734	-0.1644	25	1.9973
2036284753	neuropsychological effects of interferon ?? 1a in relapsing multiple sclerosis	2000	-0.2414	0.2127	55	2.9932
2036334085	bidirectional pharmacological treatment selegiline and donepezil in cognitive impairment of alzheimer disease a possibility	2000	-0.5342	0.3844	73	1.4856
2036362108	gene dose of apolipoprotein e type 4 allele and the risk of alzheimer s disease in late onset families	1993	-0.7288	-0.171	29	5.9065
2036443591	olanzapine in huntington s disease	2002	-0.2283	-0.1467	112	0.9973
2036465631	reduction in dha transport to the brain of mice expressing human apoe4 compared to apoe2	2014	-1.0106	-0.2744	5	0.9404
2036493655	caregiving in alzheimer dementia	1991	-2.1425	2.1685	121	0.8984
2036556074	ueber die bohne von calabar	1864	-0.3032	0.1546	13	0.7993
2036732716	selegiline treatment and the extent of degenerative changes in brain tissue of patients with alzheimer s disease	2000	-0.3237	0.1971	22	15.2549
2036736649	a multicentre randomized double blind placebo controlled study to evaluate the efficacy tolerability and safety of two doses of metrifonate in patients with mild to moderate alzheimer s disease the malt study	1999	-0.2658	0.0614	44	0.8242
2036772755	monoamine oxidase inhibitors in the treatment of atypical depression	1985	-0.1962	0.1508	37	0.816
2036870369	can the pattern of neuropsychological improvement obtained with cholinergic drugs be used to infer a cholinergic mechanism in other nootropic drugs	1989	0.018	0.384	48	13.2611
2036908296	effects of a mao b inhibitor in the treatment of alzheimer disease	1991	-0.1977	0.1193	37	29.2927
2036958703	diuretic use is associated with better learning and memory in older adults in the ginkgo evaluation of memory study	2012	-0.2629	0.1635	9	13.2215
2037099066	improved cognitive performance in human volunteers following administration of guarana paullinia cupana extract comparison and interaction with panax ginseng	2004	-0.6556	-0.1204	65	1.7578
2037099926	effects of rofecoxib or naproxen vs placebo on alzheimer disease progression a randomized controlled trial	2003	-0.4298	-0.0763	32	31.7655
2037138617	community occupational therapy for older patients with dementia and their care givers cost effectiveness study	2008	0.5361	-0.1043	34	2.474
2037420155	symptoms of anxiety in depression assessment of item performance of the hamilton anxiety rating scale in patients with depression	2008	0.2621	0.0262	31	0.7563
2037425193	changes in serum dhea and eleven of its metabolites during 12 month percutaneous administration of dhea	2008	-1.4117	-1.8491	20	0.8101
2037468903	efficacy of rivastigmine in subjects with moderately severe alzheimer s disease	2004	-0.2147	0.0467	6	21.4722
2037505626	a prospective study of delirium in hospitalized elderly	1990	2.165	-0.0415	2	3
2037605474	578 galanthamine hydrobromide interim results of a group comparative placebo controlled study of efficacy and safety in patients with a diagnosis of senile dementia of the alzheimer s type	1996	-0.411	0.0798	51	0.7128
2037614372	delirium as a predictor of mortality in mechanically ventilated patients in the intensive care unit	2004	2.1995	-0.044	2	9.6406
2037640718	domain specific improvement of cognition on memantine in patients with alzheimer s disease treated with rivastigmine	2007	-0.2795	0.1044	133	0.7684
2037650041	donepezil for the symptomatic treatment of patients with mild to moderate alzheimer s disease a meta analysis of individual patient data from randomised controlled trials	2004	-0.2293	0.0125	6	1.7528
2037675512	music music therapy and dementia a review of literature and the recommendations of the italian psychogeriatric association	2012	0.5376	-0.052	21	1.6904
2037678947	increased light exposure consolidates sleep and strengthens circadian rhythms in severe alzheimer s disease patients	2003	0.2974	-0.0173	17	30.94
2037735378	the process of change in cognitive therapy and pharmacotherapy for depression changes in mood and cognition	1984	-0.2585	0.1787	11	0.6638
2037787365	dietary docosahexaenoic acid improves red blood cell deformability in rats	1996	-1.1031	-0.3023	5	0.8179
2037796739	long term efficacy of olanzapine in the control of psychotic and behavioral symptoms in patients with alzheimer s dementia	2000	0.3074	0.1428	81	16.8137
2037902784	efficacy and safety of modafinil provigil for the treatment of fatigue in multiple sclerosis a two centre phase 2 study	2002	-0.2422	0.2113	55	1
2037936493	the cost effectiveness of donepezil therapy in swedish patients with alzheimer s disease a markov model	1999	-0.1954	0.0358	6	0.9584
2037988949	amisulpride versus quetiapine for the treatment of delirium a randomized open prospective study	2005	2.131	-0.0414	2	0.991
2038012828	frontal subcortical circuits and human behavior	1993	-0.4419	-0.001	12	0.9713
2038014538	efficacy and tolerability of ginkgo biloba extract egb 761 in alzheimer s disease and vascular dementia analyses of a randomised controlled trial	2008	-0.4606	-0.0598	68	1.5815
2038074592	the impact of dementia on the family	1982	0.0516	0.0974	47	2.8736
2038095204	acute effects of the selective cholinergic channel activator nicotinic agonist abt 418 in alzheimer s disease	1999	0.0307	0.4332	48	1.6909
2038103531	the effects of meclofenoxate on cognitive performance in elderly individuals with memory impairment a placebo controlled study	1986	-0.2413	0.1578	9	1.328
2038144697	donepezil compared to rivastigmine in alzheimer s disease similar efficacy but better tolerability and physician and caregiver satisfaction in a multinational randomized trial	2001	-0.2432	0.0582	19	0.7757
2038217063	randomized controlled trial of two simple ed interventions to improve the rate of primary care follow up for patients with acute asthma 6 month follow up results	2002	-0.5975	-0.0271	99	0.683
2038267675	meta analysis of randomized controlled trials of cranial electrostimulation efficacy in treating selected psychological and physiological conditions	1995	0.2261	-0.0085	17	0.8843
2038364707	review of effects of physical activity on strength balance mobility and adl performance in elderly subjects with dementia	2010	0.4869	-0.1799	25	1.9557
2038447514	olanzapine in dementia with lewy bodies a clinical study	1999	-0.1921	0.122	7	0.9973
2038471975	for alzheimer s caregivers	1990	-2.1425	2.1685	121	0.9233
2038491582	a 12 month randomized placebo controlled trial of propentofylline hwa 285 in patients with dementia according to dsm iii r	1997	-0.3895	0.0737	13	3.5779
2038495853	deprenyl reduces the death of motoneurons caused by axotomy	1992	-0.1986	0.1207	37	0.9996
2038504749	benefits and risks of corticosteroid prophylaxis in adult cardiac surgery a dose response meta analysis	2009	2.5489	-0.0698	35	0.769
2038509428	modulation of intracellular formation of reactive oxygen intermediates in peritoneal macrophages and microglia brain macrophages by propentofylline	1994	-0.326	0.1086	13	0.7993
2038673967	a double blind crossover study evaluating the efficacy of korean red ginseng in patients with erectile dysfunction a preliminary report	2002	-0.6545	-0.1195	65	0.9939
2038707210	the phenotypic spectrum of cadasil clinical findings in 102 cases	1998	-0.45	-0.0021	12	1
2038729642	comparison of restrictive and liberal transfusion strategy on postoperative delirium in aged patients following total hip replacement a preliminary study	2014	2.566	-0.0494	125	0.9404
2038739154	response to clozapine in acute mania is more rapid than that of chlorpromazine	1997	0.1301	0.1278	47	0.6935
2038752860	piracetam treatment in patients with cognitive impairment	2013	-0.2585	0.1787	11	0.7623
2038759435	evaluating two group programmes of cognitive training in mild to moderate ad is there any difference between a global stimulation and a cognitive specific one	2006	0.2296	-0.097	10	0.916
2038762280	donepezil for alzheimer s disease in clinical practice the donald study	2004	-0.2667	0.0526	124	1.6423
2038799193	neuroleptic drugs in dementia benefits and harm	2006	0.1988	0.0531	16	6.9938
2038810061	components of placebo effect randomised controlled trial in patients with irritable bowel syndrome	2008	-0.2945	-0.1543	45	0.6845
2038884259	cognitive decline after hospitalization in a community population of older persons	2012	1.6418	-0.0325	24	0.7993
2038900071	seizures in a diabetic patient on monoamine oxidase inhibitors	1999	-0.1962	0.1508	37	0.8106
2038939338	active exercise education and cognitive behavioral therapy for persistent disabling low back pain a randomized controlled trial	2007	0.305	-0.0919	39	0.695
2039053627	our experience when treating early and moderate alzheimer s disease with donepezil	2011	-0.3188	0.1182	33	1.65
2039078093	enhancing care for hospitalized older adults with memory problems the e champ trial	2010	1.6418	-0.0325	24	0.7972
2039089562	oral tetrahydroaminoacridine treatment of alzheimer s disease evaluated clinically and by regional cerebral blood flow and eeg	1993	-0.215	0.093	67	2.3328
2039141908	using a combined randomized start withdrawal design to assess propentofylline s effects on disease progression in alzheimer s disease and vascular dementia results of clinical studies	1999	-0.4056	0.0825	85	0.7632
2039158734	15 epilepsy co morbidities in nursing homes focus on alzheimer s	2010	0.4399	-0.0044	104	0.8125
2039167848	treatment of alcohol organic mental disorder with piracetam	1987	-0.22	0.1008	23	0.6639
2039186639	blood glucose influences memory and attention in young adults	1994	-0.4598	1.8033	96	0.845
2039226220	family caregivers of older adults on home enteral nutrition have multiple unmet task related training needs and low overall preparedness for caregiving	2004	0.6788	-0.15	75	0.7939
2039236263	long term memory cuing to reduce visuo spatial disorientation in alzheimer s disease patients in a special care unit	1991	0.6759	-0.0228	24	0.7993
2039291573	prevalence of sleep disturbances in mild cognitive impairment and dementing disorders a multicenter italian clinical cross sectional study on 431 patients	2012	0.196	-0.0166	28	0.8843
2039294854	5 ht6 receptor antagonists as novel cognitive enhancing agents for alzheimer s disease	2008	-1.5582	0.2221	115	0.9996
2039453997	cyclooxygenase 2 expression is increased in frontal cortex of alzheimer s disease brain	1998	-0.414	-0.0404	32	1
2039457372	a combined analysis of double blind studies with risperidone vs placebo and other antipsychotic agents factors associated with extrapyramidal symptoms	1999	-0.1168	0.194	114	0.6998
2039514754	low dose dehydroepiandrosterone affects behavior in hypopituitary androgen deficient women a placebo controlled trial	2002	-1.4161	-1.838	20	1
2039523677	eeg changes during long term treatment with donepezil in alzheimer s disease patients	2001	-0.2587	0.0318	67	1.5148
2039524897	the role of reality orientaion therapy in restorative care of elderly patients with dementia plus stroke in the subacute nursing home setting	2002	0.2586	-0.081	10	2.7194
2039534020	donepezil in patients with severe alzheimer s disease	2006	-0.3225	0.1167	33	1.7129
2039585634	cost effectiveness of donepezil in the treatment of mild or moderate alzheimer s disease	1999	-0.1831	0.0275	6	1.9951
2039595489	widely spread butyrylcholinesterase can hydrolyze acetylcholine in the normal and alzheimer brain	2002	-0.2606	0.0405	72	1.6443
2039604129	compliance to requests made by gazing and touching experimenters in field settings	1977	0.5917	-0.0633	123	0.9804
2039752037	the processing speed theory of adult age differences in cognition	1996	0.4767	-0.254	4	3
2039847604	the effects of bromvincamine and vincamine on regional cerebral blood flow and mental functions in patients with multi infarct dementia	1984	-0.4209	0.3343	90	0.7736
2039857080	strong association of the rest activity rhythm with well being in demented elderly women	2007	0.245	-0.0133	17	1.9117
2039920863	further studies on cerebrospinal fluid acid base status in patients with brain lesions	1970	-0.6362	0.0864	122	0.7402
2039927774	physical activity and cognitive function in alzheimer disease	2009	-0.5194	0.3697	73	0.7595
2039934896	atorvastatin for the treatment of mild to moderate alzheimer disease preliminary results	2005	-0.721	-0.1678	29	25.9837
2039940349	observations in a preliminary open trial of estradiol therapy for senile dementia alzheimer s type	1986	-0.7657	-0.7732	3	3
2040061772	health status and hypertension a population based study	1996	-0.7617	-0.1539	14	0.916
2040088037	management of patients with alzheimer s disease plus cerebrovascular disease 12 month treatment with galantamine	2004	-0.3015	0.0339	12	22.2851
2040102408	challenging behaviours in nursing home residents with dementia a randomized controlled trial of multidisciplinary interventions	2002	0.4706	-0.0392	18	0.9584
2040221388	randomized double blind placebo controlled multicenter study to evaluate the safety and tolerability of metrifonate in patients with probable alzheimer disease the metrifonate study group	2000	-0.2653	0.0614	44	14.5641
2040307572	ginkgo biloba extract for the treatment of intermittent claudication a meta analysis of randomized trials	2000	-0.3317	-0.0945	8	0.75
2040325460	effects of behavioral interventions on disruptive behavior and affect in demented nursing home residents	2002	0.3834	-0.0266	18	4.6867
2040369419	stabilization of mitochondrial function by ginkgo biloba extract egb 761	2007	-0.4005	-0.0536	8	0.9713
2040416929	long term safety and tolerability of donepezil 23 mg in patients with moderate to severe alzheimer s disease	2012	-0.266	0.0546	124	18.1885
2040431826	clinical evaluation of 5 hydroxy l tryptophan as an antidepressant drug	1978	-0.2197	0.1016	23	0.6647
2040501521	calcium and the aging nervous system	1987	-0.3426	0.1147	53	0.845
2040507899	behavioural analysis and control of psychosomatic symptoms of patients receiving intensive cancer treatment	1982	0.4318	-0.0417	34	0.6243
2040581223	tolerability of memantine in combination with cholinesterase inhibitors in dementia therapy	2003	-0.1841	0.0651	6	1.8003
2040603470	10 malabsorption of food cobalamin	1995	-0.9233	-0.1078	30	0.9939
2040675711	the effects of nicotine on cognition are dependent on baseline performance	2014	-0.662	-0.1224	65	0.694
2040765069	haemorheological pattern in initial mental deterioration results of a long term study using piracetam and pentoxifylline	1985	-0.3801	-0.2165	45	13.5041
2040869151	utilization of citrate acetylcarnitine acetate pyruvate and glucose for the synthesis of acetylcholine in rat brain slices	1981	-0.3129	0.0109	63	0.9992
2040885812	persistent platelet accumulation of eicosapentaenoic acid and docosahexaenoic acid following withdrawal of a short course supplementation of n 3 fatty acids ethyl esters association with impairment of the aggregation	1995	-1.1026	-0.3016	5	0.8066
2040934693	galantamine treatment of vascular dementia a randomized trial	2007	-0.4201	0.0003	12	24.5492
2041057298	alzheimer dementia associated cognitive and non cognitive symptoms evolution during donepezil treatment	2008	-0.5186	0.3694	73	0.7265
2041116475	the impact of age and task domain on cognitive performance a meta analytic review of the glucose facilitation effect	2004	-0.4598	1.8033	96	0.8843
2041131399	inappropriate medication prescribing in skilled nursing facilities	1992	0.5411	0.0026	52	1
2041135149	a review of the effects of physical activity and exercise on cognitive and brain functions in older adults	2013	0.538	-0.2242	136	0.9584
2041240420	candesartan and cognitive decline in older patients with hypertension a substudy of the scope trial	2008	-0.6916	-0.1919	79	0.7631
2041286012	does vitamin d improve liver enzymes oxidative stress and inflammatory biomarkers in adults with non alcoholic fatty liver disease a randomized clinical trial	2014	-1.1801	-0.326	129	0.6969
2041320073	does fluoxetine have any effect on the cognition of patients with mild cognitive impairment a double blind placebo controlled clinical trial	2007	0.0383	0.1961	61	0.9584
2041325253	distinct patterns of brain activity in young carriers of the apoe epsilon4 allele	2009	-0.2499	0.1367	22	0.9584
2041355017	reduced incidence of ad with nsaid but not h2 receptor antagonists the cache county study	2002	-0.4273	-0.0793	32	2.9849
2041362984	a phase response curve to single bright light pulses in human subjects	2003	0.2937	-0.0183	17	1
2041371057	riluzole in huntington s disease a 3 year randomized controlled study	2007	-0.2283	-0.1467	112	0.9997
2041468347	fatigue after stroke	1999	-1.1671	1.5699	64	0.7993
2041474698	a meta analysis of the efficacy of second generation antipsychotics	2003	0.6426	0.1008	91	0.7993
2041513477	a randomized controlled clinical trial of activity therapy for apathy in patients with dementia residing in long term care	2004	0.38	-0.0829	18	4.6539
2041513819	open label multicenter 28 week extension study of the safety and tolerability of memantine in patients with mild to moderate alzheimer s disease	2007	-0.2396	0.059	19	1.4846
2041523804	an efficacy and safety analysis of exelon in alzheimer s disease patients with concurrent vascular risk factors	2000	-0.3158	0.025	12	28.6672
2041601072	memantine therapy of behavioral symptoms in community dwelling patients with moderate to severe alzheimer s disease	2009	-0.162	0.1081	11	2.3732
2041608694	opioid rotation from morphine to fentanyl in delirious cancer patients an open label trial	2005	2.2267	-0.0443	2	0.7543
2041614190	a systemic review of the roles of n 3 fatty acids in health and disease	2009	-1.1085	-0.3042	5	0.9804
2041771861	a systematic review of the clinical effectiveness and cost effectiveness of sensory psychological and behavioural interventions for managing agitation in older adults with dementia	2014	0.4754	-0.0665	34	1.4335
2041829445	using risperidone for alzheimer s dementia associated psychosis	2008	0.5902	0.421	40	1.5562
2041841253	the p1 component of the middle latency auditory evoked potential predicts a practice effect during clinical trials in alzheimer s disease	1995	-0.175	0.0554	67	1.3966
2041863334	a double blind trial of sulpiride in huntington s disease and tardive dyskinesia	1984	-0.2288	-0.146	112	0.9804
2041898349	pnd45 differential outcomes in patients with alzheimer s disease ad treated with donepezil 23	2012	-0.311	0.0163	57	0.7024
2041926796	cerebrolysin in vascular dementia improvement of clinical outcome in a randomized double blind placebo controlled multicenter trial	2011	-0.3708	-0.0075	70	15.0339
2041937626	effect of different subtypes of cognition enhancers on long term potentiation in the rat dentate gyrus in vivo	1992	-0.3068	0.1281	23	0.9804
2041976344	l deprenyl in alzheimer s disease preliminary evidence for behavioral change with monoamine oxidase b inhibition	1987	-0.1928	0.1093	37	8.1017
2042042304	favorable anticholinergic profile of olanzapine in elderly patients with dementia	2001	0.6164	0.4438	40	0.8088
2042068792	venlafaxine and dothispin in depressed elderly patients a comparison of efficacy and effects on cognition	1998	-0.289	0.2822	9	0.6944
2042078576	the effect of sedation during upper gastrointestinal endoscopy	2010	2.345	0.1894	103	0.7296
2042148641	effect of memantine on resting state default mode network activity in alzheimer s disease	2011	-0.2498	0.1368	22	19.3319
2042158944	a controlled trial of antidepressants in patients with parkinson disease and depression	2009	-0.1869	0.1146	7	1.9992
2042226906	preventive effect of liothyronine on electroconvulsive therapy induced memory deficit in patients with major depressive disorder a double blind controlled clinical trial	2015	-0.2514	0.1578	9	0.6656
2042240757	apoe and cognitive decline in preclinical alzheimer disease and non demented aging	2004	-0.7714	-0.1862	29	0.9404
2042270575	senile dementia of the alzheimer type treated with aniracetam a new nootropic agent	1987	-0.2439	0.2318	15	0.685
2042282528	concentration of donepezil to the cognitive response in alzheimer disease	2013	-0.31	0.111	33	3.4492
2042352454	vinpocetine prevents ischemic cell damage in rat hippocampus	1988	-0.22	0.1008	23	0.75
2042430625	neurobiological and neuropsychiatric effects of dehydroepiandrosterone dhea and dhea sulfate dheas	2009	-1.4128	-1.8331	20	0.9584
2042461121	evaluation of a home based exercise program in the treatment of alzheimer s disease the maximizing independence in dementia mind study	2009	0.4721	-0.1832	25	32.2402
2042472315	principles of educational outreach academic detailing to improve clinical decision making	1990	0.5411	0.0026	52	1
2042542641	evaluating multiple treatment courses in clinical trials	2000	0.246	0.0854	141	0.9992
2042557239	functional connectivity tracks clinical deterioration in alzheimer s disease	2012	-0.2499	0.1367	22	0.916
2042571633	the prince henry hospital dementia caregivers training programme	1997	0.5085	-0.1112	1	3.9153
2042630135	fish consumption and depression the northern finland 1966 birth cohort study	2004	-1.0974	-0.3005	5	0.9939
2042665602	statin therapy in alzheimer s disease	2006	-0.7194	-0.1682	29	19.3724
2042681995	fipexide an effective cognition activator in the elderly a placebo controlled double blind clinical trial	1986	-0.2833	-0.1109	80	2.0773
2042690206	a randomized controlled trial of prednisone in alzheimer s disease	2000	-0.4212	-0.084	32	27.9641
2042695207	increased monoamine oxidase b activity in plaque associated astrocytes of alzheimer brains revealed by quantitative enzyme radioautography	1994	-0.3446	0.2068	126	0.8843
2042706422	a double blind placebo controlled trial of diclofenac misoprostol in alzheimer s disease	1999	-0.4263	-0.0763	32	7.9993
2042739961	nursing home care as an alternative to psychiatric hospitalization a veterans administration cooperative study	1985	0.9841	-0.0257	24	0.7133
2042749728	herbal medicine for dementia a systematic review	2009	-0.375	-0.0366	70	0.6745
2042794212	effect of central cholinergic stimulation on regional cerebral blood flow in alzheimer disease	1990	-0.2975	0.1615	13	1.7993
2042838185	effect of cholinesterase inhibitors on attention	2013	0.0183	0.3851	48	0.6635
2042853753	visual processing impairment and risk of motor vehicle crash among older adults	1998	0.4853	-0.2604	4	1
2042910921	a double blind placebo controlled study of tacrine in chinese patients with alzheimer s disease	1999	-0.3118	0.0161	57	0.6997
2042912152	effects of cholinergic drugs and cognitive training on dementia 2 year follow up	2006	0.2372	-0.0973	10	23.542
2042920190	efficacy of the peptidergic nootropic drug cerebrolysin in patients with senile dementia of the alzheimer type sdat	1994	-0.334	0.0043	70	0.845
2043049815	effects of care management and telehealth a longitudinal analysis using medicare data	2013	0.5772	-0.1221	139	0.7447
2043188780	senile dementia of the alzheimer type	1986	-0.3847	0.3365	59	0.8273
2043245810	d cycloserine treatment of alzheimer disease	1994	-0.3019	0.1887	43	4.6175
2043322849	the effects of l amphetamine sulfate on cognition in ms patients results of a randomized controlled trial	2009	-0.2413	0.2136	55	1.9979
2043385475	a randomized double blind placebo controlled study of oral vitamin b12 supplementation in older patients with subnormal or borderline serum vitamin b12 concentrations	2002	-0.9198	-0.1071	30	22.736
2043446856	docosahexaenoic acid derived neuroprotectin d1 induces neuronal survival via secretase and ppar?? mediated mechanisms in alzheimer s disease models	2011	-1.0106	-0.2744	5	0.916
2043595836	inflammation and white matter damage in vascular cognitive impairment	2009	-0.7263	0.0224	107	0.6903
2043620869	acetyl l carnitine fed to old rats partially restores mitochondrial function and ambulatory activity	1998	-0.3129	0.0109	63	0.9988
2043659733	a vinca alkaloid enhances morphological dynamics of dendritic spines of neocortical layer 2 3 pyramidal cells	2003	-0.3068	0.128	23	0.9584
2043730082	home visits in the outpatient treatment of individuals dependent on alcohol randomized clinical trial	2010	-0.5975	-0.0271	99	0.6996
2043742417	combined behavioral and drug therapy for urge incontinence in older women	2000	-0.3252	-0.1421	45	0.7079
2043768383	fdg pet changes in brain glucose metabolism from normal cognition to pathologically verified alzheimer s disease	2009	-0.0645	0.0399	22	0.75
2043819730	risperidone in the treatment of psychosis and aggressive behavior in patients with dementia	1998	0.5633	0.398	40	14.4676
2043903489	impact of in home behavioral management versus telephone support to reduce depressive symptoms and perceived stress in chinese caregivers results of a pilot study	2007	0.5266	-0.1129	1	21.8117
2043922703	a placebo controlled trial of valproate for agitation and aggression in alzheimer s disease	2007	0.1689	0.0794	16	22.5361
2043932628	a curvilinear relationship between testosterone and spatial cognition in humans possible influence of hand preference	1996	-0.9327	-1.0635	54	1
2044070944	the effect of selegiline in the treatment of people with alzheimer s disease a meta analysis of published trials	2002	-0.3245	0.1979	22	0.75
2044120816	improving physicians recognition and treatment of depression in general medical care results from a randomized clinical trial	1990	-0.5982	-0.0277	99	0.6971
2044141338	hidden caregivers providing appropriate services	2012	0.6888	-0.1557	76	0.8441
2044178472	blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the value trial	2004	-0.7135	-0.1354	14	0.991
2044241508	hormone replacement therapy and incidence of alzheimer disease in older women the cache county study	2002	-0.7409	-0.742	3	18.9783
2044246760	effects of dehydroepiandrosterone dhea supplementation on hormonal metabolic and behavioral status in patients with hypoadrenalism	2004	-1.4127	-1.8486	20	0.8051
2044315129	decreased mt1 melatonin receptor expression in the suprachiasmatic nucleus in aging and alzheimer s disease	2007	0.205	-0.0171	28	1.9099
2044345027	comparative outcomes of two distance based interventions for male caregivers of family members with dementia	2007	0.5101	-0.1124	1	19.4121
2044358931	a phase ii study in patients with alzheimer s disease to assess the preliminary efficacy and maximum tolerated dose of rivastigmine exelon	1999	-0.2361	0.0339	6	23.2725
2044384631	efficacy and safety of cholinesterase inhibitors and memantine in cognitive impairment in parkinson s disease parkinson s disease dementia and dementia with lewy bodies systematic review with meta analysis and trial sequential analysis	2015	-0.1927	0.1232	92	1.5883
2044444390	psychopharmacological effects of vinpocetine in normal healthy volunteers	1985	-0.3603	0.2247	23	1.6183
2044493951	a randomized placebo controlled trial of thiothixene in agitated demented nursing home patients	1995	0.166	0.093	47	0.9996
2044512913	effects of bright light on cognitive and sleep wake circadian rhythm disturbances in alzheimer type dementia	2000	0.3031	-0.0183	17	1.9119
2044518393	omega 3 fatty acid for the prevention of cognitive decline and dementia	2012	-0.7667	-0.196	5	3.9432
2044533734	cognition enhancing effects of donepezil in traumatic brain injury	2005	-0.8474	1.0199	71	0.9804
2044560940	effects of antipsychotic withdrawal in elderly nursing home residents	1994	0.496	0.0074	52	2.927
2044762417	an improvement in cognitive function following polypharmacy reduction in a group of epileptic patients	2009	-0.417	0.0419	41	0.6571
2044773944	renoprotective effect of the angiotensin receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes	2001	-0.7235	-0.1417	14	2.9959
2044818791	relation of nimodipine dose and serum concentration to learning enhancement in aging rabbits	1994	-0.3426	0.1147	53	0.845
2044846829	opioid treatment for agitation in patients with advanced dementia	2003	0.1419	0.0443	58	0.7194
2044850402	effects of omega 3 fatty acids on cognitive performance a meta analysis	2012	-1.007	-0.2728	5	0.9404
2044862890	development of cholinergic drugs for the treatment of alzheimer s disease	1985	0.0571	0.5351	48	0.6823
2044864138	sertraline for major depression in children and adolescents preliminary clinical experience	1995	0.4586	0.2348	116	0.7675
2044913340	interventions with care givers of dementia patients comparison of two approaches	1987	0.5529	-0.1143	1	4.8615
2044920702	down syndrome and alzheimer disease response to donepezil	2002	-0.2236	0.1792	11	0.687
2044922153	effects of a restraint reduction intervention and obra 87 regulations on psychoactive drug use in nursing homes	1997	0.8435	-0.1027	42	0.9992
2044939863	p2 377 a phase 2 double blind placebo controlled study to evaluate the safety tolerability and effect on cognitive function of al 108 after 12 weeks of intranasal administration in subjects with mild cognitive impairment	2008	-0.289	0.2822	9	0.7085
2044972527	gw25 e2381 effects of ginkgo biloba extract in combination with anti platelet drugs on platelet aggregation a meta analysis of randomized controlled trials	2014	-0.4856	-0.072	68	0.6951
2044987694	hypocretin 1 orexin a deficiency in acute traumatic brain injury	2005	-1.2578	1.7621	64	0.991
2045009959	ginkgo biloba and donepezil a comparison in the treatment of alzheimer s dementia in a randomized placebo controlled double blind study	2006	-0.4363	-0.0858	8	28.6347
2045044146	discordance between cerebral spinal fluid and plasma hiv replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy	2010	-0.4008	0.502	87	0.9867
2045079671	effects of extended release memantine 28 mg once daily on language and communication abilities in a randomized trial of patients with moderate to severe alzheimer s disease	2012	-0.1262	0.0945	11	0.7919
2045101379	melatonin rhythmicity effect of age and alzheimer s disease	2003	0.263	-0.0163	28	2.9984
2045111237	paroxetine does not improve symptoms and impairs cognition in frontotemporal dementia a double blind randomized controlled trial	2004	-0.2334	0.2549	66	3.7904
2045122897	nicotinic systems and cognitive function	1992	0.0437	0.4832	48	0.9999
2045192759	dietary lecithin supplements in dementia of alzheimer type	1977	-0.3562	0.2958	59	1.6842
2045196111	panax ginseng enhances cognitive performance in alzheimer disease	2008	-0.6492	-0.1181	65	0.9713
2045289035	effects of physostigmine and lecithin on memory in alzheimer disease	1979	-0.3194	0.1941	13	6.2667
2045308875	the buffering effect of a computer support network on caregiver strain	1998	0.5531	-0.1195	1	0.991
2045369681	donepezil treatment of older adults with cognitive impairment and depression dotcode study clinical rationale and design	2014	-0.1897	0.1519	11	1.4047
2045413014	rivastigmine exposure provided by a transdermal patch versus capsules	2007	-0.2362	0.0512	19	3.8219
2045445680	a randomized controlled trial comparing an intraoperative goal directed strategy with routine clinical practice in patients undergoing peripheral arterial surgery	2010	3.1484	0.109	110	0.7643
2045453498	rivastigmine skin patch for alzheimer disease approved	2007	-0.2795	0.1044	133	0.7056
2045610235	a double blind comparison of olanzapine versus risperidone in the acute treatment of dementia related behavioral disturbances in extended care facilities	2003	0.1723	0.0872	16	0.916
2045640790	the effects of snoezelen multi sensory behavior therapy and psychiatric care on agitation apathy and activities of daily living in dementia patients on a short term geriatric psychiatric inpatient unit	2007	0.4238	-0.0767	18	1.9908
2045680640	a comparison of the effects of snoezelen and reminiscence therapy on the agitated behaviour of patients with dementia	2004	0.4236	-0.0761	18	1.998
2045695957	naftidrofuryl in the treatment of vascular dementia	2001	-0.3159	-0.0016	23	16.7322
2045707228	soymilk supplementation does not alter plasma markers of inflammation and oxidative stress in postmenopausal women	2009	-1.1803	-0.3252	129	0.6837
2045739108	memory improvement without toxicity during chronic low dose intravenous arecoline in alzheimer s disease	1993	-0.6082	0.5205	119	0.75
2045790758	mental and physical activities delay cognitive decline in older persons with dementia	2012	-0.2409	-0.2597	49	0.7157
2045819903	is dhea replacement beneficial in chronic adrenal failure	2015	-1.3848	-1.7808	54	0.8254
2045836468	efficacy of galantamine in probable vascular dementia and alzheimer s disease combined with cerebrovascular disease a randomised trial	2002	-0.3213	0.0172	12	49.2006
2045869017	benefits of home health care after inpatient rehabilitation for hip fracture health service use by medicare beneficiaries 1987 1992	1998	0.5774	-0.1229	139	0.7402
2045923955	severe impairment battery a neuropsychological test for severely demented patients	1994	-0.1973	0.0534	6	1.8964
2045964149	doxepin in the treatment of climacteric symptoms a double blind pilot study	1975	-0.1374	0.0374	80	0.6897
2046017074	galantamine in the treatment of minor depression with mild to moderate alzheimer s dementia in an elderly woman	2010	-0.3852	0.1417	134	0.6407
2046048507	metabolism and actions of cdp choline as an endogenous compound and administered exogenously as citicoline	1995	-0.3962	-0.2515	62	1.7498
2046054972	statins for the treatment of dementia	2014	-0.6974	-0.1635	29	1.9992
2046073886	a 3 month randomized placebo controlled neuroleptic discontinuation study in 100 people with dementia the neuropsychiatric inventory median cutoff is a predictor of clinical outcome	2004	0.2223	0.0621	16	26.9059
2046083791	p1 367 tolerability safety and efficacy in patients with alzheimer s disease who are switched from donepezil to galantamine	2004	-0.2408	0.0603	19	0.7479
2046119291	paroxetine and fluoxetine effects on mood and cognitive functions in depressed nondemented elderly patients	2002	-0.2633	0.1641	9	0.6528
2046180717	a classical mnemonic for older learners a trip that works	1976	0.5107	-0.2858	4	0.75
2046318072	effects of s adenosyl l methionine on cognitive and vigilance functions in the elderly	1994	-0.3936	-0.2409	62	0.7204
2046393612	effects of music therapy on behavioral and psychological symptoms of dementia a systematic review and meta analysis	2013	0.4992	-0.0535	21	6.8045
2046410001	the moderating effect of self efficacy on intervention response in women family caregivers of older adults with dementia	2006	0.5285	-0.1133	1	0.9584
2046429594	regional metabolic patterns in mild cognitive impairment and alzheimer s disease a 1h mrs study	2000	-0.1606	0.0143	46	1
2046454316	clinical trial of indomethacin in alzheimer s disease	1993	-0.4125	-0.0392	32	35.2543
2046481610	aspirin for primary prevention of cardiovascular events meta analysis of randomized controlled trials and subgroup analysis by sex and diabetes status	2014	-0.5188	-0.0906	68	0.706
2046506691	p 4 67 effect of olanzapine on deficit syndrome symptoms in chronic schizophrenia	1995	0.3076	0.1434	81	0.7009
2046624824	poster 70 training memory self efficacy in the chronic stage after stroke a randomized controlled trial	2011	-0.2868	0.2068	15	0.7575
2046718416	association between statin use and alzheimer s disease	2004	-0.7145	-0.167	29	1.8808
2046793183	probing the safety of medications in the frail elderly evidence from a randomized clinical trial of sertraline and venlafaxine in depressed nursing home residents	2003	0.103	0.1503	61	0.7202
2046846582	two year treatment of alzheimer s disease with eptastigmine	1999	-0.2814	0.0803	44	0.916
2046917916	cerebrolysin in alzheimer s disease a randomized double blind placebo controlled trial with a neurotrophic agent	2002	-0.2417	-0.0118	6	0.74
2046943573	a pilot study to evaluate the effects of cerebrolysin on cognition and qeeg in vascular dementia cognitive improvement correlates with qeeg acceleration	2008	-0.3326	0.0053	70	17.1418
2046949772	cognitive decline and dementia in diabetes systematic overview of prospective observational studies	2005	-0.445	1.5721	56	1.9982
2046953005	changing everyday memory behaviour in amnestic mild cognitive impairment a randomised controlled trial	2008	0.2621	-0.1316	10	4.7737
2047020796	a six month placebo controlled trial of d cycloserine co administered with conventional antipsychotics in schizophrenia patients	2005	-0.2975	0.1887	43	0.9404
2047056461	the memorial delirium assessment scale	1997	2.1663	-0.0437	2	2.8774
2047074652	effects of galantamine versus donepezil on sleep in patients with mild to moderate alzheimer disease and their caregivers a double blind head to head randomized pilot study	2005	0.1281	0.0261	28	0.9584
2047079927	effects of two antidepressants on memory performance in depressed outpatients a double blind study	1984	-0.2514	0.1578	9	0.6708
2047095305	a 1 year placebo controlled preservation of function survival study of donepezil in ad patients	2001	-0.2147	0.0418	6	54.2782
2047154566	statistical image analysis of cerebral glucose metabolism in patients with cognitive impairment following diffuse traumatic brain injury	2007	-0.4858	0.0852	117	0.6811
2047158766	intraventricular bethanechol infusion for alzheimer s disease results of double blind and escalating dose trials	1988	-0.2984	0.1487	13	0.845
2047349398	high dose estradiol improves cognition for women with ad results of a randomized study	2001	-0.7416	-0.7364	3	23
2047425535	is antidepressant treatment associated with reduced cognitive decline in alzheimer s disease	2008	-0.3415	0.9111	113	0.719
2047469357	depression in alzheimer s disease heterogeneity and related issues	2003	0.0383	0.1961	61	0.845
2047487074	the modified mini mental state 3ms examination	1987	-0.3317	-0.0945	8	0.9804
2047507940	the human pineal gland and melatonin in aging and alzheimer s disease	2005	0.2503	-0.0164	28	2.9981
2047511834	rofecoxib no effect on alzheimer s disease in a 1 year randomized blinded controlled study	2004	-0.4111	-0.0693	32	27
2047558006	and c is for clioquinol the a??cs of alzheimer s disease	2002	-1.0873	-0.5741	69	0.7498
2047579625	efficacy and adverse effects of memantine treatment for alzheimer s disease from randomized controlled trials	2015	-0.0767	0.0687	58	2.2521
2047613132	decreased prevalence of alzheimer disease associated with 3 hydroxy 3 methyglutaryl coenzyme a reductase inhibitors	2000	-0.7296	-0.1716	29	9.9076
2047643900	enhanced recovery pathways optimize health outcomes and resource utilization a meta analysis of randomized controlled trials in colorectal surgery	2011	2.7899	-0.0532	118	0.7993
2047653584	effect of physostigmine on constructional and memory tasks in alzheimer s disease	1979	-0.3056	0.1856	13	1.7154
2047670437	the movement disorder society evidence based medicine review update treatments for the non motor symptoms of parkinson s disease	2011	-0.1887	0.1076	7	3.5944
2047693500	postmenopausal estrogen replacement therapy and risk of ad a population based study	1999	-0.7366	-0.7251	3	2
2047704857	protective effects of nsaids on the development of alzheimer disease	2008	-0.4392	-0.0857	32	1.9957
2047869919	the efficacy of ginseng a systematic review of randomised clinical trials	1999	-0.6515	-0.1186	65	1.9898
2048051035	intervening with everyday memory problems in dementia of alzheimer type an errorless learning approach	2000	0.2699	-0.1054	10	4.8235
2048095794	outcome and utilization differences for older persons with stroke in hmo and fee for service systems	2000	0.5772	-0.1221	139	0.7399
2048122875	modulation of mood and cognitive performance following acute administration of melissa officinalis lemon balm	2002	0.4005	-0.0296	34	1
2048160501	effect of rivastigmine on regional cerebral blood flow in alzheimer s disease	2007	-0.0978	0.0504	67	2.0184
2048226899	enhancing antiretroviral therapy for human immunodeficiency virus cognitive disorders	2004	-0.401	0.502	87	1.9377
2048322943	effects of hatha yoga and african dance on perceived stress affect and salivary cortisol	2004	1.6805	-0.9881	108	0.9994
2048340877	the efficacy of psychosocial approaches to behaviour disorders in dementia a systematic literature review	1999	0.4444	-0.0351	21	1.9343
2048382616	haloperidol versus thioridazine for the treatment of psychogeriatric patients a double blind clinical trial	1974	0.1165	0.1318	38	0.6645
2048400721	treatment effects of memantine on language in moderate to severe alzheimer s disease patients	2009	-0.1971	0.1158	92	0.7404
2048424306	single doses of panax ginseng g115 reduce blood glucose levels and improve cognitive performance during sustained mental activity	2005	-0.6576	-0.1212	65	3.7661
2048449891	animal behavioral models in the discovery of compounds to treat memory dysfunction	1985	-0.2882	0.3063	15	0.75
2048483249	high dose donepezil 23 mg day for the treatment of moderate and severe alzheimer s disease drug profile and clinical guidelines	2013	-0.0755	0.0727	58	17.3233
2048515815	evidence for a central cholinergic effect of high dose thiamine	1993	-0.7838	-0.0988	86	1.8564
2048527175	a randomized trial of modafinil for the treatment of fatigue and excessive daytime sleepiness in individuals with chronic traumatic brain injury	2008	-1.2579	1.759	64	19.9257
2048531219	randomised multicentre trial on safety and efficacy of rivastigmine in cognitively impaired multiple sclerosis patients	2013	-0.2317	0.1988	55	15.8627
2048610622	dose dependent effects of anapsos in senile dementia patients a double blind randomized placebo controlled study	2000	-0.411	0.0798	51	0.7746
2048638763	cognitive dysfunctions in mild parkinson s disease dementia comparison with patients having mild alzheimer s disease and normal controls	2008	-0.2001	0.0881	78	0.6831
2048713544	in home respite intervention reduces plasma epinephrine in stressed alzheimer caregivers	2003	0.5571	-0.1155	142	17.8165
2048780418	tramiprosate in mild to moderate alzheimer s disease a randomized double blind placebo controlled multi centre study the alphase study	2011	-0.5779	-0.1503	32	0.9939
2048800171	a randomized controlled cross over trial of dermally applied lavender lavandula angustifolia oil as a treatment of agitated behaviour in dementia	2013	0.4045	-0.0335	34	2.8277
2048886349	no ergogenic effects of ginseng panax ginseng c a meyer during graded maximal aerobic exercise	1997	-0.6511	-0.1188	65	1.9673
2048911743	regulation of cognitive processes through perceived self efficacy	1989	0.4859	-0.2694	4	0.9404
2048927739	might dhea be considered a beneficial replacement therapy in the elderly	2007	-1.3848	-1.7808	54	0.75
2048943469	subcortical ischaemic vascular dementia	2002	-0.4922	0.0082	12	5.3754
2048964830	a two year longitudinal study of cognitive function in normal aging and alzheimer s disease	1993	-0.1816	0.0898	37	0.7517
2049066516	assessing the clinical importance of statistically significant improvement in anti dementia drug trials	2001	-0.285	0.0852	33	0.6462
2049144579	high versus low dose piracetam in alcohol organic mental disorder a placebo controlled study	1990	-0.22	0.1008	23	0.668
2049186585	simvastatin enhances learning and memory independent of amyloid load in mice	2006	-0.7214	-0.169	29	0.9404
2049190733	a phase ii trial of huperzine a in mild to moderate alzheimer disease	2011	-0.5769	-0.1488	32	19.7864
2049280926	the effects of a multimodal intervention on outcomes of persons with early stage dementia	2008	0.4827	-0.1787	25	20.982
2049282065	effects of donepezil on central processing speed and attentional measures in parkinson s disease with dementia and dementia with lewy bodies	2007	-0.1371	0.201	100	0.7517
2049320972	the effect of testosterone on health related quality of life in elderly males a pilot study	2000	-0.9263	-0.257	79	0.7306
2049325983	comparison of haemodynamic and cardiovascular effects of vima with sevoflurane versus tiva with propofol in patients undergoing coronary artery bypass surgery	2008	3.1473	0.1092	110	0.7763
2049334534	cholinesterase inhibitors for alzheimer s disease	2001	-0.2658	0.0614	44	0.75
2049343395	cognitive interventions to improve face name recall the role of personality trait differences	1990	0.5099	-0.2864	4	1.5493
2049383023	cluster randomised trial of a targeted multifactorial intervention to prevent falls among older people in hospital	2008	2.2795	-0.0629	35	0.845
2049466420	long term safety tolerability and clinical improvement with quetiapine in elderly patients with schizophrenia	2000	0.6164	0.4438	40	0.7623
2049511526	a synaptic model of memory long term potentiation in the hippocampus	1993	-0.2817	0.1568	43	0.75
2049583304	beyond the cholinergic hypothesis the effect of metrifonate and other cholinesterase inhibitors on neuropsychiatric symptoms in alzheimer s disease	1998	-0.1976	0.0759	44	19.4602
2049683617	effects of rivastigmine on cognitive function in dementia with lewy bodies a randomised placebo controlled international study using the cognitive drug research computerised assessment system	2002	-0.198	0.123	7	22.9868
2049710692	investigating the natural course and treatment of vascular dementia and alzheimer s disease parallel study populations in two randomized placebo controlled trials	2000	-0.4772	-0.0167	12	16.0389
2049833912	attitudes of family and professional caregivers towards the use of gps for people with dementia	2010	0.7067	-0.1575	76	0.7706
2049884888	safety and tolerability of the rivastigmine patch results of a 28 week open label extension	2009	-0.2464	0.0521	19	4.5356
2049890856	cholinesterase inhibitors in mild cognitive impairment a systematic review of randomised trials	2007	-0.1382	-0.0462	46	1.9954
2049977944	predictors of antipsychotic withdrawal or dose reduction in a randomized controlled trial of provider education	1997	0.5951	-0.0136	52	20.8908
2050009016	pharmacokinetics of a rivastigmine transdermal patch formulation in healthy volunteers relative effects of body site application	2007	-0.2366	0.0512	19	2.787
2050035967	how should a group living unit for demented elderly be designed to decrease psychiatric symptoms	1997	0.6741	-0.0194	24	0.9713
2050065482	transdermal physostigmine in the treatment of alzheimer s disease	1994	-0.2924	0.1361	13	1.6904
2050096860	physostigmine and tetrahydroaminoacridine treatment of alzheimer s disease	2009	-0.4294	0.3498	90	1.3972
2050142220	effect of meeting centres support program on feelings of competence of family carers and delay of institutionalization of people with dementia	2004	0.6854	-0.1437	97	0.677
2050162004	improving caregiver well being delays nursing home placement of patients with alzheimer disease	2006	0.5178	-0.1089	1	27.9694
2050187494	rivastigmine augmentation in the management of chronic schizophrenia with comorbid dementia an open label study investigating effects on cognition behaviour and activities of daily living	2004	-0.195	0.1795	11	0.6894
2050190016	age at onset and regional cerebral glucose metabolism in alzheimer s disease	1998	-0.4858	0.0852	117	0.7177
2050206187	cns acetylcholine receptor activity in european medicinal plants traditionally used to improve failing memory	2000	0.4009	-0.0293	34	1
2050233854	effective caregiving approaches for patients with alzheimer s disease	1998	0.5585	-0.1156	1	0.9867
2050270894	brain monoamines in dementia of alzheimer type	1984	-0.3309	0.2597	59	0.7528
2050393823	olanzapine versus fluphenazine 6 weeks treatment of anxiety symptoms during acute schizophrenia	1998	0.104	0.1382	38	0.7326
2050401382	a 48 week placebo controlled study examining propentofylline s safety efficacy and impact on disease progression in patients with vascular dementia	1999	-0.4056	0.0825	85	0.7192
2050554121	relinquishing in home dementia care difficulties and preceived helpfulness during the nursing home trasition	2001	0.7067	-0.1575	76	0.7825
2050609730	an open label study of memantine treatment in 3 subtypes of frontotemporal lobar degeneration	2009	-0.2339	0.2589	66	2.9867
2050680831	a double fdg pet study of the effects of scopolamine in older adults	1994	-0.4858	0.0852	117	0.6925
2050687814	treatment of dementia with behavioral disturbance using divalproex or a combination of divalproex and a neuroleptic	1997	0.174	0.0804	16	0.991
2050716208	long term estrogen replacement therapy in female patients with dementia of the alzheimer type 7 case reports	1995	-0.7647	-0.7717	3	0.9994
2050721184	quetiapine to treat agitation in dementia a randomized double blind placebo controlled study	2007	0.1852	0.0924	16	1.9991
2050795430	can training community mental health nurses to support family carers reduce behavioural problems in dementia an exploratory pragmatic randomised controlled trial	2008	0.4676	-0.0966	1	17.9944
2050850506	the effects of a special computer network on caregivers of persons with alzheimer s disease	1995	0.546	-0.1138	1	4.7794
2050922749	the role of long chain omega 3 polyunsaturated fatty acids in reducing lipid peroxidation among elderly patients with mild cognitive impairment a case control study	2013	-1.1801	-0.326	129	0.7032
2051118933	a large community based open label trial of donepezil in the treatment of alzheimer s disease	2003	-0.2801	0.075	51	0.7117
2051145831	pentoxifylline in cerebrovascular dementia	1992	-0.417	0.0419	41	0.6596
2051207687	estrogen replacement therapy and alzheimer s disease in the italian longitudinal study on aging	1998	-0.7437	-0.7385	3	1
2051259264	posatirelin in the treatment of vascular dementia a double blind multicentre study vs placebo	2009	-0.3555	-0.1214	62	1.5527
2051303441	influence of regular exercise on subjective sense of burden and physical symptoms in community dwelling caregivers of dementia patients a randomized controlled trial	2011	0.1351	-0.0723	93	0.7906
2051335728	no research versus research with compromised results a study of validation therapy	1986	0.4373	-0.0695	18	10.1202
2051359310	fish oil supplementation in the treatment of major depression a randomised double blind placebo controlled trial	2007	-1.0972	-0.3014	5	0.991
2051365626	analgesia before a spinal block for femoral neck fracture fascia iliaca compartment block	2009	2.2485	-0.0454	138	0.9867
2051392022	the effects of social pressure on group recall	2003	0.5107	-0.2858	4	0.7696
2051393616	a nursing intervention to decrease depression in family caregivers of persons with dementia	1999	0.5503	-0.1093	1	7.5246
2051413962	low folate levels in the cognitive decline of elderly patients and the efficacy of folate as a treatment for improving memory deficits	1997	-0.8824	-0.1038	30	24.9397
2051423109	low dehydroepiandrosterone and ischemic heart disease in middle aged men prospective results from the massachusetts male aging study	2001	-1.3848	-1.7808	54	0.75
2051432233	treatment for dementia	1995	-0.2909	0.1288	53	0.7848
2051516838	treatment with a copper zinc chelator markedly and rapidly inhibits ?? amyloid accumulation in alzheimer s disease transgenic mice	2001	-1.0107	-0.5241	69	1
2051520593	intact working memory in early alzheimer disease	1998	-0.5495	0.3992	73	0.6925
2051530373	computerized methods in the assessment and prediction of dementia	2007	-0.0747	-0.1034	127	0.7847
2051581511	risperidone reduced psychotic symptoms in dementia study	2005	0.3085	0.1434	81	0.7961
2051614606	efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder significant placebo practice effects in a 12 week randomized double blind placebo controlled trial	2008	-0.22	0.1008	23	0.6825
2051635625	effects of l amphetamine sulfate on cognitive function in multiple sclerosis patients	2008	-0.2415	0.2141	55	1.9937
2051683762	outcomes for patients with dementia from the cleveland alzheimer s managed care demonstration	2004	0.5406	-0.1125	74	23.108
2051776695	a randomized double blind study of rofecoxib in patients with mild cognitive impairment	2005	-0.3182	-0.0655	32	10.9906
2051834772	intracerebroventricular bethanechol chloride infusion in alzheimer s disease results of a collaborative double blind study	1989	-0.3316	0.2205	13	0.9404
2051882532	fascia iliaca compartment blockade for acute pain control in hip fracture patients a randomized placebo controlled trial	2007	2.2485	-0.0454	138	0.9992
2051925617	caregiver preference for rivastigmine patches versus capsules for the treatment of alzheimer disease	2007	-0.2377	0.0524	19	21.0459
2051929221	efficacy and tolerability of a once daily formulation of ginkgo biloba extract egb 761 in alzheimer s disease and vascular dementia results from a randomised controlled trial	2012	-0.4319	-0.0462	8	19.4945
2051938557	buddhist group therapy for diabetes patients with depressive symptoms	2011	-0.3252	-0.1421	45	0.7057
2052011640	a six month double blind randomized placebo controlled study of a transdermal patch in alzheimer s disease rivastigmine patch versus capsule	2007	-0.2359	0.0534	19	31.5336
2052062173	group activity and cognitive improvement among patients with alzheimer s disease	1991	0.284	-0.0923	10	25.2976
2052091788	a 12 month study of the efficacy of rivastigmine in patients with advanced moderate alzheimer s disease	2005	-0.2103	0.0483	6	20.4337
2052182600	explicit criteria for determining inappropriate medication use in nursing home residents ucla division of geriatric medicine	1991	0.6308	-0.0224	52	0.991
2052203707	redox regulation of heat shock protein expression in aging and neurodegenerative disorders associated with oxidative stress a nutritional approach	2003	-0.319	0.0032	63	0.916
2052293470	memantine in the treatment of senile dementia of the alzheimer type	1986	0.1165	0.1318	38	0.6457
2052365764	extended release physostigmine in alzheimer disease a multicenter double blind 12 week study with dose enrichment	2000	-0.2551	0.0484	44	17.348
2052406749	a 12 week double blind placebo controlled trial of donepezil as an adjunct to haloperidol for treating cognitive impairments in patients with chronic schizophrenia	2007	-0.2149	0.169	9	1.5307
2052496664	the clinical efficacy of citalopram in treatment of emotional disturbances in dementia disorders a nordic multicentre study	1990	0.1821	0.0879	31	17.3644
2052588755	plasma homocysteine as a risk factor for dementia and alzheimer s disease	2002	-0.8817	-0.1037	30	9.9481
2052589051	a novel treatment for patients with alzheimer s disease and with vascular dementia	2002	-0.3846	0.0857	94	2.4405
2052638649	cognitive dysfunction in early onset multiple sclerosis a reappraisal after 10 years	2001	-0.2383	0.2082	55	2.7084
2052742260	neuropathological stageing of alzheimer related changes	1991	-0.02	-0.0137	46	2.75
2052744035	the effective duration of analgesia after intrathecal morphine in patients without additional opioid analgesia a randomized double blind multicentre study on orthopaedic patients	2009	2.3863	-0.0472	130	0.8787
2052874641	the midas touch the effects of interpersonal touch on restaurant tipping	1984	0.5917	-0.0633	123	0.9804
2052951558	physical fitness and cognitive functioning in aging	1994	0.5817	-0.2527	27	0.9404
2053079057	physical restraint of the hospitalized elderly perceptions of patients and nurses	1988	0.8435	-0.1027	42	1
2053088233	delirium acute confusional states	1987	2.217	-0.0392	36	1
2053122286	neuroendocrine responses to intravenous infusion of physostigmine in patients with alzheimer disease	1999	0.057	0.5344	48	6.6384
2053202725	nanoparticle technology for delivery of drugs across the blood brain barrier	1998	-1.5747	-1.2603	101	0.75
2053204882	a study of antipsychotic drug use in nursing homes epidemiologic evidence suggesting misuse	1980	0.3517	0.0485	47	1.9999
2053250668	intravenous continuous drop infusion	1925	-0.6082	0.5205	119	0.626
2053254879	the relationship between donepezil and behavioral disturbances in patients with alzheimer s disease	2000	-0.2169	0.141	11	2.3039
2053269808	the effects of touch on nutritional intake of chronic organic brain syndrome patients	1987	0.5917	-0.0633	123	0.9985
2053585074	aripiprazole for the treatment of psychosis in patients with alzheimer s disease a randomized placebo controlled study	2005	0.1844	0.0922	16	21.9974
2053612684	omega 3 fatty acids in major depressive disorder a preliminary double blind placebo controlled trial	2003	-1.0974	-0.3005	5	0.9973
2053666331	elderly patients with dementia and psychosis treated with risperidone	2002	0.6156	0.442	40	15.8283
2053713082	supplementation with dhea effect on muscle size strength quality of life and lipids	2005	-1.4116	-1.8466	20	16.2873
2053739940	long term choline treatment of memory impaired elderly patients	1979	-0.3346	0.2225	59	0.845
2053765784	p2 279 cognitive response to acute donepezil in mild alzheimer s disease	2008	-0.3195	0.1168	33	0.8057
2053771014	beneficial effects of docosahexaenoic acid on cognition in age related cognitive decline	2010	-1.0491	-0.2854	5	8.477
2054025659	pre clinical models of human cerebral small vessel disease utility for clinical application	2012	-0.7263	0.0224	107	0.6724
2054091180	estradiol replacement enhances working memory in middle aged rats when initiated immediately after ovariectomy but not after a long term period of ovarian hormone deprivation	2006	-0.7466	-0.7493	3	1
2054096290	placebo controlled study of divalproex sodium for agitation in dementia	2001	0.1644	0.0811	16	4.9991
2054113864	intramuscular desferrioxamine in patients with alzheimer s disease	1991	-1.0077	-0.5223	69	20.8843
2054201087	the impact of the type of anaesthesia on cognitive status and delirium during the first postoperative days in elderly patients	2005	2.2229	-0.0304	36	19.1137
2054232191	delirium in elderly patients and the risk of postdischarge mortality institutionalization and dementia a meta analysis	2010	2.2572	-0.045	2	15.2406
2054235149	testosterone supplementation improves spatial and verbal memory in healthy older men	2001	-0.9327	-1.0635	54	1
2054286586	clinical evaluation of deprenyl selegiline in the treatment of parkinson s disease	1983	-0.1911	0.1104	137	0.716
2054290601	melatonin decreases delirium in elderly patients a randomized placebo controlled trial	2011	2.1775	-0.0429	2	26.7826
2054393069	trazodone improves sleep parameters in alzheimer disease patients a randomized double blind and placebo controlled study	2014	0.196	-0.0166	28	0.8843
2054616191	increases in bone mineral density in response to oral dehydroepiandrosterone replacement in older adults appear to be mediated by serum estrogens	2008	-1.4117	-1.8491	20	0.8068
2054616394	results of a randomized placebo controlled study of memory training for mildly impaired alzheimer s disease patients	2003	0.2527	-0.1115	10	29.735
2054654522	use of music to decrease aggressive behaviors in people with dementia	1998	0.4819	-0.051	21	24.9904
2054659813	estrogen use and verbal memory in healthy postmenopausal women	1994	-0.7615	-0.7685	3	6
2054664500	cognitive frailty rational and definition from an i a n a i a g g international consensus group	2013	0.538	-0.2242	136	0.9713
2054665046	cns pharmacology and clinical therapeutic effects of oxiracetam	1986	-0.2439	0.2318	15	0.6533
2054727147	the effect of skill training on functional abilities of nursing home residents with dementia	1994	0.494	-0.1739	25	1.871
2054777335	3008 effectiveness of cognitive behavioral anxiety treatments for children and adolescents	2013	0.7627	-0.2018	77	0.7945
2054796764	use of blood pressure lowering drugs in the prevention of cardiovascular disease meta analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies	2009	-0.7322	-0.152	14	1
2054798938	apolipoprotein e and cognitive performance a meta analysis	2004	-0.7714	-0.1862	29	0.9999
2054844062	alpha linolenic acid supplementation during human pregnancy does not effect cognitive functioning	2004	-1.0951	-0.3005	5	0.6978
2055028830	lorazepam is an independent risk factor for transitioning to delirium in intensive care unit patients	2006	2.1856	-0.0442	2	3.8753
2055063894	continued clinical validation of dementia diagnosed in the community using the cambridge mental disorders of the elderly examination	1991	-0.2861	0.0292	63	0.7015
2055105496	indices of neuropsychological functioning and decline over time in dementia	1998	-0.0747	-0.1034	127	0.7667
2055107057	galantamine improves non cognitive symptoms as compared to nootropics in outpatients with mild to moderate alzheimer s disease	2009	-0.2173	0.141	11	1.4304
2055151241	non cognitive symptoms of dementia in nursing homes frequency course and consequences	2003	0.9833	-0.0254	24	0.7079
2055163829	relationship between pharmacodynamic activity and cognitive effects of eptastigmine in patients with alzheimer s disease	1996	-0.2732	0.0875	44	1.4587
2055198312	efficacy of cognitive behavioral therapy for insomnia associated with traumatic brain injury a single case experimental design	2007	-1.2578	1.7621	64	0.9997
2055245690	appropriate prescribing in elderly people how well can it be measured and optimised	2007	0.6709	-0.0348	52	1.786
2055358932	safety and efficacy of rivastigmine in adolescents with down syndrome long term follow up	2010	-0.2326	0.2003	55	0.8139
2055453667	rationale and design of a multicenter study of selegiline and alpha tocopherol in the treatment of alzheimer disease using novel clinical outcomes alzheimer s disease cooperative study	1996	-0.2895	0.0718	37	18.3031
2055499702	aging and cognition facilitation of recent memory in aged nonhuman primates by nimodipine	1990	-0.3432	0.1147	53	0.9404
2055586346	donepezil for severe alzheimer s disease author s reply	2006	-0.3241	0.1165	33	16.6958
2055638140	oxiracetam in the treatment of primary dementia of the alzheimer s type a small case series	1992	-0.0587	0.0835	58	0.7345
2055649795	mild cognitive impairment beyond controversies towards a consensus report of the international working group on mild cognitive impairment	2004	-0.1097	-0.0709	46	9.6277
2055724853	cognitive impairment and dementia in parkinson s disease	2010	-0.1375	0.2003	100	0.7471
2055727638	donepezil improves cognition and global function in alzheimer disease a 15 week double blind placebo controlled study	1998	-0.2295	0.0531	6	27.5256
2055735954	residual risk for acute stroke in patients with type 2 diabetes and hypertension in primary care skaraborg hypertension and diabetes project	2006	-0.4276	1.4428	56	0.7657
2055772555	an instructional dvd fall prevention program for patients with cancer and family caregivers	2014	0.6283	-0.1218	42	0.7001
2055821827	effects of n 3 fatty acids on cognitive decline a randomized double blind placebo controlled trial in stable myocardial infarction patients	2011	-1.0046	-0.2719	5	21.0446
2055846817	two years follow up of rivastigmine treatment in huntington disease	2007	-0.2283	-0.1467	112	1
2055865399	reality orientation and staff attention a controlled study	1979	0.3191	-0.0915	10	25.4663
2055868466	neuropsychological functioning in a patient with essential tremor with and without bilateral vim stimulation	2000	0.2064	-0.0071	17	0.7576
2055929952	p1 344 donepezil is safe and well tolerated in alzheimer s disease patients at doses of up to 20 mg day	2004	-0.2662	0.0553	124	0.855
2056034609	efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe alzheimer s disease and the effect on caregiver burden	2003	-0.2182	0.0509	6	24.7121
2056046133	effects of oral physostigmine in alzheimer s disease	1987	-0.3077	0.1766	13	27.2227
2056067421	egb 761 enhances adult hippocampal neurogenesis and phosphorylation of creb in transgenic mouse model of alzheimer s disease	2007	-0.4085	-0.0525	8	1.9388
2056136848	stress and treatment induced elevations of cortisol levels associated with impaired declarative memory in healthy adults	1996	-1.4235	-1.8465	20	0.9973
2056150258	effects of testosterone on muscle strength physical function body composition and quality of life in intermediate frail and frail elderly men a randomized double blind placebo controlled study	2010	-1.2687	-1.5977	54	1
2056199568	a pilot clinical trial of the angiotensin converting enzyme inhibitor ceranapril in alzheimer disease	1993	-0.2801	0.075	51	0.7445
2056209987	long term low dose dehydroepiandrosterone oral supplementation in early and late postmenopausal women modulates endocrine parameters and synthesis of neuroactive steroids	2003	-1.4127	-1.8486	20	0.8021
2056217285	outcomes of minor and subsyndromal depression among elderly patients in primary care settings	2006	0.4586	0.2348	116	0.7625
2056277021	a randomized controlled trial of rivastigmine in patients with cognitive impairment no dementia because of cerebrovascular disease	2010	-0.4498	-0.0108	12	17.2433
2056337234	effect of respite care training on the knowledge attitude and self esteem of volunteer providers	2003	0.6854	-0.1437	97	0.8385
2056357915	the association of intraoperative factors with the development of postoperative delirium	1998	2.2205	-0.0345	36	1.8843
2056365507	exercise rehabilitation on home dwelling patients with alzheimer disease a randomized controlled trial baseline findings and feasibility	2011	0.0173	-0.0839	93	1.4548
2056419427	risperidone in the management of disruptive behavior disorders	2006	0.557	0.393	40	1.4119
2056449162	propentofylline enhances cerebral metabolic response to auditory memory stimulation in alzheimer s disease	1998	-0.1592	0.0558	67	13.5605
2056453292	experiments with ucb 6215 a drug which enhances acquisition in rats its effects compared with those of metamphetamine	1971	-0.2991	0.2328	15	0.7993
2056471297	cognitive assessment batteries for patients with mild vascular cognitive impairment	2009	-0.8154	0.8222	102	0.6702
2056482261	internet based support for rural caregivers of persons with stroke shows promise	2004	0.6854	-0.1437	97	0.6701
2056490900	a metaanalysis of studies of the effects of cancer chemotherapy on various domains of cognitive function	2005	-0.2975	-0.2456	49	0.7029
2056638435	reality orientation a critical appraisal	1982	0.305	-0.0894	10	3.82
2056745382	hormone therapy and cognitive function is there a critical period for benefit	2006	-0.7624	-0.7727	3	1.9959
2056761491	pmh28 is donepezil cost effective in the treatment of alzheimer s disease ad	2002	-0.3191	0.1184	33	1.5943
2056806649	fatty acids antioxidants and oxidative stress in pre eclampsia	2008	-1.1801	-0.326	129	0.7083
2056857284	do piracetam like compounds act centrally via peripheral mechanisms	1987	-0.2983	0.2325	15	0.845
2056870954	dhea therapy in postmenopausal women the need to move forward beyond the lack of evidence	2010	-1.3848	-1.7808	54	0.7931
2056886217	evidence based treatment of alzheimer s disease	2009	-0.328	0.1753	22	1.5941
2056893352	a randomized trial of the angiotensin receptor blocker valsartan in chronic heart failure	2001	-0.7293	-0.1452	14	2
2056976690	effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy	2001	-0.7339	-0.1451	14	3.9523
2057002872	binswanger type vascular cognitive impairment no dementia vcind and vascular dementia vad	2013	-0.3858	0.0611	50	0.7423
2057005657	neuropsychologic status in multiple sclerosis after treatment with glatiramer	1999	-0.242	0.2126	55	1.9804
2057005933	rivastigmine a brain selective acetylcholinesterase inhibitor ameliorates cognitive and motor deficits induced by closed head injury in the mouse	1998	-0.8474	1.0199	71	0.9584
2057041650	desensitization of the nmda receptor complex by glycinergic ligands in cerebellar granule cell cultures	1993	-0.2896	0.1831	43	0.7993
2057042201	diabetes mellitus and the risk of dementia the rotterdam study	1999	-0.445	1.5721	56	1.9959
2057099669	piracetam combined with lecithin in the treatment of alzheimer s disease	1986	-0.3348	0.2762	15	2.6464
2057144523	does rehabilitation matter in patients with femoral neck fracture and cognitive impairment a prospective study of 246 patients	2010	2.1885	-0.0861	26	0.7993
2057144863	factors associated with non completion in a double blind randomized controlled trial of olanzapine plus sertraline versus olanzapine plus placebo for psychotic depression	2012	0.103	0.1503	61	0.7014
2057196462	effects of nicotinic stimulation on cognitive performance	2004	0.0444	0.4825	48	0.9997
2057254150	preclinical vascular cognitive impairment	2011	-0.8148	0.8226	102	0.6803
2057293596	two trials comparing hydergine with placebo in the treatment of patients suffering from cerebrovascular insufficiency	1973	-0.2914	0.0885	41	3.1534
2057315927	an exploratory study of state trait anxiety as a function of automated relaxation training desired changes and drinking behavior	1980	-0.3865	0.3792	98	0.6915
2057349977	educational program for nursing home physicians and staff to reduce use of non steroidal anti inflammatory drugs among nursing home residents a randomized controlled trial	2001	0.5971	-0.0135	52	0.9804
2057381997	a reminiscence program intervention to improve the quality of life of long term care residents with alzheimer s disease a randomized controlled trial	2012	0.3586	-0.094	39	1.761
2057427474	parallel improvement of cognitive functions and p300 latency following donepezil treatment in patients with alzheimer s disease a case control study	2014	-0.2939	0.1114	50	0.6923
2057500061	group therapy for patients with mild cognitive impairment and their significant others results of a waiting list controlled trial	2010	0.415	-0.0781	18	0.7033
2057679568	a 24 week double blind placebo controlled trial of donepezil in patients with alzheimer s disease	1998	-0.2428	0.0471	6	60.7425
2057760505	abnormal amino acid metabolism in patients with early stage alzheimer dementia	1998	-0.4081	0.3096	120	0.6258
2057775085	vitamins b12 b6 and folic acid for cognition in older men	2010	-0.487	-0.1297	8	0.9584
2057791111	decreased pyruvate dehydrogenase complex activity in huntington and alzheimer brain	1983	-0.7874	-0.0992	86	0.845
2057841757	memantine dosing in patients with dementia	2009	-0.2361	0.0581	19	0.7193
2057962863	subjective reports of fatigue during early recovery from traumatic brain injury	2005	-1.2594	1.7614	64	0.9939
2057995596	improving care of older adults with dementia description of 6299 hospitalizations over 11 years in a special acute care unit	2012	1.3029	-0.029	24	1.4862
2058030893	effectiveness of a psychoeducational intervention program in the reduction of caregiver burden in alzheimer s disease patients caregivers	2009	0.3596	-0.0948	1	2.7939
2058062724	in home cognitive training with older married couples individual versus collaborative learning	2006	0.459	-0.2364	4	17.7901
2058075693	bright light therapy for demented nursing home patients with behavioral disturbance	2000	0.2982	-0.0181	17	0.9404
2058091820	a preliminary study of carbamazepine in the treatment of assaultive patients with dementia	1988	0.0875	0.0984	47	0.9584
2058112065	a 24 week randomized controlled trial of memantine in patients with moderate to severe alzheimer disease	2007	-0.1619	0.0662	6	29.6242
2058140100	language enriched exercise plus socialization slows cognitive decline in alzheimer s disease	2007	0.512	-0.1989	25	0.9939
2058146916	can primary care visits reduce hospital utilization among medicare beneficiaries at the end of life	2008	0.5772	-0.1221	139	0.7513
2058247742	preliminary findings behavioral worsening on donepezil in patients with frontotemporal dementia	2007	-0.234	0.2588	66	2.9999
2058285428	donepezil for severe alzheimer s disease	2006	-0.3208	0.1174	33	2.5836
2058315750	omega 3 n 3 fatty acids down regulate nuclear factor kappa b nf ??b gene and blood cell adhesion molecule expression in patients with homozygous sickle cell disease	2015	-1.2104	-0.3345	128	0.7166
2058316847	value and efficacy of early supported discharge from stroke units	2009	-0.3446	0.2068	126	0.8244
2058350561	age changes and sex differences in serum dehydroepiandrosterone sulfate concentrations throughout adulthood	1984	-1.3939	-1.7994	20	5.94
2058373257	effects of chelators on iron uptake and release by the brain in the rat	1994	-1.5747	-1.2603	101	0.7993
2058379278	supporting family caregivers communicating with family caregivers	2011	0.7067	-0.1575	76	0.7745
2058413990	human serial learning enhancement with arecholine and choline impairment with scopolamine	1978	-0.3356	0.2226	59	0.916
2058417743	the impact study a randomised controlled trial to evaluate a hospital palliative care team	2002	0.8533	-0.0193	95	0.916
2058454186	ginkgo biloba extract egb 761 and cns functions basic studies and clinical applications	2000	-0.3422	-0.0742	8	5.5571
2058478275	the effects of an engaged lifestyle on cognitive vitality a field experiment	2008	0.4595	-0.2378	4	0.916
2058542952	the effects of an aerobic exercise program on psychological variables in older adults	1985	0.5831	-0.251	27	1.9999
2058619742	p03 11 clozapine as an antiagressive agent in an adolescent with autism	2009	0.5641	0.3999	40	0.6941
2058663867	rehabilitation of executive functioning an experimental clinical validation of goal management training	2000	0.4805	-0.2649	4	1
2058667257	effects of memantine on clinical ratings fluorodeoxyglucose positron emission tomography measurements and cerebrospinal fluid assays in patients with moderate to severe alzheimer dementia a 24 week randomized clinical trial	2013	-0.2936	0.0287	57	14.6377
2058680444	individualized care alternatives used in the process of removing physical restraints in the nursing home	1994	0.8432	-0.1021	42	0.9992
2058707813	positron emission tomography in normal aging and alzheimer s disease	1986	-0.4858	0.0852	117	0.6776
2058803950	plasma nutrient status of patients with alzheimer s disease systematic review and meta analysis	2014	-0.4426	-0.1104	82	0.9959
2058817917	decreased awareness of cognitive deficits in patients with mild dementia of the alzheimer type	1999	0.2476	-0.1139	10	0.9804
2058852406	video rating analysis of effect of maprotiline in patients with dementia and depression	1993	0.2354	0.0778	31	20.4599
2058864393	a pilot randomized open label trial assessing safety and pharmakokinetic parameters of co administration of rivastigmine with risperidone in dementia patients with behavioral disturbances	2002	-0.2326	0.2003	55	0.7458
2058879779	donepezil in vascular dementia a randomized placebo controlled study	2003	-0.4023	0.0089	12	38.3698
2058994916	the effect of exercise on depressive symptoms in the moderately depressed elderly	1991	0.5825	-0.2513	27	0.9994
2059013002	liberal versus restrictive blood transfusion strategy 3 year survival and cause of death results from the focus randomised controlled trial	2015	2.566	-0.0494	125	0.7993
2059014479	safety and pharmacokinetics following a single 10 minute intravenous infusion of the anti amyloid mab ponezumab pf 04360365 in patients with mild to moderate alzheimer s disease	2010	-0.6078	0.5212	119	0.6328
2059022259	preventing the use of physical restraints on residents newly admitted to psycho geriatric nursing home wards a cluster randomized trial	2009	0.8161	-0.0998	42	22.0522
2059191144	neuropsychological test performance and affect in myasthenia gravis	1995	-0.2977	-0.2464	49	0.6953
2059237121	a randomized controlled trial to examine the effectiveness of case management model for community dwelling older persons with mild dementia in hong kong	2010	0.545	-0.1166	74	23.6004
2059255809	glucose enhancement of memory in elderly humans an inverted u dose response curve	1992	-0.4598	1.8033	96	0.7993
2059375413	safety of soy derived phosphatidylserine in elderly people	2002	-0.289	0.2822	9	0.6434
2059393353	a double blind placebo controlled randomized trial of melissa officinalis oil and donepezil for the treatment of agitation in alzheimer s disease	2011	0.3875	-0.0267	34	22.7979
2059448132	bispectral index monitoring to prevent awareness during anaesthesia the b aware randomised controlled trial	2004	2.202	-0.038	36	1
2059495695	nicotinic effects on cognitive function behavioral characterization pharmacological specification and anatomic localization	2006	0.0437	0.4832	48	0.9998
2059543385	propentofylline treatment for alzheimer disease and vascular dementia an economic evaluation based on functional abilities	2000	0.526	-0.0876	34	13.882
2059563090	cognition changes in placebo controlled trials in severe dementia	2002	-0.4786	-0.0169	12	0.788
2059586369	the pharmacology of selegiline deprenyl new aspects	1989	-0.1873	0.1192	37	0.9959
2059645476	measuring the wellbeing of family caregivers using the time trade off technique	1988	0.5283	-0.1112	1	0.9713
2059674362	impact of donepezil hydrochloride on the care burden of family caregivers of patients with alzheimer s disease	2009	0.4586	0.2348	116	0.7541
2059752275	high and low potency neuroleptics in elderly psychiatric patients	1978	0.0848	0.1025	47	0.6639
2059756889	dehydroepiandrosterone treatment of midlife dysthymia	1999	-1.4189	-1.8388	20	3.9542
2059792793	development and evaluation of home based speed of processing training for older adults	2006	0.4861	-0.2607	4	1
2059804586	changes in cognitive abilities over a 4 year period are unfavorably affected in elderly diabetic subjects results of the epidemiology of vascular aging study	2001	-0.4441	1.5721	56	1.9713
2059847922	a review of the use of cognitive stimulation therapy in dementia management	2006	0.2185	-0.072	10	0.8277
2059855678	regression to the mean implications for clinical trials of psychotropic agents in dementia	2004	0.1419	0.0443	58	0.7316
2059883453	double blind study of the therapeutic efficacy and tolerability of amitriptylinoxide in comparison with amitriptyline	1990	-0.6355	0.0863	122	0.7245
2060129459	cognitive dysfunction in multiple sclerosis i frequency patterns and prediction	1991	-0.2389	0.2091	55	3.7975
2060132796	the evaluation of cognitive behavioral group therapy on patient depression and self esteem	2006	-0.3244	-0.142	45	0.7005
2060176821	methylphenidate and desipramine in hospitalized children with comorbid behavior and mood disorders separate and combined effects on behavior and mood	1995	-0.1547	0.2301	15	0.6356
2060179338	the efficacy of pentoxifylline in the treatment of vascular dementia a systematic review	2003	-0.3167	-0.002	23	0.75
2060206336	the efficacy of egb 761 in patients with senile dementia of the alzheimer type a double blind placebo controlled study on different levels of investigation	1994	-0.4159	-0.0121	8	11.9303
2060229578	lavender aroma therapy for behavioral and psychological symptoms in dementia patients	2008	0.41	-0.0361	34	1.7304
2060332652	brain ?? ketoglutarate dehydrotenase complex activity in alzheimer s disease	1993	-0.7851	-0.0993	86	2.7724
2060348672	in vivo effects by estrone sulfate on the central nervous system senile dementia alzheimer s type	1989	-0.7654	-0.7711	3	0.9992
2060394171	pmc14 determining costs of concomitant medications in randomized clinical trials a case study	2009	-0.5975	-0.0271	99	0.7055
2060448576	ginkgo biloba for the prevention and treatment of cardiovascular disease a review of the literature	2002	-0.3317	-0.0945	8	0.7993
2060524361	p4 405 a multinational randomized double blind placebo controlled parallel group trial of memantine extended release capsule 28 mg once daily in patients with moderate to severe alzheimer s disease	2008	-0.2361	0.0581	19	0.8172
2060551691	is exercise effective in promoting mental well being in older age a systematic review	2010	0.4834	-0.1436	60	0.8843
2060559377	a c t h by intravenous infusion	1951	-0.6082	0.5205	119	0.614
2060657502	decreased antioxidant enzymes and membrane essential polyunsaturated fatty acids in schizophrenic and bipolar mood disorder patients	2003	-1.1801	-0.326	129	0.6904
2060676259	in search of the molecular basis of memory loss in alzheimer disease	2006	-0.5495	0.3992	73	0.6821
2060744432	feasibility of enhanced recovery programme in various patient groups	2012	2.7899	-0.0532	118	0.7993
2060756352	rivastigmine in the treatment of dementia associated with parkinson s disease effects on activities of daily living	2010	-0.208	0.0679	7	18.08
2060781273	donepezil provides benefits in global function in moderate to severe alzheimer s disease	2000	-0.3186	0.1164	33	16.5634
2060827220	a crossover trial of bromocriptine in the treatment of vascular dementia	1988	-0.417	0.0419	41	0.6618
2060836042	benefits of cognitive motor intervention in mci and mild to moderate alzheimer disease	2004	0.2573	-0.104	10	16.7593
2060844066	broad therapeutic benefits in patients with probable vascular dementia or alzheimer s disease with cerebrovascular disease after treatment with galantamine	2002	-0.378	0.0979	94	17.5792
2061040672	citicoline protects hippocampal neurons against apoptosis induced by brain beta amyloid deposits plus cerebral hypoperfusion in rats	1999	-0.4003	-0.2667	62	0.916
2061070794	one extra month of depression the effects of caregiving on depression outcomes in the impact trial	2008	0.6566	-0.1432	75	0.7803
2061202327	low blood pressure and dementia in elderly people the kungsholmen project	1996	-0.6771	-0.1149	14	1
2061244084	factors affecting the use of a telephone based intervention for caregivers of people with alzheimer s disease	2001	0.6283	-0.1218	42	0.7308
2061245441	anti inflammatory and analgesic properties of the leaf extracts and essential oil of lavandula angustifolia mill	2003	0.4064	-0.0321	34	0.9404
2061333078	effects of conjugated equine estrogens on cognition and affect in postmenopausal women with prior hysterectomy	2009	-0.7299	-0.7345	3	3.842
2061423247	professional environmental assessment procedure for special care units for elders with dementing illness and its relationship to the therapeutic environment screening schedule	2000	0.6741	-0.0194	24	0.991
2061445611	donepezil as add on treatment of psychotic symptoms in patients with dementia of the alzheimer s type	2003	0.104	0.1382	38	0.6901
2061474728	cognitive effects of nicotine	2001	0.0437	0.4832	48	1
2061664301	human memory and the cholinergic system a relationship to aging	1974	-0.3144	0.2062	13	4.4233
2061677561	risk associated with preoperative anemia in cardiac surgery a multicenter cohort study	2008	2.5491	-0.0689	35	0.75
2061830520	piracetam in elderly psychiatric patients with mild diffuse cerebral impairment	1983	-0.2983	0.2313	15	20.8139
2061877884	memory self efficacy and performance differences in young and old adults the effect of mnemonic training	1989	0.5081	-0.2844	4	2.826
2061879267	double blind placebo controlled study comparing effects of zopiclone and temazepam on cognitive functioning of insomniacs	1999	-0.2514	0.1578	9	0.6584
2061879864	delirium superimposed on dementia a systematic review	2002	2.1013	-0.0419	2	1
2061927966	selegiline in the treatment of mild and moderate stages of alzheimer disease	1998	-0.3245	0.1979	22	0.786
2061948213	cognitive relapse after discontinuation of drug therapy in alzheimer s disease cholinesterase inhibitors versus nootropics	2001	-0.2244	0.1787	11	0.6762
2062024523	frontotemporal dementia paroxetine as a possible treatment of behavior symptoms	2003	-0.2334	0.255	66	3.7367
2062029914	utility of the mattis dementia rating scale to assess the efficacy of rivastigmine in dementia associated with parkinson s disease	2006	-0.1886	0.0704	7	16.2328
2062077243	electroencephalographic and behavioral changes associated with papaverine administration in healthy geriatric subjects	1975	-0.4209	0.3343	90	0.6346
2062120524	exercise training is beneficial for alzheimer s patients	2008	0.4854	-0.1785	25	30.3044
2062122326	benefits of rivastigmine on attention in dementia associated with parkinson disease	2005	-0.1832	0.1105	7	23.4816
2062128885	efficacy and safety of memantine in lewy body dementia	2009	-0.2313	0.2459	66	0.6826
2062157811	effects of cholinergic drugs and cognitive training on dementia	2004	0.2287	-0.0963	10	20.3327
2062197542	memantine in moderate to severe alzheimer s disease	2003	-0.3146	0.1729	22	0.856
2062204763	donepezil in patients with subcortical vascular cognitive impairment	2008	-0.8154	0.8222	102	0.6867
2062210283	risperidone versus zuclopenthixol in the treatment of acute schizophrenic episodes a double blind parallel group trial	1995	0.1301	0.1278	47	0.8112
2062246297	the impact of metrifonate therapy on caregivers of patients with alzheimer s disease results from the malt clinical trial	2000	0.1337	-0.0717	93	16.1023
2062249338	dementia severity and the magnitude of cognitive benefit by memantine treatment a subgroup analysis of two placebo controlled clinical trials in vascular dementia	2000	-0.3858	0.0611	50	0.85
2062276473	oral dehydroepiandrosterone supplementation modulates spontaneous and growth hormone releasing hormone induced growth hormone and insulin like growth factor 1 secretion in early and late postmenopausal women	2001	-1.4117	-1.8491	20	0.8096
2062279563	effectiveness of validation therapy vt in group preliminary results	2007	0.4141	-0.0769	18	15.2864
2062367843	evaluating rivastigmine in mild to moderate parkinson s disease dementia using adas cog items	2010	-0.1968	0.0104	7	3.1411
2062371309	health related quality of life during treatment of elderly patients with hypertension results from the study on cognition and prognosis in the elderly scope	2004	-0.7596	-0.1533	14	19.6089
2062419094	nicotine enhancement of fast excitatory synaptic transmission in cns by presynaptic receptors	1995	0.0437	0.4832	48	0.9997
2062557126	a cluster randomized controlled trial of cognitive behaviour therapy for common mental disorders in patients with advanced cancer	2009	0.6751	-0.1736	77	0.7398
2062645773	propentofylline improves regional cerebral glucose metabolism and neuropsychologic performance in vascular dementia	1996	-0.4837	0.0846	117	14.2153
2062652595	epa 1806 motor symptoms related to alzheimer s disease treatment	2014	-0.2373	0.0397	72	0.7931
2062667692	virtual support groups for family caregivers of persons with dementia	2005	0.7067	-0.1575	76	0.8144
2062810910	cognitive status at admission does it affect the rehabilitation outcome of elderly patients with hip fracture	1999	2.0384	-0.0877	26	1.75
2062825859	cerebral blood flow in dementia	1975	-0.464	-0.0103	12	1.5493
2062918847	association of dementia with early rehospitalization among medicare beneficiaries	2014	0.5774	-0.1229	139	0.7615
2062944931	is music therapy an effective intervention for dementia a meta analytic review of literature	1999	0.4805	-0.0526	21	1.9918
2063055024	epidural versus general anaesthesia for total hip arthroplasty in elderly patients	1980	2.217	-0.0383	36	1
2063086502	randomized pilot study of nimesulide treatment in alzheimer s disease	2002	-0.4108	-0.0712	32	23.9965
2063138855	progression of impairment in patients with vascular cognitive impairment without dementia	2001	-0.4516	-0.0103	12	0.845
2063256456	neurophysiologic correlates of side effects in normal subjects randomized to venlafaxine or placebo	2005	-0.4209	0.3343	90	0.6304
2063294725	haloperidol versus thioridazine for hospitalized psychogeriatric patients double blind study	1971	0.0859	0.1004	47	1.612
2063342775	memantine for non motor features of parkinson s disease a double blind placebo controlled exploratory pilot trial	2011	-0.1662	0.1004	7	1.6343
2063391965	effects of estrogen replacement therapy on pet cerebral blood flow and neuropsychological performance	1998	-0.7555	-0.7616	3	1.9982
2063406023	the effects of alternative support strategies on family caregiving	1989	0.6407	-0.1343	97	1.7993
2063423141	a double blind study on the effects of piracetam upon perceptual and psychomotor performance at varied heart rates in patients treated with artificial pacemakers	1974	-0.3171	0.2625	15	0.9804
2063454995	awareness in early stage alzheimer s disease relationship to outcome of cognitive rehabilitation	2004	0.2476	-0.1139	10	0.9939
2063486198	single case evaluation of the effects of aromatherapy and massage on disturbed behaviour in severe dementia	1997	0.3976	-0.0291	34	1.9995
2063673978	effects of a multicomponent intervention on functional outcomes and process of care in hospitalized older patients a randomized controlled trial of acute care for elders ace in a community hospital	2000	2.3262	-0.0634	35	1.4939
2063682916	residual cognitive impairment in late life depression after a 12 month period follow up	2003	-0.2271	0.0538	84	0.6778
2063698042	schema therapy for patients with chronic depression a single case series study	2014	-0.3095	-0.1483	45	1.3805
2063726958	is frailty a prodromal stage of vascular dementia results from the three city study	2012	0.538	-0.2242	136	0.9404
2063936165	electroencephalographic and clinical changes as correlated in geriatric patients treated three months with an ergot alkaloid preparation	1979	-0.289	0.1016	41	0.75
2063975661	effects of chronic papaverine administration on mild senile organic brain syndrome	1977	-0.4293	0.35	90	1.3094
2064006284	quetiapine for agitation or psychosis in patients with dementia and parkinsonism	2007	-0.1493	0.1232	7	0.7993
2064054282	comparison of teniloxazine and piracetam in alzheimer type or vascular dementia	1995	-0.2363	0.2272	15	3.6695
2064075508	alzheimer disease cancer link to alzheimer disease but not vascular dementia	2010	-0.3792	0.0982	94	0.7974
2064104052	citicoline cognizin in the treatment of cognitive impairment	2006	-0.4003	-0.2667	62	0.845
2064218953	randomized controlled trial of atomoxetine for cognitive dysfunction in early huntington disease	2009	-0.2288	-0.146	112	0.9939
2064404113	the effects of exercise on cognition in older adults with and without cognitive decline a systematic review	2008	0.5368	-0.188	27	0.8843
2064412594	acetylcholinesterase inhibition in dementia with lewy bodies results of a prospective pilot trial	2000	-0.1986	0.1245	7	0.9988
2064425811	melatonin fails to improve sleep or agitation in double blind randomized placebo controlled trial of institutionalized patients with alzheimer disease	2009	0.2162	-0.0177	28	27.8554
2064444969	does recombinant human erythropoietin not only treat anemia but reduce postpartum emotional distress as well	1995	-0.3438	0.2071	126	0.8245
2064470295	a method for assessing drug therapy appropriateness	1992	0.7088	-0.0469	52	0.8843
2064507890	effects of transcutaneous electrical nerve stimulation tens on cognition and behaviour in aging	2000	0.1918	-0.0096	17	20.9559
2064511862	long term treatment of alzheimer disease efficacy and safety of acetylcholinesterase inhibitors	2004	-0.0587	0.0835	58	0.7617
2064549315	randomized double blind parallel group 48 week study for efficacy and safety of a higher dose rivastigmine patch 15 vs 10 cm2 in alzheimer s disease	2012	-0.2285	0.0583	19	4.6429
2064590051	the relationship of postoperative delirium with psychoactive medications	1994	2.217	-0.0383	36	1
2064628807	short term long chain omega3 diet protects from neuroinflammatory processes and memory impairment in aged mice	2012	-1.103	-0.3022	5	1.5493
2064649894	open label multicenter phase 3 extension study of the safety and efficacy of donepezil in patients with alzheimer disease	2001	-0.2081	0.0442	6	36.004
2064770195	citalopram versus sertraline in late life nonmajor clinically significant depression a 1 year follow up clinical trial	2005	0.2436	0.0888	31	0.7767
2064775311	reduced serotonin 5 ht1a receptor binding in the temporal cortex correlates with aggressive behavior in alzheimer disease	2003	-0.3861	0.1418	134	0.6269
2064822632	effects of two caregiver training programs on burden and attitude toward help	1994	0.557	-0.1145	1	20.6682
2064863031	treatment trial of oxiracetam in alzheimer s disease	1992	-0.2244	0.1787	11	0.6994
2064871711	galantamine shows mixed results for vascular dementia patients	2005	-0.3855	0.0603	50	0.7688
2064887457	a randomized double blind placebo controlled study of the efficacy and safety of donepezil in patients with alzheimer s disease in the nursing home setting	2001	-0.1434	0.056	6	23.7181
2064903807	end of life experience of demented elderly patients at home findings from death project	2006	0.9833	-0.0254	24	0.7069
2064942197	transfer of a speed of processing intervention to near and far cognitive functions	2002	0.4802	-0.2572	4	2
2065052203	long term tacrine cognex treatment effects on nursing home placement and mortality	1996	-0.2364	0.0793	13	3.4804
2065081638	fragrance compounds and essential oils with sedative effects upon inhalation	1993	0.3952	-0.0284	34	0.9713
2065132667	interventions that can reduce inappropriate prescribing in the elderly a systematic review	2009	0.7088	-0.0469	52	0.845
2065166046	clinical pharmacokinetics of physostigmine in patients with alzheimer s disease	1995	-0.2799	0.1138	13	15.4072
2065168181	a combination of galantamine and memantine modifies cognitive function in subjects with amnestic mci	2012	-0.1891	0.0236	78	17.2429
2065195216	cognitive and affective changes in mild to moderate alzheimer s disease patients undergoing switch of cholinesterase inhibitors a 6 month observational study	2014	-0.2244	0.1787	11	0.6802
2065205610	ginkgo biloba extract egb 761 in dementia with neuropsychiatric features a randomised placebo controlled trial to confirm the efficacy and safety of a daily dose of 240 mg	2012	-0.4051	-0.0502	8	27.576
2065226992	family functioning in the caregivers of patients with dementia one year follow up	2006	0.657	-0.144	75	0.7743
2065276300	regional brain perfusion correlates of visuospatial impairment in dementia with lewy bodies parkinson s disease with dementia and alzheimer s disease	2011	-0.1375	0.2003	100	0.7726
2065294305	central acetylcholinesterase inhibitors in the treatment of chronic traumatic brain injury clinical experience in 111 patients	2005	-0.8474	1.0199	71	1
2065407531	dehydroepiandrosterone replacement in aging humans	1999	-1.4161	-1.838	20	1
2065671170	use of environmental manipulation and modified informal reality orientation with institutionalized confused elderly subjects a replication	1987	0.322	-0.0925	10	1.9298
2065722132	decreased verbal memory associated with anticholinergic treatment in parkinson s disease patients	1981	-0.2392	0.1669	9	2.0211
2065735162	long term safety and cognitive effects of galantamine in the treatment of probable vascular dementia or alzheimer s disease with cerebrovascular disease	2003	-0.3387	0.0347	12	23.4901
2065741910	efficacy of donepezil on behavioral symptoms in patients with moderate to severe alzheimer s disease	2002	-0.0799	0.0591	6	24.6035
2065746234	collaborative memory intervention in dementia caregiver participation matters	2009	0.3146	-0.1277	10	16.9966
2065763048	amphetamine self administration by humans modulation by contingencies associated with task performance	1996	-0.3865	0.3792	98	0.6795
2065932595	economic evaluation of a support program for caregivers of demented elderly	1991	0.5265	-0.1108	1	20.3863
2066041164	donepezil treatment in severe alzheimer s disease a pooled analysis of three clinical trials	2009	-0.2152	0.1394	11	0.8083
2066056333	memantine induces reversible neurologic impairment in patients with ms	2009	-0.2419	0.2133	55	0.9959
2066091758	evaluation of the convenience of changing the rivastigmine administration route in patients with alzheimer disease	2011	-0.2552	0.0519	72	1.6717
2066108884	memantine for cognitive impairment in multiple sclerosis a randomized placebo controlled trial	2010	-0.2275	0.1871	55	4.2853
2066115280	effects of donepezil on memory and cognition in multiple sclerosis	2006	-0.2381	0.1662	9	3.7547
2066146930	donepezil in vascular dementia a neurosonological and neuropsychological study	2005	-0.3855	0.0603	50	0.7299
2066149726	interaction between psychological and pharmacological treatment in cognitive impairment	1994	-0.2589	0.1783	11	14.0093
2066195788	hydergine in senile mental impairment	1982	-0.289	0.1016	41	0.75
2066223250	dehydroepiandrosterone replacement therapy	2004	-1.3848	-1.7808	54	0.813
2066245716	a controlled double blind study of high dose dihydroergotoxine mesylate hyderginer in mild dementia	1987	-0.2279	0.0814	80	2.4404
2066255846	effect of omega 3 fatty acid supplementation on the arachidonic acid eicosapentaenoic acid ratio	2007	-1.0853	-0.2965	5	0.7983
2066297161	a spiritually based caregiver intervention with telephone delivery for family caregivers of veterans with dementia	2009	0.5963	-0.1335	131	0.75
2066297786	the effect of donepezil on sleep in elderly healthy persons a double blind placebo controlled study	2006	0.1281	0.0261	28	0.916
2066313462	aniracetam ro 13 5057 in the treatment of senile dementia of alzheimer type sdat results of a placebo controlled multicentre clinical study	1991	-0.2439	0.2318	15	0.6582
2066363689	illumination levels in nursing home patients effects on sleep and activity rhythms	2000	0.3022	-0.0184	17	3.8937
2066403547	cdp choline in the treatment of chronic cerebrovasculopathies	1994	-0.3937	-0.24	62	15.8288
2066445203	a pilot study of yoga for breast cancer survivors physical and psychological benefits	2006	1.6805	-0.9881	108	0.9992
2066448639	a randomized controlled trial of risperidone in the treatment of aggression in hospitalized adolescents with subaverage cognitive abilities	2001	0.1573	0.0923	16	0.7845
2066518350	treatment of panic disorder with agoraphobia randomized placebo controlled trial of four psychosocial treatments combined with imipramine or placebo	2008	-0.1544	0.2293	15	0.63
2066560997	the coping with caregiving group program for chinese caregivers of patients with alzheimer s disease in hong kong	2010	0.5285	-0.1133	1	0.916
2066642377	six months outcomes of a randomised trial of supportive text messaging for depression and comorbid alcohol use disorder	2013	-0.2945	-0.1543	45	0.6844
2066698241	the quality of antipsychotic drug prescribing in nursing homes	2005	0.2177	0.0645	16	0.9584
2066734262	memantine in moderately severe to severe alzheimer s disease ad results of a placebo controlled 6 month trial	2000	-0.3053	0.0169	57	17.9195
2066756297	the effect of pramiracetam ci 879 on the acquisition of a radial arm maze task	1986	-0.2983	0.2325	15	0.8843
2066863557	risperidone in dementia	2000	0.5483	0.3861	40	0.8643
2066946777	androgens and coronary artery disease	2003	-1.384	-1.781	54	0.7993
2066966946	a 30 week randomized controlled trial of high dose tacrine in patients with alzheimer s disease the tacrine study group	1994	-0.266	0.0809	37	20.7993
2067042856	patient populations in clinical studies of donepezil in vascular dementia	2003	-0.3243	0.1121	33	0.8463
2067162295	metrifonate therapy in alzheimer s disease a pooled analysis of four randomized double blind placebo controlled trials	2000	-0.2734	0.0683	51	1.5549
2067176619	effect of patient controlled sedation with propofol on patient satisfaction a randomized study	2013	2.345	0.1894	103	0.6982
2067178446	cognitive effects of l deprenyl in alzheimer s disease	1987	-0.1712	0.1772	37	6.178
2067229092	a randomized double blind placebo controlled trial of donepezil hydrochloride aricept for reducing the incidence of postoperative delirium after elective total hip replacement	2007	2.1974	-0.0428	2	7.9155
2067254358	plasma as42 as40 ratio is decreased in amnestic mild cognitive impairment mci and mild alzheimer s disease ad	2009	-0.1901	0.0234	78	0.8456
2067275115	a comparison of two phenothiazines in the treatment of schizophrenics	1963	0.0852	0.1033	47	0.6906
2067358754	support of homeostatic glial cell signaling a novel therapeutic approach by propentofylline	1997	-0.417	0.0206	85	1.8808
2067363531	efficacy of a support group programme for care givers of demented patients in the community a randomized controlled trial	1994	0.5474	-0.1131	1	4.7846
2067418199	effects of xanomeline a selective muscarinic receptor agonist on cognitive function and behavioral symptoms in alzheimer disease	1997	-0.2758	0.0799	44	1.7854
2067439875	nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration an update	2010	-0.2335	0.2595	66	0.9939
2067448615	lecithin treatment of cognitively impaired parkinson s patients	1982	-0.2336	0.1833	9	13.2944
2067457311	efficacy and safety of memantine in patients with mild to moderate vascular dementia a randomized placebo controlled trial mmm 300	2002	-0.3646	0.0251	12	41.942
2067556591	endocrinological aspects of aging in men is hormone replacement of benefit	2000	-1.3848	-1.7808	54	0.7485
2067591531	the use of clinical case management for early stage alzheimer patients and their families	2000	0.5356	-0.1088	1	5.5119
2067592030	baseline neuropsychiatric symptoms are effect modifiers in ginkgo biloba extract egb 761 treatment of dementia with neuropsychiatric features retrospective data analyses of a randomized controlled trial	2010	-0.3716	-0.041	8	18.8547
2067592497	clinical studies with oxiracetam in patients with dementia of alzheimer type and multi lnfarct dementia of mild to moderate degree	1992	-0.3281	0.1275	13	1.4958
2067634709	learning and memory impairment with benzhexol	1987	-0.2522	0.1582	9	0.6522
2067712656	cognitive rehabilitation in the elderly effects on memory	2007	0.4564	-0.2444	4	22.6862
2067723782	salivary cortisol secretion in remitted bipolar patients and offspring of bipolar parents	2006	0.3277	-0.0246	89	1.4114
2067751704	combined memory and executive function tests can screen mild cognitive impairment and converters to dementia in a community the osaki tajiri project	2009	-0.0749	-0.1026	127	16.4083
2067754196	vitamin e and memantine in alzheimer s disease clinical trial methods and baseline data	2014	-0.4194	-0.0627	82	15.1219
2067777747	safety and efficacy of galantamine reminyl in severe alzheimer s disease the serad study a randomised placebo controlled double blind trial	2009	-0.2089	0.0517	6	4.7099
2067799130	transfer of learning after updating training mediated by the striatum	2008	0.4644	-0.2472	4	2.9982
2067810785	tryptophan supplementation and postoperative delirium a randomized controlled trial	2014	2.566	-0.0494	125	0.7846
2067851639	brainstem neural mechanisms of sleep and wakefulness	1998	0.1966	-0.0068	17	2.2993
2067886181	a geriatric anesthesiologic program to reduce acute confusional states in elderly patients treated for femoral neck fractures	1991	2.217	-0.0383	36	1
2067936686	changes in eeg blood levels mood scales and performance scores during long term treatment with diazepam phenobarbital or placebo in patients	1982	-0.4209	0.3343	90	0.6432
2068140181	evaluation of the efficacy of piracetam in treating information processing reading and writing disorders in dyslexic children	1986	-0.2983	0.2325	15	0.845
2068154832	a pilot study of haloperidol treatment of psychosis and behavioral disturbance in alzheimer s disease	1989	-0.2108	0.1795	11	1.3699
2068163749	follow up investigation of patients with mild alzheimer disease vascular and mixed dementia	1998	-0.4056	0.0825	85	0.6943
2068206844	learning mnemonics roles of aging and subtle cognitive impairment	1990	0.5093	-0.2848	4	3.4543
2068228829	salivary cortisol and dhea association with measures of cognition and well being in normal older men and effects of three months of dhea supplementation	2001	-1.421	-1.8413	20	22.939
2068228921	l deprenyl in alzheimer s disease cognitive and behavioral effects	1998	-0.2682	0.0785	44	21.4791
2068233333	sedation depth during spinal anesthesia and the development of postoperative delirium in elderly patients undergoing hip fracture repair	2010	2.1796	-0.0396	36	24.7865
2068289517	efficacy and safety of galantamine reminyl for dementia in patients with parkinson s disease an open controlled trial	2008	-0.1872	0.1174	7	0.9988
2068329556	randomized controlled trial of yoga and exercise in multiple sclerosis	2004	1.6796	-0.9881	108	1
2068350676	using multi sensory environments with older people with dementia	1997	0.4308	-0.0751	18	0.9404
2068395904	l deprenil a selective monoamine oxidase type b inhibitor in the treatment of depression a double blind evaluation	1983	-0.1954	0.1512	37	0.845
2068443827	addendum to efficacy of music therapy treatment based on cycles of sessions a randomised controlled trial raglio et al 2010	2012	-0.2941	-0.1534	45	14.0329
2068453976	a randomized double blind placebo controlled trial of donepezil to improve memory in epilepsy	2007	-0.2367	0.1589	11	1.4155
2068454697	a?? metallobiology and the development of novel metal protein attenuating compounds mpacs for alzheimers disease	2003	-1.0874	-0.5733	69	0.707
2068477037	arthritis and anti inflammatory agents as possible protective factors for alzheimer s disease a review of 17 epidemiologic studies	1996	-0.4231	-0.0606	32	7.9735
2068658047	the acute effects of glucose ingestion on attentional control in fasting healthy older adults	2010	-0.4601	1.8008	96	17.2374
2068675229	phosphodiesterase inhibitory profile of some related xanthine derivatives pharmacologically active on the peripheral microcirculation	1994	-0.4137	0.0257	85	0.916
2068745164	effects of group exercise on cognitive functioning and mood in older women	1977	0.574	-0.2451	27	4.7681
2068854599	a placebo controlled trial of fluoxetine added to neuroleptic in patients with schizophrenia	1995	-0.1168	0.194	114	0.6795
2068938636	an evaluation of a family visit education program	1999	0.1419	0.0443	58	0.75
2068980363	age associated difference in circadian sleep wake and rest activity rhythms	2002	0.2473	-0.0134	17	0.9584
2068987805	effects of acute subcutaneous nicotine on attention information processing and short term memory in alzheimer s disease	1992	0.0437	0.4832	48	1
2069007387	5 12 20 the tropicamide test in patients with dementia of alzheimer type and fronto temporal dementia	1997	-0.3309	0.2597	59	0.7382
2069096680	oxiracetam in the treatment of multi infarct dementia	1989	-0.2439	0.2318	15	0.6536
2069154263	the beneficial effect of cholinesterase inhibitors on patients suffering from parkinson s disease and dementia	2001	-0.1886	0.0705	7	0.7643
2069158867	predictors of progression from mild cognitive impairment to alzheimer disease	2007	0.6751	-0.1736	77	0.75
2069241148	2254 analysis of the effect of memantine in reducing clinical symptoms in patients with moderate to severe alzheimer s disease	2013	-0.1687	0.0991	11	0.8392
2069284334	the effects of metrifonate on the cognitive behavioral and functional performance of alzheimer s disease patients	1999	-0.2241	0.0755	44	1.9494
2069317157	intravenous nicotine in alzheimer s disease a pilot study	1988	0.0522	0.5181	48	1.655
2069321502	long term improvements in cognitive performance through computer assisted cognitive training a pilot study in a residential home for older people	2003	0.2065	-0.1235	10	2
2069494503	metformin may produce antidepressant effects through improvement of cognitive function among depressed patients with diabetes mellitus	2014	-0.341	0.9093	113	15.0183
2069548351	risperidone therapy for post operative delirium in elderly patients	2005	0.617	0.4432	40	0.7649
2069550725	glucose improvement of memory a review	2004	-0.4598	1.8033	96	0.9404
2069600773	forgetting numbers in old age strategy and learning speed matter	2005	0.5027	-0.2811	4	14.6537
2069642428	effectiveness of standardized ginkgo biloba extract on cognitive symptoms of dementia with a six month treatment a bivariate random effect meta analysis	2010	-0.4235	-0.0499	8	1.8247
2069675969	ginkgo biloba for mild to moderate dementia in a community setting a pragmatic randomised parallel group double blind placebo controlled trial	2008	-0.4065	-0.0559	8	19.491
2069682416	the effects of emotion oriented approaches in the care for persons suffering from dementia a review of the literature	2000	0.4199	-0.0732	18	1.9298
2069849212	two novel 5 ht6 receptor antagonists ameliorate scopolamine induced memory deficits in the object recognition and object location tasks in wistar rats	2011	-1.5582	0.2221	115	0.9804
2069896217	the efficacy of a medical food souvenaid in alzheimer s disease results from the first trial and design of future trials	2009	-0.5169	-0.0473	12	0.6944
2069899124	the effects of 90 day supplementation with the omega 3 essential fatty acid docosahexaenoic acid dha on cognitive function and visual acuity in a healthy aging population	2012	-1.007	-0.2728	5	0.9404
2070021709	alzheimer s disease and caregiver time	1994	-2.1408	2.1667	121	17.9272
2070079507	metal chelation as a potential therapy for alzheimer s disease	2006	-1.5747	-1.2603	101	0.7993
2070081349	risperidone for psychosis of alzheimer s disease and mixed dementia results of a double blind placebo controlled trial	2005	0.0731	0.0945	16	0.8585
2070113083	p1 063 the rate of decline in mild to moderate stage alzheimer disease is associated with increased symptoms of depression	2004	-0.3118	0.0161	57	0.6886
2070142670	vascular cognitive impairment a unified approach to cognitive disorders	2007	-0.8154	0.8222	102	0.6754
2070173157	psychoactive medication use in intermediate care facility residents	1988	0.5411	0.0026	52	1
2070305883	wellbeing and activity in dementia a comparison of group reminiscence therapy structured goal directed group activity and unstructured time	2000	0.305	-0.0919	39	0.75
2070320852	p 5 a 014 functional communication in patients with moderate alzheimer s disease treated with memantine	2010	-0.3088	0.0165	57	1.6208
2070341552	p4 394 lack of evidence for the efficacy of memantine in mild alzheimer s disease and modest effects in moderate alzheimer s disease	2008	-0.3146	0.1729	22	0.84
2070366022	effectiveness of group music intervention against agitated behavior in elderly persons with dementia	2011	0.4862	-0.0526	21	24.4855
2070369189	treatment of alzheimer s disease	1998	-0.3291	0.1927	22	3.2318
2070413520	efficacy and safety of donepezil 23 mg versus donepezil 10 mg for moderate to severe alzheimer s disease a subgroup analysis in patients already taking or not taking concomitant memantine	2012	-0.2093	0.1277	11	19.5631
2070416004	subjective and objective measures of insomnia in the context of traumatic brain injury a preliminary study	2006	-1.2594	1.7614	64	0.9988
2070502382	piracetam an overview of its pharmacological properties and a review of its therapeutic use in senile cognitive disorders	1991	-0.3538	0.3242	98	1.836
2070531209	specific functional effects of memantine treatment in patients with moderate to severe alzheimer s disease	2004	-0.1685	0.098	11	18.1941
2070540982	postoperative delirium the importance of pain and pain management	2006	2.2393	-0.0445	138	1.9579
2070558791	a randomised controlled trial testing the impact of exercise on cognitive symptoms and disability of residents with dementia	2006	0.4807	-0.1709	25	31.9118
2070644314	four week nicotine skin patch treatment effects on cognitive performance in alzheimer s disease	1999	0.0432	0.4813	48	19.9985
2070734601	cardiovascular risk factors and cognitive decline in middle aged adults	2001	-0.667	-0.1114	14	0.9982
2070782477	clinical experience with risperidone haloperidol and thioridazine for dementia associated behavioral disturbances	1997	0.5483	0.3861	40	0.7295
2070806978	acute and subacute cns effects of milacemide in elderly people double blind placebo controlled quantitative eeg and psychometric investigations	1986	-0.4206	0.335	90	0.6285
2070844602	homoeopathic treatment of attention deficit hyperactivity disorder a controlled study	1997	-0.1547	0.2301	15	0.6319
2070880671	a phase ii study targeting amyloid ?? with 3aps in mild to moderate alzheimer disease	2006	-0.2942	0.0285	57	0.693
2070987376	nutritional intake use of touch and verbal cuing	1994	0.5917	-0.0633	123	0.9713
2071008297	o3 04 03 a 240 mg once daily formulation of ginkgo biloba extract egb 761 is effective in both alzheimer s disease and vascular dementia results from a randomized controlled trial	2008	-0.4609	-0.0597	68	1.5741
2071010392	a randomised controlled trial of the use of aromatherapy and hand massage to reduce disruptive behaviour in people with dementia	2013	0.4131	-0.0408	34	18.25
2071025192	cardiovascular and behavioral effects of aerobic exercise training in healthy older men and women	1989	0.5813	-0.2491	27	23.8795
2071051054	is the cognitive function of older patients affected by antihypertensive treatment results from 54 months of the medical research council s treatment trial of hypertension in older adults	1996	-0.6838	-0.1174	14	8.5947
2071056698	exploring the effectiveness of an internet based program for reducing caregiver distress using the icare stress management e training program	2013	0.5531	-0.1195	1	0.9939
2071136623	no response to high dose muscarinic agonist therapy in alzheimer s disease	1988	-0.2984	0.1487	13	0.845
2071155607	fatigue after traumatic brain injury association with neuroendocrine sleep depression and other factors	2010	-1.2594	1.7614	64	0.991
2071184036	neuropsychological function and apolipoprotein e genotype in the preclinical detection of alzheimer s disease	1999	-0.7714	-0.1862	29	0.9584
2071252381	prevalence incidence and factors associated with pre stroke and post stroke dementia a systematic review and meta analysis	2009	-0.4178	0.0017	12	0.9404
2071254369	brief psychotherapy in alzheimer s disease randomised controlled trial	2005	0.4457	-0.0924	18	19.3678
2071273368	double blind placebo controlled psychometric studies on the effects of a combined estrogen progestin regimen versus estrogen alone on performance mood and personality of menopausal syndrome patients	2011	-0.7521	-0.7576	3	20.9452
2071281966	effect of cyclandelate on dementia	1975	-0.2985	0.0512	23	0.6395
2071324656	evaluation of a special nursing home unit for dementia sufferers a randomised controlled comparison with community care	1987	0.8366	-0.0245	24	1.595
2071341699	belt restraint reduction in nursing homes effects of a multicomponent intervention program	2011	0.8045	-0.0982	42	3.8816
2071345353	effect of baseline cognitive function and antihypertensive treatment on cognitive and cardiovascular outcomes study on cognition and prognosis in the elderly scope	2005	-0.6653	-0.1117	14	19.9909
2071351901	tailored activities to manage neuropsychiatric behaviors in persons with dementia and reduce caregiver burden a randomized pilot study	2008	0.4836	-0.1044	1	9.2421
2071365474	effects of dhea administration on episodic memory cortisol and mood in healthy young men a double blind placebo controlled study	2006	-1.422	-1.8436	20	0.9973
2071385197	comparative efficacy study of haloperidol olanzapine and risperidone in delirium	2011	2.1722	-0.0424	2	0.9999
2071460877	problem solving deficits in brain injured patients a therapeutic approach	1991	0.4805	-0.2649	4	0.991
2071626737	diabetes safety and efficacy of albiglutide results from two trials	2014	-0.5169	-0.0473	12	0.6835
2071701301	p 4 021 donepezil improves cognition in patients with mild to moderate ad results of adas cog analysis in a 30 week phase iii study	1997	-0.2166	0.1405	11	0.746
2071737598	quetiapine improves psychotic symptoms and cognition in parkinson s disease	2004	-0.1501	0.1196	44	0.7303
2071755201	omega a randomized placebo controlled trial to test the effect of highly purified omega 3 fatty acids on top of modern guideline adjusted therapy after myocardial infarction	2010	-1.2428	-0.3453	83	1
2071762564	a meta regression to examine the relationship between aerobic fitness and cognitive performance	2006	0.544	-0.2077	27	1.7292
2071804866	bdnf and 5 ht a dynamic duo in age related neuronal plasticity and neurodegenerative disorders	2004	0.0378	0.1969	61	0.845
2071873638	treatment of pain in cognitively impaired compared with cognitively intact older patients with hip fracture	1998	2.1047	-0.0879	26	0.7469
2071887970	correlates of alcohol use in adults with adhd and comorbid alcohol use disorders exploratory analysis of a placebo controlled trial of atomoxetine	2011	-0.1547	0.2301	15	0.6495
2071913508	endogenous sex hormones and cognitive function in older men	1999	-0.9327	-1.0635	54	1
2072226883	acute confusional states in elderly patients treated for femoral neck fracture	1988	2.217	-0.0383	36	1
2072229818	nanoparticulate systems for brain delivery of drugs	2001	-1.5747	-1.2603	101	0.7993
2072232569	a clinical agglutinometer an apparatus for use at the bedside or in the laboratory for making rapid estimations of the agglutinin titre of the blood	1917	-0.3925	0.3624	106	0.7069
2072259992	cognitive global and functional benefits of donepezil in alzheimer s disease and vascular dementia results from large scale clinical trials	2005	-0.2144	0.1375	11	3.092
2072303299	efficacy and comparative effectiveness of atypical antipsychotic medications for off label uses in adults a systematic review and meta analysis	2011	0.1441	0.0526	80	0.9804
2072349836	attenuation of neuropsychiatric symptoms and caregiver burden in alzheimer s disease by motor intervention a controlled trial	2011	0.1351	-0.0723	93	0.7691
2072378658	cerebrolysin in vascular dementia a randomized placebo controlled study	2009	-0.411	0.0798	51	0.6856
2072511042	olanzapine in the treatment of dopamimetic induced psychosis in patients with parkinson s disease	2002	-0.1414	0.1648	114	1.685
2072525898	clinical trials in dementia with propentofylline	1997	-0.4129	0.0253	85	21.1334
2072572422	behavioral and endocrinological evaluation of music therapy for elderly patients with dementia	2004	0.3276	-0.0394	21	4.6986
2072595095	effects of different kinds of couple interaction on cortisol and heart rate responses to stress in women	2007	0.5917	-0.0633	123	0.916
2072755194	p3b versus p3a an event related potential investigation of the glucose facilitation effect	2008	-0.4598	1.8033	96	0.845
2072838342	walking and dementia in physically capable elderly men	2004	0.5514	-0.226	27	0.8843
2072886974	prevalence and covariates of subjective forgetfulness in a normal population in the netherlands	1997	0.4859	-0.2694	4	0.9713
2072965218	central cholinergic activity in alzheimer dementia	1980	-0.3309	0.2597	59	0.7713
2072966055	the natural history of cadasil a pooled analysis of previously published cases	1999	-0.4493	-0.0028	12	0.9992
2073012124	effectiveness of the number consonant mnemonic for retention of numeric material in community dwelling older adults	1997	0.5087	-0.2822	4	0.7993
2073050566	the effect of drugs for alzheimer disease assessed by means of neuroradiological techniques	2006	-0.295	0.0288	57	0.6964
2073122380	memory skills training memory complaints and depression in older adults	1985	0.5094	-0.2848	4	3.7434
2073220057	long term and high dose piracetam treatment of alzheimer s disease	1993	-0.3066	0.2473	15	22.3604
2073326226	a study on the rehabilitation of cognitive function and short term memory in patients with alzheimer s disease using transcutaneous electrical nerve stimulation	2001	0.2064	-0.0071	17	0.8164
2073442736	cognitive improvement after treatment with second generation antipsychotic medications in first episode schizophrenia is it a practice effect	2007	-0.2409	0.1654	9	0.7228
2073448856	a controlled clinical trial of sertraline in the treatment of depression in nursing home patients with late stage alzheimer s disease	2000	0.2156	0.0802	31	10.425
2073449985	staging of brain pathology related to sporadic parkinson s disease	2003	-0.1867	0.0924	7	2.75
2073542300	clinical improvement and tolerability is maintained long term in elderly patients with psychotic disorders treated with quetiapine	1999	0.6164	0.4438	40	0.7522
2073542411	22 high dose nicergoline in senile mental impairment a multicentre double blind placebo controlled study	1987	-0.411	0.0798	51	0.6894
2073550498	huperzine a for alzheimer s disease a systematic review and meta analysis of randomized clinical trials	2013	-0.5779	-0.1503	32	0.9804
2073559354	treatment effects of therapeutic cholinesterase inhibitors on visuospatial processing in alzheimer s disease a longitudinal functional mri study	2010	-0.2817	0.1568	43	0.6856
2073609930	long term observation of a multicomponent cognitive intervention in mild cognitive impairment	2012	0.1983	-0.1081	10	0.9804
2073640827	add back estrogen reverses cognitive deficits induced by a gonadotropin releasing hormone agonist in women with leiomyomata uteri	1996	-0.7623	-0.7687	3	1
2073757992	neuropsychiatric function and dehydroepiandrosterone sulfate in elderly women a prospective study	1998	-1.4201	-1.8405	20	1
2073785519	an investigation of long term effects of group music therapy on agitation levels of people with alzheimer s disease	2007	0.4711	-0.0536	21	4.9507
2073888790	donepezil treatment in ethnically diverse patients with alzheimer disease	2015	-0.0595	0.0836	58	0.7716
2073909805	adenosine and propentofylline inhibit the proliferation of cultured microglial cells	1996	-0.4137	0.0257	85	0.9584
2073928305	mri hyperintensities of the temporal lobe and external capsule in patients with cadasil	2001	-0.45	-0.0021	12	0.9988
2073955070	effects of a high intensity functional exercise programme on depressive symptoms and psychological well being among older people living in residential care facilities a cluster randomized controlled trial	2010	0.482	-0.1431	60	17.7949
2074028393	the effectiveness of validation therapy in dementia a pilot study	1991	0.4389	-0.07	18	0.845
2074054937	dehydroepiandrosterone dhea and dhea sulfate dheas protect hippocampal neurons against excitatory amino acid induced neurotoxicity	1998	-1.4242	-1.8447	20	1.9984
2074077957	protective effects of steroids in cardiac surgery a meta analysis of randomized double blind trials	2011	2.5491	-0.0689	35	0.7879
2074085250	a comparison of the efficacy of donepezil in parkinson s disease with dementia and dementia with lewy bodies	2005	-0.1886	0.0705	7	0.7549
2074113392	effect of donepezil on motor and cognitive function in huntington disease	2006	-0.2279	-0.1455	112	22.078
2074157265	sertraline augmentation reduces behavioral symptoms in outpatients with alzheimer s disease treated with donepezil	2002	-0.2183	0.1414	11	15.6048
2074209215	galantamine in frontotemporal dementia and primary progressive aphasia	2008	-0.2359	0.258	66	22.7494
2074227168	a comparison of two treatments of agitated behavior in nursing home residents with dementia simulated family presence and preferred music	2007	0.4658	-0.0504	21	21.6532
2074249519	type 2 diabetes apoe gene and the risk for dementia and related pathologies the honolulu asia aging study	2002	-0.4457	1.587	56	1
2074364602	a prospective open label randomized comparative study in alzheimer s disease between two commonly used drugs in coastal indian population	2015	-0.1971	0.1158	92	0.7121
2074378860	melatonin for treatment and prevention of postoperative delirium	2002	2.1407	-0.0417	2	1.8842
2074396582	the effect of bispectral index monitoring on long term survival in the b aware trial	2010	2.2191	-0.038	36	1.7991
2074403761	habituation of exploratory activity in mice effects of combinations of piracetam and choline on memory processes	1984	-0.2986	0.2134	15	0.7993
2074526259	risk factors for postoperative delirium after colorectal surgery for carcinoma	2009	2.7899	-0.0532	118	0.8393
2074607173	risperidone for aids associated dementia a case series	1996	0.5556	0.3927	40	1.5303
2074661113	piracetam in alcoholic organic mental disorder a placebo controlled study comparing two dosages	1986	-0.1547	0.2293	15	13.1908
2074723799	caregiver activity on respite and nonrespite days a comparison of two service approaches	1991	0.6854	-0.1437	97	0.75
2074740395	the ginkgo biloba extract egb 761 rescues the pc12 neuronal cells from ?? amyloid induced cell death by inhibiting the formation of ?? amyloid derived diffusible neurotoxic ligands	2001	-0.4383	-0.0869	8	0.9973
2074742396	frontotemporal dementia treatment response to serotonin selective reuptake inhibitors	1997	-0.2573	0.2382	66	3.5
2074751399	a beneficial effect of estrogen on working memory in postmenopausal women taking hormone replacement therapy	2000	-0.7604	-0.7657	3	1
2074759665	the striatal dopamine dependency of life span in male rats longevity study with deprenyl	1988	-0.1873	0.1192	37	0.9959
2074773055	the systemic inflammatory response to cardiac surgery implications for the anesthesiologist	2002	2.5491	-0.0689	35	0.8843
2074829442	apoe4 allele disrupts resting state fmri connectivity in the absence of amyloid plaques or decreased csf a??42	2010	-0.2503	0.1374	22	0.9404
2074860531	post operative delirium predictors and prognosis in elderly orthopedic patients	1992	2.2086	-0.0403	36	1.9973
2074928222	the effects of regular exercise on muscle strength and functional abilities of late stage alzheimer s residents	1997	0.501	-0.1755	25	20.8954
2075032507	an educational intervention to support caregivers of elders with dementia	2008	0.6788	-0.1499	75	0.8097
2075319693	the effect of improved glycemic control on cognitive functions in the elderly patient with diabetes	1993	-0.4425	1.5571	56	0.9867
2075325590	a double blind evaluation of hydergine and placebo in the treatment of patients with organic brain syndrome and cerebral arteriosclerosis in a nursing home	1974	-0.2866	0.1017	41	0.9804
2075373003	docosahexaenoic acid concentrated fish oil supplementation in subjects with mild cognitive impairment mci a 12 month randomised double blind placebo controlled trial	2013	-1.0334	-0.2802	5	3.6839
2075399513	effects of riboflavin and folic acid supplementation on plasma homocysteine levels in healthy subjects	2006	-1.9284	0.3325	109	0.7236
2075478727	pharmacological treatment of neuropsychiatric symptoms of dementia a review of the evidence	2005	0.2085	0.0601	16	28.3228
2075482140	multiple antioxidants in the prevention and treatment of alzheimer disease analysis of biologic rationale	2000	-1.5747	-1.2603	101	0.7993
2075511654	effect of olanzapine on cognition during treatment of behavioral and psychiatric symptoms in patients with dementia a post hoc analysis	2008	0.0289	0.1124	38	0.8434
2075532156	tacrine treatment modifies cerebrospinal fluid neuropeptide levels in alzheimer s disease	1994	0.0571	0.5351	48	0.6016
2075563350	a randomized double blind placebo controlled trial of nutritional supplementation during acute illness	2006	-0.9263	-0.257	79	0.7437
2075568717	testosterone improves spatial memory in men with alzheimer disease and mild cognitive impairment	2005	-0.6617	-0.6497	62	1.6989
2075570192	the effect of staff training on the use of restraint in dementia a single blind randomised controlled trial	2005	0.8131	-0.0987	42	24.5855
2075764716	combined rcbf and csf biomarkers predict progression from mild cognitive impairment to alzheimer s disease	2009	-0.2942	0.0285	57	0.6847
2075960947	a comparative study of psychiatric symptoms in dementia with lewy bodies and parkinson s disease with and without dementia	2001	-0.1921	0.122	7	0.991
2076048188	diffusion of docosahexaenoic and eicosapentaenoic acids through the blood brain barrier an in situ cerebral perfusion study	2009	-1.0105	-0.2751	5	0.916
2076097665	a systematic review of networked technologies supporting carers of people with dementia	2008	0.5297	-0.1169	1	1.7707
2076134487	does daily vitamin d 800 iu and calcium 1000 mg supplementation decrease the risk of falling in ambulatory women aged 65 71 years a 3 year randomized population based trial ostpre fps	2010	-0.9263	-0.257	79	0.7254
2076150166	selegiline and cognitive function in parkinson s disease	1991	-0.2237	0.1802	9	2.9828
2076174160	effect of respite care on dementia and nondementia patients and their caregivers	1988	0.5752	-0.1194	1	1
2076206556	a1 adenosine receptor upregulation and activation attenuates neuroinflammation and demyelination in a model of multiple sclerosis	2004	-0.4858	0.0852	117	0.75
2076228483	toxicity of synthetic a?? peptides and modeling of alzheimer s disease	1992	-1.0873	-0.5741	69	0.6795
2076325467	the study on cognition and prognosis in the elderly scope outcomes in patients not receiving add on therapy after randomization	2004	-0.7123	-0.1353	14	19.9304
2076327464	the memory function of sleep	2010	0.1281	0.0261	28	0.8843
2076334107	inverse association of anti inflammatory treatments and alzheimer s disease initial results of a co twin control study	1994	-0.414	-0.0404	32	1
2076385557	absence of ketamine effects on memory and other cognitive functions in schizophrenic patients	1996	0.0183	0.3851	48	0.642
2076399831	meniere s disease lithium treatment demonstration of placebo effect in a doubleblind cross over trial	1979	-0.411	0.0798	51	0.6556
2076675855	the effect of omega 3 fatty acid supplementation on oxidative stress in continuous ambulatory peritoneal dialysis patients	2014	-1.1801	-0.326	129	0.7598
2076676029	a 52 week study of the efficacy of rivastigmine in patients with mild to moderately severe alzheimer s disease	2000	-0.2293	0.0427	6	11.5743
2076711341	quantitative eeg in the prediction of antidepressant response to imipramine	1996	-0.4384	0.3662	90	0.6673
2076711936	saido learning as a cognitive intervention for dementia care a preliminary study	2015	0.5122	-0.1606	60	0.6857
2076737355	the effects of blood pressure reduction on cognitive function a review of effects based on pooled data from clinical trials	2006	-0.6781	-0.1152	14	0.845
2076811752	a double blind placebo controlled cross over trial of adjunctive donepezil for cognitive impairment in schizophrenia	2004	-0.2259	0.1652	9	2.0944
2076869262	the analgesic effect of morphine on postoperative pain in diabetic patients	2004	2.3864	-0.0463	130	0.8661
2076882085	p 5 a 003 risperidone vs haloperidol in treatment of delirium superimposed on dementia	2008	0.5483	0.3861	40	0.7368
2076965707	use of statins and incidence of dementia and cognitive impairment without dementia in a cohort study	2009	-0.7158	-0.1679	29	4.9954
2077019488	the ascomalva trial association between the cholinesterase inhibitor donepezil and the cholinergic precursor choline alphoscerate in alzheimer s disease with cerebrovascular injury interim results	2012	-0.2158	0.1405	11	1.4986
2077165909	p01 98 does serotonin augmentation have any effect on cognition and activities of daily living in alzheimer s dementia a double blind clinical trial	2009	-0.0705	0.1891	61	1.6596
2077174214	nicotine patches in alzheimer s disease pilot study on learning memory and safety	1995	0.0301	0.4334	48	1.6831
2077204397	ginkgo biloba did not prevent dementia or alzheimer disease in elderly people	2009	-0.3985	0.0305	53	0.7287
2077328743	immediate and long term mental recovery from general versus epidural anesthesia in elderly patients	1983	2.217	-0.0392	36	1
2077354947	cognitive and behavioral effects of quetiapine in alzheimer disease patients	2002	-0.1501	0.1196	44	0.7512
2077366051	computer based cognitive training for mild cognitive impairment results from a pilot randomized controlled trial	2009	0.2069	-0.1227	10	2
2077531153	the safety and lack of efficacy of vinpocetine in alzheimer s disease	1989	-0.3068	0.128	23	0.9867
2077625499	the impact of post operative pain on outcomes following hip fracture	2003	2.2485	-0.0454	138	0.9584
2077633683	donepezil for dementia in parkinson s disease a randomised double blind placebo controlled crossover study	2005	-0.1795	0.1105	7	29.3575
2077710671	a pilot randomized trial comparing symptomatic vs hemoglobin level driven red blood cell transfusions following hip fracture	1998	2.566	-0.0494	125	0.7993
2077725073	high prevalence of cobalamin deficiency in elderly outpatients	1992	-0.9233	-0.1078	30	0.9973
2077753352	fifteen year comparison of antipsychotic use in people with dementia within hospital and nursing home settings sequential cross sectional study	2010	0.9833	-0.0254	24	0.717
2077789483	long term treatment for patients with alzheimer disease	2004	-0.3263	0.1913	22	1.6199
2077818780	p 3 c 010 severity of negative symptoms in schizophrenic patients treated with atypical neuroleptic risperidone follow up	2009	0.104	0.1382	38	0.7047
2077887798	delayed onset of action of antidepressant drugs survey of recent results	1997	-0.293	0.0998	41	0.6592
2077893977	a controlled study of 2 doses of idebenone in the treatment of alzheimer s disease	1997	-0.3333	0.0923	51	0.6177
2078122061	remoxipride versus thioridazine in elderly psychotic patients	1990	0.1083	0.116	47	1.4042
2078146183	chronic oral physostigmine without lecithin improves memory in alzheimer s disease	1989	-0.3142	0.1839	13	24.2902
2078276663	organic brain syndrome treated with oxiracetam a double blind randomized controlled trial	1987	-0.3936	-0.2409	62	0.6985
2078303139	raloxifene and cardiovascular events in osteoporotic postmenopausal women four year results from the more multiple outcomes of raloxifene evaluation randomized trial	2002	-0.5188	-0.0906	68	0.7147
2078349288	aspirin for the prevention of cardiovascular events in patients with peripheral artery disease a meta analysis of randomized trials	2009	-0.5184	-0.0899	68	0.7083
2078362009	a phase iii randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients	2001	-0.4003	-0.2667	62	0.8843
2078417280	a 24 week randomized double blind placebo controlled study to evaluate the efficacy safety and tolerability of the rivastigmine patch in japanese patients with alzheimer s disease	2011	-0.2435	0.0583	19	16.077
2078608845	using simulated presence therapy with people with dementia	2002	0.4772	-0.0464	21	1.9777
2078664322	sertraline treatment of elderly patients with depression and cognitive impairment	2003	-0.2975	-0.2456	49	0.6974
2078678859	locus of control and alcohol placebo effects on performance in a driving simulator	1991	-0.3865	0.3792	98	0.7046
2078753627	severe alzheimer s responds to donepezil	2006	-0.3222	0.1162	33	1.6435
2078771872	differential effects of rivastigmine galantamine and donepezil on behavioral and psychological symptoms in patients with alzheimer s disease 18 month randomized open label trial	2005	-0.2175	0.1416	11	0.7496
2078786268	pilot randomized trial of donepezil hydrochloride for delirium after hip fracture	2011	2.1953	-0.0432	2	20.7075
2078788682	the effect of two types of memory training on subjective and objective memory performance in healthy individuals aged 55 years and older a randomized controlled trial	2005	0.4853	-0.2684	4	19.5693
2078790185	a placebo controlled trial of d cycloserine added to conventional neuroleptics in patients with schizophrenia	1999	-0.2983	0.1892	43	1.9826
2078869187	persons with moderate alzheimer s disease improve activities and mood via instruction technology	2009	0.512	-0.1989	25	0.991
2078922217	effect of memantine on behavioral outcomes in alzheimer s disease	2005	-0.3146	0.1729	22	0.8349
2078929060	interaction between cognitive impairment and discharge destination and its effect on rehospitalization	2013	2.1047	-0.0879	26	0.7387
2078959212	novel uses for risperidone focus on depressive anxiety and behavioral disorders	2007	0.5475	0.3864	40	0.7195
2079072785	the effects of muscle extractrj on the oxidation of pnlmitic acid by liver slices and homogenates1	1955	-0.2863	0.03	63	0.75
2079092754	caregiver identified needs and barriers to care in parkinson s disease	2015	0.5963	-0.1335	131	0.7032
2079183773	docosahexaenoic acid supplementation and cognitive decline in alzheimer disease a randomized trial	2010	-1.0162	-0.2733	5	38.7713
2079200242	effects of long term donepezil therapy on rcbf of alzheimer s patients	2002	-0.2096	0.1081	57	1.7496
2079322258	melatonin effects on sleep mood and cognition in elderly with mild cognitive impairment	1998	0.2463	-0.0165	28	1.9999
2079361340	visual cognitive potentials in patients with alzheimer disease and memantine medication	2008	-0.3896	0.2435	22	2.4867
2079399686	depressive symptom deterioration in a large primary care based elderly cohort	2006	0.4586	0.2348	116	0.7522
2079406147	antagonic stress superiority versus meclofenoxate in gerontopsychiatry alzheimer type dementia	1994	-0.417	0.0419	41	0.6868
2079443593	syncope and its consequences in patients with dementia receiving cholinesterase inhibitors a population based cohort study	2009	-0.1809	0.065	6	1.9958
2079450463	aging and everyday memory the beneficial effect of memory training	2003	0.4946	-0.2756	4	1.6885
2079490962	cholinergic correlates of cognitive impairment in parkinson s disease comparisons with alzheimer s disease	1985	-0.1829	0.1098	7	0.9992
2079637016	modulation of cognition specific cortical activity by gonadal steroids a positron emission tomography study in women	1997	-0.7579	-0.7651	3	2
2079645363	long term use of rivastigmine in patients with dementia with lewy bodies an open label trial	2001	-0.1922	0.1068	7	3.751
2079661979	reaction and movement time as a function of age and physical activity level	1975	0.5785	-0.25	27	1.9859
2079662917	assessing the impact of neuropsychiatric symptoms in alzheimer s disease the neuropsychiatric inventory caregiver distress scale	1998	-0.1977	0.0752	44	0.8843
2079709354	glucose enhancement of human memory a comprehensive research review of the glucose memory facilitation effect	2011	-0.4598	1.8033	96	0.9804
2079722596	treatment of alzheimer s disease with clioquinol	2001	-1.0501	-0.5493	69	1.7298
2079760995	effects of ginseng saponins on responses induced by various receptor stimuli	1999	-0.6539	-0.1204	65	0.9959
2079782667	measurement of depression comparison between self reports and clinical assessments of depressed outpatients	1991	0.2621	0.0262	31	0.7767
2079889678	three in one femoral nerve block as analgesia for fractured neck of femur in the emergency department a randomized controlled trial	2003	2.2485	-0.0454	138	0.9713
2079921496	behavioral benefits of trazodone are sustained for the long term in frontotemporal dementia	2006	-0.231	0.2448	66	14.7507
2079924484	acetyl 1 carnitine 2 effects on learning and memory performance of aged rats in simple and complex mazes	1990	-0.327	-0.0232	63	0.75
2079959894	after reaching retirement age physical activity sustains cerebral perfusion and cognition	1990	0.5825	-0.2513	27	0.9982
2079971865	effects of routine monitoring of delirium in a surgical trauma intensive care unit	2013	2.566	-0.0494	125	0.7698
2079999732	memory for music in alzheimer s disease unforgettable	2009	0.4818	-0.0543	21	0.9959
2080043284	a controlled trial of a nursing centered intervention in hospitalized elderly medical patients the yale geriatric care program	1993	2.1135	-0.0877	26	1.4755
2080043975	effects of memory training on the subjective memory functioning and mental health of older adults a meta analysis	1997	0.5012	-0.2793	4	3.7975
2080112585	mnemonic training in older adults effects of age length of training and type of cognitive pretraining	1999	0.5079	-0.2826	4	0.845
2080163186	lecithin in alzheimer s disease	1982	-0.3311	0.2607	59	0.8653
2080167959	adverse effects of reality orientation	1989	0.3324	-0.0909	10	1.9673
2080285331	assessment of role of perioperative melatonin in prevention and treatment of postoperative delirium after hip arthroplasty under spinal anesthesia in the elderly	2010	2.1708	-0.0427	2	3.9847
2080291124	donepezil effective in vascular dementia	2002	-0.3243	0.1121	33	0.9266
2080291833	rivastigmine in alzheimer disease efficacy over two years	2004	-0.2326	0.2003	55	0.8516
2080406649	273 long chain n 3 polyunsaturated fatty acids lcn3pufa eicosapentaenoic acid epa and docosahexaenoic acid dha modulate human thp 1 macrophage cholesterol levels	2011	-1.1026	-0.3016	5	0.8113
2080435650	behavioral treatment of chronic depression in an elderly nursing home resident	1986	0.4399	-0.0044	104	0.8164
2080437369	op60 efficacy and safety of liraglutide versus placebo in subjects with type 2 diabetes and moderate renal impairment lira renal a randomised trial	2014	-0.411	0.0798	51	0.681
2080463235	activities of daily living in moderate to severe alzheimer disease an analysis of the treatment effects of memantine in patients receiving stable donepezil treatment	2006	-0.1758	0.0637	6	22.3917
2080477464	a transdermal patch in alzheimer disease	2007	-0.2805	0.1045	133	0.699
2080523691	rehabilitation of executive functioning in patients with frontal lobe brain damage with goal management training	2011	0.4797	-0.2652	4	0.9988
2080556648	a prospective randomized controlled trial of sedation vs no sedation in outpatient diagnostic upper gastrointestinal endoscopy	1998	2.345	0.1894	103	0.7076
2080581772	physical restraint use and falls in nursing home residents	1996	0.8432	-0.1021	42	1
2080619425	dementia case management effectiveness on health care costs and resource utilization a systematic review of randomized controlled trials	2010	0.5519	-0.1152	74	6.6554
2080625627	quantitative electroencephalography power and coherence in alzheimer s disease and mild cognitive impairment	1996	-0.2809	0.1571	43	0.7071
2080696532	efficacy of antipsychotics in the treatment of the behavioral complications of dementia a review of the literature	1985	0.1214	0.0989	47	1.7992
2080702082	effect of resistance type exercise training with or without protein supplementation on cognitive functioning in frail and pre frail elderly secondary analysis of a randomized double blind placebo controlled trial	2014	0.538	-0.2242	136	0.9404
2080780832	long term lithium treatment reduces glucose metabolism in the cerebellum and hippocampus of nondemented older adults an f fdg pet study	2014	-0.3852	0.1417	134	0.6157
2080781505	loss of m2 muscarine receptors in the cerebral cortex in alzheimer s disease and experimental cholinergic denervation	1985	-0.3141	0.2056	13	0.9867
2080856702	p03 127 galantamine in long term treatment formild cognitive impairment efficacy and safety	2011	-0.289	0.2822	9	0.6402
2080951915	impairments in glucose tolerance can have a negative impact on cognitive function a systematic research review	2009	-0.4598	1.8033	96	0.916
2081033553	clarifying confusion the confusion assessment method a new method for detection of delirium	1990	2.2454	-0.0373	2	26.877
2081069399	a comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia	2002	0.6426	0.1008	91	0.75
2081226082	a randomized controlled trial of rivastigmine for chronic sequels of traumatic brain injury what it showed and taught	2009	-0.8474	1.0199	71	0.9713
2081230993	p 8 23 similarities in cognitive impairment profiles between mild dementia of alzheimer type and biperiden anticholinergic agent induced cognitive dysfunction	1995	-0.8148	0.8226	102	0.6621
2081254651	rivastigmine in parkinson s disease dementia profile report	2007	-0.2795	0.1044	133	0.7515
2081285591	the effects of donepezil in alzheimer s disease results from a multinational trial	1999	-0.2144	0.0488	6	37.1796
2081367472	the safety of 52 weeks of oral dhea therapy for postmenopausal women	2009	-1.4117	-1.8491	20	0.8227
2081380916	can multidisciplinary guidelines improve the palliation of symptoms in the terminal phase of dementia	2002	0.8533	-0.0193	95	0.9404
2081402812	bright light therapy improved sensitivity to its effects on rest activity rhythms in alzheimer patients by application of nonparametric methods	1999	0.2411	-0.0129	17	0.9713
2081499705	predicting gains in dementia caregiving	2010	0.6788	-0.15	75	0.8167
2081586704	a cholesterol lowering drug reduces ?? amyloid pathology in a transgenic mouse model of alzheimer s disease	2001	-0.7228	-0.1679	29	2
2081612639	treatment of multi infarct dementia with citicholine	1992	-0.2977	-0.2464	49	0.75
2081678712	glycine potentiates the nmda response in cultured mouse brain neurons	1987	-0.2979	0.1886	43	1.9744
2081719666	silent myocardial ischaemia and haemoglobin concentration a randomized controlled trial of transfusion strategy in lower limb arthroplasty	2006	2.566	-0.0494	125	0.7993
2081871381	the use of ginkgo biloba extract in acute ischemic stroke	2006	-0.375	-0.0366	70	0.6727
2081898812	effect of postmenopausal hormone therapy on cognitive function the heart and estrogen progestin replacement study	2002	-0.7356	-0.7425	3	7.8773
2081957327	caregivers perceptions of a consumer directed care program for adults with developmental disabilities	2010	0.6861	-0.1443	97	0.6719
2082019353	a psychometric comparison of the calgary depression scale for schizophrenia and the hamilton depression rating scale	1996	0.2621	0.0262	31	0.7705
2082027359	stories as a mnemonic aid for older learners	1991	0.5073	-0.281	4	18.7637
2082308907	p1 208 randomized placebo controlled trial of memantine for dementia in parkinson s disease	2009	-0.4986	-0.0334	12	1.4944
2082311304	effect of sedation with dexmedetomidine vs lorazepam on acute brain dysfunction in mechanically ventilated patients the mends randomized controlled trial	2007	2.2346	-0.0473	2	23
2082355424	effectiveness and safety of mlc601 in the treatment of mild to moderate alzheimer s disease a multicenter randomized controlled trial	2015	-0.2332	0.0392	72	0.8047
2082395445	training in dementia care a cluster randomized controlled trial of a training program for nursing home staff in germany	2009	0.7754	-0.0951	42	0.9404
2082400786	p 5 a 010 the effect of memantine on distinct behaviour syndromes in moderate to severe alzheimer s disease patients	2006	-0.3144	0.1739	22	0.7877
2082466535	pharmacokinetics of iv and oral acetyl l carnitine in a multiple dose regimen in patients with senile dementia of alzheimer type	1992	-0.3157	0.0064	63	1.9155
2082471028	treatment for alzheimer s disease	2000	-0.3245	0.1979	22	0.7447
2082492977	donepezil in the treatment of hallucinations and delusions in parkinson s disease	2002	-0.1815	0.1102	7	2
2082611067	restricted participation in stroke caregivers who is at risk	2015	0.6791	-0.1508	75	0.792
2082625658	efficacy and tolerance of vinpocetine in ambulant patients suffering from mild to moderate organic psychosyndromes	1991	-0.3056	0.1266	23	19.2823
2082642573	a substudy protocol of the hypertension in the very elderly trial assessing cognitive decline and dementia incidence hyvet cog an ongoing randomised double blind placebo controlled trial	2006	-0.6764	-0.1157	14	18.037
2082648762	17 ?? estradiol protects neurons from oxidative stress induced cell death in vitro	1995	-0.7647	-0.7717	3	0.9999
2082649626	novel docosatrienes and 17s resolvins generated from docosahexaenoic acid in murine brain human blood and glial cells autacoids in anti inflammation	2003	-1.1085	-0.3042	5	0.9867
2082758978	no effect of vitamin b 12 treatment on cognitive function and depression a randomized placebo controlled study	2004	-0.8781	-0.1044	30	23.7874
2082819195	differences in medication use in the alzheimer s disease neuroimaging initiative analysis of baseline characteristics	2010	-0.3141	0.0962	50	0.6469
2082859192	analysis of the effects of selegiline l deprenyl on memory in alzheimer s disease using sternberg s paradigm	1994	-0.5483	0.398	73	13.9969
2082914293	exercise plus behavioral management in patients with alzheimer disease a randomized controlled trial	2003	0.4518	-0.1295	25	45.7034
2082927421	gabapentin and postoperative pain a systematic review of randomized controlled trials	2006	2.2251	-0.0433	2	0.9992
2082945747	sleep disorders in alzheimer s disease and other dementias	2004	0.1281	0.0261	28	0.9584
2082950861	neuropsychological effects of l deprenyl in alzheimer s type dementia	1990	-0.1879	0.119	37	27.1752
2082987115	switching from donepezil tablets to rivastigmine transdermal patch in alzheimer s disease	2009	-0.256	0.0511	72	0.8304
2083019740	vitamin b6 b12 and folic acid supplementation and cognitive function a systematic review of randomized trials	2007	-0.8677	-0.1044	30	1.9713
2083064255	dehydroepiandrosterone antagonizes the neurotoxic effects of corticosterone and translocation of stress activated protein kinase 3 in hippocampal primary cultures	1999	-1.4241	-1.8447	20	1.9989
2083075014	a further exploration of the use of physical restraints in hospitalized patients	1989	0.8432	-0.1021	42	0.9999
2083220625	predictors of nursing home placement in parkinson s disease a population based prospective study	2000	-0.1733	0.1259	7	1
2083289731	double blind study of tiapride versus haloperidol and placebo in agitation and aggressiveness in elderly patients with cognitive impairment	2000	0.1652	0.0874	16	19.6359
2083322904	intravenous and subcutaneous dialysis monitoring of levodopa and 3 o methyldopa during constant rate intravenous infusion of levodopa	1990	-0.6082	0.5205	119	0.6168
2083333713	bis guided anesthesia decreases postoperative delirium and cognitive decline	2013	2.1992	-0.038	36	20.9939
2083338868	an open label dose ranging study of atomoxetine in children with attention deficit hyperactivity disorder	2001	-0.9922	1.2607	71	0.7718
2083401617	meta analysis of 6 month memantine clinical trials in alzheimer s disease	2005	-0.5169	-0.0473	12	0.7672
2083413158	p01 503 rationale for combination therapy with galantamine and memantine in alzheimer s disease the efficacy of treatment of addition	2011	-0.1907	0.1284	11	0.722
2083500052	copper iron and zinc in alzheimer s disease senile plaques	1998	-1.0099	-0.5237	69	1
2083556882	nonsteroidal antiinflammatory drugs and the risk of alzheimer s disease	2001	-0.4268	-0.076	32	7.9974
2083604329	comparison of evidence based interventions on outcomes of hospitalized cognitively impaired older adults	2014	2.1132	-0.0875	26	1.482
2083612258	neurobehavioral effects of phenytoin and carbamazepine in patients recovering from brain trauma a comparative study	1994	0.1419	0.0443	58	0.6983
2083634661	late onset depression with mild cognitive deficits electrophysiological evidences for a preclinical dementia syndrome	2004	-0.2001	0.0881	78	0.6714
2083665247	a metaanalysis of controlled trials of neuroleptic treatment in dementia	1990	0.2029	0.0794	16	26.095
2083677744	effects of two year treatment with the cholinesterase inhibitor rivastigmine on behavioural symptoms in alzheimer s disease	1999	-0.1525	0.0601	44	19.9546
2083678323	an open labeled multicentered observational study for the tolerability of rivastigmine transdermal patch for korean patients with alzheimer s disease	2010	-0.2438	0.0582	19	0.7807
2083720407	morphine is a reasonable alternative to haloperidol in the treatment of postoperative hyperactive type delirium after cardiac surgery	2013	2.2245	-0.0442	2	15.997
2083733754	ginkgo biloba extract protects brain neurons against oxidative stress induced by hydrogen peroxide	1996	-0.4313	-0.0431	8	0.9939
2083811803	efficacy of hand massage in decreasing agitation behaviors associated with care activities in persons with dementia	1995	0.4489	-0.0393	21	0.991
2083890032	maintenance of gains following multifactorial and unifactorial memory training in late adulthood	1993	0.5073	-0.2842	4	2.8414
2083915028	effects of multi sensory stimulation for people with dementia	2003	0.4204	-0.0769	18	22.7865
2083924947	a randomised controlled trial to compare the cost effectiveness of tricyclic antidepressants selective serotonin reuptake inhibitors and lofepramine	2005	0.103	0.1503	61	0.7145
2083927782	behavioural intervention for dysphagia in acute stroke a randomised controlled trial	2006	2.3691	-0.0643	35	0.7184
2083990390	long term consequences of postoperative cognitive dysfunction	2009	2.2027	-0.0374	36	1
2084000331	randomized double blind placebo controlled multicentre study of idebenone in patients suffering from multi infarct dementia	1992	-0.2977	0.0512	23	0.6491
2084023433	further testing of limits of cognitive plasticity negative age differences in a mnemonic skill are robust	1992	0.5068	-0.2839	4	0.9939
2084085323	calcium antagonists and multi infarct dementia a trial involving sequential nmr and psychometric assessment	1988	-0.4469	-0.0016	12	1.251
2084092435	responses of chronic schizophrenic females to a combination of diphenylhydantoin and neuroleptics a double blind study	1975	0.1304	0.1286	47	0.6986
2084112126	reality orientation for geriatric patients	1966	0.3014	-0.0912	10	2.9391
2084134332	the memory enhancing effects of a ginkgo biloba panax ginseng combination in healthy middle aged volunteers	2000	-0.5793	-0.0956	65	1.9427
2084143358	from molecular structure to alzheimer therapy	1997	-1.0873	-0.5741	69	0.6927
2084206292	dementia with lewy bodies	2014	-0.1375	0.2003	100	0.7496
2084247881	a double blind placebo controlled ascending dose randomized study to evaluate the safety tolerability and effects on cognition of al 108 after 12 weeks of intranasal administration in subjects with mild cognitive impairment	2013	-0.289	0.2822	9	0.6613
2084254617	exercise and physical activity for older adults	2009	0.4764	-0.1371	60	1.7439
2084284910	memantine for aids dementia complex open label report of actg 301	2010	-0.3997	0.5	87	20.5966
2084310209	occupational therapy and dementia the experience of an alzheimer special care unit	2007	0.5272	-0.0877	34	0.6804
2084399566	dose dependent csf acetylcholinesterase inhibition by sdz ena 713 in alzheimer s disease	2009	-0.2806	0.1134	13	0.75
2084511166	mechanical restraint use and fall related injuries among residents of skilled nursing facilities	1992	0.8435	-0.1027	42	1
2084522339	comparison of three rating scales as outcome measures for treatment trials of depression in alzheimer disease findings from diads	2006	0.2611	0.0261	31	16.761
2084536171	fluoxetine addition to risperidone in adult psychotic patients pharmacokinstic and clinical consequences	1998	0.5483	0.3861	40	0.7049
2084544735	a preferred music listening intervention to reduce anxiety in older adults with dementia in nursing homes	2010	0.473	-0.0535	21	4.9123
2084561734	comparison of olanzapine and risperidone in the treatment of psychosis and associated behavioral disturbances in patients with dementia	2005	0.1832	0.0921	16	22.792
2084565575	moclobemide in elderly patients with cognitive decline and depression an international double blind placebo controlled trial	1996	0.2077	0.0883	31	7.9375
2084569379	glucose intolerance hyperinsulinaemia and cognitive function in a general population of elderly men	1995	-0.4458	1.587	56	0.9999
2084710831	efficacy and safety of galantamine treatment for patients with alzheimer s disease a meta analysis of randomized controlled trials	2015	-0.3723	-0.0207	70	1.3471
2084755756	a randomized clinical trial of cpi 1189 for hiv associated cognitive motor impairment	2002	-0.3999	0.502	87	0.9804
2084794623	cognitive impairment in alzheimers disease and schizophrenia	1998	-0.5194	0.3697	73	0.7669
2084809543	reductions in qeeg slowing over 1 year and after treatment with cerebrolysin in patients with moderate severe traumatic brain injury	2008	-0.3335	0.005	70	0.8007
2084820245	mibampator ly451395 randomized clinical trial for agitation aggression in alzheimer s disease	2013	-0.1258	0.0955	11	0.7551
2084946993	a novel approach to the prevention of postoperative delirium in the elderly after gastrointestinal surgery	2002	2.1971	-0.0431	2	21.8424
2084973227	a double blind placebo controlled multicenter study of cerebrolysin for alzheimer s disease	2000	-0.3335	0.005	70	0.7993
2085016110	reduction of phosphorylated tau during memantine treatment of alzheimer s disease	2007	-0.1848	0.1075	6	0.916
2085027326	survival in frontotemporal dementia	2003	-0.2321	0.2564	66	1
2085115322	administration of d alpha tocopherol in patients with insulin dependent diabetes mellitus	1996	-1.2104	-0.3345	128	0.6713
2085252187	applicability and effects of physical exercise on physical and cognitive functions and activities of daily living among people with dementia a systematic review	2011	0.4918	-0.1933	25	0.9713
2085302169	monoamine oxidase inhibitors as treatment for depressed patients with primary degenerative dementia alzheimer??s disease	1985	-0.1954	0.1513	37	0.8128
2085397388	what happens when donepezil is suddenly withdrawn an open label trial in dementia with lewy bodies and parkinson s disease with dementia	2003	-0.2313	0.2459	66	0.7017
2085412585	effects of phosphatidylserine in age associated memory impairment	1991	-0.2916	0.1242	15	3.1457
2085450056	randomised clinically controlled trial of intensive geriatric rehabilitation in patients with hip fracture subgroup analysis of patients with dementia	2000	1.9693	-0.087	26	21.7617
2085578769	a pilot study of the physiological and behavioural effects of snoezelen in dementia	2002	0.4283	-0.0759	18	1.9826
2085590891	a signal detectability analysis of the effect of physostigmine on memory in patients with alzheimer s disease	1982	-0.3172	0.201	13	16.0819
2085721709	some effects of piracetam ucb 6215 nootropyl on chronic schizophrenia	1979	0.0183	0.3851	48	0.6855
2085739321	p 5 a 008 effects of memantine on functional communication in moderate alzheimer s disease results of a 12 week placebo controlled trial	2009	-0.1262	0.0945	11	0.8201
2085817021	donepezil provides long term clinical benefits for patients with alzheimer s disease	2000	-0.3188	0.1177	33	1.6964
2085837646	a one year randomized controlled psychosocial intervention study among family carers of dementia patients effects on patients and carers	2007	0.5397	-0.1153	74	0.916
2085860752	nicergoline in mild to moderate dementia a multicenter double blind placebo controlled study	1989	-0.2985	0.0512	23	0.6475
2085878408	neuroprotective treatment with cerebrolysin in patients with acute stroke a randomised controlled trial	2005	-0.3717	-0.0078	70	0.7993
2085979427	development of iron chelators to treat iron overload disease and their use as experimental tools to probe intracellular iron metabolism	1998	-1.5731	-1.2608	101	0.75
2086085709	choline chloride fails to improve cognition in alzheimer s disease	1981	-0.3749	0.2714	120	1.6928
2086156255	prospective validation of consensus criteria for the diagnosis of dementia with lewy bodies	2000	-0.1926	0.1212	7	0.9982
2086238232	efficiency of transcranial electrostimulation on anxiety and insomnia symptoms during a washout period in depressed patients a double blind study	1991	0.2261	-0.0085	17	0.916
2086315373	effect of cyclandelate on perception memory and cognition in a group of geriatric subjects	1972	-0.2522	0.1582	9	0.6439
2086340711	donepezil preserves functional status in alzheimer s disease patients results from a 1 year prospective placebo controlled attrition study	1999	-0.3134	0.096	50	13.8802
2086461219	efficacy of multivitamin supplementation containing vitamins b6 and b12 and folic acid as adjunctive treatment with a cholinesterase inhibitor in alzheimer s disease a 26 week randomized double blind placebo controlled study in taiwanese patients	2007	-0.8639	-0.1051	30	0.9988
2086502066	a dose ranging study of lecithin in the treatment of primary degenerative dementia alzheimer disease	1982	-0.3345	0.2215	59	18.4342
2086503579	a double blind study of combination of clozapine with risperidone in patients with schizophrenia effects on cognition	2006	-0.252	0.1654	9	1.4021
2086513403	open label treatment of combined memantine plus escitalopram treatment in elderly depressed patients with cognitive impairment	2009	-0.289	0.2822	9	0.6504
2086521875	assessment of informal services to demented people with the rud instrument	2000	0.0635	-0.0295	93	0.9867
2086546612	long term safety and efficacy of donepezil in patients with dementia with lewy bodies results from a 52 week open label multicenter extension study	2013	-0.2939	0.1114	50	0.7002
2086548924	information needs of family caregivers of persons with cognitive versus physical deficits	2011	0.6888	-0.1557	76	0.8411
2086572083	a phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate alzheimer disease	2009	-0.6224	-0.1689	32	2
2086581430	relation of higher folate intake to lower risk of alzheimer disease in the elderly	2007	-0.8726	-0.1034	30	1
2086653276	a double blind comparison of the efficacy and safety of paroxetine and imipramine in the treatment of depression with dementia	1998	0.2102	0.0884	31	6.7949
2086687329	effect of design interventions on a dementia care setting	2004	0.6741	-0.0194	24	0.9804
2086786033	potential applications for monoamine oxidase b inhibitors pp 323 334	1990	-0.1954	0.1513	37	0.7995
2086792134	changes in regional cerebral blood flow and functional connectivity in the cholinergic pathway associated with cognitive performance in subjects with mild alzheimer s disease after 12 week donepezil treatment	2012	-0.2499	0.1367	22	0.916
2086806578	the scopolamine model of dementia determination of central cholinomimetic effects of physostigmine on cognition and biochemical markers in man	1988	0.0571	0.5351	48	0.681
2086847901	effects of b vitamins and omega 3 fatty acids on cardiovascular diseases a randomised placebo controlled trial	2010	-1.2428	-0.3453	83	1
2086861353	a systematic review of assessment and treatment of moderate to severe alzheimer s disease	2006	-0.285	0.0852	33	0.6422
2086891165	treatment of acute cerebral infarction with a choline precursor in a multicenter double blind placebo controlled study	1988	-0.3989	-0.2632	62	0.9992
2086968795	acute and long term administration of anticholinergics in parkinson s disease specific effects on the subcortico frontal syndrome	1999	0.0183	0.3851	48	0.6511
2086971822	the impact of group music therapy on depression and cognition in elderly persons with dementia a randomized controlled study	2014	0.5107	-0.0524	21	19.915
2086978953	the efficacy of licensed indication use of donepezil and memantine monotherapies for treating behavioural and psychological symptoms of dementia in patients with alzheimer s disease systematic review and meta analysis	2011	-0.1907	0.1284	11	0.7226
2087085248	functional outcome of cognitively impaired hip fracture patients on a geriatric rehabilitation unit	1997	1.9722	-0.088	26	1
2087105950	nitrosative stress cellular stress response and thiol homeostasis in patients with alzheimer s disease	2006	-0.4593	-0.0962	82	0.9867
2087123644	long term efficacy and safety of celecoxib in alzheimer s disease	2007	-0.4339	-0.0829	32	23.9685
2087181643	impacts associated with special care units in long term care facilities	1990	0.6761	-0.022	24	0.9584
2087242360	aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index a randomized controlled trial	2010	-0.5188	-0.0906	68	0.7062
2087243726	delirium outcomes in a randomized trial of blood transfusion thresholds in hospitalized older adults with hip fracture	2013	2.5637	-0.0485	125	16.3709
2087322997	comments on the article by mazza et al concerning ginkgo biloba and donepezil a comparison in the treatment of alzheimer s dementia in a randomized placebo controlled double blind study	2007	-0.3985	0.0305	53	0.707
2087328255	mental fatigue and impaired information processing after mild and moderate traumatic brain injury	2009	-1.1671	1.5699	64	0.8843
2087336884	caregiving and dementia the impact of telephone helpline services	1995	0.6854	-0.1437	97	0.6669
2087347873	outcomes of a computer based cognitive rehabilitation program on alzheimer s disease patients compared with those on patients affected by mild cognitive impairment	2006	0.2176	-0.114	10	2.9804
2087423729	the neuropathogenesis of aids	2005	-0.4011	0.5019	87	1.9937
2087468607	effects of combined cognitive and exercise interventions on cognition in older adults with and without cognitive impairment a systematic review	2014	0.5368	-0.188	27	0.916
2087539933	use of memantine akatinol for the correction of cognitive impairments in parkinson s disease complicated by dementia	2010	-0.2338	0.184	9	0.6431
2087582756	testosterone influences spatial cognition in older men	1994	-0.9327	-1.0635	54	1
2087604101	differential effects of family based strategies on alzheimer s disease	1989	0.2575	-0.103	10	0.9982
2087687379	cognitive and quantified electroencephalographic correlates of cycloserine treatment in alzheimer s disease	1995	-0.2811	0.1561	43	14.9913
2087691562	a social skills training program for adult caregivers	1988	0.5589	-0.1149	1	0.991
2087703564	platelet monoamine oxidase inhibition by deprenyl and tranylcypromine implications for clinical use	1985	-0.1962	0.1508	37	0.8045
2087727383	barriers to improvement of mental health services in low income and middle income countries	2007	0.5568	-0.1275	140	0.9713
2087850309	promotion of transition metal induced reactive oxygen species formation by ?? amyloid	1998	-1.5747	-1.2603	101	0.75
2087857621	poststroke fatigue following minor infarcts a prospective study	2012	-1.1663	1.5705	64	0.7993
2087882280	efficacy of a cognitive training programme for mild cognitive impairment results of a randomised controlled study	2010	0.4051	-0.1918	4	0.7993
2087883935	double blind placebo controlled study of metrifonate an acetylcholinesterase inhibitor for alzheimer disease	1996	-0.2539	0.0753	44	0.9939
2087946531	velnacrine for the treatment of alzheimer s disease a double blind placebo controlled trial	1996	-0.2799	0.0625	44	0.8913
2087959325	sensitivity and specificity of newly proposed clinical criteria for possible vascular dementia	1997	-0.4203	0.0161	85	0.9404
2088047369	dose response analysis of the behavioral effects of diazepam ii psychomotor performance cognition and mood	1984	-0.662	-0.1224	65	0.7229
2088066151	the cns effects of ginkgo biloba extracts and ginkgolide b	2002	-0.103	-0.096	8	0.75
2088098553	music memory and alzheimer s disease is music recognition spared in dementia and how can it be assessed	2005	0.4839	-0.1366	25	0.9982
2088253893	physostigmine improvement of long term memory processes in normal humans	1978	-0.3211	0.2072	13	2.6343
2088317481	psychosis of alzheimer s disease and related dementias diagnostic criteria for a distinct syndrome	2000	0.223	0.0836	16	4.7981
2088323704	effects of short term transcutaneous electrical nerve stimulation on memory and affective behaviour in patients with probable alzheimer s disease	1995	0.199	-0.0085	17	6.6638
2088361570	prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment results from the cardiovascular health study	2002	0.207	0.0759	31	7.545
2088396659	the association between midlife blood pressure levels and late life cognitive function the honolulu asia aging study	1995	-0.664	-0.1096	14	6.8448
2088422073	memantine displaces 3h mk 801 at therapeutic concentrations in postmortem human frontal cortex	1989	-0.2742	0.0723	23	0.9996
2088512718	clinical implications of determination of plasma haloperidol levels	1989	-0.4377	0.3666	90	0.6704
2088516726	use of noben idebenone in the treatment of dementia and memory impairments without dementia	2009	-0.2055	-0.1492	49	0.7079
2088581697	are ?? blockers efficacious as first line therapy for hypertension in the elderly a systematic review	1998	-0.7617	-0.1539	14	0.9404
2088781238	cerebral blood flow changes after treatment of social phobia with the neurokinin 1 antagonist gr205171 citalopram or placebo	2005	-0.4206	0.335	90	0.6405
2088833125	plasma catecholamine and lymphocyte beta 2 adrenergic receptor alterations in elderly alzheimer caregivers under stress	1997	0.559	-0.1168	142	0.7993
2088839952	the effect of hormone replacement on physical performance in community dwelling elderly women	2005	-0.7342	-0.7361	3	17.8212
2088846607	risperidone in the treatment of agitated and aggressive patients with dementia	1995	0.5641	0.3999	40	0.7931
2088890449	treatment of behavioural disturbances and psychotic symptoms in the elderly with remoxipride	1993	0.3076	0.1434	81	0.6698
2088919930	delusions associated with elevated muscarinic binding in dementia with lewy bodies	2000	-0.195	0.123	7	1.9861
2088943580	guidage study a 5 year double blind randomised trial of egb 761 for the prevention of alzheimers disease in elderly subjects with memory complaints i rationale design and baseline data	2008	-0.1031	-0.0953	8	15.4906
2089036448	a dose ranging study of the effects of ethyl eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs	2002	-1.0896	-0.2988	5	1.9945
2089048149	olanzapine versus haloperidol in the treatment of agitation in elderly patients with dementia results of a randomized controlled double blind trial	2006	0.1165	0.1318	38	0.6139
2089094682	effects of aerobic exercise on depression a controlled study	1985	0.5835	-0.2505	27	0.9998
2089106102	the clinical trial protocol of the metrifonate in alzheimer s trial malt	1998	-0.2795	0.0749	51	14.1167
2089131917	lowering of homocysteine concentrations in elderly men and women	1999	-1.9284	0.3325	109	0.7442
2089222556	cbf and cognitive evaluation of alzheimer type patients before and after imao b treatment a pilot study	1992	-0.1791	0.0934	67	19.7703
2089293015	cognitive training research on fluid intelligence in old age what can older adults achieve by themselves	1989	0.5038	-0.2821	4	0.6909
2089333042	effects of exercise on neurobehavioral function in community dwelling older people more than 75 years of age	1996	0.5809	-0.2512	27	0.8843
2089395243	double blind placebo controlled study of velnacrine in alzheimer s disease	1996	-0.2794	0.0625	44	15.2149
2089396960	oral risperidone with lorazepam versus oral zuclopenthixol with lorazepam in the treatment of acute psychosis in emergency psychiatry a prospective comparative open label study	2005	0.1304	0.1286	47	0.7672
2089412339	improved cognition after control of risk factors for multi infarct dementia	1986	-0.4196	0.0165	85	0.9404
2089469091	concentrations of ?? tocopherol and its quinone derivative in cerebrospinal fluid from patients with vascular dementia of the binswanger type and alzheimer type dementia	1994	-0.4081	0.3096	120	0.6004
2089558828	efficacy safety and tolerability of rivastigmine patch 13 3 mg 24 h 15 cm2 versus 4 6 mg 24 h 5 cm2 in patients with severe alzheimer s disease results of the activities of daily living and cognition action study	2012	-0.2553	0.0533	72	0.7955
2089562953	characteristic plasma hormone changes in alzheimer s disease	1987	-0.4081	0.3096	120	0.6157
2089613546	the impact of regular multidisciplinary team interventions on psychotropic prescribing in swedish nursing homes	1998	0.6285	-0.0225	52	21.8866
2089650868	the suprachiasmatic nucleus of the human brain in relation to sex age and senile dementia	1985	0.2716	-0.0164	17	8.8789
2089653610	open label placebo for major depressive disorder a pilot randomized controlled trial	2012	0.1033	0.1511	61	0.7109
2089685109	impact of a psychoeducational intervention on caregiver response to behavioral problems	2002	0.479	-0.0838	1	1.9623
2089695171	clinical characteristics and complications of patients with type 2 diabetes attending an urban hospital in bangladesh	2015	-0.4276	1.4428	56	0.7724
2089796411	an interdisciplinary intervention for older taiwanese patients after surgery for hip fracture improves health related quality of life	2010	2.1136	-0.0877	26	1.5363
2089866912	alzheimer s memory	2007	-0.5495	0.3992	73	0.7429
2089927818	restraint reduction reduces serious injuries among nursing home residents	1999	0.8435	-0.1027	42	1
2089992386	p1 315 functional and behavioral effects of memantine in alzheimer s disease	2004	-0.2844	0.1558	22	1.7099
2089992487	life review and life story books for people with mild to moderate dementia a randomised controlled trial	2014	0.3589	-0.0934	39	0.845
2089998597	risperidone in the treatment of negative symptoms of schizophrenia a meta analysis	1995	0.1304	0.1286	47	0.7168
2090161678	the ginkgo evaluation of memory gem study design and baseline data of a randomized trial of ginkgo biloba extract in prevention of dementia	2006	-0.364	-0.1024	8	2.9848
2090183715	a prospective study of dehydroepiandrosterone sulfate and cognitive function in an older population the rancho bernardo study	1994	-1.4227	-1.8435	20	1.9994
2090189636	for profit hospital status and rehospitalizations at different hospitals an analysis of medicare data	2010	0.5772	-0.1221	139	0.7356
2090203163	successful treatment of a patient with alzheimer type dementia using donepezil hydrochloride and rehabilitation	2000	-0.2941	0.1105	50	0.7794
2090203467	administration of diazepam by intravenous infusion	1981	-0.6082	0.5205	119	0.6197
2090318965	effects of selegiline on fronto temporal dementia a neuropsychological evaluation	2002	-0.3245	0.1979	22	0.75
2090389523	blocking of acquisition but not expression of conditioned fear potentiated startle by nmda antagonists in the amygdala	1990	-0.2955	0.1857	43	0.845
2090407616	increased activity of brain and platelet monoamine oxidase in dementia of alzheimer type	1980	-0.1873	0.1192	37	0.9939
2090555468	traumatic brain injury and sleep disturbance a review of current research	2009	-1.2594	1.7614	64	0.991
2090597365	agitated behaviors in the elderly ii preliminary results in the cognitively deteriorated	1986	0.1665	0.0922	47	0.9992
2090609282	pro resolving lipid mediators are leads for resolution physiology	2014	-1.1027	-0.3021	5	0.9804
2090724400	cognitive and neuroendocrine response to transdermal estrogen in postmenopausal women with alzheimer s disease results of a placebo controlled double blind pilot study	1999	-0.7379	-0.7285	3	4.9999
2090897996	intravenous physostigmine treatment of alzheimer s disease evaluated by psychometric testing regional cerebral blood flow rcbf measurement and eeg	1987	-0.2922	0.1669	13	19.1492
2090929494	quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis	2004	-0.1763	0.1189	7	2
2090930997	the inflammatory response system of brain implications for therapy of alzheimer and other neurodegenerative diseases	1995	-0.414	-0.0404	32	1
2090976943	psychological and cognitive outcomes of a randomized trial of exercise among patients with chronic obstructive pulmonary disease	1998	0.5825	-0.2513	27	0.9982
2090985766	salivary alpha amylase and cortisol responsiveness following electrical stimulation stress in patients with the generalized type of social anxiety disorder	2013	0.3307	-0.0249	89	0.6876
2090987510	a meta analysis of the efficacy of psycho and pharmacotherapy in panic disorder with and without agoraphobia	2005	-0.2939	0.0995	41	0.6646
2091048148	nootropic treatment and combined therapy in age associated memory impairment	1998	-0.3247	-0.1413	45	14.0311
2091048455	changes in brain biogenic monoamines induced by the nootropic drugs adafenoxate and meclofenoxate and by citicholine experiments on rats	1990	-0.401	-0.2662	62	0.845
2091079785	effect of ginkgo biloba on blood pressure and incidence of hypertension in elderly men and women	2010	-0.503	-0.0819	68	1.5493
2091093079	role of sodium channel inhibition in neuroprotection effect of vinpocetine	2000	-0.3065	0.1272	23	0.9404
2091110888	neurochemical profiles in cerebrospinal fluid of stroke prone spontaneously hypertensive rats	1994	-0.2844	0.0411	72	0.845
2091194657	the nootropic concept and its prospective implications	1982	-0.2974	0.2779	15	1.7578
2091273404	stimulation of nerve growth factor synthesis secretion by propentofylline in cultured mouse astroglial cells	1990	-0.4137	0.0257	85	0.8843
2091319478	cognition enhancing effect of vagus nerve stimulation in patients with alzheimer s disease a pilot study	2002	0.0843	-0.0067	67	0.6887
2091337832	effect of memory impairment on training outcomes in active	2007	0.4859	-0.2694	4	0.9584
2091423401	a placebo controlled pilot discontinuation trial following haloperidol treatment of behavioral and psychotic symptoms in alzheimer s disease	2010	0.1931	0.0604	80	0.8603
2091425360	practice parameter evaluation and treatment of depression psychosis and dementia in parkinson disease an evidence based review report of the quality standards subcommittee of the american academy of neurology	2006	-0.1813	0.1129	7	4.9992
2091438490	p212 influence of propentofylline on eeg power in primary degenerative and vascular dementia	1996	-0.4056	0.0825	85	0.7331
2091604743	double blind placebo controlled clinical psychometric and neurophysiological investigations with oxiracetam in the organic brain syndrome of late life	1985	-0.4209	0.3343	90	0.648
2091621017	impact of special care unit for patients with advanced alzheimer s disease on patients discomfort and costs	1994	0.7651	-0.0213	95	1.8427
2091628499	six month randomized placebo controlled double blind pilot clinical trial of curcumin in patients with alzheimer disease	2008	-0.492	-0.0816	8	2.715
2091682403	quetiapine versus haloperidol in the treatment of delirium a double blind randomized controlled trial	2013	2.1722	-0.0424	2	0.9994
2091761541	fatigue after traumatic brain injury and its impact on participation and quality of life	2008	-1.2594	1.7614	64	0.9994
2091761748	acetyl l carnitine as a precursor of acetylcholine	1990	-0.3129	0.0109	63	0.9959
2091815332	procedural memory stimulation in alzheimer s disease impact of a training programme	1997	0.2621	-0.097	10	1.9936
2091842118	oral citicoline in acute ischemic stroke an individual patient data pooling analysis of clinical trials	2002	-0.3997	-0.2647	62	1.9763
2091951181	b ht920 a novel dopamine autoreceptor agonist in the treatment of patients with schizophrenia	1990	-0.6362	0.0864	122	0.7372
2091980518	drug therapy and memory training programs a double blind randomized trial of general practice patients with age associated memory impairment	1994	-0.2869	0.2051	15	16.3867
2091991929	improved quality of life and cognitive stimulation therapy in dementia	2006	0.2913	-0.094	10	2.9982
2092130584	comparison of the fascia iliaca compartment block with the 3 in 1 block in children	1989	2.2485	-0.0454	138	0.9804
2092259278	donepezil for the treatment of behavioral disturbances in alzheimer s disease a 6 month open trial	2001	-0.2185	0.142	11	0.7264
2092356280	memantine in moderate to severe alzheimer s disease	2003	-0.2153	0.0468	6	68.6098
2092374375	better postural balance in elderly women receiving estrogens	1997	-0.7673	-0.7803	3	0.9713
2092474731	mfsd2a is a transporter for the essential omega 3 fatty acid docosahexaenoic acid	2014	-1.0105	-0.2751	5	0.9404
2092526668	piracetam in elderly motorists	1991	-0.3862	0.3773	98	13.8672
2092674727	the effects of exercise training on elderly persons with cognitive impairment and dementia a meta analysis	2004	0.4816	-0.179	25	16.5129
2092767820	neuropathologic and neurochemical correlates of psychosis in primary dementia	1991	0.0731	0.0945	16	0.845
2092792675	the process of change in cognitive therapy and pharmacotherapy for depression	1984	-0.2585	0.1787	11	0.6652
2092844477	coping with dementia evaluation of four nonpharmacologic interventions	2000	0.3851	-0.1089	10	36.3637
2092865399	what can preservation of autobiographic memory after muscarinic blockade tell us about the scopolamine model of dementia	1995	0.0183	0.3851	48	0.6605
2092893498	a randomized controlled trial of the effects of multi sensory stimulation mss for people with dementia	2001	0.4239	-0.0756	18	22.9016
2092936855	reduced activities of thiamine dependent enzymes in the brains and peripheral tissues of patients with alzheimer s disease	1988	-0.7856	-0.0991	86	2.9987
2092967130	piracetam plus lecithin trials in senile dementia of the alzheimer type	1985	-0.3311	0.2607	59	0.7984
2093042407	l deprenyl and physostigmine for the treatment of alzheimer s disease	1995	-0.4297	0.3503	90	1.3482
2093053385	nicotine haloperidol interactions and cognitive performance in schizophrenics	1996	0.0437	0.4832	48	1
2093200944	monozygotic twins with alzheimer s disease treated with melatonin case report	1998	0.2294	-0.0176	28	1.9973
2093206585	efficacy and safety of memantine in people with moderate to severe alzheimer s disease results of a pooled analysis of randomized double blind placebo controlled trials in japan	2013	-0.5154	-0.0476	12	14.5074
2093296423	differentiation of vascular dementia from ad on neuropsychological tests	1999	-0.4482	-0.0028	12	0.7993
2093324930	effectiveness of physical training on motor performance and fall prevention in cognitively impaired older persons a systematic review	2006	0.4872	-0.1803	25	1.9777
2093335692	olanzapine in the treatment of anxiety symptoms due to alzheimer s disease a post hoc analysis	2001	0.0278	0.1114	38	16.181
2093374391	alzheimer s disease and senile dementia loss of neurons in the basal forebrain	1982	-0.2696	0.1836	13	12.7107
2093383239	depression in frail elders impact on family caregivers	2004	0.6566	-0.1432	75	0.7856
2093391499	calcium and vitamin d supplementation and cognitive impairment in the women s health initiative	2012	-0.6916	-0.1919	79	0.7398
2093564362	improvement of cognitive functions after cobalamin folate supplementation in elderly patients with dementia and elevated plasma homocysteine	2001	-0.8626	-0.1026	30	1.9937
2093635022	impact of combination antiretroviral therapy on cerebrospinal fluid hiv rna and neurocognitive performance	2009	-0.4011	0.5019	87	1.9921
2093639349	efficacy of treating pain to reduce behavioural disturbances in residents of nursing homes with dementia cluster randomised clinical trial	2011	0.3882	-0.027	34	0.916
2093641459	milacemide a glycine prodrug enhances performance of learning tasks in normal and amnestic rodents	1989	-0.2977	0.188	43	0.9939
2093651696	infusion of mk 801 and memantine contrasting effects on radial maze learning in rats with entorhinal cortex lesion	1996	-0.2735	0.0729	23	0.9867
2093750689	olanzapine reduces psychosis and behavioral disturbances associated with alzheimer s disease	1999	0.3069	0.142	81	14.5255
2093755310	effects of the 1 amino adamantanes at the mk 801 binding site of the nmda receptor gated ion channel a human postmortem brain study	1991	-0.2735	0.0729	23	0.9988
2093757589	a prospective study of physical activity and cognitive decline in elderly women women who walk	2001	0.5026	-0.1757	25	0.845
2093805969	a comparison of episodic memory deficits in neuropathologically confirmed dementia with lewy bodies and alzheimer s disease	2004	-0.1375	0.2003	100	0.7838
2093807569	a comparative study in vitro effects of epa and dha on immune functions of head kidney macrophages isolated from large yellow croaker larmichthys crocea	2013	-1.1442	-0.3148	83	0.7469
2093814555	efficacy of donepezil in early stage alzheimer disease a randomized placebo controlled trial	2004	-0.2214	0.0231	6	25.315
2093836921	a double blind placebo controlled clinical study on the effect of a standardized ginseng extract on psychomotor performance in healthy volunteers	1986	-0.6524	-0.1188	65	22.612
2093992111	psychosocial intervention for family caregivers of people with dementia reduces caregiver s burden development and effect after 6 and 12 months	2008	0.6681	-0.1472	75	1.5879
2093994918	efficacy of rivastigmine transdermal patch on activities of daily living item responder analyses	2011	-0.2277	0.0649	7	17.4719
2094024817	protective effect of vinpocetine against brain damage caused by ischemia	1991	-0.3065	0.1272	23	0.916
2094057355	insomnia in patients with traumatic brain injury frequency characteristics and risk factors	2006	-1.2594	1.7614	64	0.9988
2094126102	packages of care for dementia in low and middle income countries	2009	0.5574	-0.1268	140	0.9804
2094337384	dietary supplementation of arachidonic and docosahexaenoic acids improves cognitive dysfunction	2006	-1.0492	-0.2852	5	7.8083
2094381093	effects of olanzapine and other antipsychotics on cognitive function in chronic schizophrenia a longitudinal study	2001	-0.2626	0.1647	9	0.6528
2094418975	the design of a prospective study of pravastatin in the elderly at risk prosper	1999	-0.7864	-0.1886	88	21.9712
2094437177	evidence based psychological treatments for distress in family caregivers of older adults	2007	0.5327	-0.112	1	3.8332
2094472277	dietary patterns and risk of dementia the three city cohort study	2007	-1.056	-0.2869	5	6.804
2094554393	long term effects of phosphatidylserine pyritinol and cognitive training in alzheimer s disease	1994	-0.2809	0.1571	43	0.6396
2094581981	evaluation of simulated presence a personalized approach to enhance well being in persons with alzheimer s disease	1999	0.4842	-0.041	21	21.7386
2094587466	fluctuations of free choline levels in plasma of alzheimer patients receiving lecithin preliminary observations	1982	-0.4073	0.3088	120	11.3626
2094766256	metabolic and vascular determinants of impaired cognitive performance and abnormalities on brain magnetic resonance imaging in patients with type 2 diabetes	2007	-0.4453	1.5878	56	0.9999
2094790509	mds task force on mild cognitive impairment in parkinson s disease critical review of pd mci	2011	-0.1859	0.0725	7	0.75
2094793030	mortality within 2 years after surgery in relation to low intraoperative bispectral index values and preexisting malignant disease	2009	2.2186	-0.038	36	1.7492
2094804244	atomoxetine for attention deficits following traumatic brain injury results from a randomized controlled trial	2014	-0.9914	1.2583	71	14.3731
2094808560	rapid induction of alzheimer a beta amyloid formation by zinc	1994	-1.0099	-0.5237	69	1
2094841422	the effects of memory skills training and incentives on free recall in older learners	1990	0.5068	-0.2836	4	2.4336
2094852528	an ergot alkaloid preparation hydergine versus papaverine in treating common complaints of the aged double blind study	1973	-0.2897	0.1013	41	2.7942
2094855556	pharmacotherapy of amnestic mild cognitive impairment lessons from the memory impairment study	2005	-0.2166	0.1405	11	0.7487
2094927469	reality orientation with elderly patients in the community an empirical evaluation	1983	0.322	-0.0925	10	1.9623
2094973575	a clinical trial of bromocriptine for treatment of primary progressive aphasia	2004	-0.2363	0.2597	66	0.9999
2095048700	results of the pilot study for the hypertension in the very elderly trial	2003	-0.7503	-0.1508	14	1.94
2095049087	two weeks of transdermal estradiol treatment in postmenopausal elderly women and its effect on memory and mood verbal memory changes are associated with the treatment induced estradiol levels	1999	-0.7551	-0.7591	3	22.9703
2095073323	lack of benefit of dietary advice to men with angina results of a controlled trial	2003	-1.2428	-0.3453	83	1
2095139855	a double blind comparison of the effect on quality of life of a combination of vital substances including standardized ginseng g115 and placebo	1994	-0.6492	-0.1181	65	0.9584
2095173910	cerebrolysin in mild to moderate alzheimer s disease a meta analysis of randomized controlled clinical trials	2015	-0.3709	-0.0074	70	0.8301
2095196265	loss of independence in activities of daily living in older adults hospitalized with medical illnesses increased vulnerability with age	2003	2.3692	-0.0634	35	0.7993
2095205765	reduction in triglyceride level with n 3 polyunsaturated fatty acids in hiv infected patients taking potent antiretroviral therapy a randomized prospective study	2007	-1.2104	-0.3345	128	0.6767
2095303134	delayed matching to sample performance during a double blind trial of tacrine tha and lecithin in patients with alzheimer s disease	1993	-0.2338	0.184	9	0.6422
2095385992	piracetam induced facilitation of interhemispheric transfer of visual information in rats	1976	-0.3176	0.263	15	0.845
2095415723	fatty acids in adhd plasma profiles in a placebo controlled study of omega 3 6 fatty acids in children and adolescents	2012	-1.0951	-0.3005	5	0.7622
2095427240	effect of dhea on abdominal fat and insulin action in elderly women and men a randomized controlled trial	2004	-1.3294	-1.6929	54	1.75
2095430905	the neuroprotective effects of cerebrolysin in a transgenic model of alzheimer s disease are associated with improved behavioral performance	2003	-0.3335	0.005	70	0.845
2095460802	subcortical vascular cognitive impairment similarities and differences with multiple sclerosis	2006	-0.727	0.0219	107	0.6734
2095481775	derivation and validation of a preoperative prediction rule for delirium after cardiac surgery	2009	2.1817	-0.0398	36	1
2095539522	the effects of olanzapine in reducing the emergence of psychosis among nursing home patients with alzheimer s disease	2001	0.1713	0.0867	16	21.138
2095629702	relationships between hyperglycemia and cognitive performance among adults with type 1 and type 2 diabetes	2005	-0.4434	1.5572	56	0.9867
2095768296	association between omega 3 fatty acid supplementation and risk of major cardiovascular disease events a systematic review and meta analysis	2012	-1.2428	-0.3453	83	1
2095828172	loss of neurons of origin of the adrenergic projection to cerebral cortex nucleus locus ceruleus in senile dementia	1982	-0.323	0.2085	13	0.75
2095853952	user evaluation of the dementia specific digital interactive social chart dem disc a pilot study among informal carers on its impact user friendliness and usefulness	2010	0.5531	-0.1195	1	0.9804
2095979027	meta analysis of nonpharmacological interventions for neuropsychiatric symptoms of dementia	2012	0.3619	-0.0567	34	1.7497
2096016247	an effective approach to decrease antipsychotic and benzodiazepine use in nursing homes the reduse project	2010	0.6148	-0.0181	52	1.871
2096087540	intravenous ketorolac as an adjuvant to pediatric patient controlled analgesia with morphine	1994	2.3863	-0.0472	130	0.8519
2096103925	an outreach intervention to implement evidence based practice in residential care a randomized controlled trial isrctn67855475	2004	0.6137	-0.0181	52	1.9711
2096105435	enhancement of cognitive performance in schizophrenia by addition of tandospirone to neuroleptic treatment	2001	-0.2409	0.1654	9	0.7005
2096140307	cholesterol level and statin use in alzheimer disease ii review of human trials and recommendations	2011	-0.713	-0.1674	29	0.9996
2096224929	ginseng pharmacology multiple constituents and multiple actions	1999	-0.6512	-0.1189	65	1.9865
2096288047	does combined cognitive training and physical activity training enhance cognitive abilities more than either alone a four condition randomized controlled trial among healthy older adults	2013	0.5368	-0.188	27	0.991
2096298725	two year effects of an interdisciplinary intervention on recovery following hip fracture in older taiwanese with cognitive impairment	2012	2.1026	-0.0878	26	16.2116
2096339209	prognosis of japanese encephalitis patients with dystonia compared to those with parkinsonian features only	2002	0.2301	-0.2027	111	0.6277
2096410114	the amyloid hypothesis of alzheimer s disease progress and problems on the road to therapeutics	2002	-0.5239	-0.1388	32	1.991
2096522117	comparative effectiveness of pain management interventions for hip fracture a systematic review	2011	2.2485	-0.0454	138	0.9867
2096551681	a randomized controlled trial on early physiotherapy intervention versus usual care in acute car unit for elderly potential benefits in light of dietary intakes	2008	2.3692	-0.0634	35	0.75
2096592799	randomized controlled trial of the haemodynamic and recovery effects of xenon or propofol anaesthesia	2005	3.1484	0.109	110	0.9404
2096613981	reduced prostaglandin f2?? release from blood mononuclear leukocytes after oral supplementation of ¤ë3 fatty acids the omegad study	2010	-1.1428	-0.3139	83	17.6178
2096657471	a short physical performance battery assessing lower extremity function association with self reported disability and prediction of mortality and nursing home admission	1994	0.444	-0.1155	60	0.9584
2096744469	depression among caregivers of stroke survivors	2005	0.4586	0.2348	116	0.8153
2096843247	impact of working memory training on memory performance in old old adults	2008	0.4629	-0.2461	4	1.9992
2096864643	ginseng therapy in non insulin dependent diabetic patients effects on psychophysical performance glucose homeostasis serum lipids serum aminoterminalpropeptide concentration and body weight	1995	-0.6566	-0.1196	65	2.7441
2097127336	acetyl l carnitine induced up regulation of heat shock proteins protects cortical neurons against amyloid beta peptide 1 42 mediated oxidative stress and neurotoxicity implications for alzheimer s disease	2006	-0.3237	-0.0005	63	2.937
2097157033	influence of dinner music on food intake and symptoms common in dementia	1996	0.5425	-0.0583	123	1.8447
2097220370	cognitive performance among the elderly and dietary fish intake the hordaland health study	2007	-1.0601	-0.2893	5	0.9939
2097246785	association between cognitive performance and cortical glucose metabolism in patients with mild alzheimer s disease	2005	-0.4858	0.0852	117	0.7039
2097294495	effectiveness of a psychoeducational skill training dvd program to reduce stress in chinese american dementia caregivers results of a preliminary study	2010	0.5379	-0.1166	1	1.9671
2097341069	long term multiple risk factor interventions in japanese elderly diabetic patients the japanese elderly diabetes intervention trial study design baseline characteristics and effects of intervention	2012	-0.4271	1.4407	56	16.3418
2097460797	randomized controlled trial of yoga among a multiethnic sample of breast cancer patients effects on quality of life	2007	1.6805	-0.9881	108	0.9997
2097480540	cardiovascular risk reduction in hypertensive black patients with left ventricular hypertrophy the life study	2004	-0.7617	-0.1539	14	0.9404
2097487971	association of alzheimer s disease onset with ginkgo biloba and other symptomatic cognitive treatments in a population of women aged 75 years and older from the epidos study	2003	-0.234	-0.1059	8	1.7397
2097562152	psychological adjustment and sleep quality in a randomized trial of the effects of a tibetan yoga intervention in patients with lymphoma	2004	1.6805	-0.9881	108	0.9992
2097585218	the cholinergic synapse and the site of memory	1971	-0.3141	0.2056	13	0.991
2097631717	keep music live music and the alleviation of apathy in dementia subjects	2006	0.4753	-0.0549	21	2.9117
2097713347	controlled clinical trial of zolpidem for the treatment of insomnia associated with attention deficit hyperactivity disorder in children 6 to 17 years of age	2009	-0.1547	0.2301	15	0.6234
2097744656	aging training and the brain a review and future directions	2009	0.4573	-0.2451	4	0.9939
2097768453	aggression and schizophrenia efficacy of risperidone	1997	0.5641	0.3999	40	0.7402
2097774191	multisensory stimulation to improve functional performance in moderate to severe dementia interim results	2010	0.422	-0.0772	18	0.9939
2097799979	long chain omega 3 fatty acids improve brain function and structure in older adults	2014	-1.0086	-0.273	5	1.9711
2097804942	cognitive trajectories after postoperative delirium	2012	1.9906	-0.0368	36	2.7993
2097885652	neuropsychiatric aspects of alzheimer s disease the cholinergic hypothesis revisited	1996	-0.1978	0.076	44	0.9404
2097909970	cognitive emotional and social benefits of regular musical activities in early dementia randomized controlled study	2014	0.5124	-0.0525	21	0.9867
2098008719	memantine treatment in patients with mild to moderate alzheimer s disease results of a randomised double blind placebo controlled 6 month study	2007	-0.1829	0.0577	6	29.0029
2098034696	randomized trial of the effects of simvastatin on cognitive functioning in hypercholesterolemic adults	2004	-0.7266	-0.1701	29	0.9994
2098071975	cognitive decline and fatty acid composition of erythrocyte membranes the eva study	2003	-1.0273	-0.2791	5	2
2098111113	determination of choline betaine and dimethylglycine in plasma by a high throughput method based on normal phase chromatography tandem mass spectrometry	2003	-1.9284	0.3325	109	0.7993
2098132738	new generation antipsychotics versus low potency conventional antipsychotics a systematic review and meta analysis	2003	0.6426	0.1008	91	0.75
2098235001	consolidation of extinction learning involves transfer from nmda independent to nmda dependent memory	2001	-0.2896	0.1831	43	0.845
2098244868	circadian rest activity rhythm disturbances in alzheimer s disease	1996	0.2716	-0.0156	17	3.8837
2098255076	a systematic review of internet based supportive interventions for caregivers of patients with dementia	2014	0.5531	-0.1195	1	0.9992
2098275733	walking stabilizes cognitive functioning in alzheimer s disease ad across one year	2013	0.4823	-0.1846	25	0.7413
2098348353	a self assessment questionnaire for mental fatigue and related symptoms after neurological disorders and injuries	2010	-1.1671	1.5699	64	0.8843
2098356604	plasma and red blood cell thiamine deficiency in patients with dementia of the alzheimer s type	1995	-0.7846	-0.099	86	2.7587
2098361646	cognitive and functional influences of vildagliptin a dpp 4 inhibitor added to ongoing metformin therapy in elderly with type 2 diabetes	2013	-0.3415	0.9111	113	0.7632
2098508429	morale in the oldest old the umea 85 study	2005	0.4834	-0.1436	60	0.7993
2098533587	effect of oestrogen during menopause on risk and age at onset of alzheimer s disease	1996	-0.7437	-0.7453	3	19.9679
2098656789	effects of transcutaneous electrical nerve stimulation on memory and behavior in alzheimer s disease may be stage dependent	1999	0.1899	-0.0031	17	19.3357
2098690498	a double blind placebo controlled study of fluoxetine in depressed patients with alzheimer s disease	2001	0.1949	0.0868	31	30.3538
2098704339	a high intensity functional weight bearing exercise program for older people dependent in activities of daily living and living in residential care facilities evaluation of the applicability with focus on cognitive function	2006	0.444	-0.1155	60	0.9939
2098705946	cardiovascular effects of marine omega 3 fatty acids	2010	-1.2428	-0.3453	83	1
2098752121	dehydroepiandrosterone monotherapy in midlife onset major and minor depression	2005	-1.4128	-1.8331	20	0.9804
2098775852	dietary n 3 polyunsaturated fatty acid depletion activates caspases and decreases nmda receptors in the brain of a transgenic mouse model of alzheimer s disease	2005	-1.0106	-0.2744	5	0.845
2098780362	effects of candesartan in patients with chronic heart failure and reduced left ventricular systolic function taking angiotensin converting enzyme inhibitors the charm added trial	2003	-0.7293	-0.1452	14	2
2098790447	idebenone treatment fails to slow cognitive decline in alzheimer s disease	2003	-0.417	0.0419	41	0.6575
2098876918	use of ramipril in preventing stroke double blind randomised trial	2002	-0.6672	-0.1122	14	0.9973
2098878950	statin use and the risk of incident dementia the cardiovascular health study	2005	-0.7151	-0.1677	29	5.9677
2098984206	a longitudinal study of cognition change during early menopausal transition in a rural community	2006	-0.7469	-0.7546	3	0.9988
2098999434	rivastigmine for alzheimer s disease	2015	-0.24	0.0453	19	3.8359
2099061356	effect of aromatherapy on patients with alzheimer s disease	2009	0.4043	-0.0336	34	2.7716
2099066338	monitoring sedation status over time in icu patients reliability and validity of the richmond agitation sedation scale rass	2003	2.2375	-0.0482	2	1
2099107607	laboratory diagnosis of vitamin b12 and folate deficiency a guide for the primary care physician	1999	-0.9233	-0.1078	30	0.991
2099139008	efficacy of a vitamin nutriceutical formulation for moderate stage to later stage alzheimer s disease a placebo controlled pilot study	2009	-0.4593	-0.0962	82	0.9867
2099146382	a double blind placebo and piracetam controlled multicenter trial of vinpocetine in dementia of alzheimer s type and vascular dementia	1992	-0.3333	0.0923	51	0.6404
2099331404	impact of hospital admission on functional and cognitive measures in older subjects	2012	2.1229	-0.0869	26	0.7661
2099361738	cognitive training for persons with mild cognitive impairment	2008	0.2069	-0.1227	10	2
2099459625	lavender oil as a treatment for agitated behaviour in severe dementia a placebo controlled study	2002	0.4015	-0.0315	34	4.8427
2099489910	prediction of individual clinical outcome in mci by means of genetic assessment and 18f fdg pet	2005	-0.0532	-0.0398	46	20
2099532845	reduction of behavioral disturbances and caregiver distress by galantamine in patients with alzheimer s disease	2004	-0.1657	0.0665	6	1.9713
2099546638	reasons that prevent the inclusion of alzheimer s disease patients in clinical trials	2013	-0.4979	-0.0327	12	1.4418
2099549655	rivastigmine exelon for dementia in patients with parkinson s disease	2003	-0.2169	0.0477	7	2.5501
2099554704	dietary folate and vitamin b12 intake and cognitive decline among community dwelling older persons	2005	-0.8792	-0.1037	30	1.9973
2099556509	statins and the risk of dementia	2000	-0.6803	-0.151	29	14.9239
2099568399	probing peripheral and central cholinergic system responses	2000	-0.3446	0.2068	126	0.8243
2099576816	conservative hand therapy treatments in rheumatoid arthritis a randomized controlled trial	2006	-0.2945	-0.1543	45	0.6875
2099600673	mechanisms of action of a psychological intervention for dementia caregivers effects of behavioral activation and modification of dysfunctional thoughts	2010	0.5311	-0.1125	1	0.991
2099614709	folate vitamin b12 and serum total homocysteine levels in confirmed alzheimer disease	1998	-0.8727	-0.1038	30	7.9566
2099617267	does vitamin d stop inpatients falling a randomised controlled trial	2007	2.2795	-0.0629	35	0.7993
2099654231	barriers to excellent end of life care for patients with dementia	2004	0.8524	-0.0193	95	0.9713
2099827319	atypical antipsychotic drugs and risk of ischaemic stroke population based retrospective cohort study	2005	0.2085	0.1087	16	5.9157
2099830071	effect of rivastigmine or memantine add on therapy is affected by butyrylcholinesterase genotype in patients with probable alzheimer s disease	2014	-0.311	0.0163	57	0.717
2099833638	the efficacy of donepezil in the treatment of neuropsychiatric symptoms in alzheimer disease	2004	-0.0965	0.0572	6	33.8649
2099899980	physical activity and enhanced fitness to improve cognitive function in older people without known cognitive impairment	2008	0.5106	-0.1973	25	4.6492
2099905211	age associated memory impairment proposed diagnostic criteria and measures of clinical change report of a national institute of mental health work group	1986	-0.2875	0.2061	15	0.845
2099945778	use of donepezil for vascular dementia	1999	-0.2173	0.1409	11	1.5466
2100008637	effectiveness of an intervention led by lay health counsellors for depressive and anxiety disorders in primary care in goa india manas a cluster randomised controlled trial	2010	0.5568	-0.1275	140	0.9584
2100072124	diagnosis and treatment of alzheimer disease and related disorders consensus statement of the american association for geriatric psychiatry the alzheimer s association and the american geriatrics society	1997	0.4686	-0.0965	1	0.845
2100084977	bacterial overgrowth during treatment with omeprazole compared with cimetidine a prospective randomised double blind study	1996	-0.2799	0.0625	44	0.75
2100153406	domino ad protocol donepezil and memantine in moderate to severe alzheimer s disease a multicentre rct	2009	-0.0785	0.0681	58	18.1518
2100221295	review donepezil metrifonate rivastigmine and ginkgo biloba are more effective than placebo in alzheimer s disease	2001	-0.3985	0.0305	53	0.6955
2100245268	flying by the seat of our pants what dementia family caregivers want in an advanced caregiver training program	2012	0.6888	-0.1557	76	0.8516
2100346120	salivary cortisol day profiles in elderly with mild cognitive impairment	2002	0.3279	-0.0246	89	1.4732
2100353404	how effective are interventions with caregivers an updated meta analysis	2002	0.5364	-0.1143	1	24.7158
2100353749	symptoms of preclinical dementia in general practice up to five years before dementia diagnosis	2007	-0.0942	0.0057	84	0.711
2100464372	physical activity and risk of cognitive impairment and dementia in elderly persons	2001	0.5	-0.1809	25	4.9072
2100490307	the effect of sertraline add on to brief dynamic psychotherapy for the treatment of postpartum depression a randomized double blind placebo controlled study	2012	0.103	0.1503	61	0.7231
2100546538	the science of interpersonal touch an overview	2010	0.5917	-0.0633	123	0.916
2100605435	enhanced psychosocial support for caregiver burden for patients with chronic kidney failure choosing not to be treated by dialysis or transplantation a pilot randomized controlled trial	2016	0.1342	-0.0722	93	0.7708
2100696842	effect of cognitive rehabilitation program on cognitive function depression and activities of daily living among patients with strokes	2012	2.1137	-0.0877	26	1.4928
2100739470	withdrawal of neuroleptic medications from institutionalized dementia patients results of a double blind baseline treatment controlled pilot study	1997	0.3182	0.0402	16	26.4423
2100798181	dietary omega 3 polyunsaturated fatty acids and alzheimer s disease interaction with apolipoprotein e genotype	2011	-1.0106	-0.2744	5	0.845
2100861400	time to treatment initiation in people with alzheimer disease a meta analysis of randomized controlled trials	2016	-0.0265	0.0659	58	3.6325
2101001040	a double blind placebo controlled trial of ascorbic acid in obesity	1985	-0.3232	0.2077	13	0.7537
2101005384	the effects of liberal versus restrictive transfusion thresholds on ambulation after hip fracture surgery	2009	2.566	-0.0494	125	0.7993
2101068216	detection of mild cognitive impairment and early stage dementia with an audio recorded cognitive scale	2013	-0.0747	-0.1034	127	0.7744
2101077067	evidence that 5 cytidinediphosphocholine can affect brain phospholipid composition by increasing choline and cytidine plasma levels	2002	-0.3968	-0.2517	62	1.7492
2101118776	psychophysiologic effects of hatha yoga on musculoskeletal and cardiopulmonary function a literature review	2002	1.6796	-0.9881	108	1
2101215924	the impact of respite use on nursing home placement	1995	0.5752	-0.1194	1	1
2101265858	long term efficacy and safety of donepezil in the treatment of alzheimer s disease final analysis of a us multicentre open label study	2000	-0.2156	0.0461	6	24.9771
2101276626	eht0202 in alzheimer s disease a 3 month randomized placebo controlled double blind study	2011	-0.411	0.0798	51	0.6571
2101282109	safety and efficacy of galantamine in subjects with mild cognitive impairment	2008	-0.147	-0.044	46	24.8329
2101327029	effects of rivastigmine on cognitive function in patients with traumatic brain injury	2006	-0.8455	1.017	71	19.6365
2101332478	behavioural management of aggression in dementia a randomized controlled trial	2001	0.4555	-0.0771	1	21.8736
2101493751	an exploratory cluster randomized controlled trial of group exercise on mobility and depression in care home residents	2009	0.4834	-0.1436	60	0.7993
2101901330	lack of evidence for the efficacy of memantine in mild alzheimer disease	2011	-0.1596	0.0646	6	0.9999
2101915633	interdisciplinary intervention for hip fracture in older taiwanese benefits last for 1 year	2008	2.1047	-0.0879	26	0.7705
2101916081	impact of the treatment of isolated systolic hypertension on behavioral variables results from the systolic hypertension in the elderly program	1994	-0.6751	-0.115	14	24.9485
2101966650	hippocampal hypometabolism predicts cognitive decline from normal aging	2008	-0.0645	0.0399	22	0.75
2101968930	dementelcoach effect of telephone coaching on carers of community dwelling people with dementia	2012	0.6854	-0.1437	97	0.7373
2101991516	prediction of cognitive decline in normal elderly subjects with 2 18f fluoro 2 deoxy d glucose positron emission tomography fdg pet	2001	-0.052	-0.0405	46	1
2102033735	a responder analysis of memantine treatment in patients with alzheimer disease maintained on donepezil	2006	-0.1845	0.0657	6	22.855
2102054469	alzheimer s disease multiple intervention trial admit study protocol for a randomized controlled clinical trial	2012	0.5272	-0.0877	34	0.6869
2102076625	effect of testosterone treatment on body composition and muscle strength in men over 65 years of age	1999	-1.2696	-1.5976	54	1
2102096535	association of perioperative risk factors and cumulative duration of low bispectral index with intermediate term mortality after cardiac surgery in the b unaware trial	2010	2.2027	-0.0374	36	0.9992
2102099471	their last 6 months suffering and survival of end stage dementia patients	2006	0.8533	-0.0193	95	0.916
2102179320	treatment of delirium in older adults with quetiapine	2003	2.1317	-0.041	2	0.9804
2102188395	current and emerging pharmacological treatment options for dementia	2006	-0.3792	0.0982	94	0.7888
2102198125	national institute of neurological disorders and stroke canadian stroke network vascular cognitive impairment harmonization standards	2006	-0.4366	-0.0021	12	4.8067
2102215373	repetitive transcranial magnetic stimulation combined with cognitive training is a safe and effective modality for the treatment of alzheimer s disease a randomized double blind study	2013	-0.1764	0.0549	67	1.3367
2102240367	longitudinal assessment of serum free testosterone concentration predicts memory performance and cognitive status in elderly men	2002	-0.9327	-1.0635	54	1
2102343148	development of a functional measure for persons with alzheimer s disease the disability assessment for dementia	1999	-0.314	0.0555	37	1.7798
2102386213	long term use of quetiapine in elderly patients with psychotic disorders	2000	0.0632	0.1032	38	1.7798
2102493638	atherosclerosis apolipoprotein e and prevalence of dementia and alzheimer s disease in the rotterdam study	1997	-0.6347	-0.0952	14	1
2102499412	effects of solcos model based individual reminiscence on older adults with mild to moderate dementia due to alzheimer disease a pilot study	2013	0.3873	-0.0857	18	1.5496
2102516205	a short term cognitive group treatment program gives substantial weight reduction up to 18 months from the end of treatment a randomized controlled trial	2005	-0.3244	-0.142	45	0.6969
2102528806	risk of dementia in diabetes mellitus a systematic review	2006	-0.4441	1.572	56	1.9999
2102572922	diagnosis and management of dementia with lewy bodies third report of the dlb consortium	2005	-0.1848	0.1189	7	11.6928
2102665693	effect of pharmacological treatment of depression on a1c and quality of life in low income hispanics and african americans with diabetes a randomized double blind placebo controlled trial	2009	-0.7628	-0.1427	135	0.7289
2102698273	the efficacy of ginkgo biloba on cognitive function in alzheimer disease	1998	-0.4425	-0.0737	8	8.8683
2102795510	effectiveness of interventions that assist caregivers to support people with dementia living in the community a systematic review	2008	0.6888	-0.1557	76	0.847
2102862785	reality orientation and dementia a controlled trial of two approaches	1981	0.3213	-0.0916	10	24.7715
2102979143	effect of angiotensin converting enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension the captopril prevention project cappp randomised trial	1999	-0.7249	-0.1428	14	1
2103019815	a systematic review of prevalence studies of dementia in parkinson s disease	2005	-0.1812	0.1048	7	10.6058
2103021636	cognitive training as an intervention to improve driving ability in the older adult	2010	0.5038	-0.2821	4	0.6898
2103040941	the effect of integrated emotion oriented care versus usual care on elderly persons with dementia in the nursing home and on nursing assistants a randomized clinical trial	2005	0.4152	-0.0699	18	8.3781
2103071556	nsaids and enantiomers of flurbiprofen target ?? secretase and lower a??42 in vivo	2003	-0.4262	-0.0768	32	2.991
2103120487	risperidone versus olanzapine for the treatment of delirium	2010	2.1515	-0.0417	2	1.9804
2103236957	bispectral index monitoring in patients undergoing cardiac surgery under cardiopulmonary bypass	2005	3.1472	0.1092	110	0.7382
2103279359	docosahexaenoic acid provides protection from impairment of learning ability in alzheimer s disease model rats	2002	-1.0601	-0.2893	5	0.9713
2103324311	serotonin and human cognitive performance	2006	0.0383	0.1961	61	0.9404
2103355169	diagnostic criteria for psychosis in parkinson s disease report of an ninds nimh work group	2007	-0.1733	0.1259	7	1
2103360995	effects of dehydroepiandrosterone replacement in elderly men on event related potentials memory and well being	1998	-1.4243	-1.846	20	0.9973
2103535459	homocysteine and folate as risk factors for dementia and alzheimer disease	2005	-0.8771	-0.1041	30	3.9912
2103605221	optimised anaesthesia to reduce post operative cognitive decline pocd in older patients undergoing elective surgery a randomised controlled trial	2012	2.202	-0.038	36	1
2103702422	clinical evidence of the effectiveness of vinpocetine in the treatment of organic psychosyndrome	1989	-0.2195	0.1014	23	14.8825
2103743940	elevated red blood cell plasma choline ratio in dimentia of the alzheimer type clinical and polysomnographic correlates	1984	-0.4086	0.3103	120	0.6543
2103824419	cytidine 5 diphosphocholine cdp choline in stroke and other cns disorders	2005	-0.3989	-0.2632	62	0.9867
2103825787	effect of discontinuation of antihypertensive treatment in elderly people on cognitive functioning the dante study leiden a randomized clinical trial	2015	-0.6901	-0.1912	79	15.7733
2103860290	what is cognitive reserve theory and research application of the reserve concept	2002	0.4804	-0.2637	4	1.9404
2103860510	a controlled trial of aromatherapy for agitation in nursing home patients with dementia	2004	0.4015	-0.0315	34	4.7575
2103881469	treatment of hypertension in patients 80 years of age or older	2008	-0.7295	-0.1512	14	26.5281
2103972533	assessing clinical and functional outcomes in the clinical antipsychotic trials of intervention effectiveness catie schizophrenia trial	2003	0.6426	0.1008	91	0.9713
2104049876	fish intake contaminants and human health evaluating the risks and the benefits	2006	-1.2428	-0.3453	83	1
2104057802	depression level among family caregivers of hospice patients	2009	0.6566	-0.1432	75	0.7855
2104117223	postoperative cognitive dysfunction is independent of type of surgery and anesthetic	2011	2.202	-0.038	36	0.9982
2104177956	hypoxia induced amnesia in one trial learning and pharmacological protection by piracetam	1972	-0.3176	0.263	15	0.845
2104197073	reduced risk of incident ad with elective statin use in a clinical trial cohort	2008	-0.7253	-0.1708	29	1.9978
2104227586	selective loss of central cholinergic neurons in alzheimer s disease	1976	-0.3118	0.1944	13	11.9586
2104262847	quasi experimental evaluation of an educational model for dementia caregivers	1994	0.5572	-0.1152	1	0.9867
2104285446	distribution interconversion and dose response of n 3 fatty acids in humans	2006	-1.1085	-0.3042	5	0.9867
2104289642	interdisciplinary inpatient care for elderly people with hip fracture a randomized controlled trial	2002	2.0957	-0.0862	26	2.7154
2104318219	an early mobilization protocol successfully delivers more and earlier therapy to acute stroke patients further results from phase ii of avert	2012	2.3691	-0.0642	35	0.7075
2104565625	the prevention of dementia with antihypertensive treatment new evidence from the systolic hypertension in europe syst eur study	2002	-0.6643	-0.1104	14	28.8032
2104625737	effect of aerobic training on the cognitive performance of elderly patients with senile dementia of alzheimer type	1996	0.4732	-0.1917	25	0.9994
2104631815	treatment effect of memantine on survival in dementia with lewy bodies and parkinson s disease with dementia a prospective study	2014	-0.1953	0.1187	92	16.389
2104792456	exercise a behavioral intervention to enhance brain health and plasticity	2002	0.5509	-0.2267	27	0.845
2104893553	economic evaluation of donepezil in moderate to severe alzheimer disease	2004	-0.1952	0.036	6	20.6583
2105005652	rivastigmine a placebo controlled trial of twice daily and three times daily regimens in patients with alzheimer s disease	2007	-0.2315	0.0503	19	20.7737
2105121811	validation of the npi q a brief clinical form of the neuropsychiatric inventory	2000	0.3137	-0.0714	1	0.9939
2105206504	fish consumption fish oil omega 3 fatty acids and cardiovascular disease	2002	-1.1981	-0.3316	83	1.75
2105233285	nicotinic acetylcholine involvement in cognitive function in animals	1998	0.0437	0.4832	48	1
2105276643	speed of processing and driving simulator training result in improved driving performance	2003	0.4805	-0.2573	4	2
2105318934	transcutaneous electrical nerve stimulation tens improves the rest activity rhythm in midstage alzheimer s disease	1999	0.246	-0.0133	17	24.6733
2105381698	wayfinding in a nursing home for advanced dementia of the alzheimer s type	2000	0.6741	-0.0194	24	0.9584
2105396282	risperidone risperdal increased rate of cerebrovascular events in dementia trials	2002	0.1895	0.0946	16	2
2105404700	reality orientation therapy combined with cholinesterase inhibitors in alzheimer s disease randomised controlled trial	2005	0.2841	-0.0939	10	35.5542
2105438388	the brain and the kidney connection a model of accelerated vascular cognitive impairment	2009	-0.8155	0.8222	102	0.6621
2105540437	sleep disturbance and melatonin levels following traumatic brain injury	2010	-1.2594	1.7614	64	0.9982
2105557195	piracetam novelty in a unique mode of action	1999	-0.3068	0.2482	15	0.9713
2105632027	simvastatin is associated with a reduced incidence of dementia and parkinson s disease	2007	-0.7284	-0.1718	29	0.9973
2105737601	goal oriented cognitive rehabilitation in early stage dementia study protocol for a multi centre single blind randomised controlled trial great	2013	0.2875	-0.1111	10	0.9973
2105770750	subthalamic deep brain stimulation clinical and neuropsychological outcomes in mild cognitive impaired parkinsonian patients	2014	0.0843	-0.0067	67	0.6716
2105816186	occurrence and progression of dementia in a community population aged 75 years and older relationship of antihypertensive medication use	1999	-0.6649	-0.1097	14	4
2105944457	effect of raloxifene on prevention of dementia and cognitive impairment in older women the multiple outcomes of raloxifene evaluation more randomized trial	2005	-0.0942	0.0057	84	0.7248
2105948530	bright light therapy for agitation in dementia a randomized controlled trial	2009	0.3075	-0.0193	17	22.2
2105994630	exercise for older women a training method and its influences on physical and cognitive performance	1992	0.5722	-0.2432	27	3.7262
2105995566	postoperative delirium acute change with long term implications	2011	2.1817	-0.0398	36	0.9999
2106006471	worksite based internet multimedia program for family caregivers of persons with dementia	2005	0.551	-0.1189	1	22.7433
2106046611	memantine in patients with frontotemporal lobar degeneration a multicentre randomised double blind placebo controlled trial	2013	-0.2339	0.2576	66	21.6502
2106096253	evolution of the evidence on the effectiveness and cost effectiveness of acetylcholinesterase inhibitors and memantine for alzheimer s disease systematic review and economic model	2013	-0.285	0.0852	33	0.6041
2106178861	change in indices of distress among latino and anglo female caregivers of elderly relatives with dementia site specific results from the reach national collaborative study	2003	0.5277	-0.1104	1	7.9442
2106268880	effectiveness of multicomponent nonpharmacological delirium interventions a meta analysis	2015	2.2066	-0.0451	2	1.7798
2106340452	new concepts of iron and aluminium chelation therapy with oral l1 deferiprone and other chelators a review	1995	-1.5731	-1.2608	101	0.75
2106343349	implications of recent clinical trials for the national cholesterol education program adult treatment panel iii guidelines	2004	-0.7878	-0.1882	88	3
2106370800	effects of panax ginseng on quality of life	2002	-0.6648	-0.1223	65	0.75
2106395007	variation in nursing home antipsychotic prescribing rates	2007	0.2168	0.063	16	0.8843
2106407512	liberal or restrictive transfusion in high risk patients after hip surgery	2011	2.566	-0.0494	125	0.9804
2106544395	regional cerebral glucose metabolism in late life depression and alzheimer disease a preliminary positron emission tomography study	1993	-0.4858	0.0852	117	0.6989
2106585418	a review of compliance to treatment in alzheimer s disease potential benefits of a transdermal patch	2007	-0.2386	0.05	19	3.9891
2106611175	tactile stimulation and consumer response	1992	0.5917	-0.0633	123	0.9584
2106630714	pravastatin and cognitive function in the elderly results of the prosper study	2010	-0.7242	-0.1692	29	22.9911
2106757561	donepezil in the treatment of cognitive dysfunction associated with traumatic brain injury	2000	-0.8474	1.0199	71	0.9804
2106792813	effectiveness and safety of memantine treatment for alzheimer s disease	2013	-0.0786	0.069	58	0.7689
2106802616	cognitive affective and behavioral effects of reminiscence group therapy on demented elderly	1987	0.3213	-0.0908	39	1.7993
2106862465	multimodal markers of inflammation in the subcortical ischemic vascular disease type of vascular cognitive impairment	2014	-0.7263	0.0224	107	0.6942
2106876061	fish oil supplementation induces antiinflammatory gene expression profiles in human blood mononuclear cells	2009	-1.1091	-0.3045	5	3.7036
2106888831	n 3 fatty acid erythrocyte membrane content apoe e4 and cognitive variation an observational follow up study in late adulthood	2008	-1.026	-0.2782	5	2.9999
2106931873	research criteria for the diagnosis of alzheimer s disease revising the nincds adrda criteria	2007	-0.1031	-0.0243	46	4.7947
2107031757	statistical power analysis for the behavioral sciences	1969	0.4797	-0.2652	4	0.991
2107056441	cognitive stimulation therapy in the treatment of neuropsychiatric symptoms in alzheimer s disease a randomized controlled trial	2010	0.1643	-0.0462	10	1.5083
2107081077	vascular dementia possible role of the ischemic lesions in mild dementia	2006	-0.3792	0.0982	94	0.8355
2107172544	differences in neuropathologic characteristics across the lewy body dementia spectrum	2006	-0.1859	0.0725	7	0.75
2107246366	molecular mechanisms transducing the anesthetic analgesic and organ protective actions of xenon	2006	3.1473	0.1092	110	0.7993
2107263474	delirium is a strong risk factor for dementia in the oldest old a population based cohort study	2012	2.1944	-0.0495	2	0.845
2107295258	primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the collaborative atorvastatin diabetes study cards multicentre randomised placebo controlled trial	2004	-0.7875	-0.1892	88	3
2107327255	the influence of oestrogens on the wellbeing and mental performance in climacteric and postmenopausal women	1977	-0.7669	-0.7755	3	2
2107327698	efficacy and safety of galantamine in patients with mild to moderate alzheimer s disease multicentre randomised controlled trial	2000	-0.2236	0.0379	6	47.4646
2107329846	randomized trial to evaluate the efficacy of cognitive therapy for low functioning patients with schizophrenia	2012	0.0708	0.1428	61	0.7412
2107382304	xenon preconditioning protects against renal ischemic reperfusion injury via hif 1 alpha activation	2009	3.1474	0.1092	110	0.845
2107501599	fitness effects on the cognitive function of older adults a meta analytic study	2003	0.5727	-0.2469	25	24.6945
2107522606	chronic divalproex sodium to attenuate agitation and clinical progression of alzheimer disease	2011	-0.5785	-0.1496	32	0.991
2107820540	vitamin e and donepezil for the treatment of mild cognitive impairment	2005	-0.2987	-0.0572	46	46.5243
2107853710	interventions to optimise prescribing in care homes systematic review	2011	0.597	-0.0144	52	0.8843
2107877547	disturbance and strategies for reactivation of the circadian rhythm system in aging and alzheimer s disease	2007	0.2771	-0.0171	17	0.9999
2107881620	pimavanserin for patients with parkinson s disease psychosis a randomised placebo controlled phase 3 trial	2014	-0.1947	0.1187	92	0.7993
2107906705	psychological treatments for depression and anxiety in dementia and mild cognitive impairment	2014	0.7627	-0.2018	77	0.8012
2107943245	omega 3 fatty acid supplementation effects on weight and appetite in patients with alzheimer s disease the omega 3 alzheimer s disease study	2009	-1.0829	-0.2957	5	19.7763
2108045917	effectiveness of staff training programs for behavioral problems among older people with dementia	2007	0.5322	-0.0667	18	0.9713
2108094099	change in cognitive functioning following acute antidepressant treatment in late life depression	2009	-0.2626	0.1647	9	0.6561
2108206449	a controlled study of respite service for caregivers of alzheimer s patients	1989	0.5734	-0.1182	1	25.3798
2108229246	trough plasma concentrations of mifepristone correlate with psychotic symptom reductions a review of three randomized clinical trials	2013	-0.1168	0.194	114	0.6961
2108231975	effect of piracetam on level of consciousness after neurosurgery	1977	-0.2967	0.1624	41	1.4039
2108257991	melatonin for sleep disorders and cognition in dementia a meta analysis of randomized controlled trials	2015	0.196	-0.0166	28	0.8843
2108302312	the effects of age glucose ingestion and gluco regulatory control on episodic memory	2004	-0.4598	1.8033	96	0.8843
2108326377	treatment with simvastatin in normocholesterolemic patients with alzheimer s disease a 26 week randomized placebo controlled double blind trial	2002	-0.7198	-0.1666	29	26.9647
2108335346	neuropsychiatric symptoms in alzheimer s disease	2011	0.3137	-0.0714	1	0.9973
2108366494	rivastigmine transdermal system for the treatment of mild to moderate alzheimer s disease	2010	-0.2557	0.0526	72	1.7762
2108386918	goal oriented cognitive rehabilitation of memory in early stage alzheimer s disease single blind randomized controlled trial of clinical efficacy	2011	-0.2875	0.2061	15	0.69
2108410348	report of the second dementia with lewy body international workshop diagnosis and treatment	1999	-0.1926	0.1212	7	0.9973
2108442841	effects of immunomodulatory treatment with subcutaneous interferon beta 1a on cognitive decline in mildly disabled patients with relapsing remitting multiple sclerosis	2010	-0.2326	0.2003	55	0.7993
2108459440	management of agitation aggression and psychosis associated with dementia a pooled analysis including three randomized placebo controlled double blind trials in nursing home residents treated with risperidone	2005	0.1573	0.0923	16	0.7999
2108485082	long term cognitive impairment after critical illness	2013	2.2027	-0.0438	2	1.8753
2108517583	a histochemical study of iron transferrin and ferritin in alzheimer s diseased brains	1992	-1.0107	-0.5241	69	1
2108531037	efficacy and safety of nimodipine in subcortical vascular dementia a randomized placebo controlled trial	2005	-0.4378	0.0021	12	20.2894
2108558610	the impact of validation group therapy on nursing home residents with dementia	1997	0.4067	-0.0715	18	24.2673
2108734932	a prospective study on cortisol dehydroepiandrosterone sulfate and cognitive function in the elderly	1998	-1.4227	-1.8434	20	1.9973
2108736063	effect of combination therapy with memantine and rivastigmine transdermal patch on bpsd in patients with mild to moderate alzheimer s disease a 24 week prospective multicenter randomized open label clinical trial	2012	-0.2432	0.0563	19	1.6387
2108794919	additional exercise for older subacute hospital inpatients to prevent falls benefits and barriers to implementation and evaluation	2007	2.2795	-0.0629	35	0.75
2108841481	a systematic method for estimating individual responses to treatment with antipsychotics in catie	2009	0.6426	0.1008	91	0.7444
2108851081	psychiatric and physical morbidity effects of dementia caregiving prevalence correlates and causes	1995	0.5342	-0.0981	1	15.2677
2108894968	ethyl eicosapentaenoic acid for the treatment of psychological distress and depressive symptoms in middle aged women a double blind placebo controlled randomized clinical trial	2009	-1.0972	-0.3014	5	0.9973
2108900226	efficacy of metrifonate in improving the psychiatric and behavioral disturbances of patients with alzheimer s disease	2001	-0.1978	0.076	44	0.8843
2108913387	cognitive factors for predicting treatment response in schizophrenic patients one year follow up study	2008	-0.2521	-0.1978	49	1.4548
2109005423	early physical and occupational therapy in mechanically ventilated critically ill patients a randomised controlled trial	2009	2.3073	-0.0571	35	1.7126
2109069020	clozapine in drug induced psychosis in parkinson s disease a randomised placebo controlled study with open follow up	2004	-0.1733	0.1259	7	1
2109077430	cognitive training decreases motor vehicle collision involvement of older drivers	2010	0.4853	-0.2604	4	1
2109167237	a pilot study of low dose l deprenyl in alzheimer s disease	1991	-0.1811	0.114	37	6.2468
2109225320	n 3 polyunsaturated fatty acids inflammation and inflammatory diseases	2006	-1.1085	-0.3042	5	0.9867
2109322748	no effect of n 3 long chain polyunsaturated fatty acid epa and dha supplementation on depressed mood and cognitive function a randomised controlled trial	2008	-1.0954	-0.3007	5	2.9773
2109348896	¤ë 3 fatty acid treatment in 174 patients with mild to moderate alzheimer disease omegad study a randomized double blind trial	2006	-1.0084	-0.2676	5	19.9544
2109361903	acute hospital care how much activity is attributable to caring for patients with dementia	2016	0.9833	-0.0254	24	0.7078
2109395969	a preliminary randomized double blind placebo controlled trial of l carnosine to improve cognition in schizophrenia	2012	-0.2409	0.1654	9	0.7001
2109527205	a 2 year multidomain intervention of diet exercise cognitive training and vascular risk monitoring versus control to prevent cognitive decline in at risk elderly people finger a randomised controlled trial	2015	-0.4634	-0.0729	8	0.9804
2109544293	homocysteine lowering with folic acid and b vitamins in vascular disease	2006	-0.8724	-0.1042	30	1
2109557436	endogenous estradiol and testosterone levels are associated with cognitive performance in older women and men	2002	-0.9327	-1.0635	54	1
2109695658	a dopamine agonist pramipexole and cognitive functions in parkinson s disease	2006	-0.2338	0.184	9	0.6521
2109756097	aerobic exercise training and improved neuropsychological function of older individuals	1984	0.5802	-0.2505	27	4.9866
2109891655	efficacy and safety of tarenflurbil in mild to moderate alzheimer s disease a randomised phase ii trial	2008	-0.4942	-0.1191	32	2.9951
2109902553	improved working memory performance following administration of a single dose of american ginseng panax quinquefolius l to healthy middle age adults	2015	-0.6634	-0.1226	65	1.5631
2109916969	relapse risk after discontinuation of risperidone in alzheimer s disease	2012	0.1426	0.053	80	22.7006
2110024892	general practitioners knowledge confidence and attitudes in the diagnosis and management of dementia	2004	0.5734	-0.1262	74	0.9999
2110055177	a randomized trial of a cam therapy for stress reduction in american indian and alaskan native family caregivers	2009	0.6554	-0.1435	75	15.5766
2110066995	acetylcarnitine induces heme oxygenase in rat astrocytes and protects against oxidative stress involvement of the transcription factor nrf2	2005	-0.319	0.0032	63	0.9404
2110101821	preventing falls on an elderly care rehabilitation ward	2000	2.2795	-0.0629	35	0.845
2110105436	a reduced stimulation unit effects on patients with alzheimer s disease and related disorders	1988	0.6761	-0.022	24	0.9584
2110153914	complex mental and physical activity in older women and cognitive performance a 6 month randomized controlled trial	2010	0.5368	-0.188	27	0.8843
2110225331	efficacy of increasing donepezil in mild to moderate alzheimer s disease patients who show a diminished response to 5 mg donepezil a preliminary study	2013	-0.2145	0.1376	11	3.3074
2110287843	randomized placebo controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in alzheimer s disease	2003	-0.1607	0.0147	46	23.2334
2110290389	reality orientation and reminiscence therapy a controlled cross over study of elderly confused people	1987	0.3424	-0.0885	10	28.8464
2110303343	provision of antioxidant therapy in hemodialysis path a randomized clinical trial	2014	-1.1801	-0.326	129	0.6854
2110353868	cost effectiveness of memantine in moderate to severe alzheimer s disease patients receiving donepezil	2007	-0.1997	0.1275	11	1.5515
2110387339	acute dose dependent cognitive effects of ginkgo biloba panax ginseng and their combination in healthy young volunteers differential interactions with cognitive demand	2002	-0.658	-0.1204	65	3.5926
2110390916	current concepts in cobalamin deficiency	2000	-0.9233	-0.1078	30	0.991
2110413198	amantadine to improve neurorecovery in traumatic brain injury associated diffuse axonal injury a pilot double blind randomized trial	2002	-0.8474	1.0199	71	0.991
2110418106	survival as a function of hba1c in people with type 2 diabetes a retrospective cohort study	2010	-0.4276	1.4428	56	0.7993
2110451811	enhanced verbal memory in nondemented elderly women receiving hormone replacement therapy	2001	-0.759	-0.763	3	2
2110502449	effects of estrogen plus progestin on health related quality of life	2003	-0.7369	-0.7348	3	2.8843
2110575881	a home based training program improves taiwanese family caregivers quality of life and decreases their risk for depression a randomized controlled trial	2013	0.657	-0.144	75	0.7724
2110647017	vitamin b12 deficiency and depression in physically disabled older women epidemiologic evidence from the women s health and aging study	2000	-0.8812	-0.1041	30	0.991
2110653810	towards a theory of dementia care personhood and well being	1992	0.365	-0.0062	18	0.9999
2110656850	assessment of behavioral problems in dementia the revised memory and behavior problems checklist	1992	0.5242	-0.0997	1	5.931
2110685668	cognitive and mood effects in healthy children during 12 weeks supplementation with multi vitamin minerals	2008	-0.6634	-0.1226	65	1.3861
2110765139	necropsy evidence of central cholinergic deficits in senile dementia	1977	-0.3212	0.2072	13	2.5492
2110787335	lecithin administration in alzheimer dementia	1982	-0.3301	0.2585	59	16.5207
2110790733	comparison of desipramine and citalopram treatments for depression in parkinson s disease a double blind randomized placebo controlled study	2008	-0.1878	0.1167	7	0.9959
2110808599	estradiol or estradiol progesterone treatment in older women no strong effects on cognition	2005	-0.7482	-0.7567	3	17.9447
2110842285	cholinesterase inhibitor adjunctive therapy for cognitive impairment and depressive symptoms in older adults with depression	2012	-0.2326	0.2003	55	0.7527
2110850052	the caregiver activity survey cas development and validation of a new measure for caregivers of persons with alzheimer s disease	1997	0.0989	-0.0506	93	1.7993
2110880027	benazepril plus amlodipine or hydrochlorothiazide for hypertension in high risk patients	2008	-0.7322	-0.152	14	1
2110887671	gonadal steroids regulate dendritic spine density in hippocampal pyramidal cells in adulthood	1990	-0.7608	-0.7686	3	3.9996
2110952851	effects of transdermal testosterone on cognitive function and health perception in older men with low bioavailable testosterone levels	2002	-0.9327	-1.0635	54	1
2111042359	traumatic brain injury related attention deficits treatment outcomes with lisdexamfetamine dimesylate vyvanse	2014	-0.9922	1.2607	71	0.71
2111250918	progression to dementia according to subtype of mild cognitive impairment mci	2013	-0.1892	0.0233	78	0.8521
2111292923	effects of transcutaneous electrical nerve stimulation tens on memory in elderly with mild cognitive impairment	2005	0.1928	-0.0105	17	0.779
2111301169	ten year effects of the advanced cognitive training for independent and vital elderly cognitive training trial on cognition and everyday functioning in older adults	2014	0.4644	-0.2426	4	1.7993
2111361801	a 25 week open label trial investigating rivastigmine transdermal patches with concomitant memantine in mild to moderate alzheimer s disease a post hoc analysis	2010	-0.2401	0.0572	19	3.0031
2111414523	a systematic review of the scientific evidence for the efficacy of a palliative care approach in advanced dementia	2005	0.8533	-0.0193	95	0.9994
2111446347	consumption of wheat aleurone rich foods increases fasting plasma betaine and modestly decreases fasting homocysteine and ldl cholesterol in adults	2010	-1.9287	0.3319	109	0.7449
2111460255	adult day care for the frail elderly outcomes satisfaction and cost	2002	0.559	-0.1168	142	0.7993
2111572957	a randomized trial of vitamin e supplementation and cognitive function in women	2006	-0.451	-0.1027	82	1.9671
2111581233	biochemical assessment of serotonergic and cholinergic dysfunction and cerebral atrophy in alzheimer s disease	1983	-0.323	0.2085	13	0.75
2111634496	factors associated with short term functional recovery in elderly people with a hip fracture influence of cognitive impairment	2015	2.1047	-0.0879	26	0.771
2111640628	inpatient multidisciplinary rehabilitation after hip fracture for residents of nursing homes a randomised trial	2008	2.186	-0.0851	26	16.283
2111711625	haloperidol prophylaxis does not prevent postoperative delirium in elderly patients a randomized open label prospective trial	2014	2.2126	-0.0444	2	15.9077
2111751177	286 efficacy of duloxetine in patients with fibromyalgia pooled analysis of four placebo controlled clinical trials	2008	-0.5169	-0.0473	12	0.6806
2111757144	chronic administration of docosahexaenoic acid ameliorates the impairment of spatial cognition learning ability in amyloid ?? infused rats	2005	-1.0758	-0.294	5	0.9404
2111811285	cyclic estrogen replacement improves cognitive function in aged ovariectomized rhesus monkeys	2003	-0.7552	-0.7633	3	4.9129
2111845136	randomized double blind placebo controlled donepezil augmentation in antidepressant treated elderly patients with depression and cognitive impairment a pilot study	2008	-0.234	0.1611	9	3.5204
2111870618	eeg abnormalities in association with cognitive profile in alzheimer s disease	2010	-0.2809	0.1571	43	0.6382
2111932515	music during interventional radiological procedures effect on sedation pain and anxiety a randomised controlled trial	2012	2.3341	0.1905	103	0.7039
2111963393	the neuropsychiatric inventory comprehensive assessment of psychopathology in dementia	1994	0.0817	0.0266	6	112.6289
2112009812	effects of music on alzheimer patients	1993	0.4784	-0.0522	21	19.8104
2112121535	evaluating a cognitive behavioral therapy group program for anxious five to seven year old children a pilot study	2009	0.6749	-0.1727	77	0.7392
2112150247	vascular dementia diagnostic criteria for research studies report of the ninds airen international workshop	1993	-0.4032	0.0083	12	22.9946
2112165124	rating neurologic impairment in multiple sclerosis an expanded disability status scale edss	1983	-0.2418	0.2129	55	1.9973
2112167949	effects of snoezelen integrated in 24 h dementia care on nurse patient communication during morning care	2005	0.422	-0.0772	18	0.9973
2112482557	prevention of intraoperative awareness in a high risk surgical population	2011	2.202	-0.038	36	0.9997
2112519660	development and validation of a geriatric depression screening scale a preliminary report	1982	0.3385	-0.0857	31	3.5847
2112522119	donepezil in patients with severe alzheimer s disease double blind parallel group placebo controlled study	2006	-0.2151	0.0444	6	39.9131
2112549296	comparison of citalopram perphenazine and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized demented patients	2002	0.168	0.0822	16	42.4376
2112553056	nursing home staff training in dementia care a systematic review of evaluated programs	2007	0.5322	-0.0667	18	0.9584
2112587738	iron accumulation in alzheimer disease is a source of redox generated free radicals	1997	-1.0107	-0.5241	69	1
2112600190	evaluation of the clinical efficacy of idebenone in patients affected by chronic cerebrovascular disorders	1992	-0.417	0.0419	41	0.6604
2112668155	reduction in cardiovascular events with atorvastatin in 2 532 patients with type 2 diabetes anglo scandinavian cardiac outcomes trial lipid lowering arm ascot lla	2005	-0.5188	-0.0906	68	0.7032
2112710171	a double blind comparison of galantamine hydrobromide er and placebo in parkinson disease	2009	-0.2337	0.1908	9	1.4216
2112746718	dementia and disability outcomes in large hypertension trials lessons learned from the systolic hypertension in the elderly program shep trial	2001	-0.6645	-0.1105	14	21.7932
2112758846	improvement of episodic memory in persons with mild cognitive impairment and healthy older adults evidence from a cognitive intervention program	2006	0.3302	-0.1751	4	3.9523
2112778345	the ces d scale a self report depression scale for research in the general population	1977	0.5304	-0.1099	1	13.8181
2112785471	memory enhancement program for community based older adults development and evaluation	1996	0.5076	-0.2847	4	0.916
2112815097	olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with alzheimer s disease	2004	0.1831	0.0966	16	33.1904
2112914675	randomized controlled trial of memantine in dementia associated with parkinson s disease	2009	-0.1872	0.1168	7	24.2944
2112946832	the action study methodology of a trial to evaluate safety and efficacy of a higher dose rivastigmine transdermal patch in severe alzheimer s disease	2010	-0.2488	0.0714	19	3.2311
2112957305	longitudinal modeling of age related memory decline and the apoe e4 effect	2009	-0.7705	-0.1862	29	0.9713
2113097158	a randomised pilot study to assess the efficacy of an interactive multimedia tool of cognitive stimulation in alzheimer s disease	2006	0.2663	-0.0991	10	2.8155
2113140773	is caregiving hazardous to one s physical health a meta analysis	2003	0.5295	-0.1102	1	1.9959
2113153348	dosing of neuroleptics in elderly demented patients with aggressive and agitated behaviour a double blind study with zuclopenthixol	1994	0.1301	0.1278	47	0.8428
2113155013	long term use of standardised ginkgo biloba extract for the prevention of alzheimer s disease guidage a randomised placebo controlled trial	2012	-0.4609	-0.0711	8	27.3302
2113169386	cerebrospinal fluid biomarkers and rate of cognitive decline in very mild dementia of the alzheimer type	2009	-0.2942	0.0285	57	0.7164
2113259481	cardiovascular disease outcomes during 6 8 years of hormone therapy heart and estrogen progestin replacement study follow up hers ii	2002	-0.7355	-0.7379	3	0.845
2113264115	randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women	1998	-0.7297	-0.7203	3	4.8843
2113287856	continuous positive airway pressure deepens sleep in patients with alzheimer s disease and obstructive sleep apnea	2009	0.2279	-0.0033	28	0.9804
2113319228	relapse prevention in schizophrenia with new generation antipsychotics a systematic review and exploratory meta analysis of randomized controlled trials	2003	0.6426	0.1008	91	0.75
2113347254	the impact of speed of processing training on cognitive and everyday functions	2007	0.4778	-0.2541	4	3
2113390055	choline supplementation and measures of choline and betaine status a randomised controlled trial in postmenopausal women	2012	-1.9284	0.3325	109	0.7119
2113391500	the influence of apoe status on episodic and semantic memory data from a population based study	2006	-0.7705	-0.1862	29	0.991
2113406852	topography of cross sectional and longitudinal glucose metabolic deficits in alzheimer s disease pathophysiologic implications	1992	-0.4858	0.0852	117	0.7026
2113516763	interactive imagery and affective judgments improve face name learning in the elderly	1983	0.5077	-0.2843	4	2.7113
2113535256	hydrocortisone therapy for patients with septic shock	2008	2.5489	-0.0698	35	0.75
2113554614	project care a randomized controlled trial of a behavioral intervention group for alzheimer s disease caregivers	2006	0.4779	-0.1055	1	22.1453
2113630681	differential circadian rhythm disturbances in men with alzheimer disease and frontotemporal degeneration	2001	0.2992	-0.0174	17	1
2113638285	efficacy of omega 3 fatty acid supplements eicosapentaenoic acid and docosahexaenoic acid in the secondary prevention of cardiovascular disease a meta analysis of randomized double blind placebo controlled trials	2012	-1.2428	-0.3453	83	1
2113642314	mixed dementia alzheimer s and cerebrovascular disease	2003	-0.4055	0.0833	85	0.6751
2113649190	frailty and incident dementia	2013	0.5372	-0.2244	136	0.9404
2113682883	reliability and validity of useful field of view test scores as administered by personal computer	2005	0.4853	-0.2604	4	1
2113690827	a subset of nsaids lower amyloidogenic a??42 independently of cyclooxygenase activity	2001	-0.4212	-0.0729	32	5.9999
2113708991	current concepts in mild cognitive impairment	2001	-0.0719	-0.059	46	8.9335
2113805305	cognitive rehabilitation and cognitive training for early stage alzheimer s disease and vascular dementia	2003	0.2663	-0.1044	10	19.4996
2113839148	cholinergic serotonergic imbalance contributes to cognitive and behavioral symptoms in alzheimer s disease	2005	0.0276	0.2948	48	1.539
2113882460	caregiver supports outcomes from the medicare alzheimer s disease demonstration	1997	0.5401	-0.1067	1	4.7296
2113891227	no long term effect of behavioral treatment on psychotropic drug use for agitation in alzheimer s disease patients	2002	0.1419	0.0449	58	14.9863
2113916544	goal oriented cognitive rehabilitation for an individual with mild cognitive impairment behavioural and neuroimaging outcomes	2009	0.2875	-0.1111	10	0.9939
2113920263	can reality orientation be rehabilitated development and piloting of an evidence based programme of cognition based therapies for people with dementia	2001	0.2872	-0.0925	10	33.5532
2113931709	effects of extended release memantine 28 mg day on cognitive domains in patients with moderate to severe alzheimer s disease post hoc analysis of a randomized trial	2011	-0.2382	0.0589	19	2.38
2114073385	alzheimer s disease international	1997	-0.4424	0.2875	105	0.8547
2114074762	neuroimaging predictors of dementia in stroke patients	2002	-0.7263	0.0224	107	0.6733
2114083018	differential effect of a dopaminergic agonist on prefrontal function in traumatic brain injury patients	1998	-0.8474	1.0199	71	0.9584
2114092053	prophylactic treatment with paroxetine ameliorates behavioral deficits and retards the development of amyloid and tau pathologies in 3xtgad mice	2007	0.0383	0.1961	61	0.991
2114136027	does donepezil treatment slow the progression of hippocampal atrophy in patients with alzheimer s disease	2005	-0.1615	0.0146	46	1
2114163624	memantine a nmda receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system too little activation is bad too much is even worse	2007	-0.1848	0.1075	6	0.7993
2114206584	clinical benefits of extended release memantine 28 mg once daily as a function of disease severity in people with moderate to severe alzheimer s disease post hoc analysis from a randomized trial	2013	-0.0749	0.063	58	14.9388
2114219483	combination treatment in alzheimers disease results of a randomized controlled trial with cerebrolysin and donepezil	2011	-0.3717	-0.0078	70	0.7993
2114224394	cognitive and behavioural efficacy of amantadine in acute traumatic brain injury an initial double blind placebo controlled study	1999	-0.9182	1.1383	71	1.6615
2114242035	the fatigue severity scale application to patients with multiple sclerosis and systemic lupus erythematosus	1989	-1.212	1.6632	64	1.8753
2114248765	randomized placebo controlled double blind clinical trial of sertraline in the treatment of depression complicating alzheimer s disease initial results from the depression in alzheimer s disease study	2000	0.1929	0.1012	31	9.6308
2114262384	efficacy and safety of a paired sedation and ventilator weaning protocol for mechanically ventilated patients in intensive care awakening and breathing controlled trial a randomised controlled trial	2008	2.2375	-0.0482	2	1
2114293963	quetiapine and rivastigmine and cognitive decline in alzheimer s disease randomised double blind placebo controlled trial	2005	0.1689	0.077	16	45.2936
2114327504	eeg comparisons in early alzheimer s disease dementia with lewy bodies and parkinson s disease with dementia patients with a 2 year follow up	2008	-0.1954	0.1191	92	0.7993
2114328524	delirium in older medical inpatients and subsequent cognitive and functional status a prospective study	2001	2.1014	-0.0419	2	1
2114343024	effects of group music intervention on behavioral and psychological symptoms in patients with dementia a pilot controlled trial	2009	0.4905	-0.0533	21	4.8224
2114395018	a randomized controlled trial of olanzapine improving memory deficits in han chinese patients with first episode schizophrenia	2013	-0.2409	0.1654	9	0.709
2114437291	diabetes in older adults	2012	-0.4267	1.4429	56	0.7993
2114459473	reality orientation for dementia a systematic review of the evidence of effectiveness from randomized controlled trials	2000	0.2875	-0.0942	10	1.9993
2114509850	mediterranean diet alzheimer disease and vascular mediation	2006	-1.0758	-0.294	5	0.916
2114613490	a rating scale for depression	1960	0.2269	0.0829	31	4.9199
2114624568	serum folate and the severity of atrophy of the neocortex in alzheimer disease findings from the nun study	2000	-0.8848	-0.1035	30	0.9973
2114634962	randomised double blind comparison of placebo and active treatment for older patients with isolated systolic hypertension	1997	-0.7082	-0.131	14	12.7436
2114639118	reminiscence therapy for dementia	2005	0.3659	-0.0902	39	6.4075
2114677584	impact and recognition of cognitive impairment among hospitalized elders	2010	1.6418	-0.0325	24	0.845
2114690339	the effects of reminiscence therapy on psychological well being depression and loneliness among the institutionalized aged	2010	0.3574	-0.0939	39	0.845
2114706019	a double blind trial of haloperidol chlorpromazine and lorazepam in the treatment of delirium in hospitalized aids patients	2005	2.1517	-0.0415	2	1.9908
2114753322	minimal neuropsychological assessment of ms patients a consensus approach	2002	-0.2419	0.2132	55	2.9954
2114829862	relations of vitamin b 12 vitamin b 6 folate and homocysteine to cognitive performance in the normative aging study	1996	-0.8916	-0.1049	30	3.9856
2114888041	the pattern of cognitive performance in cadasil a monogenic condition leading to subcortical ischemic vascular dementia	2005	-0.45	-0.0021	12	0.9999
2114943413	cholinergic deficiency hypothesis in delirium a synthesis of current evidence	2008	2.2243	-0.0437	2	0.9988
2114952104	music therapy in moderate and severe dementia of alzheimer s type a case control study	2006	0.4685	-0.0564	21	31.6956
2114977515	evaluating high dose rivastigmine patch in severe alzheimer s disease analyses with concomitant memantine usage as a factor	2015	-0.2545	0.053	72	0.8234
2115005692	nicotine effects on adults with attention deficit hyperactivity disorder	1996	0.0437	0.4832	48	1
2115012618	a sharper bonferroni procedure for multiple tests of significance	1988	0.6426	0.1008	91	0.845
2115013553	visual and cognitive impairment in patients with dementia with lewy bodies and alzheimer s disease	2010	-0.1375	0.2003	100	0.7534
2115017507	the diagnosis of dementia due to alzheimer s disease recommendations from the national institute on aging alzheimer s association workgroups on diagnostic guidelines for alzheimer s disease	2011	-0.1696	-0.029	46	14.6145
2115026925	dementia associated with parkinson s disease	2003	-0.1825	0.1073	7	2
2115115146	effectiveness of second generation antipsychotics in patients with treatment resistant schizophrenia a review and meta analysis of randomized trials	2001	0.6426	0.1008	91	0.7993
2115118763	updated research nosology for hiv associated neurocognitive disorders	2007	-0.4009	0.5012	87	1.9999
2115123524	enrichment effects on adult cognitive development can the functional capacity of older adults be preserved and enhanced	2008	0.4638	-0.2439	4	3.7933
2115235249	cognitive effects of atypical antipsychotic medications in patients with alzheimer s disease outcomes from catie ad	2011	0.1685	0.0594	58	1.4925
2115260847	effect of support and counseling on caregivers of patients with alzheimer s disease	2000	-2.1415	2.1679	121	0.8789
2115264344	a multicenter trial of selegiline transdermal system for hiv associated cognitive impairment	2007	-0.401	0.5018	87	1.971
2115294836	efficacy of donepezil in mild cognitive impairment a randomized placebo controlled trial	2004	-0.1713	-0.0363	46	26.5786
2115432748	risk of mortality among individual antipsychotics in patients with dementia	2012	0.1629	0.0556	80	2.9989
2115455636	rivastigmine for dementia associated with parkinson s disease	2004	-0.1895	0.1016	7	41.645
2115479401	the value of telephone support groups among ethnically diverse caregivers of persons with dementia	2006	0.598	-0.133	1	3.6849
2115561330	acyclonucleoside iron chelators of 1 2 hydroxyethoxy methyl 2 alkyl 3 hydroxy 4 pyridinones potential oral iron chelation therapeutics	2004	-1.5731	-1.2608	101	0.7993
2115625204	using targeted risk factor reduction to prevent falls in older in patients a randomised controlled trial	2004	2.2795	-0.0629	35	0.845
2115626005	systematic detection and multidisciplinary care of delirium in older medical inpatients a randomized trial	2006	2.0988	-0.0418	2	19.9999
2115646104	increasing walking and bright light exposure to improve sleep in community dwelling persons with alzheimer s disease results of a randomized controlled trial	2011	0.2429	-0.0108	28	20.3005
2115703273	do treatment effects vary among differing baseline depression criteria in depression in alzheimer s disease study 2 diads 2	2011	0.2114	0.0899	31	1.7806
2115811583	is dementia reversible in patients with neurocysticercosis	2005	-0.4164	0.0413	41	0.6678
2115831071	clinical trials in mild cognitive impairment lessons for the future	2006	-0.1462	-0.0418	46	0.9998
2115836576	effects of aspirin plus extended release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the prevention regimen for effectively avoiding second strokes profess trial a double blind active and placebo controlled study	2008	-0.5303	-0.0471	12	1.845
2115908598	action spectrum for melatonin regulation in humans evidence for a novel circadian photoreceptor	2001	0.2937	-0.0183	17	1
2115955076	a multiple imputation strategy for sequential multiple assignment randomized trials	2014	0.6426	0.1008	91	0.7234
2116005865	metal protein attenuating compounds for the treatment of alzheimer s dementia	2014	-0.327	-0.0232	63	0.7395
2116018809	efficacy and safety of donepezil in patients with more severe alzheimer s disease a subgroup analysis from a randomized placebo controlled trial	2005	-0.1868	0.056	6	23.8932
2116140974	a double blind placebo controlled randomized trial of ginkgo biloba extract egb 761 in a sample of cognitively intact older adults neuropsychological findings	2002	-0.3627	-0.1751	8	2.7612
2116201275	determination of a cut off value for the molar ratio of retinol binding protein to transthyretin rbp ttr in bangladeshi patients with low hepatic vitamin a stores	2002	-1.2104	-0.3345	128	0.7034
2116225616	effectiveness of olanzapine quetiapine risperidone and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic	2006	0.6426	0.1008	91	0.845
2116234326	six month outcomes following an emergency hospital admission for older adults with co morbid mental health problems indicate complexity of care needs	2013	0.9833	-0.0254	24	0.7123
2116243886	strategies to secure compliance for a mall intercept interview	1988	0.5917	-0.0633	123	0.8843
2116249921	efficacy of rivastigmine in dementia with lewy bodies a randomised double blind placebo controlled international study	2000	-0.1896	0.1162	7	42.9908
2116250286	gabapentin as a possible treatment of behavioral alterations in alzheimer disease ad patients	2001	-0.3792	0.0982	94	0.7985
2116424646	dietary intake of antioxidants and risk of alzheimer disease	2002	-0.6352	-0.0923	86	5.7452
2116434252	homocysteine vitamin b 12 and folic acid and the risk of cognitive decline in old age the leiden 85 plus study	2005	-0.8708	-0.1029	30	1
2116467809	intraoperative high dose dexamethasone and severe aki after cardiac surgery	2015	2.5489	-0.0698	35	0.75
2116565943	validity of current clinical criteria for alzheimer s disease vascular dementia and dementia with lewy bodies	1999	-0.1921	0.122	7	0.9867
2116576199	cognition is not modified by large but temporary changes in sex hormones in men	2009	-0.7504	-0.7583	3	0.8073
2116611174	effects of an automated telephone support system on caregiver burden and anxiety findings from the reach for tlc intervention study	2003	0.5221	-0.1116	1	13.3891
2116650798	providing activity for people with dementia in care homes a cluster randomised controlled trial	2013	0.395	-0.1042	39	0.796
2116719944	the effects of a collaborative model of primary care on the mortality and hospital use of community dwelling older adults	2001	0.5774	-0.1229	139	0.7553
2116773974	prevention of relapse in residual depression by cognitive therapy	1999	0.0708	0.1428	61	0.7491
2116784956	inflammation and alzheimer s disease	2000	-0.4263	-0.0756	32	6.9945
2116815965	effectiveness of a follow up program for elderly heart failure patients after hospital discharge a randomized controlled trial	2014	2.3691	-0.0643	35	0.7129
2116827517	exogenous testosterone t alone or with finasteride increases physical performance grip strength and lean body mass in older men with low serum t	2005	-1.2687	-1.5977	54	1
2116861306	nonpharmacological therapies in alzheimer s disease a systematic review of efficacy	2010	0.3031	-0.1042	10	12.6299
2116867226	effect of buspirone a serotonin partial agonist on cognitive function in schizophrenia a randomized double blind placebo controlled study	2008	-0.2409	0.1654	9	0.7037
2116909099	impact of training dementia caregivers in sensitivity to nonverbal emotion signals	2002	0.5018	-0.0523	18	1.9168
2116966406	effects of community occupational therapy on quality of life mood and health status in dementia patients and their caregivers a randomized controlled trial	2007	0.4929	-0.1076	1	3.4625
2117057656	the long term effect of lifestyle interventions to prevent diabetes in the china da qing diabetes prevention study a 20 year follow up study	2008	-0.4267	1.4429	56	0.7814
2117134611	a 5 month randomized placebo controlled trial of galantamine in ad	2000	-0.2127	0.043	6	64.9161
2117164994	brain metabolic and clinical effects of rivastigmine in alzheimer s disease	2001	-0.2565	0.0489	57	1.7127
2117396078	the nmda receptor antagonist memantine as a symptomatological and neuroprotective treatment for alzheimer s disease preclinical evidence	2003	-0.1919	0.0617	6	1
2117561404	donepezil and rivastigmine improve p300 latency and neuropsychological test scores in alzheimer s disease patients one year follow up compared with vit e treated patients	2000	-0.206	-0.1485	49	0.7588
2117806419	clinical medication review by a pharmacist of elderly people living in care homes randomised controlled trial	2006	0.6744	-0.0367	52	1.971
2117826659	herbal contributions to the management of the multi factorial cognitive disorders alzheimer s disease and vascular dementia	2008	-0.3985	0.0305	53	0.6387
2117839048	delirium as a predictor of long term cognitive impairment in survivors of critical illness	2010	2.2375	-0.0482	2	1
2117868452	a trial of low doses of risperidone in the treatment of patients with first episode schizophrenia schizophreniform disorder or schizoaffective disorder	2004	0.1301	0.1278	47	0.6859
2117890073	effects of the menopause transition and hormone use on cognitive performance in midlife women	2009	-0.7576	-0.7675	3	1.984
2117980765	effect of perindopril on physical function in elderly people with functional impairment a randomized controlled trial	2007	-0.762	-0.1423	135	0.734
2117994084	cognitive therapy vs medications in the treatment of moderate to severe depression	2005	0.0708	0.1428	61	0.7789
2118104542	effects of cognitive training interventions with older adults a randomized controlled trial	2002	0.4684	-0.2489	4	39.368
2118107628	multifactorial intervention after a fall in older people with cognitive impairment and dementia presenting to the accident and emergency department randomised controlled trial	2003	2.2795	-0.0629	35	0.75
2118302279	a randomized double blind placebo controlled trial of fluvoxamine in patients with schizophrenia a preliminary study	2012	-0.2409	0.1654	9	0.7169
2118441096	longitudinal multimodal imaging in mild to moderate alzheimer disease a pilot study with memantine	2008	-0.0649	0.0408	22	16.5105
2118455963	effect of perioperative ?? blockade in patients with diabetes undergoing major non cardiac surgery randomised placebo controlled blinded multicentre trial	2006	2.5491	-0.0689	35	0.7665
2118457512	differential response to placebo among patients with social phobia panic disorder and obsessive compulsive disorder	2004	-0.1544	0.2293	15	0.6759
2118462346	cyclic nucleotide phosphodiesterases molecular regulation to clinical use	2006	-0.3068	0.128	23	0.916
2118470188	management of behavioral problems in alzheimer s disease	2010	0.1476	0.0603	31	0.9994
2118602083	dementia in residential care education intervention trial direct protocol for a randomised controlled trial	2010	0.3956	-0.1048	39	0.7666
2118696764	ergoloid mesylates hydergine in the treatment of mental deterioration in the elderly a 6 month double blind placebo controlled trial	1989	-0.1381	0.0382	80	14.0865
2118721390	tadalafil in patients with chronic obstructive pulmonary disease a randomised double blind parallel group placebo controlled trial	2014	-0.7628	-0.1427	135	0.7367
2118790060	neurosteroids a novel function of the brain	1998	-1.4243	-1.846	20	0.9959
2118833860	reality orientation a therapy for psychogeriatric patient a controlled study	1975	0.3285	-0.0912	10	2.9957
2118935254	a phase 3 trial of semagacestat for treatment of alzheimer s disease	2013	-0.2807	0.0621	44	0.7182
2119038590	a family intervention to delay nursing home placement of patients with alzheimer disease a randomized controlled trial	1996	0.5443	-0.1155	1	14.3184
2119046925	caregiver preference for rivastigmine patch relative to capsules for treatment of probable alzheimer s disease	2007	-0.2382	0.0518	19	26.9615
2119123819	the clinical course of advanced dementia	2009	0.8533	-0.0193	95	0.9584
2119263877	the effect of a pre and post operative orthogeriatric service on cognitive function in patients with hip fracture the protocol of the oslo orthogeriatrics trial	2012	2.1944	-0.0495	2	0.916
2119309005	effects of risperidone on behavioral and psychological symptoms associated with dementia in clinical practice	2005	0.1419	0.0443	58	0.6922
2119355152	the active cognitive training interventions and trajectories of performance among older adults	2013	0.5038	-0.2821	4	0.6953
2119369921	morbidity and mortality in the swedish trial in old patients with hypertension stop hypertension	1991	-0.745	-0.1508	14	2.9404
2119400520	oral physostigmine and impaired memory in adults with brain injury	1994	-0.6505	0.7053	71	1.7056
2119418338	postmenopausal hormone therapy and alzheimer s disease risk interaction with age	2005	-0.7313	-0.7204	3	1
2119467086	neuropsychology of vitamin b deficiency in elderly dementia patients and control subjects	2005	-0.2264	0.0532	84	0.6822
2119592796	a randomized trial to improve follow up care in severe uncontrolled hypertensives at an inner city walk in clinic	1996	-0.7628	-0.1427	135	0.7238
2119619136	rivastigmine an open label observational study of safety and effectiveness in treating patients with alzheimer s disease for up to 5 years	2005	-0.2432	0.0582	19	0.7991
2119642782	d cycloserine for alzheimer s disease	2002	-0.2946	0.186	43	2.7489
2119691301	increased risk of cognitive impairment or dementia in women who underwent oophorectomy before menopause	2007	-0.7453	-0.7529	3	1.9997
2119799206	delaying brain mitochondrial decay and aging with mitochondrial antioxidants and metabolites	2002	-0.3374	-0.0148	63	0.9584
2119851050	efficacy of high dose extended release memantine 28 mg once daily post hoc responder analysis from a randomized trial in patients with moderate to severe alzheimer s disease	2011	-0.2382	0.0586	19	2.3669
2119870947	memory functions in depression improvement with antidepressant medication	1976	-0.2419	0.165	9	0.7205
2119946747	cognitive dysfunction is associated with poor diabetes control in older adults	2006	-0.445	1.5722	56	1.9867
2120030830	training community consultants to help family members improve dementia care a randomized controlled trial	2005	0.4593	-0.0947	1	24.7254
2120033816	the effect of 3 year treatment with 0 25 mg day of micronized 17?? estradiol on cognitive function in older postmenopausal women	2007	-0.5191	-0.5314	3	2.7318
2120064419	a randomized trial of the efficacy and safety of the h3 antagonist abt 288 in cognitive impairment associated with schizophrenia	2014	-0.276	0.2225	9	1.2834
2120072733	donepezil in the treatment of progressive supranuclear palsy	2001	-0.2166	0.1405	11	0.7102
2120122898	effects of ginkgo biloba extract on cognitive function and blood pressure in elderly subjects	1998	-0.3807	-0.2165	45	0.6805
2120156715	the apache iii prognostic system risk prediction of hospital mortality for critically ill hospitalized adults	1991	1.6418	-0.0325	24	0.75
2120259129	hemodynamic benefits of regional anesthesia for carotid endarterectomy	2002	2.2338	-0.0385	36	0.7022
2120297934	brief problem solving training for family caregivers of persons with recent onset spinal cord injuries a randomized controlled trial	2009	0.6283	-0.1218	42	0.7452
2120321113	clozapine versus placebo in huntington s disease a double blind randomised comparative study	1997	-0.2283	-0.1467	112	0.9988
2120352446	effect of oral cdp choline on plasma choline and uridine levels in humans	2000	-0.3989	-0.2632	62	0.9959
2120745180	the experience of dying with dementia a retrospective study	1997	0.8533	-0.0193	95	0.9713
2120779247	working memory plasticity in old age practice gain transfer and maintenance	2008	0.458	-0.2457	4	0.9982
2120819163	treatment of dementia	2005	-0.0938	0.0049	84	0.7044
2120824167	the effects of rasagiline on cognitive deficits in parkinson s disease patients without dementia a randomized double blind placebo controlled multicenter study	2011	-0.2152	0.1585	9	1.475
2120899385	testing cognitive function in elderly populations the prosper study	2002	-0.7888	-0.1895	88	1
2120988966	role of catecholaminergic and cholinergic drugs in management of cognitive deficits in adults with traumatic brain injury a systematic review	2014	-0.9922	1.2607	71	0.7148
2121045936	differences in care received by patients with and without dementia who died during acute hospital admission a retrospective case note study	2006	0.8533	-0.0193	95	0.9584
2121080920	xenon or propofol anaesthesia for patients at cardiovascular risk in non cardiac surgery	2008	3.1472	0.1092	110	0.75
2121134085	delphi research exploring essential components and preconditions for case management in people with dementia	2010	0.5569	-0.1195	74	0.9404
2121250521	im olanzapine in the treatment of agitation and aggression	2001	0.5641	0.3999	40	0.7032
2121345124	a neurotropic approach to the treatment of multi infarct dementia using l ?? glycerylphosphorylcholine	1992	-0.362	-0.1401	62	1.4642
2121371688	plasma fatty acid composition and depression are associated in the elderly the rotterdam study	2003	-1.0974	-0.3005	5	0.9959
2121457428	does anaesthesia cause postoperative cognitive dysfunction a randomised study of regional versus general anaesthesia in 438 elderly patients	2003	2.2253	-0.0295	36	0.9992
2121476689	double blind controlled phase ii study of a 5 ht6 receptor antagonist sb 742457 in alzheimers disease	2010	-1.5582	0.2221	115	0.9997
2121513842	dawn dusk simulation light therapy of disturbed circadian rest activity cycles in demented elderly	2003	0.2984	-0.0183	17	8.6009
2121515004	the curry spice curcumin reduces oxidative damage and amyloid pathology in an alzheimer transgenic mouse	2001	-0.3379	-0.0141	63	0.9713
2121568676	physical restraint a descriptive study in swiss nursing homes	1998	0.8175	-0.0996	42	1.8873
2121642311	a novel gene containing a trinucleotide repeat that is expanded and unstable on huntington s disease chromosomes	1993	-0.2166	-0.1478	49	1.7499
2121683639	a 20 week randomized controlled trial of estradiol replacement therapy for women aged 70 years and older effect on mood cognition and quality of life	2006	-0.6872	-0.694	3	22.8865
2121683840	insulin resistance in depressive disorders and alzheimer s disease revisiting the missing link hypothesis	2005	-0.3852	0.1417	134	0.6041
2121788441	effectiveness and safety of velnacrine for the treatment of alzheimer s disease a double blind placebo controlled study	1995	-0.2807	0.0621	44	0.916
2121788574	multisensory stimulation for people with dementia a review of the literature	2013	0.422	-0.0772	18	0.9867
2121884967	increased light intensity prevents the age related loss of vasopressin expressing neurons in the rat suprachiasmatic nucleus	1995	0.2417	-0.0135	17	0.9584
2121970921	does an interdisciplinary network improve dementia care results from the idemuck study	2014	0.5272	-0.0877	34	0.6965
2122014319	postoperative delirium in a substudy of cardiothoracic surgical patients in the bag recall clinical trial	2014	2.2027	-0.0374	36	0.9999
2122060076	the effects of pramipexole in rem sleep behavior disorder	2003	-0.1493	0.1232	7	0.7993
2122196056	a short form of the informant questionnaire on cognitive decline in the elderly iqcode development and cross validation	1994	2.1944	-0.0495	2	0.9404
2122247978	psychological and cognitive effects of an exercise program for community residing older adults	1990	0.5803	-0.2499	27	23.8609
2122343308	preliminary findings of high dose thiamine in dementia of alzheimer s type	1993	-0.7825	-0.0987	86	20.6045
2122352743	no effect from double blind trial of physostigmine and lecithin in alzheimer disease	1983	-0.3238	0.1966	13	3.6648
2122382299	elevation of the cortisol dehydroepiandrosterone ratio in drug free depressed patients	2002	-1.4229	-1.8439	20	0.9992
2122396730	brain specific nutrients a memory cure	2003	0.0183	0.3851	48	0.6443
2122545833	diagnostic criteria for multiple sclerosis 2010 revisions to the mcdonald criteria	2005	-0.2417	0.2138	55	0.9939
2122632568	heterogeneity of brain glucose metabolism in mild cognitive impairment and clinical progression to alzheimer disease	2005	-0.052	-0.0405	46	1
2122678352	actions of dehydroepiandrosterone and its sulfate in the central nervous system effects on cognition and emotion in animals and humans	1999	-1.4234	-1.8452	20	1.9994
2122683614	double blind placebo controlled unforced titration parallel trial of quetiapine for dopaminergic induced hallucinations in parkinson s disease	2005	-0.1761	0.1179	7	2
2122692162	galantamine in ad a 6 month randomized placebo controlled trial with a 6 month extension	2000	-0.2247	0.0379	6	39.4144
2122813545	mental and behavioral disturbances in dementia findings from the cache county study on memory in aging	2000	0.1879	0.0786	16	17.2515
2122853309	ethyl epa in huntington disease a double blind randomized placebo controlled trial	2005	-0.2288	-0.146	112	0.9867
2122867853	effect of hydroxychloroquine on progression of dementia in early alzheimer s disease an 18 month randomised double blind placebo controlled study	2001	-0.3201	-0.0363	32	3.6683
2122869249	efficacy of memantine in people with moderate to severe alzheimer s disease with and without background donepezil therapy pooled analysis of four randomized trials	2013	-0.2384	0.0589	19	2.3307
2122896128	reproductive events modify the effects of estrogen replacement therapy on cognition in healthy postmenopausal women	2005	-0.746	-0.752	3	19.5609
2122900522	stress reduction for family caregivers effects of adult day care use	1998	0.6409	-0.1331	97	3.303
2122904446	results of a placebo controlled 6 month trial with memantine in moderate to severe alzheimer s disease ad	2000	-0.3102	0.0166	57	15.8901
2122966384	the impact of human computer interaction based comprehensive training on the cognitive functions of cognitive impairment elderly individuals in a nursing home	2013	-0.2409	-0.2597	49	0.7186
2122997027	pilot randomised controlled trial of occupational therapy to optimise independence in parkinson s disease the pd ot trial	2009	-0.103	-0.096	8	0.6982
2123056519	consensus guidelines for the clinical and pathologic diagnosis of dementia with lewy bodies dlb report of the consortium on dlb international workshop	1996	-0.1894	0.1148	7	7
2123098876	the richmond agitation sedation scale validity and reliability in adult intensive care unit patients	2002	2.2377	-0.0473	2	1
2123182031	mortality risk in patients with dementia treated with antipsychotics versus other psychiatric medications	2007	0.2093	0.0521	80	1
2123205023	impact of a comanaged geriatric fracture center on short term hip fracture outcomes	2009	2.1944	-0.0495	2	0.7993
2123272031	individual music therapy for agitation in dementia an exploratory randomized controlled trial	2013	0.4974	-0.0524	21	2.914
2123457140	serum lipoprotein levels statin use and cognitive function in older women	2002	-0.7383	-0.1736	29	3.9653
2123493728	cognitive behavioral therapy of socially phobic children focusing on cognition a randomised wait list control study	2011	0.7635	-0.2018	77	0.7725
2123500323	the cognitive cost of anticholinergic burden decreased response to cognitive training in schizophrenia	2009	-0.2626	0.1647	9	0.671
2123519214	dimebon in alzheimer s disease old drug for new indication	2008	-0.586	-0.1761	32	1
2123633329	epidemiology of and risk factors for psychosis of alzheimer s disease a review of 55 studies published from 1990 to 2003	2005	0.4983	0.0618	91	0.9404
2123652060	conjugated equine estrogens and global cognitive function in postmenopausal women women s health initiative memory study	2004	-0.7435	-0.7464	3	36.868
2123658022	mobility and dementia is physiotherapy treatment during respite care effective	1999	0.5026	-0.1757	25	0.845
2123686084	early treatment response in anxious outpatients treated with diazepam	1985	-0.3807	-0.2165	45	0.6624
2123743143	exercise for depression	2013	0.4834	-0.1436	60	0.845
2123774291	once weekly d cycloserine effects on negative symptoms and cognition in schizophrenia an exploratory study	2008	-0.2514	0.1578	9	0.6685
2123803218	improving fluid intelligence with training on working memory	2008	0.4613	-0.2427	4	2.8389
2123854988	frailty and cognitive impairment a review of the evidence and causal mechanisms	2013	0.5372	-0.2244	136	0.9973
2123942309	indirect bright light improves circadian rest activity rhythm disturbances in demented patients	1997	0.2797	-0.0164	17	12.4936
2123966765	the influence of group singing therapy on the behavior of alzheimer s disease patients	1989	0.48	-0.0523	21	0.9804
2123998258	effects of widespread and frequent personalized music programming on agitation and depression in assisted living facility residents with alzheimer type dementia	2012	0.53	-0.0524	21	1.7953
2124122335	effect of a gentle iyengar yoga program on gait in the elderly an exploratory study	2005	1.6796	-0.9881	108	0.9999
2124171187	effect of estrogen plus progestin on stroke in postmenopausal women the women s health initiative a randomized trial	2003	-0.7384	-0.7346	3	4
2124212092	omega 3 supplementation lowers inflammation in healthy middle aged and older adults a randomized controlled trial	2012	-1.0951	-0.3005	5	0.6964
2124214624	the spectrum of behavioral changes in alzheimer s disease	1996	-0.0089	0.0771	16	6.9512
2124214873	a rivastigmine patch for the treatment of alzheimer s disease and parkinson s disease dementia	2007	-0.2406	0.0532	19	2.6664
2124234445	randomized clinical trial of a postdischarge pharmaceutical care program vs regular follow up in patients with heart failure	2006	2.3691	-0.0643	35	0.7195
2124282132	efficacy of cytidine diphosphate choline in patients affected by chronic cerebrovascular disease	1996	-0.297	-0.2445	49	15.0258
2124298560	a nurse led interdisciplinary intervention program for delirium in elderly hip fracture patients	2001	2.1706	-0.051	2	6.6293
2124452122	physostigmine and arecoline effects of intravenous infusions in alzheimer presenile dementia	1981	-0.3354	0.2171	13	16.507
2124464326	changes in cognition with pharmacotherapy and cognitive therapy	1983	0.415	-0.0781	18	0.7079
2124469222	a randomized controlled trial of a home environmental intervention effect on efficacy and upset in caregivers and on daily function of persons with dementia	2001	0.4939	-0.1011	1	14.2424
2124484231	an evaluation of the effects of sensory stimulation with people who have dementia	1998	0.4282	-0.0752	18	1.9991
2124517301	the unity and diversity of executive functions and their contributions to complex frontal lobe tasks a latent variable analysis	2000	0.4797	-0.2652	4	0.9982
2124566456	effect of fish oil supplementation on mental well being in older subjects a randomized double blind placebo controlled trial	2008	-1.0946	-0.3005	5	21.8296
2124599804	cost effectiveness analyses for mirtazapine and sertraline in dementia randomised controlled trial	2013	0.1027	0.1505	61	14.7877
2124613245	dhea therapy for women effect on sexual function and wellbeing	2007	-1.4128	-1.8331	20	0.9404
2124620523	the northern ireland life review life storybook project for people with dementia	2006	0.3574	-0.0939	39	0.8843
2124622017	effects of rivastigmine combined with reinhartdt and sea cucumber capsule in patients with mild to moderate parkinson s disease dementia a pilot study	2014	-0.2357	0.0396	72	1.6265
2124693358	sertraline for the treatment of depression in alzheimer disease week 24 outcomes	2010	0.1752	0.0895	31	23.5568
2124731854	functional task exercise versus resistance strength exercise to improve daily function in older women a randomized controlled trial	2005	0.444	-0.1155	60	0.8843
2124736707	effects of reminiscence interventions on psychosocial outcomes a meta analysis	2012	0.3596	-0.0939	39	0.9584
2124764755	effect of timed bright light treatment for rest activity disruption in institutionalized patients with alzheimer s disease	2005	0.2903	-0.0182	17	23.7775
2124814227	the incidence of postoperative delirium in elderly patients after urologic surgery	2013	2.7899	-0.0532	118	0.8266
2124867876	d cycloserine enhances implicit memory in alzheimer patients	1996	-0.2967	0.1876	43	24.1593
2124878571	mild behavioral impairment a prodromal stage of dementia	2008	-0.1892	0.0233	78	0.8424
2124956656	effect of fish oil on cognitive performance in older subjects a randomized controlled trial	2008	-1.0438	-0.2839	5	27.6814
2125024459	evaluation of dimebon in cellular model of huntington s disease	2008	-0.5864	-0.1755	32	1
2125078674	the relationship between stroke severity nihss and lactate in brain sub regions in acute ischemic stroke	2006	-0.351	-0.0006	70	1.7213
2125170935	pet imaging in the differential diagnosis of vascular dementia	2012	-0.7263	0.0224	107	0.6834
2125178621	liberal or restrictive transfusion after cardiac surgery	2015	2.5491	-0.0689	35	0.845
2125308968	characteristics of placebo responses in medical treatment of premenstrual syndrome	1999	-0.7628	-0.1427	135	0.7243
2125315189	cognitive behavioural therapy cbt for anxiety in people with dementia study protocol for a randomised controlled trial	2012	0.7608	-0.2012	77	16.658
2125346945	clinical symptom responses to atypical antipsychotic medications in alzheimer s disease phase 1 outcomes from the catie ad effectiveness trial	2008	0.1811	0.0646	16	8.5673
2125348681	daily mood and out of home mobility in older adults does cognitive impairment matter	2015	0.4823	-0.1846	25	0.7468
2125362678	the effect of music therapy compared with general recreational activities in reducing agitation in people with dementia a randomised controlled trial	2013	0.4981	-0.0528	21	3.7216
2125365283	non pharmacological management of behavioural symptoms in nursing homes	2009	0.7747	-0.0945	42	0.9404
2125420609	mild cognitive impairment and dementia	2006	-0.1892	0.0233	78	0.8583
2125492611	rivastigmine in the treatment of postoperative delirium a pilot clinical trial	2012	2.2147	-0.0444	2	0.7601
2125528441	one year health care costs associated with delirium in the elderly population	2008	2.196	-0.0441	2	5.9971
2125638023	a double blind placebo controlled trial of high dose lecithin in alzheimer s disease	1985	-0.3082	0.1779	13	22.4596
2125643527	estrogen receptors colocalize with low affinity nerve growth factor receptors in cholinergic neurons of the basal forebrain	1992	-0.7647	-0.7717	3	0.9996
2125657871	aerobic exercise training increases brain volume in aging humans	2006	0.5069	-0.212	27	7.8541
2125669371	oral cyanocobalamin supplementation in older people with vitamin b12 deficiency a dose finding trial	2005	-0.9233	-0.1078	30	0.9998
2125674416	randomized controlled six month trial of yoga in healthy seniors effects on cognition and quality of life	2006	1.6782	-0.9866	108	19.9924
2125692663	bezafibrate in men with lower extremity arterial disease randomised controlled trial	2002	-0.5184	-0.0899	68	0.718
2125993125	projections of alzheimer s disease in the united states and the public health impact of delaying disease onset	1998	-0.3708	-0.1158	8	0.916
2126005867	efficacy of memantine in pdd and dlb an extension study including washout and open label treatment	2011	-0.0746	0.063	58	0.6784
2126013761	continuing donepezil when alzheimer symptoms worsen might delay nursing home admission study indicates	2015	-0.0786	0.069	58	0.752
2126072473	dehydroepiandrosterone dhea dhea sulfate and aging contribution of the dheage study to a sociobiomedical issue	2000	-1.3918	-1.7983	20	6.6745
2126072923	group reminiscence intervention in taiwanese elders with dementia	2009	0.3563	-0.0935	39	18.0809
2126118649	group physical activity for demented older adults feasibility and effectiveness	2007	0.486	-0.1796	25	2.9208
2126125759	2014 evidence based guideline for the management of high blood pressure in adults report from the panel members appointed to the eighth joint national committee jnc 8	2014	-0.7084	-0.1762	79	1.8843
2126200685	helping carers to care the 10 66 dementia research group s randomized control trial of a caregiver intervention in peru	2010	0.5574	-0.1268	140	0.991
2126210445	consequences from use of reminiscence a randomised intervention study in ten danish nursing homes	2010	0.3596	-0.0939	39	0.9404
2126249073	the hypertension in the very elderly trial hyvet rationale methodology and comparison with previous trials	1994	-0.7376	-0.1471	14	0.9996
2126332162	rapid stress reduction and anxiolysis among distressed women as a consequence of a three month intensive yoga program	2005	1.6805	-0.9881	108	1
2126385267	deaths caused by physical restraints	1992	0.8301	-0.1004	42	1.9584
2126424933	impact of two psychosocial interventions on white and african american family caregivers of individuals with dementia	2003	0.521	-0.1078	1	28.6404
2126508833	lack of localization of 5 ht6 receptors on cholinergic neurons implication of multiple neurotransmitter systems in 5 ht6 receptor mediated acetylcholine release	2006	-1.5582	0.2221	115	0.9713
2126510379	diagnosis of alzheimer s disease	1997	-0.4416	0.2873	105	0.85
2126536379	effect of combination therapy with memantine and rivastigmine patch on agitation behavior in patients with mild to moderate alzheimer s disease a 24 week prospective multicenter randomized open label clinical trial	2010	-0.2394	0.0581	19	2.2249
2126537713	the role of apoe e4 in longitudinal cognitive decline macarthur studies of successful aging	2003	-0.7714	-0.1862	29	0.9982
2126744554	star a dementia specific training program for staff in assisted living residences	2005	0.5305	-0.0658	18	21.2031
2126801854	magnetic resonance imaging of the brain and neuropsychological evaluation in children treated for acute lymphoblastic leukemia at a young age	1993	0.2293	-0.2025	111	0.6344
2126812562	early mobilization improves functional outcomes in critically ill patients	2010	2.3691	-0.0643	35	0.7045
2126838693	intervention effects on dementia caregiving interaction a stress adaptation modeling approach	1999	0.5341	-0.1114	1	17.7928
2126889148	short term folate vitamin b 12 or vitamin b 6 supplementation slightly affects memory performance but not mood in women of various ages	2002	-0.8691	-0.1035	30	28.9758
2126934781	special care units for demented patients a multicenter study	1998	0.7828	-0.023	24	2.586
2126951769	systematic review of the effectiveness of non pharmacological interventions to improve quality of life of people with dementia	2012	0.3956	-0.1048	39	0.7902
2127012148	the effect of a family therapy and technology based intervention on caregiver depression	2003	0.524	-0.1106	1	11.4223
2127069922	operational criteria for senile dementia of lewy body type sdlt	1992	-0.1981	0.1237	7	0.9982
2127086238	improved delayed visual reproduction test performance in multiple sclerosis patients receiving interferon beta 1b	1996	-0.242	0.2126	55	1.9867
2127088103	nurse led home based self help treatment for patients in primary care with chronic fatigue syndrome randomised controlled trial	2010	-0.2945	-0.1543	45	0.6856
2127103489	effects of emotion oriented care on elderly people with cognitive impairment and behavioral problems	2002	0.4554	-0.0691	18	2.7126
2127108053	dementia with lewy bodies	2004	-0.1902	0.1176	7	1
2127129205	meta analysis of the efficacy and safety of ginkgo biloba extract for the treatment of dementia	2015	-0.4856	-0.072	68	0.7543
2127219068	effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels	2001	-1.2687	-1.5977	54	1
2127264122	efficacy study of galantamine in possible alzheimer s disease with or without cerebrovascular disease and vascular dementia in thai patients a slow titration regimen	2006	-0.2669	0.0508	124	0.7699
2127362363	haloperidol in the psychiatric disorders of old age	1964	0.166	0.093	47	0.9994
2127401575	effect of non steroidal anti inflammatory drugs on risk of alzheimer s disease systematic review and meta analysis of observational studies	2003	-0.4224	-0.0763	32	3.9908
2127507480	behavioral and mood effects of snoezelen integrated into 24 hour dementia care	2005	0.4354	-0.0695	18	4.708
2127515011	the impact of advance care planning on end of life care in elderly patients randomised controlled trial	2010	0.8533	-0.0194	95	0.916
2127553032	donepezil in patients with subcortical vascular cognitive impairment a randomised double blind trial in cadasil	2008	-0.4481	-0.0018	12	23.892
2127559485	meta analysis of six month memantine trials in alzheimer s disease	2007	-0.1464	0.0972	11	1.6294
2127560523	assessment of safety and long term outcomes of initial treatment with placebo in tads	2009	-0.3244	-0.142	45	0.7046
2127608917	piracetam prevents cognitive decline in coronary artery bypass a randomized trial versus placebo	2006	-0.3807	-0.2165	45	0.7118
2127642100	effects of oral elnd005 scyllo inositol on neuropsychiatric symptoms in a 78 week phase 2 study in mild moderate alzheimer s disease ad potential role of myo inositol reduction	2012	-0.3118	0.0161	57	0.6823
2127673211	estrogen actions throughout the brain	2002	-0.7648	-0.7776	3	0.9973
2127802767	physical fitness of older adults in senior activity centres after 24 week silver yoga exercises	2008	1.6805	-0.9881	108	0.9992
2127842994	effect of omega 3 fatty acids supplementation on depressive symptoms and on health related quality of life in the treatment of elderly women with depression a double blind placebo controlled randomized clinical trial	2010	-0.9263	-0.257	79	0.7993
2127853351	depression among the oldest old the umea 85 study	2005	0.4834	-0.1436	60	0.7993
2128000855	the impact of reminiscence on the quality of life of residents with dementia in long stay care	2014	0.3946	-0.1044	39	15.4584
2128007559	estrogen for alzheimer s disease in women randomized double blind placebo controlled trial	2000	-0.7267	-0.7084	3	26.7993
2128030851	sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia	2011	-0.2343	0.2586	66	3
2128047032	effect of vitamin e and memantine on functional decline in alzheimer disease the team ad va cooperative randomized trial	2014	-0.4413	-0.1086	82	21.7159
2128107480	a training workshop on late stage dementia care for family caregivers	2001	0.6861	-0.1443	97	0.6693
2128111962	rivastigmine for the prevention of postoperative delirium in elderly patients undergoing elective cardiac surgery a randomized controlled trial	2009	2.1927	-0.0438	2	9.7182
2128124856	safety efficacy and biomarker findings of pbt2 in targeting a?? as a modifying therapy for alzheimer s disease a phase iia double blind randomised placebo controlled trial	2008	-0.7976	-0.3491	69	2
2128276995	feasibility and safety of delivering xenon to patients undergoing coronary artery bypass graft surgery while on cardiopulmonary bypass phase i study	2006	3.1473	0.1092	110	0.7993
2128279946	a systematic review of the effectiveness of psychosocial interventions for carers of people with dementia	2001	0.5363	-0.1082	1	0.9713
2128304259	aromatherapy and behaviour disturbances in dementia a randomized controlled trial	2001	0.3942	-0.0279	34	24.3284
2128388338	integrative and instrumental reminiscence therapies for depression in older adults intervention strategies and treatment effectiveness	2000	0.3574	-0.0939	39	0.845
2128450027	effective exercise for the prevention of falls a systematic review and meta analysis	2008	0.4434	-0.115	60	0.8843
2128499874	no effect of one year treatment with indomethacin on alzheimer s disease progression a randomized controlled trial	2008	-0.4442	-0.0896	32	23.692
2128500080	the use of cranial electrotherapy stimulation in the treatment of closed head injured patients	1994	0.2261	-0.0085	17	0.845
2128529067	assessment of older people self maintaining and instrumental activities of daily living	1969	0.4397	-0.0907	1	4.8527
2128538832	peaceful mind an open trial of cognitive behavioral therapy for anxiety in persons with dementia	2010	0.6749	-0.1727	77	0.8843
2128572333	efficacy of mirtazapine in obstructive sleep apnea syndrome	2007	0.2286	-0.0028	28	0.991
2128579955	internet based caregiver support for chinese canadians taking care of a family member with alzheimer disease and related dementia	2009	0.5531	-0.1195	1	0.9959
2128598717	animal assisted intervention in dementia effects on quality of life	2014	0.395	-0.1042	39	0.7533
2128625652	ginseng potential for the enhancement of cognitive performance and mood	2003	-0.6579	-0.1215	65	3.6382
2128670183	a randomized trial of amantadine in huntington disease	2003	-0.2288	-0.146	112	0.9994
2128672063	the impact of individual reminiscence therapy for people with dementia systematic review	2012	0.3777	-0.099	39	1.786
2128683454	quality of life on randomized treatment for isolated systolic hypertension results from the syst eur trial	2002	-0.7611	-0.1423	135	15.5072
2128746261	using acupressure and montessori based activities to decrease agitation for residents with dementia a cross over trial	2009	0.3891	-0.0267	34	0.8843
2128767446	efficacy and tolerability of donepezil in vascular dementia positive results of a 24 week multicenter international randomized placebo controlled clinical trial	2003	-0.3799	0.0177	12	21.6223
2128788220	early protection against sudden death by n 3 polyunsaturated fatty acids after myocardial infarction time course analysis of the results of the gruppo italiano per lo studio della sopravvivenza nell infarto miocardico gissi prevenzione	2002	-1.2428	-0.3453	83	1
2128817884	p 5 a 009 divalproex sodium in behavioural disturbances in dementia clinical effectiveness	2008	0.5483	0.3861	40	0.6987
2128874197	small vessel disease and subcortical vascular dementia	2006	-0.7263	0.0224	107	0.7993
2128913569	cognitive behavior therapy relaxation training and tricyclic antidepressant medication in the treatment of depression	1995	-0.3416	0.9102	113	0.7391
2128974992	cognitive behaviour therapy based intervention by community health workers for mothers with depression and their infants in rural pakistan a cluster randomised controlled trial	2008	0.5568	-0.1275	140	0.9988
2129030266	exercise training increases size of hippocampus and improves memory	2011	0.4956	-0.1996	25	8.7304
2129036744	memantine for patients with parkinson s disease dementia or dementia with lewy bodies a randomised double blind placebo controlled trial	2010	-0.1847	0.1118	7	7.6601
2129114099	caring for aged dementia care resident study cadres of person centred care dementia care mapping and usual care in dementia a cluster randomised trial	2009	0.3635	-0.0063	18	22.9419
2129146472	caring for patients with dementia how good is the quality of care results from three health systems	2007	0.6394	-0.1407	75	1.8044
2129148330	postoperative delirium in old patients with femoral neck fracture a randomized intervention study	2007	2.2029	-0.0486	2	23.9094
2129159083	efficacy of an evidence based cognitive stimulation therapy programme for people with dementia randomised controlled trial	2003	0.2982	-0.0952	10	45.3966
2129224205	effectiveness of educational interventions for informal caregivers of individuals with dementia residing in the community systematic review and meta analysis of randomised controlled trials	2015	0.395	-0.1042	39	0.7447
2129224714	effects of korean red ginseng on dry mouth a randomized double blind placebo controlled trial	2010	-0.6648	-0.1223	65	0.75
2129242877	family caregivers assessment of symptoms in persons with dementia using the gbs scale differences in rating after psychosocial intervention an 18 month follow up study	2010	0.6566	-0.1432	75	0.771
2129264765	nonpharmacologic management of behavioral symptoms in dementia	2012	0.3137	-0.0714	1	0.9992
2129353515	influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women the women s health initiative randomized trial	2003	-0.7371	-0.7322	3	2
2129442979	a 24 week study to evaluate the effect of rilapladib on cognition and cerebrospinal fluid biomarkers of alzheimer s disease	2015	-0.2942	0.0285	57	0.6987
2129447723	increase in urinary cortisol excretion and memory declines macarthur studies of successful aging	1997	-1.4243	-1.846	20	0.9973
2129497119	toward defining the preclinical stages of alzheimer s disease recommendations from the national institute on aging alzheimer s association workgroups on diagnostic guidelines for alzheimer s disease	2011	-0.2348	-0.0345	46	3.7909
2129503298	xenon consumption during general surgery a retrospective observational study	2013	3.147	0.1092	110	0.75
2129505618	a randomized controlled trial to evaluate intensity of community based rehabilitation provision following stroke or hip fracture in old age	2006	2.1882	-0.0853	26	0.7964
2129512027	contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients variations with increasing levels of hba1c	2003	-0.4434	1.5572	56	0.9804
2129579471	provisional diagnostic criteria for depression of alzheimer disease	2002	0.2046	0.0714	31	6.8307
2129623936	reduced risk of alzheimer disease in users of antioxidant vitamin supplements the cache county study	2004	-0.4097	-0.0839	82	1.9867
2129750583	primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels results of afcaps texcaps	1998	-0.7878	-0.1891	88	3
2129809216	cytidinediphosphocholine cdp choline for cognitive and behavioural disturbances associated with chronic cerebral disorders in the elderly	2005	-0.3997	-0.2646	62	1.8254
2129939370	effects of d cycloserine on extinction of conditioned freezing	2003	-0.2951	0.1867	43	3.7462
2129976365	different cognitive profiles on memory tests in parkinson s disease and alzheimer s disease	1998	-0.5495	0.3992	73	0.6856
2129991662	prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required in the anglo scandinavian cardiac outcomes trial blood pressure lowering arm ascot bpla a multicentre randomised controlled trial	2005	-0.725	-0.1437	14	3.9959
2130067887	effects of s adenosylmethionine augmentation of serotonin reuptake inhibitor antidepressants on cognitive symptoms of major depressive disorder	2012	-0.3415	0.9111	113	0.7209
2130075660	effect of a self management and follow up program on self efficacy in patients with multiple sclerosis a randomized clinical trial	2014	-0.2945	-0.1543	45	0.6864
2130095506	effects of replacement dose of dehydroepiandrosterone in men and women of advancing age	1994	-1.3926	-1.7967	20	6.7925
2130136596	effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy a losartan intervention for endpoint reduction life substudy	2002	-0.7312	-0.1465	14	1
2130195164	evaluation of rehabilitation of memory in neurological disabilities remind a randomized controlled trial	2012	-0.103	-0.096	8	0.7288
2130271602	clinical practice guidelines for the management of pain agitation and delirium in adult patients in the intensive care unit	2013	2.2184	-0.0445	2	3.8426
2130349075	the usefulness of fab scale in the screening of mild cognitive impairment in elderly patients with newly diagnosed parkinson s disease	2009	-0.2271	0.0538	84	0.688
2130407569	the philadelphia geriatric center morale scale a revision	1975	0.4834	-0.1436	60	0.7993
2130599091	hiv associated neurocognitive disorders before and during the era of combination antiretroviral therapy differences in rates nature and predictors	2011	-0.4008	0.502	87	0.9959
2130632081	cognitive impairment in multiple sclerosis	2008	-0.2389	0.2092	55	3.7482
2130735976	persistence of cognitive impairment in geriatric patients following antidepressant treatment a randomized double blind clinical trial with nortriptyline and paroxetine	2003	-0.3189	0.6478	113	1.4575
2130773716	the association of betaine homocysteine and related metabolites with cognitive function in dutch elderly people	2007	-1.9266	0.3314	109	15.1174
2130774572	medical management with or without interventional therapy for unruptured brain arteriovenous malformations aruba a multicentre non blinded randomised trial	2014	2.3692	-0.0634	35	0.7038
2130809567	anger and depression management psychoeducational skill training interventions for women caregivers of a relative with dementia	2003	0.5259	-0.1088	1	27.8962
2130900065	relatives of the impaired elderly correlates of feelings of burden	1980	0.5062	-0.1082	1	14.452
2130954024	cognitive behavioural therapy for anxiety disorders in later life protocol	2009	0.7627	-0.2018	77	0.8116
2130992306	pharmacokinetics pharmacodynamics and safety of metrifonate in patients with alzheimer s disease	1998	-0.2801	0.075	51	0.75
2131114329	severe alzheimer s disease benefits of donepezil therapy	2006	-0.0591	0.0833	58	16.9266
2131146117	depression and self esteem an investigation that used behavioral and cognitive approaches to the treatment of clinically depressed clients	1981	0.4151	-0.0772	18	0.7037
2131162932	long term effects of cognitive training on everyday functional outcomes in older adults	2006	0.44	-0.2372	4	15.3224
2131265993	effects of individualized versus classical relaxation music on the frequency of agitation in elderly persons with alzheimer s disease and related disorders	2000	0.4815	-0.05	21	12.7104
2131266318	estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women the women s health initiative memory study a randomized controlled trial	2003	-0.7306	-0.7186	3	45.7204
2131319489	effects of a three year exercise program on motor function and cognitive processing speed in older women	1991	0.5796	-0.2499	27	3.9707
2131373320	behavioral treatment of depression in dementia patients a controlled clinical trial	1997	0.4696	-0.0778	1	16.5855
2131395152	a placebo controlled double blind randomized trial of an extract of ginkgo biloba for dementia north american egb study group	1997	-0.4404	-0.0678	8	14.6956
2131422017	benefits of fatty fish on dementia risk are stronger for those without apoe e4	2005	-1.0445	-0.2837	5	4.8474
2131475566	multicenter randomized comparison of xenon and isoflurane on left ventricular function in patients undergoing elective surgery	2007	3.1472	0.1092	110	0.8843
2131524336	clinic visits in late life depression trials effects on signal detection and therapeutic outcome	2014	0.103	0.1503	61	0.698
2131633241	cu ii potentiation of alzheimer a?? neurotoxicity correlation with cell free hydrogen peroxide production and metal reduction	1999	-1.0107	-0.5241	69	1
2131673402	vitamin b12 folate and homocysteine in depression the rotterdam study	2002	-0.8812	-0.1041	30	0.9982
2131694597	dietary supplementation of omega 3 fatty acid and circulating levels of interleukin 1?? osteocalcin and c reactive protein in rats	2006	-1.1442	-0.3148	83	0.7311
2131722081	estrogen replacement therapy for treatment of mild to moderate alzheimer disease a randomized controlled trial	2000	-0.697	-0.6571	3	39.6567
2131768154	survival in end stage dementia following acute illness	2000	0.8533	-0.0193	95	0.9804
2131808744	effect of intravaginal dehydroepiandrosterone prasterone on libido and sexual dysfunction in postmenopausal women	2009	-1.4128	-1.8331	20	0.9404
2131842330	the effect of music on repetitive disruptive vocalizations of persons with dementia	1994	0.4826	-0.0523	21	1.9939
2131873172	cognitive behavioral therapy sertraline or a combination in childhood anxiety	2008	0.0703	0.1434	61	0.7502
2131885451	profound effects of combining choline and piracetam on memory enhancement and cholinergic function in aged rats	1981	-0.2934	0.2598	15	1.6443
2131888661	donepezil improved cognitive and global function in mild to moderate alzheimer s disease	1998	-0.2939	0.1114	50	0.7153
2131913049	dehydroepiandrosterone dhea treatment of depression	1997	-1.4192	-1.8407	20	1
2131963133	reduction in levels of 24s hydroxycholesterol by statin treatment in patients with alzheimer disease	2003	-0.7217	-0.1677	29	1
2131972795	the costs of caring medical costs of alzheimer s disease and the managed care environment	2001	0.5543	-0.1157	74	0.7994
2132104009	yoga for anxiety a systematic review of the research evidence	2005	1.6805	-0.9881	108	0.9998
2132201736	use of the gds 15 geriatric depression scale as a screening instrument for depressive symptomatology in patients with parkinson s disease and their carers in the community	1999	0.4586	0.2348	116	0.7599
2132248292	falls prevention the efficacy of a bed alarm system in an acute care setting	1993	2.2795	-0.0629	35	0.75
2132443029	fish consumption and cognitive decline with age in a large community study	2005	-1.0695	-0.2914	5	2.9934
2132592055	efficacy and adverse effects of atypical antipsychotics for dementia meta analysis of randomized placebo controlled trials	2006	0.2328	0.0614	16	28.4541
2132639519	application status of memantine in patients with dementia in the chongqing area of southwest china	2015	-0.0762	0.0663	58	1.5206
2132675305	modafinil combined with cognitive training pharmacological augmentation of cognitive training in schizophrenia	2015	-0.2585	0.1787	11	0.6875
2132766843	pet imaging of amyloid deposition in patients with mild cognitive impairment	2008	-0.0529	-0.0404	46	1
2132806643	memantine treatment in patients with moderate to severe alzheimer disease already receiving donepezil a randomized controlled trial	2004	-0.205	0.0441	6	89.7588
2132822469	the effect of mnemonic training on perceived recall confidence in the elderly	1987	0.5093	-0.2847	4	16.641
2132830404	working memory in alzheimer s disease and mild cognitive impairment mci assessment and intervention	2011	-0.2007	0.0876	78	0.6688
2132832208	comparing yoga exercise and a self care book for chronic low back pain a randomized controlled trial	2005	1.6805	-0.9881	108	1
2132871355	effectiveness of atypical antipsychotic drugs in patients with alzheimer s disease	2006	0.2122	0.0645	16	36.3848
2132898333	cognitive functioning in spousal caregivers of dementia patients findings from the prospective maasbed study	2006	0.3164	-0.1289	10	0.7807
2133025814	induction of alzheimer like ?? amyloid immunoreactivity in the brains of rabbits with dietary cholesterol	1994	-0.723	-0.1679	29	2
2133095503	brain microbleeds and cognitive function	2007	-0.727	0.0219	107	0.7258
2133217116	cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study life a randomised trial against atenolol	2002	-0.7285	-0.1444	14	4.9987
2133239607	long term course and effectiveness of combination therapy in alzheimer disease	2008	-0.1765	0.0639	6	7.9235
2133275687	an intervention integrated into daily clinical practice reduces the incidence of delirium during hospitalization in elderly patients	2009	2.2021	-0.0472	2	1.9987
2133278098	effects of blood glucose rate of changes on perceived mood and cognitive symptoms in insulin treated type 2 diabetes	2007	-0.3415	0.9111	113	0.7407
2133324295	metal protein attenuation with iodochlorhydroxyquin clioquinol targeting a?? amyloid deposition and toxicity in alzheimer disease a pilot phase 2 clinical trial	2003	-1.0518	-0.5504	69	1.7993
2133416234	2007 guidelines for the management of arterial hypertension the task force for the management of arterial hypertension of the european society of hypertension esh and of the european society of cardiology esc	2007	-0.7192	-0.1603	14	3.75
2133462940	thiamine and alzheimer s disease a pilot study	1988	-0.7812	-0.0986	86	20.3332
2133467178	older men are as responsive as young men to the anabolic effects of graded doses of testosterone on the skeletal muscle	2005	-1.2687	-1.5977	54	1
2133536731	low b12 levels related to high activity of platelet mao in patients with dementia disorders a retrospective study	1988	-0.4086	0.3103	120	0.64
2133546253	resolvin d1 promotes the interleukin 4 induced alternative activation in bv 2 microglial cells	2014	-1.1027	-0.3021	5	0.7993
2133565799	chronic antidepressant treatment increases neurogenesis in adult rat hippocampus	2000	0.0383	0.1961	61	0.916
2133596089	effects of basal insulin glargine and omega 3 fatty acid on cognitive decline and probable cognitive impairment in people with dysglycaemia a substudy of the origin trial	2014	-0.6916	-0.1919	79	0.7453
2133636423	effects of conjugated equine estrogen on health related quality of life in postmenopausal women with hysterectomy results from the women s health initiative randomized clinical trial	2005	-0.7355	-0.7379	3	0.845
2133688160	gait and cognitive function among elderly individuals with alzheimer s disease mild cognitive impairment mci and no alzheimer s or mci	2012	-0.1955	0.0561	78	1.5196
2133710857	a controlled multicenter clinical study of citalopram and placebo in elderly depressed patients with and without concomitant dementia	1992	0.2112	0.0896	31	6.9296
2133719530	bright light treatment improves sleep in institutionalised elderly an open trial	2003	0.2997	-0.0189	17	1.9099
2133903921	functional connectivity in the resting brain a network analysis of the default mode hypothesis	2003	-0.2503	0.1374	22	0.9404
2133910658	the nature of the effect of female gonadal hormone replacement therapy on cognitive function in post menopausal women a meta analysis	2000	-0.7374	-0.7386	3	14.8375
2133958927	effects of the uncompetitive nmda receptor antagonist memantine on hippocampal long term potentiation short term exploratory modulation and spatial memory in awake freely moving rats	1996	-0.2742	0.0723	23	0.9867
2134043280	spotlight on rivastigmine transdermal patch	2011	-0.244	0.0543	19	0.8352
2134176179	recovery from hip fracture in eight areas of function	2000	1.9721	-0.0871	26	0.9998
2134203457	a clinical evaluation of a form of intra uterine therapy	1971	-0.393	0.3617	106	0.6929
2134204196	augmentation of exposure therapy with d cycloserine for social anxiety disorder	2006	-0.2896	0.1831	43	0.845
2134210134	clinical practice guidelines for the sustained use of sedatives and analgesics in the critically ill adult	2002	2.2375	-0.0482	2	1
2134257665	a very early rehabilitation trial for stroke avert phase ii safety and feasibility	2008	2.3692	-0.0634	35	0.7026
2134346502	imaging of vascular cognitive impairment	2009	-0.8154	0.8222	102	0.6815
2134458253	midlife serum cholesterol and increased risk of alzheimer s and vascular dementia three decades later	2009	-0.7266	-0.1701	29	0.9996
2134535009	occurrence and outcome of delirium in medical in patients a systematic literature review	2006	2.1773	-0.044	2	5.9865
2134584460	vitamin b12 and folate deficiency in later life	2004	-0.9233	-0.1078	30	0.9867
2134602222	outcomes of people with psychotic disorders in a community based rehabilitation programme in rural india	2009	0.5574	-0.1268	140	0.9584
2134639622	adrenal secretion during major depression in 8 to 16 year olds i altered diurnal rhythms in salivary cortisol and dehydroepiandrosterone dhea at presentation	1996	-1.4229	-1.8439	20	0.9982
2134711807	amyloid ?? deposition neurodegeneration and cognitive decline in sporadic alzheimer s disease a prospective cohort study	2013	-0.2225	0.0108	46	0.75
2134717514	participation in cognitively stimulating activities and risk of incident alzheimer disease	2002	0.4805	-0.2638	4	1.9713
2134736198	longitudinal study of csf biomarkers in patients with alzheimer s disease	2009	-0.2942	0.0285	57	0.682
2134787735	free radicals and brain aging	2004	-0.319	0.0032	63	0.9584
2134788078	association between intraoperative blood transfusions and early postoperative delirium in older adults	2013	2.566	-0.0494	125	0.845
2134866080	acetyl l carnitine physical chemical metabolic and therapeutic properties relevance for its mode of action in alzheimer s disease and geriatric depression	2000	-0.3229	0.0021	63	4.8305
2134990392	sevoflurane remifentanil versus propofol remifentanil anesthesia at a similar bispectral level for off pump coronary artery surgery no evidence of reduced myocardial ischemia	2006	3.1484	0.109	110	0.7412
2135038122	effects of candesartan on mortality and morbidity in patients with chronic heart failure the charm overall programme	2003	-0.7293	-0.1452	14	1.9999
2135057965	zuclopenthixol decanoate and haloperidol decanoate in chronic schizophrenia a double blind multicentre study	1991	0.1304	0.1286	47	0.7529
2135070485	estrogen actions in the central nervous system	1999	-0.7648	-0.7776	3	0.9867
2135070546	hippocampal and cortical atrophy predict dementia in subcortical ischemic vascular disease	2000	-0.7263	0.0224	107	0.6985
2135093451	cholinesterase inhibitors a new class of psychotropic compounds	2000	-0.2005	0.062	44	2.6775
2135232828	efficacy of souvenaid in mild alzheimer s disease results from a randomized controlled trial	2012	-0.7013	-0.185	82	1.8389
2135304046	the ginkgo biloba extract egb 761 protects hippocampal neurons against cell death induced by ?? amyloid	2000	-0.4316	-0.0637	8	7.8092
2135364764	effect of age and glucoregulation on cognitive performance	2003	-0.4598	1.8033	96	0.916
2135436039	preoperative risk assessment for delirium after noncardiac surgery a systematic review	2006	2.2061	-0.0487	2	0.9997
2135580098	primary care interventions for dementia caregivers 2 year outcomes from the reach study	2003	0.5158	-0.1085	1	3.97
2135631433	pravastatin in elderly individuals at risk of vascular disease prosper a randomised controlled trial	2002	-0.7829	-0.187	88	30.9444
2135672238	dexmedetomidine vs midazolam for sedation of critically ill patients a randomized trial	2009	2.2067	-0.0446	2	4.991
2135728665	cost analysis of the geriatric resources for assessment and care of elders care management intervention	2009	0.5543	-0.1157	74	0.821
2135780456	safety tolerability and antibody response of active a?? immunotherapy with cad106 in patients with alzheimer s disease randomised double blind placebo controlled first in human study	2012	-0.2225	0.0108	46	0.75
2135812251	effectiveness of cholinesterase inhibitors and memantine for treating dementia evidence review for a clinical practice guideline	2008	-0.1813	0.0642	6	1.9802
2135822510	n 3 pufa dietary supplementation inhibits proliferation and store operated calcium influx in thymoma cells growing in balb c mice	2000	-1.1442	-0.3148	83	0.7412
2135910109	effect of estrogen plus progestin on global cognitive function in postmenopausal women the women s health initiative memory study a randomized controlled trial	2003	-0.7376	-0.7358	3	36.8538
2135952897	effect of enhanced psychosocial care on antipsychotic use in nursing home residents with severe dementia cluster randomised trial	2006	0.3807	0.0004	18	30.9354
2135959338	effect of testosterone treatment on bone mineral density in men over 65 years of age	1999	-1.2696	-1.5976	54	1
2135990050	exercise training for depressed older adults with alzheimer s disease	2008	0.5092	-0.1979	25	23.5697
2135996578	aromas of rosemary and lavender essential oils differentially affect cognition and mood in healthy adults	2003	0.3959	-0.0279	34	0.9404
2136043560	facilitation of fear extinction by d cycloserine theoretical and clinical implications	2004	-0.2955	0.1857	43	0.7993
2136057401	effect of 3 year folic acid supplementation on cognitive function in older adults in the facit trial a randomised double blind controlled trial	2007	-0.869	-0.1037	30	28.9842
2136125607	a randomized clinical trial of mk 0777 for the treatment of cognitive impairments in people with schizophrenia	2011	-0.2522	0.1646	9	1.3944
2136145230	effects of intensive blood pressure control in type 2 diabetes mellitus	2010	-0.7322	-0.152	14	1
2136149869	an action spectrum for melatonin suppression evidence for a novel non rod non cone photoreceptor system in humans	2001	0.2937	-0.0183	17	1
2136165261	stroke patients informal caregivers patient caregiver and service factors that affect caregiver strain	1999	0.6788	-0.1499	75	0.8104
2136216460	effects of the home environmental skill building program on the caregiver care recipient dyad 6 month outcomes from the philadelphia reach initiative	2003	0.4906	-0.1054	1	30.4977
2136237080	lack of dehydroepiandrosterone effect on a combined endurance and resistance exercise program in postmenopausal women	2008	-1.4117	-1.8491	20	0.845
2136239752	cerebral small vessel disease and decline in information processing speed executive function and memory	2005	-0.4393	0.0019	12	0.9404
2136250824	a new clinical scale for the staging of dementia	1982	0.3994	-0.0869	10	4.7154
2136307813	caregivers to dementia patients the utilization of community services	1987	0.6973	-0.1567	76	1.6498
2136327185	evaluating rural nursing home environments dementia special care units versus integrated facilities	2004	0.6741	-0.0194	24	0.9939
2136332296	donepezil for the treatment of agitation in alzheimer s disease	2007	0.0113	0.0662	6	29.6885
2136415723	comparison of adaptive pacing therapy cognitive behaviour therapy graded exercise therapy and specialist medical care for chronic fatigue syndrome pace a randomised trial	2011	-0.2945	-0.1543	45	0.6839
2136435696	the brain s default network anatomy function and relevance to disease	2008	-0.2499	0.1367	22	0.916
2136439668	delayed onset of alzheimer s disease with nonsteroidal anti inflammatory and histamine h2 blocking drugs	1995	-0.414	-0.0404	32	1
2136535020	randomised trial of blood transfusion versus a restrictive transfusion policy after hip fracture surgery	2013	2.566	-0.0494	125	0.845
2136685417	propentofylline hwa 285 a subgroup analysis of phase iii clinical studies in alzheimer s disease and vascular dementia	1997	-0.4046	0.0822	85	14.011
2136708022	goal attainment and treatment compliance in a cognitive behavioral telephone intervention for family caregivers of persons with dementia	2011	0.54	-0.1154	1	15.8461
2136743230	testosterone administration to older men improves muscle function molecular and physiological mechanisms	2002	-1.2687	-1.5977	54	1
2136850387	integrated treatment approach improves cognitive function in demented and clinically depressed patients	2005	-0.3415	0.9111	113	0.7188
2136864264	treatment of cognitive impairment after poststroke depression a double blind treatment trial	2000	-0.235	0.1992	9	0.7111
2136873160	current pharmacologic treatment of dementia a clinical practice guideline from the american college of physicians and the american academy of family physicians	2008	-0.1825	0.0642	6	0.8843
2137094038	reducing antipsychotic drug prescribing for nursing home patients a controlled trial of the effect of an educational visit	1987	0.57	-0.0063	52	1.9404
2137248376	rivastigmine for the treatment of dementia and visual hallucinations associated with parkinson s disease a case series	2002	-0.1813	0.1102	7	2
2137257726	rivastigmine for alzheimer s disease	2005	-0.2795	0.1044	133	0.695
2137321682	hiv associated neurocognitive disorders persist in the era of potent antiretroviral therapy charter study	2010	-0.4004	0.502	87	1.9906
2137325786	a controlled trial to improve care for seriously iii hospitalized patients the study to understand prognoses and preferences for outcomes and risks of treatments support	1995	0.8533	-0.0194	95	0.9404
2137408480	effects of intensive blood pressure lowering and low dose aspirin in patients with hypertension principal results of the hypertension optimal treatment hot randomised trial	1998	-0.7355	-0.149	14	1.9998
2137554996	mild cognitive impairment	2006	-0.1812	-0.0414	46	3.8834
2137575668	recovery versus retest effects in attention after closed head injury	1999	-0.387	0.3785	98	0.7035
2137599726	trajectories of cholinergic pathways within the cerebral hemispheres of the human brain	1998	-0.2844	0.0411	72	0.845
2137615734	rivastigmine transdermal patch and capsule in alzheimer s disease influence of disease stage on response to therapy	2011	-0.2337	0.039	72	17.3862
2137646375	resource utilisation and cost analysis of memantine in patients with moderate to severe alzheimer s disease	2003	-0.1712	0.02	6	20.9696
2137719391	homocysteine versus the vitamins folate b6 and b12 as predictors of cognitive function and decline in older high functioning adults macarthur studies of successful aging	2005	-0.8817	-0.1017	30	5.8769
2137728624	cognitive deficit induced by acute tryptophan depletion in patients with alzheimer s disease	2000	-0.4086	0.3103	120	0.6029
2137785805	antidepressant pharmacotherapy in the treatment of depression in the very old a randomized placebo controlled trial	2004	-0.7628	-0.1427	135	0.7215
2137881774	the impact of antidepressant treatment on cognitive functioning in depressed patients with parkinson s disease	2010	-0.3415	0.9111	113	0.7409
2137890485	ginkgo biloba and vitamin e for alzheimer s disease	2012	-0.398	0.0312	53	0.6649
2137919051	effect of age on response to rivastigmine or donepezil in patients with alzheimer s disease	2006	-0.2373	0.0397	72	0.8027
2137944397	depression and risk for alzheimer disease systematic review meta analysis and metaregression analysis	2006	0.0537	0.17	61	1.7213
2137983259	rosuvastatin to prevent vascular events in men and women with elevated c reactive protein	2008	-0.7863	-0.1891	88	1
2138002435	effects of the finnish alzheimer disease exercise trial finalex a randomized controlled trial	2013	0.4841	-0.1902	25	1.9931
2138021422	incidence risk factors and consequences of icu delirium	2007	2.2375	-0.0482	2	1
2138067285	substituted s phenylpiperidines and rigid congeners as preferential dopamine autoreceptor antagonists synthesis and structure activity relationships	1994	-1.1671	1.5699	64	0.8843
2138141660	delirium in mechanically ventilated patients validity and reliability of the confusion assessment method for the intensive care unit cam icu	2001	2.2069	-0.0431	2	7.9915
2138182140	does befriending by trained lay workers improve psychological well being and quality of life for carers of people with dementia and at what cost a randomised controlled trial	2008	0.5283	-0.1112	1	0.9584
2138190873	classification of primary progressive aphasia and its variants	2011	-0.234	0.2588	66	3
2138210540	deficits in strategy application following frontal lobe damage in man	1991	0.4805	-0.2649	4	0.991
2138234128	physical activity and executive functions in the elderly with mild cognitive impairment	2005	0.0248	-0.2339	49	1.7027
2138266081	effect of iyengar yoga therapy for chronic low back pain	2005	1.6796	-0.9881	108	0.9998
2138390830	early psychosocial intervention in alzheimer s disease cost utility evaluation alongside the danish alzheimer s intervention study daisy	2014	0.5272	-0.0878	34	0.6993
2138399355	the effects of group reminiscence therapy on depression self esteem and life satisfaction of elderly nursing home residents	2006	0.3572	-0.0931	39	0.845
2138560194	dehydroepiandrosterone supplementation in healthy men with an age related decline of dehydroepiandrosterone secretion	2001	-1.4229	-1.8439	20	0.9994
2138622161	cognitive function after supplementation with b vitamins and long chain omega 3 fatty acids ancillary findings from the su fol om3 randomized trial	2011	-1.007	-0.2728	5	0.9404
2138630297	bright light treatment in elderly patients with nonseasonal major depressive disorder a randomized placebo controlled trial	2011	0.2928	-0.0185	17	1
2138632275	pituitary adrenal function in adolescent psychiatric patients impact of depressive symptoms	2000	0.3284	-0.0245	89	1.4329
2138685200	lewy body dementias	2015	-0.1954	0.1191	92	0.845
2138733401	effects of simvastatin on cerebrospinal fluid biomarkers and cognition in middle aged adults at risk for alzheimer s disease	2008	-0.2942	0.0285	57	0.6959
2138758697	improvement in mood and fatigue after dehydroepiandrosterone replacement in addison s disease in a randomized double blind trial	2000	-1.4062	-1.8181	20	2.7988
2138883123	the neuropsychiatric inventory assessing psychopathology in dementia patients	1997	-0.3876	-0.0488	8	3.573
2138902434	pathways to neuronal injury and apoptosis in hiv associated dementia	2001	-0.4009	0.502	87	1.958
2139025135	donepezil effects on cerebral blood flow in older adults with mild cognitive deficits	2006	-0.2007	0.1465	9	15.4053
2139026464	hospital stay and mortality are increased in patients having a triple low of low blood pressure low bispectral index and low minimum alveolar concentration of volatile anesthesia	2012	2.218	-0.0386	36	1.7499
2139046272	improvement in behavioural symptoms in patients with moderate to severe alzheimer s disease by memantine a pooled data analysis	2008	-0.1244	0.0626	6	3.9991
2139059737	antihypertensive medication use and incident alzheimer disease the cache county study	2006	-0.6608	-0.109	14	3.9998
2139142148	acetyl l carnitine slows decline in younger patients with alzheimer s disease a reanalysis of a double blind placebo controlled study using the trilinear approach	1998	-0.3257	-0.0072	63	4.7893
2139168645	intensive lipid lowering with atorvastatin in patients with stable coronary disease	2005	-0.7875	-0.1892	88	3
2139211778	pharmacology of nootropics and metabolically active compounds in relation to their use in dementia	1990	-0.2998	0.2015	15	3.5224
2139214514	point and 5 year period prevalence of neuropsychiatric symptoms in dementia the cache county study	2008	0.0408	0.0628	31	6.5877
2139231915	dementia care mapping a review of the research literature	2005	0.365	-0.0062	18	1
2139281905	does delirium contribute to poor hospital outcomes a three site epidemiologic study	1998	2.1342	-0.0428	2	2
2139338664	the effects of laughter therapy on mood state and self esteem in cancer patients undergoing radiation therapy a randomized controlled trial	2015	-0.2945	-0.1543	45	0.6959
2139354631	neural correlates of donepezil induced cognitive improvement in patients with right hemisphere stroke a pilot study	2011	-0.1794	0.0945	67	0.6621
2139421920	effects of rivastigmine on motor and cognitive impairment in huntington s disease	2004	-0.2283	-0.1467	112	0.9939
2139426446	droperidol v haloperidol for sedation of aggressive behaviour in acute mental health randomised controlled trial	2015	2.2267	-0.0443	2	0.7576
2139519928	outcomes of a behavioral unit in an acute aged care service	2012	0.9833	-0.0254	24	0.7461
2139527966	care management dementia care and specialist mental health services an evaluation	2002	0.5514	-0.1183	74	1.7292
2139560403	risk of death with atypical antipsychotic drug treatment for dementia meta analysis of randomized placebo controlled trials	2005	0.2049	0.0717	16	42.9022
2139593145	reaction time unchanged in older women following aerobic training	1991	0.5791	-0.2501	27	19.2236
2139600675	a randomized controlled trial of progressive resistance training in depressed elders	1997	0.512	-0.1989	25	0.9973
2139614216	effectiveness of nonpharmacological interventions in delaying the institutionalization of patients with dementia a meta analysis	2008	0.5543	-0.1157	74	0.7993
2139634859	multifactorial intervention and cardiovascular disease in patients with type 2 diabetes	2003	-0.4276	1.4428	56	0.7993
2139685997	does ginkgo biloba reduce the risk of cardiovascular events	2010	-0.5175	-0.0901	68	14.5748
2139691646	a 10 year study of the incidence of and factors predicting dementia in parkinson s disease	2000	-0.1767	0.1105	7	1
2139747033	consumption of fish and n 3 fatty acids and risk of incident alzheimer disease	2003	-1.0636	-0.2907	5	11.3921
2139805666	randomised trial of old and new antihypertensive drugs in elderly patients cardiovascular mortality and morbidity the swedish trial in old patients with hypertension 2 study	1999	-0.7326	-0.1459	14	1.9999
2139893960	longitudinal effects of aging on serum total and free testosterone levels in healthy men	2001	-1.1015	-1.3316	54	2
2139896681	group based memory rehabilitation for people with multiple sclerosis subgroup analysis of the remind trial	2014	-0.103	-0.096	8	0.7226
2139910117	effects of dehydroepiandrosterone supplementation on cognitive function and quality of life the dhea and well ness dawn trial	2008	-1.4112	-1.8309	20	19.3741
2140116196	memantine and cholinesterase inhibitor combination therapy for alzheimer s disease a systematic review	2012	-0.1718	0.0651	6	1.8834
2140130572	an outreach geriatric medication advisory service in residential aged care a randomised controlled trial of case conferencing	2004	0.6477	-0.0293	52	2.8556
2140131793	ibuprofen suppresses plaque pathology and inflammation in a mouse model for alzheimer s disease	2000	-0.4217	-0.0733	32	5.9958
2140295766	risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients	2007	0.2093	0.0521	80	1
2140304156	patient education to prevent falls among older hospital inpatients a randomized controlled trial	2011	2.2795	-0.0629	35	0.7993
2140314797	escitalopram versus risperidone for the treatment of behavioral and psychotic symptoms associated with alzheimer s disease a randomized double blind pilot study	2011	0.1962	0.0754	31	19.018
2140320787	efficacy and tolerability of carbamazepine for agitation and aggression in dementia	1998	0.1597	0.0773	16	22.6179
2140333930	dementia and functional decline in patients with parkinson s disease	2008	-0.1886	0.0705	7	0.757
2140348797	multicenter standardized 18f fdg pet diagnosis of mild cognitive impairment alzheimer s disease and other dementias	2008	-0.052	-0.0405	46	1
2140401447	assessing skin tolerability due to the change in the mode of administration of rivastigmine oral to transdermal according to two different strategies in alzheimer patients	2010	-0.244	0.0543	19	0.8291
2140427063	memantine and comprehensive individualized person centered management ci pcm of alzheimer s disease a randomized controlled trial	2013	-0.5166	-0.0479	12	0.7354
2140455646	the risk of dementia and death after delirium	1999	2.1014	-0.0419	2	1
2140466761	clinical trials in elderly patients	2007	-0.5975	-0.0271	99	0.7355
2140498280	mediterranean diet and mild cognitive impairment	2009	-1.0765	-0.2935	5	0.916
2140508716	brain thiamine its phosphate esters and its metabolizing enzymes in alzheimer s disease	1996	-0.7853	-0.0994	86	2.9075
2140559918	the effect of hormone replacement therapy on cognitive function in elderly women	1999	-0.7676	-0.7811	3	0.9713
2140606211	the positive and negative syndrome scale panss for schizophrenia	1987	0.6426	0.1008	91	0.9404
2140643819	computer assisted delivery of cognitive behavioral therapy for anxiety disorders in primary care settings	2009	0.7635	-0.2018	77	0.7977
2140665706	cerebrolysin decreases amyloid ?? production by regulating amyloid protein precursor maturation in a transgenic model of alzheimer s disease	2006	-0.3335	0.005	70	0.845
2140672750	beneficial effect of repetitive transcranial magnetic stimulation combined with cognitive training for the treatment of alzheimer s disease a proof of concept study	2011	-0.1755	0.0553	67	1.3346
2140675537	synergistic neurotoxicity by human immunodeficiency virus proteins tat and gp120 protection by memantine	2000	-0.4005	0.5012	87	0.9973
2140719894	rivastigmine and donepezil treatment in moderate to moderately severe alzheimer s disease over a 2 year period	2005	-0.2377	0.0524	6	21.4868
2140757158	randomised multicentre placebo controlled double blind crossover study investigating the effect of solifenacin and oxybutynin in elderly people with mild cognitive impairment the senior study	2013	-0.289	0.2822	9	0.6385
2140759353	efficacy and safety of cerebrolysin in moderate to moderately severe alzheimer s disease results of a randomized double blind controlled trial investigating three dosages of cerebrolysin	2011	-0.3524	-0.0011	70	1.6836
2140783655	dehydroepiandrosterone dhea stimulates neurogenesis in the hippocampus of the rat promotes survival of newly formed neurons and prevents corticosterone induced suppression	2002	-1.4229	-1.8439	20	0.9994
2140790148	effect of exercise on depression severity in older people systematic review and meta analysis of randomised controlled trials	2012	0.4834	-0.1436	60	0.7993
2140902586	bispectral index for improving anaesthetic delivery and postoperative recovery	2014	2.2027	-0.0374	36	0.9992
2141022701	effects of isolated transcutaneous electrical nerve stimulation on memory and affective behavior in patients with probable alzheimer s disease	1998	0.206	-0.0063	17	21.1128
2141042831	donepezil for cognitive impairment in parkinson s disease a randomised controlled study	2002	-0.1766	0.109	7	30.6893
2141139696	musical intervention for patients with dementia a meta analysis	2013	0.5124	-0.0525	21	0.9713
2141150496	an iron responsive element type ii in the 5 untranslated region of the alzheimer s amyloid precursor protein transcript	2002	-1.0107	-0.5241	69	1
2141158065	effectiveness and tolerability of high dose 23 mg d versus standard dose 10 mg d donepezil in moderate to severe alzheimer s disease a 24 week randomized double blind study	2010	-0.2003	0.0648	6	25.4194
2141189151	leisure activities and the risk of dementia in the elderly	2003	0.477	-0.2589	4	2.9713
2141242099	efficacy of interventions with caregivers a reanalysis	1991	0.5579	-0.1155	1	1.9518
2141280598	psychosocial treatments of behavior symptoms in dementia a systematic review of reports meeting quality standards	2009	0.4683	-0.0508	21	0.9997
2141362400	the impact of the use of statins on the prevalence of dementia and the progression of cognitive impairment	2002	-0.7219	-0.169	29	1.94
2141443922	memantine for lewy body disorders systematic review and meta analysis	2015	-0.1488	0.1239	7	0.7648
2141463840	cortisol levels during human aging predict hippocampal atrophy and memorydeficits	1998	-1.4243	-1.846	20	0.9988
2141502079	betaine supplementation lowers plasma homocysteine in healthy men and women	2003	-1.9284	0.3325	109	0.7961
2141561874	decline in physical function following hip fracture	1992	1.9721	-0.0871	26	0.9992
2141710162	delirium in elderly people	2014	2.1965	-0.0455	2	4.874
2141768983	a 24 week multicentre open evaluation of the clinical effectiveness of the rivastigmine patch in patients with probable alzheimer s disease	2011	-0.2555	0.0526	72	1.7477
2141824368	the effect of acute administration of 400mg of panax ginseng on cognitive performance and mood in healthy young volunteers	2005	-0.6607	-0.1211	65	16.8189
2141878479	effectiveness of educational interventions in improving detection and management of dementia in primary care cluster randomised controlled study	2006	0.565	-0.1243	74	2
2141909508	inadequate treatment of depressed nursing home elderly	1992	0.9833	-0.0254	24	0.7014
2142012413	the severe cognitive impairment rating scale an instrument for the assessment of cognition in moderate to severe dementia patients	2008	-0.0756	-0.1034	127	0.7676
2142062175	the effects of the active cognitive training trial on clinically relevant declines in health related quality of life	2006	0.4853	-0.2604	4	1
2142067982	an early rehabilitation intervention to enhance recovery during hospital admission for an exacerbation of chronic respiratory disease randomised controlled trial	2014	2.3692	-0.0634	35	0.7241
2142134419	use of cholinesterase inhibitors in clinical practice evidence based recommendations	2004	-0.2843	0.0857	33	0.6049
2142240447	decreases in rat extracellular hippocampal glucose concentration associated with cognitive demand during a spatial task	2000	-0.4598	1.8033	96	0.7993
2142257966	the association between betaine and choline intakes and the plasma concentrations of homocysteine in women	2007	-1.9284	0.3325	109	0.7356
2142273776	vascular contributions to cognitive impairment and dementia a statement for healthcare professionals from the american heart association american stroke association	2011	-0.3939	-0.0026	70	1.7213
2142274632	aripiprazole for the treatment of psychoses in institutionalized patients with alzheimer dementia a multicenter randomized double blind placebo controlled assessment of three fixed doses	2007	0.1751	0.088	16	2.9981
2142347023	effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients jelis a randomised open label blinded endpoint analysis	2007	-1.2428	-0.3453	83	1
2142373991	sequelae in long term survivors of small cell lung cancer	1996	0.2301	-0.2027	111	0.6534
2142393219	molecular changes underlying reduced pineal melatonin levels in alzheimer disease alterations in preclinical and clinical stages	2003	0.2494	-0.0165	28	1.9972
2142439044	antioxidants for alzheimer disease a randomized clinical trial with cerebrospinal fluid biomarker measures	2012	-0.4456	-0.0851	82	3.7265
2142511417	alzheimer s residents cognitive and functional measures special and traditional care unit comparison	1994	0.6761	-0.022	24	0.8843
2142514031	frailty in elderly people	2013	0.5372	-0.2244	136	0.9584
2142563833	testosterone therapy in men with androgen deficiency syndromes an endocrine society clinical practice guideline	2006	-1.2687	-1.5977	54	1
2142598557	one year cortical volume change measurement for prediction of conversion to alzheimer s disease in subjects with mild cognitive impairment study on diagnosis of early alzheimer s disease japan sead j	2014	-0.2809	0.1571	43	0.6398
2142847995	statins risk of dementia and cognitive function secondary analysis of the ginkgo evaluation of memory study	2012	-0.726	-0.1703	29	20.9575
2142975609	phase iia clinical trial on alzheimer s disease with np12 a gsk3 inhibitor	2010	-0.2801	0.075	51	0.6598
2143077267	cardiopulmonary bypass induced inflammation pathophysiology and treatment an update	2002	2.5491	-0.0689	35	0.916
2143117154	effects of a caregiver intervention on negative caregiver appraisals of behavior problems in patients with alzheimer s disease results of a randomized trial	2004	0.4738	-0.1001	1	4.6873
2143132110	a randomized double blind trial of atomoxetine for cognitive impairments in 32 people with schizophrenia	2009	-0.2409	0.1654	9	0.7113
2143152245	postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause	2007	-0.7469	-0.7546	3	0.9973
2143221342	divergent associations of plasma choline and betaine with components of metabolic syndrome in middle age and elderly men and women	2008	-1.9287	0.3319	109	0.75
2143234754	small homelike care environments for older people with dementia a literature review	2009	0.6741	-0.0194	24	0.9713
2143258751	vitamin b 6 supplementation in elderly men effects on mood memory performance and mental effort	1992	-0.8726	-0.1039	30	0.9999
2143285014	default mode network activity distinguishes alzheimer s disease from healthy aging evidence from functional mri	2004	-0.1624	0.0917	22	1.741
2143294206	preoperative physical therapy for elective cardiac surgery patients	2012	2.3691	-0.0643	35	0.7126
2143310678	physical activity and cognitive performance in the older population	1995	0.5793	-0.2494	27	2.8732
2143317695	nimodipine in the treatment of primary degenerative dementia	1994	-0.3104	0.1508	22	1.7805
2143364702	frontotemporal dementia in the netherlands patient characteristics and prevalence estimates from a population based study	2003	-0.2313	0.2459	66	0.75
2143375239	behavioral therapy for childhood constipation a randomized controlled trial	2008	-0.2875	0.2061	15	0.6827
2143388909	brain atrophy in patients with arterial disease the smart mr study	2008	-0.7263	0.0224	107	0.6764
2143398871	effects of multicomponent exercise on cognitive function in older adults with amnestic mild cognitive impairment a randomized controlled trial	2012	0.5368	-0.188	27	0.8843
2143403659	resources for mental health scarcity inequity and inefficiency	2007	0.5574	-0.1268	140	0.9804
2143521222	the dementia antipsychotic withdrawal trial dart ad long term follow up of a randomised placebo controlled trial	2009	0.2076	0.0525	80	32.9197
2143532598	high homocysteine and low b vitamins predict cognitive decline in aging men the veterans affairs normative aging study	2005	-0.8775	-0.1011	30	5.9087
2143538339	patient education to prevent falls in subacute care	2006	2.2795	-0.0629	35	0.75
2143594821	glucose administration heart rate and cognitive performance effects of increasing mental effort	2000	-0.4598	1.8033	96	0.7993
2143617649	intensive care delirium screening checklist evaluation of a new screening tool	2001	2.2277	-0.0466	2	2
2143691584	environmental correlates to behavioral health outcomes in alzheimer s special care units	2003	0.6743	-0.0186	24	0.9999
2143748326	the cleveland alzheimer s managed care demonstration outcomes after 12 months of implementation	2003	0.5177	-0.1091	1	22.0494
2143756634	effects of single dose methylphenidate on cognitive performance in patients with traumatic brain injury a double blind placebo controlled study	2006	-0.9922	1.2607	71	0.723
2143790126	sleep quality and preclinical alzheimer disease	2013	0.2198	-0.0138	28	1.8556
2143799055	single photon emission tomography using 99mtc hm pao in the investigation of dementia	1987	-0.293	0.1677	13	0.916
2143810782	dose related effects of eicosapentaenoic acid on innate immune function in healthy humans a comparison of young and older men	2006	-1.1442	-0.3148	83	0.7993
2143830132	nursing outcomes for evaluations of caregiver outcomes in a rural alzheimer demonstration project	2003	0.5279	-0.087	34	0.6825
2143879671	ideal a 6 month double blind placebo controlled study of the first skin patch for alzheimer disease	2007	-0.2395	0.0436	19	27.231
2143954917	seventh report of the joint national committee on prevention detection evaluation and treatment of high blood pressure	2003	-0.7315	-0.1489	14	2
2144051538	the mental activity and exercise max trial a randomized controlled trial to enhance cognitive function in older adults	2013	0.5368	-0.188	27	0.9973
2144053883	a randomized trial of a consultation service to reduce falls in nursing homes	1997	0.8435	-0.1027	42	0.9998
2144072197	placebo in research on schizophrenia	1998	-0.1547	0.2301	15	0.6376
2144167443	long term fitness training improves the circadian rest activity rhythm in healthy elderly males	1997	0.2449	-0.0133	17	1.9142
2144337751	clinical effects of choline in alzheimer senile dementia	1977	-0.384	0.3371	59	0.8043
2144373877	incidence of and risk factors for hallucinations and delusions in patients with probable ad	2000	0.0731	0.0945	16	0.9804
2144567683	cost utility analysis of group living in dementia care	1995	0.5283	-0.1112	1	0.9804
2144625404	a randomized controlled trial of a specific reminiscence approach to promote the well being of nursing home residents with dementia	2004	0.3516	-0.0882	39	4.7031
2144631174	metabolic reduction in the posterior cingulate cortex in very early alzheimer s disease	1997	-0.052	-0.0405	46	1
2144686265	a controlled long term study with ergoloid mesylates hydergine in healthy elderly volunteers results after three years	1983	-0.1379	0.0381	80	0.8365
2144750999	plasma n 3 fatty acids and the risk of cognitive decline in older adults the atherosclerosis risk in communities study	2007	-1.0252	-0.2776	5	1.9404
2144769321	donepezil in vascular dementia combined analysis of two large scale clinical trials	2005	-0.4026	0.007	12	2.9958
2144816691	donepezil treated patients with probable vascular dementia demonstrate cognitive benefits	2002	-0.3222	0.0393	12	21.6209
2144816857	a randomised blinded placebo controlled trial in dementia patients continuing or stopping neuroleptics the dart ad trial	2008	0.2071	0.0583	16	29.8891
2144855317	antipsychotic drug use and mortality in older adults with dementia	2007	0.2093	0.0521	80	1
2145062984	sleep wake disturbances 6 months after traumatic brain injury a prospective study	2007	-1.2594	1.7614	64	0.9999
2145084335	rivastigmine in the treatment of dementia with lewy bodies preliminary findings from an open trial	2000	-0.1926	0.1212	7	0.9973
2145123193	use of lipid lowering agents indication bias and the risk of dementia in community dwelling elderly people	2002	-0.7166	-0.1674	29	8.9769
2145124160	effects of multiple exposures to d cycloserine on extinction of conditioned fear in rats	2005	-0.2904	0.1831	43	0.9404
2145131255	a feasibility study of translating living well with dementia groups into a primary care improving access to psychological therapy service innovative practice	2016	0.3596	-0.0939	39	0.8475
2145144040	mortality and morbidity results from the european working party on high blood pressure in the elderly trial	1985	-0.7376	-0.1471	14	0.9996
2145234674	melatonin for treatment of sundowning in elderly persons with dementia a preliminary study	2000	0.242	-0.0169	28	3.9979
2145262930	donepezil for treatment of dementia with lewy bodies a case series of nine patients	1998	-0.1933	0.1214	7	2.9908
2145336951	omega 3 fatty acids in bipolar disorder a preliminary double blind placebo controlled trial	1999	-1.0972	-0.3014	5	0.9959
2145355299	maintenance of effects of the home environmental skill building program for family caregivers and individuals with alzheimer s disease and related disorders	2005	0.4739	-0.0966	1	7.2638
2145373866	powerful beneficial effects of benfotiamine on cognitive impairment and ?? amyloid deposition in amyloid precursor protein presenilin 1 transgenic mice	2010	-0.7839	-0.0988	86	1.8003
2145427750	p 444 the effectiveness of group music therapy to improve depression and cognition status in elderly persons with dementia	2012	0.415	-0.0781	18	0.734
2145433639	efficacy of a psychoeducative group program for caregivers of demented persons living at home a randomized controlled trial	2003	0.5228	-0.1078	1	27.6951
2145525450	support service use and interest in support services among distressed family caregivers of lung cancer patients	2013	0.5963	-0.1335	131	0.7104
2145586396	changes in cortisol secretion during antidepressive treatment and cognitive improvement in patients with major depression a longitudinal study	2012	0.3277	-0.0246	89	1.4304
2145616005	a controlled trial of methylphenidate in adults with attention deficit hyperactivity disorder and substance use disorders	2005	-0.1547	0.2301	15	0.6559
2145662100	a double blind placebo controlled trial of tanakan in the treatment of idiopathic cognitive impairment in the elderly	1987	-0.4932	-0.0704	8	25.6129
2145662827	a pilot study examining the effectiveness of maintenance cognitive stimulation therapy mcst for people with dementia	2005	0.2751	-0.092	10	3.9946
2145673525	p4 367 impact of donepezil therapy on function in relation to mmse in patients with alzheimer s disease	2008	-0.304	0.1039	50	1.4492
2145838106	efficacy and safety of ropivacaine addition to intrathecal morphine for pain management in intractable cancer	2015	2.3863	-0.0472	130	0.8536
2145846347	sertraline or mirtazapine for depression in dementia hta sadd a randomised multicentre double blind placebo controlled trial	2011	0.1494	0.0838	31	11.5696
2146031912	donepezil mediated memory improvement in traumatic brain injury during post acute rehabilitation	1998	-0.8474	1.0199	71	0.9713
2146073951	the effects of nicotine on attention information processing and short term memory in patients with dementia of the alzheimer type	1989	0.0437	0.4832	48	1
2146082333	effects of residence in alzheimer disease special care units on functional outcomes	1997	0.6749	-0.0213	24	1.8753
2146126584	effects of estrogen on memory function in surgically menopausal women	1992	-0.7581	-0.7648	3	45.9676
2146165120	acetyl l carnitine in dementia	1991	-0.3262	-0.0227	63	17.6888
2146204489	open channel block of n methyl d aspartate nmda responses by memantine therapeutic advantage against nmda receptor mediated neurotoxicity	1992	-0.3046	0.0565	23	2
2146272386	positron emission tomography in evaluation of dementia regional brain metabolism and long term outcome	2001	-0.052	-0.0405	46	1
2146337394	modification of dysfunctional thoughts about caregiving in dementia family caregivers description and outcomes of an intervention programme	2007	0.5291	-0.1111	1	22.5339
2146361460	dietary intake of fatty acids and fish in relation to cognitive performance at middle age	2004	-1.0398	-0.282	5	2.991
2146398321	overview of clinical trials of hydergine in dementia	1994	-0.3852	0.1417	134	0.75
2146470552	clinical and cost effectiveness of donepezil rivastigmine and galantamine for alzheimer s disease	2002	-0.285	0.0852	33	0.6762
2146687529	impact of home education on levels of perceived social support for caregivers of cancer patients	2012	0.6854	-0.1437	97	0.6751
2146726370	dehydroepiandrosterone dhea supplementation for cognitive function in healthy elderly people	2006	-1.4128	-1.8331	20	0.9959
2146777698	cognitive dysfunction 24 31 years after isolated optic neuritis	2008	0.2301	-0.2027	111	0.6453
2146788881	csf biomarkers and incipient alzheimer disease in patients with mild cognitive impairment	2009	-0.1292	-0.0475	46	0.991
2146798390	morbidity and mortality after stroke eprosartan compared with nitrendipine for secondary prevention principal results of a prospective randomized controlled study moses	2005	-0.7312	-0.1465	14	1
2146851676	a comparison of outcomes with angiotensin converting enzyme inhibitors and diuretics for hypertension in the elderly	2003	-0.7376	-0.148	14	0.9988
2146853003	cognitive behavioural therapy cbt for carers of patients with parkinson s disease a preliminary randomised controlled trial	2005	0.7627	-0.2018	77	0.8048
2146896138	clinical trials of dementia with lewy bodies and parkinson s disease dementia	2012	-0.1375	0.2003	100	0.7843
2147018519	effect of nurse practitioner and pharmacist counseling on inappropriate medication use in family practice	2012	2.2795	-0.0629	35	0.747
2147030837	the impact of general and regional anesthesia on the incidence of post operative cognitive dysfunction and post operative delirium a systematic review with meta analysis	2010	2.1931	-0.0387	36	1.9999
2147048440	a randomized double blind placebo controlled trial of simvastatin to treat alzheimer disease	2011	-0.7106	-0.1665	29	23.9954
2147055201	memory enhancement training for older adults with mild cognitive impairment a preliminary study	2002	0.2118	-0.1267	10	25.7832
2147061745	the effect of speed of processing training on depressive symptoms in active	2009	0.4853	-0.2604	4	1
2147081056	estrogen replacement therapy and memory in older women	1994	-0.7657	-0.7733	3	3.9996
2147140002	effects of n 3 fatty acids epa v dha on depressive symptoms quality of life memory and executive function in older adults with mild cognitive impairment a 6 month randomised controlled trial	2012	-0.9797	-0.2677	5	2.7481
2147254207	risks of untreated and treated isolated systolic hypertension in the elderly meta analysis of outcome trials	2000	-0.7376	-0.1471	14	0.9982
2147557600	improved language performance in alzheimer disease following brain stimulation	2011	-0.1598	0.0553	67	0.6817
2147570901	effect of aerobic exercise on tracking performance in elderly people a pilot study	2001	0.5498	-0.2251	27	17.6598
2147614048	effectiveness of case management among older adults with early symptoms of dementia and their primary informal caregivers a randomized clinical trial	2011	0.5543	-0.1183	74	22.2786
2147735030	collaborative care management of late life depression in the primary care setting	2002	0.556	-0.1218	74	1
2147748281	prediction of postoperative delirium after abdominal surgery in the elderly	2009	2.7899	-0.0532	118	0.8033
2147782235	statins are associated with a reduced risk of alzheimer disease regardless of lipophilicity the rotterdam study	2009	-0.7153	-0.1671	29	6.945
2147957352	effects of alprazolam on driving ability memory functioning and psychomotor performance a randomized placebo controlled study	2002	-0.3865	0.3792	98	0.702
2148027526	does elimination of placebo responders in a placebo run in increase the treatment effect in randomized clinical trials a meta analytic evaluation	2004	-0.2939	0.0995	41	0.6677
2148122976	clinical benefit of steroid use in patients undergoing cardiopulmonary bypass a meta analysis of randomized trials	2008	2.5489	-0.0698	35	0.916
2148211031	a systematic review of neurotransmitter deficits and treatments in frontotemporal dementia	2006	-0.2343	0.2586	66	2.991
2148226383	can staff training reduce behavioural problems in residential care for the elderly mentally ill	1998	0.4712	-0.039	18	0.9959
2148473989	evaluation of a telephone based support group intervention for female caregivers of community dwelling individuals with dementia	2007	0.512	-0.1128	1	25.1782
2148535109	validation of the cns penetration effectiveness rank for quantifying antiretroviral penetration into the central nervous system	2008	-0.4009	0.5012	87	1.9958
2148562149	study of the efficacy of korean red ginseng in the treatment of erectile dysfunction	2007	-0.6648	-0.1223	65	0.75
2148658472	active a cognitive intervention trial to promote independence in older adults	2001	0.4805	-0.2573	4	2
2148685416	blood pressure and haemoglobin a1c are associated with microhaemorrhage in cadasil a two centre cohort study	2006	-0.45	-0.0021	12	0.9997
2148716787	walking the line a randomised trial on the effects of a short term walking programme on cognition in dementia	2009	0.3709	-0.199	25	25.7273
2148819058	cognitive behavioral intervention for homebound caregivers of persons with dementia	1999	0.5404	-0.1103	1	22.707
2148917936	significant correlations of plasma homocysteine and serum methylmalonic acid with movement and cognitive performance in elderly subjects but no improvement from short term vitamin therapy a placebo controlled randomized study	2005	-0.8787	-0.1014	30	6.9755
2148922998	an educational intervention can prevent delirium on acute medical wards	2005	2.2056	-0.0495	2	0.9997
2149116902	cognitive and behavioural effects of music based exercises in patients with dementia	2004	0.4818	-0.1347	25	33.0263
2149142893	mri as a biomarker of disease progression in a therapeutic trial of milameline for ad	2003	-0.1936	0.0129	46	1.75
2149303049	estrogen replacement therapy and longitudinal decline in visual memory a possible protective effect	1997	-0.7606	-0.7681	3	2.9998
2149422263	what is the effect of a support program for female family caregivers of dementia on depression 1	2013	0.6283	-0.1218	42	0.7554
2149474055	the preventive antibiotics in stroke study pass a pragmatic randomised open label masked endpoint clinical trial	2015	2.3691	-0.0643	35	0.7142
2149487349	effect of estrogen on brain activation patterns in postmenopausal women during working memory tasks	1999	-0.7559	-0.7611	3	26.9297
2149596160	predicting alzheimer s disease in subjects with cognitive impairment no dementia using the pre clinical ad scale pas	2000	-0.2007	0.0876	78	0.6729
2149614271	mild cognitive impairment represents early stage alzheimer disease	2001	-0.2181	-0.0452	46	2
2149615621	predictors of cognitive dysfunction after major noncardiac surgery	2008	2.2048	-0.0356	36	2.8843
2149626554	memantine treatment in patients with mild to moderate alzheimers disease already receiving a cholinesterase inhibitor a randomized double blind placebo controlled trial	2008	-0.1736	0.0614	6	37.577
2149626929	reduction of sleep disordered breathing after physostigmine	2003	0.2286	-0.0028	28	0.991
2149710778	the effects of omega 3 fatty acids monotherapy in alzheimer s disease and mild cognitive impairment a preliminary randomized double blind placebo controlled study	2008	-1.0548	-0.287	5	10.6408
2149715242	effect of morning bright light treatment for rest activity disruption in institutionalized patients with severe alzheimer s disease	2005	0.2965	-0.0177	17	7.8838
2149938672	a multicomponent intervention to prevent delirium in hospitalized older patients	1999	2.0788	-0.042	2	22.5893
2149944282	plasma phosphatidylcholine docosahexaenoic acid content and risk of dementia and alzheimer disease the framingham heart study	2006	-1.0561	-0.2874	5	8.6691
2150098511	exercise programs for people with dementia	2014	0.4883	-0.1913	25	1.9988
2150101787	exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone	2004	-1.2696	-1.5976	54	1
2150231759	c 11 pib pet assessment of change in fibrillar amyloid beta load in patients with alzheimer s disease treated with bapineuzumab a phase 2 double blind placebo controlled ascending dose study	2010	-0.2218	0.0114	46	0.75
2150241429	a randomized controlled trial of high versus low intensity weight training versus general practitioner care for clinical depression in older adults	2005	0.512	-0.1989	25	0.9988
2150261076	dying with advanced dementia in the nursing home	2004	0.8533	-0.0193	95	0.9867
2150283528	light therapy for improving cognition activities of daily living sleep challenging behaviour and psychiatric disturbances in dementia	2014	0.3409	-0.0185	17	0.8843
2150523249	a hexanucleotide repeat expansion in c9orf72 is the cause of chromosome 9p21 linked als ftd	2011	-0.2335	0.2595	66	0.9959
2150541210	clinical prevention of sudden cardiac death by n 3 polyunsaturated fatty acids and mechanism of prevention of arrhythmias by n 3 fish oils	2003	-1.1442	-0.3148	83	0.75
2150567881	a web based psychoeducational program for informal caregivers of patients with alzheimer s disease a pilot randomized controlled trial	2015	0.5531	-0.1195	1	0.9804
2150578706	evaluation of a community based rehabilitation model for chronic schizophrenia in rural india	2003	0.5574	-0.1268	140	0.9939
2150693120	efficacy safety and tolerability of rivastigmine capsules in patients with probable vascular dementia the vantage study	2008	-0.4161	0.0028	12	21.6044
2150798548	systematic review of psychological approaches to the management of neuropsychiatric symptoms of dementia	2005	0.3821	-0.0495	18	18.9426
2150821108	snoezelen an overview of research with people with developmental disabilities and dementia	2002	0.4254	-0.0769	18	0.9982
2150922266	relation between severity of alzheimer s disease and costs of caring	1998	-0.0533	-0.0059	93	1.9941
2150934026	dementia with lewy bodies versus alzheimer s disease and parkinson s disease dementia a comparison of cognitive profiles	2011	-0.1952	0.1292	7	0.8117
2151014134	the effects of cognitive rehabilitation on alzheimer s dementia patients cognitive assessment reference diagnosis system performance based on level of cognitive functioning	2015	-0.2243	-0.2062	49	1.4379
2151021202	improving aerobic capacity in healthy older adults does not necessarily lead to improved cognitive performance	1989	0.5714	-0.2444	27	23.9504
2151170617	lu ae58054 a 5 ht6 antagonist reverses cognitive impairment induced by subchronic phencyclidine in a novel object recognition test in rats	2010	-1.5582	0.2221	115	0.9973
2151194337	managing behavioural symptoms of dementia effectiveness of staff education and peer support	2008	0.5322	-0.0667	18	0.9584
2151351508	methylprednisolone in patients undergoing cardiopulmonary bypass sirs a randomised double blind placebo controlled trial	2015	2.5466	-0.0697	35	16.1366
2151371335	choline supplemented as phosphatidylcholine decreases fasting and postmethionine loading plasma homocysteine concentrations in healthy men	2005	-1.9284	0.3325	109	0.7228
2151445031	decreased melatonin levels in postmortem cerebrospinal fluid in relation to aging alzheimer s disease and apolipoprotein e e4 4 genotype1	1999	0.2361	-0.0165	28	2.9982
2151462277	effectiveness of targeted falls prevention programme in subacute hospital setting randomised controlled trial	2004	2.2795	-0.0629	35	0.845
2151545849	behavioral and psychological symptoms in dementia in nursing home residents the economic implications	2000	0.4399	-0.0044	104	0.8121
2151585937	donepezil and memantine for moderate to severe alzheimer s disease	2012	-0.1601	0.0653	6	27.3475
2151603390	galantamine a randomized double blind dose comparison in patients with alzheimer s disease	2001	-0.2258	0.0435	6	26.7556
2151613538	effects of oils rich in eicosapentaenoic and docosahexaenoic acids on immune cell composition and function in healthy humans	2004	-1.1085	-0.3042	5	0.9939
2151622084	statistical approaches to effectiveness measurement and outcome driven re randomizations in the clinical antipsychotic trials of intervention effectiveness catie studies	2003	0.6406	0.1012	91	16.433
2151787780	additional exercise does not change hospital or patient outcomes in older medical patients a controlled clinical trial	2007	2.3691	-0.0643	35	0.7416
2151805017	ginkgo for memory enhancement a randomized controlled trial	2002	-0.4571	-0.0827	8	3.9707
2151860672	low vitamin b 12 status and risk of cognitive decline in older adults	2007	-0.8708	-0.1029	30	1
2151876769	changes in cerebral glucose metabolism in patients with parkinson disease with dementia after cholinesterase inhibitor therapy	2008	-0.4858	0.0852	117	0.6778
2151918054	impact of donepezil treatment for alzheimer s disease on caregiver time	2004	0.1342	-0.0722	93	0.8231
2152104451	risk factors for burn out in caregivers of stroke patients and possibilities for intervention	2001	0.6788	-0.1499	75	0.7862
2152116430	behavioral complications associated with donepezil	1998	-0.2185	0.142	11	0.7591
2152141502	yoga for depression the research evidence	2005	1.6805	-0.9881	108	1
2152153214	severity of depression and response to antidepressants genpod randomised controlled trial	2012	0.1033	0.1511	61	0.7101
2152159914	divalproex sodium in nursing home residents with possible or probable alzheimer disease complicated by agitation a randomized controlled trial	2005	0.1757	0.0778	16	22.9286
2152186919	individual cognitive stimulation therapy for dementia a clinical effectiveness and cost effectiveness pragmatic multicentre randomised controlled trial	2015	0.395	-0.1042	39	0.7424
2152200621	differential effects of single versus combined cognitive and physical training with older adults the sima study in a 5 year perspective	2006	0.5359	-0.188	27	0.9939
2152221374	investigation of 99mtc labeled clioquinol derivative on amyloid plaque specificity by using an animal model of alzheimer s disease	2014	-1.0873	-0.5741	69	0.7435
2152226265	general compared with spinal anesthesia for total hip arthroplasty	2015	2.2338	-0.0385	36	0.7392
2152229384	rescue of dying neurons a new action for deprenyl in mptp parkinsonism	1991	-0.1986	0.1207	37	0.9994
2152255690	chronic effects of dopaminergic replacement on cognitive function in parkinson s disease a two year follow up study of previously untreated patients	2000	-0.2338	0.184	9	0.6635
2152285981	relearning face name associations in early alzheimer s disease	2002	0.2626	-0.1116	10	2.9957
2152365231	betaine concentration as a determinant of fasting total homocysteine concentrations and the effect of folic acid supplementation on betaine concentrations	2005	-1.9284	0.3325	109	0.8066
2152370183	effects of a flexible galantamine dose in alzheimer s disease a randomised controlled trial	2001	-0.2107	0.0365	6	29.3958
2152381395	animal models of vascular dementia translational potential at the present time and in 2050	2014	-0.7263	0.0224	107	0.7328
2152415998	ginkgo biloba for prevention of dementia a randomized controlled trial	2008	-0.4229	-0.0939	8	38.2908
2152446053	long term effects of a??42 immunisation in alzheimer s disease follow up of a randomised placebo controlled phase i trial	2008	-0.5827	-0.1626	32	1.991
2152471765	improving metabolic control leads to better working memory in adults with type 2 diabetes	2006	-0.4451	1.5842	56	20.9992
2152500484	review donepezil improves cognitive and global function in people with mild to moderate alzheimer s disease	2005	-0.3195	0.1168	33	0.796
2152507440	comparing the effects of different individualized music interventions for elderly individuals with severe dementia	2013	0.4967	-0.0518	21	2.9447
2152681246	the us economic and social costs of alzheimer s disease revisited	1994	0.0635	-0.0295	93	0.9939
2152789823	randomised trial of cholesterol lowering in 4444 patients with coronary heart disease the scandinavian simvastatin survival study 4s	2004	-0.7878	-0.1889	88	3
2152798629	telmisartan ramipril or both in patients at high risk for vascular events	2008	-0.7317	-0.1491	14	2
2152837663	pramipexole for the treatment of depressive symptoms in patients with parkinson s disease a randomised double blind placebo controlled trial	2010	-0.1878	0.1167	7	0.9959
2152907424	15 year longitudinal study of blood pressure and dementia	1996	-0.6719	-0.1138	14	7.9523
2152962282	behavioural management in nursing and residential homes a randomised controlled trial	1999	0.4694	-0.039	18	21.3762
2153038533	cardiovascular fitness cortical plasticity and aging	2004	0.5531	-0.2315	27	2.8245
2153054970	reducing inappropriate polypharmacy the process of deprescribing	2015	-0.6916	-0.1919	79	0.8843
2153065545	evaluation of cycloserine in the treatment of alzheimer s disease	1995	-0.2896	0.182	43	20.7136
2153110258	effects of guided care on family caregivers	2010	0.6788	-0.15	75	0.7884
2153179093	the accelerate study the longitudinal effect of speed of processing training on cognitive performance of older adults	2007	0.4853	-0.2604	4	1
2153237957	a randomised comparative trial of yoga and relaxation to reduce stress and anxiety	2007	1.6805	-0.9881	108	0.9998
2153253746	hallucinations in parkinson s disease prevalence phenomenology and risk factors	2000	-0.1803	0.1125	7	5
2153287135	strong clustering and stereotyped nature of notch3 mutations in cadasil patients	1997	-0.45	-0.0021	12	0.9988
2153299553	a double blind placebo controlled study of the omega 3 fatty acid docosahexaenoic acid in the treatment of major depression	2003	-1.0972	-0.3014	5	0.9959
2153402143	sustained benefit of supportive intervention for depressive symptoms in caregivers of patients with alzheimer s disease	2004	0.5252	-0.1109	1	15.6814
2153415741	a controlled trial of homocysteine lowering and cognitive performance	2006	-0.8767	-0.1015	30	8.995
2153451328	similar patterns of cognitive deficits in the preclinical phases of vascular dementia and alzheimer s disease	2004	-0.8154	0.8222	102	0.7066
2153476264	early neuropathological alzheimer s changes in aged individuals are accompanied by decreased cerebrospinal fluid melatonin levels	2003	0.2292	-0.0166	28	4.9771
2153513667	teaching and maintaining behavior management skills in the nursing home	2002	0.5322	-0.0667	18	0.9404
2153544933	yoga for cancer patients and survivors	2005	1.6796	-0.9881	108	0.9988
2153601291	community based occupational therapy for patients with dementia and their care givers randomised controlled trial	2006	0.4232	-0.1102	1	2.7985
2153613258	the effect of cognitive training in patients with mild cognitive impairment and early alzheimer s disease a preliminary study	2012	-0.224	-0.2058	49	1.4237
2153631628	practice parameter early detection of dementia mild cognitive impairment an evidence based review report of the quality standards subcommittee of the american academy of neurology	2001	-0.2996	-0.0592	46	1
2153680113	behavioral disturbances of dementia in the nursing home	1997	0.4399	-0.0044	104	0.7924
2153807853	successful behavioral treatment for reported sleep problems in elderly caregivers of dementia patients a controlled study	1998	0.5532	-0.1135	1	1.8254
2153828620	the effectiveness of an augmented cognitive behavioural intervention for post stroke depression with or without anxiety psda the restore4stroke psda trial	2012	0.7627	-0.2018	77	0.782
2153908187	an impairment and disability assessment and treatment protocol for community living elderly persons	1994	0.5122	-0.1606	60	0.657
2154120695	p2 272 assessing anxiety and agitation among nursing home residents with alzheimer s disease	2008	0.4398	-0.0044	104	0.85
2154166294	exercise and pharmacotherapy in the treatment of major depressive disorder	2007	0.512	-0.1989	25	0.9939
2154365828	a clinical prediction rule for delirium after elective noncardiac surgery	1994	2.2059	-0.0408	36	5.8839
2154394735	discrimination between alzheimer dementia and controls by automated analysis of multicenter fdg pet	2002	-0.052	-0.0404	46	1
2154531114	dementia caregivers responses to 2 internet based intervention programs	2011	0.5527	-0.1197	1	1.9973
2154596951	efficacy of memantine for agitation in alzheimer s dementia a randomised double blind placebo controlled trial	2012	-0.0487	0.0737	6	3.8644
2154633730	cognition and anatomy in three variants of primary progressive aphasia	2004	-0.236	0.2606	66	1
2154658393	what is person centred care in dementia	2003	0.365	-0.0062	18	1
2154774132	improvement of a woman s alcohol related dementia via off label memantine treatment a 16 month clinical observation	2014	-0.2313	0.2459	66	0.6828
2154784840	combination therapy with cholinesterase inhibitors and memantine for alzheimer s disease a systematic review and meta analysis	2015	-0.1834	0.0644	6	0.8843
2154787902	donepezil treatment of patients with mci a 48 week randomized placebo controlled trial	2009	-0.1297	-0.0459	46	25.5284
2154945114	expanded ggggcc hexanucleotide repeat in noncoding region of c9orf72 causes chromosome 9p linked ftd and als	2011	-0.2343	0.2592	66	0.9982
2154945520	response across multiple outcome measures in a randomized trial of extended release memantine 28 mg once daily in patients with moderate to severe alzheimer s disease	2012	-0.2365	0.0573	19	15.3892
2154990516	the dopamine stabilizers s 3 methanesulfonyl phenyl 1 propyl piperidine osu6162 and 4 3 methanesulfonylphenyl 1 propyl piperidine acr16 show high in vivo d2 receptor occupancy antipsychotic like efficacy and low potential for motor side effects in the rat	2006	-1.1671	1.5699	64	0.8843
2155033339	pharmacotherapy for organic brain syndrome in late life evaluation of an ergot derivative vs placebo	1977	-0.2932	0.0992	41	16.4561
2155044939	hypertension is related to cognitive impairment a 20 year follow up of 999 men	1998	-0.6682	-0.1121	14	5.9398
2155060429	restraint use among nursing home residents cross sectional study and prospective cohort study	2009	0.8052	-0.0983	42	3.9212
2155087576	a 30 week randomized controlled trial of high dose tacrine in patients with alzheimer s disease	1994	-0.2934	0.1073	13	26.1634
2155087925	benefits of physical exercise training on cognition and quality of life in frail older adults	2013	0.5364	-0.2232	136	19.3905
2155126658	are memory complaints predictive for dementia a review of clinical and population based studies	2000	0.4859	-0.2694	4	0.9804
2155128740	sensoristasis and imbalance in persons with dementia	2000	0.4282	-0.0752	18	1.9148
2155194411	reality orientation a milieu therapy used in an institution for the aged	1977	0.3212	-0.0918	10	1.996
2155210372	exercise is associated with reduced risk for incident dementia among persons 65 years of age and older	2006	0.4761	-0.1625	25	4.9938
2155217177	aspirin prevents stroke but not mi in women vitamin e has no effect on cv disease or cancer	2006	-0.5188	-0.0906	68	0.7093
2155217186	a meta analytic review of interventions for caregiver distress recommendations for future research	1993	0.5532	-0.1154	1	2.9208
2155233219	reduction of postoperative mortality and morbidity with epidural or spinal anaesthesia results from overview of randomised trials	2000	2.2253	-0.0295	36	0.8843
2155424617	relationship between pain and opioid analgesics on the development of delirium following hip fracture	2003	2.2333	-0.0449	138	1.9992
2155456788	brain aging and alzheimer s disease wear and tear versus use it or lose it	1991	0.2108	-0.0084	17	4.4246
2155537822	dementia prevention methodological explanations for inconsistent results	2008	-0.103	-0.0968	8	0.845
2155576766	psychotropic medication use in swiss nursing homes	2011	0.9833	-0.0254	24	0.7268
2155598961	prevention of coronary heart disease with pravastatin in men with hypercholesterolemia	1995	-0.7875	-0.1886	88	3
2155612395	panax ginseng pharmacology a nitric oxide link	1997	-0.6545	-0.1195	65	0.9982
2155669855	randomized placebo controlled clinical trial of donepezil in vascular dementia differential effects by hippocampal size	2010	-0.4312	-0.0037	12	2.8764
2155755732	identification of responders and reactive domains to rivastigmine in alzheimer s disease	2007	-0.1845	0.1066	6	0.7993
2155838553	delirium prevention program in the surgical intensive care unit improved the outcomes of older adults	2014	2.566	-0.0494	125	0.7702
2155856211	protection against cognitive deficits and markers of neurodegeneration by long term oral administration of melatonin in a transgenic model of alzheimer disease	2009	0.2175	-0.0179	28	0.9973
2155857429	a 6 month open label study of memantine in patients with frontotemporal dementia	2008	-0.2344	0.258	66	2
2155877918	adverse events associated with testosterone administration	2010	-1.2687	-1.5977	54	1
2155897645	subcortical vascular dementia therapeutical aspects	1998	-0.7255	0.0218	107	14.0909
2155946173	efficacy and tolerability of memantine extended release added to stable donepezil regimen in individuals with moderate to severe alzheimer s disease subset analysis of a randomized clinical trial	2014	-0.2385	0.0589	19	2.4445
2156013560	diagnostic criteria for mild cognitive impairment in parkinson s disease movement disorder society task force guidelines	2012	-0.1952	0.1292	7	0.845
2156056104	the prevalence of depression among type 2 diabetic patients in phangkhon hospital	2010	-0.4276	1.4428	56	0.7808
2156065126	atypical antipsychotics and risk of cerebrovascular accidents	2004	0.2118	0.112	16	4.8825
2156091145	p4 235 protein oxidation lipid peroxidation and antioxidant status are similarly altered in alzheimer disease and vascular dementia	2004	-1.1803	-0.3252	129	0.6887
2156100110	monitoring depth of anaesthesia in a randomized trial decreases the rate of postoperative delirium but not postoperative cognitive dysfunction	2013	2.2083	-0.0388	36	2.7993
2156121263	the seventh report of the joint national committee on prevention detection evaluation and treatment of high blood pressure the jnc 7 report	2003	-0.7209	-0.1406	14	4.9999
2156140272	effects of exercise programs on falls and mobility in frail and pre frail older adults a multicenter randomized controlled trial	2006	0.4434	-0.115	60	0.845
2156152760	ageing fitness and neurocognitive function	1999	0.5748	-0.2459	27	5.7953
2156204070	effect of bright light and melatonin on cognitive and noncognitive function in elderly residents of group care facilities a randomized controlled trial	2008	0.2909	-0.0183	17	33.9036
2156213990	sleep problems and institutionalization of the elderly	1991	0.3045	-0.0186	17	1.9804
2156220037	clinical diagnosis of alzheimer s disease report of the nincds adrda work group under the auspices of department of health and human services task force on alzheimer s disease	1984	-0.2016	0.053	6	157.8141
2156220503	ginkgo biloba for preventing cognitive decline in older adults a randomized trial	2009	-0.4852	-0.1286	8	24.2758
2156251628	assessing cognitive function in schizophrenics and patients with alzheimer s disease	1995	-0.2389	0.1206	78	1.4274
2156254681	a randomized effectiveness trial of cognitive behavioral therapy and medication for primary care panic disorder	2005	0.6749	-0.1727	77	0.7395
2156259977	an introduction to the free radical hypothesis in parkinson s disease	1992	-1.5731	-1.2608	101	0.75
2156427212	helping caregivers of persons with dementia which interventions work and how large are their effects	2006	0.532	-0.1154	1	14.376
2156500900	short term transdermal estradiol therapy cognition and depressive symptoms in healthy older women a randomised placebo controlled pilot cross over study	2005	-0.7504	-0.7583	3	0.9404
2156604779	lack of pharmacokinetic or pharmacodynamic interaction between memantine and donepezil	2004	-0.1833	0.0651	6	1.8988
2156635660	homocysteine lowering by b vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment a randomized controlled trial	2010	-0.8718	-0.1037	30	2
2156653462	phenserine and ring c hetero analogues drug candidates for the treatment of alzheimer s disease	1995	-0.3032	0.1546	13	0.9584
2156697484	dha supplementation improved both memory and reaction time in healthy young adults a randomized controlled trial	2013	-1.0079	-0.2726	5	0.9404
2156810185	needs of older caregivers of patients with advanced cancer	2009	0.6788	-0.15	75	0.7917
2156831074	sex steroids modify working memory	2000	-0.9309	-1.061	54	22.9494
2156837447	donepezil in the treatment of mild to moderate alzheimer s disease report of a belgian multicenter study	2003	-0.0587	0.0835	58	0.8253
2156900283	cognitive enhancers as adjuncts to psychotherapy use of d cycloserine in phobic individuals to facilitate extinction of fear	2004	-0.2958	0.186	43	3.7807
2156908503	growth hormone and sex steroid administration in healthy aged women and men a randomized controlled trial	2002	-1.2687	-1.5977	54	1
2156925579	effect of oral vitamin b 12 with or without folic acid on cognitive function in older people with mild vitamin b 12 deficiency a randomized placebo controlled trial	2006	-0.8682	-0.1027	30	28.9714
2156957018	beneficial effect of donepezil on obstructive sleep apnea a double blind placebo controlled clinical trial	2012	0.2286	-0.0028	28	0.9982
2157008706	the effect of a disease management intervention on quality and outcomes of dementia care a randomized controlled trial	2006	0.571	-0.1252	74	33.2029
2157010753	omega 3 fatty acids enhance phagocytosis of alzheimer s disease related amyloid ??42 by human microglia and decrease inflammatory markers	2013	-1.0864	-0.2968	5	2.5927
2157064933	clinical effects of a?? immunization an1792 in patients with ad in an interrupted trial	2005	-0.5153	-0.1477	32	2.8254
2157170329	a randomized efficacy trial of citicoline in patients with acute ischemic stroke	1999	-0.3977	-0.2568	62	2.6337
2157207504	altered salivary dehydroepiandrosterone levels in major depression in adults	2000	-1.4229	-1.8439	20	0.9999
2157331971	quetiapine treatment of psychosis associated with dementia a double blind randomized placebo controlled clinical trial	2006	0.1856	0.093	16	1.9998
2157340973	a role for docosahexaenoic acid derived neuroprotectin d1 in neural cell survival and alzheimer disease	2005	-1.0833	-0.2961	5	3.8244
2157382328	evaluation of atomoxetine for first line treatment of newly diagnosed treatment naive children and adolescents with attention deficit hyperactivity disorder	2009	-0.9922	1.2607	71	0.7689
2157391543	measuring the risk of alzheimer disease	2007	-0.4416	0.2873	105	0.8554
2157398032	effectiveness of cognitive behavioural family intervention in reducing the burden of care in carers of patients with alzheimer s disease	2000	0.5234	-0.107	1	32.7265
2157417040	comparison of placebo responses in alzheimer s disease clinical trials	2011	-0.5166	-0.0479	12	0.6927
2157484507	reminiscence and mental health a review of recent progress in theory research and interventions	2010	0.3574	-0.0939	39	0.8843
2157488387	telemonitoring and self management in the control of hypertension tasminh2 a randomised controlled trial	2010	-0.7628	-0.1427	135	0.7374
2157527638	reality orientation therapy a controlled trial	1983	0.2823	-0.0847	10	23.6559
2157578938	caregiver weil being a multidimensional examination of family caregivers of demented adults	1986	0.5539	-0.1151	1	1.8843
2157586615	androgen levels in adult females changes with age menopause and oophorectomy	2005	-1.413	-1.8407	20	1.7707
2157650384	no effect of omega 3 fatty acid supplementation on cognition and mood in individuals with cognitive impairment and probable alzheimer s disease a randomised controlled trial	2015	-1.0944	-0.2999	5	0.7993
2157677292	effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus the advance trial a randomised controlled trial	2007	-0.7322	-0.152	14	1
2157734892	untreated blood pressure level is inversely related to cognitive functioning the framingham study	1993	-0.6684	-0.1114	14	4.916
2157951377	clinical spectrum of cadasil a study of 7 families	1995	-0.45	-0.0021	12	1
2158087005	updating the beers criteria for potentially inappropriate medication use in older adults results of a us consensus panel of experts	2003	0.6316	-0.0227	52	0.9992
2158226583	docosahexaenoic acid protects from dendritic pathology in an alzheimer s disease mouse model	2004	-1.0465	-0.2839	5	1.9804
2158250096	systematic implementation of an advance directive program in nursing homes a randomized controlled trial	2000	0.8533	-0.0193	95	0.916
2158273573	memantine and cholinesterase inhibitors complementary mechanisms in the treatment of alzheimer s disease	2013	-0.1825	0.0642	6	0.9404
2158324160	enhancing the quality of life of dementia caregivers from different ethnic or racial groups a randomized controlled trial	2006	0.5101	-0.1086	1	18.4034
2158377229	a 24 week randomized double blind placebo controlled study to evaluate the efficacy safety and tolerability of the rivastigmine patch in japanese patients with alzheimer s disease	2011	-0.2432	0.0582	19	0.9289
2158379577	use of the tailored activities program to reduce neuropsychiatric behaviors in dementia an australian protocol for a randomized trial to evaluate its effectiveness	2014	0.5272	-0.0877	34	0.686
2158413994	nsaid use and dementia risk in the cardiovascular health study role of apoe and nsaid type	2008	-0.4391	-0.0866	32	1.9969
2158431242	antipsychotics effective for elderly patients with dementia	2003	0.617	0.4432	40	0.808
2158498152	double blind study of melatonin effects on the sleep wake rhythm cognitive and non cognitive functions in alzheimer type dementia	2003	0.2397	-0.0161	28	26.8868
2158499098	a controlled clinical trial on the effects of motor intervention on balance and cognition in institutionalized elderly patients with dementia	2008	0.4848	-0.1785	25	26.2513
2158592797	molecular structural and functional characterization of alzheimer s disease evidence for a relationship between default activity amyloid and memory	2005	-0.2499	0.1367	22	0.9404
2158609513	effects of donepezil on neuropsychiatric symptoms in patients with dementia and severe behavioral disorders	2006	-0.1874	0.1356	11	2.4439
2158666727	glucose control and vascular complications in veterans with type 2 diabetes	2009	-0.4276	1.4428	56	0.9404
2158682833	clinical characteristics and risk factors of delirium in demented and not demented elderly medical inpatients	2006	-0.2264	0.0532	84	0.6917
2158693637	efficacy of naftidrofuryl in patients with moderate senile dementia	1991	-0.4153	0.0413	41	14.1137
2158720023	dementia caregiver intervention research in search of clinical significance	2002	0.5379	-0.1094	1	8.7316
2158746773	reviews effects of transdermal rivastigmine on adas cog items in mild to moderate alzheimer s disease	2010	-0.2841	0.0856	33	6.5329
2158779638	effect of citalopram and olanzapine combinations in the treatment of refractory irritable bowel syndrome	2010	-0.0911	0.1073	38	1.454
2158843542	acupuncture for vascular dementia a pragmatic randomized clinical trial	2015	-0.326	-0.0883	45	1.4077
2158994354	dietary intake of antioxidant nutrients and the risk of incident alzheimer disease in a biracial community study	2002	-0.4098	-0.0848	82	1.9867
2159010352	behavioral and neural analysis of extinction	2002	-0.2928	0.1846	43	1.6443
2159072498	a randomized controlled trial of cognitive behavioral therapy for adherence and depression cbt ad in patients with uncontrolled type 2 diabetes	2014	-0.6916	-0.191	79	0.7325
2159122349	mild cognitive impairment clinical characterization and outcome	1999	-0.0354	-0.0531	46	12.6114
2159155203	effectiveness of antipsychotic drugs in patients with chronic schizophrenia	2005	0.6422	0.1016	91	0.9992
2159268061	validation therapy vt in nursing home a case control study	2007	0.4151	-0.0772	18	0.9404
2159399399	the study protocol of a blinded randomised controlled cross over trial of lavender oil as a treatment of behavioural symptoms in dementia	2010	0.4316	-0.0417	34	2.61
2159443014	efficacy of music therapy treatment based on cycles of sessions a randomised controlled trial	2010	0.4365	-0.0582	21	26.3451
2159449551	intensive versus moderate lipid lowering with statins after acute coronary syndromes	2004	-0.7876	-0.1889	88	3
2159518924	determinants of caregiving burden and quality of life in caregivers of stroke patients	2005	0.668	-0.1471	75	1.5552
2159529587	the association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects	1968	-0.2612	0.1261	37	2.3943
2159682792	reducing anxiety in alzheimer s disease family caregivers the effectiveness of a nine week cognitive behavioral intervention	2004	0.5285	-0.1096	1	19.8202
2159686213	improvement in behavioral symptoms and advance of activity acrophase after short term bright light treatment in severe dementia	2004	0.3251	-0.0196	17	1.8427
2159784527	the relation between the clinical subtypes of delirium and the urinary level of 6 smt	2003	2.2034	-0.044	2	0.916
2159787647	cost effectiveness of a training program for dementia carers	1991	0.5283	-0.1112	1	0.991
2159879659	curcumin inhibits formation of amyloid ?? oligomers and fibrils binds plaques and reduces amyloid in vivo	2005	-0.4593	-0.0962	82	0.9804
2160034064	effect of light on agitation in institutionalized patients with severe alzheimer disease	2003	0.3078	-0.0193	17	22.7846
2160152341	effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes the miracl study a randomized controlled trial	2001	-0.7878	-0.1889	88	3
2160370476	study of the use of antidepressants for depression in dementia the hta sadd trial a multicentre randomised double blind placebo controlled trial of the clinical effectiveness and cost effectiveness of sertraline and mirtazapine	2013	0.103	0.1503	61	0.8956
2160456898	the neuropathology of aminergic nuclei in alzheimer s disease	1988	0.2596	0.0785	31	1.9584
2160552877	pharmacokinetic rationale for the rivastigmine patch	2007	-0.2382	0.0523	19	0.9404
2160604373	hot flashes and estrogen therapy do not influence cognition in early menopausal women	2007	-0.7633	-0.7754	3	20.9
2160619416	impact of donepezil on caregiving burden for patients with alzheimer s disease	2000	0.1342	-0.0722	93	0.845
2160639597	estrogen therapy and risk of cognitive decline results from the women s estrogen for stroke trial west	2005	-0.7094	-0.7133	3	2.9399
2160643135	the age dependent relation of blood pressure to cognitive function and dementia	2005	-0.6655	-0.1106	14	4.9909
2160684552	quetiapine in the treatment of behavioral disturbances in patients with huntington s disease	2006	-0.2288	-0.146	112	0.991
2160707945	feasibility and safety of xenon compared with sevoflurane anaesthesia in coronary surgical patients a randomized controlled pilot study	2013	3.1464	0.1089	110	15.7825
2160753800	oral testosterone supplementation increases muscle and decreases fat mass in healthy elderly males with low normal gonadal status	2003	-1.2687	-1.5977	54	1
2160889265	n 3 fatty acid proportions in plasma and cognitive performance in older adults	2007	-1.0464	-0.2845	5	1
2160930085	effectiveness of a structured education reminiscence based programme for staff on the quality of life of residents with dementia in long stay units a study protocol for a cluster randomised trial	2011	0.3956	-0.1048	39	0.8831
2160952481	memory training combined with the use of oral physostigmine	1987	-0.2585	0.1787	11	0.6752
2160954114	effects of combined intervention programmes for people with dementia living at home and their caregivers a systematic review	2007	0.5963	-0.1335	131	0.7687
2161053671	cognitive improvement in mild to moderate alzheimer s dementia after treatment with the acetylcholine precursor choline alfoscerate a multicenter double blind randomized placebo controlled trial	2003	-0.2338	0.184	9	0.6569
2161057551	age trends in the level of serum testosterone and other hormones in middle aged men longitudinal results from the massachusetts male aging study	2002	-0.9327	-1.0635	54	1
2161341729	the detection of dementia in the primary care setting	2000	0.5734	-0.1262	74	0.9992
2161480337	caregiving and the stress process an overview of concepts and their measures	1990	0.4805	-0.1017	1	10.9136
2161483044	a phase 1 clinical trial of nerve growth factor gene therapy for alzheimer disease	2005	-0.5864	-0.1755	32	1
2161560323	atypical antipsychotic drugs in the treatment of behavioural and psychological symptoms of dementia systematic review	2004	0.2816	0.1633	16	0.8843
2161593639	the effect of memantine on sleep behaviour in dementia with lewy bodies and parkinson s disease dementia	2010	-0.149	0.1234	7	17.4819
2161695527	conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women women s health initiative memory study	2004	-0.7282	-0.7163	3	42.7492
2161698731	rethinking the association of high blood pressure with mortality in elderly adults the impact of frailty	2012	-0.6916	-0.191	79	0.7993
2161707533	reducing the psychological distress of family caregivers of home based palliative care patients longer term effects from a randomised controlled trial	2015	0.5415	-0.1158	1	0.7679
2161737267	association between csf biomarkers and incipient alzheimer s disease in patients with mild cognitive impairment a follow up study	2006	-0.1462	-0.0437	46	1.9937
2161767782	a systematic review of enhanced recovery care after colorectal surgery in elderly patients	2014	2.7899	-0.0532	118	0.845
2161990655	statins and serum cholesterol s associations with incident dementia and mild cognitive impairment	2011	-0.7284	-0.1718	29	0.9973
2162010696	a default mode of brain function	2001	-0.2503	0.1374	22	0.9959
2162019025	prevention of intraoperative awareness with explicit recall in an unselected surgical population a randomized comparative effectiveness trial	2012	2.202	-0.038	36	0.9992
2162055755	long term postoperative cognitive dysfunction in the elderly ispocd1 study	1998	2.2081	-0.0367	36	3.9982
2162066663	efficacy of ethyl eicosapentaenoic acid in bipolar depression randomised double blind placebo controlled study	2006	-1.0972	-0.3014	5	0.991
2162107430	a double blind placebo controlled study of ginkgo biloba extract tanakan in elderly outpatients with mild to moderate memory impairment	1991	-0.4709	-0.0604	8	25.83
2162114058	early intervention for mild cognitive impairment a randomised controlled trial	2009	0.2034	-0.1175	10	2.991
2162134510	a 24 week open label extension study of memantine in moderate to severe alzheimer disease	2006	-0.1393	0.069	6	9.799
2162141299	evidenced based cognitive rehabilitation for persons with multiple sclerosis a review of the literature	2008	-0.2417	0.2138	55	0.9939
2162142126	melatonin in alzheimer s disease	2013	0.196	-0.0167	28	0.916
2162146134	risk factors and prediction of postoperative delirium in elderly hip surgery patients implementation and validation of a medical risk factor model	2006	2.2253	-0.0295	36	0.9404
2162159672	does antidepressant therapy improve cognition in elderly depressed patients	2003	-0.2626	0.1647	9	0.6623
2162180146	the effectiveness of a telephone support program for caregivers of frail older adults	2006	0.6861	-0.1443	97	0.6766
2162206869	management of verbally disruptive behaviors in nursing home residents	1997	0.4792	-0.0479	21	2.98
2162212237	memory complaint and memory performance in the elderly the effects of memory skills training and expectancy change	1992	0.5071	-0.2836	4	1.5337
2162294150	effect of dimebon on cognition activities of daily living behaviour and global function in patients with mild to moderate alzheimer s disease a randomised double blind placebo controlled study	2008	-0.5847	-0.1745	32	20.7534
2162321662	a randomized trial of oral dhea treatment for sexual function well being and menopausal symptoms in postmenopausal women with low libido	2009	-1.4128	-1.8331	20	0.9867
2162465757	resolvins a family of bioactive products of omega 3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals	2002	-1.1051	-0.3024	5	2.5975
2162528474	efficacy and safety of quetiapine in critically ill patients with delirium a prospective multicenter randomized double blind placebo controlled pilot study	2010	2.1838	-0.0436	2	5.9948
2162566359	salvia officinalis extract in the treatment of patients with mild to moderate alzheimer s disease a double blind randomized and placebo controlled trial	2003	-0.103	-0.0968	8	0.75
2162597247	efficacy of fluvoxamine as a treatment for behavioral symptoms in frontotemporal lobar degeneration patients	2004	-0.2322	0.2509	66	1.75
2162616775	evidence based cognitive rehabilitation updated review of the literature from 2003 through 2008	2005	0.4797	-0.2652	4	0.9994
2162652570	person centred care of people with severe alzheimer s disease current status and ways forward	2008	0.3726	-0.0033	18	2
2162680540	antihypertensive drugs and incidence of dementia the rotterdam study	2001	-0.6671	-0.1111	14	1
2162685820	risperidone and the treatment of psychiatric motor and cognitive symptoms in huntington s disease	2008	0.5561	0.3928	40	1.463
2162709940	acetylcholinesterase inhibitor in combination with cognitive training in older adults	2008	-0.2008	0.1471	9	0.824
2162846333	mitochondrial damage in alzheimer s disease varies with apolipoprotein e genotype	2000	-0.7853	-0.099	86	1.7292
2162941887	cognitive training in alzheimer s disease a meta analysis of the literature	2006	0.2854	-0.1226	10	16.4743
2162993517	the national institute of mental health clinical antipsychotic trials of intervention effectiveness catie project schizophrenia trial design and protocol development	2003	0.5772	0.0831	91	1.8824
2162995716	does piracetam counteract the ect induced memory dysfunctions in depressed patients	1975	0.0183	0.3851	48	0.6459
2162998193	double blind parallel design pilot study of acetyl levocarnitine in patients with alzheimer s disease	1992	-0.3102	0.018	63	25.9361
2163034869	transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion	2016	2.566	-0.0494	125	0.7993
2163055499	age and visual search expanding the useful field of view	1988	0.4853	-0.2604	4	1
2163084094	therapeutic effects of cdp choline in alzheimer s disease cognition brain mapping cerebrovascular hemodynamics and immune factors	1996	-0.3962	-0.2514	62	1.741
2163110760	risk of alzheimer s disease and duration of nsaid use	1997	-0.4226	-0.0607	32	7.9133
2163186438	memantine treatment in mild to moderate alzheimer disease a 24 week randomized controlled trial	2006	-0.1911	0.0611	6	35.9051
2163225965	sleep drives metabolite clearance from the adult brain	2013	0.196	-0.0167	28	0.916
2163265737	a wanderer s lounge program for nursing home residents with alzheimer s disease	1988	0.4399	-0.0044	104	0.8142
2163272012	early discharge and home rehabilitation after hip fracture achieves functional improvements a randomized controlled trial	2002	2.1882	-0.0853	26	0.8171
2163378784	short term effects of an educational intervention on physical restraint use a cluster randomized trial	2006	0.8049	-0.0983	42	3.9226
2163406026	the effects of music on bathing cooperation for residents with dementia	1997	0.4833	-0.0487	21	2.9671
2163462953	a manual of standardized terminology techniques and scoring system for sleep stages of human subjects	1969	0.1281	0.0261	28	0.916
2163529094	rivastigmine transdermal patch and physical exercises for alzheimer s disease a randomized clinical trial	2014	-0.218	0.0668	7	1.5894
2163561899	the cognitive drug research computerized assessment system for demented patients a validation study	1991	-0.2418	0.1528	43	1.8447
2163624293	characteristics of sleep disturbance in community dwelling alzheimer s disease patients	1999	0.1768	0.0117	28	1.8744
2163645531	a biobehavioral home based intervention and the well being of patients with dementia and their caregivers the cope randomized trial	2010	0.3833	-0.0826	1	1.9939
2163651074	addition of omega 3 fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder	2002	-1.0972	-0.3014	5	0.9959
2163761096	effects of physical training on the physical capacity of frail demented patients with a history of falling a randomised controlled trial	2003	0.4877	-0.1798	25	0.9867
2163867458	effect of long term ace inhibitor therapy in elderly vascular disease patients	2007	-0.5188	-0.0906	68	0.7106
2163908108	bench to bedside review molecular pharmacology and clinical use of inert gases in anesthesia and neuroprotection	2010	3.1473	0.1092	110	0.7993
2163912174	induction of lipid oxidation by polyunsaturated fatty acids of marine origin in small intestine of mice fed a high fat diet	2009	-1.1031	-0.3023	5	0.7936
2163953162	memantine in patients with parkinson s disease dementia or dementia with lewy bodies a double blind placebo controlled multicentre trial	2009	-0.1848	0.1105	7	29.8432
2164059021	frailty in older adults evidence for a phenotype	2001	0.538	-0.2242	136	1
2164070319	a comprehensive support program effect on depression in spouse caregivers of ad patients	1995	0.5487	-0.1114	1	5.8096
2164079217	the relationship between testosterone levels and cognitive ability patterns	1991	-0.9327	-1.0635	54	1
2164089346	efficacy and safety of more intensive lowering of ldl cholesterol a meta analysis of data from 170 000 participants in 26 randomised trials	2010	-0.7266	-0.1701	29	0.9996
2164324917	effects of combination lipid therapy in type 2 diabetes mellitus	2010	-1.2428	-0.3453	83	1
2164361612	effects of resistance and all round functional training on quality of life vitality and depression of older adults living in long term care facilities a randomized controlled trial isrctn87177281	2004	0.4834	-0.1436	60	0.9404
2164379979	circulating androgen levels and self reported sexual function in women	2005	-1.4128	-1.8331	20	0.9713
2164517124	cognitive rehabilitation in patients with mild cognitive impairment	2009	0.2035	-0.1176	10	2.9584
2164518728	effective treatment of cobalamin deficiency with oral cobalamin	1998	-0.9225	-0.1075	30	0.991
2164647663	the impact of cognitive impairment on short term outcomes of hip fracture patients	2006	2.1135	-0.0877	26	1.5506
2164677833	a strategy of combination chemotherapy in alzheimer s disease rationale and preliminary results with physostigmine plus deprenyl	1992	-0.1918	0.1105	137	15.2848
2164803788	impact of perioperative dexamethasone on postoperative analgesia and side effects systematic review and meta analysis	2013	2.5491	-0.0689	35	0.75
2164850089	effectiveness of procedural memory stimulation in mild alzheimer s disease patients a controlled study	2001	0.0942	-0.1188	10	4.6836
2165027111	anticholinesterase effect on motor kinematic measures and brain activation in parkinson s disease	2006	-0.1591	0.0558	67	0.6709
2165053476	statins and cognition a systematic review and meta analysis of short and long term cognitive effects	2013	-0.7269	-0.1706	29	1.9936
2165136235	high dose b vitamin supplementation and cognitive decline in alzheimer disease a randomized controlled trial	2008	-0.7508	-0.1188	30	11.9184
2165146299	incident dementia and blood pressure lowering in the hypertension in the very elderly trial cognitive function assessment hyvet cog a double blind placebo controlled trial	2008	-0.6381	-0.0985	14	28.666
2165169992	supplementary administration of artificial bright light and melatonin as potent treatment for disorganized circadian rest activity and dysfunctional autonomic and neuroendocrine systems in institutionalized demented elderly persons	2000	0.2294	-0.0179	28	1.9938
2165211289	effects of a two week physiological dehydroepiandrosterone substitution on cognitive performance and well being in healthy elderly women and men	1997	-1.418	-1.8377	20	24.7481
2165262421	cognitive rehabilitation in the elderly effects on strategic behavior in relation to goal management	2007	0.479	-0.2636	4	20.9335
2165343591	type 2 diabetes mellitus hypertension dyslipidemia and obesity a systematic comparison of their impact on cognition	2009	-0.4458	1.587	56	0.9999
2165358329	an intervention that delays institutionalization of alzheimer s disease patients treatment of spouse caregivers	1993	0.5518	-0.1134	1	1.8556
2165413132	effect of memantine on the progression of driving impairment in mild alzheimer s disease	2013	-0.3138	0.1721	22	16.4919
2165431694	psychotropic drug use and the risk of hip fracture	1987	0.5411	0.0026	52	1
2165433475	effects of docosahexaenoic acid rich n 3 fatty acid supplementation on cytokine release from blood mononuclear leukocytes the omegad study	2008	-1.1047	-0.3036	5	27.7524
2165487297	fluvoxamine in the treatment of demented elderly patients a double blind placebo controlled study	1992	-0.1888	0.0697	7	0.7465
2165494060	high frequency cranial electrostimulation ces in patients with probable alzheimer s disease	2006	0.2287	-0.2018	111	13.7246
2165516458	anesthesia for bilateral sequential lung transplantation experience of 64 cases	1997	2.2338	-0.0385	36	0.7093
2165563030	long term effect of diabetes and its treatment on cognitive function	2007	-0.4441	1.5721	56	1.9867
2165603261	efficacy of risperidone for treating patients with behavioral and psychological symptoms of dementia	2004	0.1419	0.0443	58	0.6934
2165612525	optimal dynamic treatment regimes	2003	0.246	0.0854	141	0.9994
2165690848	history of symptomatic therapy in vascular dementia	2003	-0.2909	0.1288	53	0.7636
2165784974	cognitive rehabilitation of mildly impaired alzheimer disease patients on cholinesterase inhibitors	2004	0.2734	-0.1116	10	30.7663
2165799897	propentofylline for dementia	2003	-0.3167	-0.002	23	0.75
2165840219	the construct of minor and major depression in alzheimer s disease	2005	0.2436	0.0888	31	0.7993
2165846809	o1 05 04 memantine monotherapy is effective and safe for the treatment of mild to moderate alzheimer s disease a randomized controlled trial	2004	-0.2395	0.059	19	1.5575
2165935886	dietary intake of fish and omega 3 fatty acids in relation to long term dementia risk	2009	-1.1442	-0.3148	83	0.75
2165937982	the revised scale for caregiving self efficacy reliability and validity studies	2002	0.5199	-0.1135	1	1.7397
2165988683	subjective burden of husbands and wives as caregivers a longitudinal study	1986	0.5653	-0.1131	1	3.874
2166011912	ergot mesylates for alzheimer s disease a year long double blind trial of 3 mg vs 12 mg daily	1990	-0.2866	0.1017	41	0.7849
2166039854	efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia a meta analysis of randomised controlled trials	2007	-0.4185	0.0069	12	6.4991
2166084036	interaction between warfarin and korean red ginseng in patients with cardiac valve replacement	2010	-0.6648	-0.1223	65	0.75
2166124147	preventive effects of ramelteon on delirium a randomized placebo controlled trial	2014	2.1997	-0.0436	2	21.9226
2166130036	group interventions to support family caregivers a review and analysis	1989	0.553	-0.115	1	1.8842
2166155410	the efficacy of ginkgo for elderly people with dementia and age associated memory impairment new results of a randomized clinical trial	2000	-0.473	-0.0801	8	29.2317
2166169466	intraoperative high dose dexamethasone for cardiac surgery a randomized controlled trial	2012	2.5489	-0.0698	35	1
2166192353	cognitive rehabilitation in the elderly an evaluation of psychosocial factors	2007	0.4691	-0.2555	4	1.9912
2166256312	feasibility safety and preliminary evidence of the effectiveness of a home based exercise programme for older people with alzheimer s disease a pilot randomized controlled trial	2013	0.4912	-0.1939	25	0.9867
2166298434	efficacy and cost effectiveness of drug and psychological treatments for common mental disorders in general health care in goa india a randomised controlled trial	2003	0.103	0.1503	61	0.6977
2166318855	comparative cognitive effects of levo dopa plus carbidopa and dopamine agonist as an initial therapy of parkinson s disease	2008	-0.2338	0.184	9	0.6756
2166389826	efficacy of a sensory integration program on behaviors of inpatients with dementia	1994	0.4308	-0.0751	18	0.9404
2166389885	cyclic nucleotide phosphodiesterases functional implications of multiple isoforms	1995	-0.3068	0.128	23	0.9804
2166439095	the influence of physical fitness and exercise upon cognitive functioning a meta analysis	1997	0.5808	-0.2505	27	0.916
2166487622	resolution of inflammation is altered in alzheimer s disease	2015	-1.1027	-0.3021	5	0.9404
2166542465	oral physostigmine as treatment for primary degenerative dementia a double blind placebo controlled inpatient trial	1990	-0.2242	0.178	11	14.0469
2166587617	memantine in patients with alzheimer s disease receiving donepezil new analyses of efficacy and safety for combination therapy	2013	-0.2224	0.0607	19	2.4481
2166609052	clinical diagnostic criteria for dementia associated with parkinson s disease	2007	-0.1896	0.1065	7	10.4188
2166636997	long term prognosis and causes of death in cadasil a retrospective study in 411 patients	2004	-0.45	-0.0021	12	0.9999
2166843397	olanzapine vs haloperidol treating delirium in a critical care setting	2004	2.1734	-0.0423	2	4.9994
2166872968	patient depression and caregiver attitudes results from the aged in home care study	2008	0.657	-0.144	75	0.7769
2166934200	effect of occupational therapy on functional and emotional outcomes after hip fracture treatment a randomized controlled trial	2014	2.1882	-0.0853	26	0.7941
2166953500	a follow up intervention in severely demented patients after discharge from a special alzheimer acute care unit impact on early emergency room re hospitalization rate	2013	0.9833	-0.0254	24	0.7063
2167010452	effects of oral vitamin c supplementation on oxidative stress and inflammation status in haemodialysis patients	2005	-1.1801	-0.326	129	0.6896
2167015852	internet based program for dementia caregivers	2010	0.5531	-0.1195	1	0.9982
2167020153	effectiveness of a cognitive rehabilitation program in mild dementia md and mild cognitive impairment mci a case control study	2007	0.2173	-0.1179	10	2.9992
2167075471	effect of n 3 polyunsaturated fatty acids in patients with chronic heart failure the gissi hf trial a randomised double blind placebo controlled trial	2008	-1.2428	-0.3453	83	1
2167116216	effectiveness of clozapine versus olanzapine quetiapine and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment	2006	0.6426	0.1008	91	0.75
2167163400	cognitive demand and blood glucose	2001	-0.4606	1.8032	96	0.845
2167181885	validity of the minimal assessment of cognitive function in multiple sclerosis macfims	2006	-0.2392	0.2094	55	3.79
2167227695	motor performance of women as a function of age and physical activity level	1986	0.5822	-0.2519	27	0.9584
2167277581	comprehensive geriatric care for patients with hip fractures a prospective randomised controlled trial	2015	2.1944	-0.0495	2	0.9804
2167277601	melissa officinalis extract in the treatment of patients with mild to moderate alzheimer s disease a double blind randomised placebo controlled trial	2003	0.4023	-0.0326	34	3.8184
2167317773	randomized crossover study of the histamine h3 inverse agonist mk 0249 for the treatment of cognitive impairment in patients with schizophrenia	2013	-0.2197	0.1016	23	0.662
2167431281	randomized placebo controlled trial of donepezil in cognitive impairment in parkinson s disease	2004	-0.1868	0.1099	7	33.2447
2167477818	a multicenter randomized placebo controlled double blind clinical trial of escitalopram on its atrophy delaying effect in alzheimer s disease	2012	-0.5166	-0.0479	12	0.7411
2167567290	safety and efficacy of idalopirdine a 5 ht6 receptor antagonist in patients with moderate alzheimer s disease ladder a randomised double blind placebo controlled phase 2 trial	2014	-1.5582	0.2221	115	0.9939
2167606917	fish consumption n 3 fatty acids and subsequent 5 y cognitive decline in elderly men the zutphen elderly study	2007	-1.0617	-0.2897	5	2.9978
2167647325	cognitive outcomes after sertaline treatment in patients with depression of alzheimer disease	2012	0.0697	0.1428	61	15.5789
2167720733	imaging brain amyloid in alzheimer s disease with pittsburgh compound b	2004	-0.0529	-0.0404	46	1
2167735895	nonpharmacological treatment of agitation a controlled trial of systematic individualized intervention	2007	0.4089	-0.0168	18	2.9584
2167862712	effect of citalopram on agitation in alzheimer disease the citad randomized clinical trial	2014	0.1474	0.0604	31	24.7364
2167951079	treating depression in alzheimer disease efficacy and safety of sertraline therapy and the benefits of depression reduction the diads	2003	0.1943	0.0866	31	42.1656
2167964651	stroke prevention with the angiotensin ii type 1 receptor blocker candesartan in elderly patients with isolated systolic hypertension the study on cognition and prognosis in the elderly scope	2004	-0.7291	-0.1459	14	19.9998
2167999562	galantamine improved cognition and global functioning in vascular dementia or alzheimer disease with cerebrovascular disease	2002	-0.3792	0.0982	94	0.8503
2168039303	attenuation of laboratory induced stress in humans after acute administration of melissa officinalis lemon balm	2004	0.4009	-0.0293	34	0.9999
2168161787	evaluation of the fleetwood model of long term care pharmacy	2011	0.7094	-0.0475	52	0.8039
2168210393	acute and chronic effects of oral physostigmine and lecithin in alzheimer s disease	1986	-0.2895	0.1311	13	1.6343
2168256117	differences in the central nervous system distribution and pharmacology of the mouse 5 hydroxytryptamine 6 receptor compared with rat and human receptors investigated by radioligand binding site directed mutagenesis and molecular modeling	2003	-1.5582	0.2221	115	0.9804
2168287551	music therapy for individuals with dementia areas of interventions and research perspectives	2009	0.4391	-0.0588	21	0.9867
2168291682	evidence supporting a systolic blood pressure goal of less than 150 mm hg in patients aged 60 years or older the minority view	2014	-0.6916	-0.1919	79	0.75
2168365345	antiherpes virus specific treatment and cognition in schizophrenia a test of concept randomized double blind placebo controlled trial	2013	-0.2468	0.1611	9	1.3706
2168523424	cognitive rehabilitation combined with drug treatment in alzheimer s disease patients a pilot study	2005	0.2437	-0.1016	10	32.5286
2168540734	cognitive stimulation therapy for people with dementia cost effectiveness analysis	2006	0.2628	-0.0931	10	5.9127
2168558795	risk of death in elderly users of conventional vs atypical antipsychotic medications	2005	0.1794	0.0693	16	15.9139
2168616271	physical restraint initiation in nursing homes and subsequent resident health	2008	0.8172	-0.0992	42	1.9388
2168649106	cognitive effects of treating obstructive sleep apnea in alzheimer s disease a randomized controlled study	2008	0.2362	-0.0069	28	1.9583
2168649763	cognitive dysfunction in multiple sclerosis	2012	-0.2422	0.2129	55	1.9959
2168684970	can training in a real time strategy video game attenuate cognitive decline in older adults	2008	0.4649	-0.2477	4	2.9992
2168707463	a double masked study of the effects of ginseng on cognitive functions	1996	-0.6472	-0.1174	65	21.4732
2168755977	review of drugs for alzheimer s disease	2012	-0.3245	0.1979	22	0.7419
2168875379	effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia a randomized controlled trial	2003	0.6426	0.1008	91	0.7993
2168876397	association between brain functional failure and dementia severity in alzheimer s disease resting versus stimulation pet study	1999	-0.4858	0.0852	117	0.7258
2168880281	the safety and tolerability of etanercept in alzheimer s disease steadi 09 a phase ii double blind randomised placebo controlled trial	2014	-0.3229	0.2085	13	0.7696
2168895330	effect of 2 y n 3 long chain polyunsaturated fatty acid supplementation on cognitive function in older people a randomized double blind controlled trial	2010	-1.0081	-0.2732	5	22.9987
2168907840	valsartan captopril or both in myocardial infarction complicated by heart failure left ventricular dysfunction or both	2003	-0.7312	-0.1465	14	0.9999
2168910384	a placebo controlled double blind randomized trial of an extract of ginkgo biloba for dementia	1997	-0.4002	-0.0225	8	32.4929
2168956122	galantamine prolonged release formulation in the treatment of mild to moderate alzheimer s disease	2005	-0.2091	0.0438	6	22.9663
2168964262	excessive daytime sleepiness in adults with brain injuries	2001	-1.2594	1.7614	64	0.9939
2168969762	interventions to optimise prescribing for older people in care homes	2016	0.7094	-0.0475	52	0.845
2168977574	cognitive rehabilitation in the elderly overview and future directions	2007	0.4697	-0.2558	4	1.9927
2169177651	effect of person centered showering and the towel bath on bathing associated aggression agitation and discomfort in nursing home residents with dementia a randomized controlled trial	2004	0.3726	-0.0033	18	2
2169254853	haloperidol prophylaxis for elderly hip surgery patients at risk for delirium a randomized placebo controlled study	2005	2.2055	-0.0435	2	41.3417
2169371301	the ambulatory geriatric assessment a frailty intervention trial age fit a randomised controlled trial aimed to prevent hospital readmissions and functional deterioration in high risk older adults a study protocol	2013	1.6418	-0.0325	24	0.7451
2169420506	effect of a 12 week yoga intervention on fear of falling and balance in older adults a pilot study	2010	1.6796	-0.9881	108	0.9988
2169486055	the influence of cognitive function on outcome after a hip fracture	2006	2.1229	-0.0869	26	0.7525
2169530911	folic acid with or without vitamin b12 for the prevention and treatment of healthy elderly and demented people	2008	-0.8723	-0.1041	30	2.9714
2169584837	study on cognition and prognosis in the elderly scope	1999	-0.7143	-0.1359	14	0.9998
2169680922	strategies to prevent falls and fractures in hospitals and care homes and effect of cognitive impairment systematic review and meta analyses	2007	2.2795	-0.0629	35	0.845
2169689232	sensory stimulation in dementia	2002	0.3982	-0.0284	34	1.9584
2169702696	catastrophic reactions and other behaviors of alzheimer s residents special unit compared with traditional units	1993	0.674	-0.0229	24	17.701
2169735361	huntington s disease	2007	-0.2283	-0.1467	112	0.9867
2169742106	functional evaluation the barthel index	1965	2.1944	-0.0495	2	0.916
2169776352	effects of ultra low dose transdermal estradiol on cognition and health related quality of life	2006	-0.6921	-0.6973	3	25.7622
2169798421	preventing delirium in an acute hospital using a non pharmacological intervention	2012	2.196	-0.0456	2	20.8499
2169849640	national institute of mental health clinical antipsychotic trials of intervention effectiveness catie alzheimer disease trial methodology	2001	0.244	0.0853	141	20.8649
2169934361	psychotropic prescribing in long term care facilities impact of medication reviews and educational interventions	2008	0.6316	-0.0227	52	0.9982
2169967776	effects of exercise on depressive symptoms in older adults with poorly responsive depressive disorder randomised controlled trial	2002	0.5111	-0.199	25	0.9996
2170081027	the influence and changes in the dosages of concomitantly used psychotropic drugs associated with the discontinuation of donepezil in severe alzheimer s disease with behavioral and psychological symptoms on dementia a preliminary open label trial	2014	-0.2185	0.142	11	0.7382
2170085655	memantine is a clinically well tolerated n methyl d aspartate nmda receptor antagonist a review of preclinical data	1999	-0.2424	0.0598	6	7.8419
2170100018	effects of low frequency cranial electrostimulation on the rest activity rhythm and salivary cortisol in alzheimer s disease	2003	0.3246	-0.0241	89	16.7989
2170121669	selegiline for alzheimer s disease	2003	-0.3438	0.2071	126	0.916
2170233209	cerebrospinal fluid profiles and prospective course and outcome in patients with amnestic mild cognitive impairment	2011	-0.2942	0.0285	57	0.6779
2170262419	annual high dose vitamin d3 and mental well being randomised controlled trial	2011	-0.9263	-0.257	79	0.7184
2170271198	effect of a multifactorial intervention on mortality in type 2 diabetes	2008	-0.4267	1.4429	56	0.845
2170304509	reducing delirium after hip fracture a randomized trial	2001	2.1955	-0.0439	2	40.3096
2170308555	influence of yoga and ayurveda on self rated sleep in a geriatric population	2005	1.6805	-0.9881	108	0.9996
2170394849	efficacy of donepezil on cognitive functions in mildcognitive impairment	2007	-0.2483	0.1606	9	1.3057
2170397284	effect of dextromethorphan quinidine on agitation in patients with alzheimer disease dementia a randomized clinical trial	2015	-0.2889	0.0565	44	1.3639
2170462162	l amphetamine improves memory in ms patients with objective memory impairment	2011	-0.2416	0.2147	55	0.9997
2170526842	donepezil significantly improves abilities in daily lives of female down syndrome patients with severe cognitive impairment a 24 week randomized double blind placebo controlled trial	2011	-0.2652	0.2459	9	1.3546
2170575571	a naturalistic study of trazodone in the treatment of behavioral complications of dementia	1994	-0.2152	0.2167	66	1.4947
2170650084	transfer of omega 3 fatty acids across the blood brain barrier after dietary supplementation with a docosahexaenoic acid rich omega 3 fatty acid preparation in patients with alzheimer s disease the omegad study	2014	-1.008	-0.2736	5	22.1127
2170686624	postprandial plasma glucose excursions and cognitive functioning in aged type 2 diabetics	2006	-0.4427	1.5545	56	20.7604
2170783468	an open label extension trial of galantamine in patients with probable vascular dementia and mixed dementia	2003	-0.339	0.0375	12	24.616
2170792659	neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the catie trial	2007	0.6423	0.1016	91	0.7993
2170822402	clinical and functional outcomes of depression treatment in patients with and without chronic medical illness	2005	0.4586	0.2348	116	0.7577
2170867978	reducing caregiver burden a randomized psychoeducational intervention for caregivers of persons with dementia	1999	0.5314	-0.1106	1	20.9719
2170945547	mci conversion to dementia and the apoe genotype a prediction study with fdg pet	2004	-0.052	-0.0405	46	1
2170951382	lithium therapy for human immunodeficiency virus type 1 associated neurocognitive impairment	2009	-0.4008	0.502	87	0.9867
2170956799	the therapeutic design of environments for people with dementia a review of the empirical research	2000	0.6741	-0.0194	24	1
2170970156	high intensity functional exercise program and protein enriched energy supplement for older persons dependent in activities of daily living a randomised controlled trial	2006	0.4623	-0.129	60	1.871
2170982929	impact of nutrition on outcome a prospective randomized controlled trial in patients with head and neck cancer undergoing radiotherapy	2005	-0.9263	-0.257	79	0.7185
2171045291	course of depression and anxiety diagnosis in patients treated with hemodialysis a 16 month follow up	2008	0.4581	0.2355	116	0.7508
2171149762	training and maintaining memory abilities in healthy older adults traditional and novel approaches	2007	0.4859	-0.2694	4	0.9959
2171150718	improving the quality of care for mild to moderate dementia an evaluation of the croydon memory service model	2007	0.5971	-0.1331	131	0.7226
2171179502	the australian multicentre double blind comparative study of remoxipride and thioridazine in schizophrenia	1994	0.0849	0.1025	47	0.6674
2171210330	effects of multifactorial memory training in old age generalizability across tasks and individuals	1995	0.5071	-0.2841	4	1.9902
2171211918	caring for others internet video conferencing group intervention for family caregivers of older adults with neurodegenerative disease	2006	0.5522	-0.1197	1	1.9983
2171319945	positive modulation of mood and cognitive performance following administration of acute doses of salvia lavandulaefolia essential oil to healthy young volunteers	2005	-0.6634	-0.1226	65	1.4346
2171398944	potentially adaptive functional changes in cognitive processing for patients with multiple sclerosis and their acute modulation by rivastigmine	2003	-0.2422	0.2113	55	1
2171401470	omega 3 treatment of childhood depression a controlled double blind pilot study	2006	-1.0972	-0.3014	5	0.9939
2171455431	effect of fish oil supplementation on quality of life in a general population of older dutch subjects a randomized double blind placebo controlled trial	2009	-0.9248	-0.2573	79	15.0333
2171522851	influence of anosognosia on treatment outcome among dementia patients	2001	0.2464	-0.113	10	25.5309
2171539930	effect of rivastigmine on delay to diagnosis of alzheimer s disease from mild cognitive impairment the inddex study	2007	-0.1455	-0.0405	46	27.4742
2171545307	long term effects of the concomitant use of memantine with cholinesterase inhibition in alzheimer disease	2009	-0.1676	0.0648	6	9.7574
2171621354	pharmacokinetics of dehydroepiandrosterone and its metabolites after long term daily oral administration to healthy young men	2004	-1.4115	-1.8492	20	0.8041
2171779688	efficacy and safety of natural acetylcholinesterase inhibitor huperzine a in the treatment of alzheimer s disease an updated meta analysis	2009	-0.5785	-0.1496	32	0.9804
2171803917	vascular dementia and alzheimer s disease should we be studying both within the same study	1997	-0.3792	0.0982	94	0.7977
2171820264	the effects of group living homes on older people with dementia a comparison with traditional nursing home care	2009	0.6741	-0.0194	24	0.9867
2171845619	transcutaneous electrical nerve stimulation tens improves circadian rhythm disturbances in alzheimer disease	1998	0.2404	-0.0133	17	25.9148
2171908102	reminiscence therapy in dementia a review	2012	0.3589	-0.0934	39	0.916
2171933338	effect of rivastigmine as an adjunct to usual care with haloperidol on duration of delirium and mortality in critically ill patients a multicentre double blind placebo controlled randomised trial	2010	2.1874	-0.0441	2	4.9995
2171969403	comorbid type 2 diabetes mellitus and hypertension exacerbates cognitive decline evidence from a longitudinal study	2004	-0.4453	1.5878	56	1
2172032309	outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine the value randomised trial	2004	-0.7234	-0.1416	14	2.9997
2172032970	resident outcomes in small house nursing homes a longitudinal evaluation of the initial green house program	2007	0.6741	-0.0194	24	0.9992
2172080066	circadian rhythms of agitation in institutionalized patients with alzheimer s disease	2000	0.3052	-0.018	17	1.9804
2172106147	effects of exercise training on older patients with major depression	1999	0.5479	-0.2248	25	1.9992
2172111929	estrogen and cognitive functioning in surgically menopausal womena	1990	-0.7645	-0.7722	3	1
2172223517	?? endorphin intravenous infusion causes behavioral change in psychiatric inpatients	1980	-0.4209	0.3343	90	0.6314
2172225284	estrogen therapy and noncognitive psychiatric signs and symptoms in elderly patients with dementia	2002	-0.1567	0.0287	84	1.4356
2172796913	clinically useful chelators of tripositive elements	1991	-1.5747	-1.2603	101	0.7993
2173045409	thiamin and the brain	1988	-0.7833	-0.0998	86	0.845
2175596958	estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women	2003	-0.7376	-0.7326	3	2
2176065154	cognitive behavioural treatment for mild alzheimer s patients and their caregivers cbtac study protocol for a randomized controlled trial	2015	0.7627	-0.2018	77	0.7823
2177563038	molecular structure and biological and pharmacological properties of 3 hydroxy 2 methyl 1 ?? d ribofuranosyl or pyranosyl 4 pyridinone potential iron overload drugs for oral administration	1998	-1.5747	-1.2603	101	0.75
2178122306	dexmedetomidine versus propofol sedation reduces delirium after cardiac surgery a randomized controlled trial	2016	2.5491	-0.0689	35	0.75
2178216027	effects of a pharmacist s medication review in nursing homes	2000	0.6722	-0.0354	52	1.8842
2178533662	the effect of add on memantine on global function and quality of life in schizophrenia a randomized double blind controlled clinical trial	2015	-0.4204	-0.0632	82	0.7384
2179137398	ginkgo biloba for acute ischaemic stroke	2005	-0.4856	-0.072	68	0.7236
2179537484	process evaluation of physical activity counselling with and without the use of mobile technology a mixed methods study	2016	0.5131	-0.1606	60	0.6708
2179824638	combined treatment with memantine and galantamine cr compared with galantamine cr only in antidementia drug naive patients with mild to moderate alzheimer s disease	2015	-0.1959	0.1175	92	1.4997
2181605705	original article donepezil treatment in severe alzheimer s disease a pooled analysis of three clinical trials	2009	-0.2152	0.1394	11	0.7991
2181611667	caregivers informational needs on dementia and dementia care	2007	0.6892	-0.1547	76	0.8368
2181655471	clinical andnecropsystudy of260cases	1974	-0.3925	0.3624	106	0.7086
2181690043	regressionworkstationfor clinical chemistrymethodevaluation	1993	-0.393	0.3617	106	0.7086
2181841818	fluoxetine for poststroke depression a randomized placebo controlled clinical trial	2007	-0.1379	0.0381	80	0.6735
2182066760	cholinesterase inhibitors in the real world setting rivastigmine versus donepezil tolerability and effectiveness study	2006	-0.2662	0.0553	124	0.7825
2182359102	cognitive function in early clinical phase huntington disease after rivastigmine treatment	2014	-0.2053	-0.1483	49	15.3066
2182423760	patient group placebo gm clinical course in cerebral stroke	1985	-0.3807	-0.2165	45	0.673
2183347587	zuclopenthixol melperone and haloperidol levomepromazine in e fuglum m d the elderly meta analysis of two double blind trials at 15 nursing	1992	0.1304	0.1286	47	0.832
2184242991	the impact of disease course and type of episodes in bipolar disorder on caregiver burden	2014	0.4581	0.2355	116	0.7844
2184923050	rivastigmine in subcortical vascular dementia an open 22 month study	2002	-0.3502	0.029	12	9.3482
2185070425	orginal article short term treatment with rivastigmine and plasma levels of ab peptides in alzheimer s disease	2006	-0.4081	0.3096	120	0.6135
2185309247	propentofylline for dementia review	2008	-0.4056	0.0833	85	0.7563
2186149158	a double blind placebo controlled trial of intravenous methylprednisolone	1988	-0.3232	0.2077	13	0.7493
2186531302	cognitive function in early parkinsons disease a population based study	2009	-0.2055	-0.1492	49	0.7307
2186572663	experience in clinical use of tanakan in the treatment of the syndrome of mild cognitive impairment	2006	-0.289	0.2822	9	0.657
2187199361	role of oral midazolam as a procedural sedative in children aged 6 months to 12 years	2014	2.345	0.1894	103	0.7154
2187327216	a double blind placebo controlled trial ofhigh dose lecithin inalzheimer s disease	1985	-0.3327	0.0929	51	0.6582
2187548005	improved quality of life with megestrol acetate in patients with endocrine insensitive advanced cancer a randomised placebo controlled trial	1997	-0.9263	-0.257	79	0.7471
2187766730	oral physostigmine treatment of patients with alzheimer s disease	1985	-0.3075	0.1774	13	29.4568
2187887663	comparison of the intravenous haloperidol and diazepam on recovery from conversion disorders in emergency ward patients double blind randomized clinical trial of efficacy and safety	2013	2.2276	-0.0441	2	0.7565
2187950435	decreased serum homocysteine levels after micronutrient supplementation in older people	2010	-1.9284	0.3325	109	0.7546
2188679450	practice parameter diagnosis of dementia an evidence based review report of the quality standards subcommittee of the american academy of neurology	2001	-0.1052	0.0148	12	5.7853
2188723193	low folate status enhances pregnancy changes in plasma betaine and dimethylglycine concentrations and the association between betaine	2013	-1.9287	0.3319	109	0.7543
2188846692	effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes ukpds 34	1998	-0.3827	1.1661	113	1.5987
2189020854	risk factors associated with depression in type 2 diabetics	2012	-0.4276	1.4428	56	0.784
2189177069	crossover study randomised double blind placebo controlled donepezil for dementia in parkinson s disease a	2006	-0.3333	0.0923	51	0.6398
2190133562	risperidone for children with severe behavioral problems	2002	0.5645	0.399	40	0.7528
2190371629	cognitive results of cantab tests and their change due to the first dose of donepezil may predict treatment efficacy in alzheimer disease	2015	-0.2152	0.1394	11	0.7765
2191791247	treatment of alzheimer s disease with repetitive transcranial magnetic stimulation combined with cognitive training a prospective randomized double blind placebo controlled study	2016	-0.0629	0.031	67	1.3661
2191824668	mechanisms of effect of ginkgo biloba extract on experimental cerebral edema	1988	-0.4758	-0.0347	132	0.6603
2192223169	dietary supplementation with n 3 polyunsaturated fatty acids and vitamin e after myocardial infarction results of the gissi prevenzione trial	1999	-1.1727	-0.324	83	2.7367
2192583216	methylphenidate treatment of negative symptoms in patients with dementia	1997	-0.2322	0.2459	66	0.688
2193702298	comparison of haloperidol and midazolam in restless management of patients referred to the emergency department a double blinded randomized clinical trial	2015	2.2276	-0.0441	2	0.7542
2194486351	the effect of anesthesia type on major lower extremity amputation in functionally impaired elderly patients	2016	2.2338	-0.0386	36	0.7346
2194539869	feasibility and effectiveness of a combined individual and psychoeducational group intervention in psychiatric residential facilities a controlled non randomized study	2016	0.5122	-0.1606	60	0.6639
2195663802	general versus spinal anaesthesia for patients aged 70 years and older with a fracture of the hip	2015	2.2331	-0.0379	36	0.7199
2196079088	the efficacy of cognitive stimulation on depression and cognition in elderly patients with cognitive impairment a retrospective cohort study	2015	-0.2055	-0.1492	49	0.7327
2196215831	efficacy of ginkgo biloba in 90 outpatients with cerebral insufficiency caused by old age results of a placebo controlled double blind trial	1994	-0.4591	-0.0439	8	1.7292
2196998635	prevalence of depression in type 2 diabetes patients in german primary care practices	2016	-0.4267	1.4429	56	0.7748
2198678228	effects of long term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus the field study randomised controlled trial	2005	-0.5188	-0.0906	68	0.7186
2198828924	impact of an individualized physical activity intervention on improving mental health outcomes in family caregivers of persons with dementia a randomized controlled trial	2015	0.5117	-0.1129	1	0.7829
2202823327	cilostazol add on therapy suppressed cognitive decline in patients with mild dementia receiving donepezil	2014	-0.2174	0.1407	11	0.7504
2202942450	effective resolution with olanzapine of acute presentation of behavioral agitation and positive psychotic symptoms in schizophrenia	2001	0.0289	0.1124	38	0.7954
2206430942	determinants of successful aging findings from a study with ergoloid mesylates hydergine	1985	-0.1379	0.0381	80	0.7273
2209720877	multidisciplinary rehabilitation program effects of a multimodal intervention for patients with alzheimer s disease and cognitive impairment without dementia	2015	0.305	-0.0919	39	0.6988
2209763265	clinical observation of cognitive impairment after traumatic brain injury treated with acupuncture and cognitive training	2015	-0.24	-0.2603	49	0.7227
2210884025	memantine treatment in patients with alzheimer s disease already receiving donepezil	2015	-0.1687	0.0991	11	0.8136
2210971040	memantine and cognition in parkinson s disease dementia dementia with lewy bodies a meta analysis	2016	-0.1371	0.201	100	0.8399
2212831968	rivermead behavioural memory test	1990	0.1983	-0.0052	17	1.6836
2212873636	the effect of donepezil on sleep and rem sleep eeg in patients with alzheimer disease a double blind placebo controlled study	2006	0.1274	0.0261	28	18.62
2213487068	memantine for the treatment of frontotemporal dementia a meta analysis	2015	-0.3858	0.0611	50	0.7029
2213870083	the effect of a manual therapy knee protocol on osteoarthritic knee pain a randomised controlled trial	2008	-0.3438	0.2071	126	0.8331
2214590271	long term effects of alzheimer s disease treatment	2015	-0.3258	0.1834	22	1.5087
2215349211	xenon anaesthesia for patients undergoing off pump coronary artery bypass graft surgery a prospective randomized controlled pilot trial	2015	3.1484	0.109	110	0.7993
2217410625	effects of ginkgo biloba extract on two models of experimental myocardial ischemia	1988	-0.4758	-0.0347	132	0.655
2217622628	beneficial effects of omega 3 and vitamin e coadministration on gene expression of sirt1 and pgc1?? and serum antioxidant enzymes in patients with coronary artery disease	2016	-1.1801	-0.326	129	0.7038
2218853927	the pathology of ischemic vascular dementia an update	2002	-0.727	0.0219	107	0.6798
2219619821	neuropsychological performance of a patient suspected of dementia taking lorazepam and retested 1 year later following titration	2016	-0.2055	-0.1492	49	0.7065
2220278154	mrc bhf heart protection study of cholesterol lowering with simvastatin in 20 536 high risk individuals a randomised placebocontrolled trial	2002	-0.7877	-0.1885	88	1
2220690163	a randomized double blind placebo controlled 24 week phase 2b outcomes study of 3 different doses of encenicline or placebo in subjects with mild to moderate probable alzheimer s disease p7 100	2015	-0.2977	0.0512	23	0.6652
2220977225	cognitive impairment of japanese multiple sclerosis patients follow up study using brb n assessment tool	2015	-0.2055	-0.1492	49	0.7205
2222541464	oestrogen therapy and the menopausal syndrome	1977	-0.7656	-0.7755	3	2
2222602342	effect of visual training on cognitive function in stroke patients	2015	-0.2409	-0.2597	49	0.7198
2222865847	effect of two doses of ginkgo biloba extract egb 761 on the dual coding test in elderly subjects	1993	-0.4706	-0.0566	8	5.7574
2223453682	premature discontinuation of randomized trials in critical and emergency care a retrospective cohort study	2016	-0.5975	-0.0271	99	0.6811
2223710100	a randomized trial of intensive versus standard blood pressure control	2015	-0.6916	-0.1919	79	0.916
2224538797	a study of sertraline efficacy on reducing disabilities in stroke inpatients a double blind randomized clinical trial	2013	0.0874	0.147	61	1.5197
2226910893	the efficiency of supporting the quality of life of family caregivers according to the family caregivers of persons with dementia who are members of the memory association of pa?êija?êt ha?ême	2014	0.7067	-0.1575	76	0.777
2228399196	the present status of chelating agents in medicine	1983	-1.5747	-1.2603	101	0.75
2228733445	randomized placebo controlled trial of methylphenidate or galantamine for persistent emotional and cognitive symptoms associated with ptsd and or traumatic brain injury	2016	-0.9922	1.2607	71	0.6947
2230689728	memory test for alzheimer s disease	2011	-0.5503	0.3993	73	0.744
2230756913	continuous intravenous administration of drugs	1983	-0.6082	0.5205	119	0.6295
2230778873	omega 3 fatty acid status enhances the prevention of cognitive decline by b vitamins in mild cognitive impairment	2016	-1.0944	-0.2999	5	0.7172
2231349546	physical exercise in schizophrenia	2010	-0.6362	0.0865	122	0.7306
2231912968	the effects of validation therapy on disoriented elderly	1988	0.4389	-0.07	18	0.7993
2233801070	effect of folic acid betaine vitamin b6 and vitamin b12 on homocysteine and dimethylglycine levels in middle aged men drinking white wine	2016	-1.9284	0.3325	109	0.7912
2234152921	is risperidone effective and safe for treating behavioral disturbances in elderly patients with dementia	2013	0.5483	0.3861	40	0.8162
2236483702	omega 3 polyunsaturated fatty acid supplementation and white matter changes in major depression	2016	-1.0951	-0.3005	5	0.7058
2238981407	plasma fatty acid profiles in relation to cognition and gender in alzheimer s disease patients during oral omega 3 fatty acid supplementation the omegad study	2015	-1.0924	-0.2993	5	16.5441
2240758399	citicoline cdp choline mechanisms of action and effects in ischemic brain injury	1995	-0.3979	-0.2564	62	2.6818
2241034500	genetic testing in combination with preventive donepezil treatment for patients with amnestic mild cognitive impairment	2012	-0.3141	0.0962	50	0.6451
2241225343	effect of tacrine on behavioural symptoms in alzheimer s disease an open label study	1996	-0.1501	0.1196	44	0.7531
2243970579	effects of antioxidant vitamin c e and c e supplementation on plasma lipid profiles glycemic control and antioxidant status among type 2 diabetes mellitus subjects in tehran iran	2011	-1.2096	-0.3344	128	0.6842
2244034277	dementia and alzheimer s disease	2012	-0.3346	0.2225	59	0.8396
2244940789	citalopram reduces agitation in some patients with alzheimer disease	2014	0.037	0.0539	58	1.412
2247997571	efficacy and safety of cholesterol lowering treatment prospective meta analysis of data from 90 056 participants in 14 randomised trials of statins	2005	-0.7874	-0.1891	88	3
2254357607	fluorobenzamides suitable for the treatment of alzheimer s disease or senile dementia	2003	-0.384	0.3371	59	0.8072
2254646458	mirtazapine added to selective serotonin reuptake inhibitors for treatment resistant depression in primary care mir trial study protocol for a randomised controlled trial	2016	0.1033	0.1511	61	0.7752
2255358994	haloperidol adjunct with morphine on postoperative pain management in opioid addicted patients undergoing orthopedic surgery	2015	2.2276	-0.0441	2	0.828
2255756224	the world health organization quality of life assessment whoqol position paper from the world health organization	1995	-0.9263	-0.257	79	0.75
2256391914	emerging amyloid disease modifying drugs for alzheimer s disease	2016	-1.0873	-0.5741	69	0.679
2258116515	attentional benefit of stimulants in tbi	2009	-0.9922	1.2607	71	0.7058
2258489694	risperidone in the treatment of psychotic affective and behavioral symptoms associated to alzheimer s disease	1999	0.2737	0.1224	81	2.3508
2260326559	effect of flutoprazepam on skills essential for driving motor vehicles	1990	-0.387	0.3785	98	0.71
2260765777	id 295 deep repetitive transcranial magnetic stimulation with the h coil in alzheimer s disease a placebo controlled double blind study	2016	-0.1756	0.0553	67	1.3293
2261758203	efficacy and safety of bmy 21 502 in alzheimer disease	1996	-0.4204	-0.0632	82	0.7333
2261967522	cardiovascular responses of 70 to 79 yr old men and women to exercise training	1989	0.5835	-0.2505	27	0.9994
2263476732	clinical benefits of memantine treatment for alzheimer s disease in the okayama memantine study ii oms ii	2015	-0.1958	0.1174	92	1.5043
2263781166	a multicentre study to test the effectiveness of the stam sound training attention and memory protocol in the rehabilitation of patients with schizophrenia a single blind randomized control trial	2009	0.5634	-0.0514	21	0.7403
2264351527	use of clioquinol for the therapy of alzheimer s disease	2001	-1.0873	-0.5741	69	0.7471
2265157205	delaying progression to alzheimer disease	2009	-0.3141	0.0962	50	0.647
2265327585	study design of a randomized placebo controlled trial of the homeopathic treatment of attention deficit hyperactivity disorder adhd	2016	-0.1547	0.2301	15	0.6411
2267903572	older community residents with depression long term treatment with sertraline randomised double blind placebo controlled study	2003	0.103	0.1503	61	0.7464
2269189524	community occupational therapy for people with dementia and family carers cotid uk versus treatment as usual valuing active life in dementia valid programme study protocol for a randomised controlled trial	2016	0.395	-0.1042	39	0.7462
2269485623	eye movements and skills performance measures under alcohol in a driving simulator	1979	-0.387	0.3785	98	0.6643
2269764428	cerebral effects of a single dose of intravenous vinpocetine in chronic stroke patients a pet study	1998	-0.3068	0.128	23	0.9404
2270434135	neuropsychiatric symptoms in dementia and the effects of ginkgo biloba extract egb 761 treatment additional results from a 24 week randomized placebo controlled trial	2016	-0.4332	-0.0468	8	0.8517
2274558823	comparison of sedation and general anaesthesia for transcatheter aortic valve implantation on cerebral oxygen saturation and neurocognitive outcome	2016	2.2338	-0.0385	36	0.7145
2275498737	cognitive functions in patients with primary torsion dystonia treated with pallidal deep brain stimulation	2014	0.2301	-0.2027	111	0.6437
2275528140	a randomised double blind placebo control trial of cinnamon supplementation on glycemic control and lipid profile in type 2 diabetes mellitus	2012	-1.2104	-0.3345	128	0.7162
2275790368	nimodipine for psychogeriatric use methods strategies and considerations based on experience with clinical trials	1989	-0.2909	0.1288	53	0.7993
2278185631	clinical trial of a novel benzodiazepine derivative in a double blind study using the wittenborn psychiatric rating scale author s transl	1975	-0.293	0.0998	41	0.6634
2279165743	impact of omega 3 fatty acid supplementation on memory functions in healthy older adults	2016	-1.0951	-0.3005	5	0.75
2280670084	treatment of age related cognitive decline with a herbal formulation a double blind study	1998	-0.2633	0.1641	9	0.6612
2280739488	effects of ginkgo biloba extract on cerebral functional activity	1988	-0.4758	-0.0347	132	0.677
2280809537	repetitive transcranial magnetic stimulation as an alternative therapy for cognitive impairment in alzheimer s disease a meta analysis	2015	-0.1591	0.0558	67	0.6566
2280905439	optimal nonpharmacological management of agitation in alzheimer s disease challenges and solutions	2016	0.432	-0.0425	34	0.643
2281123624	rivastigmine in patients with alzheimer s disease and concurrent hypertension	2002	-0.2837	0.0413	72	19.5748
2281689004	best practice guide for the treatment of rem sleep behavior disorder rbd	2010	-0.1493	0.1232	7	0.9713
2282145689	the effects of short and long term supplementation with fish oil on the incorporation of n 3 polyunsaturated fatty acids into cells of the immune system in healthy volunteers	1993	-1.145	-0.3146	83	0.7384
2282907727	use of procholinergics in the prevention of postoperative delirium in hip fracture surgery in the elderly a randomized controlled trial	2001	2.1843	-0.044	2	16.6679
2284375092	consciousness of memory functioning in alzheimer s disease	2010	-0.5495	0.3992	73	0.6765
2287036893	the dementia of alzheimer s disease	1985	-0.3841	0.3371	59	0.8312
2287037629	therapeutic efficacy of nootropic drugs a discussion of clinical phase iii studies with nimodipine as a model	1989	-0.2909	0.1288	53	0.8843
2287097513	donepezil in alzheimer s disease and vascular dementia	2013	-0.3509	0.1038	33	2.354
2288121918	positive placebo effect in some mental and neurological disorders	1999	-0.1544	0.2293	15	0.7453
2288253210	vascular cognitive impairment definition and terms	2012	-0.7263	0.0224	107	0.6912
2288848219	3dsrt evaluation of responses of alzheimer type dementia to donepezil hydrochloride therapy	2005	-0.3243	0.1121	33	0.8247
2289249396	effects of telephone based support group program for family caregivers of elders	2014	0.7067	-0.1575	76	0.7816
2289554539	progression in the research of mild cognitive impairment	2010	-0.1892	0.0233	78	0.8953
2289853850	a pilot trial of acceptance and commitment therapy for symptoms of depression and anxiety in older adults residing in long term care facilities	2017	0.6749	-0.1727	77	0.7487
2289888620	a path analysis of patient dependence and caregiver burden in alzheimer s disease	2016	-2.1425	2.1685	121	0.8791
2290447869	piracetam rivastigmine and their joint consumption effects on mmse score status in patients with alzheimer s disease	2013	-0.2276	0.064	7	0.7753
2290746437	influence of folic acid supplementation on coagulation inflammatory lipid and kidney function parameters in subjects with low and moderate content of folic acid in the diet	2015	-1.0944	-0.2999	5	0.751
2290926773	neurotransmitters in senile dementia of alzheimer type and in vascular dementia1	1985	-0.3847	0.3365	59	0.8355
2291030427	spect identified neuroanatomical predictor of the cognitive effects of donepezil treatment in patients with alzheimer s disease	2009	-0.3039	0.104	50	1.4162
2291520700	galantamine improved cognition and global functioning in vascular dementia or alzheimer s disease with cerebrovascular disease	2002	-0.3733	0.0865	94	1.8014
2291676469	decreased vasopressin gene expression in the biological clock of alzheimer disease patients with and without depression	2000	0.2766	-0.0161	17	1.871
2292126872	depression in elderly nursing home residents	2004	0.4399	-0.0044	104	0.7778
2292694764	cognitive performance over 7 days in a distressed submarine	1999	-0.387	0.3785	98	0.6931
2293806105	clinical staging of ketamine associated urinary dysfunction a strategy for assessment and treatment	2016	-0.393	0.3617	106	0.6684
2294790026	nursing intervention using light for prevention of postoperative delirium a randomized controlled trial	2014	2.2154	-0.0448	2	0.787
2296903081	compression of risperidone and olanzapine in behavioral disturbances of alzheimer a randomized double blind clinical trial	2007	0.5483	0.3861	40	0.8264
2297034325	silybin beta cyclodextrin in the treatment of patients with diabetes mellitus and alcoholic liver disease efficacy study of a new preparation of an anti oxidant agent	2002	-1.2104	-0.3345	128	0.6734
2297107820	phase iv multicentre clinical study of risperidone in the treatment of outpatients with schizophrenia	1998	-0.3446	0.2068	126	0.8326
2297231757	intravenous infusion system	1952	-0.6082	0.5205	119	0.6255
2298293787	are psychotherapeutic effects on family caregivers of people with dementia sustainable two year long term effects of a telephone based cognitive behavioral intervention	2017	0.7627	-0.2018	77	0.7687
2299215626	family caregiver capacity building program for older people with dependency in thailand a randomized controlled trial	2016	0.6854	-0.1437	97	0.6759
2300578845	resourcefulness training for women dementia caregivers acceptability and feasibility of two methods	2016	0.6861	-0.1443	97	0.6673
2300591501	cerebrospinal fluid levels of amyloid beta 1 43 in patients with amnestic mild cognitive impairment or early alzheimer s disease a 2 year follow up study	2016	-0.295	0.0288	57	0.6851
2300801831	extract of ginkgo biloba for tardive dyskinesia meta analysis of randomized controlled trials	2016	-0.375	-0.0366	70	0.7054
2301313723	effects of the medicare alzheimer s disease demonstration on the use of community based services	1999	0.5651	-0.1081	1	26.0023
2301371005	effect of antidepressant treatment on cognitive impairments associated with depression a randomised longitudinal study	2016	0.0708	0.1428	61	0.7847
2301404923	effects of tocopherol and deprenyl on the progression of disability in early parkinson s disease	1993	-0.2536	0.0915	37	1.916
2305257370	rivastigmine patch in chinese patients with probable alzheimer s disease a 24 week randomized double blind parallel group study comparing rivastigmine patch 9 5 mg 24 h with capsule 6 mg twice daily	2016	-0.2553	0.0533	72	0.8586
2309131021	donepezil study group a 24 week double blind placebo controlled trial of donepezil in patients with alzheimer s dis ease	1998	-0.3333	0.0923	51	0.6436
2310992267	behavioral effects of extended release memantine 28 mg once daily across a wide range of disease severity in patients with moderate to severe alzheimer s disease post hoc analysis from a randomized trial p01 012	2013	-0.1974	0.1165	92	0.8351
2311209172	does the cholinesterase inhibitor donepezil benefit both declarative and non declarative processes in mild to moderate alzheimers disease	2007	-0.2008	0.1471	9	0.7304
2312613726	efficacy of oral physostigmine in primary degenerative dementia a double blind study of response to different dose level	1985	-0.3132	0.2034	13	23.6169
2312721407	kinematic analysis of the effects of donepezil hydrochloride on hand motor function in patients with alzheimer dementia	2003	-0.2932	0.1111	50	14.2616
2312742905	a randomized trial of a program to reduce the use of psychoactive drugs in nursing homes	1992	0.5396	0.0029	52	22.9997
2312965018	improving drug therapy decisions through educational outreach a randomized controlled trial of academically based detailing	1983	0.5411	0.0026	52	1
2313223023	music and dementias a review of literature	1997	0.481	-0.0521	21	0.9867
2313350126	poster 168 attention and memory training in stable schizophrenic patients a double blind randomized controlled trial using simple resources	2012	-0.2875	0.2061	15	0.7091
2313443760	cardiovascular risk of celecoxib in 6 randomized placebo controlled trials the cross trial safety analysis	2009	-0.5166	-0.0479	12	0.6902
2313743169	effects of body weight on tolerability of rivastigmine transdermal patch a post hoc analysis of a double blind trial in patients with alzheimer disease	2011	-0.2562	0.0517	72	17.1376
2313887247	improving memory and control beliefs through cognitive restructuring and self generated strategies	1992	0.5037	-0.2809	4	4.7564
2314133009	a double blind placebo controlled multicenter study of tacrine for alzheimer s disease	1992	-0.2896	0.1328	13	16.2307
2314583944	antidepressant treatment improves estrogen levels and cognitive function in postmenopausal anxiety depression patients	2013	-0.3415	0.9111	113	0.7429
2314815976	double blind placebo controlled comparison of the efficacy of sertraline as treatment for a major depressive episode in patients with remitted schizophrenia	2002	-0.2551	0.0998	23	1.3331
2314897384	a phase ii safety and tolerability study to investigate the effect of azd5213 on sleep in subjects with mild cognitive impairment and mild alzheimer s disease	2013	-0.289	0.2822	9	0.639
2315027775	simvastatin and stroke	2004	-0.5188	-0.0906	68	0.7165
2316064176	donepezil for alzheimer s dementia	2006	-0.3224	0.116	33	2.4525
2316134431	treatment of negative symptoms in schizophrenia and schizoaffective disorder by selegiline augmentation of antipsychotic medication a pilot study examining the role of dopamine	1996	0.104	0.1382	38	0.69
2316323064	the effect of music participation on the social behavior of alzheimer s disease patients	1992	0.48	-0.0523	21	0.9867
2316414538	sedation depth during spinal anesthesia and survival in elderly patients undergoing hip fracture repair	2014	2.2317	-0.0385	36	15.044
2316758542	continuous intravenous infusion of opioid drugs	1987	-0.6082	0.5205	119	0.6152
2317202224	effects of extra training on the ability of stroke survivors to perform an independent sit to stand a randomized controlled trial	2004	2.2795	-0.0629	35	0.845
2318295817	donepezil in more advanced alzheimer s disease	2005	-0.3099	0.111	33	3.4523
2318310598	snoezelen its long term and short term effects on older people with dementia	1997	0.4291	-0.074	18	21.2051
2318501167	204 continuous intravenous morphine infusion for postoperative analgesia following posterior spinal fusion for idiopathic scoliosis	2011	2.3863	-0.0472	130	0.8646
2318579539	comparison of active treatment and placebo in older chinese patients with isolated systolic hypertension	1998	-0.7376	-0.1471	14	0.9992
2318682740	snoezelen its effects on concentration and responsiveness in people with profound multiple handicaps	1995	0.4307	-0.0743	18	0.9713
2319054455	the effect of touch on nutritional intake of chronic organic brain syndrome patients	1986	0.5899	-0.0632	123	17.8386
2319553634	case of pick s central lobar atrophy with apparent stabilization of cognitive decline after treatment with risperidone	2000	-0.2313	0.2459	66	0.75
2320119757	efficacy and safety of quetiapine in critically ill patients with delirium a prospective multicenter randomized double blind placebo controlled pilot study	2011	-0.5975	-0.0271	99	0.6991
2320412159	long term maintenance of gains from memory training in older adults two 3 year follow up studies	1993	0.5044	-0.2818	4	23.58
2320791449	telpi performance in subjects with mild cognitive impairment and alzheimer disease a validation study	2013	-0.2007	0.0876	78	0.6952
2321011665	effect of aerobic and resistance training on fractionated reaction time and speed of movement	1990	0.5802	-0.2507	27	21.5389
2321073895	dental care utilization among older adults with cognitive impairment in the usa dental care utilization among older adults	2015	1.6418	-0.0325	24	0.7487
2321200945	alzheimer s and senile dementia	1987	-0.3847	0.3365	59	0.8396
2321865259	features of spontaneous speech in patients with amnestic mild cognitive impairment mci and mild alzheimer s disease	2008	-0.1901	0.0234	78	0.8391
2321966631	incidence and risk factors of acute postoperative delirium in elderly patients after elective and emergency surgery 18ap2 6	2011	2.7899	-0.0532	118	0.8048
2322095705	the effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels	1996	-0.7874	-0.189	88	3
2322182900	effectiveness of a mindfulness based walking programme in reducing symptoms of stress a randomised controlled trial	2012	-0.2945	-0.1543	45	0.7003
2322532448	effects of methylphenidate on attentional function after traumatic brain injury a randomized placebo controlled trial	1997	-0.8474	1.0199	71	0.991
2322707526	daily interruption of sedative infusions in critically ill patients undergoing mechanical ventilation	2000	2.2377	-0.0473	2	1
2322994938	a comparison of the snoezelen environment and a music relaxation group on the mood and behaviour of patients with senile dementia	1997	0.4308	-0.0751	18	0.9994
2323075374	a clinical trial comparing hydergine with placebo in the treatment of cerebrovascular insufficiency in elderly patients	1973	-0.2858	0.1013	41	20.1731
2324268873	dehydroepiandrosterone replacement in women with adrenal insufficiency	1999	-1.418	-1.8391	20	2
2324408877	trazodone and cognitive performance in alzheimer disease	2015	-0.5174	0.3683	73	15.1871
2324458150	absence of neuropsychologic deficits in patients receiving long term treatment with alprazolam xr for panic disorder	2001	-0.2351	0.1992	9	0.7177
2325092015	the effects of music therapy intervention on agitation behaviors of alzheimer s disease patients	1996	0.4826	-0.0521	21	1.9909
2325383590	a 24 week open label extension study to investigate the long term safety tolerability and efficacy of 13 3 mg 24 h rivastigmine patch in patients with severe alzheimer disease	2014	-0.2432	0.0567	19	1.7154
2325675769	ginkgo biloba for dementia a reasonable alternative	1999	-0.3985	0.0305	53	0.7361
2325678009	vascular dementia changing the paradigm	2003	-0.3243	0.1121	33	0.8124
2325781319	a yoga intervention for young adults with elevated symptoms of depression	2004	1.6805	-0.9881	108	0.9992
2325867355	remote ischemic preconditioning and outcomes of cardiac surgery	2015	2.5491	-0.0689	35	0.845
2326088310	evaluation of subject advocate procedures in the clinical antipsychotic trials of intervention effectiveness catie schizophrenia study	2007	0.4983	0.0618	91	0.7852
2326200998	a controlled trial of selegiline alpha tocopherol or both as treatment for alzheimer s disease	1997	-0.3704	0.024	63	51.1335
2326274075	exercise training of men at retirement a clinical trial	1987	0.584	-0.2513	27	1
2326308792	alzheimer s disease as a calciumopathy	2011	-0.4416	0.2873	105	0.8654
2326469489	neuropsychiatric disorders caused by cobalamin deficiency in the absence of anemia or macrocytosis	1988	-0.9233	-0.1078	30	0.991
2326588570	investigation of 99mtc labeled clioquinol derivative on amyloid plaque specifity by using animal model of alzheimer s disease	2015	-1.0873	-0.5741	69	0.7121
2327520147	cognitive dysfunction in multiple sclerosis a review of recent developments	2003	-0.2421	0.2104	55	1
2327904574	tacrine in the treatment of alzheimer s disease	1999	-0.3267	0.1688	22	0.7085
2327941408	op0101 hpr in patients with hand oa there is no evidence that a booster session after multidisciplinary treatment is effective results of a randomised controlled trial	2013	-0.2945	-0.1543	45	0.6981
2328096418	ginkgo biloba extract egb 761 independently improves changes in passive avoidance learning and brain membrane fluidity in the aging mouse	2007	-0.4729	-0.0611	8	0.9959
2328171144	how do clients benefit from snoezelen an exploratory study	1992	0.4308	-0.0751	18	0.9804
2328228672	computerized training of working memory in children with adhd a randomized controlled trial	2006	-0.2875	0.2061	15	0.7305
2328525606	neuropsychological prediction of conversion to alzheimer disease in patients with mild cognitive impairment	2008	-0.2007	0.0876	78	0.6861
2328529137	gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high density lipoprotein cholesterol	1999	-0.7869	-0.1892	88	2
2328973867	age differences in perceiving the direction of self motion from optical flow	1989	0.584	-0.2513	27	0.9997
2329004996	the dopamine stabilizer osu6162 occupies a subpopulation of striatal dopamine d2 d3 receptors an 11 c raclopride pet study in healthy human subjects	2015	-1.1671	1.5699	64	0.845
2329038319	rivastigmine transdermal patch role in the management of alzheimer s disease	2008	-0.2795	0.1044	133	0.7155
2329788888	stam protocol in dementia a multicenter single blind randomized and controlled trial	2012	0.5618	-0.0513	21	16.2997
2330829489	identification of the risk factors for postoperative complications in elderly patients with colorectal cancer	2016	2.7899	-0.0532	118	0.8148
2330848806	effect of betahistine combined with donepezil on amnestic mild cognitive impairment	2011	-0.2008	0.1471	9	0.7388
2330984559	discontinuing donepezil or starting memantine for alzheimer s disease	2012	-0.0709	0.0754	58	2.2508
2331041387	executive function in adults with attention deficit hyperactivity disorder during treatment with atomoxetine in a randomized placebo controlled withdrawal study	2014	-0.9922	1.2607	71	0.7301
2331112732	therapeutic psychosocial intervention for elderly subjects with very mild alzheimer disease in a community the tajiri project	2002	-0.2689	-0.2528	49	1.415
2331607882	memantine for alzheimer s disease a systematic review of randomized controlled trials in china memantine for alzheimer s disease a systematic review of randomized controlled trials in china	2011	-0.5166	-0.0479	12	0.7817
2331917096	387 a meta analysis and meta regression of randomized controlled icu trials with interventions hypothesized to reduce delirium	2012	-0.5975	-0.0271	99	0.7068
2332389703	a multicenter trial of remote ischemic preconditioning for heart surgery	2015	2.5491	-0.0689	35	0.845
2332472874	our sedation experience on mentally retarded patients	2015	2.345	0.1894	103	0.7016
2333040758	effectiveness of domestic occupational therapy for patients with dementia and their caregivers ergodem results from a multi site rct	2011	0.5272	-0.0877	34	0.6837
2333098158	cumulative benefits of extended release memantine 28 mg once daily across clinical domains in patients with moderate to severe alzheimer s disease an area under the curve analysis	2014	-0.1973	0.1161	92	14.7693
2333118341	evaluation of a yearlong reality orientation program	1981	0.3212	-0.0918	10	1.9912
2333343699	the occurrence of sleep disordered breathing among middle aged adults	1993	0.2279	-0.0033	28	0.9713
2333568650	schlafverhalten bei patienten mit morbus parkinson sleep behaviour in patients with parkinson s disease	1998	-0.6362	0.0864	122	0.7388
2333793022	a description of agitation in a nursing home	1989	0.3312	-0.0087	34	3.629
2333803251	improved neurobehavioral functioning in emphysema patients following medical therapy	2010	-0.2409	-0.2597	49	0.716
2334354041	the cost utility of the rivastigmine transdermal patch in the management of patients with moderate alzheimer s disease in the us	2009	-0.244	0.0543	19	0.8364
2334534397	spect monitoring of improved cerebral blood flow during long term treatment of elderly patients with nootropic drugs	1999	-0.4206	0.335	90	0.658
2334583744	exercise training and nutritional supplementation for physical frailty in very elderly people	1994	0.444	-0.1155	60	0.8843
2334661146	aging clinical aspects of alzheimer s disease and senile dementia	1982	-0.3847	0.3365	59	0.8178
2334770172	effect of home based multi component activity program home map for mild alzheimer s disease patients and caregivers	2015	0.1342	-0.0722	93	0.765
2335041971	therapeutic drug monitoring for patients with alzheimer dementia to improve treatment with donepezil	2015	-0.321	0.1163	33	1.6113
2335327803	targeting two amyloid plaque inhibitors found effective and safe in alzheimer disease mice	2010	-1.0873	-0.5741	69	0.6808
2335377904	a randomized double blind placebo controlled trial of antidepressants in parkinson disease	2013	-0.5166	-0.0479	12	0.712
2335865511	atypical antipsychotics for aggression	2006	0.5645	0.399	40	0.7008
2335875561	the effect of sensory stimulation in the sensory stimulation room on the well being of demented elderly a cross over trial in residents of the r c care center bernardus in amsterdam	1997	0.4307	-0.0743	18	0.9404
2336012456	noben idebenone in the treatment of dementia and memory impairment without dementia	2008	-0.417	0.0419	41	0.6713
2336273414	transdermal testosterone treatment in women with impaired sexual function after oophorectomy	2000	-1.4169	-1.8377	20	1
2336847247	effect of n 3 fatty acids on the expression of inflammatory genes in thp 1 macrophages	2016	-1.1031	-0.3023	5	0.8116
2337404608	memantine for behavior problems in alzheimer disease	2006	-0.1591	0.1122	11	1.5456
2337429073	an assessment of cerebrolysin effect on bdnf level in patients with post stroke aphasia depending on carbohydrate metabolism disorders	2015	-0.1943	0.0545	67	0.6949
2337454357	intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes ukpds 33	1998	-0.4344	1.4955	56	1.9119
2337574009	tolerability safety and efficacy of the 1 step titration scheme of rivastigmine patch 10 cm2 in japanese patients with mild to moderate alzheimer s disease a 24 week randomized controlled study	2015	-0.2432	0.0582	19	0.844
2338234526	a comparison of the efficacy and safety of memantal and original memantine in the treatment of mild and moderate dementia in alzheimer s disease	2015	-0.1927	0.1518	11	1.446
2338678376	donepezil tolerability and safety in alzheimer s disease	2002	-0.2669	0.0557	124	2.3743
2338803032	pyridoxine ascorbic acid and thiamine in alzheimer and comparison subjects	1992	-0.7848	-0.099	86	0.8843
2338818106	cognitive behavioral therapy for depression in advanced schistosomiasis patients	2012	0.0708	0.1428	61	0.7634
2338915833	comparison of different doses of escitalopram in the prevention of dementia in patients with depression and moderate cognitive dysfunction associated with chronic brain ischemia	2015	-0.2439	0.2318	15	0.6772
2340004999	trial of atorvastatin for the primary prevention of cardiovascular events in patients with rheumatoid arthritis trace ra	2015	-0.5188	-0.0906	68	0.7183
2340060279	dual n back working memory training in healthy adults a randomized comparison to processing speed training	2016	0.5038	-0.2821	4	0.6921
2340582330	the effects of dementia prevention program on cognition depression self esteem and quality of life in the elderly with mild cognitive disorder	2007	0.415	-0.0781	18	0.7211
2340709135	home based exercise following formal rehabilitation for hip fracture	2014	2.1885	-0.0861	26	0.7857
2341149533	influence of vascular burden on the effect of donepezil in patients with alzheimer s disease	2015	-0.3243	0.1121	33	0.7948
2341581210	cognitive deficits of patients with alzheimer s disease with and without delusions	1992	-0.0714	0.0909	78	1.5633
2341582119	a prospective open label trial of memantine hydrochloride for the treatment of social deficits in intellectually capable adults with autism spectrum disorder	2016	-0.1907	0.1284	11	0.7299
2341628747	representation of patients with dementia in clinical trials of donepezil	2004	-0.3855	0.0603	50	0.6878
2342914669	outline for science of the paper dementia and ginkgo biloba	2015	-0.3985	0.0305	53	0.7993
2343129795	effects on agitation with rivastigmine patch monotherapy and combination therapy with memantine in mild to moderate alzheimer s disease a multicenter 24 week prospective randomized open label study the korean exelon patch and combination with memantine comparative trial study	2017	-0.2404	0.0586	19	1.4805
2343628432	aromatherapy in aged care	2006	0.4318	-0.0417	34	0.6107
2344666894	the effect of nutritional supplementation on quality of life in people living with hiv a randomised controlled trial	2016	-0.9263	-0.257	79	0.7192
2345143564	vitamin e outpaces memantine in mild to moderate alzheimer disease	2014	-0.3088	0.0165	57	1.53
2345279028	training rehabilitation as an effective treatment for patients with vascular cognitive impairment with no dementia	2017	-0.8154	0.8222	102	0.7012
2345840153	is alzheimer s dementia a systemic disease	2015	-0.3792	0.0982	94	0.7909
2345907171	does risperidone improve verbal working memory in treatment resistant schizophrenia	1997	-0.2493	0.1726	9	1.3835
2346201839	a double blind controlled study of dipyridamole perlongets and placebo in patients with chronic glomerulonephritis multi clinical study	1987	-0.411	0.0798	51	0.688
2347417443	effect of risperidone and chlorpromazine on plasma level of tnf ?? in patients with first episode schizophrenia	2011	-0.1168	0.194	114	0.678
2347720741	effect of paroxetine combined with low dose olanzapine in elderly patients with depression	2013	-0.3807	-0.2165	45	0.6672
2347888337	clinical effect analysis of family rehabilitation nursing for the postoperative functional recovery of elderly patients with hip fractures	2012	2.1885	-0.0861	26	0.793
2348226916	analysis of risk factors of elderly patients with hypertension and intervention measures	2012	-0.4267	1.4429	56	0.7818
2348572846	clinical analysis of olanzapine in the treatment of behavioral and psychological symptoms of 50 patients with senile dementia	2014	0.0289	0.1124	38	0.7816
2348598908	a study of quetiapine and risperidone in the treatment of patients with senile dementia accompanied by mental and behavioral symptoms	2009	0.1166	0.1309	38	0.6307
2348965976	clinical efficacy and safety of memantine in the treatment of alzheimer disease	2008	-0.2093	0.1347	11	2.993
2348969709	interventional therapy on patients with hypertensive disorder complicating pregnancy accompanied with hyperhomocysteinemia	2008	-1.2104	-0.3345	128	0.6721
2349108628	clinical research on effect of memantine in treating patients with alzheimer s disease	2008	-0.1465	0.0968	11	1.6316
2350310804	comparative study of quetiapine in the treatment of patients with senile dementia accompanied with psychiatric symptoms	2008	0.1166	0.1309	38	0.6762
2350313079	clinical study of donepezil in treatment of patients with mild to moderate alzheimer s disease	2005	-0.2332	0.0392	72	0.8333
2350672205	the application of team social skills training in the community rehabilitation of patients with mental disorders	2014	0.5122	-0.1606	60	0.6607
2351449318	a controlled study on risperidone and aripiprazole in the treatment for behavioral and psychiatric symptoms in elderly patients with dementia	2011	0.1165	0.1318	38	0.6119
2351653127	effects of rehabilition training on patients with vascular dementia	2007	0.305	-0.0919	39	0.714
2351692514	clinical observation on acupuncture in treating vascular dementia after cerebral infarction	2013	0.0843	-0.0067	67	0.6683
2351811147	memantine treatment in alzheimer disease a randomized double blind controlled trial	2008	-0.1964	0.1178	92	1.4731
2351920876	a nimodipine interventional study of patients with mild cognitive impairment	2006	-0.206	-0.1485	49	0.7093
2352318351	the clinical study of donepezil in the treatment of alzheimer s disease	2010	-0.2666	0.053	124	1.6156
2352657413	comparison between the clinical effects of olanzapine and risperidone in treatment of alzheimer patients with behavioral and psychological symptoms	2013	0.0289	0.1124	38	0.7927
2353866154	clinical study of the sexual dysfunction in men induced by lumbar diseases	2008	0.2301	-0.2027	111	0.6482
2354119288	curative effect observation of risperidone oral solution in the treatment of organic mental disorders for elderly	2014	-0.1379	0.0381	80	0.6874
2354252592	a control study on risperidone oral solution in the treatment of psychiatric symptoms of senile dementia patients	2010	0.1165	0.1318	38	0.6124
2354406915	surgical treatment of the elderly patients with colorectal carcinoma	2003	2.7899	-0.0532	118	0.8019
2354539180	parkinson s disease and dementia	2006	-0.1375	0.2003	100	0.7692
2355043231	donepezil in moderate to severe alzheimer s disease	2001	-0.2939	0.1114	50	0.6869
2355803036	semantic clustering and sleep in patients with amnestic mild cognitive impairment or with vascular cognitive impairment no dementia	2016	-0.8154	0.8222	102	0.6733
2356405311	comparative study of rivastigmine and donepezil treatment in patients with mild to moderate alzheimer disease	2004	-0.234	0.0387	72	0.8153
2356719495	efficacy of rivastigmine in treating vascular dementia	2004	-0.234	0.0387	72	0.7966
2356844847	a control study of galantamine and donepezil treatment in dementia of alzheimer s disease	2011	-0.3037	0.1041	50	1.4006
2356883360	effect of donepzil on alzheimer s disease and mild cognitive impairment	2007	-0.3118	0.0161	57	0.6826
2356933492	investigation of donepezil therapy and electrophysiology on multi infarct dementia	2007	0.0847	-0.0074	67	0.6655
2357138848	a comparative study of memantine and donepezil on the treatment of alzheimer s disease	2011	-0.2137	0.1349	11	1.5774
2357436355	influence study of early rehabilitation nursing intervention on joint function of elderly patients with hip arthroplasty	2014	2.1885	-0.0861	26	0.7885
2357493499	application of perphenazine to treat psychotic symptoms of senile dementia 31 case report	2008	0.1105	0.1344	38	1.372
2358094242	clinical efficacy of selegiline added to levodopa decarboxylase inhibitor in parkinson s disease	2002	-0.411	0.0798	51	0.6536
2358185122	assessment of the cognitive impairment in elderly cancer patients treated with chemotherapy	2012	-0.2264	0.0532	84	0.7016
2358686159	iv ketorolac combined with morphine pca in postoperative pain control after lumbar disc surgery	2000	2.3864	-0.0463	130	0.8505
2358688694	plassma cortisol plassma prolactin and dexamethasone suppression test in patients with depression	2005	0.3307	-0.0249	89	0.6848
2359225727	effects of memantine on cognitive impairment of patients with stroke a randomized placebo controlled trial	2010	-0.4202	-0.0623	82	0.7675
2359253222	effect of community intervention on the rehabilitation of patients with senile dementia	2012	0.305	-0.0919	39	0.6952
2359446680	evaluation of effect of nursing guided family cognitive training on patients with senile dementia	2013	0.305	-0.0919	39	0.6954
2360149492	efficacy of memantine for elderly patients in the mild stage of alzheimer s and vascular dementia in ukraine	2016	-0.3019	0.0224	57	1.4234
2360432782	a correlated study on dysregulation of cortisol circadian rhythm and depression disorder in patients with myasthenia gravis	2013	0.3286	-0.0242	89	1.4578
2361316245	a prospective random control study comparison of olanzapine and haloperidol in senile delirium	2004	2.1292	-0.041	2	19.7437
2361475931	comparative study of olanzapine in treatment of behavioral and psychological symptoms of alzheimer s disease	2015	0.0654	0.1244	38	1.5458
2361687626	comparative study of olanzapine in the treatment of patients with senile dementia accompanied with behavioral and mental symptoms	2011	0.1106	0.1344	38	1.3643
2362199915	clinical efficacy and safety of rivastigmine in treatment of vascular dementia a multi center open label randomized controlled trial	2005	-0.2184	0.0664	7	1.5991
2362613508	rehabilitation efficacy on ability of daily life and cognition in alzheimer disease	2003	-0.2409	-0.2597	49	0.7165
2362742162	a clinical study of dexmedetomidine on cognitive function in elderly patients after gastrointestinal operation perioperative	2013	2.345	0.1894	103	0.7017
2362853891	clinical efficacy of hyperzine on memory function of schizophenia	2004	-0.2409	0.1654	9	0.7456
2363062074	analysis of the comprehensive treatment for patients with severe dementia in alzheimer s disease in community	2014	-0.1886	0.0705	7	0.7398
2363125682	effect observation of olanzapine and ziprasidone in treatment of schizophrenia	2014	0.0289	0.1124	38	0.7757
2363470885	therapeutic effect of paroxetine on patients with early poststroke depression and the serum interleu kins	2011	-0.3807	-0.2165	45	0.6558
2363632110	early nursing intervention on total hip replacement patients clinical observation of functional recovery	2011	2.1885	-0.0861	26	0.7927
2364528491	study on the effects of cognitive rehabilitation on cognitive function for inpatients with schizophrenia	2011	-0.24	-0.2603	49	0.7152
2364621840	efficacy and safety study of olanzapine joint donepezil in the treatment of behavioral and psychological symptoms of dementia	2015	-0.2175	0.1416	11	0.7258
2364859665	the efficacy of oxiracetam in the treatment of senile dementia	2015	-0.417	0.0419	41	0.6707
2366325592	intervention effect of community rehabilitation training on patients with early alzheimer s disease	2014	2.1136	-0.0877	26	1.497
2367138037	efficacy of combined treatment of drugs and electric acupunture on cognitive function of patients with mild cognitive impairment	2013	-0.2977	-0.2464	49	0.7258
2367226842	preliminary study of omentum transposition to brain for treatment of alzheimer s disease	2007	0.2293	-0.2025	111	0.6389
2367822195	a follow up study on a randomized single blind control of king s brain pills in treatment of memory disorder in elderly people with mci in a beijing community	2003	-0.3529	-0.1801	45	1.4206
2368914704	efficacy and safety of memantine for alzheimer s disease	2013	-0.4202	-0.0623	82	0.7731
2368940376	effect of escitalopram combined with cognitive behavioral therapy in the treatment of elderly depression	2013	-0.1379	0.0381	80	0.6798
2369072303	evaluation with quantitative eeg on effect of oxiracetam on mild and moderate brain injury	2005	-0.1943	0.0545	67	0.7559
2369262625	the efficacy of mirtazapine for acute poststroke depression and its effect on post stroke rehabilitation	2007	-0.1379	0.0381	80	0.6732
2369621898	the efficacy of the treatment of senile dementia with donepezil and nao ling decotion of 60 cases	2013	-0.2174	0.1407	11	0.7661
2369653562	clinical observation of risperidone in the treatment of postoperative delirium in elderly orthopedics patients	2013	2.2276	-0.0441	2	0.8034
2369990901	the clinical curative effect of memantine hydrochloride in treatment of senile parkinson dementia pdd and its analysis of influence on cognitive function	2014	-0.1954	0.1191	92	0.7861
2370018612	subcortical features in patients with subcortical ischemic vascular disease	2012	-0.7263	0.0224	107	0.7251
2370227033	effect of electric biofeedback on serum cortisol and nerve growth factor in children with bronchial asthma and its significance	2011	0.3313	-0.0243	89	0.6939
2370648319	analysis of clinical value of donepezil hydrochloride for treatment of senile dementia	2015	0.1166	0.1309	38	0.6438
2371142327	effects of huperzine a combined with risperidone on cognitive function in chronic schizophrenic patients	2012	-0.2977	-0.2464	49	0.6996
2371638215	memantine in the treatment of patients with moderate to severe alzheimer disease	2010	-0.1971	0.1158	92	0.7727
2372591646	clinical effect and influence in cognitive function of aripiprazole and risperidone in patients with schizophrenia	2013	-0.2975	-0.2456	49	0.7006
2372706566	study of cognitive dysfunction before and after operation in patients with cerebral tumors	2011	0.2301	-0.2027	111	0.6305
2373096615	the effect of donepezil on senile dementia complicated with psychosis	2012	-0.1988	0.2308	15	1.3319
2373129984	effect of donepezil combined memantine on alzheimer s disease	2010	-0.1992	0.1276	11	1.5522
2373317592	related factors analysis on community elderly patients with type 2 diabetes self management situation	2014	-0.4276	1.4428	56	0.7957
2373453860	supportive care demands of family caregivers of community dwelling patients with dementia	2015	0.6888	-0.1557	76	0.8509
2373557889	clinical observation of donepezil on improving cognitive impairment after stroke	2010	-0.3807	-0.2165	45	0.674
2373681270	the curative effects of fluoxetine on vascular dementia	2005	-0.2439	0.2318	15	0.6497
2373799420	observation of the effect of memantine combined with donepezil on alzheimer s disease	2011	-0.2139	0.1354	11	2.3512
2374170795	clinical observation of the long term efficacy of rivastigmine in the treatment of alzheimer s disease	2011	-0.2357	0.0393	72	1.6741
2374395901	study on the effect of systems clinic intervention on activities of daily living and cognition of patients with stroke	2011	2.1222	-0.0874	26	0.7645
2374607623	memantine oral solution in treatment of moderate to severe alzheimer s disease a multicenter randomized double blind parallel group controlled study	2011	-0.2225	0.0108	46	0.812
2374715914	a clinical trail of galanthamine for improving cognitive function in patients with schizophrenia	2013	-0.2977	-0.2464	49	0.7117
2375112031	clinical observation of acupuncture treatment of vascular dementia	2009	0.0847	-0.0074	67	0.6843
2375365971	clinical efficacy of cognitive behavioral therapy in elderly patients with mild to moderate cognitive dysfunction	2014	-0.2264	0.0532	84	0.6956
2375689324	the pharmacodynamic studies of ginkgo biloba extract on diabetes mellitus	2004	-0.4758	-0.0347	132	0.6664
2375972586	a control study on the treatment of olanzapine and risperidone on mental disorders caused by the cerebrovascular disease	2011	0.104	0.1382	38	0.7169
2376222494	efficacy and safety of rivastigmine in alzheimer s disease	2012	-0.2795	0.1044	133	0.701
2376353314	effects of preoperative application of huperzine a on postoperative cognitive function in elderly patients	2012	-0.3807	-0.2165	45	0.6616
2376401006	influence of antidepressant treatment on the recovery of neurological function in elderly patients with ischemic stroke	2011	-0.22	0.1008	23	0.6613
2376482708	the treatment by using rivastigmine for patients with alzheimer disease results of a multicenter randomized open labeled controlled clinical trial	2001	-0.2183	0.0668	7	1.5485
2376533621	clinical value discussion of recreation therapy in cognitive disorder after stroke	2015	-0.3244	-0.142	45	0.6985
2376926636	a comparative study of ziprasidone and haloperidol in the treatment of patients with senile dementia accompanied by mental and behavioral symptoms	2010	0.1166	0.1309	38	0.6254
2377254720	comparative study of brain evoked potentials in patients with dementia or non dementia parkinson disease and binswanger disease	2000	0.2301	-0.2027	111	0.6247
2377369886	clinical efficacy and safety of amisulpride in treatment of patients with mental disorders due to alcohol	2015	-0.2197	0.1016	23	0.6651
2377878537	a randomized controlled trial of jin three needle therapy for vascular dementia	2011	-0.3807	-0.2165	45	0.6695
2377925145	cognitive effects of olanzapine and clozapine in chronic schizophrenia	2011	-0.2307	0.1568	9	0.6605
2377983054	the correlation of cognitive impairment in female elderly patients with osteoporosis and cortisol levels	2013	0.3248	-0.0245	89	0.7364
2378209315	clinical efficacy and safety of huperzine alpha in treatment of mild to moderate alzheimer disease a placebo controlled double blind randomized trial	2002	-0.5779	-0.1503	32	0.9973
2378555455	the efficacy comparison of small dose aripiprazole combined with diazepam in treatment of mental disorders caused by alcohol	2015	-0.3807	-0.2165	45	0.6697
2378890415	a randomized study comparing the effect and safety of galantamine and donepezil in patients with mild to moderate alzheimer s disease	2006	-0.2667	0.0527	124	1.5365
2379199085	the evaluation of early rehabilitation after hip replacement among elderly patients	2011	2.1885	-0.0861	26	0.7959
2379396272	a meta analysis of ginkgo biloba extract in treating diabetic nephropathy	2013	-0.4758	-0.0347	132	0.669
2379451964	a study of effect of anti hypertension treatment on cognitive function in elderly patients with hypertension	2011	-0.3807	-0.2165	45	0.6599
2379511720	efficacy and safety of quetiapine vs haloperidol for mental behavioral symptoms in patients with senile dementia a control study	2015	0.1166	0.1309	38	0.6522
2379530550	a control study on risperidone and perphenazine in the treatment of psychiatric symptoms of senile dementia patients	2005	0.1165	0.1318	38	0.6312
2380049748	effects of donepezil vs risperidone in treatment for behavioral and psychologi cal symptoms of dementia of alzheimer s disease	2006	-0.2156	0.1375	11	3.0648
2380631247	control study of efficacy between memantine and donepezil in treatment of patients with mild to moderate alzheimer s disease	2010	-0.1974	0.1165	92	0.6953
2382621714	subcortical ischemic vascular dementia	2008	-0.7263	0.0224	107	0.713
2382768253	clinical effect of citicoline on parkinson s disease complicated with cognitive dysfunction and its impact on daily life ability	2015	-0.2975	-0.2456	49	0.6971
2382803598	changes in electroencephalogram of 43 patients with first episode patients with schizophrenia	2009	-0.289	0.1016	41	0.6989
2382882713	effect of mouse nerve growth factor on dysgnosia in patients with general paralysis of the insane	2010	0.2301	-0.2027	111	0.6328
2383017058	clinical observation of sertraline for preventing elderly post stroke depression	2014	-0.3807	-0.2165	45	0.6568
2383089362	effect of comprehensive nursing intervention on improving the level of cognition and prognosis of patients with chronic heart failure	2015	2.1229	-0.0869	26	0.762
2383149255	analysis on senile dementia praecox treated with risperdone clozapine	2005	0.1166	0.1309	38	0.6478
2383609142	the effects of making by hand on cognitive function of schizophrenic patients	2005	-0.2409	-0.2597	49	0.7129
2383849517	to observe the effect of nicergoline in treatment of multi infarct dementia	2001	-0.447	-0.0016	12	0.607
2383916711	curative effect of risperidone in the treatment of patients with senile dementia accompanied with psychiatric symptoms	2013	0.617	0.4432	40	0.7652
2384010523	comparison on clinical efficacy between oxiracetam and piracetam in treatment of elderly cognitive dysfunction after cerebral hemorrhage	2014	-0.3807	-0.2165	45	0.7032
2385262918	the research status of relationship of dehydroepiandrosterone and its sulphate with atherosclerosis	2013	-1.3848	-1.7808	54	0.795
2386061956	a prospective multicenter randomized double blinded controlled clinical trial on effects of tiantai no 1 in treating mild cognitive impairment	2010	-0.289	0.2822	9	0.6248
2386310041	a comparative study of the effect of rtms on cognitive function in patients with chronic schizophrenia	2013	-0.2975	-0.2456	49	0.7079
2387726435	contrasting of olanzapine and perphenazine treating psychiatric symptoms of alzheimer s disease	2011	0.104	0.1382	38	0.7468
2387946618	effects of donepezil in treatment of vascular dementia	2006	-0.2927	0.0364	23	2.1833
2388161559	rehabilitation nursing of elderly patients with hip joint fractures after surgery	2015	2.1882	-0.0853	26	0.8078
2388355708	clinical study of efficacy and safety of olanzapine tablets on patients with psychotic disorders after brain trauma	2012	0.104	0.1382	38	0.7516
2388978249	efficacy and safety study of olanzapine or quetiapine joint donepezil in the treatment of behavioral and psychological symptoms of dementia	2012	0.0289	0.1124	38	0.7719
2389109856	control study of zirasidone and perphenazine in the treatment of senile schizophrenia	2011	0.1165	0.1318	38	0.6373
2389228315	the efficacy and safety of butylphthalide for patients with vascular dementia a systematic review	2012	-0.3709	-0.0074	70	0.6572
2389306309	therapeutic effect of memantine hydrochloride on parkinsonism dementia	2015	-0.1374	0.0374	80	0.6738
2390401608	effect of mild cognitive impairment on postoperative delirium in elderly patients	2014	-0.2264	0.0532	84	0.7227
2391249856	systemic analysis of the efficacy and safety of cerebrolysin in the treatment of alzheimer s disease	2006	-0.3709	-0.0074	70	0.825
2391299476	the therapeutic effects and safety of atorvastatin in the treatment of patients with vascular dementia	2011	-0.3167	-0.002	23	0.7123
2391333970	donepezil in the treatment of patients with alzheimers disease	2009	-0.3242	0.1168	33	0.8162
2391542124	cognitive impairment in alzheimer disease	2002	-0.2007	0.0876	78	0.6967
2392408454	donepezil hydrochloride in the treatment of vascular dementia 40 cases	2011	-0.3167	-0.002	23	0.7095
2392634616	the comparison of clinical efficacy of donepezil and piracetam on treatment of vascular cognitive impairment	2006	-0.2439	0.2318	15	0.7491
2393082246	the clinical study of huperzine a in the treatment of vascular dementia	2009	-0.2977	0.0512	23	0.6322
2393134067	the preliminary observation on the treatment on cognitive impairment in patients with parkinson s disease by donepezil	2006	-0.2239	0.1567	11	2.1982
2393177492	observation on the effect of postoperative rehabilitation nursing care in the treatment of elderly patients with femoral neck fracture by total hip replacement	2012	2.1882	-0.0853	26	0.8055
2393386037	effect of home rehabilitation nursing intervention on quality of life and function of patients after total hip replacement surgery	2014	2.1885	-0.0861	26	0.7947
2393608624	clinical efficacy of vinpocetina for cognitive impairment in patients with vascular dementia	2008	-0.0942	0.0057	84	0.7325
2393664787	influence of nursing intervention on rehabilitation of patients with schizophrenia after discharge	2012	2.1222	-0.0874	26	0.75
2393961236	clinical study on effect of oxiracetam on mild and moderate brain injury	2006	-0.1943	0.0545	67	0.7289
2394014176	clinical study on p300 as the method for early diagnosis of the vascular dementia	2000	-0.0938	0.0049	84	0.7218
2394324131	analysis on clinical therapeutic effect of donepezil in treating alzheimer s disease	2004	-0.2213	0.16	11	3.0591
2394554746	extrapyramidal symptoms and their relationship to clinical efficacy under perphenazine treatment a controlled prospective handwriting test study in 22 acutely ill schizophrenic patients	1991	-0.6362	0.0864	122	0.7446
2394643822	trial of piracetam in children with cerebral organic mental deficiency	1977	-0.1547	0.2301	15	0.7416
2394716915	alzheimer s disease and caregiver stress	1994	-2.1425	2.1685	121	0.936
2394827697	effects and results of prolonged treatment with thioridazine melleril in mental patients	1964	0.0852	0.1033	47	0.6657
2394926546	quality of life in mild cognitive impairment mci and alzheimer s dementia ad patient versus caregiver perspective and predictors	2015	-0.2007	0.0876	78	0.6688
2395148832	parallel double blind clinical trial of nifedipine versus a placebo in patients with chronic cerebrovascular insufficiency	1985	-0.411	0.0798	51	0.6773
2395280750	disorders of brain performance of vascular origin randomized double blind study of the effectiveness of gingko biloba extract	1988	-0.4746	-0.0344	132	14.8976
2395631217	striatal uptake of i 123 s cit and i 123 ibzm in patients with extrapyramidal symptoms	1997	-0.6362	0.0864	122	0.7359
2395681920	new regression models for long term cognitive change in donepezil treated alzheimer patients	2006	-0.2939	0.1114	50	0.6842
2396159623	risk diagnosis and treatment to postoperative delirium in elderly patients with gastrointestinal cancers	2015	2.7899	-0.0532	118	0.7996
2396405469	effects of dongsasub training for family caregivers of patients with dementia on their burden depression and self esteem	2016	0.6566	-0.1432	75	0.7665
2396468861	treatment of alzheimer disease and the main primary degenerative dementias	1999	-0.3356	0.2226	59	0.8653
2396595108	clinical findings with nimodipine in dementia test of the calcium hypothesis	1995	-0.3457	0.1042	53	0.916
2396781709	effects of citicholine in subcortical dementia associated with parkinson s disease assessed by quantified electroencephalography	1992	-0.2809	0.1571	43	0.6896
2397130820	clinical rating of compliance in chronic hemodialysis patients	1999	-0.3438	0.2071	126	0.8293
2397171909	effect of a buzepide metiodide haloperidol combination in treating functional intestinal disorders randomized double blind controlled versus placebo study	1989	-0.411	0.0798	51	0.6653
2397538062	comparative study of the effectiveness of zuclopenthixol acetate and haloperidol in acutely disturbed psychotic patients	2002	0.1304	0.1286	47	0.7378
2397982625	effectiveness of donepezil on several cognitive functions in patients with alzheimer s disease over 12 months	2001	-0.2939	0.1114	50	0.7197
2398237601	use of tha in treatment of alzheimer like dementia pilot study in twelve patients	1981	-0.3281	0.2166	13	1.9404
2398364523	effects of a psychosocial intervention on survival among patients with stage i breast and prostate cancer a matched case control study	1999	0.4816	-0.0518	21	1.9861
2398526675	symptomatic treatment of cerebrovascular insufficiency with hydergine	1969	-0.2946	0.1297	41	2.3276
2398590460	neuroleptics for behavioral symptoms of dementia	2000	0.3077	0.1439	81	0.7571
2398650533	cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs	1993	-1.5582	0.2221	115	0.9867
2398740439	induction of depression with oxotremorine in patients with alzheimer s disease	1987	-0.2984	0.1487	13	0.845
2398750331	mental impairment in aging selection of patients methods of evaluation and therapeutic possibilities of acetyl l carnitine	1988	-0.2863	0.03	63	0.7993
2398758222	relieving select symptoms of the elderly	1975	-0.2879	0.102	41	1.6443
2398797545	effects of phosphatidylserine in alzheimer s disease	1992	-0.3177	0.0389	63	2.511
2399383561	donepezil minimally effective for patients with vascular dementia	2004	-0.3855	0.0603	50	0.7022
2400046791	depressive symptoms and associated factors in caregivers of patients with chronic mental illness	2008	0.4586	0.2348	116	0.7842
2400306713	evaluation and treatment of dementia	1987	-0.3855	0.0603	50	0.7051
2400616081	safety of donepezil in korean patients with severe alzheimer s disease	2015	-0.3242	0.1168	33	0.8077
2400620463	nonpharmacologic treatments for memory losses with normal aging	1985	0.5093	-0.2855	4	0.845
2401396734	the use of intravenous infusion of chlorpromazine in accelerated hypertension	1973	-0.6082	0.5205	119	0.623
2401410694	on the treatment of cerebral nutrition disorders a double blind study	1969	-0.3333	0.0923	51	0.6292
2401667079	demonstration of the therapeutic activity of 5023 se on intellectual and psychomotor efficacy in elderly impaired patients double blind controlled study versus placebo	1983	-0.289	0.2822	9	0.6597
2401757348	intravenous nicardipine for the treatment of severe hypertension a dose titration infusion to therapeutic response	1995	-0.6082	0.5205	119	0.6379
2401804393	drugs that target metal beta amyloid interactions can effect alzheimer s disease commentary metal protein attenuation with iodochlorohydroxyquine clioquinol targeting beta amyloid deposition and toxicity in alzheimer disease a pilot phase 2 clinical trial	2004	-1.0873	-0.5741	69	0.8015
2401874707	alzheimer s disease and the grieving caregiver alzheimer s from the point of view of the caregiver	2014	-2.1425	2.1685	121	0.8849
2402074932	the efficacy of donepezil on cognitive dysfunction in subacute post stroke patients	2006	-0.2977	-0.2464	49	0.7061
2402203869	intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged 75 years a randomized clinical trial	2016	-0.6916	-0.1919	79	0.7993
2403041350	piracetam activity may differ according to the age of the recipient mouse	1980	-0.2882	0.3063	15	0.75
2403238426	response patterns of egb 761 in alzheimer s disease influence of neuropsychological profiles	2003	-0.3727	-0.0416	8	0.8018
2404003702	neuroleptic treatment of elderly patients	1995	0.617	0.4432	40	0.7524
2404471346	failure of long term high dose lecithin to retard progression of early onset alzheimer s disease	1987	-0.28	0.0806	44	18.8538
2404545036	carbamazepine treatment of agitation in alzheimer s outpatients refractory to neuroleptics	1990	0.0875	0.0984	47	0.9584
2404691818	memantine in mild to moderate alzheimer s disease	2007	-0.3079	0.0164	57	1.7136
2405079176	double blind therapeutic trial with l s 701 and placebo	1972	-0.323	0.2085	13	0.7484
2405331954	effect of donepezil on cognitive function in patients with brain injury	2002	-0.2055	-0.1492	49	0.7175
2405397611	subcutaneous apomorphine infusion in the treatment of parkinson disease	1992	-0.6082	0.5205	119	0.6192
2405750899	dihydroergocristine in the treatment of organic brain psychosyndrome dose finding study against placebo	1992	-0.2977	0.0512	23	0.6535
2405791571	evaluation of the demented patient	1987	-0.2007	0.0876	78	0.6791
2406088904	how u s doctors die a cohort study of healthcare use at the end of life	2016	0.5772	-0.1221	139	0.7434
2406305767	drug therapy of disorders of cerebral performance randomized comparative study of dihydroergotoxine and ginkgo biloba extract	1990	-0.4838	-0.0687	68	1.4827
2406479850	a comparison of thioridazine trifluoperazine chlorpromazine and placebo a double blind controlled study on the treatment of chronic hospitalized schizophrenic patients	1961	0.1166	0.1309	38	0.6337
2407120486	effect of piracetam on the brain organic psychosyndrome in cerebrovascular insufficiency results of a double blind study in 40 cases	1977	-0.2965	0.1461	41	3.7231
2407148303	senile dementia of alzheimer type	1999	-0.384	0.3371	59	0.8266
2407253195	behavior of monoamine oxidase in the brain of man after therapy with monoamine oxidase inhibitors	1962	-0.1954	0.1513	37	0.805
2407347311	combined hydrogenated alkaloids of ergot in mental and nervous disorders associated with old age	1955	-0.2932	0.1266	41	0.75
2407385661	use of memantine for elderly patients in the mild stage of alzheimer s and vascular dementia	2013	-0.3144	0.1739	22	0.8022
2407511054	deprenyl in the treatment of parkinson s disease a specific type b monoamine oxidase inhibitor	1984	-0.1962	0.1508	37	0.8229
2407766199	modest facilitation on memory in dementia with combined lecithin and anticholinerestase treatment	1982	-0.3356	0.2226	59	0.8843
2407852135	myo inositol d chiro inositol folic acid and manganese in second trimester of pregnancy a preliminary investigation	2014	-1.2096	-0.3344	128	0.6918
2408147879	treatment of sleep disorders with zopiclone clinical trials using a double blind method versus placebo	1979	-0.411	0.0798	51	0.6615
2408794518	double blind trial of tiapride versus placebo in patients with sub perennial idiopathic headache	1982	-0.2977	0.0512	23	0.6508
2408840249	atypical antipsychotics in elderly patients with dementia	2008	0.617	0.4432	40	0.7878
2408918226	the switching of risperidone to olanzapine in elderly nursing home patients with dementia a retrospective study	2007	0.617	0.4432	40	0.7886
2408996056	new drug treatment for alzheimer s disease treatment with metrifonate warrants multicentre trials	1998	-0.2801	0.075	51	0.7482
2409241156	rapid changes in central beta adrenergic receptors after chronic intravenous infusion of antidepressants	1986	-0.6082	0.5205	119	0.6335
2409403553	consequences for management of nursing home residents with dementia	2005	0.4399	-0.0044	104	0.7792
2409558110	memantine akatinol therapy of cognitive impairment in parkinson s disease complicated by dementia	2008	-0.1375	0.2003	100	0.7757
2409603650	effects of ginkgo biloba extract on functional brain activity an assessment of clinical and experimental studies	1986	-0.4764	-0.0354	132	0.6973
2409900664	cause of postoperative delirium in elderly patients	1996	2.7899	-0.0532	118	0.8197
2410072723	the clinical use of piracetam a new nootropic drug the treatment of symptoms of senile involution	1972	-0.3087	0.2483	15	1.69
2410206959	pharmacological treatment of primary degenerative dementia	1988	-0.348	0.0768	53	1.4315
2410277500	caregiving aspects of alzheimer s disease	1986	-2.1425	2.1685	121	0.8894
2410282613	a study of the effect of donepezil hydrochloride on cognitive function in patients with dementia of alzheimer s type using wais r	2004	-0.2939	0.1114	50	0.8226
2410451329	continuous subcutaneous infusion of apomorphine for the treatment of parkinson s disease	2006	-0.6082	0.5205	119	0.617
2410454983	the beneficial effect of hypnosis in elective cardiac surgery a preliminary study	2016	2.345	0.1894	103	0.6976
2410542897	review donepezil improves cognitive and functional outcomes in vascular cognitive impairment	2004	-0.8148	0.8226	102	0.722
2410549360	one year follow up of neuropsychology mri rcbf and glucose metabolism rmrglu in cerebral microangiopathy	2000	-0.4858	0.0852	117	0.6875
2410710383	alzheimer s disease and family caregivers	2005	-2.1425	2.1685	121	0.9072
2410773806	variations in circadian rhythms of activity sleep and light exposure related to dementia in nursing home patients	1997	0.2992	-0.0174	17	1
2410789926	drug therapy for senile dementia of the alzheimer type	1988	-0.3847	0.3365	59	0.8142
2410882276	deprenyl in perspective prophylaxis for parkinson s disease	1986	-0.1918	0.1108	137	0.6712
2410935583	cerebral metabolic response to passive audiovisual stimulation in patients with alzheimer s disease and healthy volunteers assessed by pet	2000	-0.4858	0.0852	117	0.6831
2410982124	donepezil for alzheimer s disease	1998	-0.3099	0.111	33	3.5374
2411002719	a double blind crossover pilot study of l deprenyl selegiline combined with cholinesterase inhibitor in alzheimer s disease	1993	-0.1719	0.1026	37	4.3432
2411075130	bright light treatment of behavioral and sleep disturbances in patients with alzheimer s disease	1992	0.2831	-0.0166	17	7.8063
2411146576	memory aging and alzheimer s disease	1991	-0.5503	0.3993	73	0.7052
2411208878	long term effects of phosphatidylserine pyritinol and cognitive training in alzheimer s disease a neuropsychological eeg and pet investigation	1994	0.2476	-0.1139	10	0.9804
2411216007	selegiline in the treatment of mild to moderate alzheimer type dementia	1990	-0.1878	0.118	37	6.0488
2411273229	dihydroergotoxine mesylate in the treatment of senile cerebral insufficiency result of a long term multicenter double blind clinical trial with a placebo	1983	-0.411	0.0798	51	0.6996
2411370857	selegiline in the treatment of alzheimer s disease	1995	-0.5503	0.3993	73	0.7997
2411391102	treatment of psychotic symptoms with lamotrigine in alzheimer disease	2004	0.3085	0.1429	81	1.4461
2411664904	pflegebedurftigkeit bei morbus parkinson zu selten an erkannt	2015	-0.6362	0.0864	122	0.7425
2411754136	effectiveness of ipd treatment for delirium prevention in hospitalized elderly a controlled randomized clinical trial	2007	-0.5968	-0.0275	99	14.1126
2411805004	cognition and behavior in patients with alzheimer s disease	1999	-0.5194	0.3697	73	0.7689
2411812809	an integrative review of standardized clinical evaluation tool utilization in anticholinergic drug trials for neurogenic lower urinary tract dysfunction	2016	-0.393	0.3617	106	0.6541
2411876928	clinical evaluation of selenium tocopherol therapy	1966	-0.393	0.3617	106	0.7298
2411952163	clinical stage of dementia of alzheimer s type	2001	-0.4056	0.0825	85	0.6769
2412021590	clinical response to choline plus piracetam in senile dementia relation to red cell choline level	1981	-0.2865	0.2503	15	3.2154
2412117866	selegiline versus oxiracetam in patients with alzheimer type dementia	1990	-0.188	0.1187	37	1.836
2412127764	evaluation and classification of dysfunction patients	1990	-0.393	0.3617	106	0.6978
2412134327	multicenter randomized double blind drug vs placebo study of the treatment of tinnitus with ginkgo biloba extract	1986	-0.4812	-0.0642	68	0.8888
2412200509	short term effects of acetylcholinesterase inhibitor treatment on eeg and memory performance in alzheimer patients an open controlled trial	2003	0.0183	0.3851	48	0.6798
2412214704	preliminary results of a long term double blind study of naftidrofuryl and a placebo in patients with moderate alzheimer type senile dementia	1985	-0.2971	0.0513	23	13.884
2412250252	donepezil and alzheimer s dementia	2000	-0.3225	0.1158	33	2.4535
2412284870	senile dementia alzheimer s type and estrogen	1995	-0.7638	-0.7691	3	19.9955
2412556452	citicoline for treatment of experimental focal ischemia histologic and behavioral outcome	1996	-0.3989	-0.2632	62	0.9939
2412666076	vascular dementia stroke risk and sequelae define therapeutic approaches	2005	-0.3792	0.0982	94	0.7867
2412894570	oral physostigmine treatment for patients with presenile and senile dementia of the alzheimer s type a double blind placebo controlled trial	1990	-0.3318	0.1749	13	16.3716
2412921178	naftidrofuryl in the treatment of mild senile dementia a double blind study	1990	-0.6346	0.0862	122	15.4943
2413098434	exhaustion resulting from association with and treatment of demented patients	1999	-0.2861	0.0292	63	0.7411
2413204268	divergent neuroprotective effects of nimodipine in pdd and mid provide indirect evidence of disturbances in ca2 homeostasis in dementia	1993	-0.3854	0.1415	134	9.7809
2413411019	comparison of naming impairment among patients with parkinson s disease without dementia parkinson s disease dementia and alzheimer s disease	2016	-0.1371	0.201	100	0.7493
2413465592	safety and efficacy of cognitive training plus epigallocatechin 3 gallate in young adults with down s syndrome tesdad a double blind randomised placebo controlled phase 2 trial	2016	-0.5071	-0.1671	79	1.4544
2413632673	methylphenidate on cognitive improvement in patients with traumatic brain injury a meta analysis	2016	-0.9922	1.2607	71	0.708
2413829444	exercise for individuals with lewy body dementia a systematic review	2016	-0.1375	0.2003	100	0.7498
2414150328	memantine in moderate to severe alzheimer s disease	2003	-0.3298	0.1839	22	0.9018
2414215051	the effect of acupuncture on mood and working memory in patients with depression and schizophrenia	2015	-0.2409	0.1654	9	0.7257
2414325864	placebo placebo effect and clinical trials	2007	-0.411	0.0798	51	0.6798
2414357349	pathogenetic mechanisms of traumatic brain disease and main lines of their treatment	2009	0.2293	-0.2025	111	0.6586
2414498919	effects of cytidine diphosphate choline on rats with memory deficits	1993	-0.3936	-0.2409	62	0.7993
2414513803	a clinical and neurophysiological trial on nootropic drugs in patients with mental decline	1991	-0.2585	0.1787	11	0.6991
2414621404	cognitive effects of therapy with topiramate in patients with refractory partial epilepsy	2002	-0.2585	0.1787	11	0.6703
2414635179	study of the long term action of a ginkgo biloba extract on vigilance and mental performance as determined by means of quantitative pharmaco eeg and psychometric measurements	1985	-0.4795	-0.0618	8	3.8179
2414802187	advanced dementia in alzheimer s disease and memantine	2005	-0.3298	0.1839	22	0.8871
2414842722	efficacy of cdp choline in the treatment of senile alterations in memory	1991	-0.3936	-0.2409	62	0.75
2414861367	enhancement of memory by physostigmine	1979	-0.3173	0.2025	13	0.75
2414941237	alzheimer s disease and dementia	1988	-0.3346	0.2225	59	0.84
2414984994	biochemical changes in alzheimer s disease senile dementia neurotransmitters in senile dementia of the alzheimer s type	1979	-0.384	0.3371	59	0.8078
2415002761	alpha tocopherol and alzheimer s disease	1997	-0.4416	0.2873	105	0.9995
2415051004	effects of long term continuous infusion of the muscarinic cholinergic agonist arecoline on verbal memory in dementia of the alzheimer type	1991	0.0571	0.5351	48	0.6271
2415180099	thu0639 hpr acceptability of a novel physical activity and self management intervention for managing fatigue in rheumatoid arthritis	2015	0.5122	-0.1606	60	0.6617
2415362162	estrogen use and depressive symptoms in postmenopausal women	1992	-0.769	-0.7802	3	1
2415402200	benefits of cognitive stimulation for people with dementia	2012	0.2185	-0.072	10	0.8474
2415431623	an open trial of cedemin a gingko biloba extract with paf antagonistic effects for ulcerative colitis	1993	-0.4758	-0.0347	132	0.7155
2415533701	therapeutic effect of clioquinol for alzheimer disease	2008	-1.0873	-0.5741	69	0.7996
2415597512	comparison of risperidone and other neuroleptics in the management of chronic schizophrenia using cognitive therapy	2000	0.5483	0.3861	40	0.7185
2415759826	drug therapy of alzheimer dementia	2003	-0.3309	0.2597	59	0.7543
2415944825	depression in the spouses of demented patients	1984	-0.2861	0.0292	63	0.7213
2416021244	efficacy and tolerance of long term naftidrofuryl treatment of patients with senile dementia controlled study versus placebo	1987	-0.4098	0.0804	51	13.5621
2416186383	effect of ginkgo biloba extract in arterial occlusive disease randomized placebo controlled crossover study	1987	-0.4812	-0.0642	68	0.766
2416317959	alzheimer s disease and cognitive impairment	1988	-0.5194	0.3697	73	0.7711
2416340480	treatment of cerebral aging disorders with ginkgo biloba extract a longitudinal multicenter double blind drug vs placebo study	1986	-0.4797	-0.0643	68	21.7423
2416389372	selegiline versus l acetylcarnitine in the treatment of alzheimer type dementia	1990	-0.2023	0.0942	37	2.6599
2416553030	primary degenerative dementia therapy with ginkgo biloba extract placebo controlled double blind and comparative study	1986	-0.3976	0.0306	53	12.679
2417005433	special steps an effective visiting walking program for persons with cognitive impairment	2000	0.6267	-0.1215	42	14.9752
2417035224	effects of piracetam in children with learning disorders	1980	-0.3171	0.2625	15	0.7993
2417113140	intravenous infusion of diazepam	1977	-0.6082	0.5205	119	0.6168
2417180619	the impact of antipsychotic drug regulations on psychotropic prescribing practices in nursing homes	1992	0.5411	0.0026	52	1
2417259859	randomized double blind study of flunarizine versus placebo in patients with chronic cerebrovascular disorders	1988	-0.411	0.0798	51	0.6732
2417419624	follow up of patients with initial symptoms of cerebrovascular insufficiency	1988	-0.2959	0.1461	41	0.6523
2417582644	cognitive stimulation therapy in the italian context its efficacy in cognitive and non cognitive measures in older adults with dementia	2017	0.2185	-0.072	10	0.8162
2417657079	efficacy of antipsychotic medications in behaviorally disturbed dementia patients	1982	0.1654	0.0917	47	22.535
2417678783	1 fluoro 1 deoxy scyllo inositol for the treatment of alzheimer s disease	2006	-0.3245	0.1979	22	0.7501
2417708879	mild cognitive impairment	2016	-0.1901	0.0234	78	0.8616
2417738412	treatment of acute and transient psychotic disorders with low and high doses of oral haloperidol	1997	-0.1168	0.194	114	0.6925
2417742701	successful combined neuroleptic and lithium treatment of a chronic schizophrenic patient with recurrent aggressive behavior	1986	0.5645	0.399	40	0.7113
2417744543	double blind study of lecithin in patients with alzheimer s disease	1981	-0.332	0.0927	51	12.7595
2417815521	caregiver strain following critical care discharge an exploratory evaluation	2016	0.6788	-0.15	75	0.8091
2418038065	alzheimer s dementia	1995	-0.3309	0.2597	59	0.7805
2418213616	structural analysis of histamine n methyltransferase gene	1995	-0.3989	-0.2632	62	0.9939
2418364785	on the pharmacology of cortical evoked potentials	1972	-0.3171	0.2625	15	0.7993
2418408480	improved verbal learning after outpatient oral physostigmine therapy in patients with dementia of the alzheimer type	1991	-0.2172	0.1731	11	2.1934
2418654089	a multiple course trial of desferrioxamine in chronic progressive multiple sclerosis	2000	-1.5747	-1.2603	101	0.7993
2418772821	donepezil in the treatment of alzheimer disease	2000	-0.3128	0.111	33	4.3027
2418778117	a double blind crossover comparison between clothiapine and diazepam in the treatment of mental symptoms in chronic alcoholics	1974	-0.1547	0.2301	15	0.6467
2418813771	comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents a network meta analysis	2016	0.103	0.1503	61	0.707
2419028138	primary degenerative dementia	1986	-0.2909	0.1288	53	0.821
2419099959	alzheimer s disease cognitive and behavioral pharmacotherapy	1997	-0.5194	0.3697	73	0.7436
2419169686	cognitive impairment of alzheimer disease	1983	-0.5186	0.3694	73	0.7735
2419175888	memantine in the treatment of mild to moderate dementia syndrome a double blind placebo controlled study	1992	-0.2734	0.0722	23	21.3122
2419229657	drug treatment for alzheimer s disease commentary memantine treatment in patients with moderate to severe alzheimer s disease already receiving donepezil a randomized controlled trial	2004	-0.2853	0.0757	51	2.0417
2419508528	the effects of long term administration of lecithin on the course of alzheimer senile dementia	1985	-0.3831	0.3357	59	17.2167
2420108838	effect of memantine on cognitive performance in patients under electroconvulsive therapy a double blind randomized clinical trial	2015	-0.2522	0.1582	9	0.6466
2422121651	physostigmine and its effect on six patients with dementia	1981	-0.3173	0.2025	13	0.75
2423909460	computer based cognitive intervention for dementia preliminary results of a randomized clinical trial	2007	0.3164	-0.1289	10	0.8843
2428023306	improving health care for older adults	2005	1.6418	-0.0325	24	0.7537
2428055684	slow intravenous infusion of drugs	1981	-0.6082	0.5205	119	0.6201
2428783228	carbamazepine in the treatment of aggressive behavior in schizophrenic patients a case report	1984	0.5641	0.3999	40	0.7309
2429265366	pharmaco electroencephalographic and clinical effects of the cholinergic substance acetyl l carnitine in patients with organic brain syndrome	1990	-0.2861	0.0292	63	0.7993
2429573622	donepezil improved the clinical state and quality of life in moderate to severe alzheimer disease	2002	-0.3163	0.119	33	16.3557
2429897320	a pilot randomized controlled trial of the feasibility of a multicomponent delirium prevention intervention versus usual care in acute stroke	2017	-0.5975	-0.0271	99	0.7506
2429978207	from memory deficits to the diagnosis of alzheimer s disease	2008	-0.5495	0.3992	73	0.6749
2430370151	deprenyl prolongs the therapeutic efficacy of combined l dopa in parkinson s disease	1984	-0.1911	0.1104	137	0.6856
2430496535	hydergine for treatment of symptoms of cerebrovascular insufficiency	1969	-0.2936	0.1258	41	3.9449
2431472183	brain performance and behavior in senile dementias of the alzheimer type	1984	-0.3847	0.3365	59	0.7961
2431760191	sleep related outcomes in persons with mild to moderate alzheimer disease in a placebo controlled trial of galantamine	2003	0.1281	0.0261	28	0.9584
2432166694	pharmacologic treatment of the psychotic symptoms in schizophrenia	2002	0.3077	0.1439	81	0.7418
2433782533	helping to make the final years meaningful for the elderly residents of nursing homes	1976	-0.2883	0.1019	41	1.595
2435988985	placebo effect in the drug therapy of depression	2000	-0.411	0.0798	51	0.6527
2439270078	effectiveness of brief infusions with ginkgo biloba special extract egb 761 in dementia of the vascular and alzheimer type	1996	-0.4509	-0.0376	8	19.7718
2439414673	quantified electroencephalographic correlates of neuropsychological deficits in alzheimer s disease	1995	-0.2809	0.1571	43	0.7071
2440326502	a trial of thioridazine melleril in the maintenance of chronic schizophrenics	1962	0.1165	0.1318	38	0.6375
2440787391	evaluation of oxazepam and placebo in emotionally disturbed aged patients	1965	0.0875	0.0984	47	0.9713
2441237850	the pharmacological management of cognitive dysfunction in alzheimer s disease	1999	-0.5186	0.3694	73	0.7515
2442676216	clinical evaluation of hesper c therapy	1957	-0.3925	0.3624	106	0.7298
2443215841	a follow up of blind diabetic patients	1975	-0.3327	0.0929	51	0.6161
2460078328	repetition priming effects in alzheimer s disease	1989	-0.5495	0.3992	73	0.7058
2460096287	a double blind investigation of hydergine in the treatment of cerebrovascular insufficiency in the elderly	1972	-0.2879	0.102	41	1.666
2460154904	mild cognitive impairment a preclinical phase of alzheimer s disease	2002	-0.3146	0.1729	22	0.773
2460254169	buronil and promazine therapy of patients with senile dementia a double blind study	1967	0.1166	0.1309	38	0.6754
2460853517	can the clinical dementia rating scale identify mild cognitive impairment and predict cognitive and functional decline	2016	-0.0756	-0.1034	127	0.8514
2461191288	the caregiver of a person with alzheimer s disease	2008	-2.1425	2.1685	121	0.8889
2461330732	use of cognitive assessment with alzheimer s disease	2007	-0.5194	0.3697	73	0.7696
2462017003	alzheimer s disease research in the nursing home setting	2000	0.4399	-0.0044	104	0.8393
2462253167	clinical commwnkations owgyn	1997	-0.393	0.3617	106	0.7086
2462386161	a controlled double blind trial comparing etoperidone with thioridazine in the management of severe senile dementia	1983	0.1161	0.1304	38	12.8118
2463000085	donepezil a meta analysis of individual patient data from randomized controlled trials in the treatment of patients with mild to moderate alzheimer s disease	2001	-0.2379	0.0581	19	2.1868
2463469513	platelet aggregation after naftidrofuryl application in vitro and ex vivo	1995	-0.0942	0.0057	84	0.75
2464068509	enhancement of memory processes in alzheimer s disease with multiple dose intravenous physostigmine	1982	-0.3228	0.2099	13	29.4196
2464094693	double blind study using amantadine hydrochloride in the therapy of parkinson s disease	1971	-0.3333	0.0923	51	0.6309
2464532212	ginkgo biloba no better than placebo in preventing dementia	2012	-0.4838	-0.0687	68	1.4327
2464917883	pituitary adrenal function and cognitive performance in demented patients on acetyl l carnitine treatment	1993	-0.2006	0.0874	78	13.7211
2464982987	ginkgo biloba for dementia	1998	-0.398	0.0312	53	0.8338
2467363678	attention to caregivers for alzheimer disease	2006	-2.1425	2.1685	121	0.8724
2467553437	the effects of lecithin on memory in patients with senile dementia of the alzheimer s type proceedings	1981	-0.3309	0.2597	59	0.7926
2467706629	methylphenidate as a cognitive enhancer in healthy young people	2016	-0.2593	0.1791	11	0.6704
2467769383	galantamine for alzheimer s disease and alzheimer s disease with cerebrovascular disease	2016	-0.3267	0.1688	22	0.7363
2467950986	a time to event analysis of the efficacy of memantine in a pooled population of moderate to severe alzheimer s disease patients	2015	-0.3087	0.0164	57	1.5779
2468467050	cerebral convulsions and acute psychosyndrome following vincristine therapy	1974	-0.2966	0.1463	41	0.6206
2468509886	on the treatment of depression with monoamine oxidase inhibitors	1962	-0.1954	0.1512	37	0.8141
2468986308	donepezil for vascular cognitive impairment	2004	-0.8148	0.8226	102	0.6873
2469053542	efficacy and safety of the standardised ginseng extract g115 for potentiating vaccination against the influenza syndrome and protection against the common cold corrected	1996	-0.6545	-0.1195	65	0.9973
2471102382	influence of treatment on symptomatology and correlated electroencephalographic eeg changes in the aged	1973	-0.2883	0.1013	41	16.114
2471961332	table evidence table 5 studies of the efficacy of gingko biloba in treatment of alzheimer s disease	2003	-0.3985	0.0305	53	0.6289
2472287472	use of an extract of ginkgo biloba tebonin in the therapy of cerebral vascular diseases	1969	-0.4758	-0.0347	132	0.7261
2472660697	does an independent predictor of in hospital mortality exist for patients with isolated proximal femoral fracture a retrospective two year observational study	2015	2.2338	-0.0386	36	0.7182
2473013814	efficacy of donepezil in vascular dementia	2003	-0.3233	0.1118	33	16.8775
2473513740	an evaluation of community based cognitive stimulation therapy a pilot study with an irish population of people with dementia	2017	0.2185	-0.072	10	0.7999
2474048401	combination therapy of parkinsonism with deprenyl	1992	-0.1918	0.1108	137	0.7119
2474576143	the efficacy and safety of extended release methylphenidate following traumatic brain injury a randomised controlled pilot study	2017	-0.9922	1.2607	71	0.7158
2475139562	improving recognition of vascular cognitive impairment	2008	-0.8148	0.8226	102	0.6792
2475226557	comparison between intravenous patient controlled analgesia and subcutaneous morphine in patients after gastrectomy	2009	2.3864	-0.0463	130	0.8641
2475551200	does stopping donepezil for alzheimer disease increase nursing home placement	2015	-0.0761	0.0687	58	2.2884
2475993248	a double blind clinical trial of vinpocetine in the treatment of cerebral insufficiency of vascular and degenerative origin	1986	-0.2592	0.1132	23	1.7292
2476751064	long term efficacy and safety of donepezil in the treatment of alzheimer s disease an interim analysis of the results of a us multicentre open label extension study	1998	-0.2673	0.0501	124	0.8281
2477872031	detection evaluation and treatment of high blood cholesterol in adults adult treatment panel iii	2002	-0.787	-0.189	88	1
2478616877	guidelines for randomised clinical studies in parkinson s disease with dementia and dementia with lewy bodies	2006	-0.1371	0.201	100	0.7821
2478920888	clinical experience of memantine in alzheimer s disease	2008	-0.3219	0.1791	22	1.7549
2479216874	effect of long term ace inhibitor therapy in elderly vascular disease patients editorial	2007	-0.5188	-0.0906	68	0.7028
2480428692	dementia alzheimer s	2007	-0.3311	0.2607	59	0.7797
2480518455	chapter 126 alzheimer s disease	2015	-0.4424	0.2875	105	0.8732
2481484679	postmenopausal dehydroepiandrosterone administration increases free insulin like growth factor 1 and decreases high density lipoprotein a six month trial	1998	-1.4127	-1.8486	20	0.809
2482768183	a randomized trial of vitamin e supplementation and cognitive function in women commentary	2006	-0.8109	-0.2255	79	1.4527
2484215398	prevention and treatment of vascular dementia	2002	-0.2909	0.1288	53	0.7722
2489957040	a pilot study to develop a cognitive intervention to support dementia caregivers a focus group of caregivers caring for persons with dementia as informants	2013	0.6888	-0.1557	76	0.8491
2490970189	memantine for alzheimer s disease	2016	-0.3054	0.1652	22	3.4131
2491047509	donepezil for severe alzheimer s disease author s reply	2006	-0.3242	0.1168	33	0.9902
2492005228	a review of the first transdermal treatment for alzheimer s disease the rivastigmine patch	2008	-0.244	0.0543	19	0.8629
2492513668	clinical trials for memantine	2006	-0.5169	-0.0473	12	0.7395
2492562821	complementary benefit of memantine and donepezil on activities of daily living by disease stage when used together post hoc analysis of two trials in moderate to severe alzheimer s disease	2015	-0.1879	0.1127	11	1.6038
2492790985	solcos model based individual reminiscence for older adults with mild to moderate dementia in nursing homes a randomized controlled intervention study	2016	0.395	-0.1042	39	0.7917
2492940624	randomised trial of a perindopril based blood pressure lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack	2001	-0.7159	-0.1379	14	4.9912
2494815194	efficacy and tolerability of rivastigmine in patients with dementia of the alzheimer type commentary	1998	-0.2648	0.052	72	3.2184
2495810720	clinical experience in extrapyramidal disease with selective mao b inhibitor deprenyl	1980	-0.1918	0.1108	137	0.6499
2496888165	a clinical trial of ginkgo biloba in refractory partial epilepsy	1997	-0.4856	-0.072	68	0.7106
2497007078	research report patient depression and caregiver attitudes results from the aged in home care study	2008	0.657	-0.144	75	0.7803
2497700505	caregiving for alzheimer s disease and related disorders	2013	-2.1425	2.1685	121	0.8868
2498446791	memantine treatment in patients with alzheimer s disease	2012	-0.3219	0.1791	22	1.643
2499374973	4 vascular cognitive impairment	2016	-0.8148	0.8226	102	0.6871
2499864907	pharmacological treatment strategies for alzheimer s disease	2002	-1.0873	-0.5741	69	0.6969
2501300155	a preliminary longitudinal study on the cognitive and functional outcome of bipolar excellent lithium responders	2016	-0.2055	-0.1492	49	0.7075
2501635415	alzheimer s disease and alzheimer s dementia	2014	-0.3309	0.2597	59	0.7591
2501899756	case 097 alzheimer disease	2011	-0.4416	0.2873	105	0.8657
2503910289	a phase ii study of fornix deep brain stimulation in mild alzheimer s disease	2016	-0.1591	0.0558	67	0.6988
2504927640	comparative analysis of mortality in patients with alzheimer s disease treated with donepezil and galantamine authors reply	2007	-0.3242	0.1168	33	0.8357
2506378952	understanding and using the placebo effect	2006	-0.1544	0.2293	15	0.7644
2506552804	cognitive changes associated with alzheimer dementia	1982	-0.5186	0.3694	73	0.7248
2508658525	combined epidural general anesthesia vs general anesthesia alone for elective abdominal aortic aneurysm repair	2016	2.2338	-0.0386	36	0.7265
2510238100	cognitive impairment in older patients receiving care in an urban primary care practice	2016	1.6418	-0.0325	24	0.7658
2510490399	960 determinants of recovery of physical functioning after hip fracture in older people	2016	2.1047	-0.0879	26	0.7248
2512473949	comparison of neuropsychological and functional outcomes in alzheimer s disease patients with good or bad response to a cognitive stimulation treatment a retrospective analysis	2016	-0.3141	0.0962	50	0.6384
2512657511	peer support and reminiscence therapy for people with dementia and their family carers a factorial pragmatic randomised trial	2016	0.3779	-0.0995	39	1.6133
2514098085	b alzheimer s disease	1989	-0.4416	0.2873	105	0.8556
2514568916	memantine for patients with alzheimer disease author s reply	2004	-0.325	0.1169	33	0.8095
2514912494	cognitive function did not improve after initiation of natalizumab treatment in relapsing remitting multiple sclerosis a prospective one year dual control group study	2016	-0.2975	-0.2456	49	0.7152
2515031451	preliminary communication pituitary adrenal function in adolescent psychiatric patients impact of depressive symptoms	2000	0.3307	-0.0249	89	0.708
2516510247	transdermal nicotine improves testing but not overall cognition in patients with mild cognitive impairment	2012	-0.289	0.2822	9	0.6463
2517718245	short communication transcutaneous electrical nerve stimulation tens improves the rest activity rhythm in midstage alzheimer s disease	1999	0.2473	-0.0134	17	0.9457
2518781864	occupational therapy for delirium management in elderly patients without mechanical ventilation in an intensive care unit a pilot randomized clinical trial	2017	2.3692	-0.0634	35	0.7191
2519135988	the use of clozapine in an individual with moderate intellectual disability aggressive behaviour and resistant psychosis	1999	0.5641	0.3999	40	0.7148
2519784644	sertraline for preventing mood disorders following traumatic brain injury a randomized clinical trial	2016	0.0708	0.1428	61	0.7632
2520150886	informal caregivers of older persons with dementia in eight european countries experiences support well being and burden	2016	0.6888	-0.1557	76	0.8442
2520218093	clinical recommendations for the use of donepezil 23 mg in moderate to severe alzheimer s disease in the asia pacific region	2016	-0.3208	0.115	33	1.6051
2520883770	treatment of alzheimer s disease authors reply	1998	-0.3242	0.1168	33	0.8017
2521309828	memantine improves attention and verbal episodic memory in parkinson s disease dementia and dementia with lewy bodies a double blind	2013	-0.1371	0.201	100	0.9484
2521344850	a home based exercise intervention for caregivers of persons with dementia study protocol for a randomised controlled trial	2016	0.5421	-0.1163	1	0.773
2522226281	neuropsychological characteristics of clinical dementia rating 0 5 with uncertain impairment	2015	-0.0747	-0.1034	127	0.7793
2522300838	efficacy and safety of a novel acetylcholinesterase inhibitor octohydroaminoacridine in mild to moderate alzheimer s disease a phase ii multicenter randomized controlled trial	2015	-0.2801	0.075	51	0.66
2522417081	the cost effectiveness of two forms of case management compared to a control group for persons with dementia and their informal caregivers from a societal perspective	2016	0.5279	-0.087	34	0.6926
2522637047	l dopa carbidopa treatment of senile dementia a control study	1995	-0.3807	-0.2165	45	0.657
2522777522	clinical diagnosis and differential diagnosis of dementia	2006	-0.2909	0.1288	53	0.7636
2523088214	outcomes for family carers of a nurse delivered hospital discharge intervention for older people the further enabling care at home program single blind randomised controlled trial	2016	0.6854	-0.1437	97	0.6948
2523135434	quality of life and functioning of adhd patients treated with atomoxetine compared to standard treatment after 6 and 12 months	2010	-0.9925	1.2599	71	0.7356
2523311484	in the information age do dementia caregivers get the information they need semi structured interviews to determine informal caregivers education needs barriers and preferences	2016	0.6888	-0.1557	76	0.8531
2523414493	cognitive stimulation therapy cst for people with dementia in practice an observational study	2016	0.2185	-0.072	10	0.8025
2525801063	hybrid antioxidant and metal sequestering small molecules targeting the molecular features of alzheimer s disease	2017	-1.0873	-0.5741	69	0.6777
2525966121	haloperidol prophylaxis in cardiac surgery for patients at risk for delirium a randomized placebo controlled pilot study	2016	2.2154	-0.0448	2	0.8333
2526906484	effect of multi component intervention on preventing delirium in patients after open heart surgery	2015	2.1874	-0.0437	2	0.7636
2527054457	clinical social work interventions for nursing home residents with depression	2016	0.4399	-0.0044	104	0.7992
2527062329	case studies on the use of risperidone for the treatment of agitation in elderly patients with dementia	1999	0.617	0.4432	40	0.8567
2527476076	impact on outcomes of adding memantine to donepezil among patients with alzheimer s disease	2015	-0.2148	0.1352	11	1.5807
2527619853	cognitive impairment in depression and its non response to antidepressant treatment	2016	-0.3415	0.9111	113	0.782
2528227393	improving access to a multi component intervention for caregivers and people with dementia	2016	0.6888	-0.1557	76	0.8417
2528253699	an open label multicenter observational study for patients with alzheimer s disease treated with memantine in the clinical practice	2011	-0.4202	-0.0623	82	0.7903
2528531117	haloperidol use in acute traumatic brain injury a safety analysis	2016	2.2276	-0.0441	2	0.807
2529583304	awareness of subjective memory assessment in patients with mild cognitive impairment alzheimer s disease and parkinson s disease	2015	-0.6362	0.0864	122	0.7352
2531232486	memantine in treatment of alzheimer s disease 20 years of clinical use	2016	-0.3298	0.1839	22	0.8551
2532591582	an investigation of the efficacy of training care home staff in a formulation based functional analysis approach to understanding stress and distress behaviours with dementia	2016	0.5122	-0.1606	60	0.6563
2535447638	phase 3 trial of the tau aggregation inhibitor leuco methylthioninium bis hydromethanesulfonate lmtm in mild to moderate alzheimer s disease	2016	-0.311	0.0163	57	0.6835
2535834188	a phase 2 clinical trial of pf 05212377 sam 760 in subjects with mild to moderate alzheimer s disease with existing neuropsychiatric symptoms on a stable daily dose of donepezil	2016	-0.2175	0.1416	11	1.572
2536113368	lithium treatment prevents amyloid toxicity and mir 489 down regulation in an alzheimer s disease in vitro model	2016	-1.0873	-0.5741	69	0.7094
2538649573	building an online support program for family caregivers of persons with dementia	2016	0.7067	-0.1575	76	0.7894
2538731285	driving performance of older adults with early dementia with lewy bodies or early alzheimer s disease	2014	-0.1375	0.2003	100	0.7619
2538747993	prediction of relapse following discontinuation of antipsychotic treatment in alzheimer s disease the role of hallucinations	2016	0.1939	0.06	80	0.758
2540739152	c reactive protein is an independent predictor for 1 year mortality in elderly patients undergoing hip fracture surgery a retrospective analysis	2016	2.2338	-0.0385	36	0.7249
2541234539	effectiveness of an internet delivered intervention for generalized anxiety disorder in routine care a randomised controlled trial in a student population	2016	0.7635	-0.2018	77	0.7862
2544627296	delivering solid treatments on shaky ground feasibility study of an online therapy for child anxiety in the aftermath of a natural disaster	2018	0.7209	-0.1877	77	1.5374
2545409266	effect of conscious sedation vs general anesthesia on early neurological improvement among patients with ischemic stroke undergoing endovascular thrombectomy a randomized clinical trial	2016	2.2338	-0.0385	36	0.7741
2546487677	14 alzheimer s disease	2002	-0.4424	0.2875	105	0.8519
2548658751	hmpao spect in dementia of the alzheimer type and major depression with memory impairment	1993	-0.6362	0.0864	122	0.7228
2549310345	early use of memantine in the treatment of lewy body dementia	2016	-0.1375	0.2003	100	0.7977
2549744895	13 alzheimer s disease	2012	-0.4416	0.2873	105	0.8512
2550016226	olfactory ability in normal pressure hydrocephalus as compared to alzheimer s disease and healthy controls	2017	0.2301	-0.2027	111	0.6318
2550042849	analyses of a randomised controlled trial	2009	-0.417	0.0419	41	0.6726
2550445885	in hospitalized patients is there randomized controlled trial evidence to support the use of medication review	2016	-0.5975	-0.0271	99	0.7255
2551854222	cognitive effects of rasagiline in mild to moderate stage parkinson s disease without dementia	2017	-0.2338	0.184	9	0.6622
2552433781	sat0432 blended physical activity intervention with reduced face to face contact and usual physical therapy show similar effectiveness in patients with knee and hip osteoarthritis a randomized controlled trial	2016	-0.2945	-0.1543	45	0.6975
2552497287	a prospective randomized study for comparison of haemodynamic changes and recovery characteristics with propofol and sevoflurane anaesthesia during laparoscopic cholecystectomies	2016	3.1484	0.109	110	0.7498
2552579379	the effects of reminiscence therapy on cognitive function depression and quality of life among the community dwelling elderly	2016	0.415	-0.0781	18	0.7587
2553774099	efficacy and safety of tau aggregation inhibitor therapy in patients with mild or moderate alzheimer s disease a randomised controlled double blind parallel arm phase 3 trial	2016	-0.4204	-0.0632	82	0.7345
2554377008	haloperidol prophylaxis for preventing aggravation of postoperative delirium in elderly patients a randomized open label prospective trial	2017	2.2147	-0.0444	2	0.9648
2555962087	effect of cognitively stimulating activities on symptom management of delirium superimposed on dementia a randomized controlled trial	2016	-0.6916	-0.191	79	0.7428
2556479820	appropriate care for older people with cognitive impairment in hospital	2016	1.6418	-0.0325	24	0.8072
2558739631	cognitive effects of adjunctive n acetyl cysteine in psychosis	2017	-0.2419	0.165	9	0.7043
2560266276	tolerability of orm 12741 and effects on episodic memory in patients with alzheimer s disease	2017	-0.2244	0.1787	11	0.6833
2560454230	rivastigmine in the treatment of alzheimer s disease	2002	-0.3035	0.1427	133	1.5444
2560615354	m12 a randomised controlled trial of a 12 week multi modal exercise intervention in huntington s disease	2016	-0.2945	-0.1543	45	0.7018
2560814253	cognitive and social treatments in a model of alzheimer s disease	2016	-0.5186	0.3694	73	0.7545
2561715480	positive effects of face to face communication among family caregivers in caregiver support provided by the alzheimer s association	2014	0.7066	-0.1584	76	0.7856
2562329777	major outcomes in high risk hypertensive patients randomized to angiotensin converting enzyme inhibitor or calcium channel blocker vs diuretic the antihypertensive and lipid lowering treatment to prevent heart attack trial allhat	2002	-0.7274	-0.1452	14	4.9973
2562914079	effect of cognitive rehabilitation on set shifting attention of adult with mild cognitive impairment	2016	-0.24	-0.2603	49	0.7193
2563929827	p1 the relationship between cognitive impairment and placebo response	2011	-0.2975	-0.2456	49	0.6984
2564006760	does music therapy enhance behavioral and cognitive function in elderly dementia patients a systematic review and meta analysis	2017	0.415	-0.0781	18	0.7037
2564633555	life with alzheimer s disease	2016	-0.4424	0.2875	105	0.8521
2565008802	effect of galantamine on attention in patients with alzheimer s disease combined with cerebrovascular disease	2016	-0.3792	0.0982	94	0.8845
2565437182	tacrine firstdrugapproved for alzheimer s disease	1994	-0.2843	0.0857	33	0.6498
2565522084	age differences in perceptions of memory strategy effectiveness for recent and remote memory	2018	0.5038	-0.2821	4	0.6889
2566336058	treatment and risk factors for depression long term results of a randomized controlled trial in primary care	2000	-0.5975	-0.0271	99	0.6855
2566357485	effects of long term vitamin d supplementation on regression and metabolic status of cervical intraepithelial neoplasia a randomized double blind placebo controlled trial	2017	-1.2104	-0.3345	128	0.6739
2568933195	changes in the comprehensive health related qol of patients with dementia of alzheimer type dat treated with donepezil and their primary caregivers	2009	-0.3141	0.0962	50	0.6694
2571002748	dementia in parkinson s disease	2017	-0.1375	0.2003	100	0.7664
2577253455	depression in palliative care cancer patients prevalence and influence of pain	2016	0.4586	0.2348	116	0.7567
2579766792	310procedural memory in alzheimer s disease	1996	-0.5495	0.3992	73	0.7546
2580122699	memantine for fibromyalgia and alzheimer s disease an observational case comparison	2017	-0.0757	0.065	58	1.448
2581124105	mild cognitive impairment mci	2016	-0.1892	0.0233	78	0.8494
2581138085	american geriatrics society abstracted clinical practice guideline for postoperative delirium in older adults	2015	2.2154	-0.0448	2	0.7993
2582401618	depression in caregivers of alzheimer s disease patients	2001	-2.1413	2.1678	121	0.8718
2582886902	alzheimer disease and other dementias	2012	-0.3847	0.3366	59	0.7971
2583052788	donepezil plus solifenacin cpc 201 treatment for alzheimer s disease	2017	-0.2662	0.0553	124	0.824
2583153513	repetitive transcranial magnetic stimulation combined with cognitive training for the treatment of alzheimer s disease	2017	-0.1591	0.0558	67	0.6636
2583332892	the value of spect in detecting alzheimer type neurodegeneration in mild cognitive impairment	2011	-0.1892	0.0233	78	0.8347
2584282835	factors influencing the quality of life of caregiver using day care service	2013	0.6788	-0.1499	75	0.7966
2584314249	efficacy and safety of donepezil in chinese patients with severe alzheimer s disease a randomized controlled trial	2017	-0.2667	0.0528	124	1.6437
2585053309	relationship of depression with cognitive insight and socio occupational outcome in patients with schizophrenia	2017	0.2621	0.0262	31	0.7599
2586157726	impact of dexmedetomidine on the incidence of delirium in elderly patients after cardiac surgery a randomized controlled trial	2017	2.2147	-0.0444	2	0.7833
2586322664	an adapted mindfulness intervention for people with dementia in care homes feasibility pilot study	2017	0.3956	-0.1048	39	0.7631
2586591911	the differences of behavioral and psychological symptoms in the patients of alzheimer s disease and vascular dementia	2006	-0.3792	0.0982	94	0.7854
2586604195	p2 089 progression in mild cognitive impairment mci and premci	2006	-0.1892	0.0233	78	0.8447
2586610431	comparing approaches to optimize cut off scores for short cognitive screening instruments in mild cognitive impairment and dementia	2017	-0.0747	-0.1034	127	0.7715
2586905188	improving prospective memory in persons with parkinson disease a randomized controlled trial	2017	-0.2875	0.2061	15	0.6981
2587232235	significant improvement in cognition in mild to moderately severe dementia cases treated with transcranial plus intranasal photobiomodulation case series report	2017	-0.1598	0.0553	67	0.6549
2587379050	p2 416 a randomized controlled trial of a group reminiscence approach for vascular dementia	2006	-0.4786	-0.0169	12	0.776
2588249775	efficacy and safety of ginkgo biloba standardized extract in the treatment of vascular cognitive impairment a randomized double blind placebo controlled clinical trial	2017	-0.4839	-0.0688	68	1.4824
2588375135	p1 456 the effect of memantine on distinct behavior syndromes in moderate to severe ad patients	2006	-0.3087	0.0164	57	1.5811
2590129048	caution versus closure the use of atypical antipsychotics for the treatment of behavioral disturbances in dementia	2005	0.5483	0.3861	40	0.7157
2590539668	longitudinal association of hypertension and diabetes mellitus with cognitive functioning in a general 70 year old population the sonic study	2017	-0.4276	1.4428	56	0.769
2590859328	response of patients to randomized clinical trials in japan	1997	-0.5169	-0.0473	12	0.683
2591321251	adjuvant sertraline treallnent for chronic schizophrenia a randomized double blind placeho controlled study	1997	-0.3327	0.0929	51	0.6089
2591328430	individual reminiscence therapy can decrease depression level on elderly at social homes	2015	0.3574	-0.0939	39	0.8241
2591498235	galantamine effective choice for symptomatic treatment of mild to moderate dementia of the alzheimer s type	2015	-0.3792	0.0982	94	0.8163
2591842655	evidence for narrow transfer after short term cognitive training in older adults	2017	0.4602	-0.2374	4	0.7763
2592016143	determinants of dropout and nonadherence in a dementia prevention randomized controlled trial the prevention of dementia by intensive vascular care trial	2017	-0.5975	-0.0271	99	0.6786
2592716476	family burden and stress among caregiver of oral cancer patients at krishna hospital karad	2017	0.657	-0.144	75	0.7662
2592888995	a school nurse delivered intervention for anxious children an open trial	2017	0.6749	-0.1727	77	0.738
2593764540	variation in placebo effect sizes in clinical trials of oral interventions for management of the behavioral and psychological symptoms of dementia bpsd a systematic review and meta analysis	2017	-0.375	-0.0366	70	0.7063
2594345304	oraldomperidone double blind comparison with placebo inirritable bowel syndrome	1983	-0.3333	0.0923	51	0.6243
2594633659	free cortisol levels in older hysterectomized women treated with estradiol or estradiol progesterone results from a randomised placebo controlled double blind study	2005	-0.7504	-0.7583	3	0.8029
2594984561	cognitive effects of long term treatment with waking hoursubcutaneous apomorphine infusions in patients with advancedparkinson s disease	2011	-0.2338	0.184	9	0.6395
2595749119	research progress of donepezil for treating mild to moderate alzheimer s disease	2017	-0.3195	0.1168	33	0.8074
2596274667	a family centered intervention for the transition to living with multiple myeloma as a chronic illness a pilot study	2017	0.5415	-0.1158	1	0.7679
2596691898	training working memory in older adults is there an advantage of using strategies	2017	0.5038	-0.2821	4	0.7194
2596886333	diagnostic and statistical manual of mental disorders	1994	1.3621	-0.0115	2	5.4659
2598819486	dietary supplementation with n 3 polyunsaturated fatty acids and vitamin e after myocardial infarction results of the gissi prevenzione trial gruppo italiano per lo studio della sopravvivenza nell infarto miocardico	1999	-1.2428	-0.3453	83	1
2598972443	the effect of desflurane versus propofol anesthesia on postoperative delirium in elderly obese patients undergoing total knee replacement a randomized controlled double blinded clinical trial	2017	2.345	0.1894	103	0.7464
2599410194	decline of cognitive functions among elderly localized breast cancer patients after adjuvant treatment cog age study	2017	-0.2264	0.0532	84	0.6847
2599531256	cognitive training to improve memory in individuals undergoing electroconvulsive therapy negative findings	2017	-0.2585	0.1787	11	0.6584
2600137014	8 allostatic load is associated with positive symptoms in schizophrenia and first episode psychosis and decreases with antipsychotic therapy	2017	0.3076	0.1434	81	0.6536
2601323225	nanoparticles for therapy of alzheimer disease	2013	-1.0873	-0.5741	69	0.6768
2603737919	systematic review of the efficacy of rivastigmine for patients with alzheimer s disease	1998	-0.2319	0.0502	19	0.916
2604172034	effects of cognitive leisure activity on cognition in mild cognitive impairment results of a randomized controlled trial	2017	-0.2409	-0.2597	49	0.748
2604858684	techniques for postoperative pain management after total knee arthroplasty in srinagarind hospital	2017	2.3863	-0.0472	130	0.8796
2605141896	the neuropatholgy of alzheimer s disease	2002	-0.4424	0.2875	105	0.8727
2605792689	alzheimer and the dementias	2017	-0.3841	0.3371	59	0.7987
2606572887	effect of deprenyl on the progression of disability in early parkinson s disease	1989	-0.1927	0.1198	37	1.9998
2606580002	deprenyl for the treatment of early parkinson s disease reply	1990	-0.1911	0.1104	137	0.668
2606710341	unified huntington s disease rating scale reliability and consistency	2001	-0.2283	-0.1467	112	0.9973
2606849374	efficacy and safety of a novel acetylcholinesterase inhibitor octohydroaminoacridine in mild to moderate alzheimer s disease a phase ii multicenter randomised controlled trial	2017	-0.2792	0.0752	51	0.6463
2607294761	the effectiveness of creating an online life story book on persons with early dementia and their informal caregivers a protocol of a randomized controlled trial	2017	0.3956	-0.1048	39	0.7601
2608657902	intrathecal morphine versus extended release epidural morphine for postoperative pain control in pediatric patients undergoing posterior spinal fusion	2017	2.3864	-0.0463	130	0.8497
2608904565	efficacy of citalopram on acute ischemic stroke outcome a randomized clinical trial	2017	-0.3709	-0.0074	70	0.6568
2609038778	web based health interventions for family caregivers of elderly individuals a scoping review	2017	0.5963	-0.1335	131	0.7315
2609873149	effect of monthly high dose vitamin d supplementation on falls and non vertebral fractures secondary and post hoc outcomes from the randomised double blind placebo controlled vida trial	2017	-0.9263	-0.257	79	0.7179
2609912923	randomized controlled trial of ethyl eicosapentaenoic acid in huntington disease	2008	-0.2283	-0.1467	112	0.9867
2610711543	treating behavioral and psychological symptoms of dementia	2004	0.5559	0.3927	40	1.4299
2610716829	the alzheimer s caregiver study	2006	-2.1425	2.1685	121	0.9452
2610727609	assessment and treatment of nursing home residents with depression or behavioral symptoms associated with dementia a review of the literature mental health in nursing homes	2003	0.4403	-0.0052	104	0.8061
2611845885	efficacy of a multi component psychosocial intervention program for caregivers of persons living with neurocognitive disorders alexandria egypt a randomized controlled trial	2017	0.5415	-0.1158	1	0.7702
2612658973	feasibility and baseline findings of a finnish cognitive training fincog intervention in a randomised controlled trial among community dwelling persons with dementia	2017	0.1	-0.094	39	1.4412
2612678242	galantamine in ad a 6 month randomized placebo controlled trial with a 6 month extension the galantamine usa 1 study group	2000	-0.2212	0.044	6	23.9994
2612845260	effects of nimodipine on postoperative delirium in elderly under general anesthesia a prospective randomized controlled clinical trial	2017	2.2154	-0.0448	2	0.8133
2613287638	combination therapy clinical evaluation 2014	2014	-0.393	0.3617	106	0.6574
2613603062	donepezil in vascular dementia a viewpoint	2003	-0.3243	0.1121	33	0.8961
2614088678	caregiver burden in different stages of alzheimer s disease	2017	-2.1425	2.1685	121	0.8731
2614154277	caregiver coping experiences on taking care the dementia elderly in a nursing home	2016	0.6892	-0.1547	76	0.8452
2614282478	n 3 fatty acids in patients with multiple cardiovascular risk factors	2013	-1.2428	-0.3453	83	1
2614387965	s3 02 03 results of a one year randomized placebo controlled trial of dimebon for the treatment of mild to moderate alzheimer s disease	2007	-0.2379	0.0591	19	0.6964
2614666091	early protection against sudden death by n 3 polyunsaturated fatty acids after myocardial infarction	2002	-1.2428	-0.3453	83	1
2615260629	depression in nursing home residents with dementia	2017	0.4399	-0.0044	104	0.7787
2615372103	frontotemporal dementia paroxetine as a possible treatment of behavior symptoms a randomized controlled open 14 month study	2003	-0.2329	0.2531	66	2.7281
2615633730	abstract wp298 patient and caregiver physical health during the first year post stroke	2016	0.6788	-0.1499	75	0.7834
2616124858	safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis a randomised double blind placebo controlled trial	2017	-0.3244	-0.142	45	0.6943
2616176975	128comprehensive geriatric assessment for prevention of delirium post hip fracture a systematic review of randomised controlled trials	2017	-0.5976	-0.0271	99	0.7133
2616936040	treatment of patients with alzheimer s disease	2000	-0.3245	0.1979	22	0.7426
2617310949	memantine for treatment of alzheimer s disease	2004	-0.3058	0.1658	22	3.4312
2617919156	el tratamiento hipolipemiante intensivo frente al moderado con estatinas tras sindromes coronarios agudos	2004	-0.787	-0.1883	88	2
2620144746	treatment options and considerations for hypertensive patients to prevent dementia	2017	-0.6781	-0.1152	14	0.7993
2620557103	training in clinical trial design	2018	-0.2875	0.2061	15	0.6984
2621293967	efficacy and safety of cerebrolysin for acute ischemic stroke a meta analysis of randomized controlled trials	2017	-0.3709	-0.0074	70	0.7907
2624142896	effect of high dose simvastatin on cognitive neuropsychiatric and health related quality of life measures in secondary progressive multiple sclerosis secondary analyses from the ms stat randomised placebo controlled trial	2017	-0.2409	-0.2597	49	0.7169
2624671796	beta atrophy in alzheimer s disease	2017	-0.4416	0.2873	105	0.8729
2625609406	deficits in executive control function in parkinson s disease with dementia compared to alzheimer s disease and parkinson s disease without dementia	2004	-0.1375	0.2003	100	0.7519
2625720834	a 6 month double blind placebo controlled trial of epastigmine in alzheimer s disease	2000	-0.3061	0.0837	51	1.2969
2642291021	placebo response and practice effects in schizophrenia cognition trials	2017	-0.2409	-0.2597	49	0.7225
2678487466	famous faces and lexical geographical knowledge as low effort tasks in patients with subjective cognitive decline scd mild cognitive impairment mci and parkinson s disease pd in detecting conversion to dementia	2014	-0.6362	0.0864	122	0.7361
2682044253	effectiveness of rivastigmine in alzheimer s disease	2000	-0.2795	0.1044	133	0.7153
2746359225	patch clamp studies on the kinetics and selectivity of receptor antagonism by memantine 1 amino 3 5 dimethyladamantan	1993	-0.2735	0.0729	23	0.9988
2747315066	psychosocial interventions to reduce depressive symptoms of dementia caregivers a randomized clinical trial comparing two approaches	2004	0.4997	-0.1043	1	18.8846
2752014617	hypertension in the very elderly trial hyvet protocol for the main trial	2001	-0.7354	-0.1465	14	20.9594
2752287204	2013 alzheimer s disease facts and figures	2013	-0.0719	-0.0915	82	1.9899
2765286685	functional evaluation the barthel index a simple index of the independence useful in scoring improvement in the rehabilitation of the chronically ill	1965	2.1944	-0.0495	2	0.7993
2799948996	ginseng therapy in non insulin dependent diabetic patients	1995	-0.6521	-0.1195	65	1.9861